0	Nonreplicating	O
1	vaccinia	O
2	vector	O
3	efficiently	O
4	expresses	O
5	recombinant	O
6	genes	O
7	.	O

0	Wherever	O
1	the	O
2	site	O
3	of	O
4	the	O
5	conditioning	O
6	stimulation	O
7	,	O
8	these	O
9	modifications	O
10	disappeared	O
11	after	O
12	ischaemia	O
13	of	O
14	the	O
15	leg	O
16	.	O

0	Necrosis	O
1	appears	O
2	6	O
3	h	O
4	after	O
5	TA	O
6	infusion	O
7	,	O
8	being	O
9	5	O
10	.	O
11	77	O
12	%	O
13	in	O
14	extent	O
15	after	O
16	12	O
17	h	O
18	,	O
19	14	O
20	.	O
21	9	O
22	%	O
23	after	O
24	24	O
25	h	O
26	and	O
27	animals	O
28	die	O
29	with	O
30	an	O
31	area	O
32	of	O
33	29	O
34	.	O
35	5	O
36	%	O
37	necrosis	O
38	.	O

0	It	O
1	also	O
2	suggests	O
3	that	O
4	there	O
5	is	O
6	another	O
7	pathway	O
8	which	O
9	can	O
10	activate	O
11	SWI4	B
12	transcription	O
13	in	O
14	the	O
15	absence	O
16	of	O
17	SWI6	B
18	.	O

0	An	O
1	evolutionary	O
2	conserved	O
3	element	O
4	is	O
5	essential	O
6	for	O
7	somite	O
8	and	O
9	adjacent	O
10	mesenchymal	O
11	expression	O
12	of	O
13	the	O
14	Hoxa1	B
15	gene	I
16	.	O

0	Mitochondria	O
1	-	O
2	lytic	O
3	action	O
4	of	O
5	warfarin	B
6	in	O
7	lymphocytes	O
8	.	O

0	Substitution	O
1	of	O
2	either	O
3	Val33	O
4	(	O
5	by	O
6	Gly	O
7	)	O
8	or	O
9	Gly28	O
10	(	O
11	by	O
12	Ser	O
13	),	O
14	two	O
15	of	O
16	the	O
17	most	O
18	conserved	O
19	residues	O
20	in	O
21	all	O
22	protein	O
23	kinases	O
24	,	O
25	resulted	O
26	in	O
27	enzyme	O
28	with	O
29	marginally	O
30	detectable	O
31	activity	O
32	.	O

0	Computer	O
1	assisted	O
2	mapping	O
3	in	O
4	quantitative	O
5	analysis	O
6	of	O
7	cerebral	O
8	positron	O
9	emission	O
10	tomograms	O
11	.	O

0	Pathogens	O
1	(	O
2	Staphylococcus	O
3	aureus	O
4	or	O
5	Gram	O
6	-	O
7	negative	O
8	bacilli	O
9	)	O
10	were	O
11	isolated	O
12	from	O
13	only	O
14	one	O
15	member	O
16	of	O
17	staff	O
18	in	O
19	small	O
20	numbers	O
21	and	O
22	irregularly	O
23	and	O
24	rarely	O
25	in	O
26	large	O
27	numbers	O
28	from	O
29	patients	O
30	.	O

0	In	O
1	a	O
2	Hoosier	O
3	Oncology	O
4	Group	O
5	randomized	O
6	study	O
7	involving	O
8	extensive	O
9	-	O
10	disease	O
11	SCLC	O
12	patients	O
13	,	O
14	VIP	O
15	was	O
16	superior	O
17	to	O
18	etoposide	O
19	/	O
20	cisplatin	O
21	with	O
22	regard	O
23	to	O
24	median	O
25	time	O
26	to	O
27	progression	O
28	(	O
29	6	O
30	.	O
31	6	O
32	v	O
33	5	O
34	.	O
35	8	O
36	months	O
37	),	O
38	median	O
39	survival	O
40	times	O
41	(	O
42	9	O
43	.	O
44	1	O
45	v	O
46	7	O
47	.	O
48	3	O
49	months	O
50	),	O
51	and	O
52	2	O
53	-	O
54	and	O
55	3	O
56	-	O
57	year	O
58	survival	O
59	rates	O
60	(	O
61	13	O
62	%	O
63	v	O
64	5	O
65	%	O
66	and	O
67	5	O
68	%	O
69	v	O
70	0	O
71	%,	O
72	respectively	O
73	).	O

0	Neural	O
1	-	O
2	specific	O
3	expression	O
4	,	O
5	genomic	O
6	structure	O
7	,	O
8	and	O
9	chromosomal	O
10	localization	O
11	of	O
12	the	O
13	gene	O
14	encoding	O
15	the	O
16	zinc	B
17	-	I
18	finger	I
19	transcription	I
20	factor	I
21	NGFI	I
22	-	I
23	C	I
24	.	O

0	Sleep	O
1	was	O
2	determined	O
3	again	O
4	for	O
5	an	O
6	additional	O
7	3	O
8	days	O
9	and	O
10	6	O
11	hours	O
12	.	O

0	The	O
1	5	O
2	'-	O
3	terminus	O
4	of	O
5	the	O
6	p	B
7	-	I
8	gvpF	I
9	-	I
10	M	I
11	mRNA	I
12	was	O
13	located	O
14	169	O
15	nucleotides	O
16	upstream	O
17	of	O
18	p	B
19	-	I
20	gvpF	I
21	within	O
22	p	B
23	-	I
24	gvpE	I
25	.	O

0	Two	O
1	episodes	O
2	of	O
3	peritonitis	O
4	occurred	O
5	while	O
6	the	O
7	patient	O
8	received	O
9	CAPD	O
10	(	O
11	1	O
12	episode	O
13	/	O
14	3	O
15	.	O
16	5	O
17	patient	O
18	-	O
19	months	O
20	).	O

0	NMR	O
1	of	O
2	diffusing	O
3	atoms	O
4	in	O
5	a	O
6	periodic	O
7	porous	O
8	medium	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	a	O
14	nonuniform	O
15	magnetic	O
16	field	O
17	.	O

0	These	O
1	findings	O
2	suggest	O
3	that	O
4	the	O
5	increase	O
6	in	O
7	V	O
8	O2	O
9	may	O
10	have	O
11	been	O
12	a	O
13	consequence	O
14	of	O
15	the	O
16	increase	O
17	in	O
18	Q	O
19	O2	O
20	rather	O
21	than	O
22	a	O
23	response	O
24	to	O
25	the	O
26	procedure	O
27	itself	O
28	.	O

0	A	O
1	brief	O
2	discussion	O
3	of	O
4	color	O
5	deficiencies	O
6	.	O

0	MCh	O
1	infusion	O
2	caused	O
3	a	O
4	concentration	O
5	-	O
6	dependent	O
7	increase	O
8	in	O
9	airway	O
10	resistance	O
11	at	O
12	constant	O
13	QBA	O
14	.	O

0	When	O
1	vascular	O
2	pressure	O
3	(	O
4	Pvas	O
5	)	O
6	was	O
7	raised	O
8	abruptly	O
9	from	O
10	-	O
11	5	O
12	to	O
13	+	O
14	25	O
15	cmH2O	O
16	by	O
17	air	O
18	inflation	O
19	for	O
20	60	O
21	min	O
22	,	O
23	Px	O
24	(	O
25	f	O
26	)	O
27	became	O
28	abruptly	O
29	less	O
30	negative	O
31	,	O
32	then	O
33	remained	O
34	stable	O
35	.	O

0	The	O
1	effects	O
2	of	O
3	contrast	O
4	media	O
5	on	O
6	coagulation	B
7	factor	I
8	XII	I
9	.	O

0	Symposium	O
1	on	O
2	presenile	O
3	spongy	O
4	encephalopathies	O
5	.	O

0	Assembly	O
1	of	O
2	a	O
3	complex	O
4	between	O
5	FAK	B
6	and	O
7	Src	B
8	kinases	I
9	may	O
10	serve	O
11	to	O
12	regulate	O
13	the	O
14	subcellular	O
15	localization	O
16	and	O
17	the	O
18	enzymatic	O
19	activity	O
20	of	O
21	members	O
22	of	O
23	the	O
24	Src	B
25	family	I
26	of	I
27	kinases	I
28	.	O

0	We	O
1	characterized	O
2	three	O
3	Arabidopsis	O
4	thaliana	O
5	cDNA	O
6	clones	O
7	that	O
8	could	O
9	rescue	O
10	the	O
11	sterile	O
12	phenotype	O
13	of	O
14	the	O
15	Schizosaccharomyces	B
16	pombe	I
17	pde1	B
18	mutant	I
19	,	O
20	which	O
21	is	O
22	defective	O
23	in	O
24	cAMP	B
25	phosphodiesterase	I
26	.	O

0	Evidence	O
1	that	O
2	therapeutic	O
3	alterations	O
4	of	O
5	a	O
6	circadian	O
7	rhythm	O
8	for	O
9	gastric	O
10	emptying	O
11	response	O
12	may	O
13	be	O
14	possible	O
15	.	O

0	Moreover	O
1	,	O
2	the	O
3	mass	O
4	estimated	O
5	with	O
6	the	O
7	QCM	O
8	response	O
9	through	O
10	the	O
11	Sauerbrey	O
12	equation	O
13	and	O
14	the	O
15	mass	O
16	which	O
17	can	O
18	be	O
19	measured	O
20	thanks	O
21	to	O
22	other	O
23	analytical	O
24	techniques	O
25	,	O
26	in	O
27	our	O
28	case	O
29	an	O
30	enzymatic	O
31	assay	O
32	,	O
33	are	O
34	different	O
35	:	O
36	the	O
37	deposited	O
38	mass	O
39	is	O
40	generally	O
41	overestimated	O
42	by	O
43	the	O
44	QCM	O
45	.	O

0	Plasma	B
1	histaminase	I
2	in	O
3	patients	O
4	of	O
5	bronchial	O
6	asthma	O
7	and	O
8	the	O
9	effect	O
10	of	O
11	prednisolone	O
12	administration	O
13	on	O
14	it	O
15	.	O

0	It	O
1	has	O
2	been	O
3	previously	O
4	shown	O
5	that	O
6	genes	O
7	transcribed	O
8	by	O
9	RNA	B
10	polymerase	I
11	II	I
12	(	O
13	RNAP	B
14	II	I
15	)	O
16	are	O
17	subject	O
18	to	O
19	position	O
20	effect	O
21	variegation	O
22	when	O
23	located	O
24	near	O
25	yeast	O
26	telomeres	O
27	.	O

0	M	B
1	.	I
2	leprae	I
3	OxyR	I
4	was	O
5	overproduced	O
6	and	O
7	purified	O
8	,	O
9	and	O
10	its	O
11	binding	O
12	to	O
13	the	O
14	oxyR	B
15	-	O
16	ahpC	B
17	intergenic	O
18	region	O
19	of	O
20	M	O
21	.	O
22	leprae	O
23	was	O
24	demonstrated	O
25	.	O

0	Discrepant	O
1	results	O
2	with	O
3	a	O
4	latex	O
5	agglutination	O
6	test	O
7	in	O
8	the	O
9	assessment	O
10	of	O
11	cytomegalovirus	O
12	antibody	O
13	status	O
14	of	O
15	cardiac	O
16	transplant	O
17	donors	O
18	.	O

0	Because	O
1	the	O
2	number	O
3	of	O
4	parameters	O
5	required	O
6	by	O
7	a	O
8	Volterra	O
9	series	O
10	grows	O
11	rapidly	O
12	with	O
13	both	O
14	the	O
15	length	O
16	of	O
17	its	O
18	memory	O
19	and	O
20	the	O
21	order	O
22	of	O
23	its	O
24	nonlinearity	O
25	,	O
26	methods	O
27	for	O
28	identifying	O
29	these	O
30	models	O
31	from	O
32	measurements	O
33	of	O
34	input	O
35	/	O
36	output	O
37	data	O
38	are	O
39	limited	O
40	to	O
41	low	O
42	-	O
43	order	O
44	systems	O
45	with	O
46	relatively	O
47	short	O
48	memories	O
49	.	O

0	Beyond	O
1	the	O
2	Tower	O
3	of	O
4	Babel	O
5	:	O
6	a	O
7	nomenclature	O
8	for	O
9	suicidology	O
10	.	O

0	In	O
1	addition	O
2	,	O
3	mapping	O
4	of	O
5	the	O
6	promoter	O
7	region	O
8	and	O
9	the	O
10	identification	O
11	of	O
12	putative	O
13	promoter	O
14	regulatory	O
15	sequences	O
16	should	O
17	give	O
18	insight	O
19	into	O
20	the	O
21	transcriptional	O
22	regulation	O
23	of	O
24	UCP2	B
25	expression	O
26	--	O
27	in	O
28	particular	O
29	by	O
30	anyone	O
31	of	O
32	the	O
33	above	O
34	mentioned	O
35	factors	O
36	--	O
37	in	O
38	vitro	O
39	and	O
40	in	O
41	vivo	O
42	.	O

0	The	O
1	observation	O
2	that	O
3	beta	B
4	2m	I
5	with	O
6	covalently	O
7	attached	O
8	peptide	O
9	can	O
10	effectively	O
11	create	O
12	CTL	B
13	target	O
14	structures	O
15	in	O
16	vitro	O
17	offers	O
18	new	O
19	possibilities	O
20	for	O
21	the	O
22	in	O
23	vivo	O
24	induction	O
25	of	O
26	epitope	O
27	-	O
28	specific	O
29	CTL	B
30	responses	O
31	by	O
32	either	O
33	DNA	O
34	immunization	O
35	or	O
36	injection	O
37	of	O
38	the	O
39	purified	O
40	epitope	O
41	-	O
42	linked	O
43	beta	B
44	2m	I
45	.	O

0	Conservative	O
1	treatment	O
2	of	O
3	central	O
4	nervous	O
5	system	O
6	injuries	O

0	This	O
1	lack	O
2	of	O
3	correlation	O
4	may	O
5	be	O
6	due	O
7	to	O
8	variations	O
9	in	O
10	the	O
11	metabolic	O
12	activity	O
13	of	O
14	the	O
15	endometriotic	O
16	implants	O
17	present	O
18	at	O
19	different	O
20	stages	O
21	of	O
22	the	O
23	disease	O
24	.	O

0	When	O
1	the	O
2	entire	O
3	diet	O
4	consisted	O
5	of	O
6	SBF	O
7	,	O
8	voluntary	O
9	feed	O
10	intake	O
11	was	O
12	reduced	O
13	,	O
14	indicating	O
15	that	O
16	SBF	O
17	should	O
18	not	O
19	be	O
20	fed	O
21	to	O
22	ponies	O
23	as	O
24	the	O
25	sole	O
26	dietary	O
27	ingredient	O
28	.	O

0	We	O
1	conclude	O
2	from	O
3	this	O
4	study	O
5	that	O
6	Arix	B
7	and	O
8	NBPhox	B
9	exhibit	O
10	indistinguishable	O
11	and	O
12	independent	O
13	transcriptional	O
14	regulatory	O
15	properties	O
16	on	O
17	the	O
18	DBH	B
19	promoter	I
20	.	O

0	Mastocytosis	O
1	.	O

0	Given	O
1	its	O
2	relative	O
3	longevity	O
4	on	O
5	the	O
6	Web	O
7	,	O
8	TIE	O
9	researchers	O
10	have	O
11	been	O
12	in	O
13	a	O
14	unique	O
15	position	O
16	to	O
17	observe	O
18	trends	O
19	in	O
20	telemedicine	O
21	.	O

0	Environmental	O
1	factors	O
2	were	O
3	more	O
4	important	O
5	in	O
6	the	O
7	older	O
8	cohorts	O
9	(	O
10	perhaps	O
11	because	O
12	of	O
13	less	O
14	reliable	O
15	recall	O
16	).	O

0	Genomic	O
1	and	O
2	cDNA	O
3	clones	O
4	homologous	O
5	to	O
6	the	O
7	yeast	B
8	GCN2	I
9	eIF	I
10	-	I
11	2alpha	I
12	kinase	I
13	(	O
14	yGCN2	B
15	)	O
16	were	O
17	isolated	O
18	from	O
19	Drosophila	O
20	melanogaster	O
21	.	O

0	The	O
1	latter	O
2	method	O
3	adds	O
4	clamping	O
5	of	O
6	the	O
7	inferior	O
8	vena	O
9	cava	O
10	,	O
11	which	O
12	results	O
13	in	O
14	hypotension	O
15	,	O
16	requiring	O
17	invasive	O
18	anesthetic	O
19	management	O
20	.	O

0	Ectopic	O
1	expression	O
2	of	O
3	Apo	B
4	-	I
5	3	I
6	in	O
7	HEK293	O
8	or	O
9	HeLa	O
10	cells	O
11	induced	O
12	marked	O
13	apoptosis	O
14	.	O

0	The	O
1	27	O
2	-	O
3	base	O
4	element	O
5	interacts	O
6	with	O
7	a	O
8	PDGF	B
9	-	O
10	activated	O
11	serine	B
12	/	I
13	threonine	I
14	phosphoprotein	I
15	that	O
16	is	O
17	detected	O
18	only	O
19	within	O
20	the	O
21	nucleus	O
22	of	O
23	PDGF	B
24	-	O
25	treated	O
26	3T3	O
27	cells	O
28	.	O

0	In	O
1	a	O
2	randomized	O
3	study	O
4	on	O
5	150	O
6	patients	O
7	(	O
8	ASA	O
9	1	O
10	)	O
11	undergoing	O
12	induction	O
13	of	O
14	anaesthesia	O
15	,	O
16	the	O
17	effects	O
18	of	O
19	Fentanyl	O
20	(	O
21	0	O
22	.	O
23	1	O
24	mg	O
25	),	O
26	the	O
27	combination	O
28	of	O
29	Fentanyl	O
30	(	O
31	0	O
32	.	O
33	1	O
34	mg	O
35	)	O
36	and	O
37	Droperidol	O
38	(	O
39	5	O
40	mg	O
41	)	O
42	(	O
43	Innovar	O
44	,	O
45	Thalamonal	O
46	)	O
47	and	O
48	Atropine	O
49	(	O
50	0	O
51	.	O
52	01	O
53	mg	O
54	/	O
55	kg	O
56	b	O
57	.	O
58	w	O
59	.)	O
60	alone	O
61	on	O
62	cardiocirculatory	O
63	parameters	O
64	were	O
65	studied	O
66	.	O

0	OBJECTIVE	O
1	:	O
2	To	O
3	investigate	O
4	the	O
5	incidence	O
6	and	O
7	presentation	O
8	of	O
9	acute	O
10	pernicious	O
11	or	O
12	fulminating	O
13	beriberi	O
14	in	O
15	a	O
16	general	O
17	district	O
18	hospital	O
19	.	O

0	The	O
1	3	O
2	'	O
3	stem	O
4	-	O
5	loop	O
6	is	O
7	highly	O
8	divergent	O
9	in	O
10	structure	O
11	among	O
12	species	O
13	and	O
14	lies	O
15	immediately	O
16	upstream	O
17	of	O
18	the	O
19	binding	O
20	site	O
21	for	O
22	Sm	B
23	proteins	I
24	.	O

0	In	O
1	all	O
2	eight	O
3	cases	O
4	,	O
5	neither	O
6	FL	O
7	nor	O
8	DLL	O
9	cells	O
10	showed	O
11	alterations	O
12	of	O
13	bcl	B
14	-	I
15	2	I
16	gene	I
17	sequences	I
18	in	O
19	the	O
20	breakpoint	O
21	region	O
22	,	O
23	suggesting	O
24	high	O
25	conservation	O
26	of	O
27	the	O
28	bcl	B
29	-	I
30	2	I
31	gene	I
32	during	O
33	both	O
34	t	O
35	(	O
36	14	O
37	;	O
38	18	O
39	)	O
40	translocation	O
41	and	O
42	morphologic	O
43	transformation	O
44	of	O
45	the	O
46	FL	O
47	cells	O
48	.	O

0	All	O
1	of	O
2	the	O
3	indigo	O
4	-	O
5	producing	O
6	bacteria	O
7	had	O
8	an	O
9	indoxyl	B
10	phosphatase	I
11	with	O
12	a	O
13	pI	O
14	of	O
15	6	O
16	.	O
17	4	O
18	.	O

0	Sequencing	O
1	of	O
2	the	O
3	three	O
4	pag	B
5	-	I
6	3	I
7	alleles	I
8	showed	O
9	that	O
10	two	O
11	apparent	O
12	null	O
13	alleles	O
14	encode	O
15	a	O
16	nonsense	O
17	mutation	O
18	before	O
19	the	O
20	zinc	O
21	fingers	O
22	and	O
23	a	O
24	missense	O
25	mutation	O
26	in	O
27	the	O
28	fourth	O
29	zinc	O
30	finger	O
31	that	O
32	changes	O
33	a	O
34	coordinating	O
35	histidine	O
36	to	O
37	a	O
38	tyrosine	O
39	.	O

0	A	O
1	phylogenetic	O
2	analysis	O
3	of	O
4	the	O
5	reverse	B
6	transcriptase	I
7	domain	I
8	confirms	O
9	our	O
10	differential	O
11	genetic	O
12	assessment	O
13	that	O
14	Cyclops	O
15	from	O
16	pea	O
17	is	O
18	a	O
19	novel	O
20	element	O
21	with	O
22	no	O
23	specific	O
24	relationship	O
25	to	O
26	the	O
27	previously	O
28	described	O
29	Gypsy	O
30	-	O
31	like	O
32	elements	O
33	from	O
34	plants	O
35	.	O

0	The	O
1	GEF	B
2	and	O
3	GAP	B
4	activities	O
5	for	O
6	Ypt1p	B
7	localize	O
8	to	O
9	particulate	O
10	cellular	O
11	fractions	O
12	.	O

0	The	O
1	two	O
2	main	O
3	experimental	O
4	variables	O
5	were	O
6	the	O
7	attended	O
8	hemifield	O
9	(	O
10	left	O
11	or	O
12	right	O
13	)	O
14	and	O
15	the	O
16	proportion	O
17	of	O
18	trials	O
19	requiring	O
20	a	O
21	shift	O
22	within	O
23	that	O
24	hemifield	O
25	(	O
26	20	O
27	%	O
28	or	O
29	80	O
30	%).	O

0	For	O
1	symptomatic	O
2	relief	O
3	and	O
4	inhibition	O
5	of	O
6	the	O
7	growth	O
8	of	O
9	the	O
10	metastases	O
11	interferon	B
12	-	I
13	a	I
14	and	O
15	somatostatin	B
16	analogues	O
17	can	O
18	be	O
19	employed	O
20	.	O

0	Characterization	O
1	of	O
2	an	O
3	EcR	B
4	/	O
5	USP	B
6	heterodimer	O
7	target	O
8	site	O
9	that	O
10	mediates	O
11	ecdysone	O
12	responsiveness	O
13	of	O
14	the	O
15	Drosophila	B
16	Lsp	I
17	-	I
18	2	I
19	gene	I
20	.	O

0	In	O
1	addition	O
2	,	O
3	a	O
4	21	O
5	-	O
6	mer	O
7	subrepeat	O
8	structure	O
9	is	O
10	also	O
11	present	O
12	in	O
13	each	O
14	unit	O
15	.	O

0	Epigenetic	O
1	switching	O
2	of	O
3	transcriptional	O
4	states	O
5	:	O
6	cis	O
7	-	O
8	and	O
9	trans	O
10	-	O
11	acting	O
12	factors	O
13	affecting	O
14	establishment	O
15	of	O
16	silencing	O
17	at	O
18	the	O
19	HMR	B
20	locus	I
21	in	O
22	Saccharomyces	O
23	cerevisiae	O
24	.	O

0	These	O
1	and	O
2	other	O
3	data	O
4	presented	O
5	suggest	O
6	that	O
7	TAg	B
8	'	O
9	re	O
10	-	O
11	models	O
12	'	O
13	host	O
14	cell	O
15	transcription	O
16	factors	O
17	that	O
18	are	O
19	used	O
20	early	O
21	in	O
22	viral	O
23	infection	O
24	,	O
25	and	O
26	thereby	O
27	mimics	O
28	an	O
29	event	O
30	that	O
31	naturally	O
32	occurs	O
33	during	O
34	transformation	O
35	.	O

0	A	O
1	larger	O
2	region	O
3	upstream	O
4	of	O
5	human	B
6	CMV	I
7	dbp	I
8	also	O
9	mediated	O
10	replication	O
11	in	O
12	transient	O
13	assays	O
14	.	O

0	A	O
1	distinct	O
2	staining	O
3	pattern	O
4	for	O
5	the	O
6	N	B
7	-	I
8	utrophin	I
9	was	O
10	not	O
11	detectable	O
12	,	O
13	although	O
14	it	O
15	was	O
16	expected	O
17	to	O
18	localise	O
19	at	O
20	the	O
21	actin	B
22	stress	O
23	fibers	O
24	.	O

0	Organisms	O
1	were	O
2	recovered	O
3	from	O
4	the	O
5	conjunctiva	O
6	for	O
7	several	O
8	weeks	O
9	,	O
10	and	O
11	persistent	O
12	genital	O
13	and	O
14	gastrointestinal	O
15	infection	O
16	also	O
17	resulted	O
18	from	O
19	the	O
20	ocular	O
21	infection	O
22	in	O
23	some	O
24	cats	O
25	.	O

0	The	O
1	predominant	O
2	sensitizing	O
3	allergens	O
4	in	O
5	Swedish	O
6	asthmatic	O
7	children	O
8	are	O
9	furred	O
10	pet	O
11	animals	O
12	.	O

0	Thioredoxin	B
1	(	O
2	TR	B
3	)	O
4	is	O
5	a	O
6	small	O
7	ubiquitous	O
8	dithiol	B
9	-	I
10	reductase	I
11	enzyme	I
12	first	O
13	identified	O
14	in	O
15	bacteria	O
16	and	O
17	plants	O
18	.	O

0	Furthermore	O
1	,	O
2	a	O
3	pTyr317	B
4	Shc	I
5	phosphopeptide	I
6	selectively	O
7	recognized	O
8	Grb2	B
9	,	O
10	Sos1	B
11	,	O
12	SHIP	B
13	,	O
14	and	O
15	the	O
16	p85	B
17	subunit	I
18	of	O
19	phosphatidylinositol	B
20	3	I
21	'	I
22	kinase	I
23	from	O
24	mast	O
25	cells	O
26	,	O
27	as	O
28	characterized	O
29	by	O
30	mass	O
31	spectrometry	O
32	.	O

0	Slap	B
1	negatively	O
2	regulates	O
3	Src	B
4	mitogenic	O
5	function	O
6	but	O
7	does	O
8	not	O
9	revert	O
10	Src	B
11	-	O
12	induced	O
13	cell	O
14	morphology	O
15	changes	O
16	.	O

0	Primer	O
1	extension	O
2	and	O
3	mung	B
4	bean	B
5	and	O
6	S1	B
7	nuclease	I
8	mapping	O
9	indicated	O
10	multiple	O
11	transcription	O
12	initiation	O
13	sites	O
14	and	O
15	were	O
16	consistent	O
17	with	O
18	Northern	O
19	analyses	O
20	.	O

0	Droperidol	O
1	-	O
2	induced	O
3	extrapyramidal	O
4	symptoms	O
5	in	O
6	an	O
7	adolescent	O
8	following	O
9	strabismus	O
10	surgery	O
11	.	O

0	The	O
1	distribution	O
2	of	O
3	cryptosporidia	O
4	in	O
5	the	O
6	intestine	O
7	and	O
8	number	O
9	of	O
10	cryptosporidia	O
11	per	O
12	ileal	O
13	villus	O
14	on	O
15	different	O
16	DPI	O
17	were	O
18	also	O
19	estimated	O
20	for	O
21	detailed	O
22	characterization	O
23	of	O
24	the	O
25	infection	O
26	in	O
27	kids	O
28	as	O
29	a	O
30	model	O
31	for	O
32	experimental	O
33	cryptosporidiosis	O
34	.	O

0	We	O
1	compared	O
2	the	O
3	inhibitory	O
4	effect	O
5	of	O
6	naturally	O
7	occurring	O
8	mutant	O
9	hTR	I
10	beta	I
11	1	I
12	,	O
13	artificially	O
14	created	O
15	hTR	B
16	alpha	I
17	1	I
18	mutants	I
19	,	O
20	c	B
21	-	I
22	erbA	I
23	alpha	I
24	2	I
25	and	O
26	the	O
27	human	B
28	peroxisome	I
29	proliferator	I
30	-	I
31	activated	I
32	receptor	I
33	(	O
34	hPPAR	B
35	)	O
36	on	O
37	three	O
38	prototypic	O
39	T3	O
40	-	O
41	response	O
42	elements	O
43	(	O
44	TREs	O
45	),	O
46	TRE	O
47	-	O
48	PAL	O
49	,	O
50	DR	O
51	+	O
52	4	O
53	and	O
54	TRE	O
55	-	O
56	LAP	O
57	.	O

0	In	O
1	a	O
2	randomised	O
3	double	O
4	-	O
5	blind	O
6	study	O
7	,	O
8	46	O
9	first	O
10	episode	O
11	schizophrenics	O
12	were	O
13	given	O
14	pimozide	O
15	or	O
16	flupenthixol	O
17	for	O
18	up	O
19	to	O
20	5	O
21	weeks	O
22	;	O
23	the	O
24	mean	O
25	daily	O
26	dose	O
27	at	O
28	the	O
29	end	O
30	was	O
31	18	O
32	.	O
33	8	O
34	mg	O
35	pimozide	O
36	and	O
37	20	O
38	mg	O
39	flupenthixol	O
40	.	O

0	Both	O
1	functional	O
2	analyses	O
3	in	O
4	undifferentiated	O
5	and	O
6	differentiated	O
7	F9	O
8	cells	O
9	and	O
10	characterization	O
11	of	O
12	DNA	O
13	-	O
14	protein	O
15	complexes	O
16	in	O
17	vitro	O
18	have	O
19	identified	O
20	the	O
21	sequence	O
22	motifs	O
23	GTGACT	O
24	(	O
25	C	O
26	),	O
27	ATTGT	O
28	,	O
29	and	O
30	GATA	O
31	as	O
32	the	O
33	key	O
34	transcription	O
35	factor	O
36	binding	O
37	sites	O
38	.	O

0	Apart	O
1	from	O
2	iron	O
3	regulation	O
4	,	O
5	sodA	B
6	expression	O
7	was	O
8	affected	O
9	by	O
10	changes	O
11	in	O
12	DNA	O
13	topology	O
14	induced	O
15	by	O
16	coumermycin	B
17	A	I
18	but	O
19	not	O
20	by	O
21	the	O
22	global	O
23	virulence	O
24	regulatory	O
25	Bvg	B
26	system	O
27	.	O

0	Simple	O
1	reaction	O
2	time	O
3	(	O
4	RT	O
5	)	O
6	to	O
7	a	O
8	peripheral	O
9	visual	O
10	target	O
11	(	O
12	S2	O
13	)	O
14	is	O
15	shortened	O
16	when	O
17	a	O
18	non	O
19	-	O
20	informative	O
21	cue	O
22	(	O
23	S1	O
24	)	O
25	is	O
26	flashed	O
27	at	O
28	the	O
29	S2	O
30	location	O
31	100	O
32	-	O
33	150	O
34	ms	O
35	before	O
36	target	O
37	onset	O
38	(	O
39	early	O
40	facilitation	O
41	).	O

0	The	O
1	Oct	B
2	-	I
3	3	I
4	/	I
5	4	I
6	gene	I
7	product	I
8	,	O
9	which	O
10	belongs	O
11	to	O
12	the	O
13	POU	B
14	family	I
15	of	I
16	transcription	I
17	factors	I
18	,	O
19	is	O
20	a	O
21	good	O
22	candidate	O
23	for	O
24	regulating	O
25	initial	O
26	differentiation	O
27	decisions	O
28	.	O

0	Feed	O
1	intake	O
2	and	O
3	BW	O
4	gains	O
5	were	O
6	decreased	O
7	(	O
8	P	O
9	<	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	dietary	O
16	treatments	O
17	containing	O
18	M	O
19	.	O

0	Cerebral	O
1	flow	O
2	and	O
3	resistance	O
4	showed	O
5	minor	O
6	reductions	O
7	with	O
8	HD	O
9	.	O

0	A	O
1	dose	O
2	-	O
3	dependent	O
4	fall	O
5	in	O
6	GABA	B
7	content	O
8	was	O
9	observed	O
10	;	O
11	GABA	B
12	decrease	O
13	was	O
14	evident	O
15	15	O
16	min	O
17	after	O
18	the	O
19	administration	O
20	,	O
21	reached	O
22	its	O
23	nadir	O
24	at	O
25	60	O
26	min	O
27	and	O
28	disappeared	O
29	at	O
30	120	O
31	minutes	O
32	.	O

0	(	O
1	1988	O
2	)	O
3	J	O
4	.	O

0	Engagement	O
1	of	O
2	human	B
3	CD2	I
4	by	O
5	mitogenic	O
6	pairs	O
7	of	O
8	anti	B
9	-	I
10	CD2	I
11	mAb	I
12	induces	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	a	O
17	number	O
18	of	O
19	intracellular	O
20	proteins	O
21	including	O
22	a	O
23	120	O
24	kDa	O
25	phosphoprotein	O
26	that	O
27	we	O
28	identify	O
29	as	O
30	the	O
31	proto	O
32	-	O
33	oncogene	O
34	c	B
35	-	I
36	Cbl	I
37	.	O

0	Under	O
1	these	O
2	schedules	O
3	,	O
4	a	O
5	reinforced	O
6	response	O
7	run	O
8	consisted	O
9	of	O
10	responding	O
11	between	O
12	eight	O
13	and	O
14	12	O
15	times	O
16	on	O
17	one	O
18	response	O
19	key	O
20	(	O
21	work	O
22	key	O
23	)	O
24	and	O
25	then	O
26	responding	O
27	once	O
28	on	O
29	a	O
30	second	O
31	response	O
32	key	O
33	(	O
34	reinforced	O
35	key	O
36	).	O

0	BIAcore	O
1	analysis	O
2	gave	O
3	a	O
4	Kaff	O
5	of	O
6	4	O
7	.	O
8	4	O
9	x	O
10	10	O
11	(	O
12	10	O
13	)	O
14	M	O
15	-	O
16	1	O
17	for	O
18	the	O
19	binding	O
20	of	O
21	N	O
22	-	O
23	A3	O
24	to	O
25	T84	O
26	.	O
27	1	O
28	and	O
29	2	O
30	.	O
31	2	O
32	x	O
33	10	O
34	(	O
35	10	O
36	)	O
37	M	O
38	-	O
39	1	O
40	for	O
41	the	O
42	binding	O
43	of	O
44	N	O
45	-	O
46	A3	O
47	to	O
48	T84	O
49	.	O
50	66	O
51	.	O

0	Rhesus	O
1	macaques	O
2	and	O
3	BALB	O
4	/	O
5	c	O
6	mice	O
7	inoculated	O
8	with	O
9	the	O
10	Mengo	O
11	virus	O
12	SIV	O
13	recombinants	O
14	failed	O
15	to	O
16	develop	O
17	CTL	O
18	responses	O
19	against	O
20	the	O
21	SIV	B
22	gene	I
23	products	I
24	,	O
25	while	O
26	one	O
27	of	O
28	the	O
29	HIV	O
30	-	O
31	Nef	O
32	recombinants	O
33	induced	O
34	a	O
35	weak	O
36	CTL	O
37	response	O
38	in	O
39	mice	O
40	directed	O
41	to	O
42	an	O
43	HIV1	B
44	Nef	I
45	peptide	I
46	spanning	O
47	positions	O
48	182	O
49	-	O
50	198	O
51	.	O

0	Therefore	O
1	,	O
2	the	O
3	results	O
4	indicate	O
5	that	O
6	repeated	O
7	exposure	O
8	to	O
9	amphetamine	O
10	or	O
11	apomorphine	O
12	overcomes	O
13	the	O
14	context	O
15	-	O
16	dependent	O
17	component	O
18	of	O
19	sensitization	O
20	of	O
21	amphetamine	O
22	-	O
23	or	O
24	apomorphine	O
25	-	O
26	induced	O
27	stereotyped	O
28	behavior	O
29	.	O

0	Malonate	O
1	decarboxylation	O
2	in	O
3	Malonomonas	O
4	rubra	O
5	involves	O
6	the	O
7	formation	O
8	of	O
9	malonyl	B
10	-	I
11	S	I
12	-[	I
13	acyl	I
14	-	I
15	carrier	I
16	protein	I
17	]	O
18	from	O
19	acetyl	B
20	-	I
21	S	I
22	-[	I
23	acyl	I
24	-	I
25	carrier	I
26	protein	I
27	]	O
28	and	O
29	malonate	O
30	,	O
31	carboxyltransfer	O
32	to	O
33	a	O
34	biotin	O
35	protein	O
36	and	O
37	its	O
38	decarboxylation	O
39	that	O
40	is	O
41	coupled	O
42	to	O
43	delta	O
44	mu	O
45	Na	O
46	+	O
47	generation	O
48	.	O

0	No	O
1	TATA	O
2	box	O
3	was	O
4	found	O
5	in	O
6	the	O
7	putative	O
8	promoter	O
9	region	O
10	,	O
11	but	O
12	multiple	O
13	GC	O
14	boxes	O
15	were	O
16	found	O
17	around	O
18	the	O
19	cap	O
20	sites	O
21	,	O
22	supporting	O
23	the	O
24	previously	O
25	inferred	O
26	housekeeping	O
27	nature	O
28	of	O
29	CYP51	B
30	gene	I
31	and	O
32	the	O
33	existence	O
34	of	O
35	the	O
36	multiple	O
37	transcription	O
38	initiation	O
39	sites	O
40	.	O

0	Blood	O
1	pressure	O
2	also	O
3	was	O
4	increased	O
5	by	O
6	lidocaine	O
7	(	O
8	6	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	).	O

0	Clinical	O
1	use	O
2	of	O
3	absorbable	O
4	polyglycolic	O
5	acid	O
6	suture	O
7	in	O
8	Blalock	O
9	-	O
10	Taussig	O
11	'	O
12	s	O
13	operation	O

0	All	O
1	of	O
2	the	O
3	newly	O
4	acquired	O
5	proviruses	O
6	identified	O
7	in	O
8	mosaic	O
9	founder	O
10	SWR	O
11	/	O
12	J	O
13	-	O
14	RF	O
15	/	O
16	J	O
17	mice	O
18	that	O
19	could	O
20	be	O
21	transmitted	O
22	through	O
23	the	O
24	germ	O
25	line	O
26	were	O
27	also	O
28	present	O
29	in	O
30	somatic	O
31	tissues	O
32	,	O
33	demonstrating	O
34	that	O
35	viral	O
36	integration	O
37	occurred	O
38	before	O
39	the	O
40	germ	O
41	line	O
42	was	O
43	set	O
44	aside	O
45	from	O
46	the	O
47	somatic	O
48	lineages	O
49	.	O

0	The	O
1	DNA	O
2	binding	O
3	activities	O
4	of	O
5	the	O
6	three	O
7	repressor	O
8	preparations	O
9	were	O
10	studied	O
11	using	O
12	fragments	O
13	containing	O
14	CIRs	O
15	(	O
16	CIR3	O
17	-	O
18	CIR6	O
19	)	O
20	from	O
21	the	O
22	essential	O
23	early	O
24	region	O
25	as	O
26	templates	O
27	for	O
28	DNase	B
29	I	I
30	footprinting	O
31	.	O

0	In	O
1	the	O
2	same	O
3	period	O
4	we	O
5	pointed	O
6	out	O
7	an	O
8	increase	O
9	of	O
10	hematocrit	O
11	(	O
12	from	O
13	29	O
14	%	O
15	to	O
16	35	O
17	%)	O
18	and	O
19	of	O
20	the	O
21	Hb	B
22	(	O
23	from	O
24	9	O
25	.	O
26	3	O
27	to	O
28	11	O
29	.	O
30	2	O
31	g	O
32	/	O
33	dl	O
34	).	O

0	In	O
1	this	O
2	study	O
3	,	O
4	a	O
5	common	O
6	mechanism	O
7	has	O
8	been	O
9	identified	O
10	to	O
11	coordinate	O
12	the	O
13	growth	O
14	-	O
15	and	O
16	FC	B
17	-	O
18	dependent	O
19	expression	O
20	of	O
21	caveolin	B
22	.	O

0	The	O
1	minimal	O
2	promoter	O
3	of	O
4	the	O
5	RII	B
6	beta	I
7	gene	I
8	was	O
9	composed	O
10	of	O
11	two	O
12	adjacent	O
13	functional	O
14	elements	O
15	.	O

0	IL	B
1	-	I
2	12	I
3	production	O
4	was	O
5	correlated	O
6	with	O
7	C3a	O
8	concentration	O
9	measured	O
10	at	O
11	the	O
12	outlet	O
13	of	O
14	hemodialyzer	O
15	after	O
16	15	O
17	min	O
18	of	O
19	dialysis	O
20	(	O
21	r	O
22	=	O
23	0	O
24	.	O
25	69	O
26	,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	01	O
32	).	O

0	Cyclic	B
1	AMP	I
2	-	I
3	dependent	I
4	protein	I
5	kinase	I
6	binding	O
7	to	O
8	A	B
9	-	I
10	kinase	I
11	anchoring	I
12	proteins	I
13	in	O
14	living	O
15	cells	O
16	by	O
17	fluorescence	O
18	resonance	O
19	energy	O
20	transfer	O
21	of	O
22	green	B
23	fluorescent	I
24	protein	I
25	fusion	I
26	proteins	I
27	.	O

0	55	O
1	+/-	O
2	11	O
3	%),	O
4	all	O
5	other	O
6	parameters	O
7	showed	O
8	a	O
9	significant	O
10	increase	O
11	:	O
12	RS	O
13	index	O
14	5	O
15	.	O
16	4	O
17	+/-	O
18	1	O
19	.	O
20	4	O
21	mVolt	O
22	to	O
23	6	O
24	.	O
25	0	O
26	+/-	O
27	1	O
28	.	O
29	7	O
30	mVolt	O
31	(	O
32	p	O
33	less	O
34	than	O
35	0	O
36	.	O
37	01	O
38	);	O
39	EDD	O
40	6	O
41	.	O
42	3	O
43	+/-	O
44	0	O
45	.	O
46	7	O
47	to	O
48	6	O
49	.	O
50	8	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	cm	O
56	(	O
57	p	O
58	less	O
59	than	O
60	0	O
61	.	O
62	001	O
63	);	O
64	HV	O
65	1017	O
66	+/-	O
67	151	O
68	ml	O
69	to	O
70	1099	O
71	+/-	O
72	261	O
73	ml	O
74	(	O
75	p	O
76	less	O
77	than	O
78	0	O
79	.	O
80	01	O
81	);	O
82	EDV	O
83	371	O
84	+/-	O
85	131	O
86	ml	O
87	to	O
88	441	O
89	+/-	O
90	175	O
91	ml	O
92	(	O
93	p	O
94	less	O
95	than	O
96	0	O
97	.	O
98	001	O
99	);	O
100	RBV	O
101	117	O
102	+/-	O
103	57	O
104	ml	O
105	to	O
106	151	O
107	+/-	O
108	77	O
109	ml	O
110	(	O
111	p	O
112	less	O
113	than	O
114	0	O
115	.	O
116	001	O
117	).	O

0	An	O
1	automated	O
2	method	O
3	for	O
4	the	O
5	quantitative	O
6	analysis	O
7	of	O
8	the	O
9	polyamines	O
10	putrescine	O
11	,	O
12	spermidine	O
13	and	O
14	spermine	O
15	in	O
16	cerebrospinal	O
17	fluid	O
18	(	O
19	CSF	O
20	)	O
21	was	O
22	used	O
23	to	O
24	analyze	O
25	CSF	B
26	samples	O
27	from	O
28	37	O
29	patients	O
30	with	O
31	central	O
32	nervous	O
33	system	O
34	(	O
35	CNS	O
36	)	O
37	tumors	O
38	and	O
39	from	O
40	13	O
41	patients	O
42	without	O
43	tumors	O
44	.	O

0	To	O
1	understand	O
2	the	O
3	basis	O
4	for	O
5	the	O
6	increased	O
7	cell	O
8	surface	O
9	stability	O
10	compared	O
11	with	O
12	wild	O
13	-	O
14	type	O
15	peptide	O
16	and	O
17	to	O
18	understand	O
19	the	O
20	differences	O
21	in	O
22	T	O
23	cell	O
24	recognition	O
25	between	O
26	I1Y	B
27	and	O
28	I1F	B
29	,	O
30	we	O
31	determined	O
32	the	O
33	x	O
34	-	O
35	ray	O
36	crystal	O
37	structures	O
38	of	O
39	the	O
40	two	O
41	class	O
42	I	O
43	MHC	B
44	-	I
45	peptide	I
46	complexes	I
47	.	O

0	In	O
1	1993	O
2	and	O
3	1994	O
4	and	O
5	infection	O
6	with	O
7	body	O
8	lice	O
9	was	O
10	registered	O
11	41	O
12	times	O
13	in	O
14	31	O
15	patients	O
16	at	O
17	the	O
18	clinic	O
19	for	O
20	homeless	O
21	of	O
22	the	O
23	Community	O
24	Health	O
25	Service	O
26	of	O
27	Utrecht	O
28	.	O

0	Mutational	O
1	analysis	O
2	of	O
3	mRNA	B
4	capping	I
5	enzyme	I
6	identifies	O
7	amino	O
8	acids	O
9	involved	O
10	in	O
11	GTP	O
12	binding	O
13	,	O
14	enzyme	O
15	-	O
16	guanylate	O
17	formation	O
18	,	O
19	and	O
20	GMP	O
21	transfer	O
22	to	O
23	RNA	O
24	.	O

0	The	O
1	present	O
2	research	O
3	evaluated	O
4	the	O
5	possibility	O
6	that	O
7	polyethylene	O
8	glycol	O
9	400	O
10	(	O
11	PEG	O
12	400	O
13	)	O
14	might	O
15	be	O
16	efficacious	O
17	,	O
18	toxic	O
19	,	O
20	or	O
21	both	O
22	.	O

0	Sequence	O
1	comparison	O
2	of	O
3	the	O
4	0	O
5	.	O
6	38	O
7	kb	O
8	promoter	O
9	sequence	O
10	with	O
11	the	O
12	promoters	O
13	of	O
14	the	O
15	Sm	B
16	-	I
17	E	I
18	gene	I
19	and	O
20	U1	B
21	snRNA	I
22	genes	I
23	revealed	O
24	several	O
25	homologous	O
26	motifs	O
27	,	O
28	suggesting	O
29	that	O
30	genes	O
31	encoding	O
32	the	O
33	snRNP	O
34	components	O
35	may	O
36	be	O
37	coordinately	O
38	regulated	O
39	.	O

0	Both	O
1	can	O
2	be	O
3	elevated	O
4	on	O
5	a	O
6	single	O
7	vascular	O
8	pedicle	O
9	based	O
10	on	O
11	the	O
12	superficial	O
13	temporal	O
14	artery	O
15	,	O
16	the	O
17	double	O
18	-	O
19	layered	O
20	temporal	O
21	fascia	O
22	flap	O
23	.	O

0	LCBF	O
1	in	O
2	normal	O
3	and	O
4	hypoxic	O
5	puppies	O
6	was	O
7	correlated	O
8	with	O
9	local	O
10	cerebral	O
11	glucose	O
12	utilization	O
13	(	O
14	LCGU	O
15	)	O
16	obtained	O
17	under	O
18	the	O
19	same	O
20	experimental	O
21	conditions	O
22	(	O
23	Duffy	O
24	et	O
25	al	O
26	,	O
27	1982	O
28	).	O

0	The	O
1	C	O
2	-	O
3	terminal	O
4	end	O
5	of	O
6	this	O
7	polypeptide	O
8	harbors	O
9	three	O
10	types	O
11	of	O
12	repeated	O
13	sequences	O
14	.	O

0	A	O
1	cDNA	O
2	library	O
3	of	O
4	tumour	O
5	cells	O
6	was	O
7	screened	O
8	with	O
9	an	O
10	interleukin	B
11	2	I
12	gene	I
13	-	O
14	specific	O
15	probe	O
16	.	O

0	This	O
1	E	O
2	box	O
3	sequence	O
4	(	O
5	CACGTG	O
6	)	O
7	is	O
8	identical	O
9	to	O
10	the	O
11	binding	O
12	element	O
13	for	O
14	USF	B
15	(	O
16	upstream	B
17	stimulatory	I
18	factor	I
19	),	O
20	a	O
21	member	O
22	of	O
23	the	O
24	helix	B
25	-	I
26	loop	I
27	-	I
28	helix	I
29	family	I
30	of	O
31	transcription	O
32	factors	O
33	.	O

0	When	O
1	a	O
2	tumour	O
3	is	O
4	present	O
5	nipple	O
6	discharge	O
7	is	O
8	of	O
9	little	O
10	importance	O
11	for	O
12	the	O
13	diagnosis	O
14	and	O
15	treatment	O
16	.	O

0	Clinical	O
1	and	O
2	haematological	O
3	signs	O
4	are	O
5	not	O
6	specific	O
7	in	O
8	this	O
9	setting	O
10	,	O
11	and	O
12	the	O
13	diagnosis	O
14	relies	O
15	on	O
16	histological	O
17	features	O
18	,	O
19	mainly	O
20	bone	O
21	marrow	O
22	examination	O
23	.	O

0	Electronic	O
1	data	O
2	processing	O
3	(	O
4	EDP	O
5	)	O
6	latex	O
7	immunoassay	O
8	using	O
9	anti	B
10	-	I
11	human	I
12	seminal	I
13	acid	I
14	phosphatase	I
15	(	O
16	anti	B
17	-	I
18	HSAP	I
19	)	O
20	immune	O
21	serum	O
22	was	O
23	applied	O
24	for	O
25	the	O
26	species	O
27	and	O
28	organ	O
29	identification	O
30	of	O
31	human	O
32	seminal	O
33	stains	O
34	.	O

0	Zebrafish	O
1	cyclops	O
2	(	O
3	cyc	B
4	)	O
5	encodes	O
6	a	O
7	Transforming	B
8	Growth	I
9	Factor	I
10	beta	I
11	(	O
12	TGFbeta	B
13	)	O
14	signaling	O
15	factor	O
16	closely	O
17	related	O
18	to	O
19	mouse	B
20	Nodal	I
21	.	O

0	Furthermore	O
1	,	O
2	Zelen	O
3	'	O
4	s	O
5	method	O
6	is	O
7	used	O
8	to	O
9	balance	O
10	the	O
11	number	O
12	of	O
13	patients	O
14	allocated	O
15	to	O
16	the	O
17	two	O
18	groups	O
19	within	O
20	each	O
21	institution	O
22	(	O
23	M	O
24	.	O

0	Congruent	O
1	with	O
2	empirical	O
3	predictions	O
4	,	O
5	the	O
6	most	O
7	homesick	O
8	children	O
9	perceived	O
10	low	O
11	control	O
12	over	O
13	homesickness	O
14	and	O
15	separation	O
16	,	O
17	and	O
18	coped	O
19	by	O
20	relinquishing	O
21	control	O
22	.	O

0	We	O
1	studied	O
2	the	O
3	role	O
4	of	O
5	prostaglandins	O
6	in	O
7	acid	O
8	-	O
9	induced	O
10	esophagitis	O
11	and	O
12	the	O
13	associated	O
14	LES	O
15	hypotension	O
16	by	O
17	simultaneous	O
18	treatment	O
19	of	O
20	some	O
21	animals	O
22	with	O
23	indomethacin	O
24	(	O
25	150	O
26	micrograms	O
27	/	O
28	kg	O
29	intravenous	O
30	),	O
31	a	O
32	specific	O
33	inhibitor	O
34	of	O
35	prostaglandin	O
36	synthesis	O
37	,	O
38	either	O
39	during	O
40	production	O
41	of	O
42	esophagitis	O
43	or	O
44	during	O
45	recovery	O
46	.	O

0	Asymptomatic	O
1	bacteriospermia	O
2	and	O
3	fertility	O

0	This	O
1	suggests	O
2	that	O
3	mechanisms	O
4	other	O
5	than	O
6	an	O
7	excessive	O
8	increase	O
9	in	O
10	myocardial	O
11	oxygen	O
12	demand	O
13	may	O
14	be	O
15	responsible	O
16	for	O
17	the	O
18	many	O
19	episodes	O
20	occurring	O
21	outside	O
22	the	O
23	hospital	O
24	.	O

0	Deaths	O
1	stopped	O
2	11	O
3	hours	O
4	after	O
5	copper	O
6	concentrations	O
7	decreased	O
8	below	O
9	0	O
10	.	O
11	2	O
12	ppm	O
13	and	O
14	signs	O
15	of	O
16	distress	O
17	stopped	O
18	in	O
19	surviving	O
20	pinfish	O
21	by	O
22	approximately	O
23	6	O
24	hours	O
25	after	O
26	the	O
27	last	O
28	death	O
29	.	O

0	The	O
1	pyrR	B
2	and	O
3	pyrP	B
4	genes	I
5	encoded	O
6	polypeptides	O
7	with	O
8	calculated	O
9	molecular	O
10	masses	O
11	of	O
12	19	O
13	.	O
14	9	O
15	and	O
16	45	O
17	.	O
18	2	O
19	kDa	O
20	,	O
21	respectively	O
22	.	O

0	Interleukin	B
1	-	I
2	12	I
3	(	O
4	IL	B
5	-	I
6	12	I
7	)	O
8	is	O
9	a	O
10	cytokine	O
11	produced	O
12	by	O
13	peripheral	O
14	blood	O
15	mononuclear	O
16	cells	O
17	(	O
18	PBMC	O
19	)	O
20	that	O
21	causes	O
22	interferon	B
23	-	I
24	gamma	I
25	(	O
26	IFN	B
27	-	I
28	gamma	I
29	)	O
30	production	O
31	and	O
32	enhancement	O
33	of	O
34	cell	O
35	-	O
36	mediated	O
37	cytotoxicity	O
38	.	O

0	When	O
1	introduced	O
2	into	O
3	recJ	B
4	+	I
5	strains	O
6	,	O
7	srjA	B
8	mutations	I
9	conferred	O
10	hyperrecombinational	O
11	and	O
12	hyper	O
13	-	O
14	UVr	O
15	phenotypes	O
16	.	O

0	Human	O
1	antitetanus	O
2	serum	O
3	:	O
4	an	O
5	unused	O
6	wealth	O

0	In	O
1	sixteen	O
2	patients	O
3	with	O
4	moderate	O
5	essential	O
6	hypertension	O
7	the	O
8	effects	O
9	of	O
10	10	O
11	-	O
12	day	O
13	nifedipine	O
14	treatment	O
15	on	O
16	serum	O
17	uric	O
18	acid	O
19	and	O
20	renal	O
21	excretion	O
22	of	O
23	uric	O
24	acid	O
25	were	O
26	evaluated	O
27	.	O

0	The	O
1	mRNAs	O
2	of	O
3	these	O
4	genes	O
5	contain	O
6	respectively	O
7	one	O
8	(	O
9	YAP1	B
10	uORF	I
11	)	O
12	and	O
13	two	O
14	(	O
15	YAP2	B
16	uORF1	I
17	and	O
18	uORF2	B
19	)	O
20	upstream	O
21	open	O
22	reading	O
23	frames	O
24	.	O
25	uORF	B
26	-	O
27	mediated	O
28	modulation	O
29	of	O
30	post	O
31	-	O
32	termination	O
33	events	O
34	on	O
35	the	O
36	5	O
37	'-	O
38	untranslated	O
39	region	O
40	(	O
41	5	O
42	'-	O
43	UTR	O
44	)	O
45	directs	O
46	differential	O
47	control	O
48	not	O
49	only	O
50	of	O
51	translation	O
52	but	O
53	also	O
54	of	O
55	mRNA	O
56	decay	O
57	.	O

0	In	O
1	11	O
2	patients	O
3	with	O
4	Horton	O
5	'	O
6	s	O
7	headache	O
8	morphological	O
9	investigations	O
10	(	O
11	differential	O
12	white	O
13	blood	O
14	cell	O
15	count	O
16	),	O
17	cytoenzymatic	O
18	determinations	O
19	(	O
20	alkaline	B
21	and	I
22	acid	I
23	phosphatase	I
24	,	O
25	non	B
26	-	I
27	specific	I
28	esterase	I
29	)	O
30	and	O
31	cytoimmunological	O
32	tests	O
33	(	O
34	IgM	B
35	and	O
36	IgG	B
37	binding	O
38	)	O
39	were	O
40	carried	O
41	out	O
42	on	O
43	capillary	O
44	blood	O
45	neutrophils	O
46	obtained	O
47	from	O
48	the	O
49	area	O
50	of	O
51	pain	O
52	,	O
53	non	O
54	-	O
55	painful	O
56	area	O
57	of	O
58	the	O
59	skin	O
60	on	O
61	the	O
62	head	O
63	on	O
64	the	O
65	contralateral	O
66	side	O
67	,	O
68	and	O
69	from	O
70	the	O
71	finger	O
72	.	O

0	They	O
1	also	O
2	negatively	O
3	modulate	O
4	the	O
5	PI	B
6	3	I
7	-	I
8	kinase	I
9	catalytic	O
10	activity	O
11	but	O
12	to	O
13	different	O
14	extents	O
15	,	O
16	dependent	O
17	on	O
18	the	O
19	unique	O
20	N	O
21	-	O
22	terminal	O
23	structure	O
24	of	O
25	each	O
26	isoform	O
27	.	O

0	Our	O
1	results	O
2	concluded	O
3	that	O
4	1	O
5	)	O
6	the	O
7	two	O
8	inhibin	B
9	/	O
10	activin	B
11	beta	I
12	B	I
13	-	I
14	subunit	I
15	mRNAs	I
16	were	O
17	transcribed	O
18	from	O
19	different	O
20	initiation	O
21	sites	O
22	;	O
23	2	O
24	)	O
25	both	O
26	promoters	O
27	may	O
28	be	O
29	controlled	O
30	by	O
31	up	O
32	-	O
33	stream	O
34	negative	O
35	regulatory	O
36	elements	O
37	;	O
38	and	O
39	3	O
40	)	O
41	neither	O
42	of	O
43	these	O
44	promoters	O
45	is	O
46	responsive	O
47	to	O
48	cAMP	O
49	and	O
50	/	O
51	or	O
52	phorbol	O
53	esters	O
54	under	O
55	the	O
56	conditions	O
57	employed	O
58	.	O

0	Protein	O
1	splicing	O
2	:	O
3	evidence	O
4	for	O
5	an	O
6	N	O
7	-	O
8	O	O
9	acyl	O
10	rearrangement	O
11	as	O
12	the	O
13	initial	O
14	step	O
15	in	O
16	the	O
17	splicing	O
18	process	O
19	.	O

0	This	O
1	report	O
2	describes	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	gene	O
8	of	O
9	related	O
10	function	O
11	,	O
12	SMD1	B
13	,	O
14	located	O
15	immediately	O
16	3	O
17	'	O
18	to	O
19	PRP38	B
20	.	O

0	The	O
1	PAC	B
2	clone	O
3	with	O
4	an	O
5	insert	O
6	size	O
7	of	O
8	120kb	O
9	was	O
10	isolated	O
11	and	O
12	mapped	O
13	by	O
14	restriction	O
15	analysis	O
16	.	O

0	Lysine	B
1	-	I
2	ketoglutarate	I
3	reductase	I
4	and	O
5	saccharopine	B
6	dehydrogenase	I
7	from	O
8	Arabidopsis	O
9	thaliana	O
10	:	O
11	nucleotide	O
12	sequence	O
13	and	O
14	characterization	O
15	.	O

0	The	O
1	5	O
2	'	O
3	end	O
4	of	O
5	the	O
6	coding	O
7	region	O
8	was	O
9	located	O
10	precisely	O
11	by	O
12	comparing	O
13	the	O
14	deduced	O
15	amino	O
16	acid	O
17	sequence	O
18	to	O
19	the	O
20	actual	O
21	N	O
22	-	O
23	terminal	O
24	amino	O
25	acid	O
26	sequence	O
27	of	O
28	IHF	B
29	.	O

0	A	O
1	cause	O
2	of	O
3	increase	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	in	O
8	children	O

0	Twelve	O
1	genomic	O
2	fragments	O
3	containing	O
4	novel	O
5	response	O
6	elements	O
7	are	O
8	described	O
9	,	O
10	and	O
11	the	O
12	transcription	O
13	unit	O
14	associated	O
15	with	O
16	one	O
17	of	O
18	them	O
19	,	O
20	NN	O
21	-	O
22	84AG	O
23	,	O
24	was	O
25	characterized	O
26	in	O
27	detail	O
28	.	O

0	Cloning	O
1	by	O
2	complementation	O
3	and	O
4	subsequent	O
5	physical	O
6	and	O
7	genetic	O
8	analysis	O
9	revealed	O
10	that	O
11	it	O
12	maps	O
13	to	O
14	RAF1	O
15	.	O

0	Location	O
1	and	O
2	orientation	O
3	of	O
4	an	O
5	activating	O
6	region	O
7	in	O
8	the	O
9	Escherichia	B
10	coli	I
11	transcription	I
12	factor	I
13	,	O
14	FNR	B
15	.	O

0	The	O
1	sequences	O
2	following	O
3	the	O
4	X	O
5	.	O
6	borealis	O
7	oocyte	O
8	and	O
9	somatic	B
10	5S	I
11	genes	I
12	are	O
13	identical	O
14	in	O
15	12	O
16	of	O
17	the	O
18	first	O
19	14	O
20	residues	O
21	and	O
22	contain	O
23	two	O
24	or	O
25	more	O
26	T	O
27	clusters	O
28	,	O
29	as	O
30	does	O
31	the	O
32	corresponding	O
33	region	O
34	of	O
35	X	O
36	.	O
37	laevis	O
38	oocyte	O
39	5S	O
40	DNA	O
41	.	O

0	These	O
1	data	O
2	strongly	O
3	implicate	O
4	the	O
5	normal	O
6	product	O
7	of	O
8	the	O
9	int	B
10	-	I
11	2	I
12	gene	I
13	,	O
14	which	O
15	is	O
16	related	O
17	to	O
18	the	O
19	fibroblast	B
20	growth	I
21	factor	I
22	family	I
23	,	O
24	as	O
25	a	O
26	contributory	O
27	factor	O
28	in	O
29	virally	O
30	induced	O
31	mammary	O
32	tumors	O
33	.	O

0	The	O
1	MCA	O
2	and	O
3	UA	O
4	PI	O
5	values	O
6	showed	O
7	the	O
8	greatest	O
9	deviation	O
10	for	O
11	any	O
12	single	O
13	-	O
14	vessel	O
15	parameter	O
16	.	O

0	Ste18p	B
1	was	O
2	targeted	O
3	to	O
4	the	O
5	plasma	O
6	membrane	O
7	even	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	prenylation	O
13	or	O
14	thioacylation	O
15	.	O

0	Regarding	O
1	"	O
2	the	O
3	relation	O
4	between	O
5	sexual	O
6	orientation	O
7	and	O
8	penile	O
9	size	O
10	,"	O
11	by	O
12	A	O
13	.	O

0	The	O
1	potency	O
2	of	O
3	the	O
4	effect	O
5	of	O
6	Nim	O
7	(	O
8	0	O
9	.	O
10	5	O
11	mg	O
12	.	O
13	kg	O
14	-	O
15	1	O
16	i	O
17	.	O
18	p	O
19	.)	O
20	was	O
21	similar	O
22	to	O
23	that	O
24	of	O
25	NBP	O
26	(	O
27	10	O
28	mg	O
29	.	O
30	kg	O
31	-	O
32	1	O
33	i	O
34	.	O
35	p	O
36	.).	O

0	Abundant	O
1	infiltration	O
2	of	O
3	lymphocytes	O
4	and	O
5	plasma	O
6	cells	O
7	was	O
8	also	O
9	wide	O
10	-	O
11	spread	O
12	beneath	O
13	the	O
14	carcinoma	O
15	in	O
16	situ	O
17	,	O
18	together	O
19	with	O
20	the	O
21	lymphoid	O
22	follicles	O
23	.	O

0	Further	O
1	investigation	O
2	on	O
3	the	O
4	chemotactic	O
5	influence	O
6	of	O
7	thymic	B
8	hormone	I
9	on	O
10	lymphocytes	O

0	1	O
1	.	O

0	However	O
1	,	O
2	the	O
3	BCH	O
4	group	O
5	showed	O
6	inferior	O
7	gross	O
8	motor	O
9	performance	O
10	on	O
11	the	O
12	Bruininks	O
13	-	O
14	Oseretsky	O
15	Test	O
16	of	O
17	Motor	O
18	Proficiency	O
19	(	O
20	Bruininks	O
21	1978	O
22	).	O

0	PATIENTS	O
1	AND	O
2	METHODS	O
3	:	O
4	In	O
5	807	O
6	consecutive	O
7	patients	O
8	from	O
9	the	O
10	Chilean	O
11	National	O
12	Registry	O
13	of	O
14	Acute	O
15	Myocardial	O
16	Infarction	O
17	we	O
18	analyzed	O
19	the	O
20	resolution	O
21	of	O
22	chest	O
23	pain	O
24	and	O
25	ST	O
26	segment	O
27	elevation	O
28	over	O
29	50	O
30	%	O
31	within	O
32	the	O
33	first	O
34	90	O
35	min	O
36	,	O
37	abrupt	O
38	CK	B
39	rise	O
40	within	O
41	8	O
42	h	O
43	and	O
44	T	O
45	wave	O
46	inversion	O
47	in	O
48	infarct	O
49	related	O
50	EKG	O
51	leads	O
52	within	O
53	the	O
54	first	O
55	24	O
56	h	O
57	after	O
58	thrombolysis	O
59	.	O

0	However	O
1	,	O
2	it	O
3	is	O
4	not	O
5	known	O
6	whether	O
7	the	O
8	recently	O
9	identified	O
10	isoforms	O
11	Vav2	B
12	and	O
13	Vav3	B
14	,	O
15	which	O
16	are	O
17	broadly	O
18	expressed	O
19	,	O
20	can	O
21	couple	O
22	with	O
23	similar	O
24	classes	O
25	of	O
26	receptors	O
27	,	O
28	nor	O
29	is	O
30	it	O
31	known	O
32	whether	O
33	all	O
34	Vav	B
35	isoforms	I
36	possess	O
37	identical	O
38	functional	O
39	activities	O
40	.	O

0	The	O
1	gene	O
2	encodes	O
3	an	O
4	ATP	B
5	-	I
6	binding	I
7	cassette	I
8	,	O
9	ABC	B
10	transporter	I
11	.	O

0	Furthermore	O
1	,	O
2	45Ca	O
3	-	O
4	binding	O
5	assays	O
6	revealed	O
7	that	O
8	CCaMK	B
9	directly	O
10	binds	O
11	Ca2	O
12	+.	O

0	Patients	O
1	with	O
2	lesions	O
3	affecting	O
4	the	O
5	PRC	O
6	but	O
7	sparing	O
8	the	O
9	PHC	O
10	,	O
11	and	O
12	patients	O
13	with	O
14	lesions	O
15	affecting	O
16	both	O
17	PRC	O
18	and	O
19	PHC	O
20	,	O
21	performed	O
22	an	O
23	oculomotor	O
24	delayed	O
25	response	O
26	task	O
27	with	O
28	unpredictably	O
29	varied	O
30	memory	O
31	delays	O
32	of	O
33	up	O
34	to	O
35	30	O
36	s	O
37	.	O

0	Thus	O
1	,	O
2	Fis	B
3	acts	O
4	as	O
5	an	O
6	accessory	O
7	transcriptional	O
8	activator	O
9	at	O
10	the	O
11	mar	B
12	promoter	I
13	.	O

0	One	O
1	cDNA	O
2	clone	O
3	designated	O
4	NCoA	B
5	-	I
6	62	I
7	,	O
8	encoded	O
9	a	O
10	62	O
11	,	O
12	000	O
13	-	O
14	Da	O
15	protein	O
16	that	O
17	is	O
18	highly	O
19	related	O
20	to	O
21	BX42	B
22	,	O
23	a	O
24	Drosophila	O
25	melanogaster	O
26	nuclear	O
27	protein	O
28	involved	O
29	in	O
30	ecdysone	O
31	-	O
32	stimulated	O
33	gene	O
34	expression	O
35	.	O

0	50	O
1	kDa	O
2	and	O
3	130	O
4	-	O
5	170	O
6	kDa	O
7	were	O
8	detected	O
9	.	O

0	The	O
1	ARG	B
2	SH2	I
3	domain	I
4	exhibited	O
5	relatively	O
6	weak	O
7	affinity	O
8	for	O
9	BCR	B
10	and	O
11	was	O
12	determined	O
13	to	O
14	bind	O
15	about	O
16	10	O
17	-	O
18	fold	O
19	less	O
20	strongly	O
21	than	O
22	the	O
23	ABL	B
24	SH2	I
25	domain	I
26	.	O

0	The	O
1	article	O
2	deals	O
3	with	O
4	the	O
5	diagnosing	O
6	and	O
7	correction	O
8	of	O
9	reversible	O
10	ischemia	O
11	of	O
12	the	O
13	intestine	O
14	.	O

0	Nutritional	O
1	cataracts	O
2	in	O
3	timber	O
4	wolves	O
5	.	O

0	Molecular	O
1	analysis	O
2	of	O
3	a	O
4	novel	O
5	schizosaccharomyces	O
6	pombe	O
7	gene	O
8	containing	O
9	two	O
10	RNP	O
11	consensus	O
12	-	O
13	sequence	O
14	RNA	O
15	-	O
16	binding	O
17	domains	O
18	.	O

0	Whole	O
1	blood	O
2	serotonin	O
3	levels	O
4	were	O
5	investigated	O
6	in	O
7	a	O
8	control	O
9	group	O
10	(	O
11	n	O
12	=	O
13	35	O
14	)	O
15	and	O
16	in	O
17	a	O
18	group	O
19	of	O
20	chronic	O
21	renal	O
22	failure	O
23	patients	O
24	(	O
25	n	O
26	=	O
27	127	O
28	)	O
29	on	O
30	various	O
31	treatment	O
32	regimen	O
33	i	O
34	.	O
35	e	O
36	.	O
37	conservative	O
38	treatment	O
39	(	O
40	n	O
41	=	O
42	39	O
43	),	O
44	maintenance	O
45	haemodialysis	O
46	(	O
47	n	O
48	=	O
49	35	O
50	)	O
51	and	O
52	after	O
53	renal	O
54	transplantation	O
55	(	O
56	n	O
57	=	O
58	53	O
59	).	O

0	Sequence	O
1	analysis	O
2	of	O
3	a	O
4	6	O
5	.	O
6	3	O
7	-	O
8	kbp	O
9	genomic	O
10	EcoRI	B
11	-	I
12	fragment	I
13	of	I
14	Alcaligenes	I
15	eutrophus	I
16	,	O
17	which	O
18	was	O
19	recently	O
20	identified	O
21	by	O
22	using	O
23	a	O
24	dihydrolipoamide	B
25	dehydrogenase	I
26	-	O
27	specific	O
28	DNA	O
29	probe	O
30	(	O
31	A	O
32	.	O

0	PCR	O
1	-	O
2	derived	O
3	fragments	O
4	were	O
5	used	O
6	as	O
7	probes	O
8	for	O
9	the	O
10	isolation	O
11	of	O
12	the	O
13	U3	B
14	snRNA	I
15	genes	I
16	from	O
17	a	O
18	genomic	O
19	library	O
20	of	O
21	Arabidopsis	O
22	.	O

0	In	O
1	Saccharomyces	O
2	cerevisiae	O
3	the	O
4	cAMP	B
5	-	I
6	dependent	I
7	kinases	I
8	(	O
9	PKAs	B
10	)	O
11	promote	O
12	cytoplasmic	O
13	growth	O
14	and	O
15	modulate	O
16	the	O
17	growth	O
18	-	O
19	regulated	O
20	mechanism	O
21	triggering	O
22	the	O
23	begin	O
24	of	O
25	DNA	O
26	synthesis	O
27	.	O

0	He	O
1	visited	O
2	our	O
3	hospital	O
4	and	O
5	left	O
6	solitary	O
7	renal	O
8	cyst	O
9	was	O
10	suspected	O
11	.	O

0	Each	O
1	half	O
2	molecule	O
3	contains	O
4	four	O
5	disulfide	O
6	linkages	O
7	and	O
8	four	O
9	cis	O
10	peptides	O
11	.	O

0	Identification	O
1	of	O
2	Ste4	B
3	as	O
4	a	O
5	potential	O
6	regulator	O
7	of	O
8	Byr2	B
9	in	O
10	the	O
11	sexual	O
12	response	O
13	pathway	O
14	of	O
15	Schizosaccharomyces	O
16	pombe	O
17	.	O

0	S1	B
1	nuclease	I
2	analysis	O
3	of	O
4	RNA	O
5	from	O
6	chemically	O
7	induced	O
8	B95	O
9	-	O
10	8	O
11	cells	O
12	and	O
13	from	O
14	Vero	O
15	cells	O
16	cotransfected	O
17	with	O
18	NotI	B
19	repeat	I
20	promoter	I
21	-	O
22	CAT	B
23	and	O
24	Z	B
25	showed	O
26	that	O
27	Z	B
28	transactivation	O
29	increased	O
30	the	O
31	level	O
32	of	O
33	correctly	O
34	initiated	O
35	,	O
36	stable	O
37	RNA	O
38	transcripts	O
39	.	O

0	Abrogation	O
1	of	O
2	p53	B
3	function	O
4	by	O
5	E6	B
6	resulted	O
7	in	O
8	an	O
9	increase	O
10	in	O
11	the	O
12	spontaneous	O
13	mutation	O
14	frequencies	O
15	at	O
16	the	O
17	heterozygous	B
18	thymidine	B
19	kinase	I
20	(	O
21	TK	B
22	)	O
23	locus	O
24	but	O
25	not	O
26	at	O
27	the	O
28	hemizygous	O
29	hypoxanthine	B
30	phosphoribosyl	I
31	transferase	I
32	(	O
33	HPRT	B
34	)	O
35	locus	O
36	.	O

0	Intron	B
1	K1	I
2	cox1	I
3	.	I
4	2	I
5	is	O
6	not	O
7	found	O
8	in	O
9	S	O
10	.	O
11	cerevisiae	O
12	and	O
13	appears	O
14	at	O
15	an	O
16	unique	O
17	location	O
18	in	O
19	K	O
20	.	O
21	lactis	O
22	.	O

0	Clinical	O
1	aspects	O
2	of	O
3	early	O
4	increase	O
5	in	O
6	serum	B
7	gamma	I
8	-	I
9	glutamyl	I
10	transferase	I
11	in	O
12	cerebral	O
13	infarction	O
14	.	O

0	This	O
1	site	O
2	is	O
3	upstream	O
4	from	O
5	the	O
6	TATA	O
7	box	O
8	used	O
9	in	O
10	somatic	O
11	cells	O
12	.	O

0	Auditory	O
1	threshold	O
2	shifts	O
3	,	O
4	as	O
5	measured	O
6	by	O
7	the	O
8	auditory	O
9	evoked	O
10	brainstem	O
11	response	O
12	,	O
13	were	O
14	measured	O
15	at	O
16	2	O
17	,	O
18	4	O
19	,	O
20	8	O
21	,	O
22	12	O
23	,	O
24	16	O
25	,	O
26	20	O
27	and	O
28	24	O
29	kHz	O
30	.	O

0	Biol	O
1	.	O

0	After	O
1	nitric	O
2	oxide	O
3	inhalation	O
4	,	O
5	the	O
6	results	O
7	showed	O
8	moderate	O
9	increases	O
10	in	O
11	PaO2	O
12	and	O
13	SaO2	O
14	(	O
15	P	O
16	>	O
17	0	O
18	.	O
19	05	O
20	)	O
21	and	O
22	a	O
23	significant	O
24	decrease	O
25	in	O
26	Qs	O
27	/	O
28	Q	O
29	tau	O
30	ratio	O
31	(	O
32	P	O
33	<	O
34	0	O
35	.	O
36	01	O
37	).	O

0	Oleate	O
1	induced	O
2	steady	O
3	-	O
4	state	O
5	levels	O
6	of	O
7	M	B
8	-	I
9	CPT	I
10	I	I
11	mRNA	I
12	4	O
13	.	O
14	5	O
15	-	O
16	fold	O
17	.	O

0	A	O
1	newly	O
2	developed	O
3	broad	O
4	-	O
5	spectrum	O
6	fluoroquinolone	O
7	,	O
8	levofloxacin	O
9	(	O
10	LVFX	O
11	,	O
12	DR	O
13	-	O
14	3355	O
15	),	O
16	was	O
17	evaluated	O
18	in	O
19	vitro	O
20	and	O
21	in	O
22	vivo	O
23	in	O
24	comparison	O
25	with	O
26	ciprofloxacin	O
27	(	O
28	CPFX	O
29	),	O
30	ofloxacin	O
31	(	O
32	OFLX	O
33	)	O
34	and	O
35	norfloxacin	O
36	(	O
37	NFLX	O
38	).	O

0	Also	O
1	,	O
2	samples	O
3	of	O
4	serum	O
5	were	O
6	absorbed	O
7	with	O
8	the	O
9	various	O
10	solid	O
11	-	O
12	phase	O
13	allergens	O
14	and	O
15	the	O
16	reactivity	O
17	of	O
18	the	O
19	remaining	O
20	IgE	B
21	antibodies	I
22	was	O
23	determined	O
24	.	O

0	We	O
1	describe	O
2	a	O
3	case	O
4	of	O
5	a	O
6	perinephric	O
7	abscess	O
8	treated	O
9	with	O
10	amphotericin	O
11	B	O
12	and	O
13	nephrectomy	O
14	.	O

0	Thus	O
1	,	O
2	SPECT	O
3	was	O
4	not	O
5	as	O
6	sensitive	O
7	as	O
8	PET	O
9	in	O
10	this	O
11	activation	O
12	task	O
13	.	O

0	The	O
1	inhibition	O
2	by	O
3	the	O
4	RIalpha	B
5	subunit	I
6	is	O
7	reversed	O
8	by	O
9	addition	O
10	of	O
11	nanomolar	O
12	concentrations	O
13	of	O
14	cAMP	O
15	(	O
16	Ka	O
17	=	O
18	40	O
19	nM	O
20	),	O
21	thus	O
22	demonstrating	O
23	that	O
24	PrKX	B
25	is	O
26	a	O
27	novel	O
28	,	O
29	type	B
30	I	I
31	cAMP	I
32	-	I
33	dependent	I
34	protein	I
35	kinase	I
36	that	O
37	is	O
38	activated	O
39	at	O
40	lower	O
41	cAMP	O
42	concentrations	O
43	than	O
44	the	O
45	holoenzyme	O
46	with	O
47	the	O
48	Calpha	B
49	subunit	I
50	of	O
51	cAMP	B
52	-	I
53	dependent	I
54	protein	I
55	kinase	I
56	.	O

0	The	O
1	induced	O
2	respiratory	O
3	burst	O
4	was	O
5	investigated	O
6	by	O
7	the	O
8	intracellular	O
9	oxidative	O
10	transformation	O
11	of	O
12	dihydrorhodamine	O
13	123	O
14	to	O
15	the	O
16	fluorescent	O
17	dye	O
18	rhodamine	O
19	123	O
20	via	O
21	flow	O
22	cytometry	O
23	.	O

0	The	O
1	c	B
2	-	I
3	Ets	I
4	-	I
5	1	I
6	oncoprotein	I
7	is	O
8	a	O
9	transcription	O
10	activator	O
11	that	O
12	specifically	O
13	binds	O
14	to	O
15	DNA	O
16	.	O

0	Senior	O
1	systems	O
2	--	O
3	45	O
4	;	O
5	Mental	O
6	health	O
7	and	O
8	illness	O
9	in	O
10	old	O
11	age	O
12	--	O
13	3	O
14	.	O

0	Regulation	O
1	at	O
2	37	O
3	degrees	O
4	C	O
5	,	O
6	therefore	O
7	,	O
8	involves	O
9	the	O
10	action	O
11	of	O
12	three	O
13	protein	O
14	kinase	O
15	cascades	O
16	that	O
17	repress	O
18	HSF1	B
19	through	O
20	phosphorylation	O
21	of	O
22	serine	O
23	residues	O
24	303	O
25	,	O
26	307	O
27	,	O
28	and	O
29	363	O
30	and	O
31	may	O
32	promote	O
33	growth	O
34	by	O
35	suppressing	O
36	the	O
37	heat	O
38	shock	O
39	response	O
40	.	O

0	Human	B
1	acid	I
2	ceramidase	I
3	((	I
4	AC	I
5	)	I
6	N	I
7	-	I
8	acylsphingosine	I
9	amidohydrolase	I
10	,	O
11	EC	B
12	3	I
13	.	I
14	5	I
15	.	O

0	The	O
1	construction	O
2	of	O
3	a	O
4	small	O
5	library	O
6	of	O
7	mouse	O
8	repetitive	O
9	DNA	O
10	has	O
11	been	O
12	previously	O
13	reported	O
14	(	O
15	Pietras	O
16	et	O
17	al	O
18	.,	O
19	Nucleic	B
20	Acids	I
21	Res	O
22	.	O

0	Interestingly	O
1	,	O
2	an	O
3	increase	O
4	of	O
5	distance	O
6	per	O
7	se	O
8	did	O
9	not	O
10	have	O
11	a	O
12	deleterious	O
13	effect	O
14	on	O
15	translation	O
16	efficiency	O
17	.	O

0	The	O
1	addition	O
2	of	O
3	an	O
4	equimolar	O
5	complex	O
6	of	O
7	the	O
8	fourth	O
9	and	O
10	seventh	O
11	largest	O
12	subunits	O
13	,	O
14	purified	O
15	from	O
16	pol	B
17	II	I
18	holoenzyme	O
19	by	O
20	ion	O
21	-	O
22	exchange	O
23	chromatography	O
24	in	O
25	the	O
26	presence	O
27	of	O
28	urea	O
29	,	O
30	restored	O
31	promoter	O
32	-	O
33	directed	O
34	initiation	O
35	activity	O
36	to	O
37	pol	B
38	II	I
39	delta	I
40	4	I
41	/	I
42	7	I
43	.	O

0	From	O
1	an	O
2	RNK	B
3	-	O
4	16	O
5	lambda	O
6	-	O
7	gt11	O
8	library	O
9	,	O
10	we	O
11	have	O
12	isolated	O
13	and	O
14	sequenced	O
15	a	O
16	novel	O
17	cDNA	B
18	rat	B
19	NK	I
20	cell	I
21	protease	I
22	1	I
23	(	O
24	RNKP	B
25	-	I
26	1	I
27	)	O
28	that	O
29	has	O
30	characteristics	O
31	unique	O
32	to	O
33	serine	B
34	proteases	I
35	.	O

0	Localization	O
1	of	O
2	the	O
3	intronless	O
4	gene	O
5	coding	O
6	for	O
7	calmodulin	B
8	-	I
9	like	I
10	protein	I
11	CLP	I
12	to	O
13	human	O
14	chromosome	O
15	10p13	O
16	-	O
17	ter	O
18	.	O

0	One	O
1	hundred	O
2	twenty	O
3	units	O
4	of	O
5	deglycerolized	O
6	red	O
7	blood	O
8	cells	O
9	,	O
10	some	O
11	with	O
12	glycerol	O
13	added	O
14	so	O
15	as	O
16	to	O
17	exceed	O
18	an	O
19	acceptable	O
20	1	O
21	%	O
22	glycerol	O
23	content	O
24	,	O
25	had	O
26	measurements	O
27	made	O
28	of	O
29	the	O
30	post	O
31	-	O
32	wash	O
33	supernatant	O
34	fluid	O
35	by	O
36	refractive	O
37	index	O
38	and	O
39	osmometry	O
40	.	O

0	When	O
1	pollen	O
2	allergen	O
3	from	O
4	three	O
5	grass	O
6	species	O
7	were	O
8	used	O
9	,	O
10	The	O
11	RAST	O
12	-	O
13	test	O
14	results	O
15	did	O
16	not	O
17	differ	O
18	from	O
19	duplicate	O
20	values	O
21	either	O
22	.	O

0	The	O
1	topography	O
2	and	O
3	trajectories	O
4	of	O
5	the	O
6	commissural	O
7	fibers	O
8	of	O
9	the	O
10	superior	O
11	temporal	O
12	region	O
13	(	O
14	STR	O
15	)	O
16	are	O
17	studied	O
18	using	O
19	the	O
20	autoradiographic	O
21	technique	O
22	.	O

0	However	O
1	,	O
2	we	O
3	did	O
4	detect	O
5	lot	O
6	-	O
7	to	O
8	-	O
9	lot	O
10	variation	O
11	and	O
12	differences	O
13	in	O
14	performance	O
15	between	O
16	narrow	O
17	bandpass	O
18	and	O
19	wide	O
20	bandpass	O
21	spectrophotometers	O
22	.	O

0	Induction	O
1	of	O
2	B	O
3	cell	O
4	apoptosis	O
5	by	O
6	co	O
7	-	O
8	cross	O
9	-	O
10	linking	O
11	CD23	B
12	and	O
13	sIg	B
14	involves	O
15	aberrant	O
16	regulation	O
17	of	O
18	c	B
19	-	I
20	myc	I
21	and	O
22	is	O
23	inhibited	O
24	by	O
25	bcl	B
26	-	I
27	2	I
28	.	O

0	CPAP	O
1	reduced	O
2	isotime	O
3	(	O
4	defined	O
5	as	O
6	the	O
7	last	O
8	common	O
9	minute	O
10	of	O
11	exercise	O
12	)	O
13	VO2	O
14	and	O
15	dyspnea	O
16	in	O
17	those	O
18	patients	O
19	with	O
20	more	O
21	severe	O
22	lung	O
23	disease	O
24	,	O
25	but	O
26	these	O
27	values	O
28	tended	O
29	to	O
30	increase	O
31	slightly	O
32	in	O
33	the	O
34	patients	O
35	with	O
36	only	O
37	mild	O
38	lung	O
39	disease	O
40	.	O

0	We	O
1	cloned	O
2	a	O
3	DNA	O
4	fragment	O
5	encoding	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	part	O
11	of	O
12	a	O
13	protein	O
14	with	O
15	significant	O
16	similarity	O
17	to	O
18	members	O
19	of	O
20	the	O
21	LysR	B
22	family	I
23	of	I
24	transcriptional	I
25	regulators	I
26	(	O
27	LTTRs	B
28	).	O

0	Once	O
1	HIT	O
2	II	O
3	is	O
4	suspected	O
5	,	O
6	heparin	O
7	(	O
8	and	O
9	low	O
10	-	O
11	molecular	O
12	-	O
13	weight	O
14	heparins	O
15	)	O
16	should	O
17	be	O
18	stopped	O
19	immediately	O
20	.	O

0	NiCl	O
1	(	O
2	2	O
3	)-	O
4	induced	O
5	MCP	B
6	-	I
7	1	I
8	synthesis	O
9	required	O
10	activation	O
11	of	O
12	NF	B
13	-	I
14	kappaB	I
15	since	O
16	mutation	O
17	of	O
18	NF	B
19	-	I
20	kappaB	I
21	-	I
22	binding	I
23	sites	I
24	in	O
25	the	O
26	promoter	O
27	resulted	O
28	in	O
29	complete	O
30	loss	O
31	of	O
32	inducible	O
33	promoter	O
34	activity	O
35	.	O

0	Our	O
1	results	O
2	indicate	O
3	that	O
4	interaction	O
5	between	O
6	Jak2	B
7	and	O
8	PRLR	B
9	requires	O
10	a	O
11	proline	O
12	-	O
13	rich	O
14	sequence	O
15	in	O
16	the	O
17	membrane	O
18	proximal	O
19	region	O
20	of	O
21	the	O
22	receptor	O
23	,	O
24	which	O
25	is	O
26	conserved	O
27	among	O
28	the	O
29	different	O
30	members	O
31	of	O
32	the	O
33	cytokine	B
34	receptor	I
35	superfamily	I
36	.	O

0	The	O
1	use	O
2	of	O
3	CRF	O
4	-	O
5	41	O
6	in	O
7	the	O
8	differential	O
9	diagnosis	O
10	of	O
11	Cushing	O
12	'	O
13	s	O
14	syndrome	O
15	and	O
16	obesity	O
17	.	O

0	The	O
1	inhibition	O
2	of	O
3	StAR	B
4	gene	I
5	transcription	O
6	by	O
7	DAX	B
8	-	I
9	1	I
10	was	O
11	dose	O
12	-	O
13	dependent	O
14	reducing	O
15	transcription	O
16	to	O
17	6	O
18	%	O
19	of	O
20	control	O
21	levels	O
22	.	O

0	For	O
1	higher	O
2	expression	O
3	of	O
4	lipA	B
5	in	O
6	S	O
7	.	O
8	lividans	O
9	,	O
10	the	O
11	gene	O
12	was	O
13	cloned	O
14	next	O
15	to	O
16	the	O
17	strong	O
18	aphII	B
19	promoter	I
20	.	O

0	Female	O
1	mice	O
2	were	O
3	significantly	O
4	more	O
5	resistant	O
6	to	O
7	infection	O
8	than	O
9	males	O
10	.	O

0	Picture	O
1	the	O
2	smell	O
3	.	O

0	We	O
1	describe	O
2	a	O
3	novel	O
4	zinc	B
5	finger	I
6	protein	I
7	,	O
8	dsRBP	B
9	-	I
10	ZFa	I
11	,	O
12	isolated	O
13	by	O
14	screening	O
15	an	O
16	expression	O
17	library	O
18	with	O
19	dsRNA	O
20	.	O

0	According	O
1	to	O
2	symptoms	O
3	,	O
4	signs	O
5	,	O
6	imaging	O
7	features	O
8	,	O
9	operation	O
10	findings	O
11	,	O
12	the	O
13	original	O
14	places	O
15	and	O
16	the	O
17	expansive	O
18	directions	O
19	of	O
20	the	O
21	tumor	O
22	,	O
23	they	O
24	were	O
25	divided	O
26	into	O
27	four	O
28	clinical	O
29	types	O
30	:	O
31	sellar	O
32	,	O
33	clival	O
34	,	O
35	occipito	O
36	-	O
37	temporal	O
38	and	O
39	extent	O
40	.	O

0	The	O
1	mutation	O
2	within	O
3	the	O
4	asgB480	B
5	allele	I
6	was	O
7	identified	O
8	as	O
9	an	O
10	A	O
11	-	O
12	to	O
13	-	O
14	G	O
15	transition	O
16	that	O
17	results	O
18	in	O
19	a	O
20	threonine	O
21	-	O
22	to	O
23	-	O
24	alanine	O
25	substitution	O
26	in	O
27	the	O
28	predicted	O
29	protein	O
30	product	O
31	.	O

0	TB	O
1	bone	O
2	area	O
3	(	O
4	p	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	height	O
11	(	O
12	p	O
13	<	O
14	0	O
15	.	O
16	01	O
17	),	O
18	years	O
19	in	O
20	present	O
21	colony	O
22	(	O
23	p	O
24	=	O
25	0	O
26	.	O
27	03	O
28	),	O
29	and	O
30	menses	O
31	(	O
32	p	O
33	<	O
34	0	O
35	.	O
36	01	O
37	)	O
38	predicted	O
39	TB	O
40	BMC	O
41	.	O

0	Polysorbate	O
1	80	O
2	did	O
3	not	O
4	have	O
5	a	O
6	direct	O
7	stimulant	O
8	or	O
9	relaxant	O
10	effect	O
11	on	O
12	either	O
13	guinea	O
14	pig	O
15	ileum	O
16	or	O
17	rat	O
18	uterus	O
19	,	O
20	however	O
21	,	O
22	it	O
23	antagonised	O
24	the	O
25	contractions	O
26	induced	O
27	by	O
28	acetylcholine	O
29	,	O
30	histamine	O
31	,	O
32	barium	O
33	,	O
34	5	O
35	-	O
36	hydroxytryptamine	O
37	and	O
38	carbachol	O
39	in	O
40	a	O
41	dose	O
42	-	O
43	dependent	O
44	manner	O
45	.	O

0	The	O
1	frequency	O
2	of	O
3	lactase	B
4	phenotypes	O
5	in	O
6	Aymara	O
7	children	O
8	.	O

0	To	O
1	identify	O
2	these	O
3	sites	O
4	,	O
5	Cdk2	B
6	-	O
7	phosphorylated	O
8	MARCKS	I
9	was	O
10	digested	O
11	with	O
12	lysyl	B
13	endoprotease	I
14	and	O
15	analysed	O
16	by	O
17	electrospray	O
18	MS	O
19	.	O

0	Among	O
1	mucus	O
2	-	O
3	secreting	O
4	cells	O
5	,	O
6	the	O
7	gastric	O
8	gland	O
9	mucous	O
10	cells	O
11	,	O
12	Brunner	O
13	'	O
14	s	O
15	glands	O
16	,	O
17	accessory	O
18	glands	O
19	of	O
20	pancreaticobiliary	O
21	tract	O
22	,	O
23	and	O
24	pancreatic	O
25	ducts	O
26	exhibiting	O
27	gastric	O
28	metaplasia	O
29	are	O
30	unique	O
31	in	O
32	that	O
33	they	O
34	express	O
35	class	B
36	III	I
37	mucin	I
38	identified	O
39	by	O
40	paradoxical	O
41	Con	B
42	A	I
43	staining	O
44	composed	O
45	of	O
46	periodate	O
47	oxidation	O
48	,	O
49	sodium	O
50	borohydride	O
51	reduction	O
52	,	O
53	Con	B
54	A	I
55	,	O
56	and	O
57	horseradish	B
58	peroxidase	I
59	reaction	O
60	.	O

0	According	O
1	to	O
2	the	O
3	biochemical	O
4	tests	O
5	,	O
6	high	O
7	activity	O
8	(	O
9	over	O
10	200	O
11	U	O
12	/	O
13	l	O
14	)	O
15	of	O
16	alkaline	B
17	phosphatase	I
18	was	O
19	recorded	O
20	exclusively	O
21	in	O
22	patients	O
23	with	O
24	the	O
25	lymphogranulomatosis	O
26	-	O
27	induced	O
28	liver	O
29	damage	O
30	.	O

0	XYL1	B
1	was	O
2	isolated	O
3	as	O
4	a	O
5	highly	O
6	expressed	O
7	fusion	O
8	clone	O
9	from	O
10	a	O
11	'	O
12	lacZ	B
13	translational	O
14	fusion	O
15	library	O
16	.	O

0	None	O
1	had	O
2	a	O
3	past	O
4	history	O
5	of	O
6	opportunistic	O
7	infections	O
8	;	O
9	neither	O
10	did	O
11	any	O
12	have	O
13	lymphopenia	O
14	.	O

0	General	O
1	formulae	O
2	for	O
3	estimating	O
4	heritability	O
5	in	O
6	a	O
7	population	O
8	with	O
9	related	O
10	parents	O
11	.	O

0	These	O
1	data	O
2	indicate	O
3	that	O
4	although	O
5	218leu	O
6	retains	O
7	normal	O
8	transactivation	O
9	activity	O
10	on	O
11	a	O
12	p53	B
13	promoter	I
14	in	O
15	yeast	O
16	at	O
17	physiological	O
18	temperatures	O
19	,	O
20	it	O
21	is	O
22	not	O
23	capable	O
24	of	O
25	normal	O
26	p53	B
27	function	O
28	in	O
29	the	O
30	presence	O
31	of	O
32	a	O
33	248trp	B
34	allele	O
35	in	O
36	SNU	O
37	-	O
38	C5	O
39	cells	O
40	.	O

0	We	O
1	examined	O
2	the	O
3	hypothesis	O
4	that	O
5	the	O
6	coronary	O
7	vasomotor	O
8	responses	O
9	to	O
10	etomidate	O
11	(	O
12	ETO	O
13	),	O
14	propofol	O
15	(	O
16	PRO	O
17	),	O
18	and	O
19	sodium	O
20	thiopental	O
21	(	O
22	STP	O
23	)	O
24	are	O
25	mediated	O
26	through	O
27	contrasting	O
28	effects	O
29	on	O
30	the	O
31	resting	O
32	nitric	O
33	oxide	O
34	(	O
35	NO	O
36	)-	O
37	dependent	O
38	vasodilator	O
39	tone	O
40	that	O
41	opposes	O
42	adrenergic	O
43	vasoconstrictor	O
44	activity	O
45	in	O
46	the	O
47	intact	O
48	dog	O
49	.	O

0	Antiviral	O
1	agents	O
2	.	O

0	Elimination	O
1	of	O
2	ETH1	B
3	in	O
4	apn1	B
5	strains	O
6	also	O
7	increased	O
8	spontaneous	O
9	mutation	O
10	rates	O
11	9	O
12	-	O
13	or	O
14	31	O
15	-	O
16	fold	O
17	compared	O
18	to	O
19	the	O
20	wild	O
21	type	O
22	as	O
23	determined	O
24	by	O
25	reversion	O
26	to	O
27	adenine	O
28	or	O
29	lysine	O
30	prototrophy	O
31	,	O
32	respectively	O
33	.	O

0	We	O
1	reviewed	O
2	the	O
3	records	O
4	of	O
5	151	O
6	patients	O
7	with	O
8	optic	O
9	neuritis	O
10	examined	O
11	over	O
12	an	O
13	eight	O
14	-	O
15	year	O
16	period	O
17	.	O

0	The	O
1	disease	O
2	ran	O
3	an	O
4	atypical	O
5	course	O
6	;	O
7	with	O
8	early	O
9	jaundice	O
10	syndrome	O
11	,	O
12	severe	O
13	enterorrhagia	O
14	and	O
15	late	O
16	appearance	O
17	of	O
18	roseola	O
19	.	O

0	BACKGROUND	O
1	:	O
2	Studies	O
3	in	O
4	lean	O
5	men	O
6	show	O
7	poor	O
8	regulation	O
9	of	O
10	energy	O
11	(	O
12	EB	O
13	)	O
14	and	O
15	fat	O
16	balance	O
17	(	O
18	FB	O
19	)	O
20	during	O
21	manipulation	O
22	of	O
23	dietary	O
24	ratios	O
25	of	O
26	fat	O
27	to	O
28	carbohydrate	O
29	.	O

0	Amisulpride	O
1	400	O
2	mg	O
3	had	O
4	several	O
5	adverse	O
6	effects	O
7	on	O
8	psychomotor	O
9	and	O
10	,	O
11	although	O
12	less	O
13	severe	O
14	,	O
15	on	O
16	cognitive	O
17	performance	O
18	on	O
19	the	O
20	fifth	O
21	day	O
22	only	O
23	.	O

0	Surprisingly	O
1	,	O
2	TFIIIC	B
3	alpha	I
4	has	O
5	no	O
6	homology	O
7	to	O
8	any	O
9	of	O
10	the	O
11	yeast	B
12	TFIIIC	I
13	subunits	I
14	already	O
15	cloned	O
16	,	O
17	suggesting	O
18	a	O
19	significant	O
20	degree	O
21	of	O
22	evolutionary	O
23	divergence	O
24	for	O
25	RNA	B
26	polymerase	I
27	III	I
28	factors	I
29	.	O

0	Dissolution	O
1	of	O
2	the	O
3	Pt	O
4	-	O
5	30	O
6	%	O
7	Ir	O
8	microelectrode	O
9	tip	O
10	was	O
11	observed	O
12	by	O
13	scanning	O
14	electron	O
15	microscopy	O
16	at	O
17	charge	O
18	densities	O
19	as	O
20	low	O
21	as	O
22	200	O
23	microC	O
24	/	O
25	cm2	O
26	X	O
27	ph	O
28	(	O
29	1	O
30	A	O
31	/	O
32	cm2	O
33	),	O
34	whereas	O
35	erosion	O
36	of	O
37	activated	O
38	iridium	O
39	microelectrodes	O
40	occurred	O
41	only	O
42	at	O
43	the	O
44	highest	O
45	charge	O
46	and	O
47	current	O
48	densities	O
49	(	O
50	3200	O
51	microC	O
52	/	O
53	cm2	O
54	X	O
55	ph	O
56	,	O
57	16	O
58	A	O
59	/	O
60	cm2	O
61	).	O

0	Crohn	O
1	'	O
2	s	O
3	disease	O
4	in	O
5	prolonged	O
6	remission	O
7	:	O
8	should	O
9	one	O
10	augment	O
11	protein	O
12	-	O
13	calorie	O
14	intake	O
15	as	O
16	compared	O
17	to	O
18	healthy	O
19	subjects	O
20	?]	O
21	The	O
22	aim	O
23	of	O
24	our	O
25	two	O
26	year	O
27	prospective	O
28	study	O
29	was	O
30	to	O
31	evaluate	O
32	whether	O
33	adult	O
34	Crohn	O
35	'	O
36	s	O
37	disease	O
38	patients	O
39	in	O
40	prolonged	O
41	remission	O
42	(	O
43	CDAI	O
44	<	O
45	150	O
46	),	O
47	in	O
48	order	O
49	to	O
50	maintain	O
51	their	O
52	body	O
53	weight	O
54	as	O
55	close	O
56	as	O
57	possible	O
58	to	O
59	the	O
60	ideal	O
61	one	O
62	,	O
63	need	O
64	a	O
65	protein	O
66	-	O
67	calorie	O
68	intake	O
69	higher	O
70	than	O
71	the	O
72	predicted	O
73	one	O
74	and	O
75	that	O
76	of	O
77	healthy	O
78	controls	O
79	.	O

0	These	O
1	results	O
2	are	O
3	consistent	O
4	with	O
5	the	O
6	well	O
7	established	O
8	polarity	O
9	of	O
10	RXR	B
11	heterodimer	I
12	binding	O
13	to	O
14	bipartite	O
15	hormone	O
16	response	O
17	elements	O
18	,	O
19	with	O
20	the	O
21	VDR	B
22	recognizing	O
23	the	O
24	3	O
25	'-	O
26	half	O
27	-	O
28	element	O
29	.	O

0	However	O
1	,	O
2	the	O
3	inability	O
4	to	O
5	export	O
6	RNA	O
7	from	O
8	the	O
9	nucleus	O
10	to	O
11	the	O
12	cytoplasm	O
13	was	O
14	not	O
15	limited	O
16	to	O
17	a	O
18	particular	O
19	phase	O
20	of	O
21	the	O
22	cell	O
23	division	O
24	cycle	O
25	.	O

0	Polypeptide	B
1	growth	I
2	factors	I
3	and	O
4	cytokines	O
5	mediate	O
6	their	O
7	biochemical	O
8	functions	O
9	through	O
10	their	O
11	responsive	O
12	receptors	O
13	.	O

0	Interspecific	O
1	mouse	O
2	back	O
3	-	O
4	cross	O
5	analysis	O
6	identified	O
7	the	O
8	loci	O
9	for	O
10	mouse	B
11	3Ost	I
12	genes	I
13	and	O
14	syntenic	O
15	assignments	O
16	of	O
17	corresponding	O
18	human	O
19	isologs	O
20	were	O
21	confirmed	O
22	by	O
23	the	O
24	identification	O
25	of	O
26	mapped	O
27	sequence	O
28	-	O
29	tagged	O
30	site	O
31	markers	O
32	.	O

0	Thus	O
1	,	O
2	blocks	O
3	in	O
4	the	O
5	RARalpha	B
6	-	O
7	specific	O
8	pathway	O
9	of	O
10	retinoid	O
11	-	O
12	induced	O
13	differentiation	O
14	may	O
15	be	O
16	bypassed	O
17	during	O
18	retinoid	O
19	induction	O
20	of	O
21	FR	B
22	-	I
23	beta	I
24	expression	O
25	.	O

0	Kinetics	O
1	of	O
2	the	O
3	inhibition	O
4	indicated	O
5	that	O
6	this	O
7	polymerase	O
8	domain	O
9	can	O
10	inhibit	O
11	viral	O
12	replication	O
13	only	O
14	during	O
15	the	O
16	preinitiation	O
17	stage	O
18	.	O

0	An	O
1	intact	O
2	neurovascular	O
3	supply	O
4	is	O
5	essential	O
6	for	O
7	the	O
8	viability	O
9	of	O
10	a	O
11	muscle	O
12	flap	O
13	.	O

0	The	O
1	rat	O
2	incisor	O
3	is	O
4	an	O
5	excellent	O
6	model	O
7	system	O
8	in	O
9	which	O
10	to	O
11	study	O
12	amelgenesis	O
13	.	O

0	Use	O
1	of	O
2	Selenastrum	O
3	capricornutum	O
4	and	O
5	Microfeast	O
6	as	O
7	food	O
8	for	O
9	Daphnia	O
10	pulex	O
11	.	O

0	The	O
1	combination	O
2	of	O
3	Pitx2	B
4	and	O
5	another	O
6	homeodomain	B
7	protein	I
8	,	O
9	Pit	B
10	-	I
11	1	I
12	,	O
13	yielded	O
14	a	O
15	synergistic	O
16	55	O
17	-	O
18	fold	O
19	activation	O
20	of	O
21	the	O
22	prolactin	B
23	promoter	I
24	in	O
25	transfection	O
26	assays	O
27	.	O

0	Respiratory	B
1	chain	I
2	enzyme	I
3	activity	O
4	was	O
5	normal	O
6	.	O

0	Northern	O
1	blotting	O
2	analysis	O
3	indicates	O
4	that	O
5	expression	O
6	of	O
7	the	O
8	genes	O
9	corresponding	O
10	to	O
11	these	O
12	clones	O
13	is	O
14	confined	O
15	to	O
16	pollen	O
17	tissue	O
18	.	O

0	If	O
1	NCR	B
2	-	O
3	sensitive	O
4	gene	O
5	expression	O
6	occurs	O
7	exclusively	O
8	by	O
9	this	O
10	pathway	O
11	,	O
12	as	O
13	has	O
14	been	O
15	thought	O
16	to	O
17	be	O
18	the	O
19	case	O
20	,	O
21	then	O
22	the	O
23	NCR	B
24	sensitivity	O
25	of	O
26	a	O
27	gene	O
28	'	O
29	s	O
30	expression	O
31	should	O
32	be	O
33	abolished	O
34	by	O
35	a	O
36	ure2	B
37	delta	I
38	mutation	I
39	.	O

0	The	O
1	predicted	O
2	domain	O
3	structures	O
4	of	O
5	FkbB	B
6	and	O
7	FkbC	B
8	are	O
9	analogous	O
10	to	O
11	that	O
12	of	O
13	FkbA	B
14	and	O
15	comprise	O
16	30	O
17	fatty	B
18	-	I
19	acid	I
20	-	I
21	synthase	I
22	(	O
23	FAS	B
24	)-	O
25	like	O
26	domains	O
27	arranged	O
28	in	O
29	6	O
30	modules	O
31	.	O

0	However	O
1	,	O
2	the	O
3	signaling	O
4	cascade	O
5	utilized	O
6	by	O
7	the	O
8	urokinase	B
9	receptor	I
10	is	O
11	only	O
12	incompletely	O
13	understood	O
14	.	O

0	Pathogenetic	O
1	relationships	O
2	between	O
3	renal	O
4	tubular	O
5	acidosis	O
6	and	O
7	sodium	O
8	metabolism	O
9	alterations	O
10	in	O
11	liver	O
12	cirrhosis	O
13	.	O

0	Fifty	O
1	-	O
2	seven	O
3	patients	O
4	aged	O
5	<	O
6	55	O
7	years	O
8	with	O
9	acute	O
10	lymphoblastic	O
11	leukemia	O
12	(	O
13	ALL	O
14	)	O
15	in	O
16	second	O
17	or	O
18	third	O
19	bone	O
20	marrow	O
21	(	O
22	BM	O
23	)	O
24	relapse	O
25	or	O
26	refractory	O
27	to	O
28	first	O
29	-	O
30	line	O
31	therapy	O
32	were	O
33	enrolled	O
34	in	O
35	an	O
36	Italian	O
37	cooperative	O
38	study	O
39	.	O

0	Results	O
1	demonstrated	O
2	that	O
3	the	O
4	presence	O
5	of	O
6	myofibroblasts	O
7	varied	O
8	considerably	O
9	from	O
10	case	O
11	to	O
12	case	O
13	and	O
14	was	O
15	always	O
16	related	O
17	to	O
18	smooth	O
19	muscle	O
20	cell	O
21	dispersion	O
22	,	O
23	which	O
24	occurred	O
25	around	O
26	medium	O
27	-	O
28	sized	O
29	damaged	O
30	portal	O
31	vein	O
32	branches	O
33	.	O

0	The	O
1	paramyxovirus	B
2	fusion	I
3	(	I
4	F	I
5	)	I
6	protein	I
7	mediates	O
8	membrane	O
9	fusion	O
10	.	O

0	A	O
1	32P	O
2	-	O
3	labeled	O
4	LAP	B
5	DNA	O
6	-	O
7	binding	O
8	and	O
9	dimerization	O
10	domain	O
11	"	O
12	zipper	O
13	probe	O
14	"	O
15	was	O
16	used	O
17	to	O
18	isolate	O
19	a	O
20	clone	O
21	that	O
22	encodes	O
23	a	O
24	new	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	homologous	I
30	protein	I
31	:	O
32	CHOP	B
33	-	I
34	10	I
35	.	O

0	A	O
1	lambda	O
2	gt10	O
3	cDNA	O
4	library	O
5	was	O
6	constructed	O
7	from	O
8	poly	O
9	(	O
10	A	O
11	)+	O
12	RNA	O
13	of	O
14	young	O
15	green	O
16	leaves	O
17	of	O
18	spinach	O
19	.	O

0	These	O
1	results	O
2	demonstrate	O
3	a	O
4	specific	O
5	association	O
6	of	O
7	SIV	O
8	and	O
9	HIV	O
10	-	O
11	2	O
12	nef	O
13	,	O
14	but	O
15	not	O
16	HIV	O
17	-	O
18	1	O
19	nef	O
20	,	O
21	with	O
22	TCRzeta	B
23	.	O

0	Evidence	O
1	for	O
2	such	O
3	peak	O
4	shifts	O
5	has	O
6	been	O
7	found	O
8	in	O
9	the	O
10	responses	O
11	of	O
12	auditory	O
13	nerve	O
14	fibers	O
15	,	O
16	cochlear	O
17	microphonics	O
18	,	O
19	and	O
20	the	O
21	responses	O
22	of	O
23	outer	O
24	hair	O
25	cells	O
26	and	O
27	supporting	O
28	cells	O
29	in	O
30	the	O
31	cochlea	O
32	,	O
33	as	O
34	well	O
35	as	O
36	in	O
37	basilar	O
38	membrane	O
39	vibration	O
40	measurements	O
41	,	O
42	and	O
43	indirectly	O
44	,	O
45	in	O
46	psychophysical	O
47	data	O
48	.	O

0	We	O
1	have	O
2	determined	O
3	the	O
4	molecular	O
5	lesions	O
6	of	O
7	nine	O
8	Scm	B
9	mutant	I
10	alleles	I
11	,	O
12	which	O
13	identify	O
14	functional	O
15	requirements	O
16	for	O
17	specific	O
18	domains	O
19	.	O

0	In	O
1	controls	O
2	,	O
3	only	O
4	modest	O
5	differences	O
6	were	O
7	observed	O
8	.	O

0	To	O
1	our	O
2	knowledge	O
3	,	O
4	type	O
5	IV	O
6	renal	O
7	tubular	O
8	acidosis	O
9	has	O
10	not	O
11	been	O
12	reported	O
13	previously	O
14	in	O
15	association	O
16	with	O
17	Alport	O
18	'	O
19	s	O
20	syndrome	O
21	in	O
22	an	O
23	adult	O
24	patient	O
25	.	O

0	Five	O
1	patients	O
2	developed	O
3	metastatic	O
4	spread	O
5	,	O
6	and	O
7	all	O
8	of	O
9	them	O
10	died	O
11	of	O
12	tumor	O
13	.	O

0	When	O
1	the	O
2	cervical	O
3	Pap	O
4	smear	O
5	is	O
6	positive	O
7	.	O

0	Studies	O
1	on	O
2	Coxsackie	O
3	B	O
4	Type	O
5	5	O
6	virus	O
7	infections	O
8	.	O

0	The	O
1	proposed	O
2	algorithm	O
3	consists	O
4	of	O
5	several	O
6	steps	O
7	.	O

0	Relief	O
1	from	O
2	autoinhibition	O
3	and	O
4	a	O
5	subsequent	O
6	10	O
7	-	O
8	60	O
9	-	O
10	fold	O
11	increase	O
12	in	O
13	V	O
14	(	O
15	max	O
16	)	O
17	have	O
18	been	O
19	observed	O
20	upon	O
21	N	O
22	-	O
23	SH2	O
24	domain	O
25	engagement	O
26	by	O
27	a	O
28	specific	O
29	phosphotyrosyl	O
30	ligand	O
31	or	O
32	upon	O
33	deletion	O
34	of	O
35	the	O
36	SH2	B
37	domains	I
38	to	O
39	yield	O
40	the	O
41	catalytic	B
42	PTPase	B
43	domain	I
44	.	O

0	These	O
1	are	O
2	two	O
3	regions	O
4	of	O
5	known	O
6	conserved	O
7	synteny	O
8	,	O
9	providing	O
10	further	O
11	evidence	O
12	that	O
13	the	O
14	human	B
15	STEP	I
16	is	O
17	a	O
18	true	O
19	homolog	O
20	of	O
21	the	O
22	murine	B
23	STEP	I
24	gene	I
25	.	O

0	To	O
1	identify	O
2	structural	O
3	features	O
4	of	O
5	residues	O
6	flanking	O
7	the	O
8	c	B
9	-	I
10	region	I
11	that	O
12	influence	O
13	the	O
14	fidelity	O
15	and	O
16	efficiency	O
17	of	O
18	signal	B
19	peptidase	B
20	cleavage	O
21	as	O
22	well	O
23	as	O
24	co	O
25	-	O
26	translational	O
27	translocation	O
28	,	O
29	we	O
30	introduced	O
31	six	O
32	amino	O
33	acid	O
34	substitutions	O
35	into	O
36	the	O
37	COOH	O
38	terminus	O
39	of	O
40	the	O
41	hydrophobic	O
42	core	O
43	and	O
44	seven	O
45	substitutions	O
46	at	O
47	the	O
48	NH2	O
49	terminus	O
50	of	O
51	the	O
52	mature	O
53	region	O
54	(	O
55	the	O
56	+	O
57	1	O
58	position	O
59	)	O
60	of	O
61	a	O
62	model	O
63	eukaryotic	O
64	preprotein	O
65	-	O
66	human	B
67	pre	I
68	(	I
69	delta	I
70	pro	I
71	)	I
72	apoA	I
73	-	I
74	II	I
75	.	O

0	The	O
1	rate	O
2	of	O
3	decrement	O
4	in	O
5	DPOAE	O
6	amplitude	O
7	over	O
8	a	O
9	prescribed	O
10	time	O
11	period	O
12	was	O
13	utilized	O
14	as	O
15	a	O
16	measure	O
17	of	O
18	susceptibility	O
19	to	O
20	the	O
21	acoustic	O
22	trauma	O
23	.	O

0	The	O
1	high	O
2	sequence	O
3	homology	O
4	,	O
5	similar	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	identical	O
11	chromosomal	O
12	loci	O
13	of	O
14	hKID	B
15	,	O
16	MIP	B
17	,	O
18	and	O
19	AQP	B
20	-	I
21	2	I
22	suggest	O
23	a	O
24	MIP	B
25	family	I
26	gene	I
27	cluster	O
28	at	O
29	chromosome	O
30	locus	O
31	12q13	O
32	.	O

0	Instead	O
1	,	O
2	it	O
3	contained	O
4	two	O
5	tandem	O
6	kappaB	B
7	elements	I
8	and	O
9	a	O
10	variant	O
11	activating	O
12	transcription	O
13	factor	O
14	/	O
15	cAMP	O
16	response	O
17	element	O
18	site	O
19	,	O
20	which	O
21	closely	O
22	resembled	O
23	sites	O
24	in	O
25	the	O
26	E	B
27	-	I
28	selectin	I
29	gene	I
30	that	O
31	are	O
32	required	O
33	for	O
34	TNF	B
35	-	I
36	alpha	I
37	-	O
38	or	O
39	LPS	O
40	-	O
41	inducible	O
42	expression	O
43	.	O

0	Because	O
1	ATF	B
2	-	I
3	1	I
4	and	O
5	CREM	B
6	are	O
7	known	O
8	to	O
9	bind	O
10	to	O
11	cAMP	O
12	response	O
13	elements	O
14	(	O
15	CRE	O
16	),	O
17	this	O
18	functional	O
19	sequence	O
20	was	O
21	named	O
22	the	O
23	kappa	B
24	E3	O
25	'-	O
26	CRE	O
27	.	O

0	In	O
1	patients	O
2	in	O
3	group	O
4	A	O
5	("	O
6	normal	O
7	"	O
8	CI	O
9	),	O
10	the	O
11	CI	O
12	,	O
13	heart	O
14	rate	O
15	and	O
16	the	O
17	mean	O
18	circumferential	O
19	fiber	O
20	shortening	O
21	velocity	O
22	(	O
23	mVCF	O
24	)	O
25	were	O
26	normal	O
27	,	O
28	but	O
29	the	O
30	TPR	O
31	was	O
32	increased	O
33	significantly	O
34	.	O

0	The	O
1	degree	O
2	of	O
3	hypoperfusion	O
4	was	O
5	slightly	O
6	related	O
7	to	O
8	decrease	O
9	in	O
10	FEV1	O
11	.	O
12	0	O
13	%,	O
14	V25	O
15	and	O
16	PaO2	O
17	and	O
18	increase	O
19	in	O
20	circulating	O
21	blood	O
22	volume	O
23	and	O
24	peripheral	O
25	red	O
26	blood	O
27	cell	O
28	counts	O
29	.	O

0	Thromboplastic	O
1	and	O
2	fibrynolytic	O
3	activity	O
4	of	O
5	the	O
6	blood	O
7	after	O
8	administration	O
9	of	O
10	intralipid	O
11	in	O
12	men	O
13	with	O
14	history	O
15	of	O
16	myocardial	O
17	infarction	O
18	up	O
19	to	O
20	45	O
21	year	O
22	of	O
23	life	O

0	Grade	O
1	3	O
2	mucositis	O
3	was	O
4	reported	O
5	in	O
6	1	O
7	patient	O
8	.	O

0	Preceptorship	O
1	of	O
2	CNS	O
3	students	O
4	:	O
5	an	O
6	exploratory	O
7	study	O
8	.	O

0	Myocardial	O
1	interstitial	O
2	edema	O
3	is	O
4	more	O
5	likely	O
6	a	O
7	potential	O
8	mechanism	O
9	of	O
10	diastolic	O
11	dysfunction	O
12	after	O
13	DC	O
14	shocks	O
15	.	O

0	A	O
1	38	O
2	-	O
3	bp	O
4	poly	O
5	(	O
6	dA	O
7	-	O
8	dT	O
9	)	O
10	region	O
11	was	O
12	found	O
13	to	O
14	be	O
15	a	O
16	positive	O
17	regulator	O
18	of	O
19	Act1	B
20	promoter	I
21	activity	O
22	.	O

0	Nor	O
1	is	O
2	such	O
3	adjustment	O
4	possible	O
5	unless	O
6	one	O
7	posits	O
8	a	O
9	model	O
10	that	O
11	relates	O
12	the	O
13	missing	O
14	observations	O
15	to	O
16	other	O
17	observed	O
18	information	O
19	for	O
20	each	O
21	subject	O
22	-	O
23	models	O
24	that	O
25	are	O
26	inherently	O
27	untestable	O
28	.	O

0	It	O
1	has	O
2	repeatedly	O
3	been	O
4	shown	O
5	that	O
6	HCMV	B
7	IE1	B
8	/	O
9	IE2	B
10	can	O
11	independently	O
12	transactivate	O
13	HIV	B
14	-	I
15	1	I
16	LTR	I
17	.	O

0	The	O
1	genome	O
2	organization	O
3	of	O
4	the	O
5	mite	O
6	-	O
7	transmitted	O
8	wheat	O
9	streak	O
10	mosaic	O
11	virus	O
12	(	O
13	WSMV	O
14	)	O
15	appears	O
16	to	O
17	parallel	O
18	that	O
19	of	O
20	members	O
21	of	O
22	the	O
23	Potyviridae	O
24	with	O
25	monopartite	O
26	genomes	O
27	,	O
28	but	O
29	there	O
30	are	O
31	substantial	O
32	amino	O
33	acid	O
34	dissimilarities	O
35	with	O
36	other	O
37	potyviral	O
38	polyproteins	O
39	.	O

0	Consistent	O
1	with	O
2	the	O
3	hepatic	O
4	and	O
5	epidermal	O
6	expression	O
7	of	O
8	histidase	B
9	,	O
10	this	O
11	finding	O
12	suggests	O
13	that	O
14	histidase	B
15	transcription	O
16	may	O
17	be	O
18	regulated	O
19	by	O
20	these	O
21	factors	O
22	.	O

0	The	O
1	genomic	O
2	and	O
3	transcriptional	O
4	complexity	O
5	of	O
6	the	O
7	Crry	B
8	and	O
9	Crry	B
10	-	O
11	ps	B
12	genes	I
13	.	O

0	Microvessels	O
1	were	O
2	counted	O
3	in	O
4	a	O
5	x200	O
6	field	O
7	(	O
8	0	O
9	.	O
10	754	O
11	mm2	O
12	)	O
13	in	O
14	the	O
15	area	O
16	of	O
17	maximal	O
18	angiogenesis	O
19	.	O

0	Moreover	O
1	,	O
2	the	O
3	reconstitution	O
4	of	O
5	eUSF	B
6	and	O
7	TFIID	B
8	-	O
9	depleted	O
10	transcription	O
11	complexes	O
12	with	O
13	purified	O
14	protein	O
15	fractions	O
16	demonstrate	O
17	that	O
18	not	O
19	only	O
20	TFIID	B
21	but	O
22	also	O
23	eUSF	B
24	essentially	O
25	participates	O
26	in	O
27	complex	O
28	formation	O
29	even	O
30	on	O
31	H5	B
32	promoter	I
33	mutations	I
34	lacking	O
35	the	O
36	TATA	O
37	-	O
38	box	O
39	.	O

0	Rainbow	O
1	trout	O
2	were	O
3	obtained	O
4	from	O
5	a	O
6	commercial	O
7	trout	O
8	farm	O
9	,	O
10	kept	O
11	in	O
12	running	O
13	water	O
14	and	O
15	feeding	O
16	in	O
17	experimental	O
18	pellets	O
19	for	O
20	4	O
21	to	O
22	8	O
23	weeks	O
24	.	O

0	In	O
1	addition	O
2	,	O
3	the	O
4	time	O
5	to	O
6	engraftment	O
7	was	O
8	significantly	O
9	shorter	O
10	in	O
11	the	O
12	amifostine	O
13	arm	O
14	in	O
15	both	O
16	cohorts	O
17	.	O

0	To	O
1	identify	O
2	the	O
3	DNA	O
4	sequences	O
5	that	O
6	cis	O
7	-	O
8	regulate	O
9	the	O
10	expression	O
11	of	O
12	the	O
13	rat	B
14	liver	I
15	pyruvate	I
16	kinase	I
17	(	O
18	L	B
19	-	I
20	PK	I
21	)	O
22	genes	O
23	,	O
24	a	O
25	series	O
26	of	O
27	constructs	O
28	in	O
29	which	O
30	the	O
31	chloramphenicol	B
32	acetyltransferase	I
33	reporter	I
34	genes	I
35	is	O
36	driven	O
37	by	O
38	various	O
39	deleted	O
40	fragments	O
41	of	O
42	the	O
43	3200	O
44	base	O
45	pairs	O
46	(	O
47	bp	O
48	)	O
49	upstream	O
50	of	O
51	the	O
52	L	B
53	-	I
54	PK	I
55	gene	I
56	cap	I
57	site	I
58	have	O
59	been	O
60	assayed	O
61	for	O
62	transient	O
63	expression	O
64	after	O
65	introduction	O
66	into	O
67	hepatoma	O
68	HepG2	O
69	cells	O
70	,	O
71	rat	O
72	hepatocytes	O
73	in	O
74	primary	O
75	culture	O
76	,	O
77	fibroblast	O
78	LTK	O
79	-	O
80	cells	O
81	,	O
82	myogenic	O
83	C2C12	O
84	cells	O
85	,	O
86	and	O
87	CHO	O
88	cells	O
89	.	O

0	In	O
1	another	O
2	study	O
3	,	O
4	intravenous	O
5	administration	O
6	of	O
7	devazepide	O
8	,	O
9	a	O
10	specific	O
11	cholecystokinin	B
12	-	I
13	A	I
14	receptor	I
15	antagonist	O
16	,	O
17	at	O
18	a	O
19	dose	O
20	of	O
21	0	O
22	.	O
23	1	O
24	mg	O
25	/	O
26	kg	O
27	/	O
28	hr	O
29	was	O
30	begun	O
31	15	O
32	min	O
33	before	O
34	postprandial	O
35	saline	O
36	intake	O
37	and	O
38	continued	O
39	for	O
40	1	O
41	hr	O
42	.	O

0	Taurine	O
1	deficiency	O
2	significantly	O
3	depressed	O
4	the	O
5	amplitude	O
6	of	O
7	OP1	O
8	and	O
9	OP4	O
10	.	O

0	A	O
1	database	O
2	search	O
3	has	O
4	revealed	O
5	as	O
6	the	O
7	most	O
8	significative	O
9	homology	O
10	a	O
11	match	O
12	with	O
13	the	O
14	human	B
15	mitochondrial	I
16	transcription	I
17	termination	I
18	factor	I
19	(	O
20	mTERF	B
21	),	O
22	a	O
23	protein	O
24	that	O
25	also	O
26	binds	O
27	DNA	O
28	as	O
29	a	O
30	monomer	O
31	and	O
32	contains	O
33	three	O
34	leucine	O
35	zippers	O
36	forming	O
37	intramolecular	O
38	interactions	O
39	.	O

0	The	O
1	localization	O
2	of	O
3	ZAP	B
4	-	I
5	70	I
6	to	O
7	the	O
8	cell	O
9	cortex	O
10	is	O
11	,	O
12	therefore	O
13	,	O
14	regulated	O
15	by	O
16	the	O
17	activity	O
18	of	O
19	SRC	B
20	-	I
21	family	I
22	kinases	I
23	,	O
24	independently	O
25	of	O
26	their	O
27	ability	O
28	to	O
29	phosphorylate	O
30	immunoreceptor	O
31	tyrosine	O
32	-	O
33	based	O
34	activation	O
35	motifs	O
36	of	O
37	the	O
38	TCR	B
39	.	O

0	Guinea	O
1	pigs	O
2	weighing	O
3	300	O
4	approximately	O
5	350	O
6	g	O
7	were	O
8	used	O
9	.	O

0	Subcutaneous	O
1	administration	O
2	of	O
3	the	O
4	somatostatin	B
5	analogue	O
6	,	O
7	octreotide	O
8	,	O
9	100	O
10	micrograms	O
11	thrice	O
12	daily	O
13	,	O
14	resulted	O
15	in	O
16	a	O
17	sustained	O
18	improvement	O
19	in	O
20	diarrhoea	O
21	and	O
22	disappearance	O
23	of	O
24	faecal	O
25	incontinence	O
26	without	O
27	reducing	O
28	calcitonin	B
29	levels	O
30	.	O

0	With	O
1	steady	O
2	illumination	O
3	,	O
4	outer	O
5	retinal	O
6	(	O
7	photoreceptor	O
8	)	O
9	QO2	O
10	decreased	O
11	to	O
12	1	O
13	.	O
14	4	O
15	+/-	O
16	0	O
17	.	O
18	9	O
19	ml	O
20	O2	O
21	/(	O
22	100	O
23	g	O
24	.	O
25	min	O
26	),	O
27	but	O
28	inner	O
29	retinal	O
30	QO2	O
31	remained	O
32	unchanged	O
33	at	O
34	3	O
35	.	O
36	7	O
37	+/-	O
38	1	O
39	.	O
40	5	O
41	ml	O
42	O2	O
43	/(	O
44	100	O
45	g	O
46	.	O
47	min	O
48	)	O
49	(	O
50	5	O
51	cats	O
52	).	O

0	This	O
1	indicates	O
2	that	O
3	under	O
4	certain	O
5	experimental	O
6	conditions	O
7	cdc2	B
8	/	O
9	p58	B
10	and	O
11	cdc2	B
12	/	O
13	p62	B
14	may	O
15	express	O
16	some	O
17	differences	O
18	in	O
19	their	O
20	catalytic	O
21	activity	O
22	.	O

0	Sibling	O
1	aggregation	O
2	of	O
3	low	B
4	-	I
5	and	I
6	high	I
7	-	I
8	density	I
9	lipoprotein	I
10	cholesterol	I
11	and	O
12	apolipoproteins	B
13	B	I
14	and	I
15	A	I
16	-	I
17	I	I
18	levels	O
19	in	O
20	black	O
21	and	O
22	white	O
23	children	O
24	:	O
25	the	O
26	Bogalusa	O
27	Heart	O
28	Study	O
29	.	O

0	The	O
1	revertant	O
2	TATA	O
3	boxes	O
4	accelerated	O
5	the	O
6	kinetics	O
7	of	O
8	HIV	O
9	replication	O
10	when	O
11	present	O
12	in	O
13	the	O
14	context	O
15	of	O
16	an	O
17	LTR	O
18	containing	O
19	a	O
20	Sp1	B
21	mutation	I
22	(	O
23	deletion	O
24	or	O
25	site	O
26	specific	O
27	);	O
28	no	O
29	effect	O
30	was	O
31	observed	O
32	on	O
33	the	O
34	infectivity	O
35	of	O
36	wild	O
37	-	O
38	type	O
39	HIV	O
40	.	O

0	These	O
1	data	O
2	suggest	O
3	that	O
4	the	O
5	levels	O
6	of	O
7	oxygen	O
8	free	O
9	radicals	O
10	were	O
11	increased	O
12	in	O
13	hepatocytes	O
14	and	O
15	mitochondria	O
16	.	O

0	The	O
1	end	O
2	-	O
3	stage	O
4	or	O
5	involutional	O
6	phase	O
7	of	O
8	proliferative	O
9	diabetic	O
10	retinopathy	O
11	may	O
12	result	O
13	in	O
14	stabilization	O
15	of	O
16	vision	O
17	for	O
18	long	O
19	periods	O
20	of	O
21	time	O
22	.	O

0	BACKGROUND	O
1	:	O
2	Fluoroquinolones	O
3	(	O
4	FQ	O
5	)	O
6	are	O
7	contraindicated	O
8	in	O
9	children	O
10	because	O
11	of	O
12	the	O
13	risk	O
14	of	O
15	cartilage	O
16	damage	O
17	.	O

0	Nephrectomy	O
1	applied	O
2	to	O
3	cattle	O

0	In	O
1	about	O
2	770	O
3	bp	O
4	upstream	O
5	region	O
6	of	O
7	Spam1	B
8	that	O
9	has	O
10	been	O
11	cloned	O
12	and	O
13	sequenced	O
14	,	O
15	multiple	O
16	transcription	O
17	factor	O
18	binding	O
19	sites	O
20	including	O
21	a	O
22	CRE	O
23	(	O
24	cAMP	O
25	-	O
26	responsive	O
27	element	O
28	)	O
29	were	O
30	found	O
31	.	O

0	Furthermore	O
1	,	O
2	the	O
3	initial	O
4	plasma	O
5	retinol	O
6	level	O
7	in	O
8	conjunction	O
9	with	O
10	RBP	O
11	was	O
12	found	O
13	to	O
14	be	O
15	even	O
16	lower	O
17	in	O
18	12	O
19	patients	O
20	(	O
21	35	O
22	.	O
23	1	O
24	micrograms	O
25	dl	O
26	-	O
27	1	O
28	,	O
29	3	O
30	.	O
31	7	O
32	mg	O
33	dl	O
34	-	O
35	1	O
36	)	O
37	who	O
38	subsequently	O
39	had	O
40	cancer	O
41	recurrence	O
42	than	O
43	in	O
44	those	O
45	who	O
46	remained	O
47	free	O
48	of	O
49	apparent	O
50	cancer	O
51	(	O
52	44	O
53	.	O
54	5	O
55	micrograms	O
56	dl	O
57	-	O
58	1	O
59	,	O
60	4	O
61	.	O
62	6	O
63	mg	O
64	dl	O
65	-	O
66	1	O
67	).	O

0	Hair	O
1	and	O
2	blood	O
3	samples	O
4	were	O
5	taken	O
6	before	O
7	vitamin	O
8	C	O
9	or	O
10	placebo	O
11	supplementation	O
12	was	O
13	started	O
14	and	O
15	at	O
16	monthly	O
17	intervals	O
18	thereafter	O
19	for	O
20	three	O
21	months	O
22	.	O

0	After	O
1	tilting	O
2	,	O
3	systolic	O
4	blood	O
5	pressure	O
6	fell	O
7	an	O
8	average	O
9	of	O
10	17	O
11	%	O
12	in	O
13	patients	O
14	who	O
15	cramped	O
16	infrequently	O
17	(	O
18	p	O
19	=	O
20	0	O
21	.	O
22	0031	O
23	)	O
24	but	O
25	only	O
26	10	O
27	%	O
28	in	O
29	frequently	O
30	cramping	O
31	patients	O
32	.	O

0	Two	O
1	major	O
2	and	O
3	one	O
4	minor	O
5	transcription	O
6	initiation	O
7	sites	O
8	were	O
9	assigned	O
10	to	O
11	positions	O
12	+	O
13	1	O
14	and	O
15	+	O
16	24	O
17	and	O
18	position	O
19	+	O
20	14	O
21	,	O
22	respectively	O
23	,	O
24	by	O
25	a	O
26	combination	O
27	of	O
28	ribonuclease	O
29	protection	O
30	,	O
31	primer	O
32	extension	O
33	,	O
34	and	O
35	5	O
36	'	O
37	RACE	O
38	analyses	O
39	.	O

0	This	O
1	is	O
2	predicted	O
3	to	O
4	encode	O
5	a	O
6	315	O
7	-	O
8	residue	O
9	protein	O
10	containing	O
11	seven	O
12	hydrophobic	O
13	helical	O
14	regions	O
15	and	O
16	a	O
17	17	O
18	amino	O
19	acid	O
20	motif	O
21	characteristic	O
22	of	O
23	the	O
24	R7G	B
25	family	O
26	of	O
27	G	B
28	-	I
29	protein	I
30	coupled	I
31	membrane	I
32	-	I
33	bound	I
34	receptors	I
35	.	O

0	We	O
1	have	O
2	been	O
3	able	O
4	to	O
5	map	O
6	specific	O
7	DNA	O
8	fragments	O
9	at	O
10	the	O
11	bases	O
12	of	O
13	chromatin	O
14	loops	O
15	with	O
16	the	O
17	help	O
18	of	O
19	a	O
20	novel	O
21	extraction	O
22	procedure	O
23	by	O
24	using	O
25	lithium	O
26	-	O
27	3	O
28	',	O
29	5	O
30	'-	O
31	diiodosalicylate	O
32	.	O

0	Examination	O
1	of	O
2	nuclear	O
3	magnetic	O
4	resonance	O
5	(	O
6	NMR	O
7	)	O
8	spectra	O
9	of	O
10	a	O
11	series	O
12	of	O
13	N	O
14	-	O
15	terminally	O
16	truncated	O
17	MIP	B
18	-	I
19	1	I
20	beta	I
21	variants	I
22	reveals	O
23	that	O
24	these	O
25	proteins	O
26	possess	O
27	a	O
28	range	O
29	of	O
30	ability	O
31	to	O
32	dimerize	O
33	.	O

0	Another	O
1	stem	O
2	-	O
3	loop	O
4	called	O
5	structure	O
6	III	O
7	near	O
8	the	O
9	3	O
10	'-	O
11	end	O
12	of	O
13	repY	B
14	sequesters	O
15	both	O
16	the	O
17	5	O
18	'-	O
19	rCGCC	O
20	-	O
21	3	O
22	'	O
23	sequence	O
24	and	O
25	the	O
26	repZ	B
27	ribosome	I
28	-	I
29	binding	I
30	site	I
31	.	O

0	The	O
1	uteroglobin	B
2	promoter	I
3	contains	O
4	a	O
5	noncanonical	O
6	estrogen	O
7	responsive	O
8	element	O
9	.	O

0	In	O
1	summary	O
2	,	O
3	Ca	O
4	(	O
5	2	O
6	+)-	O
7	dependent	O
8	activation	O
9	of	O
10	NO	O
11	production	O
12	mediates	O
13	apoptosis	O
14	after	O
15	TG	O
16	exposure	O
17	in	O
18	JT	O
19	/	O
20	Neo	O
21	cells	O
22	.	O

0	At	O
1	least	O
2	some	O
3	of	O
4	the	O
5	difference	O
6	in	O
7	stability	O
8	of	O
9	the	O
10	two	O
11	kinds	O
12	of	O
13	complexes	O
14	was	O
15	due	O
16	to	O
17	the	O
18	fact	O
19	that	O
20	the	O
21	dissociation	O
22	rate	O
23	of	O
24	the	O
25	A	O
26	stem	O
27	substrate	O
28	from	O
29	the	O
30	protein	O
31	-	O
32	DNA	O
33	complexes	O
34	was	O
35	approximately	O
36	fourfold	O
37	faster	O
38	than	O
39	that	O
40	of	O
41	the	O
42	complete	O
43	TR	O
44	.	O

0	Mutations	O
1	in	O
2	three	O
3	loci	O
4	(	O
5	SIC1	B
6	,	O
7	SWI5	B
8	,	O
9	and	O
10	RIC3	B
11	)	O
12	were	O
13	identified	O
14	.	O

0	In	O
1	contrast	O
2	,	O
3	receptor	B
4	/	O
5	G	B
6	protein	I
7	coupling	O
8	appeared	O
9	unaffected	O
10	by	O
11	expression	O
12	of	O
13	loop	O
14	3i	O
15	domains	O
16	derived	O
17	from	O
18	two	O
19	receptors	O
20	coupled	O
21	to	O
22	G	B
23	(	I
24	i	I
25	/	I
26	o	I
27	)	I
28	proteins	I
29	(	O
30	M2Ach	B
31	-	O
32	muscarinic	B
33	and	O
34	alpha2A	B
35	-	I
36	adrenergic	I
37	receptors	I
38	).	O

0	The	O
1	plasmid	O
2	shuffle	O
3	technique	O
4	was	O
5	used	O
6	to	O
7	replace	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	gene	O
13	with	O
14	the	O
15	mutant	O
16	form	O
17	,	O
18	resulting	O
19	in	O
20	failure	O
21	of	O
22	the	O
23	yeast	O
24	cells	O
25	to	O
26	grow	O
27	.	O

0	The	O
1	various	O
2	muscles	O
3	of	O
4	the	O
5	pelvic	O
6	floor	O
7	region	O
8	could	O
9	be	O
10	reflexly	O
11	activated	O
12	either	O
13	individually	O
14	or	O
15	as	O
16	a	O
17	mass	O
18	unit	O
19	depending	O
20	on	O
21	the	O
22	intensity	O
23	of	O
24	stimulation	O
25	.	O

0	Negatively	O
1	supercoiled	O
2	plasmid	O
3	pUC19	O
4	did	O
5	not	O
6	compete	O
7	,	O
8	whereas	O
9	an	O
10	otherwise	O
11	identical	O
12	plasmid	O
13	pUC19	O
14	(	O
15	CG	O
16	),	O
17	which	O
18	contained	O
19	a	O
20	(	O
21	dG	O
22	-	O
23	dC	O
24	)	O
25	7	O
26	segment	O
27	in	O
28	the	O
29	Z	O
30	-	O
31	form	O
32	was	O
33	an	O
34	excellent	O
35	competitor	O
36	.	O

0	Control	O
1	of	O
2	fatty	O
3	liver	O
4	syndrome	O
5	in	O
6	a	O
7	Jersey	O
8	herd	O
9	by	O
10	a	O
11	change	O
12	of	O
13	diet	O
14	and	O
15	the	O
16	use	O
17	of	O
18	recombinant	B
19	bovine	I
20	somatotrophin	I
21	.	O

0	Mutational	O
1	analysis	O
2	shows	O
3	that	O
4	both	O
5	an	O
6	AP	B
7	-	I
8	1	I
9	like	I
10	sequence	I
11	(-	O
12	294	O
13	/-	O
14	285	O
15	,	O
16	TGAATCATCA	O
17	)	O
18	and	O
19	an	O
20	A	B
21	/	I
22	T	I
23	-	I
24	rich	I
25	myocyte	I
26	enhancer	I
27	factor	I
28	(	O
29	MEF	B
30	)-	I
31	2	I
32	like	O
33	sequence	O
34	(-	O
35	310	O
36	/-	O
37	298	O
38	,	O
39	TTAAAAATAAAAA	O
40	)	O
41	in	O
42	the	O
43	33	O
44	-	O
45	bp	O
46	region	O
47	are	O
48	necessary	O
49	for	O
50	the	O
51	OP	B
52	-	I
53	1	I
54	effect	O
55	.	O

0	To	O
1	analyze	O
2	the	O
3	VH	B
4	regions	I
5	of	O
6	polyreactive	O
7	antibodies	O
8	,	O
9	with	O
10	particular	O
11	attention	O
12	at	O
13	their	O
14	somatically	O
15	mutated	O
16	status	O
17	,	O
18	we	O
19	generated	O
20	five	O
21	IgG	B
22	(	O
23	three	O
24	IgG1	B
25	and	O
26	two	O
27	IgG3	B
28	)	O
29	mAb	B
30	(	O
31	using	O
32	B	O
33	cells	O
34	from	O
35	a	O
36	healthy	O
37	subject	O
38	,	O
39	a	O
40	patient	O
41	with	O
42	insulin	B
43	-	O
44	dependent	O
45	diabetes	O
46	mellitus	O
47	and	O
48	a	O
49	patient	O
50	with	O
51	SLE	O
52	),	O
53	which	O
54	bound	O
55	with	O
56	various	O
57	efficiencies	O
58	a	O
59	number	O
60	of	O
61	different	O
62	self	O
63	and	O
64	foreign	O
65	Ag	B
66	.	O

0	The	O
1	E1	B
2	nuclear	I
3	transport	I
4	motif	I
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	the	O
10	animal	O
11	and	O
12	human	O
13	papillomaviruses	O
14	and	O
15	is	O
16	encoded	O
17	in	O
18	a	O
19	similar	O
20	region	O
21	in	O
22	the	O
23	related	O
24	E1	B
25	genes	I
26	.	O

0	Purified	O
1	Hsk1	B
2	phosphorylates	O
3	the	O
4	Cdc19	B
5	(	O
6	Mcm2	B
7	)	O
8	subunit	O
9	of	O
10	the	O
11	six	O
12	-	O
13	member	O
14	minichromosome	B
15	maintenance	I
16	protein	I
17	complex	I
18	purified	O
19	from	O
20	fission	O
21	yeast	O
22	.	O

0	Vertebrate	B
1	synapsins	I
2	constitute	O
3	a	O
4	family	O
5	of	O
6	synaptic	O
7	proteins	O
8	that	O
9	participate	O
10	in	O
11	the	O
12	regulation	O
13	of	O
14	neurotransmitter	O
15	release	O
16	.	O

0	This	O
1	points	O
2	to	O
3	a	O
4	specific	O
5	interference	O
6	with	O
7	HSV	O
8	-	O
9	induced	O
10	DNA	O
11	amplification	O
12	.	O

0	DNA	B
1	polymerase	I
2	E	I
3	,	O
4	DNA	B
5	ligase	I
6	III	I
7	and	O
8	a	O
9	DNA	O
10	structure	O
11	-	O
12	specific	O
13	endonuclease	O
14	co	O
15	-	O
16	purify	O
17	with	O
18	the	O
19	five	O
20	polypeptide	O
21	complex	O
22	.	O

0	We	O
1	previously	O
2	described	O
3	the	O
4	purification	O
5	of	O
6	an	O
7	83	B
8	-	I
9	kDa	I
10	phosphatidic	I
11	acid	I
12	phosphatase	I
13	(	O
14	PAP	B
15	)	O
16	from	O
17	the	O
18	porcine	O
19	thymus	O
20	membranes	O
21	(	O
22	Kanoh	O
23	,	O
24	H	O
25	.,	O
26	Imai	O
27	,	O
28	S	O
29	.-	O
30	i	O
31	.,	O
32	Yamada	O
33	,	O
34	K	O
35	.	O
36	and	O
37	Sakane	O
38	,	O
39	F	O
40	.(	O
41	1992	O
42	)	O
43	J	O
44	.	O

0	Although	O
1	isl	B
2	-	I
3	1	I
4	binds	O
5	to	O
6	both	O
7	the	O
8	insulin	B
9	and	O
10	amylin	B
11	gene	I
12	promoter	I
13	elements	I
14	in	O
15	vitro	O
16	,	O
17	these	O
18	sequences	O
19	display	O
20	marked	O
21	differences	O
22	in	O
23	their	O
24	relative	O
25	transcriptional	O
26	properties	O
27	when	O
28	ligated	O
29	adjacent	O
30	to	O
31	a	O
32	heterologous	O
33	promoter	O
34	and	O
35	transfected	O
36	into	O
37	InR1	O
38	-	O
39	G9	O
40	islet	O
41	cells	O
42	.	O

0	Circulating	O
1	oxytocin	O
2	in	O
3	male	O
4	guinea	O
5	pigs	O
6	affected	O
7	by	O
8	the	O
9	female	O
10	cohabitation	O
11	and	O
12	reproductive	O
13	condition	O
14	.	O

0	Conditions	O
1	influencing	O
2	inhibitors	O
3	of	O
4	the	O
5	colony	B
6	-	I
7	stimulating	I
8	factor	I
9	(	O
10	CSF	B
11	).	O

0	Large	O
1	strain	O
2	differences	O
3	were	O
4	found	O
5	for	O
6	all	O
7	variables	O
8	recorded	O
9	,	O
10	i	O
11	.	O
12	e	O
13	.,	O
14	the	O
15	proportion	O
16	of	O
17	attacking	O
18	males	O
19	,	O
20	the	O
21	time	O
22	spent	O
23	in	O
24	the	O
25	brightly	O
26	lit	O
27	box	O
28	,	O
29	and	O
30	the	O
31	number	O
32	of	O
33	transitions	O
34	between	O
35	the	O
36	lit	O
37	and	O
38	the	O
39	dark	O
40	boxes	O
41	.	O

0	Chronic	O
1	thyroiditis	O
2	as	O
3	a	O
4	risk	O
5	factor	O
6	of	O
7	B	O
8	-	O
9	cell	O
10	lymphoma	O
11	in	O
12	the	O
13	thyroid	O
14	gland	O
15	.	O

0	This	O
1	experiment	O
2	was	O
3	conducted	O
4	to	O
5	determine	O
6	if	O
7	the	O
8	sex	O
9	or	O
10	actual	O
11	egg	O
12	production	O
13	was	O
14	the	O
15	important	O
16	factor	O
17	.(	O
18	ABSTRACT	O
19	TRUNCATED	O
20	AT	O
21	250	O
22	WORDS	O
23	)	O

0	12	O
1	:	O
2	2684	O
3	-	O
4	2697	O
5	,	O
6	1998	O
7	):	O
8	a	O
9	key	O
10	step	O
11	of	O
12	this	O
13	model	O
14	is	O
15	the	O
16	activation	O
17	of	O
18	the	O
19	MAPK	B
20	Fus3p	I
21	through	O
22	the	O
23	G	O
24	(	O
25	betagamma	O
26	)-	O
27	dependent	O
28	relocalization	O
29	of	O
30	the	O
31	Ste5p	B
32	-	O
33	MAPK	B
34	cascade	O
35	to	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O

0	The	O
1	ORF	B
2	4	I
3	gene	I
4	was	O
5	minimally	O
6	active	O
7	,	O
8	whereas	O
9	the	O
10	ORF	B
11	62	I
12	gene	I
13	gave	O
14	twofold	O
15	induction	O
16	;	O
17	both	O
18	genes	O
19	,	O
20	acting	O
21	together	O
22	,	O
23	gave	O
24	fivefold	O
25	induction	O
26	.	O

0	The	O
1	duration	O
2	of	O
3	diabetes	O
4	mellitus	O
5	in	O
6	these	O
7	patients	O
8	was	O
9	from	O
10	5	O
11	months	O
12	to	O
13	6	O
14	years	O
15	,	O
16	and	O
17	in	O
18	all	O
19	patients	O
20	this	O
21	was	O
22	the	O
23	first	O
24	myocardial	O
25	infarction	O
26	.	O

0	We	O
1	evaluated	O
2	regional	O
3	right	O
4	ventricular	O
5	wall	O
6	motion	O
7	during	O
8	systole	O
9	in	O
10	patients	O
11	with	O
12	surgically	O
13	repaired	O
14	tetralogy	O
15	of	O
16	Fallot	O
17	(	O
18	TOF	O
19	)	O
20	using	O
21	color	O
22	kinesis	O
23	imaging	O
24	.	O

0	The	O
1	scr	B
2	regulon	I
3	of	I
4	pUR400	I
5	and	O
6	the	O
7	chromosomally	O
8	encoded	O
9	scr	B
10	regulon	I
11	of	I
12	Klebsiella	I
13	pneumoniae	I
14	KAY2026	I
15	are	O
16	both	O
17	negatively	O
18	controlled	O
19	by	O
20	a	O
21	specific	O
22	repressor	O
23	(	O
24	ScrR	B
25	).	O

0	Members	O
1	of	O
2	SVA	B
3	are	O
4	also	O
5	present	O
6	in	O
7	the	O
8	complement	B
9	C2	I
10	gene	I
11	located	O
12	about	O
13	20	O
14	kilobases	O
15	upstream	O
16	of	O
17	RP1	B
18	in	O
19	the	O
20	HLA	B
21	and	O
22	in	O
23	the	O
24	cytochrome	B
25	CYP1A1	I
26	gene	I
27	.	O

0	Quantitative	O
1	analysis	O
2	of	O
3	DNA	O
4	using	O
5	flow	O
6	cytometry	O
7	and	O
8	immunocytochemical	O
9	findings	O
10	in	O
11	16	O
12	cases	O
13	of	O
14	cardiac	O
15	myxomas	O

0	Parodoxical	O
1	rise	O
2	in	O
3	urinary	B
4	albumin	B
5	levels	O
6	after	O
7	treatment	O
8	of	O
9	essential	O
10	hypertension	O
11	.	O

0	The	O
1	human	B
2	eps15	I
3	gene	I
4	,	O
5	encoding	O
6	a	O
7	tyrosine	B
8	kinase	I
9	substrate	I
10	,	O
11	is	O
12	conserved	O
13	in	O
14	evolution	O
15	and	O
16	maps	O
17	to	O
18	1p31	B
19	-	O
20	p32	B
21	.	O

0	We	O
1	then	O
2	demonstrated	O
3	that	O
4	1	O
5	)	O
6	GAL4	B
7	-	O
8	REV	B
9	-	O
10	erbA	B
11	alpha	O
12	chimeras	O
13	that	O
14	contain	O
15	the	O
16	'	O
17	AB	O
18	'	O
19	region	O
20	and	O
21	lack	O
22	the	O
23	'	O
24	E	O
25	'	O
26	region	O
27	activated	O
28	transcription	O
29	of	O
30	GAL4	B
31	response	O
32	elements	O
33	in	O
34	the	O
35	presence	O
36	of	O
37	8	O
38	-	O
39	Br	O
40	-	O
41	cAMP	O
42	and	O
43	2	O
44	)	O
45	the	O
46	ligand	O
47	-	O
48	binding	O
49	domain	O
50	(	O
51	LBD	O
52	)	O
53	contains	O
54	an	O
55	active	O
56	transcriptional	O
57	silencer	O
58	.	O

0	A	O
1	single	O
2	case	O
3	of	O
4	an	O
5	adenocarcinoma	O
6	,	O
7	arising	O
8	in	O
9	a	O
10	retroperitoneal	O
11	enterogenous	O
12	cyst	O
13	and	O
14	which	O
15	presented	O
16	as	O
17	a	O
18	left	O
19	renal	O
20	cyst	O
21	,	O
22	is	O
23	reported	O
24	.	O

0	Among	O
1	non	O
2	-	O
3	cirrhotics	O
4	,	O
5	lack	O
6	of	O
7	portal	O
8	vein	O
9	visualisation	O
10	had	O
11	a	O
12	90	O
13	%	O
14	sensitivity	O
15	,	O
16	88	O
17	%	O
18	specificity	O
19	,	O
20	94	O
21	%	O
22	negative	O
23	predictive	O
24	value	O
25	,	O
26	and	O
27	83	O
28	%	O
29	positive	O
30	predictive	O
31	value	O
32	in	O
33	the	O
34	diagnosis	O
35	of	O
36	pre	O
37	-	O
38	sinusoidal	O
39	portal	O
40	hypertension	O
41	.	O

0	The	O
1	5	O
2	'	O
3	end	O
4	of	O
5	the	O
6	genomic	O
7	RNA	O
8	of	O
9	rubella	O
10	virus	O
11	(	O
12	RUB	O
13	)	O
14	contains	O
15	a	O
16	14	O
17	-	O
18	nucleotide	O
19	(	O
20	nt	O
21	)	O
22	single	O
23	-	O
24	stranded	O
25	leader	O
26	(	O
27	ss	O
28	-	O
29	leader	O
30	)	O
31	followed	O
32	by	O
33	a	O
34	stem	O
35	-	O
36	and	O
37	-	O
38	loop	O
39	structure	O
40	[	O
41	5	O
42	'(+)	O
43	SL	O
44	]	O
45	(	O
46	nt	O
47	15	O
48	to	O
49	65	O
50	),	O
51	the	O
52	complement	O
53	of	O
54	which	O
55	at	O
56	the	O
57	3	O
58	'	O
59	end	O
60	of	O
61	the	O
62	minus	O
63	-	O
64	strand	O
65	RNA	O
66	[	O
67	3	O
68	'(-)	O
69	SL	O
70	]	O
71	has	O
72	been	O
73	proposed	O
74	to	O
75	function	O
76	as	O
77	a	O
78	promoter	O
79	for	O
80	synthesis	O
81	of	O
82	genomic	O
83	plus	O
84	strands	O
85	.	O

0	The	O
1	exon	O
2	-	O
3	intron	O
4	distribution	O
5	of	O
6	Cdebp	B
7	appears	O
8	strikingly	O
9	similar	O
10	to	O
11	that	O
12	of	O
13	the	O
14	App	B
15	gene	I
16	in	O
17	the	O
18	regions	O
19	encoding	O
20	the	O
21	conserved	O
22	domains	O
23	,	O
24	with	O
25	a	O
26	divergent	O
27	structure	O
28	in	O
29	the	O
30	other	O
31	parts	O
32	.	O

0	Glucose	O
1	disappearance	O
2	rate	O
3	and	O
4	changes	O
5	in	O
6	plasma	O
7	nutrients	O
8	after	O
9	intravenouly	O
10	injected	O
11	glucose	O
12	in	O
13	normoglycaemic	O
14	and	O
15	hypoglycaemic	O
16	underweight	O
17	newborns	O
18	.	O

0	Although	O
1	RAD17	B
2	,	O
3	RAD24	B
4	and	O
5	MEC3	B
6	are	O
7	not	O
8	required	O
9	for	O
10	cell	O
11	cycle	O
12	arrest	O
13	when	O
14	S	O
15	phase	O
16	is	O
17	inhibited	O
18	by	O
19	hydroxyurea	O
20	(	O
21	HU	O
22	),	O
23	they	O
24	do	O
25	contribute	O
26	to	O
27	the	O
28	viability	O
29	of	O
30	yeast	O
31	cells	O
32	grown	O
33	in	O
34	the	O
35	presence	O
36	of	O
37	HU	O
38	,	O
39	possibly	O
40	because	O
41	they	O
42	are	O
43	required	O
44	for	O
45	the	O
46	repair	O
47	of	O
48	HU	B
49	-	O
50	induced	O
51	DNA	O
52	damage	O
53	.	O

0	We	O
1	report	O
2	here	O
3	the	O
4	discovery	O
5	of	O
6	a	O
7	new	O
8	actin	B
9	-	I
10	related	I
11	gene	I
12	in	O
13	this	O
14	organism	O
15	,	O
16	which	O
17	we	O
18	have	O
19	named	O
20	ACT4	B
21	.	O

0	R	O
1	-	O
2	wave	O
3	voltage	O
4	in	O
5	the	O
6	right	O
7	precordial	O
8	leads	O
9	in	O
10	anthracycline	O
11	cardiomyopathy	O
12	:	O
13	a	O
14	clinical	O
15	study	O
16	.	O

0	To	O
1	investigate	O
2	the	O
3	mechanisms	O
4	involved	O
5	in	O
6	the	O
7	transcriptional	O
8	control	O
9	of	O
10	retinoid	B
11	X	I
12	receptor	I
13	(	O
14	RXR	B
15	)	O
16	gene	O
17	expression	O
18	,	O
19	the	O
20	5	O
21	'-	O
22	flanking	O
23	region	O
24	of	O
25	the	O
26	human	B
27	RXRgamma2	I
28	isoform	I
29	was	O
30	characterized	O
31	.	O

0	The	O
1	concentration	O
2	of	O
3	PGI2	O
4	on	O
5	the	O
6	newly	O
7	-	O
8	formed	O
9	luminal	O
10	surface	O
11	remained	O
12	low	O
13	.	O

0	Analysis	O
1	of	O
2	homologous	O
3	DNA	O
4	sequences	O
5	within	O
6	the	O
7	first	O
8	intron	O
9	of	O
10	the	O
11	mouse	O
12	and	O
13	human	B
14	mts1	I
15	genes	I
16	:	O
17	kB	O
18	-	O
19	like	O
20	site	O
21	and	O
22	microsatellite	O
23	DNA	O

0	In	O
1	the	O
2	chicken	O
3	liver	O
4	,	O
5	levels	O
6	of	O
7	chicken	B
8	MT	I
9	mRNA	I
10	were	O
11	rapidly	O
12	induced	O
13	by	O
14	metals	O
15	(	O
16	Cd2	O
17	+,	O
18	Zn2	O
19	+,	O
20	Cu2	O
21	+),	O
22	glucocorticoids	O
23	and	O
24	lipopolysaccharide	O
25	.	O

0	These	O
1	results	O
2	suggested	O
3	that	O
4	the	O
5	GG	O
6	motifs	O
7	contributed	O
8	to	O
9	the	O
10	cell	O
11	-	O
12	specific	O
13	transcription	O
14	of	O
15	the	O
16	human	B
17	insulin	I
18	gene	I
19	in	O
20	association	O
21	with	O
22	the	O
23	binding	O
24	of	O
25	the	O
26	sequence	O
27	-	O
28	specific	O
29	nuclear	O
30	factor	O
31	.	O

0	The	O
1	unphosphorylated	O
2	form	O
3	of	O
4	RNA	B
5	polymerase	I
6	II	I
7	is	O
8	designated	O
9	IIA	B
10	,	O
11	whereas	O
12	the	O
13	phosphorylated	O
14	form	O
15	is	O
16	designated	O
17	IIO	B
18	.	O

0	Within	O
1	this	O
2	sequence	O
3	the	O
4	MSAS	B
5	gene	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	5322	O
11	-	O
12	bp	O
13	-	O
14	long	O
15	open	O
16	reading	O
17	frame	O
18	coding	O
19	for	O
20	a	O
21	protein	O
22	of	O
23	1774	O
24	amino	O
25	acids	O
26	and	O
27	190	O
28	,	O
29	731	O
30	Da	O
31	molecular	O
32	mass	O
33	.	O

0	Identification	O
1	,	O
2	purification	O
3	,	O
4	and	O
5	molecular	O
6	cloning	O
7	of	O
8	autonomously	O
9	replicating	B
10	sequence	B
11	-	I
12	binding	I
13	protein	I
14	1	I
15	from	O
16	fission	O
17	yeast	O
18	Schizosaccharomyces	O
19	pombe	O
20	.	O

0	Common	O
1	history	O
2	and	O
3	prospects	O
4	in	O
5	surgical	O
6	gynecology	O
7	of	O
8	the	O
9	Charite	O
10	and	O
11	the	O
12	Vienna	O
13	University	O
14	Clinic	O

0	A	O
1	neuropsychological	O
2	test	O
3	battery	O
4	was	O
5	used	O
6	that	O
7	contained	O
8	the	O
9	Wisconsin	O
10	card	O
11	sorting	O
12	test	O
13	,	O
14	Street	O
15	completion	O
16	test	O
17	,	O
18	Stroop	O
19	test	O
20	,	O
21	a	O
22	dichotic	O
23	memory	O
24	listening	O
25	test	O
26	,	O
27	and	O
28	a	O
29	facial	O
30	recognition	O
31	test	O
32	.	O

0	A	O
1	total	O
2	of	O
3	1459	O
4	men	O
5	aged	O
6	48	O
7	to	O
8	84	O
9	years	O
10	,	O
11	who	O
12	were	O
13	diagnosed	O
14	for	O
15	the	O
16	first	O
17	time	O
18	by	O
19	physicians	O
20	as	O
21	having	O
22	BPH	O
23	in	O
24	1994	O
25	and	O
26	who	O
27	had	O
28	not	O
29	received	O
30	treatment	O
31	,	O
32	participated	O
33	in	O
34	the	O
35	study	O
36	.	O

0	GTRE	B
1	,	O
2	TRE	B
3	,	O
4	and	O
5	CRE	O
6	oligonucleotides	O
7	all	O
8	compete	O
9	more	O
10	efficiently	O
11	for	O
12	protein	O
13	binding	O
14	to	O
15	their	O
16	labeled	O
17	congeners	O
18	than	O
19	for	O
20	protein	O
21	binding	O
22	to	O
23	either	O
24	of	O
25	the	O
26	other	O
27	labeled	O
28	oligonucleotides	O
29	,	O
30	suggesting	O
31	that	O
32	the	O
33	GTRE	O
34	,	O
35	TRE	O
36	,	O
37	and	O
38	CRE	O
39	oligonucleotides	O
40	,	O
41	suggesting	O
42	that	O
43	the	O
44	GTRE	O
45	,	O
46	TRE	O
47	,	O
48	and	O
49	CRE	O
50	oligonucleotides	O
51	each	O
52	bind	O
53	unique	O
54	as	O
55	well	O
56	as	O
57	common	O
58	proteins	O
59	,	O
60	likely	O
61	to	O
62	be	O
63	members	O
64	of	O
65	the	O
66	Jun	B
67	/	O
68	Fos	B
69	and	O
70	cAMP	B
71	-	I
72	responsive	I
73	element	I
74	-	I
75	binding	I
76	protein	I
77	/	I
78	activating	I
79	transcription	I
80	factors	I
81	(	O
82	CREB	B
83	/	O
84	ATF	B
85	)	O
86	families	O
87	of	O
88	transcription	O
89	factors	O
90	,	O
91	in	O
92	chromaffin	O
93	cells	O
94	.	O

0	This	O
1	suggests	O
2	that	O
3	while	O
4	underpredictions	O
5	of	O
6	pain	O
7	do	O
8	not	O
9	hurt	O
10	more	O
11	,	O
12	disruption	O
13	on	O
14	primary	O
15	tasks	O
16	and	O
17	physiological	O
18	impact	O
19	are	O
20	higher	O
21	.	O

0	Serodiagnosis	O
1	of	O
2	trypanosomiasis	O
3	in	O
4	dromedary	O
5	camels	O
6	using	O
7	a	O
8	card	O
9	agglutination	O
10	test	O
11	set	O
12	(	O
13	Testryp	O
14	CATT	O
15	).	O

0	Finally	O
1	,	O
2	we	O
3	determined	O
4	that	O
5	the	O
6	P68	O
7	amino	O
8	terminus	O
9	was	O
10	both	O
11	necessary	O
12	and	O
13	sufficient	O
14	for	O
15	binding	O
16	dsRNA	O
17	as	O
18	we	O
19	were	O
20	able	O
21	to	O
22	transfer	O
23	dsRNA	O
24	-	O
25	binding	O
26	properties	O
27	to	O
28	a	O
29	reporter	O
30	gene	O
31	product	O
32	previously	O
33	unable	O
34	to	O
35	bind	O
36	RNA	O
37	.	O

0	For	O
1	sputum	B
2	interleukin	B
3	-	I
4	8	I
5	there	O
6	was	O
7	an	O
8	estimated	O
9	true	O
10	treatment	O
11	median	O
12	difference	O
13	of	O
14	142	O
15	pg	O
16	/	O
17	ml	O
18	(	O
19	95	O
20	%	O
21	confidence	O
22	interval	O
23	(	O
24	CI	O
25	)	O
26	8	O
27	to	O
28	2866	O
29	pg	O
30	/	O
31	ml	O
32	)	O
33	in	O
34	favour	O
35	of	O
36	placebo	O
37	;	O
38	while	O
39	for	O
40	maximal	O
41	expiratory	O
42	flow	O
43	at	O
44	25	O
45	%	O
46	(	O
47	MEF25	O
48	%)	O
49	remaining	O
50	forced	O
51	vital	O
52	capacity	O
53	predicted	O
54	for	O
55	sex	O
56	and	O
57	height	O
58	there	O
59	was	O
60	a	O
61	15	O
62	percentage	O
63	points	O
64	(	O
65	pp	O
66	)	O
67	(	O
68	95	O
69	%	O
70	CI	O
71	4	O
72	to	O
73	26	O
74	pp	O
75	)	O
76	mean	O
77	treatment	O
78	difference	O
79	in	O
80	favour	O
81	of	O
82	placebo	O
83	.	O

0	The	O
1	results	O
2	of	O
3	induced	O
4	coexpression	O
5	were	O
6	also	O
7	supported	O
8	by	O
9	rapid	O
10	generation	O
11	of	O
12	FeLV	O
13	recombinants	O
14	when	O
15	FeLV	B
16	-	I
17	C	I
18	was	O
19	used	O
20	to	O
21	infect	O
22	the	O
23	feline	O
24	3201B	O
25	cell	O
26	line	O
27	that	O
28	constitutively	O
29	expresses	O
30	high	O
31	levels	O
32	of	O
33	endogenous	O
34	FeLV	B
35	-	I
36	specific	I
37	mRNAs	I
38	.	O

0	The	O
1	sequenced	O
2	genomic	O
3	region	O
4	thus	O
5	accounts	O
6	for	O
7	essentially	O
8	all	O
9	of	O
10	the	O
11	longest	O
12	known	O
13	transcript	O
14	(	O
15	4	O
16	.	O
17	5	O
18	kb	O
19	),	O
20	although	O
21	the	O
22	precise	O
23	ends	O
24	of	O
25	this	O
26	transcript	O
27	have	O
28	not	O
29	been	O
30	defined	O
31	.	O

0	The	O
1	mutant	O
2	allele	O
3	of	O
4	the	O
5	alpha	B
6	1	I
7	-	I
8	tubulin	I
9	gene	I
10	was	O
11	designated	O
12	tua1	B
13	-	I
14	1	I
15	.	O

0	Plasmid	O
1	pAL618	O
2	contains	O
3	the	O
4	genetic	O
5	determinants	O
6	for	O
7	H2	B
8	uptake	O
9	(	O
10	hup	B
11	)	O
12	from	O
13	Rhizobium	O
14	leguminosarum	O
15	bv	O
16	.	O
17	viciae	O
18	,	O
19	including	O
20	a	O
21	cluster	O
22	of	O
23	17	O
24	genes	O
25	named	O
26	hupSLCDEFGHIJK	B
27	-	O
28	hypABFCDE	O
29	.	O

0	We	O
1	suggest	O
2	that	O
3	CT	O
4	scan	O
5	be	O
6	preferable	O
7	in	O
8	diagnosis	O
9	of	O
10	tumors	O
11	in	O
12	that	O
13	area	O
14	.	O

0	The	O
1	transposon	B
2	-	O
3	inactivated	O
4	gene	O
5	,	O
6	designated	O
7	pilP	B
8	,	O
9	is	O
10	525	O
11	bp	O
12	long	O
13	,	O
14	potentially	O
15	encoding	O
16	a	O
17	19	O
18	.	O
19	1	O
20	-	O
21	kDa	O
22	protein	O
23	precursor	O
24	that	O
25	contains	O
26	a	O
27	typical	O
28	membrane	O
29	lipoprotein	O
30	leader	O
31	sequence	O
32	.	O

0	A	O
1	technique	O
2	for	O
3	thermal	O
4	imaging	O
5	of	O
6	the	O
7	animal	O
8	and	O
9	human	O
10	brain	O
11	cortex	O
12	using	O
13	an	O
14	infrared	O
15	optical	O
16	system	O
17	is	O
18	described	O
19	.	O

0	The	O
1	CRE	O
2	,	O
3	5	O
4	'-	O
5	TGACGTCA	O
6	-	O
7	3	O
8	',	O
9	has	O
10	been	O
11	described	O
12	as	O
13	the	O
14	consensus	O
15	sequence	O
16	for	O
17	the	O
18	cis	O
19	-	O
20	element	O
21	that	O
22	directs	O
23	cAMP	O
24	-	O
25	regulated	O
26	gene	O
27	expression	O
28	.	O

0	Transcription	O
1	factors	O
2	of	O
3	the	O
4	Stat	B
5	family	I
6	are	O
7	controlled	O
8	by	O
9	protein	O
10	kinases	O
11	.	O

0	The	O
1	first	O
2	group	O
3	of	O
4	sequential	O
5	BMB	O
6	showed	O
7	a	O
8	significant	O
9	progress	O
10	to	O
11	myelofibrosis	O
12	in	O
13	so	O
14	-	O
15	called	O
16	"	O
17	Chronic	O
18	Megakaryocytic	O
19	-	O
20	Granulocytic	O
21	Myelosis	O
22	"--	O
23	CMGM	O
24	-,	O
25	which	O
26	corresponds	O
27	to	O
28	Agnogenic	O
29	Myeloid	O
30	Metaplasia	O
31	-	O
32	AMM	O
33	-	O
34	in	O
35	72	O
36	.	O
37	4	O
38	%	O
39	(	O
40	21	O
41	/	O
42	29	O
43	patients	O
44	),	O
45	as	O
46	well	O
47	as	O
48	in	O
49	CML	O
50	with	O
51	megakaryocytic	O
52	increase	O
53	-	O
54	CML	O
55	.	O
56	MI	O
57	-	O
58	in	O
59	39	O
60	.	O
61	2	O
62	%	O
63	(	O
64	20	O
65	/	O
66	51	O
67	).	O

0	Confirmatory	O
1	statistics	O
2	included	O
3	item	O
4	2	O
5	of	O
6	the	O
7	Clinical	O
8	Global	O
9	Impression	O
10	(	O
11	CGI	O
12	),	O
13	the	O
14	total	O
15	score	O
16	of	O
17	the	O
18	Sandoz	O
19	Clinical	O
20	Assessment	O
21	Geriatric	O
22	(	O
23	SCAG	O
24	)	O
25	scale	O
26	,	O
27	the	O
28	subscale	O
29	'	O
30	need	O
31	for	O
32	help	O
33	'	O
34	of	O
35	the	O
36	nurse	O
37	'	O
38	s	O
39	rating	O
40	of	O
41	geriatric	O
42	patients	O
43	(	O
44	Beurteilungsskala	O
45	fur	O
46	geriatrische	O
47	Patienten	O
48	;	O
49	BGP	O
50	)	O
51	and	O
52	the	O
53	total	O
54	score	O
55	of	O
56	the	O
57	Short	O
58	Cognitive	O
59	Performance	O
60	Test	O
61	(	O
62	Syndrom	O
63	-	O
64	Kurztest	O
65	;	O
66	SKT	O
67	).	O

0	Recipients	O
1	with	O
2	acute	O
3	leukaemia	O
4	in	O
5	first	O
6	remission	O
7	or	O
8	chronic	O
9	myeloid	O
10	leukaemia	O
11	in	O
12	first	O
13	chronic	O
14	phase	O
15	were	O
16	analysed	O
17	as	O
18	good	O
19	risk	O
20	,	O
21	and	O
22	those	O
23	beyond	O
24	these	O
25	stages	O
26	,	O
27	as	O
28	poor	O
29	risk	O
30	patients	O
31	.	O

0	Analysis	O
1	of	O
2	RAR	B
3	alpha	I
4	mutants	I
5	in	O
6	transfection	O
7	studies	O
8	reveals	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	is	O
15	sufficient	O
16	for	O
17	inhibition	O
18	of	O
19	BZLF1	B
20	activity	O
21	.	O

0	A	O
1	coiled	O
2	-	O
3	coil	O
4	domain	O
5	,	O
6	conserved	O
7	within	O
8	each	O
9	encoded	O
10	protein	O
11	,	O
12	serves	O
13	as	O
14	a	O
15	potential	O
16	interaction	O
17	motif	O
18	for	O
19	FLI	B
20	LRR	I
21	.	O

0	The	O
1	N1	O
2	and	O
3	P2	O
4	were	O
5	comparable	O
6	in	O
7	amplitude	O
8	and	O
9	both	O
10	had	O
11	prolonged	O
12	refractory	O
13	periods	O
14	.	O

0	Because	O
1	of	O
2	the	O
3	small	O
4	number	O
5	of	O
6	visceral	O
7	angiography	O
8	procedures	O
9	performed	O
10	(	O
11	38	O
12	),	O
13	no	O
14	definitive	O
15	conclusions	O
16	could	O
17	be	O
18	drawn	O
19	as	O
20	to	O
21	the	O
22	differences	O
23	between	O
24	ionic	O
25	and	O
26	nonionic	O
27	agents	O
28	regarding	O
29	grade	O
30	-	O
31	2	O
32	and	O
33	grade	O
34	-	O
35	3	O
36	adverse	O
37	events	O
38	.	O

0	Organization	O
1	of	O
2	the	O
3	human	B
4	LU	I
5	gene	I
6	and	O
7	molecular	O
8	basis	O
9	of	O
10	the	O
11	Lu	B
12	(	I
13	a	I
14	)/	I
15	Lu	B
16	(	I
17	b	I
18	)	I
19	blood	I
20	group	I
21	polymorphism	O
22	.	O

0	After	O
1	28	O
2	days	O
3	of	O
4	haloperidol	O
5	treatment	O
6	,	O
7	similar	O
8	changes	O
9	were	O
10	observed	O
11	for	O
12	delta	O
13	,	O
14	together	O
15	with	O
16	an	O
17	increase	O
18	of	O
19	alpha	O
20	1	O
21	,	O
22	and	O
23	a	O
24	decrease	O
25	of	O
26	fast	O
27	beta	O
28	.	O

0	All	O
1	six	O
2	ARF	B
3	cDNAs	I
4	are	O
5	more	O
6	similar	O
7	to	O
8	each	O
9	other	O
10	than	O
11	to	O
12	other	O
13	approximately	B
14	20	B
15	-	I
16	kDa	I
17	guanine	I
18	nucleotide	I
19	-	I
20	binding	I
21	proteins	I
22	.	O

0	Monitoring	O
1	patients	O
2	with	O
3	acute	O
4	leukemia	O
5	for	O
6	IL	B
7	-	I
8	1	I
9	and	O
10	TNF	B
11	levels	O
12	throughout	O
13	the	O
14	clinical	O
15	course	O
16	of	O
17	disease	O
18	may	O
19	help	O
20	clarify	O
21	the	O
22	causes	O
23	of	O
24	febrile	O
25	episodes	O
26	.	O

0	METHODS	O
1	:	O
2	Forty	O
3	-	O
4	nine	O
5	cases	O
6	with	O
7	intrahepatic	O
8	multiple	O
9	nodules	O
10	of	O
11	HCC	O
12	,	O
13	by	O
14	gross	O
15	examination	O
16	,	O
17	among	O
18	184	O
19	consecutive	O
20	resected	O
21	HCCs	O
22	were	O
23	examined	O
24	clinicopathologically	O
25	.	O

0	This	O
1	reveals	O
2	a	O
3	new	O
4	test	O
5	for	O
6	short	O
7	saphenous	O
8	incompetence	O
9	and	O
10	shows	O
11	that	O
12	14	O
13	per	O
14	cent	O
15	of	O
16	varices	O
17	stem	O
18	from	O
19	a	O
20	saphenopopliteal	O
21	reflux	O
22	.	O

0	In	O
1	26	O
2	patients	O
3	with	O
4	angina	O
5	pectoris	O
6	,	O
7	the	O
8	changes	O
9	of	O
10	LVEF	O
11	,	O
12	LVESV	O
13	and	O
14	PSP	O
15	/	O
16	LVESV	O
17	were	O
18	more	O
19	sensitive	O
20	for	O
21	the	O
22	detection	O
23	of	O
24	exercise	O
25	-	O
26	induced	O
27	ischemia	O
28	than	O
29	the	O
30	appearance	O
31	of	O
32	chest	O
33	pain	O
34	and	O
35	the	O
36	changes	O
37	of	O
38	ECG	O
39	.	O

0	I	O
1	.	O

0	Purification	O
1	and	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	serine	B
7	protease	I
8	,	O
9	RNK	B
10	-	I
11	Met	I
12	-	I
13	1	I
14	,	O
15	from	O
16	the	O
17	granules	O
18	of	O
19	a	O
20	rat	O
21	natural	O
22	killer	O
23	cell	O
24	leukemia	O
25	.	O

0	At	O
1	some	O
2	sites	O
3	,	O
4	%	O
5	T	O
6	is	O
7	greatly	O
8	increased	O
9	by	O
10	Cl	O
11	-	O
12	concentrations	O
13	up	O
14	to	O
15	1	O
16	M	O
17	,	O
18	while	O
19	at	O
20	other	O
21	sites	O
22	%	O
23	T	O
24	is	O
25	reduced	O
26	or	O
27	unaffected	O
28	by	O
29	these	O
30	conditions	O
31	.	O

0	The	O
1	MVV	O
2	-	O
3	value	O
4	is	O
5	under	O
6	the	O
7	predicted	O
8	level	O
9	in	O
10	the	O
11	case	O
12	of	O
13	67	O
14	-	O
15	76	O
16	percent	O
17	.	O

0	We	O
1	have	O
2	utilized	O
3	the	O
4	human	B
5	4F2	I
6	heavy	I
7	chain	I
8	(	I
9	4F2HC	I
10	)	O
11	gene	O
12	as	O
13	a	O
14	model	O
15	system	O
16	in	O
17	studies	O
18	designed	O
19	to	O
20	elucidate	O
21	the	O
22	molecular	O
23	events	O
24	involved	O
25	in	O
26	regulating	O
27	inducible	O
28	gene	O
29	expression	O
30	during	O
31	normal	O
32	human	O
33	T	O
34	-	O
35	cell	O
36	activation	O
37	.	O

0	Detailed	O
1	molecular	O
2	organization	O
3	of	O
4	the	O
5	coding	O
6	and	O
7	upstream	O
8	regulatory	O
9	regions	O
10	of	O
11	the	O
12	murine	B
13	homeodomain	I
14	-	I
15	containing	I
16	gene	I
17	,	O
18	Msx	B
19	-	I
20	1	I
21	,	O
22	is	O
23	reported	O
24	.	O

0	A	O
1	total	O
2	of	O
3	174	O
4	primer	O
5	pairs	O
6	gave	O
7	interpretable	O
8	banding	O
9	patterns	O
10	,	O
11	137	O
12	(	O
13	79	O
14	%)	O
15	of	O
16	which	O
17	revealed	O
18	at	O
19	least	O
20	two	O
21	alleles	O
22	on	O
23	native	O
24	polyacrylamide	O
25	gels	O
26	.	O

0	STP1	B
1	is	O
2	an	O
3	unessential	O
4	yeast	O
5	gene	O
6	involved	O
7	in	O
8	the	O
9	removal	O
10	of	O
11	intervening	O
12	sequences	O
13	from	O
14	some	O
15	,	O
16	but	O
17	not	O
18	all	O
19	,	O
20	families	O
21	of	O
22	intervening	O
23	sequence	O
24	-	O
25	containing	O
26	pre	O
27	-	O
28	tRNAs	O
29	.	O

0	Enoxacin	O
1	appears	O
2	to	O
3	be	O
4	well	O
5	suited	O
6	for	O
7	the	O
8	treatment	O
9	of	O
10	complicated	O
11	UTI	O
12	.	O

0	The	O
1	effect	O
2	of	O
3	low	O
4	dosage	O
5	radiation	O
6	on	O
7	metabolism	O
8	and	O
9	function	O
10	of	O
11	the	O
12	rat	O
13	kidney	O
14	damaged	O
15	by	O
16	ischemia	O

0	The	O
1	critical	O
2	mutations	O
3	were	O
4	likely	O
5	to	O
6	have	O
7	been	O
8	multiple	O
9	and	O
10	dispersed	O
11	,	O
12	including	O
13	elongation	O
14	of	O
15	the	O
16	TM	B
17	and	O
18	Nef	B
19	coding	I
20	sequences	I
21	;	O
22	changes	O
23	in	O
24	RNA	O
25	splice	O
26	donor	O
27	and	O
28	acceptor	O
29	sites	O
30	,	O
31	TATA	O
32	box	O
33	sites	O
34	,	O
35	and	O
36	Sp1	B
37	sites	I
38	;	O
39	multiple	O
40	changes	O
41	in	O
42	the	O
43	V2	O
44	region	O
45	of	O
46	SU	B
47	,	O
48	including	O
49	a	O
50	consensus	O
51	neutralization	O
52	epitope	O
53	;	O
54	and	O
55	five	O
56	new	O
57	N	O
58	-	O
59	linked	O
60	glycosylation	O
61	sites	O
62	in	O
63	SU	B
64	.	O

0	In	O
1	the	O
2	premating	O
3	period	O
4	male	O
5	rate	O
6	of	O
7	aggression	O
8	was	O
9	not	O
10	significantly	O
11	correlated	O
12	with	O
13	testosterone	O
14	level	O
15	.	O

0	To	O
1	test	O
2	the	O
3	feasibility	O
4	of	O
5	using	O
6	liposomes	O
7	to	O
8	deliver	O
9	therapeutic	O
10	agents	O
11	to	O
12	the	O
13	lungs	O
14	,	O
15	the	O
16	effect	O
17	of	O
18	liposome	B
19	-	I
20	encapsulated	I
21	superoxide	I
22	dismutase	I
23	(	O
24	SOD	B
25	)	O
26	or	O
27	catalase	B
28	on	O
29	pulmonary	O
30	oxygen	O
31	toxicity	O
32	was	O
33	studied	O
34	in	O
35	rats	O
36	.	O

0	Importantly	O
1	,	O
2	in	O
3	HeLa	O
4	and	O
5	293	O
6	cells	O
7	,	O
8	endogenous	O
9	and	O
10	transfected	O
11	I	B
12	kappaB	I
13	alpha	I
14	coimmunoprecipitated	O
15	with	O
16	Myc	B
17	-	O
18	tagged	O
19	or	O
20	endogenous	O
21	Dlc	I
22	-	I
23	1	I
24	.	O

0	The	O
1	coexpression	O
2	of	O
3	full	O
4	-	O
5	length	O
6	expression	O
7	constructs	O
8	for	O
9	both	O
10	DBP	B
11	and	O
12	hepatic	B
13	leukemia	I
14	factor	I
15	resulted	O
16	in	O
17	a	O
18	dramatic	O
19	increase	O
20	in	O
21	activation	O
22	mediated	O
23	by	O
24	the	O
25	GAL4	B
26	-	O
27	DBP	B
28	fusion	O
29	proteins	O
30	,	O
31	suggesting	O
32	the	O
33	involvement	O
34	of	O
35	a	O
36	regulated	O
37	coactivator	O
38	in	O
39	this	O
40	process	O
41	.	O

0	MEK	B
1	itself	O
2	is	O
3	activated	O
4	via	O
5	serine	O
6	phosphorylation	O
7	by	O
8	upstream	O
9	activator	O
10	kinases	O
11	,	O
12	including	O
13	c	B
14	-	I
15	raf	I
16	,	O
17	mos	B
18	and	O
19	MEK	B
20	kinase	I
21	.	O

0	A	O
1	multi	O
2	-	O
3	centre	O
4	evaluation	O
5	of	O
6	the	O
7	card	O
8	indirect	O
9	agglutination	O
10	test	O
11	for	O
12	trypanosomiasis	O
13	(	O
14	TrypTect	O
15	CIATT	O
16	).	O

0	The	O
1	7	O
2	-	O
3	day	O
4	treatment	O
5	resulted	O
6	in	O
7	a	O
8	decrease	O
9	in	O
10	mitochondrial	O
11	uptake	O
12	of	O
13	Rh123	O
14	and	O
15	an	O
16	increase	O
17	in	O
18	NAO	O
19	uptake	O
20	.	O

0	Oxidative	O
1	degradation	O
2	of	O
3	adrenaline	O
4	solutions	O
5	:	O
6	study	O
7	of	O
8	the	O
9	intermediate	O
10	stages	O
11	and	O
12	their	O
13	analytic	O
14	value	O
15	for	O
16	the	O
17	control	O
18	of	O
19	this	O
20	solute	O

0	The	O
1	P165	O
2	component	O
3	,	O
4	however	O
5	,	O
6	could	O
7	be	O
8	differentiated	O
9	from	O
10	the	O
11	two	O
12	later	O
13	components	O
14	since	O
15	it	O
16	increased	O
17	in	O
18	amplitude	O
19	with	O
20	increased	O
21	task	O
22	demands	O
23	while	O
24	the	O
25	N2	O
26	and	O
27	P3	O
28	amplitudes	O
29	remained	O
30	constant	O
31	.	O

0	During	O
1	the	O
2	conditioning	O
3	procedure	O
4	,	O
5	the	O
6	C	O
7	-	O
8	fiber	O
9	reflex	O
10	was	O
11	facilitated	O
12	(	O
13	wind	O
14	-	O
15	up	O
16	)	O
17	in	O
18	a	O
19	stimulus	O
20	-	O
21	dependent	O
22	fashion	O
23	in	O
24	intact	O
25	,	O
26	anesthetized	O
27	animals	O
28	during	O
29	the	O
30	application	O
31	of	O
32	the	O
33	first	O
34	seven	O
35	conditioning	O
36	stimuli	O
37	;	O
38	thereafter	O
39	,	O
40	the	O
41	magnitude	O
42	of	O
43	the	O
44	responses	O
45	reached	O
46	a	O
47	plateau	O
48	and	O
49	then	O
50	decreased	O
51	.	O

0	Of	O
1	the	O
2	single	O
3	-	O
4	stranded	O
5	DNA	O
6	transformants	O
7	,	O
8	65	O
9	%	O
10	resulted	O
11	from	O
12	replacement	O
13	of	O
14	the	O
15	resident	O
16	met2	B
17	mutation	I
18	by	O
19	the	O
20	exogenous	O
21	wild	O
22	-	O
23	type	O
24	allele	O
25	.	O

0	Their	O
1	use	O
2	resulted	O
3	in	O
4	a	O
5	sensitivity	O
6	of	O
7	73	O
8	%	O
9	and	O
10	a	O
11	specificity	O
12	of	O
13	74	O
14	%	O
15	with	O
16	regard	O
17	to	O
18	predictability	O
19	of	O
20	ALT	B
21	levels	O
22	increasing	O
23	during	O
24	the	O
25	trial	O
26	.	O

0	Fourteen	O
1	patients	O
2	were	O
3	in	O
4	the	O
5	multifocal	O
6	disease	O
7	group	O
8	;	O
9	13	O
10	were	O
11	detected	O
12	by	O
13	SPECT	O
14	and	O
15	10	O
16	by	O
17	TCT	O
18	.	O

0	The	O
1	application	O
2	of	O
3	ISH	O
4	and	O
5	IHC	O
6	did	O
7	not	O
8	change	O
9	significantly	O
10	the	O
11	routine	O
12	histologic	O
13	classification	O
14	of	O
15	pneumonias	O
16	into	O
17	CMV	O
18	-	O
19	IP	O
20	and	O
21	IIP	O
22	.	O

0	The	O
1	ultrastructure	O
2	of	O
3	retinal	O
4	vessels	O
5	was	O
6	examined	O
7	in	O
8	three	O
9	eyes	O
10	from	O
11	diabetic	O
12	patients	O
13	and	O
14	two	O
15	eyes	O
16	from	O
17	control	O
18	subjects	O
19	.	O

0	A	O
1	study	O
2	in	O
3	vivo	O
4	of	O
5	adrenergic	B
6	receptors	I
7	in	O
8	the	O
9	rectum	O
10	and	O
11	in	O
12	the	O
13	internal	O
14	and	O
15	sphincter	O
16	of	O
17	the	O
18	cat	O
19	.	O

0	Among	O
1	953	O
2	infants	O
3	in	O
4	22	O
5	neonatal	O
6	care	O
7	units	O
8	studied	O
9	,	O
10	23	O
11	%	O
12	(	O
13	median	O
14	value	O
15	,	O
16	range	O
17	0	O
18	-	O
19	78	O
20	)	O
21	were	O
22	found	O
23	to	O
24	be	O
25	faecally	O
26	colonized	O
27	with	O
28	one	O
29	of	O
30	21	O
31	distinct	O
32	nosocomial	O
33	strains	O
34	of	O
35	Escherichia	O
36	coli	O
37	,	O
38	Klebsiella	O
39	or	O
40	Enterobacter	O
41	spp	O
42	.	O

0	Surgical	O
1	treatment	O
2	of	O
3	pulmonary	O
4	metastases	O
5	.	O

0	Negative	O
1	-	O
2	staining	O
3	,	O
4	refractile	O
5	mycobacteria	O
6	in	O
7	Romanowsky	O
8	-	O
9	stained	O
10	smears	O
11	.	O

0	We	O
1	also	O
2	localized	O
3	the	O
4	Fra	O
5	-	O
6	2	O
7	phosphorylation	O
8	sites	O
9	by	O
10	MAPK	B
11	to	O
12	three	O
13	threonine	O
14	and	O
15	three	O
16	serine	O
17	residues	O
18	in	O
19	the	O
20	COOH	O
21	-	O
22	terminal	O
23	region	O
24	by	O
25	means	O
26	of	O
27	site	O
28	-	O
29	directed	O
30	mutagenesis	O
31	and	O
32	showed	O
33	that	O
34	the	O
35	threonine	O
36	residues	O
37	were	O
38	more	O
39	susceptible	O
40	to	O
41	MAPK	B
42	.	O

0	Six	O
1	tandem	O
2	repeats	O
3	of	O
4	the	O
5	P	O
6	element	O
7	linked	O
8	to	O
9	the	O
10	SV40	B
11	promoter	I
12	responded	O
13	to	O
14	phorbol	O
15	12	O
16	-	O
17	myristate	O
18	13	O
19	-	O
20	acetate	O
21	,	O
22	while	O
23	that	O
24	of	O
25	other	O
26	elements	O
27	did	O
28	not	O
29	.	O

0	Soluble	O
1	FasR	B
2	ligand	I
3	-	I
4	binding	I
5	domain	I
6	:	O
7	high	O
8	-	O
9	yield	O
10	production	O
11	of	O
12	active	O
13	fusion	O
14	and	O
15	non	O
16	-	O
17	fusion	O
18	recombinant	O
19	proteins	O
20	using	O
21	the	O
22	baculovirus	O
23	/	O
24	insect	O
25	cell	O
26	system	O
27	.	O

0	Upon	O
1	induction	O
2	of	O
3	SOS	O
4	,	O
5	viability	O
6	increased	O
7	2	O
8	-	O
9	6	O
10	-	O
11	fold	O
12	.	O

0	Radioligand	O
1	binding	O
2	was	O
3	indistinguishable	O
4	for	O
5	both	O
6	transiently	O
7	expressed	O
8	constructs	O
9	.	O

0	The	O
1	mean	O
2	serum	O
3	creatinine	O
4	levels	O
5	were	O
6	similar	O
7	at	O
8	one	O
9	year	O
10	(	O
11	SPK	O
12	1	O
13	.	O
14	8	O
15	,	O
16	KTA	O
17	1	O
18	.	O
19	9	O
20	mg	O
21	/	O
22	d	O
23	).(	O
24	ABSTRACT	O
25	TRUNCATED	O
26	AT	O
27	250	O
28	WORDS	O
29	)	O

0	The	O
1	test	O
2	was	O
3	not	O
4	performed	O
5	in	O
6	3923	O
7	patients	O
8	because	O
9	of	O
10	contraindications	O
11	.	O

0	These	O
1	results	O
2	suggest	O
3	that	O
4	less	O
5	antidopaminergic	O
6	activity	O
7	of	O
8	RHAL	B
9	in	O
10	this	O
11	neuroleptic	O
12	test	O
13	might	O
14	be	O
15	explained	O
16	by	O
17	the	O
18	lesser	O
19	conversion	O
20	of	O
21	RHAL	B
22	to	O
23	HAL	O
24	.	O

0	Although	O
1	the	O
2	fertility	O
3	decline	O
4	in	O
5	the	O
6	black	O
7	population	O
8	in	O
9	the	O
10	Mississippi	O
11	Delta	O
12	between	O
13	the	O
14	late	O
15	1870	O
16	'	O
17	s	O
18	and	O
19	early	O
20	1930	O
21	'	O
22	s	O
23	closely	O
24	paralleled	O
25	that	O
26	of	O
27	the	O
28	national	O
29	black	O
30	population	O
31	,	O
32	it	O
33	rose	O
34	much	O
35	more	O
36	dramatically	O
37	in	O
38	the	O
39	1940	O
40	'	O
41	s	O
42	and	O
43	1950	O
44	'	O
45	s	O
46	to	O
47	almost	O
48	1880	O
49	levels	O
50	.	O

0	In	O
1	contrast	O
2	,	O
3	the	O
4	differentiation	O
5	of	O
6	neoplastically	O
7	transformed	O
8	cells	O
9	does	O
10	not	O
11	repress	O
12	mitogenic	O
13	responsiveness	O
14	or	O
15	junB	B
16	or	O
17	c	B
18	-	I
19	fos	I
20	inducibility	O
21	.	O

0	Neither	O
1	Ha	B
2	-	I
3	Ras	I
4	(	O
5	G12V	O
6	,	O
7	T35S	O
8	)	O
9	(	O
10	Ha	B
11	-	I
12	RasV12S35	I
13	),	O
14	which	O
15	activates	O
16	the	O
17	Rafl	B
18	signaling	O
19	pathway	O
20	,	O
21	nor	O
22	Ha	B
23	-	I
24	Ras	I
25	(	O
26	G12V	O
27	,	O
28	E37G	O
29	)	O
30	(	O
31	Ha	B
32	-	I
33	RasV12G37	I
34	),	O
35	which	O
36	stimulates	O
37	the	O
38	RalGDS	B
39	pathway	O
40	,	O
41	did	O
42	not	O
43	have	O
44	significant	O
45	effects	O
46	on	O
47	factor	O
48	-	O
49	withdrawal	O
50	apoptosis	O
51	of	O
52	myeloid	O
53	cells	O
54	.	O

0	Redistribution	O
1	of	O
2	mannosidase	B
3	I	I
4	was	O
5	also	O
6	observed	O
7	in	O
8	cells	O
9	incubated	O
10	at	O
11	15	O
12	degrees	O
13	C	O
14	.	O

0	Copyright	O
1	2000	O
2	The	O
3	Royal	O
4	College	O
5	of	O
6	Radiologists	O
7	.	O

0	Under	O
1	resting	O
2	conditions	O
3	,	O
4	activity	O
5	levels	O
6	of	O
7	cardiac	O
8	vagal	O
9	and	O
10	sympathetic	O
11	outflows	O
12	are	O
13	not	O
14	related	O
15	across	O
16	young	O
17	,	O
18	healthy	O
19	human	O
20	subjects	O
21	and	O
22	peripheral	O
23	interaction	O
24	is	O
25	not	O
26	manifest	O
27	between	O
28	the	O
29	autonomic	O
30	divisions	O
31	.	O

0	Using	O
1	16	O
2	strains	O
3	of	O
4	C	O
5	.	O
6	trachomatis	O
7	in	O
8	triplicate	O
9	assays	O
10	,	O
11	we	O
12	found	O
13	the	O
14	RT	O
15	-	O
16	PCR	O
17	method	O
18	consistently	O
19	more	O
20	sensitive	O
21	than	O
22	the	O
23	conventional	O
24	technique	O
25	for	O
26	all	O
27	eight	O
28	antimicrobials	O
29	tested	O
30	,	O
31	with	O
32	resultant	O
33	MICs	O
34	determined	O
35	by	O
36	RT	O
37	-	O
38	PCR	O
39	ranging	O
40	from	O
41	1	O
42	.	O
43	6	O
44	-	O
45	fold	O
46	higher	O
47	(	O
48	erythromycin	O
49	)	O
50	to	O
51	>/=	O
52	195	O
53	-	O
54	fold	O
55	higher	O
56	(	O
57	amoxicillin	O
58	).	O

0	Autotransfusion	O
1	was	O
2	performed	O
3	as	O
4	follows	O
5	:	O
6	Heparin	O
7	-	O
8	ACD	O
9	-	O
10	B	O
11	-	O
12	Heparin	O
13	-	O
14	DPD	O
15	-	O
16	Heparin	O
17	-	O
18	ACD	O
19	-	O
20	B	O
21	etc	O
22	.	O

0	Infection	O
1	with	O
2	Neisseria	O
3	meningitidis	O
4	group	O
5	B	O
6	has	O
7	been	O
8	difficult	O
9	to	O
10	detect	O
11	,	O
12	partly	O
13	because	O
14	this	O
15	bacterial	O
16	group	O
17	'	O
18	s	O
19	polysaccharide	O
20	is	O
21	a	O
22	weak	O
23	immunogen	O
24	.	O

0	These	O
1	mutants	O
2	were	O
3	tested	O
4	for	O
5	ability	O
6	to	O
7	bind	O
8	each	O
9	of	O
10	the	O
11	Site	B
12	II	I
13	cognate	I
14	proteins	I
15	,	O
16	and	O
17	subsequently	O
18	evaluated	O
19	for	O
20	ability	O
21	to	O
22	confer	O
23	H4	B
24	transcriptional	O
25	activity	O
26	using	O
27	chimeric	O
28	H4	B
29	promoter	I
30	/	O
31	CAT	B
32	fusion	O
33	constructs	O
34	in	O
35	different	O
36	cell	O
37	types	O
38	.	O

0	However	O
1	,	O
2	essential	O
3	contrast	O
4	differences	O
5	existing	O
6	between	O
7	the	O
8	FSE	B
9	sequences	I
10	and	O
11	their	O
12	routine	O
13	asymmetric	O
14	dual	O
15	SE	O
16	counterpart	O
17	can	O
18	be	O
19	identified	O
20	.	O

0	For	O
1	replication	O
2	reporter	O
3	constructs	O
4	where	O
5	E1	B
6	and	O
7	E2	B
8	are	O
9	supplied	O
10	in	O
11	trans	O
12	by	O
13	the	O
14	respective	O
15	expression	O
16	vectors	O
17	,	O
18	distance	O
19	between	O
20	the	O
21	half	O
22	sites	O
23	seems	O
24	to	O
25	play	O
26	a	O
27	major	O
28	role	O
29	,	O
30	yet	O
31	the	O
32	phasing	O
33	relationships	O
34	are	O
35	measurable	O
36	.	O

0	Regulation	O
1	of	O
2	myosin	B
3	phosphatase	I
4	activity	O
5	involves	O
6	changes	O
7	in	O
8	subunit	O
9	interactions	O
10	,	O
11	although	O
12	molecular	O
13	mechanisms	O
14	are	O
15	not	O
16	defined	O
17	.	O

0	Significance	O
1	of	O
2	the	O
3	pulmonary	O
4	gas	O
5	exchange	O
6	reaction	O
7	to	O
8	physical	O
9	loading	O
10	in	O
11	evaluating	O
12	the	O
13	effectiveness	O
14	of	O
15	mitral	O
16	commissurotomy	O

0	The	O
1	227	O
2	-	O
3	to	O
4	-	O
5	239	O
6	region	O
7	blocked	O
8	ADR1	B
9	activity	O
10	independently	O
11	of	O
12	the	O
13	TAD	B
14	present	O
15	on	O
16	ADR1	B
17	,	O
18	ADR1	B
19	DNA	O
20	binding	O
21	,	O
22	and	O
23	specific	O
24	ADH2	B
25	promoter	I
26	sequences	I
27	.	O

0	Dissociation	O
1	and	O
2	complexation	O
3	of	O
4	the	O
5	fluoroquinolone	O
6	antimicrobials	O
7	--	O
8	an	O
9	update	O
10	.	O

0	The	O
1	hIGF	B
2	-	I
3	I	I
4	gene	I
5	has	O
6	two	O
7	promoters	O
8	,	O
9	P1	O
10	and	O
11	P2	O
12	.	O

0	Mining	O
1	the	O
2	diagnostic	O
3	iron	O
4	ore	O
5	.	O

0	Arm	O
1	function	O
2	tests	O
3	.	O

0	Expression	O
1	of	O
2	the	O
3	human	O
4	papillomavirus	O
5	type	I
6	11	I
7	E5A	I
8	protein	I
9	from	O
10	the	O
11	E1E4	B
12	,	O
13	E5	B
14	transcript	I
15	.	O

0	Second	O
1	report	O
2	of	O
3	the	O
4	Norwegian	O
5	Cancer	O
6	Society	O
7	.	O

0	Endogenous	O
1	RMP	B
2	was	O
3	immunologically	O
4	detected	O
5	interacting	O
6	with	O
7	assembled	O
8	RPB5	B
9	in	O
10	RNA	B
11	polymerase	I
12	in	O
13	mammalian	O
14	cells	O
15	.	O

0	Endostatin	B
1	treatment	O
2	for	O
3	10	O
4	minutes	O
5	or	O
6	24	O
7	hours	O
8	induced	O
9	tyrosine	O
10	phosphorylation	O
11	of	O
12	Shb	B
13	and	O
14	formation	O
15	of	O
16	multiprotein	O
17	complexes	O
18	.	O

0	The	O
1	mean	O
2	power	O
3	(	O
4	in	O
5	mu	O
6	W	O
7	)	O
8	required	O
9	to	O
10	produce	O
11	the	O
12	observed	O
13	flow	O
14	rate	O
15	was	O
16	estimated	O
17	at	O
18	each	O
19	outflow	O
20	pressure	O
21	as	O
22	the	O
23	product	O
24	of	O
25	the	O
26	flow	O
27	rate	O
28	and	O
29	the	O
30	pressure	O
31	across	O
32	the	O
33	lymphatic	O
34	vessel	O
35	.	O

0	Surgical	O
1	treatment	O
2	of	O
3	pathologic	O
4	scars	O
5	of	O
6	myocardial	O
7	infarct	O

0	PURPOSE	O
1	:	O
2	To	O
3	evaluate	O
4	the	O
5	disease	O
6	-	O
7	free	O
8	survival	O
9	(	O
10	DFS	O
11	)	O
12	and	O
13	overall	O
14	survival	O
15	(	O
16	OS	O
17	),	O
18	prognostic	O
19	factors	O
20	,	O
21	and	O
22	treatment	O
23	-	O
24	related	O
25	mortality	O
26	of	O
27	women	O
28	with	O
29	stage	O
30	IIIB	O
31	inflammatory	O
32	breast	O
33	cancer	O
34	(	O
35	IBC	O
36	)	O
37	treated	O
38	with	O
39	combined	O
40	modality	O
41	therapy	O
42	(	O
43	CMT	O
44	)	O
45	and	O
46	high	O
47	-	O
48	dose	O
49	chemotherapy	O
50	(	O
51	HDCT	O
52	)	O
53	with	O
54	autologous	O
55	stem	O
56	-	O
57	cell	O
58	transplantation	O
59	.	O

0	Collaborative	O
1	study	O
2	of	O
3	Japanese	O
4	Pharmacopoeia	O
5	Heparin	O
6	Sodium	O
7	Reference	O
8	Standard	O

0	We	O
1	have	O
2	identified	O
3	and	O
4	characterized	O
5	the	O
6	structure	O
7	of	O
8	the	O
9	Spec1	B
10	gene	I
11	in	O
12	the	O
13	sea	O
14	urchin	O
15	Strongylocentrotus	O
16	purpuratus	O
17	.	O

0	Among	O
1	the	O
2	mixed	O
3	race	O
4	persons	O
5	one	O
6	Chukcha	O
7	-	O
8	Eskimo	O
9	had	O
10	AS	O
11	,	O
12	one	O
13	Eskimo	O
14	-	O
15	Russian	O
16	had	O
17	psoriatic	O
18	arthritis	O
19	(	O
20	PsA	O
21	).	O

0	Thromboxane	O
1	B2	O
2	increased	O
3	(	O
4	97	O
5	+/-	O
6	105	O
7	versus	O
8	40	O
9	+/-	O
10	26	O
11	pg	O
12	/	O
13	ml	O
14	)	O
15	and	O
16	was	O
17	significantly	O
18	higher	O
19	during	O
20	heparin	O
21	free	O
22	hemodialysis	O
23	than	O
24	during	O
25	hemodialysis	O
26	with	O
27	heparin	O
28	(	O
29	p	O
30	=	O
31	0	O
32	.	O
33	01	O
34	,	O
35	Wilcoxon	O
36	matched	O
37	pairs	O
38	signed	O
39	rank	O
40	test	O
41	).	O

0	BACKGROUND	O
1	:	O
2	Left	O
3	ventricular	O
4	hypertrophy	O
5	is	O
6	a	O
7	heterogeneous	O
8	disorder	O
9	with	O
10	distinct	O
11	morphologies	O
12	.	O

0	In	O
1	contrast	O
2	,	O
3	AP	B
4	-	I
5	2	I
6	binding	O
7	activity	O
8	was	O
9	significantly	O
10	greater	O
11	in	O
12	T47D	O
13	cells	O
14	,	O
15	and	O
16	Western	O
17	blots	O
18	confirmed	O
19	increased	O
20	AP	B
21	-	I
22	2	I
23	protein	I
24	levels	O
25	in	O
26	these	O
27	cells	O
28	.	O

0	It	O
1	has	O
2	been	O
3	proposed	O
4	that	O
5	the	O
6	parCBA	B
7	operon	I
8	encodes	O
9	a	O
10	plasmid	O
11	partitioning	O
12	system	O
13	(	O
14	M	O
15	.	O

0	The	O
1	encoded	O
2	sequence	O
3	revealed	O
4	a	O
5	typical	O
6	signal	O
7	peptide	O
8	,	O
9	a	O
10	predominantly	O
11	hydrophilic	O
12	707	O
13	amino	O
14	acid	O
15	residue	O
16	domain	O
17	with	O
18	8	O
19	N	O
20	-	O
21	glycosylation	O
22	sites	O
23	,	O
24	a	O
25	transmembrane	O
26	domain	O
27	,	O
28	and	O
29	a	O
30	C	O
31	-	O
32	terminal	O
33	domain	O
34	of	O
35	52	O
36	amino	O
37	acids	O
38	.	O

0	Both	O
1	genes	O
2	comprise	O
3	three	O
4	exons	O
5	,	O
6	two	O
7	introns	O
8	and	O
9	an	O
10	unusually	O
11	long	O
12	3	O
13	'-	O
14	untranslated	O
15	region	O
16	(	O
17	3	O
18	.	O
19	2	O
20	kilobase	O
21	pairs	O
22	),	O
23	specificying	O
24	a	O
25	mRNA	O
26	of	O
27	approximately	O
28	4	O
29	.	O
30	1	O
31	kilobases	O
32	.	O

0	Mycobacterium	O
1	avium	O
2	-	O
3	intracellulare	O
4	complex	O
5	infections	O
6	in	O
7	the	O
8	acquired	O
9	immunodeficiency	O
10	syndrome	O
11	.	O

0	LH	B
1	/	O
2	CG	B
3	receptor	I
4	activation	O
5	of	O
6	ARNO	B
7	is	O
8	not	O
9	mediated	O
10	by	O
11	activation	O
12	of	O
13	phosphatidylinositol	B
14	3	I
15	-	I
16	kinase	I
17	(	O
18	PI	B
19	3	I
20	-	I
21	kinase	I
22	)	O
23	or	O
24	by	O
25	G	B
26	protein	I
27	beta	I
28	gamma	I
29	subunits	I
30	.	O

0	Volume	O
1	of	O
2	distribution	O
3	of	O
4	total	O
5	DMDZ	O
6	(	O
7	range	O
8	,	O
9	1	O
10	.	O
11	33	O
12	to	O
13	6	O
14	.	O
15	30	O
16	l	O
17	/	O
18	kg	O
19	)	O
20	and	O
21	of	O
22	unbound	O
23	DMDZ	O
24	after	O
25	correction	O
26	for	O
27	protein	O
28	binding	O
29	(	O
30	range	O
31	,	O
32	43	O
33	to	O
34	243	O
35	l	O
36	/	O
37	kg	O
38	)	O
39	was	O
40	larger	O
41	in	O
42	women	O
43	than	O
44	in	O
45	men	O
46	of	O
47	all	O
48	ages	O
49	,	O
50	and	O
51	in	O
52	the	O
53	elderly	O
54	as	O
55	opposed	O
56	to	O
57	the	O
58	young	O
59	.	O

0	Brucellosis	O
1	--	O
2	1990	O

0	This	O
1	computerized	O
2	list	O
3	was	O
4	linked	O
5	to	O
6	the	O
7	central	O
8	files	O
9	of	O
10	the	O
11	Massachusetts	O
12	Cancer	O
13	Registry	O
14	and	O
15	cases	O
16	diagnosed	O
17	between	O
18	1982	O
19	and	O
20	1988	O
21	were	O
22	identified	O
23	.	O

0	Its	O
1	cognate	O
2	binding	O
3	protein	O
4	,	O
5	REST	B
6	/	O
7	NRSF	B
8	,	O
9	is	O
10	an	O
11	essential	O
12	transcription	O
13	factor	O
14	;	O
15	its	O
16	null	O
17	mutations	O
18	result	O
19	in	O
20	embryonic	O
21	lethality	O
22	,	O
23	and	O
24	its	O
25	dominant	O
26	negative	O
27	mutants	O
28	produce	O
29	aberrant	O
30	expression	O
31	of	O
32	neuron	O
33	-	O
34	specific	O
35	genes	O
36	.	O

0	Determination	O
1	of	O
2	potassium	O
3	iodide	O
4	in	O
5	Polish	O
6	edible	O
7	salt	O

0	These	O
1	results	O
2	indicate	O
3	that	O
4	the	O
5	sulfhydryl	O
6	group	O
7	of	O
8	certain	O
9	angiotensin	B
10	converting	I
11	enzyme	I
12	inhibitors	O
13	can	O
14	potentiate	O
15	their	O
16	effect	O
17	on	O
18	the	O
19	endogenous	O
20	nitrovasodilator	O
21	EDRF	O
22	.	O

0	Human	B
1	thymine	I
2	-	I
3	DNA	I
4	glycosylase	I
5	maps	O
6	at	O
7	chromosome	O
8	12q22	O
9	-	O
10	q24	O
11	.	O
12	1	O
13	:	O
14	a	O
15	region	O
16	of	O
17	high	O
18	loss	O
19	of	O
20	heterozygosity	O
21	in	O
22	gastric	O
23	cancer	O
24	.	O

0	Copyright	O
1	2000	O
2	Academic	O
3	Press	O
4	.	O

0	An	O
1	examination	O
2	was	O
3	performed	O
4	in	O
5	15	O
6	patients	O
7	who	O
8	had	O
9	developed	O
10	pronounced	O
11	osteomalacia	O
12	following	O
13	gastric	O
14	resection	O
15	.	O

0	Several	O
1	lines	O
2	of	O
3	evidence	O
4	demonstrate	O
5	that	O
6	this	O
7	growth	O
8	inhibition	O
9	requires	O
10	active	O
11	PKA	B
12	subunits	I
13	and	O
14	cAMP	O
15	:	O
16	(	O
17	i	O
18	)	O
19	this	O
20	phenotype	O
21	is	O
22	dependent	O
23	on	O
24	cAMP	O
25	since	O
26	it	O
27	is	O
28	not	O
29	seen	O
30	in	O
31	a	O
32	strain	O
33	lacking	O
34	adenylyl	B
35	cyclase	I
36	activity	O
37	,	O
38	but	O
39	the	O
40	growth	O
41	rate	O
42	of	O
43	these	O
44	transformants	O
45	is	O
46	slower	O
47	when	O
48	exogenous	O
49	cAMP	O
50	is	O
51	added	O
52	;	O
53	(	O
54	ii	O
55	)	O
56	normal	O
57	growth	O
58	occurs	O
59	when	O
60	wild	B
61	-	I
62	type	I
63	RI	I
64	cDNA	I
65	is	O
66	replaced	O
67	by	O
68	a	O
69	mutant	B
70	RI	I
71	cDNA	I
72	encoding	O
73	a	O
74	RI	B
75	protein	I
76	with	O
77	reduced	O
78	cAMP	O
79	binding	O
80	;	O
81	and	O
82	(	O
83	iii	O
84	)	O
85	the	O
86	growth	O
87	-	O
88	inhibited	O
89	phenotype	O
90	of	O
91	the	O
92	transformed	O
93	BL21	O
94	(	O
95	DE3	O
96	)	O
97	cells	O
98	requires	O
99	soluble	O
100	,	O
101	active	O
102	C	B
103	alpha	I
104	protein	I
105	.	O

0	The	O
1	models	O
2	accurately	O
3	localized	O
4	the	O
5	common	O
6	boundaries	O
7	between	O
8	the	O
9	PBB	O
10	and	O
11	CN	O
12	.	O

0	Prostaglandin	O
1	synthesis	O
2	inhibitors	O
3	have	O
4	been	O
5	shown	O
6	to	O
7	delay	O
8	healing	O
9	of	O
10	bone	O
11	and	O
12	this	O
13	has	O
14	led	O
15	to	O
16	limitations	O
17	on	O
18	their	O
19	use	O
20	clinically	O
21	in	O
22	some	O
23	situations	O
24	.	O

0	We	O
1	further	O
2	demonstrate	O
3	that	O
4	the	O
5	Stress	B
6	-	I
7	Activated	I
8	-	I
9	Protein	I
10	-	I
11	Kinase	I
12	(	O
13	SAPK	B
14	)	O
15	target	O
16	sites	O
17	of	O
18	ATF2	B
19	,	O
20	Thr69	O
21	and	O
22	Thr71	O
23	are	O
24	not	O
25	required	O
26	for	O
27	the	O
28	formation	O
29	of	O
30	the	O
31	p300	B
32	/	O
33	CBP	B
34	-	O
35	ATF2	B
36	multiprotein	I
37	complex	O
38	.	O

0	The	O
1	ATR	B
2	-	O
3	X	O
4	syndrome	O
5	results	O
6	from	O
7	mutations	O
8	of	O
9	the	O
10	XH2	B
11	gene	I
12	,	O
13	located	O
14	on	O
15	the	O
16	X	O
17	chromosome	O
18	(	O
19	Xq13	O
20	.	O
21	3	O
22	)	O
23	and	O
24	coding	O
25	for	O
26	a	O
27	transacting	O
28	factor	O
29	which	O
30	regulates	O
31	gene	O
32	expression	O
33	.	O

0	Transcription	O
1	start	O
2	site	O
3	mapping	O
4	identified	O
5	the	O
6	presence	O
7	of	O
8	an	O
9	aphidicolin	B
10	-	O
11	sensitive	O
12	late	O
13	transcript	O
14	arising	O
15	from	O
16	a	O
17	TAAG	O
18	motif	O
19	located	O
20	at	O
21	-	O
22	352	O
23	nucleotides	O
24	and	O
25	an	O
26	aphidicolin	B
27	-	O
28	insensitive	O
29	early	O
30	transcript	O
31	originating	O
32	from	O
33	a	O
34	TTGT	O
35	motif	O
36	located	O
37	35	O
38	nucleotides	O
39	downstream	O
40	to	O
41	a	O
42	TATA	O
43	box	O
44	at	O
45	-	O
46	312	O
47	nucleotides	O
48	,	O
49	with	O
50	respect	O
51	to	O
52	the	O
53	+	O
54	1	O
55	ATG	O
56	of	O
57	lef2	B
58	.	O

0	About	O
1	20	O
2	%	O
3	of	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	binding	O
9	was	O
10	observed	O
11	in	O
12	the	O
13	presence	O
14	of	O
15	MgdTDP	B
16	,	O
17	but	O
18	none	O
19	was	O
20	detectable	O
21	in	O
22	the	O
23	absence	O
24	of	O
25	nucleotides	O
26	.	O

0	Our	O
1	results	O
2	indicate	O
3	that	O
4	RA	B
5	-	O
6	mediated	O
7	repression	O
8	of	O
9	the	O
10	hMGP	B
11	gene	I
12	is	O
13	due	O
14	to	O
15	binding	O
16	of	O
17	liganded	O
18	RAR	B
19	/	O
20	RXR	B
21	to	O
22	a	O
23	novel	O
24	negative	O
25	RA	B
26	response	O
27	element	O
28	.	O

0	The	O
1	IE0	B
2	gene	I
3	product	I
4	also	O
5	transactivated	O
6	the	O
7	IE1	B
8	promoter	I
9	but	O
10	did	O
11	not	O
12	affect	O
13	expression	O
14	from	O
15	its	O
16	own	O
17	promoter	O
18	.	O

0	Recombinant	B
1	AROM	I
2	-	O
3	p64	B
4	displayed	O
5	high	O
6	binding	O
7	to	O
8	single	O
9	-	O
10	stranded	O
11	DNA	O
12	and	O
13	poly	O
14	(	O
15	A	O
16	)	O
17	homopolymers	O
18	suggesting	O
19	that	O
20	this	O
21	protein	O
22	could	O
23	play	O
24	a	O
25	role	O
26	in	O
27	mRNA	O
28	maturation	O
29	/	O
30	metabolism	O
31	.	O

0	Selection	O
1	of	O
2	the	O
3	22	O
4	items	O
5	of	O
6	the	O
7	Clinical	O
8	Institute	O
9	Withdrawal	O
10	Assessment	O
11	-	O
12	Benzodiazepines	O
13	(	O
14	CIWA	O
15	-	O
16	B	O
17	)	O
18	was	O
19	based	O
20	on	O
21	statistically	O
22	significant	O
23	differences	O
24	between	O
25	baseline	O
26	and	O
27	critical	O
28	withdrawal	O
29	periods	O
30	in	O
31	high	O
32	-	O
33	dose	O
34	subjects	O
35	and	O
36	between	O
37	symptoms	O
38	associated	O
39	with	O
40	placebo	O
41	and	O
42	diazepam	O
43	in	O
44	low	O
45	-	O
46	dose	O
47	subjects	O
48	,	O
49	using	O
50	contingency	O
51	tables	O
52	and	O
53	logistic	O
54	regression	O
55	analysis	O
56	.	O

0	In	O
1	electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	,	O
6	the	O
7	PERE	B
8	formed	O
9	three	O
10	major	O
11	complexes	O
12	(	O
13	P1	O
14	,	O
15	P2	O
16	and	O
17	P3	O
18	)	O
19	with	O
20	proteins	O
21	in	O
22	nuclear	O
23	extracts	O
24	from	O
25	HeLa	O
26	or	O
27	293	O
28	cells	O
29	.	O

0	The	O
1	unexpected	O
2	presence	O
3	of	O
4	the	O
5	tRNA	B
6	(	I
7	trp	I
8	)(	I
9	CCA	I
10	)-	I
11	gene	I
12	transcript	I
13	in	O
14	mitochondria	O
15	is	O
16	also	O
17	reported	O
18	.	O

0	The	O
1	R	B
2	.	I
3	meliloti	I
4	nifH	I
5	promoter	I
6	but	O
7	not	O
8	the	O
9	K	B
10	.	I
11	pneumoniae	I
12	nifH	I
13	promoter	I
14	showed	O
15	sigma	B
16	54	I
17	-	O
18	dependent	O
19	methylation	O
20	protection	O
21	of	O
22	guanine	O
23	residues	O
24	at	O
25	-	O
26	14	O
27	,	O
28	-	O
29	25	O
30	and	O
31	-	O
32	26	O
33	,	O
34	the	O
35	most	O
36	conserved	O
37	nucleotides	O
38	characteristic	O
39	of	O
40	sigma	B
41	54	I
42	-	I
43	dependent	I
44	promoters	I
45	.	O

0	The	O
1	protein	B
2	-	I
3	tyrosine	I
4	kinase	I
5	fer	I
6	associates	O
7	with	O
8	signaling	O
9	complexes	O
10	containing	O
11	insulin	B
12	receptor	I
13	substrate	I
14	-	I
15	1	I
16	and	O
17	phosphatidylinositol	B
18	3	I
19	-	I
20	kinase	I
21	.	O

0	Abnormal	O
1	characteristics	O
2	and	O
3	verticillation	O
4	in	O
5	Platynothrus	O
6	peltifer	O

0	In	O
1	throttling	O
2	valves	O
3	,	O
4	the	O
5	aim	O
6	is	O
7	to	O
8	correlate	O
9	the	O
10	effect	O
11	of	O
12	shear	O
13	to	O
14	a	O
15	parameter	O
16	related	O
17	to	O
18	the	O
19	inner	O
20	geometry	O
21	of	O
22	the	O
23	valve	O
24	and	O
25	to	O
26	operating	O
27	conditions	O
28	.	O

0	To	O
1	this	O
2	end	O
3	,	O
4	we	O
5	analyzed	O
6	the	O
7	phosphorylation	O
8	status	O
9	of	O
10	a	O
11	universal	O
12	tyrosine	B
13	kinase	I
14	substrate	I
15	,	O
16	the	O
17	transforming	B
18	Shc	I
19	adapter	I
20	protein	I
21	,	O
22	in	O
23	fibroblasts	O
24	expressing	O
25	the	O
26	viral	O
27	oncogene	O
28	.	O

0	In	O
1	endemic	O
2	BL	O
3	,	O
4	the	O
5	RB2	B
6	/	O
7	p130	B
8	gene	I
9	is	O
10	mutated	O
11	in	O
12	most	O
13	of	O
14	the	O
15	cases	O
16	,	O
17	and	O
18	the	O
19	protein	O
20	is	O
21	restricted	O
22	to	O
23	the	O
24	cytoplasm	O
25	.	O

0	This	O
1	study	O
2	tested	O
3	the	O
4	hypothesis	O
5	that	O
6	sodium	O
7	channel	O
8	blocking	O
9	drugs	O
10	selectively	O
11	prolong	O
12	the	O
13	late	O
14	potential	O
15	,	O
16	or	O
17	terminal	O
18	low	O
19	amplitude	O
20	signal	O
21	,	O
22	portion	O
23	of	O
24	the	O
25	signal	O
26	-	O
27	averaged	O
28	QRS	O
29	complex	O
30	and	O
31	that	O
32	prolongation	O
33	of	O
34	the	O
35	late	O
36	potential	O
37	would	O
38	correlate	O
39	with	O
40	slowing	O
41	of	O
42	ventricular	O
43	tachycardia	O
44	.	O

0	Cells	O
1	respond	O
2	to	O
3	the	O
4	accumulation	O
5	of	O
6	unfolded	O
7	proteins	O
8	in	O
9	the	O
10	endoplasmic	O
11	reticulum	O
12	(	O
13	ER	O
14	)	O
15	by	O
16	increasing	O
17	the	O
18	transcription	O
19	of	O
20	the	O
21	genes	O
22	encoding	O
23	ER	B
24	-	I
25	resident	I
26	chaperone	I
27	proteins	I
28	.	O

0	Co	O
1	-	O
2	administration	O
3	of	O
4	5FU	O
5	,	O
6	angiotensin	B
7	II	I
8	and	O
9	microspheres	O
10	via	O
11	the	O
12	hepatic	O
13	artery	O
14	may	O
15	reduce	O
16	drug	O
17	exposure	O
18	in	O
19	the	O
20	systemic	O
21	compartment	O
22	and	O
23	therefore	O
24	may	O
25	increase	O
26	the	O
27	therapeutic	O
28	ratio	O
29	of	O
30	5FU	O
31	administration	O
32	via	O
33	the	O
34	hepatic	O
35	artery	O
36	.	O

0	Together	O
1	,	O
2	our	O
3	data	O
4	suggest	O
5	that	O
6	the	O
7	TR2	B
8	orphan	I
9	receptor	I
10	may	O
11	be	O
12	a	O
13	master	O
14	regulator	O
15	in	O
16	modulating	O
17	the	O
18	activation	O
19	of	O
20	two	O
21	key	O
22	HREs	O
23	,	O
24	RARE	B
25	beta	I
26	and	O
27	CRBPIIp	O
28	,	O
29	involved	O
30	in	O
31	the	O
32	retinoic	O
33	acid	O
34	signal	O
35	transduction	O
36	pathway	O
37	.	O

0	The	O
1	transcription	O
2	factor	O
3	Sp1	B
4	bound	O
5	to	O
6	eight	O
7	sites	O
8	,	O
9	as	O
10	demonstrated	O
11	by	O
12	footprinting	O
13	assays	O
14	and	O
15	gel	O
16	shift	O
17	analysis	O
18	with	O
19	purified	O
20	Sp1	B
21	.	O

0	Both	O
1	parents	O
2	are	O
3	clinically	O
4	normal	O
5	and	O
6	unrelated	O
7	.	O

0	Identification	O
1	of	O
2	an	O
3	AfsA	B
4	homologue	I
5	(	O
6	BarX	B
7	)	O
8	from	O
9	Streptomyces	O
10	virginiae	O
11	as	O
12	a	O
13	pleiotropic	O
14	regulator	O
15	controlling	O
16	autoregulator	O
17	biosynthesis	O
18	,	O
19	virginiamycin	O
20	biosynthesis	O
21	and	O
22	virginiamycin	O
23	M1	O
24	resistance	O
25	.	O

0	As	O
1	control	O
2	,	O
3	the	O
4	cells	O
5	were	O
6	transfected	O
7	with	O
8	DNA	O
9	mixtures	O
10	containing	O
11	vector	O
12	mU6	B
13	-	O
14	C1	O
15	or	O
16	mU6	B
17	-	O
18	C2	O
19	.	O

0	The	O
1	ns2	B
2	gene	I
3	comprises	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	(	O
9	ORF	O
10	)	O
11	encoding	O
12	a	O
13	putative	O
14	nonstructural	O
15	(	O
16	ns	O
17	)	O
18	protein	O
19	of	O
20	279	O
21	amino	O
22	acids	O
23	with	O
24	a	O
25	predicted	O
26	molecular	O
27	mass	O
28	of	O
29	32	O
30	-	O
31	kDa	O
32	.	O

0	Taken	O
1	together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	Dbf8p	B
8	plays	O
9	an	O
10	essential	O
11	role	O
12	in	O
13	chromosome	O
14	segregation	O
15	.	O

0	We	O
1	have	O
2	identified	O
3	in	O
4	the	O
5	5	O
6	'	O
7	untranslated	O
8	region	O
9	of	O
10	the	O
11	Drosophila	B
12	copia	I
13	retrotransposon	I
14	,	O
15	3	O
16	'	O
17	to	O
18	the	O
19	left	O
20	LTR	O
21	,	O
22	a	O
23	sequence	O
24	for	O
25	transcriptional	O
26	regulation	O
27	by	O
28	homeoproteins	O
29	.	O

0	T	B
1	antigen	I
2	contains	O
3	four	O
4	H	B
5	-	I
6	2Db	I
7	-	O
8	restricted	O
9	cytotoxic	O
10	T	O
11	lymphocyte	O
12	(	O
13	CTL	O
14	)	O
15	recognition	O
16	epitopes	O
17	that	O
18	are	O
19	targets	O
20	for	O
21	CTL	B
22	clones	O
23	Y	O
24	-	O
25	1	O
26	,	O
27	Y	O
28	-	O
29	2	O
30	,	O
31	Y	O
32	-	O
33	3	O
34	,	O
35	and	O
36	Y	O
37	-	O
38	5	O
39	.	O

0	Identification	O
1	and	O
2	characterization	O
3	of	O
4	the	O
5	promoter	O
6	for	O
7	the	O
8	cytotactin	B
9	gene	I
10	.	O

0	The	O
1	COOH	O
2	-	O
3	terminal	O
4	region	O
5	of	O
6	the	O
7	transcripts	O
8	contained	O
9	fifteen	O
10	triplet	O
11	repeats	O
12	(	O
13	GCT	O
14	;	O
15	alanine	O
16	)	O
17	at	O
18	nucleotide	O
19	465	O
20	to	O
21	509	O
22	,	O
23	which	O
24	is	O
25	significantly	O
26	expanded	O
27	compared	O
28	to	O
29	the	O
30	rat	B
31	RL14	I
32	.	O

0	In	O
1	a	O
2	gntR	B
3	deletion	I
4	mutant	I
5	,	O
6	the	O
7	expression	O
8	of	O
9	a	O
10	chromosomal	B
11	gntT	B
12	::	O
13	lacZ	B
14	fusion	O
15	is	O
16	both	O
17	high	O
18	and	O
19	constitutive	O
20	,	O
21	confirming	O
22	that	O
23	GntR	B
24	is	O
25	the	O
26	negative	O
27	regulator	O
28	of	O
29	gntT	B
30	.	O

0	Mean	O
1	(+/-	O
2	SE	O
3	)	O
4	measurements	O
5	of	O
6	clearance	O
7	(	O
8	24	O
9	.	O
10	5	O
11	+/-	O
12	2	O
13	.	O
14	06	O
15	v	O
16	26	O
17	.	O
18	5	O
19	+/-	O
20	2	O
21	.	O
22	05	O
23	mL	O
24	/	O
25	min	O
26	/	O
27	m2	O
28	),	O
29	half	O
30	-	O
31	life	O
32	(	O
33	5	O
34	.	O
35	7	O
36	+/-	O
37	0	O
38	.	O
39	5	O
40	v	O
41	6	O
42	.	O
43	4	O
44	+/-	O
45	0	O
46	.	O
47	5	O
48	hours	O
49	),	O
50	and	O
51	volume	O
52	of	O
53	distribution	O
54	(	O
55	12	O
56	.	O
57	4	O
58	+/-	O
59	1	O
60	.	O
61	1	O
62	v	O
63	13	O
64	.	O
65	7	O
66	+/-	O
67	1	O
68	.	O
69	6	O
70	L	O
71	/	O
72	m2	O
73	)	O
74	were	O
75	not	O
76	significantly	O
77	different	O
78	in	O
79	patients	O
80	with	O
81	jaundice	O
82	when	O
83	compared	O
84	with	O
85	controls	O
86	.	O

0	Normocapnic	O
1	(	O
2	PACO2	O
3	=	O
4	40	O
5	mm	O
6	Hg	O
7	)	O
8	ventilatory	O
9	drive	O
10	increased	O
11	significantly	O
12	(	O
13	p	O
14	less	O
15	than	O
16	0	O
17	.	O
18	05	O
19	)	O
20	in	O
21	six	O
22	subjects	O
23	(	O
24	Type	O
25	1	O
26	response	O
27	)	O
28	and	O
29	decreased	O
30	substantially	O
31	in	O
32	the	O
33	others	O
34	(	O
35	Type	O
36	2	O
37	response	O
38	);	O
39	with	O
40	hypercapnia	O
41	,	O
42	the	O
43	changes	O
44	in	O
45	drive	O
46	were	O
47	attenuated	O
48	in	O
49	both	O
50	groups	O
51	.	O

0	Determination	O
1	of	O
2	transaminases	O
3	with	O
4	an	O
5	autoanalyzer	O

0	The	O
1	data	O
2	show	O
3	conclusively	O
4	that	O
5	phosphorylation	O
6	of	O
7	His	O
8	-	O
9	304	O
10	is	O
11	not	O
12	essential	O
13	for	O
14	any	O
15	of	O
16	the	O
17	known	O
18	functions	O
19	of	O
20	A	O
21	.	O
22	vinelandii	O
23	NifL	O
24	.	O

0	Deletion	O
1	analysis	O
2	was	O
3	carried	O
4	out	O
5	within	O
6	a	O
7	part	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	showing	O
15	homology	O
16	to	O
17	the	O
18	upstream	O
19	region	O
20	of	O
21	the	O
22	yeast	B
23	CYC1	I
24	gene	I
25	.	O

0	The	O
1	N	O
2	-	O
3	terminus	O
4	of	O
5	another	O
6	open	O
7	reading	O
8	frame	O
9	was	O
10	found	O
11	3	O
12	'	O
13	from	O
14	nifA	B
15	and	O
16	tentatively	O
17	identified	O
18	as	O
19	nifB	B
20	by	O
21	amino	O
22	acid	O
23	sequence	O
24	comparison	O
25	.	O

0	Stoichiometric	O
1	phosphorylation	O
2	of	O
3	human	B
4	p53	I
5	at	O
6	Ser315	O
7	stimulates	O
8	p53	B
9	-	O
10	dependent	O
11	transcription	O
12	.	O
13	p53	B
14	protein	I
15	activity	O
16	as	O
17	a	O
18	transcription	O
19	factor	O
20	can	O
21	be	O
22	activated	O
23	in	O
24	vivo	O
25	by	O
26	antibodies	O
27	that	O
28	target	O
29	its	O
30	C	O
31	-	O
32	terminal	O
33	negative	O
34	regulatory	O
35	domain	O
36	suggesting	O
37	that	O
38	cellular	O
39	enzymes	O
40	that	O
41	target	O
42	this	O
43	domain	O
44	may	O
45	play	O
46	a	O
47	role	O
48	in	O
49	stimulating	O
50	p53	B
51	-	O
52	dependent	O
53	gene	O
54	expression	O
55	.	O

0	TPO	B
1	by	O
2	itself	O
3	did	O
4	not	O
5	activate	O
6	ERK1	B
7	,	O
8	ERK2	B
9	and	O
10	protein	B
11	kinase	I
12	C	I
13	(	O
14	PKC	B
15	),	O
16	whereas	O
17	TPO	B
18	directly	O
19	enhanced	O
20	the	O
21	PKC	B
22	-	O
23	dependent	O
24	activation	O
25	of	O
26	ERKs	B
27	induced	O
28	by	O
29	other	O
30	agonists	O
31	including	O
32	thrombin	B
33	and	O
34	phorbol	O
35	esters	O
36	,	O
37	without	O
38	affecting	O
39	the	O
40	PKC	B
41	activation	O
42	by	O
43	those	O
44	agonists	O
45	.	O

0	Critical	O
1	evaluation	O
2	of	O
3	various	O
4	methods	O
5	of	O
6	determining	O
7	markers	O
8	of	O
9	fetal	O
10	maturity	O
11	in	O
12	amniotic	O
13	fluid	O

0	The	O
1	low	O
2	molecular	O
3	mass	O
4	polypeptide	O
5	complex	O
6	is	O
7	assumed	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	antigen	O
13	presentation	O
14	,	O
15	generating	O
16	peptides	O
17	from	O
18	cytosolic	B
19	protein	I
20	antigens	I
21	,	O
22	which	O
23	are	O
24	subsequently	O
25	presented	O
26	to	O
27	cytotoxic	O
28	T	O
29	-	O
30	lymphocytes	O
31	on	O
32	the	O
33	cell	O
34	surface	O
35	.	O

0	Dose	O
1	of	O
2	20	O
3	ig	O
4	were	O
5	administered	O
6	within	O
7	a	O
8	scheme	O
9	from	O
10	0	O
11	.	O
12	1	O
13	to	O
14	6	O
15	months	O
16	in	O
17	order	O
18	to	O
19	study	O
20	its	O
21	immunogenicity	O
22	,	O
23	which	O
24	was	O
25	evaluated	O
26	at	O
27	2	O
28	,	O
29	7	O
30	,	O
31	and	O
32	12	O
33	months	O
34	after	O
35	the	O
36	first	O
37	dose	O
38	.	O

0	Two	O
1	variant	O
2	PRP	B
3	-	I
4	precursor	I
5	alleles	I
6	occur	O
7	which	O
8	slightly	O
9	differ	O
10	in	O
11	the	O
12	number	O
13	of	O
14	repeats	O
15	in	O
16	domain	O
17	C	O
18	.	O

0	The	O
1	mei4	B
2	+	I
3	gene	I
4	of	O
5	the	O
6	fission	O
7	yeast	O
8	Schizosaccharomyces	O
9	pombe	O
10	was	O
11	cloned	O
12	by	O
13	functional	O
14	complementation	O
15	.	O

0	Abnormal	O
1	technetium	O
2	Tc	O
3	99m	O
4	medronate	O
5	scans	O
6	in	O
7	patients	O
8	with	O
9	previously	O
10	undiagnosed	O
11	polyarthralgias	O
12	suggested	O
13	inflammatory	O
14	arthropathy	O
15	and	O
16	influenced	O
17	management	O
18	decisions	O
19	with	O
20	favorable	O
21	therapeutic	O
22	outcomes	O
23	.	O

0	2	O
1	-	O
2	Chemical	O
3	occlusion	O
4	of	O
5	vas	O
6	is	O
7	quite	O
8	effective	O
9	in	O
10	producing	O
11	a	O
12	block	O
13	in	O
14	the	O
15	vas	O
16	deferens	O
17	of	O
18	dogs	O
19	.	O

0	Its	O
1	application	O
2	in	O
3	Madagascar	O
4	:	O
5	advantages	O
6	and	O
7	disadvantages	O

0	A	O
1	retrospective	O
2	study	O
3	of	O
4	banked	O
5	sera	O
6	from	O
7	19	O
8	cats	O
9	with	O
10	the	O
11	eosinophilic	O
12	granuloma	O
13	complex	O
14	revealed	O
15	that	O
16	68	O
17	%	O
18	of	O
19	affected	O
20	cats	O
21	had	O
22	circulating	O
23	antibodies	O
24	to	O
25	components	O
26	of	O
27	normal	O
28	cat	O
29	epithelium	O
30	.	O

0	We	O
1	report	O
2	here	O
3	on	O
4	the	O
5	molecular	O
6	nature	O
7	of	O
8	an	O
9	EMS	O
10	-	O
11	induced	O
12	mutant	O
13	,	O
14	mn1	B
15	-	I
16	89	I
17	,	O
18	a	O
19	leaky	O
20	semidominant	O
21	allele	O
22	of	O
23	the	O
24	Miniature1	B
25	(	O
26	Mn1	B
27	)	I
28	seed	I
29	locus	I
30	that	O
31	encodes	O
32	a	O
33	seed	B
34	-	I
35	specific	I
36	cell	I
37	wall	I
38	invertase	I
39	,	O
40	INCW2	B
41	.	O

0	Primer	O
1	extension	O
2	experiments	O
3	revealed	O
4	a	O
5	strong	O
6	transcription	O
7	initiation	O
8	site	O
9	102	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	translational	O
15	start	O
16	site	O
17	.	O

0	This	O
1	0	O
2	.	O
3	74	O
4	kb	O
5	cDNA	O
6	contains	O
7	an	O
8	open	O
9	reading	O
10	frame	O
11	(	O
12	ORF	O
13	)	O
14	of	O
15	477	O
16	bp	O
17	encoding	O
18	a	O
19	polypeptide	O
20	of	O
21	159	O
22	amino	O
23	acids	O
24	(	O
25	aa	O
26	)	O
27	which	O
28	differs	O
29	at	O
30	only	O
31	one	O
32	position	O
33	(	O
34	position	O
35	65	O
36	)	O
37	from	O
38	the	O
39	human	B
40	U1	I
41	-	I
42	C	I
43	protein	I
44	.	O

0	Although	O
1	large	O
2	epidemiologic	O
3	studies	O
4	are	O
5	best	O
6	able	O
7	to	O
8	identify	O
9	the	O
10	relative	O
11	contributions	O
12	of	O
13	specific	O
14	risk	O
15	factors	O
16	while	O
17	controlling	O
18	for	O
19	other	O
20	risk	O
21	factors	O
22	,	O
23	new	O
24	studies	O
25	need	O
26	to	O
27	focus	O
28	on	O
29	important	O
30	unresolved	O
31	questions	O
32	.	O

0	Gel	O
1	route	O
2	preparation	O
3	of	O
4	low	O
5	fusing	O
6	dental	O
7	porcelain	O
8	frit	O
9	.	O

0	Iodine	O
1	metabolism	O
2	in	O
3	chronic	O
4	thyroiditis	O
5	.	O

0	Deletion	O
1	of	O
2	the	O
3	POR2	B
4	gene	I
5	alone	O
6	had	O
7	no	O
8	detectable	O
9	phenotype	O
10	,	O
11	while	O
12	yeasts	O
13	with	O
14	deletions	O
15	of	O
16	both	O
17	the	O
18	POR1	B
19	and	O
20	POR2	B
21	genes	I
22	were	O
23	viable	O
24	and	O
25	able	O
26	to	O
27	grow	O
28	on	O
29	glycerol	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	,	O
35	albeit	O
36	more	O
37	slowly	O
38	than	O
39	delta	B
40	por1	I
41	single	I
42	mutants	I
43	.	O

0	Some	O
1	artificial	O
2	promoter	O
3	constructs	O
4	containing	O
5	multiple	O
6	Sp1	B
7	sites	I
8	were	O
9	highly	O
10	responsive	O
11	to	O
12	ethanol	O
13	,	O
14	but	O
15	others	O
16	were	O
17	not	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	organization	O
23	of	O
24	the	O
25	proximal	O
26	promoter	O
27	region	O
28	was	O
29	an	O
30	additional	O
31	factor	O
32	that	O
33	affected	O
34	the	O
35	ethanol	O
36	response	O
37	.	O

0	Invertases	O
1	are	O
2	responsible	O
3	for	O
4	the	O
5	breakdown	O
6	of	O
7	sucrose	O
8	to	O
9	fructose	O
10	and	O
11	glucose	O
12	.	O

0	The	O
1	effect	O
2	of	O
3	diffusion	O
4	limitation	O
5	was	O
6	quantified	O
7	in	O
8	terms	O
9	of	O
10	the	O
11	ratio	O
12	O2	O
13	uptake	O
14	/	O
15	O2	O
16	requirement	O
17	(=	O
18	fraction	O
19	of	O
20	cross	O
21	-	O
22	sectional	O
23	area	O
24	supplied	O
25	with	O
26	O2	O
27	),	O
28	assuming	O
29	local	O
30	O2	O
31	requirement	O
32	per	O
33	unit	O
34	volume	O
35	to	O
36	be	O
37	constant	O
38	and	O
39	independent	O
40	of	O
41	PO2	O
42	at	O
43	PO2	O
44	greater	O
45	than	O
46	0	O
47	.	O

0	Comparison	O
1	of	O
2	the	O
3	deduced	O
4	amino	O
5	acid	O
6	sequences	O
7	with	O
8	protein	O
9	sequences	O
10	of	O
11	T	B
12	.	I
13	pyriformis	I
14	H2As	I
15	showed	O
16	only	O
17	two	O
18	and	O
19	three	O
20	differences	O
21	respectively	O
22	,	O
23	in	O
24	a	O
25	total	O
26	of	O
27	137	O
28	amino	O
29	acids	O
30	for	O
31	H2A1	B
32	,	O
33	and	O
34	132	O
35	amino	O
36	acids	O
37	for	O
38	H2A2	B
39	,	O
40	indicating	O
41	the	O
42	two	O
43	genes	O
44	arose	O
45	before	O
46	the	O
47	divergence	O
48	of	O
49	these	O
50	two	O
51	species	O
52	.	O

0	Amikacin	O
1	concentrations	O
2	in	O
3	serum	O
4	and	O
5	blister	O
6	fluid	O
7	in	O
8	healthy	O
9	volunteers	O
10	and	O
11	in	O
12	patients	O
13	with	O
14	renal	O
15	impairment	O
16	.	O

0	The	O
1	present	O
2	study	O
3	investigated	O
4	dose	O
5	dependence	O
6	and	O
7	time	O
8	course	O
9	effects	O
10	of	O
11	the	O
12	benzodiazepine	O
13	(	O
14	BDZ	O
15	)	O
16	partial	O
17	inverse	O
18	agonist	O
19	,	O
20	RO19	O
21	-	O
22	4603	O
23	(	O
24	0	O
25	.	O
26	005	O
27	-	O
28	0	O
29	.	O
30	30	O
31	mg	O
32	/	O
33	kg	O
34	)	O
35	alone	O
36	,	O
37	and	O
38	in	O
39	combination	O
40	with	O
41	the	O
42	BDZ	B
43	receptor	I
44	antagonists	O
45	flumazenil	O
46	,	O
47	ZK	O
48	93426	O
49	,	O
50	and	O
51	CGS	O
52	8216	O
53	(	O
54	20	O
55	mg	O
56	/	O
57	kg	O
58	)	O
59	in	O
60	selectively	O
61	bred	O
62	alcohol	O
63	-	O
64	preferring	O
65	(	O
66	P	O
67	)	O
68	rats	O
69	provided	O
70	a	O
71	two	O
72	-	O
73	bottle	O
74	choice	O
75	test	O
76	between	O
77	ethanol	O
78	(	O
79	EtOH	O
80	)	O
81	(	O
82	10	O
83	%	O
84	v	O
85	/	O
86	v	O
87	),	O
88	and	O
89	a	O
90	palatable	O
91	saccharin	O
92	(	O
93	0	O
94	.	O
95	0125	O
96	%	O
97	g	O
98	/	O
99	v	O
100	)	O
101	solution	O
102	.	O

0	Interference	O
1	with	O
2	rheumatoid	B
3	factor	I
4	was	O
5	only	O
6	observed	O
7	in	O
8	the	O
9	ELISA	O
10	enzygnost	O
11	if	O
12	sera	O
13	were	O
14	not	O
15	pretreated	O
16	with	O
17	latex	O
18	adsorbents	O
19	.	O

0	Three	O
1	of	O
2	the	O
3	short	O
4	ORFs	O
5	in	O
6	the	O
7	central	O
8	region	O
9	of	O
10	BIV	O
11	have	O
12	been	O
13	identified	O
14	by	O
15	location	O
16	and	O
17	structural	O
18	similarity	O
19	to	O
20	the	O
21	nonstructural	O
22	/	O
23	regulatory	O
24	genes	O
25	(	O
26	vif	B
27	,	O
28	tat	B
29	,	O
30	and	O
31	rev	B
32	)	O
33	of	O
34	other	O
35	lentiviruses	O
36	;	O
37	we	O
38	also	O
39	discovered	O
40	two	O
41	unique	O
42	ORFs	O
43	,	O
44	termed	O
45	W	O
46	and	O
47	Y	O
48	,	O
49	which	O
50	may	O
51	serve	O
52	as	O
53	exons	O
54	for	O
55	novel	O
56	genes	O
57	.	O

0	From	O
1	250	O
2	g	O
3	of	O
4	cells	O
5	,	O
6	we	O
7	isolated	O
8	1	O
9	mg	O
10	of	O
11	PDH	B
12	complex	I
13	with	O
14	a	O
15	specific	O
16	activity	O
17	of	O
18	12	O
19	.	O
20	6	O
21	U	O
22	/	O
23	mg	O
24	of	O
25	protein	O
26	.	O

0	We	O
1	analyzed	O
2	an	O
3	EBV	O
4	B	O
5	-	O
6	cell	O
7	clone	O
8	,	O
9	E29	O
10	.	O
11	1	O
12	,	O
13	derived	O
14	from	O
15	an	O
16	11	O
17	week	O
18	-	O
19	old	O
20	embryo	O
21	,	O
22	and	O
23	secreting	O
24	both	O
25	IgM	B
26	kappa	I
27	and	O
28	IgM	B
29	lambda	O
30	.	O

0	Role	O
1	of	O
2	g2	O
3	in	O
4	relating	O
5	the	O
6	Schwinger	O
7	and	O
8	Gerasimov	O
9	-	O
10	Drell	O
11	-	O
12	Hearn	O
13	sum	O
14	rules	O
15	.	O

0	A	O
1	randomised	O
2	,	O
3	controlled	O
4	trial	O
5	was	O
6	undertaken	O
7	in	O
8	40	O
9	patients	O
10	with	O
11	active	O
12	Crohn	O
13	'	O
14	s	O
15	disease	O
16	to	O
17	evaluate	O
18	clinical	O
19	and	O
20	nutritional	O
21	outcomes	O
22	after	O
23	an	O
24	amino	O
25	acid	O
26	based	O
27	diet	O
28	containing	O
29	3	O
30	%	O
31	fat	O
32	was	O
33	given	O
34	by	O
35	a	O
36	feeding	O
37	tube	O
38	compared	O
39	with	O
40	a	O
41	peptide	O
42	based	O
43	diet	O
44	containing	O
45	33	O
46	%	O
47	fat	O
48	.	O

0	Our	O
1	study	O
2	differs	O
3	from	O
4	previous	O
5	studies	O
6	in	O
7	that	O
8	it	O
9	is	O
10	limited	O
11	to	O
12	one	O
13	diagnostic	O
14	entity	O
15	,	O
16	yet	O
17	at	O
18	the	O
19	same	O
20	time	O
21	evaluates	O
22	a	O
23	broad	O
24	range	O
25	of	O
26	social	O
27	and	O
28	work	O
29	-	O
30	related	O
31	factors	O
32	in	O
33	disability	O
34	.	O

0	Normal	O
1	baseline	O
2	(	O
3	day	O
4	-	O
5	8	O
6	)	O
7	PC	O
8	levels	O
9	(	O
10	86	O
11	and	O
12	89	O
13	%)	O
14	were	O
15	markedly	O
16	reduced	O
17	in	O
18	both	O
19	patients	O
20	at	O
21	the	O
22	time	O
23	of	O
24	VOD	O
25	manifestation	O
26	on	O
27	day	O
28	20	O
29	and	O
30	40	O
31	,	O
32	respectively	O
33	(	O
34	26	O
35	and	O
36	31	O
37	%).	O

0	This	O
1	GAP	B
2	activity	O
3	was	O
4	observed	O
5	in	O
6	3T3	O
7	-	O
8	L1	O
9	adipocyte	O
10	lysates	O
11	,	O
12	and	O
13	was	O
14	able	O
15	to	O
16	accelerate	O
17	the	O
18	hydrolysis	O
19	of	O
20	the	O
21	[	O
22	alpha	O
23	-	O
24	32P	O
25	]	O
26	GTP	O
27	bound	O
28	to	O
29	GST	B
30	-	O
31	Rab4	O
32	into	O
33	[	O
34	alpha	O
35	-	O
36	32P	O
37	]	O
38	GDP	O
39	.	O

0	The	O
1	alpha	B
2	2A	I
3	-	I
4	adrenergic	I
5	receptor	I
6	(	O
7	alpha	B
8	2AAR	I
9	)	O
10	is	O
11	coupled	O
12	to	O
13	a	O
14	variety	O
15	of	O
16	effectors	O
17	via	O
18	pertussis	B
19	toxin	I
20	-	O
21	sensitive	O
22	GTP	B
23	-	I
24	binding	I
25	proteins	I
26	.	O

0	Comparison	O
1	of	O
2	immunoassay	O
3	kits	O
4	for	O
5	detection	O
6	of	O
7	staphylococcal	O
8	enterotoxins	O
9	produced	O
10	by	O
11	Staphylococcus	O
12	aureus	O

0	Mutations	O
1	within	O
2	conserved	O
3	region	O
4	2	O
5	(	O
6	CR2	B
7	)	O
8	of	O
9	E1A	B
10	that	O
11	inhibit	O
12	the	O
13	binding	O
14	of	O
15	E1A	B
16	to	O
17	the	O
18	retinoblastoma	B
19	gene	I
20	product	I
21	(	O
22	pRb	B
23	)	O
24	further	O
25	enhanced	O
26	the	O
27	stimulation	O
28	of	O
29	transcription	O
30	from	O
31	the	O
32	PEPCK	B
33	promoter	I
34	by	O
35	2	O
36	3	O
37	-	O
38	fold	O
39	compared	O
40	with	O
41	wild	B
42	type	I
43	E1A	I
44	.	O

0	Many	O
1	canonical	O
2	TATA	O
3	sequences	O
4	are	O
5	present	O
6	upstream	O
7	from	O
8	these	O
9	VZV	O
10	transcriptional	O
11	start	O
12	sites	O
13	but	O
14	,	O
15	apparently	O
16	,	O
17	are	O
18	not	O
19	used	O
20	.	O

0	The	O
1	effects	O
2	of	O
3	loading	O
4	the	O
5	respiratory	O
6	pumps	O
7	on	O
8	the	O
9	oxygen	O
10	consumption	O
11	of	O
12	Callionymus	O
13	lyra	O
14	.	O

0	It	O
1	was	O
2	shown	O
3	that	O
4	estradiol	O
5	concentrations	O
6	obtained	O
7	after	O
8	estradiol	O
9	valerate	O
10	and	O
11	micronized	O
12	estradiol	O
13	ingestion	O
14	were	O
15	dependent	O
16	on	O
17	the	O
18	patient	O
19	'	O
20	s	O
21	age	O
22	as	O
23	well	O
24	as	O
25	on	O
26	the	O
27	constitutional	O
28	type	O
29	.	O

0	Immunologically	O
1	reactive	O
2	insulin	B
3	levels	O
4	were	O
5	determined	O
6	in	O
7	freely	O
8	-	O
9	moving	O
10	normal	O
11	rats	O
12	offered	O
13	three	O
14	different	O
15	test	O
16	-	O
17	meals	O
18	.	O

0	Examination	O
1	of	O
2	immediate	B
3	-	I
4	early	I
5	transcription	I
6	factor	I
7	expression	O
8	during	O
9	the	O
10	MDI	O
11	regimen	O
12	revealed	O
13	that	O
14	RA	B
15	mediated	O
16	an	O
17	elevated	O
18	,	O
19	prolonged	O
20	expression	O
21	of	O
22	c	B
23	-	I
24	Jun	I
25	mRNA	I
26	accompanied	O
27	by	O
28	diminished	O
29	expression	O
30	of	O
31	c	B
32	-	I
33	Fos	I
34	and	O
35	Jun	B
36	-	I
37	B	I
38	mRNAs	I
39	.	O

0	Taken	O
1	together	O
2	,	O
3	these	O
4	data	O
5	indicate	O
6	that	O
7	the	O
8	VirD2	B
9	omega	I
10	domain	I
11	is	O
12	important	O
13	for	O
14	efficient	O
15	T	O
16	-	O
17	DNA	O
18	integration	O
19	.	O

0	Notably	O
1	,	O
2	these	O
3	residues	O
4	are	O
5	located	O
6	in	O
7	different	O
8	domains	O
9	.	O

0	CONCLUSIONS	O
1	:	O
2	While	O
3	INR	O
4	correction	O
5	may	O
6	be	O
7	achieved	O
8	by	O
9	all	O
10	the	O
11	above	O
12	methods	O
13	,	O
14	that	O
15	relating	O
16	log	O
17	reference	O
18	INR	O
19	to	O
20	log	O
21	local	O
22	prothrombin	B
23	time	O
24	by	O
25	linear	O
26	regression	O
27	analysis	O
28	is	O
29	the	O
30	simplest	O
31	to	O
32	perform	O
33	.	O

0	The	O
1	Lp	B
2	mouse	I
3	mutant	I
4	provides	O
5	a	O
6	model	O
7	for	O
8	the	O
9	severe	O
10	human	O
11	neural	O
12	tube	O
13	defect	O
14	(	O
15	NTD	O
16	),	O
17	cranio	O
18	-	O
19	rachischisis	O
20	.	O

0	In	O
1	addition	O
2	,	O
3	the	O
4	transcription	O
5	of	O
6	c	B
7	-	I
8	IAP2	I
9	promoter	I
10	was	O
11	strongly	O
12	up	O
13	-	O
14	regulated	O
15	when	O
16	CD40	B
17	or	O
18	Epstein	B
19	-	I
20	Barr	I
21	virus	I
22	latent	I
23	membrane	I
24	protein	I
25	1	I
26	was	O
27	overexpressed	O
28	.	O

0	1	O
1	.	O

0	Substitution	O
1	of	O
2	the	O
3	DR1	B
4	beta	I
5	chain	I
6	with	O
7	H	O
8	-	O
9	2E	O
10	beta	O
11	k	O
12	led	O
13	to	O
14	a	O
15	dramatic	O
16	loss	O
17	of	O
18	recognition	O
19	;	O
20	alpha	O
21	chain	O
22	substitution	O
23	had	O
24	a	O
25	less	O
26	marked	O
27	effect	O
28	.	O

0	Inclusion	O
1	of	O
2	the	O
3	extended	O
4	N	O
5	terminus	O
6	into	O
7	the	O
8	originally	O
9	reported	O
10	protein	O
11	resulted	O
12	in	O
13	a	O
14	striking	O
15	similarity	O
16	to	O
17	the	O
18	lymphoid	B
19	factor	I
20	Lef	I
21	-	I
22	1	I
23	.	O

0	No	O
1	consistent	O
2	correlation	O
3	between	O
4	blood	O
5	pressure	O
6	change	O
7	and	O
8	SCR	O
9	-	O
10	change	O
11	was	O
12	seen	O
13	.	O

0	The	O
1	history	O
2	of	O
3	exposure	O
4	and	O
5	carboxyhemoglobin	B
6	levels	O
7	should	O
8	alert	O
9	the	O
10	physician	O
11	to	O
12	this	O
13	diagnosis	O
14	.	O

0	The	O
1	amount	O
2	of	O
3	these	O
4	factors	O
5	was	O
6	reduced	O
7	in	O
8	GEO	O
9	cells	O
10	in	O
11	which	O
12	the	O
13	u	B
14	-	I
15	PAR	I
16	gene	I
17	is	O
18	only	O
19	weakly	O
20	transcriptionally	O
21	activated	O
22	.	O

0	Cerebrospinal	B
1	fluid	I
2	transferrin	I
3	II	I
4	studies	O
5	in	O
6	ischemic	O
7	disorders	O
8	of	O
9	the	O
10	central	O
11	nervous	O
12	system	O
13	.	O

0	Frog	O
1	type	O
2	I	O
3	(	O
4	Ft	O
5	I	O
6	)	O
7	and	O
8	frog	O
9	type	O
10	II	O
11	(	O
12	Ft	O
13	II	O
14	)	O
15	slowly	O
16	adapting	O
17	(	O
18	SA	O
19	)	O
20	units	O
21	produced	O
22	spikes	O
23	only	O
24	at	O
25	the	O
26	indentation	O
27	phase	O
28	,	O
29	and	O
30	the	O
31	threshold	O
32	response	O
33	phase	O
34	(	O
35	TRP	O
36	),	O
37	i	O
38	.	O
39	e	O
40	..	O
41	the	O
42	phase	O
43	of	O
44	the	O
45	first	O
46	spike	O
47	was	O
48	for	O
49	ca	O
50	.	O

0	We	O
1	have	O
2	partially	O
3	sequenced	O
4	the	O
5	RAP74	B
6	protein	I
7	from	O
8	purified	O
9	HeLa	O
10	cells	O
11	,	O
12	cloned	O
13	its	O
14	complementary	O
15	DNA	O
16	and	O
17	shown	O
18	that	O
19	its	O
20	translation	O
21	product	O
22	can	O
23	interact	O
24	with	O
25	RAP30	B
26	in	O
27	vitro	O
28	as	O
29	well	O
30	as	O
31	in	O
32	vivo	O
33	.	O

0	Until	O
1	such	O
2	investigations	O
3	are	O
4	performed	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	the	O
10	role	O
11	for	O
12	adjuvant	O
13	treatment	O
14	is	O
15	questionable	O
16	and	O
17	that	O
18	TME	O
19	surgery	O
20	is	O
21	preferred	O
22	as	O
23	the	O
24	treatment	O
25	option	O
26	for	O
27	Stage	O
28	T1	O
29	-	O
30	T3	O
31	rectal	O
32	cancers	O
33	.	O

0	Thus	O
1	,	O
2	the	O
3	bovine	B
4	PEDF	I
5	cDNA	I
6	isolated	O
7	here	O
8	codes	O
9	for	O
10	a	O
11	functional	O
12	soluble	O
13	secreted	O
14	PEDF	B
15	glycoprotein	I
16	.	O

0	HIV	O
1	infectiousness	O
2	and	O
3	the	O
4	AIDS	O
5	epidemic	O
6	.	O

0	For	O
1	SMX	B
2	at	O
3	pH	O
4	7	O
5	.	O
6	0	O
7	,	O
8	a	O
9	1	O
10	:	O
11	1	O
12	complex	O
13	is	O
14	formed	O
15	,	O
16	but	O
17	at	O
18	pH	O
19	7	O
20	.	O
21	5	O
22	HPCD	O
23	has	O
24	little	O
25	effect	O
26	on	O
27	the	O
28	solubility	O
29	of	O
30	the	O
31	highly	O
32	ionized	O
33	SMX	B
34	,	O
35	presumably	O
36	since	O
37	only	O
38	un	O
39	-	O
40	ionized	O
41	molecules	O
42	can	O
43	form	O
44	inclusion	O
45	complexes	O
46	with	O
47	the	O
48	HPCD	O
49	.	O

0	Vitrectomy	O
1	in	O
2	ocular	O
3	traumatology	O

0	EMBO	O
1	J	O
2	.	O

0	M	O
1	.	O
2	M	O
3	.	O
4	C	O
5	.	O
6	was	O
7	used	O
8	for	O
9	2	O
10	.	O
11	5	O
12	minutes	O
13	in	O
14	44	O
15	cases	O
16	(	O
17	20	O
18	HR	O
19	patients	O
20	,	O
21	24	O
22	LR	O
23	patients	O
24	),	O
25	and	O
26	for	O
27	5	O
28	minutes	O
29	in	O
30	66	O
31	cases	O
32	(	O
33	46	O
34	HR	O
35	patients	O
36	,	O
37	20	O
38	LR	O
39	patients	O
40	).	O

0	The	O
1	distribution	O
2	phase	O
3	is	O
4	followed	O
5	by	O
6	an	O
7	elimination	O
8	phase	O
9	with	O
10	a	O
11	much	O
12	longer	O
13	half	O
14	-	O
15	life	O
16	(	O
17	mean	O
18	value	O
19	375	O
20	min	O
21	)	O
22	and	O
23	a	O
24	volume	O
25	of	O
26	distribution	O
27	of	O
28	approximately	O
29	200	O
30	-	O
31	400	O
32	l	O
33	.	O

0	(	O
1	iii	O
2	)	O
3	In	O
4	these	O
5	cells	O
6	,	O
7	PKCbeta	B
8	plays	O
9	a	O
10	unique	O
11	Ras	B
12	-	O
13	independent	O
14	role	O
15	in	O
16	mediating	O
17	insulin	B
18	but	O
19	not	O
20	EGF	B
21	or	O
22	other	O
23	growth	B
24	factor	I
25	mitogenic	O
26	signals	O
27	.	O

0	A	O
1	developmentally	O
2	modulated	O
3	chromatin	O
4	structure	O
5	at	O
6	the	O
7	mouse	B
8	immunoglobulin	I
9	kappa	I
10	3	I
11	'	I
12	enhancer	I
13	.	O

0	Reconstitution	O
1	of	O
2	Raf	B
3	-	I
4	1	I
5	activity	O
6	was	O
7	observed	O
8	only	O
9	with	O
10	kinase	O
11	active	O
12	Jak1	B
13	in	O
14	both	O
15	cell	O
16	lines	O
17	.	O

0	The	O
1	remainder	O
2	(	O
3	18	O
4	.	O
5	4	O
6	%)	O
7	was	O
8	with	O
9	IgA	B
10	nephropathy	O
11	,	O
12	which	O
13	was	O
14	histologically	O
15	mild	O
16	.	O

0	Biologically	O
1	significant	O
2	amounts	O
3	of	O
4	platelet	B
5	activating	I
6	factor	I
7	were	O
8	eluted	O
9	from	O
10	the	O
11	sorbent	O
12	during	O
13	the	O
14	entire	O
15	treatment	O
16	time	O
17	.	O

0	At	O
1	both	O
2	water	O
3	temperatures	O
4	,	O
5	VO2	O
6	increased	O
7	linearly	O
8	with	O
9	increasing	O
10	swimming	O
11	velocity	O
12	.	O

0	The	O
1	trk	B
2	-	I
3	2h	I
4	oncogene	I
5	,	O
6	isolated	O
7	from	O
8	the	O
9	human	O
10	breast	O
11	carcinoma	O
12	cell	O
13	line	O
14	MDA	O
15	-	O
16	MB	O
17	231	O
18	by	O
19	genomic	O
20	DNA	O
21	-	O
22	transfection	O
23	into	O
24	NIH3T3	O
25	cells	O
26	,	O
27	consists	O
28	of	O
29	the	O
30	trk	B
31	proto	I
32	-	I
33	oncogene	I
34	receptor	I
35	kinase	I
36	domain	I
37	fused	O
38	to	O
39	a	O
40	N	O
41	-	O
42	terminal	O
43	41	O
44	amino	O
45	acid	O
46	activating	O
47	sequence	O
48	(	O
49	Kozma	O
50	,	O
51	S	O
52	.	O
53	C	O
54	.,	O
55	Redmond	O
56	,	O
57	S	O
58	.	O
59	M	O
60	.	O
61	S	O
62	.,	O
63	Xiao	O
64	-	O
65	Chang	O
66	,	O
67	F	O
68	.,	O
69	Saurer	O
70	,	O
71	S	O
72	.	O
73	M	O
74	.,	O
75	Groner	O
76	,	O
77	B	O
78	.	O
79	and	O
80	Hynes	O
81	,	O
82	N	O
83	.	O
84	E	O
85	.	O

0	Both	O
1	filters	O
2	equally	O
3	contributed	O
4	to	O
5	elevation	O
6	of	O
7	iliac	O
8	venous	O
9	pressure	O
10	(	O
11	median	O
12	,	O
13	9	O
14	.	O
15	3	O
16	and	O
17	7	O
18	.	O
19	2	O
20	mm	O
21	Hg	O
22	[	O
23	n	O
24	=	O
25	9	O
26	]	O
27	with	O
28	the	O
29	spring	O
30	filter	O
31	and	O
32	RF02	O
33	filter	O
34	,	O
35	respectively	O
36	).	O

0	Treatment	O
1	of	O
2	unstable	O
3	angina	O
4	:	O
5	role	O
6	of	O
7	antithrombotic	O
8	therapy	O
9	.	O

0	CONCLUSION	O
1	:	O
2	The	O
3	alpha2	O
4	-	O
5	adrenergic	O
6	antagonist	O
7	idazoxan	O
8	increases	O
9	glucose	O
10	-	O
11	induced	O
12	sympathetic	O
13	activity	O
14	but	O
15	not	O
16	energy	O
17	expenditure	O
18	in	O
19	obese	O
20	subjects	O
21	.	O

0	The	O
1	adeno	B
2	-	I
3	associated	I
4	virus	I
5	(	I
6	AAV	I
7	)	I
8	rep	I
9	gene	I
10	encodes	O
11	four	O
12	proteins	O
13	(	O
14	Rep78	B
15	,	O
16	Rep68	B
17	,	O
18	Rep52	B
19	,	O
20	and	O
21	Rep40	B
22	)	O
23	required	O
24	for	O
25	AAV	O
26	DNA	O
27	replication	O
28	and	O
29	AAV	O
30	gene	O
31	regulation	O
32	.	O

0	Cloning	O
1	and	O
2	sequencing	O
3	revealed	O
4	that	O
5	dMax	B
6	contains	O
7	a	O
8	deletion	O
9	spanning	O
10	the	O
11	basic	O
12	region	O
13	and	O
14	helix	O
15	1	O
16	and	O
17	the	O
18	loop	O
19	of	O
20	the	O
21	helix	O
22	-	O
23	loop	O
24	-	O
25	helix	O
26	region	O
27	,	O
28	presumably	O
29	as	O
30	a	O
31	result	O
32	of	O
33	alternative	O
34	splicing	O
35	of	O
36	max	B
37	RNA	I
38	.	O

0	Experiences	O
1	with	O
2	the	O
3	clinical	O
4	and	O
5	experimental	O
6	use	O
7	of	O
8	Urat	O
9	-	O
10	I	O
11	lithotriptor	O
12	.	O

0	Primary	O
1	invasive	O
2	Haemophilus	O
3	influenzae	O
4	type	O
5	b	O
6	disease	O
7	:	O
8	a	O
9	population	O
10	-	O
11	based	O
12	assessment	O
13	of	O
14	risk	O
15	factors	O
16	.	O

0	On	O
1	the	O
2	other	O
3	hand	O
4	,	O
5	neither	O
6	phosphate	O
7	buffered	O
8	saline	O
9	injection	O
10	into	O
11	the	O
12	ES	O
13	nor	O
14	primary	O
15	KLH	O
16	challenges	O
17	of	O
18	the	O
19	ES	O
20	were	O
21	capable	O
22	of	O
23	elevating	O
24	the	O
25	threshold	O
26	level	O
27	and	O
28	changing	O
29	the	O
30	latency	O
31	.	O

0	We	O
1	demonstrate	O
2	that	O
3	a	O
4	VT	B
5	+	I
6	peptide	I
7	was	O
8	specifically	O
9	phosphorylated	O
10	by	O
11	protein	B
12	kinase	I
13	C	I
14	(	O
15	PKC	B
16	)	O
17	in	O
18	vitro	O
19	,	O
20	but	O
21	not	O
22	by	O
23	protein	B
24	kinase	I
25	A	I
26	(	O
27	PKA	B
28	).	O

0	We	O
1	report	O
2	a	O
3	prevalence	O
4	study	O
5	of	O
6	the	O
7	best	O
8	visual	O
9	acuity	O
10	in	O
11	the	O
12	affected	O
13	eye	O
14	of	O
15	100	O
16	selected	O
17	patients	O
18	with	O
19	herpetic	O
20	keratitis	O
21	seen	O
22	during	O
23	a	O
24	two	O
25	-	O
26	year	O
27	period	O
28	.	O

0	Neutron	O
1	scattering	O
2	measurements	O
3	of	O
4	critical	O
5	exponents	O
6	in	O
7	CsMnBr3	O
8	:	O
9	A	O
10	Z2	O
11	&	O
12	gt	O
13	;=	O
14	1	O
15	antiferromagnet	O
16	.	O

0	Interspecific	O
1	backcross	O
2	analysis	O
3	using	O
4	progeny	O
5	derived	O
6	from	O
7	matings	O
8	of	O
9	(	O
10	C57BL	O
11	/	O
12	6J	O
13	x	O
14	Mus	O
15	spretus	O
16	)	O
17	F1	O
18	x	O
19	C57BL	O
20	/	O
21	6J	O
22	mice	O
23	indicates	O
24	that	O
25	the	O
26	thrombospondin	B
27	gene	I
28	is	O
29	tightly	O
30	linked	O
31	to	O
32	the	O
33	Fshb	B
34	,	O
35	Actcl	B
36	,	O
37	Ltk	B
38	,	O
39	and	O
40	B2M	B
41	loci	I
42	on	O
43	murine	O
44	chromosome	O
45	2	O
46	.	O

0	This	O
1	was	O
2	performed	O
3	in	O
4	a	O
5	double	O
6	blinded	O
7	,	O
8	randomized	O
9	,	O
10	placebo	O
11	-	O
12	controlled	O
13	study	O
14	.	O

0	The	O
1	pheromone	O
2	response	O
3	pathway	O
4	activates	O
5	transcription	O
6	of	O
7	Ty5	B
8	retrotransposons	I
9	located	O
10	within	O
11	silent	O
12	chromatin	O
13	of	O
14	Saccharomyces	O
15	cerevisiae	O
16	.	O

0	Lengthy	O
1	and	O
2	repeated	O
3	hemodialyses	O
4	were	O
5	required	O
6	to	O
7	lower	O
8	lithemia	O
9	to	O
10	nontoxic	O
11	ranges	O
12	.	O

0	The	O
1	major	O
2	myosin	B
3	-	I
4	binding	I
5	domain	I
6	of	O
7	skeletal	B
8	muscle	I
9	MyBP	I
10	-	I
11	C	I
12	(	I
13	C	I
14	protein	I
15	)	O
16	resides	O
17	in	O
18	the	O
19	COOH	O
20	-	O
21	terminal	O
22	,	O
23	immunoglobulin	B
24	C2	I
25	motif	I
26	.	O

0	In	O
1	this	O
2	paper	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	binding	O
8	of	O
9	the	O
10	GA	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	GABP	B
16	)	O
17	to	O
18	ets	B
19	sequence	O
20	motifs	O
21	within	O
22	each	O
23	repeated	O
24	unit	O
25	is	O
26	required	O
27	for	O
28	transcriptional	O
29	activation	O
30	of	O
31	the	O
32	COXIV	B
33	promoter	I
34	.	O

0	PULSE	O
1	is	O
2	used	O
3	to	O
4	set	O
5	such	O
6	NMR	O
7	spectroscopic	O
8	parameters	O
9	as	O
10	the	O
11	delay	O
12	and	O
13	duration	O
14	of	O
15	rf	O
16	transmit	O
17	and	O
18	receive	O
19	gates	O
20	,	O
21	rf	O
22	phase	O
23	,	O
24	sampling	O
25	times	O
26	,	O
27	and	O
28	such	O
29	imaging	O
30	parameters	O
31	as	O
32	rf	O
33	pulse	O
34	shape	O
35	and	O
36	gradient	O
37	waveforms	O
38	.	O

0	Phosphorylation	O
1	analyses	O
2	indicated	O
3	that	O
4	inhibition	O
5	of	O
6	ERK	B
7	-	I
8	1	I
9	/	I
10	2	I
11	decreased	O
12	okadaic	O
13	acid	O
14	-	O
15	elevated	O
16	phosphorylation	O
17	of	O
18	JunD	B
19	and	O
20	FosB	B
21	.	O

0	Evoked	O
1	potential	O
2	and	O
3	single	O
4	unit	O
5	responses	O
6	to	O
7	olfactory	O
8	nerve	O
9	volleys	O
10	in	O
11	the	O
12	isolated	O
13	turtle	O
14	olfactory	O
15	bulb	O
16	.	O

0	This	O
1	report	O
2	substantiates	O
3	that	O
4	at	O
5	least	O
6	two	O
7	of	O
8	the	O
9	18	O
10	kDa	O
11	hsps	O
12	in	O
13	maize	O
14	are	O
15	products	O
16	of	O
17	different	O
18	but	O
19	related	O
20	genes	O
21	.	O

0	Using	O
1	one	O
2	of	O
3	the	O
4	six	O
5	fragments	O
6	(	O
7	CPK3	B
8	-	I
9	8	I
10	),	O
11	we	O
12	isolated	O
13	a	O
14	2022	O
15	bp	O
16	cDNA	O
17	(	O
18	VrCDPK	B
19	-	O
20	1	O
21	)	O
22	from	O
23	a	O
24	Vigna	O
25	radiata	O
26	lambda	O
27	gt11	O
28	library	O
29	.	O

0	Next	O
1	,	O
2	to	O
3	identify	O
4	regions	O
5	of	O
6	the	O
7	promoter	O
8	involved	O
9	,	O
10	we	O
11	examined	O
12	a	O
13	series	O
14	of	O
15	tenascin	B
16	-	I
17	C	I
18	promoter	I
19	constructs	I
20	with	O
21	5	O
22	'	O
23	deletions	O
24	and	O
25	showed	O
26	that	O
27	denatured	O
28	collagen	B
29	-	O
30	dependent	O
31	promoter	O
32	activity	O
33	was	O
34	retained	O
35	by	O
36	a	O
37	122	O
38	-	O
39	base	O
40	pair	O
41	element	O
42	,	O
43	located	O
44	-	O
45	43	O
46	to	O
47	-	O
48	165	O
49	bp	O
50	upstream	O
51	of	O
52	the	O
53	RNA	O
54	start	O
55	site	O
56	.	O

0	Serum	O
1	concentrations	O
2	of	O
3	bone	B
4	specific	I
5	alkaline	I
6	phosphatase	I
7	(	O
8	BALP	B
9	)	O
10	and	O
11	osteocalcin	B
12	(	O
13	bone	B
14	Gla	I
15	protein	I
16	,	O
17	BGP	B
18	),	O
19	urinary	O
20	levels	O
21	of	O
22	pyridinoline	O
23	(	O
24	Pyr	O
25	)	O
26	and	O
27	deoxypyridinoline	O
28	(	O
29	Dpyr	O
30	)	O
31	and	O
32	computed	O
33	tomography	O
34	(	O
35	CT	O
36	)	O
37	measurements	O
38	of	O
39	the	O
40	cross	O
41	-	O
42	sectional	O
43	areas	O
44	of	O
45	the	O
46	vertebrae	O
47	and	O
48	the	O
49	femurs	O
50	,	O
51	the	O
52	apparent	O
53	density	O
54	of	O
55	cancellous	O
56	bone	O
57	in	O
58	the	O
59	vertebrae	O
60	,	O
61	and	O
62	the	O
63	volume	O
64	and	O
65	the	O
66	material	O
67	density	O
68	of	O
69	cortical	O
70	bone	O
71	in	O
72	the	O
73	femurs	O
74	were	O
75	determined	O
76	in	O
77	126	O
78	boys	O
79	and	O
80	143	O
81	girls	O
82	,	O
83	ages	O
84	7	O
85	-	O
86	18	O
87	years	O
88	.	O

0	I	O
1	.	O

0	UDP	O
1	-	O
2	Gal	O
3	:	O
4	Gal	I
5	beta	I
6	1	I
7	----	I
8	4GlcNAc	I
9	alpha	I
10	1	I
11	----	I
12	3	I
13	-	I
14	galactosyltransferase	I
15	is	O
16	a	O
17	terminal	O
18	glycosyltransferase	O
19	that	O
20	is	O
21	widely	O
22	expressed	O
23	in	O
24	a	O
25	variety	O
26	of	O
27	mammalian	O
28	species	O
29	,	O
30	with	O
31	the	O
32	notable	O
33	exception	O
34	of	O
35	man	O
36	,	O
37	apes	O
38	,	O
39	and	O
40	Old	O
41	World	O
42	monkeys	O
43	.	O

0	This	O
1	fragment	O
2	contained	O
3	the	O
4	C	O
5	-	O
6	terminal	O
7	47	O
8	nucleotides	O
9	of	O
10	leuB	B
11	,	O
12	encoding	O
13	3	B
14	-	I
15	isopropylmalate	I
16	dehydrogenase	I
17	;	O
18	asd	B
19	,	O
20	encoding	O
21	aspartate	B
22	-	I
23	beta	I
24	-	I
25	semialdehyde	I
26	dehydrogenase	I
27	(	O
28	Asd	B
29	);	O
30	and	O
31	orfA	B
32	,	O
33	whose	O
34	product	O
35	showed	O
36	similarity	O
37	to	O
38	the	O
39	Asd	B
40	proteins	I
41	from	O
42	Vibrio	B
43	spp	I
44	.	O

0	Overall	O
1	prevalences	O
2	of	O
3	antibody	O
4	were	O
5	70	O
6	per	O
7	cent	O
8	in	O
9	cattle	O
10	,	O
11	67	O
12	per	O
13	cent	O
14	in	O
15	sheep	O
16	and	O
17	76	O
18	per	O
19	cent	O
20	in	O
21	goats	O
22	as	O
23	assessed	O
24	by	O
25	an	O
26	immunodiffusion	O
27	test	O
28	.	O

0	Artificial	O
1	ventilation	O
2	was	O
3	conducted	O
4	using	O
5	a	O
6	tidal	O
7	volume	O
8	of	O
9	10	O
10	ml	O
11	X	O
12	kg	O
13	-	O
14	1	O
15	and	O
16	a	O
17	rate	O
18	of	O
19	10	O
20	to	O
21	12	O
22	c	O
23	X	O
24	min	O
25	-	O
26	1	O
27	.	O

0	Finally	O
1	,	O
2	we	O
3	show	O
4	that	O
5	PhLP	B
6	complexes	O
7	,	O
8	at	O
9	least	O
10	partially	O
11	,	O
12	with	O
13	Gbetagamma	B
14	in	O
15	vivo	O
16	.	O

0	Canine	O
1	reproduction	O
2	:	O
3	effects	O
4	of	O
5	a	O
6	single	O
7	injection	O
8	of	O
9	medroxyprogesterone	O
10	acetate	O
11	on	O
12	the	O
13	reproductive	O
14	organs	O
15	of	O
16	the	O
17	bitch	O
18	.	O

0	Here	O
1	,	O
2	it	O
3	is	O
4	shown	O
5	that	O
6	TAFII250	B
7	,	O
8	the	O
9	largest	O
10	subunit	O
11	of	O
12	TFIID	B
13	,	O
14	contains	O
15	two	O
16	tandem	O
17	bromodomain	O
18	modules	O
19	that	O
20	bind	O
21	selectively	O
22	to	O
23	multiply	O
24	acetylated	O
25	histone	B
26	H4	I
27	peptides	I
28	.	O

0	With	O
1	each	O
2	of	O
3	the	O
4	three	O
5	pairs	O
6	of	O
7	isolates	O
8	(	O
9	case	O
10	and	O
11	suspicious	O
12	case	O
13	),	O
14	identical	O
15	IS6110	B
16	banding	O
17	patterns	O
18	were	O
19	found	O
20	suggesting	O
21	identical	O
22	MTB	O
23	strains	O
24	.	O

0	Fgd3	B
1	and	O
2	FGD1	B
3	share	O
4	a	O
5	high	O
6	degree	O
7	of	O
8	sequence	O
9	identity	O
10	that	O
11	spans	O
12	>	O
13	560	O
14	contiguous	O
15	amino	O
16	acid	O
17	residues	O
18	.	O

0	In	O
1	addition	O
2	,	O
3	a	O
4	noncanonical	O
5	C	B
6	/	I
7	EBP	I
8	-	I
9	binding	I
10	site	I
11	within	O
12	the	O
13	Gadd45gamma	B
14	promoter	I
15	where	O
16	C	B
17	/	I
18	EBPbeta	I
19	and	O
20	C	B
21	/	I
22	EBPdelta	I
23	could	O
24	bind	O
25	,	O
26	was	O
27	identified	O
28	by	O
29	electrophoretic	O
30	mobility	O
31	shift	O
32	assay	O
33	(	O
34	EMSA	O
35	)	O
36	and	O
37	reporter	O
38	gene	O
39	analysis	O
40	.	O

0	Patients	O
1	receiving	O
2	VPA	O
3	showed	O
4	differences	O
5	in	O
6	attention	O
7	,	O
8	visuomotor	O
9	performance	O
10	,	O
11	verbal	O
12	span	O
13	and	O
14	sensory	O
15	discrimination	O
16	tasks	O
17	at	O
18	T1	O
19	,	O
20	in	O
21	visuomotor	O
22	performance	O
23	at	O
24	T2	O
25	and	O
26	in	O
27	spatial	O
28	span	O
29	at	O
30	T3	O
31	,	O
32	whereas	O
33	no	O
34	differences	O
35	were	O
36	detected	O
37	at	O
38	T4	O
39	.	O

0	Expression	O
1	of	O
2	constitutively	O
3	active	O
4	MEK1	B
5	,	O
6	the	O
7	kinase	O
8	that	O
9	activates	O
10	ERKs	B
11	,	O
12	or	O
13	overexpression	O
14	of	O
15	ERK2	B
16	,	O
17	but	O
18	not	O
19	JNK1	B
20	,	O
21	inhibited	O
22	Stat3	B
23	activation	O
24	.	O

0	A	O
1	human	B
2	SPT3	I
3	-	O
4	TAFII31	B
5	-	O
6	GCN5	B
7	-	I
8	L	I
9	acetylase	I
10	complex	O
11	distinct	O
12	from	O
13	transcription	B
14	factor	I
15	IID	I
16	.	O

0	Point	O
1	mutations	O
2	in	O
3	the	O
4	third	O
5	SH3	B
6	domain	I
7	abolished	O
8	the	O
9	vinexin	B
10	-	O
11	Sos	B
12	interaction	O
13	.	O

0	After	O
1	2	O
2	min	O
3	of	O
4	dobutamine	O
5	injection	O
6	,	O
7	or	O
8	after	O
9	20	O
10	min	O
11	of	O
12	pimobendan	O
13	injection	O
14	,	O
15	the	O
16	myocardium	O
17	was	O
18	removed	O
19	,	O
20	and	O
21	used	O
22	for	O
23	determination	O
24	of	O
25	the	O
26	tissue	O
27	levels	O
28	of	O
29	metabolites	O
30	of	O
31	energy	O
32	and	O
33	carbohydrate	O
34	metabolism	O
35	.	O

0	In	O
1	a	O
2	PC12	O
3	cell	O
4	mutant	O
5	that	O
6	is	O
7	deficient	O
8	in	O
9	protein	B
10	kinase	I
11	A	I
12	activity	O
13	(	O
14	AB	B
15	.	I
16	11	I
17	),	O
18	all	O
19	three	O
20	differentiating	O
21	agents	O
22	were	O
23	unable	O
24	to	O
25	down	O
26	-	O
27	regulate	O
28	nrg	B
29	-	I
30	1	I
31	mRNA	I
32	.	O

0	This	O
1	repression	O
2	was	O
3	mediated	O
4	through	O
5	binding	O
6	to	O
7	the	O
8	E2	B
9	DNA	I
10	-	I
11	binding	I
12	site	I
13	immediately	O
14	upstream	O
15	of	O
16	the	O
17	P105	B
18	promoter	I
19	TATA	I
20	box	I
21	and	O
22	could	O
23	be	O
24	abrogated	O
25	by	O
26	preincubation	O
27	of	O
28	the	O
29	HPV	O
30	-	O
31	18	O
32	P105	O
33	promoter	O
34	template	O
35	with	O
36	the	O
37	nuclear	O
38	extract	O
39	allowing	O
40	the	O
41	formation	O
42	of	O
43	the	O
44	preinitiation	O
45	complex	O
46	.	O

0	We	O
1	also	O
2	identified	O
3	an	O
4	alternative	O
5	spliced	O
6	form	O
7	of	O
8	Lyp	B
9	RNA	I
10	,	O
11	Lyp2	B
12	.	O

0	RT	O
1	-	O
2	PCR	O
3	was	O
4	performed	O
5	using	O
6	previously	O
7	reported	O
8	degenerate	O
9	oligonucleotide	O
10	primers	O
11	to	O
12	the	O
13	ligand	O
14	binding	O
15	domain	O
16	(	O
17	LBD	O
18	)	O
19	of	O
20	known	O
21	beta	B
22	integrin	I
23	subunits	I
24	and	O
25	Bge	B
26	cDNA	I
27	.	O

0	Both	O
1	mutations	O
2	completely	O
3	abolished	O
4	binding	O
5	of	O
6	the	O
7	Abl	B
8	SH3	I
9	domain	I
10	to	O
11	proline	O
12	-	O
13	rich	O
14	target	O
15	proteins	O
16	in	O
17	a	O
18	filter	O
19	-	O
20	binding	O
21	assay	O
22	.	O

0	(	O
1	3	O
2	).	O

0	Oncogenic	O
1	activation	O
2	of	O
3	the	O
4	tyrosine	B
5	kinase	I
6	domain	I
7	of	O
8	the	O
9	human	B
10	trk	I
11	proto	I
12	-	I
13	oncogene	I
14	by	O
15	fusion	O
16	to	O
17	a	O
18	cell	O
19	adhesion	O
20	molecule	O
21	.	O

0	The	O
1	elevations	O
2	achieved	O
3	by	O
4	LDEE	O
5	given	O
6	s	O
7	.	O
8	c	O
9	.	O
10	were	O
11	higher	O
12	than	O
13	those	O
14	achieved	O
15	after	O
16	i	O
17	.	O
18	p	O
19	.	O
20	administration	O
21	and	O
22	lasted	O
23	for	O
24	longer	O
25	periods	O
26	.	O

0	When	O
1	combined	O
2	with	O
3	independent	O
4	activating	O
5	mutations	O
6	in	O
7	the	O
8	c	B
9	-	I
10	abl	I
11	kinase	I
12	domain	I
13	or	O
14	NH2	O
15	-	O
16	terminus	O
17	,	O
18	the	O
19	G128R	B
20	mutation	I
21	blocked	O
22	transformation	O
23	by	O
24	the	O
25	double	O
26	mutant	O
27	,	O
28	suggesting	O
29	that	O
30	the	O
31	G128R	B
32	mutant	I
33	was	O
34	unable	O
35	to	O
36	transform	O
37	cells	O
38	for	O
39	trivial	O
40	reasons	O
41	.	O

0	Primary	O
1	adrenal	O
2	hypersensitivity	O
3	to	O
4	ACTH	B
5	drive	O
6	in	O
7	obesity	O
8	has	O
9	also	O
10	been	O
11	suggested	O
12	.	O

0	Antivitamin	O
1	K	O
2	agents	O

0	ECM	O
1	disruption	O
2	in	O
3	Lytechinus	O
4	embryos	O
5	caused	O
6	a	O
7	relative	O
8	drop	O
9	in	O
10	USF	B
11	RNA	I
12	accumulation	O
13	levels	O
14	to	O
15	approximately	O
16	60	O
17	%	O
18	of	O
19	control	O
20	embryos	O
21	,	O
22	while	O
23	LpS1	B
24	RNA	I
25	accumulation	O
26	levels	O
27	dropped	O
28	to	O
29	less	O
30	than	O
31	5	O
32	%.	O

0	The	O
1	5	O
2	'-	O
3	flanking	O
4	region	O
5	,	O
6	from	O
7	nucleotide	O
8	-	O
9	837	O
10	to	O
11	-	O
12	336	O
13	,	O
14	contains	O
15	TATA	O
16	and	O
17	inverted	O
18	CAAT	O
19	boxes	O
20	as	O
21	well	O
22	as	O
23	GATA	B
24	-	I
25	1	I
26	/	O
27	SP1	B
28	erythroid	O
29	-	O
30	specific	O
31	cis	O
32	-	O
33	acting	O
34	regulatory	O
35	elements	O
36	.	O

0	Jerseys	O
1	had	O
2	higher	O
3	hepatic	O
4	Cu	O
5	concentrations	O
6	than	O
7	did	O
8	Holsteins	O
9	on	O
10	d	O
11	60	O
12	(	O
13	346	O
14	vs	O
15	.	O

0	PKC	B
1	-	I
2	gamma	I
3	,	O
4	which	O
5	is	O
6	not	O
7	present	O
8	in	O
9	keratinocytes	O
10	,	O
11	also	O
12	induces	O
13	involucrin	B
14	gene	I
15	expression	O
16	in	O
17	a	O
18	TPA	O
19	-	O
20	independent	O
21	manner	O
22	,	O
23	when	O
24	introduced	O
25	into	O
26	SVHK	O
27	cells	O
28	.	O

0	To	O
1	test	O
2	the	O
3	role	O
4	of	O
5	ML	B
6	in	O
7	human	O
8	reproductive	O
9	axis	O
10	,	O
11	128	O
12	healthy	O
13	children	O
14	,	O
15	68	O
16	boys	O
17	and	O
18	60	O
19	girls	O
20	,	O
21	were	O
22	studied	O
23	.	O

0	nos	B
1	-	I
2	1	I
3	and	O
4	nos	B
5	-	I
6	2	I
7	,	O
8	two	O
9	genes	O
10	related	O
11	to	O
12	Drosophila	B
13	nanos	I
14	,	O
15	regulate	O
16	primordial	O
17	germ	O
18	cell	O
19	development	O
20	and	O
21	survival	O
22	in	O
23	Caenorhabditis	O
24	elegans	O
25	.	O

0	Regulation	O
1	of	O
2	embryonic	O
3	growth	O
4	and	O
5	lysosomal	O
6	targeting	O
7	by	O
8	the	O
9	imprinted	O
10	Igf2	B
11	/	O
12	Mpr	B
13	gene	I
14	.	O

0	Thus	O
1	,	O
2	the	O
3	P	B
4	.	I
5	aeruginosa	I
6	orfX	I
7	and	O
8	vfr	B
9	promoters	I
10	are	O
11	arranged	O
12	in	O
13	a	O
14	back	O
15	-	O
16	to	O
17	-	O
18	back	O
19	orientation	O
20	rather	O
21	than	O
22	the	O
23	face	O
24	-	O
25	to	O
26	-	O
27	face	O
28	orientation	O
29	of	O
30	the	O
31	dorf	B
32	and	O
33	crp	B
34	promoters	I
35	.	O

0	PURPOSE	O
1	:	O
2	To	O
3	introduce	O
4	an	O
5	image	O
6	analysis	O
7	of	O
8	the	O
9	cornea	O
10	in	O
11	photorefractive	O
12	keratectomy	O
13	(	O
14	PRK	O
15	)	O
16	for	O
17	preoperative	O
18	and	O
19	early	O
20	postoperative	O
21	determination	O
22	of	O
23	changes	O
24	in	O
25	the	O
26	condition	O
27	of	O
28	the	O
29	cornea	O
30	.	O

0	These	O
1	consisted	O
2	of	O
3	beading	O
4	and	O
5	strictures	O
6	mainly	O
7	of	O
8	the	O
9	intrahepatic	O
10	biliary	O
11	tree	O
12	(	O
13	IHB	O
14	).	O

0	Commonly	O
1	observed	O
2	systemic	O
3	toxic	O
4	effects	O
5	(	O
6	bone	O
7	marrow	O
8	,	O
9	gastrointestinal	O
10	tract	O
11	,	O
12	and	O
13	heart	O
14	)	O
15	were	O
16	not	O
17	seen	O
18	in	O
19	this	O
20	study	O
21	.	O

0	Comparative	O
1	study	O
2	on	O
3	acute	O
4	oral	O
5	overload	O
6	using	O
7	tolbutamide	O
8	and	O
9	tolazamide	O
10	in	O
11	normal	O
12	and	O
13	diabetic	O
14	subjects	O
15	.	O

0	Increasing	O
1	the	O
2	RH	O
3	beyond	O
4	32	O
5	%	O
6	resulted	O
7	in	O
8	solvation	O
9	of	O
10	the	O
11	peroxy	O
12	radical	O
13	,	O
14	sterically	O
15	hindering	O
16	the	O
17	radical	O
18	from	O
19	entering	O
20	the	O
21	propagation	O
22	transition	O
23	state	O
24	.	O

0	Transcription	O
1	of	O
2	the	O
3	gene	O
4	for	O
5	ivanolysin	B
6	O	I
7	and	O
8	expression	O
9	of	O
10	other	O
11	genes	O
12	of	O
13	the	O
14	virulence	O
15	gene	O
16	cluster	O
17	in	O
18	L	O
19	.	O
20	ivanovii	O
21	were	O
22	dependent	O
23	on	O
24	PrfA	B
25	.	O

0	Takayasu	O
1	'	O
2	s	O
3	disease	O
4	:	O
5	association	O
6	with	O
7	HLA	B
8	-	I
9	B5	I
10	.	O

0	This	O
1	motif	O
2	,	O
3	first	O
4	described	O
5	for	O
6	the	O
7	Drosophila	B
8	homeobox	I
9	activator	I
10	DEAF	I
11	-	I
12	1	I
13	,	O
14	identifies	O
15	an	O
16	emerging	O
17	group	O
18	of	O
19	metazoan	O
20	transcriptional	O
21	modulators	O
22	.	O

0	Furthermore	O
1	,	O
2	this	O
3	element	O
4	confers	O
5	p53	B
6	induction	O
7	to	O
8	the	O
9	otherwise	O
10	nonresponsive	O
11	adenovirus	B
12	major	I
13	late	I
14	promoter	I
15	.	O

0	However	O
1	,	O
2	Cbf5p	B
3	was	O
4	found	O
5	to	O
6	be	O
7	nucleolar	O
8	and	O
9	is	O
10	highly	O
11	homologous	O
12	to	O
13	the	O
14	rat	B
15	nucleolar	I
16	protein	I
17	NAP57	I
18	,	O
19	which	O
20	coimmunoprecipitates	O
21	with	O
22	Nopp140	B
23	and	O
24	which	O
25	is	O
26	postulated	O
27	to	O
28	be	O
29	involved	O
30	in	O
31	nucleolar	O
32	-	O
33	cytoplasmic	O
34	shuttling	O
35	(	O
36	U	O
37	.	O

0	The	O
1	terminator	O
2	region	O
3	supported	O
4	termination	O
5	of	O
6	transcripts	O
7	initiated	O
8	by	O
9	RNA	B
10	polymerase	I
11	I	I
12	in	O
13	vivo	O
14	.	O

0	The	O
1	final	O
2	predicted	O
3	structure	O
4	has	O
5	an	O
6	overall	O
7	backbone	O
8	deviation	O
9	of	O
10	0	O
11	.	O
12	7	O
13	A	O
14	from	O
15	that	O
16	of	O
17	ras	B
18	-	O
19	p21	B
20	.	O

0	E2	O
1	treatments	O
2	elevated	O
3	hen	O
4	plasma	O
5	TG	O
6	7	O
7	.	O
8	2X	O
9	,	O
10	PL	O
11	5	O
12	.	O
13	1X	O
14	,	O
15	and	O
16	C	O
17	7	O
18	.	O
19	2X	O
20	;	O
21	and	O
22	pullet	O
23	plasma	O
24	TG	O
25	6	O
26	.	O
27	8X	O
28	,	O
29	PL	O
30	3	O
31	.	O
32	7X	O
33	,	O
34	and	O
35	C	O
36	2	O
37	.	O
38	5X	O
39	.	O

0	In	O
1	rubella	O
2	patients	O
3	with	O
4	serologic	O
5	confirmation	O
6	by	O
7	HI	O
8	,	O
9	the	O
10	IF	O
11	test	O
12	detected	O
13	significant	O
14	rises	O
15	in	O
16	219	O
17	(	O
18	99	O
19	.	O
20	1	O
21	%)	O
22	of	O
23	221	O
24	patients	O
25	and	O
26	the	O
27	PHA	O
28	test	O
29	detected	O
30	antibody	O
31	conversion	O
32	in	O
33	68	O
34	(	O
35	93	O
36	%)	O
37	of	O
38	73	O
39	patients	O
40	.	O

0	After	O
1	i	O
2	.	O
3	v	O
4	.	O
5	administration	O
6	of	O
7	500	O
8	mg	O
9	acetazolamide	O
10	and	O
11	disinfection	O
12	of	O
13	the	O
14	conjunctiva	O
15	,	O
16	50	O
17	micrograms	O
18	rt	O
19	-	O
20	PA	O
21	in	O
22	0	O
23	.	O
24	1	O
25	ml	O
26	(	O
27	BSS	O
28	)	O
29	and	O
30	0	O
31	.	O
32	5	O
33	ml	O
34	SF6	O
35	were	O
36	injected	O
37	intravitreally	O
38	.	O

0	The	O
1	binding	O
2	of	O
3	transcription	O
4	factor	O
5	AP	B
6	-	I
7	1	I
8	and	O
9	vitamin	B
10	D	I
11	receptor	I
12	(	O
13	VDR	B
14	)	O
15	to	O
16	the	O
17	composite	O
18	AP	B
19	-	I
20	1	I
21	plus	O
22	vitamin	B
23	-	I
24	D	I
25	-	I
26	responsive	I
27	promoter	I
28	region	I
29	(	O
30	AP	B
31	-	I
32	1	I
33	+	O
34	VDRE	B
35	)	O
36	of	O
37	the	O
38	human	B
39	osteocalcin	I
40	gene	I
41	was	O
42	characterized	O
43	in	O
44	osteocalcin	B
45	-	O
46	producing	O
47	(	O
48	MG	B
49	-	I
50	63	I
51	)	O
52	and	O
53	non	O
54	-	O
55	producing	O
56	(	O
57	U2	B
58	-	I
59	Os	I
60	,	O
61	SaOs	B
62	-	I
63	2	I
64	)	O
65	human	O
66	osteosarcoma	O
67	cell	O
68	lines	O
69	.	O

0	Lowering	O
1	of	O
2	the	O
3	renal	O
4	blood	O
5	flow	O
6	alters	O
7	the	O
8	glomerular	O
9	and	O
10	tubular	O
11	excretion	O
12	processes	O
13	.	O

0	RNA	O
1	transcripts	O
2	that	O
3	hybridize	O
4	to	O
5	the	O
6	introduced	O
7	foreign	O
8	gene	O
9	have	O
10	been	O
11	identified	O
12	.	O

0	Its	O
1	potential	O
2	as	O
3	a	O
4	diagnostic	O
5	tool	O
6	for	O
7	epidemiological	O
8	surveillance	O
9	was	O
10	assessed	O
11	in	O
12	comparison	O
13	with	O
14	three	O
15	other	O
16	diagnostic	O
17	tests	O
18	:	O
19	stool	O
20	examination	O
21	,	O
22	ELISA	O
23	with	O
24	soluble	B
25	egg	I
26	antigen	I
27	(	O
28	SEA	O
29	)	O
30	and	O
31	the	O
32	circumoval	O
33	precipitin	O
34	test	O
35	(	O
36	COPT	O
37	).	O

0	The	O
1	FinO	B
2	protein	I
3	of	O
4	IncF	O
5	plasmids	O
6	binds	O
7	FinP	B
8	antisense	I
9	RNA	I
10	and	O
11	its	O
12	target	O
13	,	O
14	traJ	B
15	mRNA	I
16	,	O
17	and	O
18	promotes	O
19	duplex	O
20	formation	O
21	.	O

0	Induction	O
1	of	O
2	AtP5CS1	B
3	mRNA	I
4	accumulation	O
5	in	O
6	salt	O
7	-	O
8	treated	O
9	seedlings	O
10	involves	O
11	an	O
12	immediate	O
13	early	O
14	transcriptional	O
15	response	O
16	regulated	O
17	by	O
18	ABA	B
19	signalling	O
20	that	O
21	is	O
22	not	O
23	inhibited	O
24	by	O
25	cycloheximide	O
26	,	O
27	but	O
28	abolished	O
29	by	O
30	the	O
31	deficiency	O
32	of	O
33	ABA	B
34	biosynthesis	O
35	in	O
36	the	O
37	aba1	B
38	Arabidopsis	I
39	mutant	I
40	.	O

0	Selective	O
1	activation	O
2	of	O
3	adrenaline	O
4	secretion	O
5	by	O
6	the	O
7	rat	O
8	adrenal	O
9	in	O
10	neuroglycopenia	O
11	detected	O
12	via	O
13	microdialysis	O

0	QBMDs	O
1	for	O
2	a	O
3	5	O
4	%	O
5	change	O
6	in	O
7	response	O
8	(	O
9	QBMD05	O
10	)	O
11	were	O
12	6	O
13	-	O
14	fold	O
15	lower	O
16	,	O
17	on	O
18	average	O
19	,	O
20	than	O
21	the	O
22	corresponding	O
23	NOAEL	O
24	.	O

0	Self	O
1	or	O
2	foreign	O
3	cellular	O
4	proteins	O
5	provide	O
6	peptides	O
7	for	O
8	presentation	O
9	by	O
10	major	B
11	histocompatibility	I
12	complex	I
13	(	O
14	MHC	B
15	)	O
16	class	O
17	I	O
18	molecules	O
19	on	O
20	the	O
21	surface	O
22	of	O
23	antigen	O
24	presenting	O
25	cells	O
26	(	O
27	APC	O
28	).	O

0	The	O
1	domains	O
2	involved	O
3	in	O
4	superactivation	O
5	appear	O
6	to	O
7	be	O
8	a	O
9	subset	O
10	of	O
11	those	O
12	necessary	O
13	to	O
14	achieve	O
15	synergistic	O
16	activation	O
17	.	O

0	NuA4	B
1	has	O
2	an	O
3	apparent	O
4	molecular	O
5	mass	O
6	of	O
7	1	O
8	.	O
9	3	O
10	MDa	O
11	.	O

0	A	O
1	single	O
2	exon	O
3	encodes	O
4	the	O
5	carboxyl	O
6	-	O
7	terminal	O
8	26	O
9	amino	O
10	acids	O
11	of	O
12	the	O
13	ssd	O
14	chain	O
15	and	O
16	the	O
17	3	O
18	'	O
19	untranslated	O
20	region	O
21	of	O
22	its	O
23	mRNA	O
24	,	O
25	ending	O
26	with	O
27	a	O
28	poly	O
29	(	O
30	A	O
31	)-	O
32	addition	O
33	site	O
34	.	O

0	The	O
1	RI	B
2	alpha	I
3	gene	I
4	is	O
5	composed	O
6	of	O
7	nine	O
8	coding	O
9	exons	O
10	of	O
11	varying	O
12	lengths	O
13	,	O
14	separated	O
15	by	O
16	introns	O
17	,	O
18	giving	O
19	the	O
20	gene	O
21	a	O
22	total	O
23	length	O
24	of	O
25	at	O
26	least	O
27	21	O
28	kb	O
29	.	O
30	our	O
31	recent	O
32	cloning	O
33	of	O
34	a	O
35	processed	O
36	RI	B
37	alpha	I
38	pseudogene	I
39	with	O
40	a	O
41	5	O
42	'-	O
43	noncoding	O
44	region	O
45	different	O
46	from	O
47	the	O
48	previously	O
49	reported	O
50	RI	B
51	alpha	I
52	complementary	I
53	RNA	I
54	indicated	O
55	that	O
56	the	O
57	RI	B
58	alpha	I
59	gene	I
60	may	O
61	have	O
62	multiple	O
63	leader	O
64	exons	O
65	giving	O
66	rise	O
67	to	O
68	alternately	O
69	spliced	O
70	messenger	O
71	RNAs	O
72	(	O
73	mRNAs	O
74	).	O

0	We	O
1	report	O
2	here	O
3	that	O
4	,	O
5	for	O
6	a	O
7	constant	O
8	amount	O
9	of	O
10	transfected	O
11	DNA	O
12	,	O
13	the	O
14	level	O
15	of	O
16	chloramphenicol	B
17	acetyltransferase	I
18	(	O
19	CAT	B
20	)	O
21	mRNA	O
22	is	O
23	increased	O
24	in	O
25	Vpr	B
26	-	O
27	expressing	O
28	cells	O
29	using	O
30	either	O
31	HIV	O
32	-	O
33	1	O
34	or	O
35	a	O
36	murine	O
37	leukemia	O
38	virus	O
39	(	O
40	MLV	O
41	)	O
42	SL3	B
43	-	I
44	3	I
45	LTR	I
46	-	O
47	CAT	B
48	reporter	O
49	construct	O
50	.	O

0	Nuclear	B
1	factor	I
2	III	I
3	(	O
4	NFIII	B
5	)	O
6	is	O
7	a	O
8	protein	O
9	from	O
10	HeLa	O
11	cells	O
12	that	O
13	stimulates	O
14	the	O
15	initiation	O
16	of	O
17	adenovirus	O
18	type	O
19	2	O
20	(	O
21	Ad2	O
22	)	O
23	DNA	O
24	replication	O
25	by	O
26	binding	O
27	to	O
28	a	O
29	specific	O
30	nucleotide	O
31	sequence	O
32	in	O
33	the	O
34	origin	O
35	,	O
36	adjacent	O
37	to	O
38	the	O
39	nuclear	B
40	factor	I
41	I	I
42	recognition	I
43	site	I
44	.	O

0	In	O
1	the	O
2	DNAs	O
3	of	O
4	all	O
5	Ph1	B
6	-	O
7	positive	O
8	chronic	O
9	myelocytic	O
10	leukemia	O
11	patients	O
12	studied	O
13	to	O
14	date	O
15	,	O
16	a	O
17	breakpoint	O
18	on	O
19	chromosome	O
20	22	O
21	(	O
22	the	O
23	Ph1	O
24	chromosome	O
25	)	O
26	can	O
27	be	O
28	demonstrated	O
29	with	O
30	a	O
31	probe	O
32	from	O
33	the	O
34	bcr	O
35	(	O
36	breakpoint	O
37	cluster	O
38	region	O
39	).	O

0	The	O
1	ORF	O
2	was	O
3	analyzed	O
4	for	O
5	secondary	O
6	structural	O
7	features	O
8	,	O
9	and	O
10	the	O
11	sequence	O
12	data	O
13	bases	O
14	were	O
15	searched	O
16	for	O
17	homologies	O
18	.	O

0	Tightly	O
1	ordered	O
2	proteasomal	O
3	degradation	O
4	of	O
5	proteins	O
6	critical	O
7	for	O
8	cell	O
9	cycle	O
10	control	O
11	implies	O
12	a	O
13	role	O
14	of	O
15	the	O
16	proteasome	O
17	in	O
18	maintaining	O
19	cell	O
20	proliferation	O
21	and	O
22	cell	O
23	survival	O
24	.	O

0	Most	O
1	apneic	O
2	events	O
3	occurred	O
4	during	O
5	Stages	O
6	I	O
7	and	O
8	II	O
9	,	O
10	and	O
11	REM	O
12	,	O
13	but	O
14	this	O
15	proportion	O
16	was	O
17	less	O
18	during	O
19	the	O
20	gamma	O
21	OH	O
22	study	O
23	(	O
24	77	O
25	.	O
26	9	O
27	+/-	O
28	8	O
29	.	O
30	9	O
31	%)	O
32	than	O
33	during	O
34	the	O
35	control	O
36	studies	O
37	(	O
38	92	O
39	.	O
40	3	O
41	+/-	O
42	1	O
43	.	O
44	9	O
45	and	O
46	95	O
47	.	O
48	9	O
49	+/-	O
50	2	O
51	.	O
52	2	O
53	%),	O
54	apneas	O
55	occurring	O
56	even	O
57	during	O
58	SWS	O
59	with	O
60	gamma	O
61	OH	O
62	.(	O
63	ABSTRACT	O
64	TRUNCATED	O
65	AT	O
66	250	O
67	WORDS	O
68	)	O

0	Subsequent	O
1	experiments	O
2	showed	O
3	that	O
4	motoric	O
5	tasks	O
6	rather	O
7	than	O
8	cognitive	O
9	aspects	O
10	of	O
11	the	O
12	COWA	O
13	task	O
14	were	O
15	critical	O
16	in	O
17	potentiating	O
18	finger	O
19	-	O
20	tapping	O
21	performance	O
22	.	O

0	A	O
1	rise	O
2	of	O
3	hemoglobin	B
4	concentration	O
5	accompanied	O
6	by	O
7	an	O
8	increase	O
9	of	O
10	the	O
11	total	O
12	iron	O
13	in	O
14	the	O
15	blood	O
16	serum	O
17	of	O
18	white	O
19	mice	O
20	was	O
21	found	O
22	under	O
23	oxygen	O
24	pressure	O
25	of	O
26	4	O
27	atm	O
28	for	O
29	an	O
30	hour	O
31	(	O
32	preconvulsive	O
33	state	O
34	)	O
35	and	O
36	6	O
37	atm	O
38	(	O
39	convulsive	O
40	state	O
41	).	O

0	End	O
1	-	O
2	tidal	O
3	PO2	O
4	and	O
5	the	O
6	ratio	O
7	of	O
8	minute	O
9	ventilation	O
10	to	O
11	oxygen	O
12	consumption	O
13	(	O
14	VE	O
15	/	O
16	VO2	O
17	)	O
18	were	O
19	lower	O
20	while	O
21	PETCO2	O
22	was	O
23	higher	O
24	for	O
25	Hyp	O
26	(	O
27	P	O
28	<	O
29	or	O
30	=	O
31	0	O
32	.	O
33	01	O
34	).	O

0	New	O
1	beta	O
2	-	O
3	blocking	O
4	drugs	O
5	have	O
6	been	O
7	introduced	O
8	which	O
9	may	O
10	prove	O
11	beneficial	O
12	in	O
13	certain	O
14	clinical	O
15	situations	O
16	since	O
17	they	O
18	exert	O
19	more	O
20	selective	O
21	blockade	O
22	of	O
23	the	O
24	cardiac	O
25	receptors	O
26	(	O
27	beta1	B
28	)	O
29	as	O
30	opposed	O
31	to	O
32	smooth	B
33	muscle	I
34	receptors	I
35	(	O
36	beta2	B
37	).	O

0	Ti	O
1	exhibited	O
2	a	O
3	feather	O
4	-	O
5	like	O
6	morphology	O
7	.	O

0	1	O
1	-(	O
2	1	O
3	-	O
4	Naphthyl	O
5	)	O
6	piperazine	O
7	(	O
8	1	O
9	-	O
10	NP	O
11	)	O
12	has	O
13	been	O
14	reported	O
15	to	O
16	have	O
17	serotonin	O
18	antagonist	O
19	properties	O
20	at	O
21	the	O
22	5	O
23	-	O
24	HT2	O
25	subtype	O
26	of	O
27	receptor	O
28	,	O
29	and	O
30	it	O
31	has	O
32	been	O
33	suggested	O
34	that	O
35	it	O
36	may	O
37	have	O
38	agonist	O
39	actions	O
40	at	O
41	the	O
42	5	O
43	-	O
44	HT1	O
45	site	O
46	.	O

0	Fas	B
1	-	O
2	resistant	O
3	DT	O
4	-	O
5	40	O
6	lymphoma	O
7	B	O
8	-	O
9	cells	O
10	rendered	O
11	BTK	B
12	-	O
13	deficient	O
14	through	O
15	targeted	O
16	disruption	O
17	of	O
18	the	O
19	btk	B
20	gene	I
21	by	O
22	homologous	O
23	recombination	O
24	knockout	O
25	underwent	O
26	apoptosis	O
27	after	O
28	Fas	B
29	ligation	O
30	,	O
31	but	O
32	wild	O
33	-	O
34	type	O
35	DT	O
36	-	O
37	40	O
38	cells	O
39	or	O
40	BTK	B
41	-	O
42	deficient	O
43	DT	O
44	-	O
45	40	O
46	cells	O
47	reconstituted	O
48	with	O
49	wild	B
50	-	I
51	type	I
52	human	I
53	btk	I
54	gene	I
55	did	O
56	not	O
57	.	O

0	These	O
1	results	O
2	suggest	O
3	that	O
4	5	O
5	KE	O
6	X	O
7	3	O
8	/	O
9	W	O
10	may	O
11	be	O
12	the	O
13	optimal	O
14	regimen	O
15	to	O
16	augment	O
17	the	O
18	antitumor	O
19	immunity	O
20	of	O
21	RNL	O
22	.	O

0	The	O
1	smaller	O
2	uptake	O
3	rate	O
4	and	O
5	faster	O
6	clearance	O
7	rate	O
8	resulted	O
9	in	O
10	the	O
11	lower	O
12	BCF	O
13	for	O
14	SWA	O
15	killifish	O
16	.	O

0	Both	O
1	immunophilins	O
2	may	O
3	have	O
4	important	O
5	roles	O
6	in	O
7	receptor	O
8	assembly	O
9	and	O
10	may	O
11	represent	O
12	a	O
13	new	O
14	category	O
15	of	O
16	ligand	O
17	-	O
18	and	O
19	calcium	O
20	-	O
21	dependent	O
22	modulators	O
23	of	O
24	protein	O
25	function	O
26	.	O

0	Cloning	O
1	,	O
2	sequencing	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	3	B
8	-	I
9	phosphoglycerate	I
10	kinase	I
11	gene	I
12	of	I
13	Pyrococcus	I
14	woesei	I
15	in	I
16	Escherichia	I
17	coli	O
18	and	O
19	characterization	O
20	of	O
21	the	O
22	protein	O
23	.	O

0	Site	O
1	-	O
2	directed	O
3	mutagenesis	O
4	of	O
5	the	O
6	traI	B
7	structural	I
8	gene	I
9	and	O
10	application	O
11	of	O
12	purified	O
13	mutant	B
14	TraI	I
15	proteins	I
16	for	O
17	in	O
18	vitro	O
19	assays	O
20	served	O
21	to	O
22	evaluate	O
23	the	O
24	functional	O
25	importance	O
26	of	O
27	conserved	O
28	amino	O
29	acid	O
30	residues	O
31	.	O

0	The	O
1	delta	B
2	srb10	I
3	mutation	I
4	also	O
5	influenced	O
6	on	O
7	the	O
8	transcript	O
9	levels	O
10	of	O
11	meiosis	O
12	-	O
13	inducing	O
14	genes	O
15	called	O
16	IME1	B
17	and	O
18	IME2	B
19	:	O
20	the	O
21	mutation	O
22	elevated	O
23	the	O
24	transcript	O
25	level	O
26	of	O
27	IME1	B
28	but	O
29	reduced	O
30	that	O
31	of	O
32	IME2	B
33	,	O
34	resulting	O
35	in	O
36	partial	O
37	defects	O
38	in	O
39	premeiotic	O
40	DNA	O
41	synthesis	O
42	and	O
43	meiosis	O
44	.	O

0	Bacteria	O
1	can	O
2	also	O
3	cause	O
4	a	O
5	labyrinthitis	O
6	acting	O
7	directly	O
8	on	O
9	the	O
10	inner	O
11	ear	O
12	:	O
13	among	O
14	these	O
15	,	O
16	Treponemas	O
17	Pallidum	O
18	,	O
19	a	O
20	spirochaete	O
21	which	O
22	causes	O
23	syphilis	O
24	and	O
25	Borrelia	O
26	Burgdorferi	O
27	,	O
28	a	O
29	spirochaete	O
30	that	O
31	causes	O
32	Lyme	O
33	Disease	O
34	,	O
35	must	O
36	be	O
37	mentioned	O
38	.	O

0	Landsberg	O
1	(	O
2	La	O
3	-	O
4	O	O
5	)	O
6	and	O
7	cv	O
8	.	O

0	LysR	B
1	proteins	I
2	have	O
3	been	O
4	shown	O
5	to	O
6	regulate	O
7	urease	B
8	in	O
9	Klebsiella	O
10	aerogenes	O
11	(	O
12	NAC	B
13	),	O
14	and	O
15	catalase	B
16	in	O
17	Escherichia	O
18	coli	O
19	(	O
20	OxyR	B
21	),	O
22	which	O
23	offers	O
24	the	O
25	intracellular	O
26	bacterium	O
27	protection	O
28	from	O
29	phagolysosome	O
30	damage	O
31	.	O

0	Alternative	O
1	splicing	O
2	of	O
3	RNA	O
4	transcripts	O
5	encoded	O
6	by	O
7	the	O
8	murine	B
9	p105	I
10	NF	I
11	-	I
12	kappa	I
13	B	I
14	gene	I
15	generates	O
16	I	B
17	kappa	I
18	B	I
19	gamma	I
20	isoforms	I
21	with	O
22	different	O
23	inhibitory	O
24	activities	O
25	.	O

0	Basal	O
1	midexpiratory	O
2	lower	O
3	esophageal	O
4	sphincter	O
5	pressure	O
6	was	O
7	similar	O
8	in	O
9	the	O
10	study	O
11	group	O
12	(	O
13	mean	O
14	[	O
15	SD	O
16	]	O
17	20	O
18	.	O
19	1	O
20	[	O
21	9	O
22	.	O
23	1	O
24	]	O
25	mmHg	O
26	)	O
27	and	O
28	controls	O
29	(	O
30	17	O
31	.	O
32	6	O
33	[	O
34	6	O
35	.	O
36	0	O
37	]	O
38	mmHg	O
39	);	O
40	the	O
41	pressure	O
42	did	O
43	not	O
44	change	O
45	following	O
46	EVS	O
47	or	O
48	EVL	O
49	.	O

0	Testing	O
1	blood	O
2	donors	O
3	for	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	hepatitis	O
12	:	O
13	irrational	O
14	,	O
15	perhaps	O
16	,	O
17	but	O
18	inescapable	O
19	.	O

0	I	O
1	.	O

0	Regulation	O
1	of	O
2	mitochondrial	B
3	single	I
4	-	I
5	stranded	I
6	DNA	I
7	-	I
8	binding	I
9	protein	I
10	gene	I
11	expression	O
12	links	O
13	nuclear	O
14	and	O
15	mitochondrial	O
16	DNA	O
17	replication	O
18	in	O
19	drosophila	O
20	.	O

0	During	O
1	the	O
2	following	O
3	9	O
4	1	O
5	/	O
6	2	O
7	years	O
8	three	O
9	sequential	O
10	liver	O
11	biopsies	O
12	were	O
13	performed	O
14	.	O

0	The	O
1	tramtrack	B
2	(	O
3	ttk	B
4	)	O
5	gene	O
6	of	O
7	Drosophila	O
8	encodes	O
9	69	O
10	-	O
11	kDa	O
12	and	O
13	88	O
14	-	O
15	kDa	O
16	proteins	O
17	through	O
18	alternative	O
19	splicing	O
20	of	O
21	the	O
22	primary	O
23	ttk	B
24	transcript	I
25	.	O

0	Southern	O
1	blot	O
2	analyses	O
3	demonstrated	O
4	a	O
5	low	O
6	,	O
7	if	O
8	not	O
9	single	O
10	,	O
11	copy	O
12	number	O
13	for	O
14	this	O
15	gene	O
16	and	O
17	conservation	O
18	of	O
19	this	O
20	domain	O
21	in	O
22	other	O
23	vertebrates	O
24	.	O

0	Contingency	O
1	contracting	O
2	between	O
3	clients	O
4	and	O
5	their	O
6	parents	O
7	/	O
8	caregivers	O
9	was	O
10	used	O
11	to	O
12	specify	O
13	consequences	O
14	for	O
15	daily	O
16	self	O
17	-	O
18	monitoring	O
19	,	O
20	reduced	O
21	caloric	O
22	intake	O
23	,	O
24	weight	O
25	loss	O
26	,	O
27	and	O
28	exercise	O
29	.	O

0	This	O
1	is	O
2	the	O
3	first	O
4	report	O
5	of	O
6	the	O
7	successful	O
8	resection	O
9	of	O
10	a	O
11	MFH	O
12	originating	O
13	in	O
14	the	O
15	renal	O
16	capsular	O
17	tissue	O
18	and	O
19	extending	O
20	into	O
21	the	O
22	inferior	O
23	vena	O
24	cava	O
25	.	O

0	The	O
1	location	O
2	of	O
3	the	O
4	IBS	B
5	within	O
6	the	O
7	catB	B
8	structural	I
9	gene	I
10	,	O
11	the	O
12	cooperativity	O
13	observed	O
14	in	O
15	footprinting	O
16	studies	O
17	and	O
18	phasing	O
19	studies	O
20	suggest	O
21	that	O
22	the	O
23	IBS	B
24	participates	O
25	in	O
26	the	O
27	interaction	O
28	of	O
29	CatR	B
30	with	O
31	the	O
32	upstream	O
33	binding	O
34	sites	O
35	by	O
36	looping	O
37	out	O
38	the	O
39	intervening	O
40	DNA	O
41	.	O

0	The	O
1	proteins	O
2	encoded	O
3	downstream	O
4	of	O
5	rpoN	B
6	are	O
7	known	O
8	to	O
9	negatively	O
10	regulate	O
11	sigma	B
12	54	I
13	activity	O
14	.	O

0	The	O
1	present	O
2	investigation	O
3	conducted	O
4	in	O
5	a	O
6	population	O
7	of	O
8	258	O
9	dentally	O
10	aware	O
11	individuals	O
12	in	O
13	the	O
14	age	O
15	range	O
16	20	O
17	-	O
18	69	O
19	years	O
20	,	O
21	was	O
22	initiated	O
23	to	O
24	elucidate	O
25	the	O
26	relationship	O
27	between	O
28	tobacco	O
29	smoking	O
30	and	O
31	supragingival	O
32	calculus	O
33	,	O
34	taking	O
35	into	O
36	account	O
37	possible	O
38	confounding	O
39	factors	O
40	such	O
41	as	O
42	age	O
43	,	O
44	gender	O
45	,	O
46	oral	O
47	hygiene	O
48	and	O
49	gingival	O
50	inflammation	O
51	.	O

0	Furthermore	O
1	,	O
2	competitor	O
3	containing	O
4	the	O
5	YY1	B
6	consensus	I
7	sequence	I
8	competed	O
9	for	O
10	protein	B
11	B	I
12	binding	O
13	,	O
14	whereas	O
15	competitor	O
16	containing	O
17	a	O
18	perfect	O
19	yeast	B
20	ABF	I
21	-	I
22	1	I
23	consensus	I
24	sequence	I
25	did	O
26	not	O
27	.(	O
28	ABSTRACT	O
29	TRUNCATED	O
30	AT	O
31	400	O
32	WORDS	O
33	)	O

0	Is	O
1	leishmaniasis	O
2	endemic	O
3	on	O
4	the	O
5	island	O
6	of	O
7	Minorca	O
8	(	O
9	Spain	O
10	)?	O
11	A	O
12	human	O
13	visceral	O
14	case	O
15	after	O
16	living	O
17	13	O
18	years	O
19	in	O
20	Minorca	O
21	.	O

0	Charcoal	O
1	-	O
2	facilitated	O
3	dialysis	O
4	.	O

0	The	O
1	enzymic	O
2	hydrolysis	O
3	of	O
4	urea	O
5	produces	O
6	ammonia	O
7	which	O
8	causes	O
9	a	O
10	vivid	O
11	yellow	O
12	to	O
13	purple	O
14	colour	O
15	change	O
16	in	O
17	the	O
18	pH	O
19	indicator	O
20	.	O

0	Slowly	O
1	adapting	O
2	type	O
3	I	O
4	mechanoreceptor	O
5	discharge	O
6	as	O
7	a	O
8	function	O
9	of	O
10	dynamic	O
11	force	O
12	versus	O
13	dynamic	O
14	displacement	O
15	of	O
16	glabrous	O
17	skin	O
18	of	O
19	raccoon	O
20	and	O
21	squirrel	O
22	monkey	O
23	hand	O
24	.	O

0	In	O
1	humans	O
2	,	O
3	four	O
4	AMP	B
5	deaminase	I
6	variants	I
7	,	O
8	termed	O
9	M	O
10	(	O
11	muscle	O
12	),	O
13	L	O
14	(	O
15	liver	O
16	),	O
17	E1	O
18	,	O
19	and	O
20	E2	O
21	(	O
22	erythrocyte	O
23	)	O
24	can	O
25	be	O
26	distinguished	O
27	by	O
28	a	O
29	variety	O
30	of	O
31	biochemical	O
32	and	O
33	immunological	O
34	criteria	O
35	.	O

0	Thus	O
1	E14	B
2	.	I
3	1TG3B1	I
4	is	O
5	a	O
6	useful	O
7	ES	O
8	cell	O
9	line	O
10	for	O
11	modifying	O
12	the	O
13	mouse	O
14	genome	O
15	using	O
16	the	O
17	HPRT	B
18	gene	I
19	as	O
20	a	O
21	selection	O
22	marker	O
23	and	O
24	for	O
25	transmission	O
26	at	O
27	a	O
28	high	O
29	frequency	O
30	into	O
31	the	O
32	mouse	O
33	germ	O
34	line	O
35	.	O

0	PRH75	B
1	,	O
2	a	O
3	new	O
4	nucleus	O
5	-	O
6	localized	O
7	member	O
8	of	O
9	the	O
10	DEAD	B
11	-	I
12	box	I
13	protein	I
14	family	I
15	from	O
16	higher	O
17	plants	O
18	.	O

0	DMCM	O
1	also	O
2	permits	O
3	extension	O
4	of	O
5	the	O
6	possibilities	O
7	of	O
8	obtaining	O
9	and	O
10	transplanting	O
11	donor	O
12	organs	O
13	.	O

0	Most	O
1	pituitary	B
2	hormone	I
3	-	I
4	coding	I
5	gene	I
6	promoters	I
7	are	O
8	activated	O
9	by	O
10	Ptx1	B
11	.	O

0	In	O
1	addition	O
2	to	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	,	O
8	protein	O
9	-	O
10	protein	O
11	interactions	O
12	with	O
13	partner	O
14	proteins	O
15	often	O
16	play	O
17	major	O
18	roles	O
19	in	O
20	targeting	O
21	ETS	B
22	-	I
23	domain	I
24	proteins	I
25	to	O
26	specific	O
27	promoters	O
28	.	O

0	Also	O
1	,	O
2	the	O
3	BALB	B
4	/	I
5	c	I
6	gene	I
7	contains	O
8	a	O
9	single	O
10	substitution	O
11	in	O
12	a	O
13	conserved	O
14	octamer	O
15	sequence	O
16	approximately	O
17	equal	O
18	to	O
19	100	O
20	nucleotides	O
21	upstream	O
22	of	O
23	the	O
24	coding	O
25	region	O
26	,	O
27	which	O
28	could	O
29	affect	O
30	its	O
31	expression	O
32	.	O

0	Gastric	O
1	CO2	O
2	/	O
3	HCO3	O
4	was	O
5	determined	O
6	in	O
7	absence	O
8	of	O
9	simultaneous	O
10	inhibition	O
11	of	O
12	acid	O
13	secretion	O
14	by	O
15	intra	O
16	-	O
17	and	O
18	extragastric	O
19	pCO2	O
20	/	O
21	pH	O
22	measurements	O
23	in	O
24	23	O
25	persons	O
26	and	O
27	calculated	O
28	using	O
29	the	O
30	equation	O
31	of	O
32	Henderson	O
33	-	O
34	Hasselbalch	O
35	.	O
36	pCO2	O
37	was	O
38	measured	O
39	with	O
40	use	O
41	of	O
42	a	O
43	new	O
44	electrode	O
45	.	O

0	Among	O
1	known	O
2	flea	O
3	larvae	O
4	,	O
5	the	O
6	genus	O
7	Anomiopsyllus	O
8	(	O
9	Anomiopsyllinae	O
10	,	O
11	Anomiopsyllini	O
12	)	O
13	is	O
14	as	O
15	distinctive	O
16	in	O
17	larval	O
18	form	O
19	as	O
20	are	O
21	the	O
22	adults	O
23	.	O

0	Estrogen	O
1	replacement	O
2	therapy	O
3	and	O
4	risk	O
5	of	O
6	breast	O
7	cancer	O
8	:	O
9	results	O
10	of	O
11	two	O
12	meta	O
13	-	O
14	analyses	O
15	.	O

0	Inductively	O
1	coupled	O
2	plasma	O
3	atomic	O
4	emission	O
5	spectroscopy	O
6	was	O
7	employed	O
8	to	O
9	obtain	O
10	the	O
11	tissue	O
12	silicon	O
13	measurements	O
14	.	O

0	Such	O
1	studied	O
2	acquired	O
3	with	O
4	low	O
5	energy	O
6	or	O
7	medium	O
8	energy	O
9	collimation	O
10	and	O
11	a	O
12	window	O
13	centered	O
14	on	O
15	the	O
16	159	O
17	keV	O
18	123I	O
19	photopeak	O
20	contain	O
21	appreciable	O
22	septal	O
23	breakthrough	O
24	signals	O
25	originating	O
26	from	O
27	Compton	O
28	scatter	O
29	of	O
30	high	O
31	energy	O
32	photons	O
33	primarily	O
34	from	O
35	124I	O
36	.	O

0	Hydropathy	O
1	analysis	O
2	of	O
3	KCC1	B
4	indicates	O
5	structural	O
6	homology	O
7	to	O
8	NKCC	B
9	,	O
10	including	O
11	12	O
12	transmembrane	O
13	domains	O
14	,	O
15	a	O
16	large	O
17	extracellular	O
18	loop	O
19	with	O
20	potential	O
21	N	O
22	-	O
23	linked	O
24	glycosylation	O
25	sites	O
26	,	O
27	and	O
28	cytoplasmic	O
29	N	O
30	-	O
31	and	O
32	C	O
33	-	O
34	terminal	O
35	regions	O
36	.	O

0	Natural	O
1	and	O
2	induced	O
3	malarias	O
4	in	O
5	western	O
6	hemisphere	O
7	monkeys	O
8	.	O

0	Positive	O
1	shifts	O
2	of	O
3	basal	O
4	skin	O
5	potentials	O
6	during	O
7	human	O
8	sleep	O
9	.	O

0	It	O
1	has	O
2	a	O
3	grave	O
4	prognosis	O
5	with	O
6	>	O
7	70	O
8	%	O
9	mortality	O
10	in	O
11	3	O
12	months	O
13	,	O
14	despite	O
15	mechanical	O
16	ventilation	O
17	.	O

0	The	O
1	response	O
2	of	O
3	the	O
4	plasma	O
5	fibrinogen	B
6	level	O
7	to	O
8	the	O
9	subucutaneous	O
10	injection	O
11	of	O
12	turpentine	O
13	and	O
14	to	O
15	the	O
16	intravenous	O
17	injection	O
18	of	O
19	endotoxin	O
20	was	O
21	measured	O
22	in	O
23	normal	O
24	rabbits	O
25	and	O
26	in	O
27	rabbits	O
28	made	O
29	granulocytopenic	O
30	and	O
31	thrombocytopenic	O
32	with	O
33	busulfan	O
34	.	O

0	Although	O
1	popular	O
2	this	O
3	hypothesis	O
4	is	O
5	far	O
6	from	O
7	explaining	O
8	all	O
9	the	O
10	clinical	O
11	facts	O
12	,	O
13	namely	O
14	that	O
15	rigidity	O
16	is	O
17	equal	O
18	in	O
19	extensor	O
20	and	O
21	flexor	O
22	,	O
23	proximal	O
24	and	O
25	distal	O
26	muscles	O
27	.	O

0	A	O
1	unique	O
2	leucine	O
3	-	O
4	proline	O
5	repeat	O
6	element	O
7	found	O
8	N	O
9	-	O
10	terminal	O
11	to	O
12	the	O
13	DNA	O
14	-	O
15	binding	O
16	domain	O
17	of	O
18	EmBP	B
19	-	I
20	1	I
21	does	O
22	not	O
23	appear	O
24	to	O
25	play	O
26	a	O
27	role	O
28	in	O
29	DNA	O
30	-	O
31	binding	O
32	or	O
33	dimerization	O
34	.	O

0	The	O
1	decrease	O
2	of	O
3	TNF	B
4	receptors	I
5	by	O
6	IL	B
7	-	I
8	4	I
9	was	O
10	accompanied	O
11	by	O
12	down	O
13	-	O
14	regulation	O
15	of	O
16	TNF	B
17	-	O
18	induced	O
19	activities	O
20	,	O
21	including	O
22	cytotoxicity	O
23	,	O
24	caspase	B
25	-	I
26	3	I
27	activation	O
28	,	O
29	NF	B
30	-	I
31	kappaB	I
32	and	O
33	AP	B
34	-	I
35	1	I
36	activation	O
37	,	O
38	and	O
39	c	B
40	-	I
41	Jun	I
42	N	I
43	-	I
44	terminal	I
45	kinase	I
46	induction	O
47	.	O

0	Takahashi	O
1	,	O
2	H	O
3	.	O

0	The	O
1	hp55	B
2	gamma	I
3	protein	I
4	interacts	O
5	strongly	O
6	with	O
7	the	O
8	activated	O
9	IGFIR	B
10	but	O
11	not	O
12	with	O
13	the	O
14	kinase	B
15	-	I
16	negative	I
17	mutant	I
18	receptor	I
19	.	O
20	hp55	B
21	gamma	I
22	also	O
23	interacts	O
24	with	O
25	the	O
26	insulin	B
27	receptor	I
28	(	O
29	IR	B
30	)	O
31	in	O
32	the	O
33	yeast	O
34	two	O
35	-	O
36	hybrid	O
37	system	O
38	.	O

0	Effects	O
1	of	O
2	aging	O
3	and	O
4	beta	O
5	-	O
6	adrenergic	O
7	-	O
8	blockade	O
9	on	O
10	standing	O
11	-	O
12	induced	O
13	QT	O
14	/	O
15	QS2	O
16	changes	O
17	.	O

0	The	O
1	pathogenesis	O
2	of	O
3	Limited	O
4	Joint	O
5	Mobility	O
6	(	O
7	LJM	O
8	)	O
9	in	O
10	diabetes	O
11	is	O
12	unknown	O
13	,	O
14	but	O
15	the	O
16	abnormality	O
17	is	O
18	said	O
19	to	O
20	be	O
21	associated	O
22	with	O
23	an	O
24	increased	O
25	incidence	O
26	of	O
27	microangiopathy	O
28	.	O

0	SAECG	O
1	,	O
2	echocardiography	O
3	and	O
4	thallium	O
5	-	O
6	201	O
7	imaging	O
8	were	O
9	performed	O
10	before	O
11	and	O
12	1	O
13	month	O
14	after	O
15	attempted	O
16	angioplasty	O
17	.	O

0	In	O
1	order	O
2	to	O
3	investigate	O
4	to	O
5	what	O
6	extent	O
7	this	O
8	interaction	O
9	might	O
10	contribute	O
11	to	O
12	tumor	O
13	induction	O
14	by	O
15	the	O
16	virus	O
17	,	O
18	we	O
19	have	O
20	introduced	O
21	two	O
22	different	O
23	point	O
24	mutations	O
25	within	O
26	the	O
27	putative	O
28	pRb	B
29	-	I
30	binding	I
31	sequence	I
32	of	O
33	large	B
34	T	I
35	antigen	I
36	,	O
37	and	O
38	as	O
39	a	O
40	preliminary	O
41	to	O
42	in	O
43	vivo	O
44	experiments	O
45	we	O
46	have	O
47	studied	O
48	their	O
49	effects	O
50	in	O
51	vitro	O
52	on	O
53	some	O
54	biological	O
55	activities	O
56	relevant	O
57	to	O
58	tumor	O
59	induction	O
60	.	O

0	The	O
1	other	O
2	transmembrane	O
3	regions	O
4	as	O
5	well	O
6	as	O
7	the	O
8	nucleoplasmic	O
9	domain	O
10	are	O
11	not	O
12	required	O
13	for	O
14	sorting	O
15	.	O

0	Using	O
1	fluorescence	O
2	in	O
3	situ	O
4	hybridization	O
5	,	O
6	we	O
7	mapped	O
8	the	O
9	chromosome	O
10	-	O
11	17	O
12	breakpoint	O
13	in	O
14	a	O
15	patient	O
16	with	O
17	acampomelic	O
18	CMPD	O
19	and	O
20	sex	O
21	reversal	O
22	,	O
23	who	O
24	carries	O
25	a	O
26	de	O
27	novo	O
28	constitutional	O
29	t	O
30	(	O
31	12	O
32	;	O
33	17	O
34	)	O
35	translocation	O
36	,	O
37	between	O
38	two	O
39	known	O
40	cosmid	O
41	markers	O
42	in	O
43	the	O
44	17q24	O
45	-	O
46	q25	O
47	region	O
48	.	O

0	Deletion	O
1	analysis	O
2	revealed	O
3	that	O
4	the	O
5	essential	O
6	domain	O
7	of	O
8	this	O
9	promoter	O
10	,	O
11	termed	O
12	the	O
13	ORF5	B
14	/	O
15	deltaX	B
16	transcript	I
17	promoter	I
18	,	O
19	mapped	O
20	to	O
21	nucleotides	O
22	1525	O
23	-	O
24	1625	O
25	.	O

0	BSE	O
1	and	O
2	farmworkers	O
3	.	O

0	In	O
1	the	O
2	region	O
3	Walgau	O
4	with	O
5	mixed	O
6	industrial	O
7	-	O
8	rural	O
9	population	O
10	an	O
11	iodine	O
12	deficiency	O
13	I	O
14	was	O
15	found	O
16	in	O
17	81	O
18	%	O
19	and	O
20	an	O
21	iodine	O
22	deficiency	O
23	II	O
24	in	O
25	45	O
26	%.	O

0	The	O
1	phosphorylation	O
2	efficiency	O
3	is	O
4	improved	O
5	by	O
6	increasing	O
7	the	O
8	number	O
9	of	O
10	N	O
11	-	O
12	terminal	O
13	arginine	O
14	residues	O
15	and	O
16	by	O
17	moving	O
18	the	O
19	arginyl	O
20	cluster	O
21	one	O
22	residue	O
23	further	O
24	away	O
25	from	O
26	the	O
27	serine	O
28	,	O
29	the	O
30	nonapeptide	O
31	(	O
32	Arg	O
33	)	O
34	4	O
35	-	O
36	Ala	O
37	-	O
38	Ala	O
39	-	O
40	Ser	O
41	-	O
42	Val	O
43	-	O
44	Ala	O
45	being	O
46	the	O
47	best	O
48	substrate	O
49	among	O
50	all	O
51	the	O
52	short	O
53	peptides	O
54	tested	O
55	(	O
56	Km	O
57	=	O
58	15	O
59	microM	O
60	).	O

0	The	O
1	molecular	O
2	associations	O
3	dictating	O
4	INCENP	O
5	behavior	O
6	during	O
7	mitosis	O
8	are	O
9	currently	O
10	unknown	O
11	.	O

0	The	O
1	small	B
2	monomeric	I
3	GTP	I
4	-	I
5	binding	I
6	proteins	I
7	of	O
8	the	O
9	RAB	B
10	subfamily	I
11	are	O
12	key	O
13	regulatory	O
14	elements	O
15	of	O
16	the	O
17	machinery	O
18	that	O
19	controls	O
20	membrane	O
21	traffic	O
22	in	O
23	eukaryotic	O
24	cells	O
25	.	O

0	Chinese	B
1	Spring	I
2	(	O
3	CS	B
4	)	O
5	carrying	O
6	the	O
7	Q	B
8	gene	I
9	to	O
10	those	O
11	of	O
12	a	O
13	chromosome	O
14	deletion	O
15	line	O
16	of	O
17	CS	B
18	,	O
19	namely	O
20	,	O
21	q5	B
22	,	O
23	which	O
24	lacks	O
25	15	O
26	%	O
27	of	O
28	5AL	O
29	including	O
30	the	O
31	Q	B
32	gene	I
33	.	O

0	The	O
1	capacity	O
2	to	O
3	repair	O
4	8	O
5	-	O
6	OxoG	O
7	has	O
8	been	O
9	measured	O
10	in	O
11	cell	O
12	-	O
13	free	O
14	extracts	O
15	of	O
16	wild	O
17	-	O
18	type	O
19	and	O
20	ogg1	B
21	strains	O
22	using	O
23	a	O
24	34mer	O
25	DNA	O
26	fragment	O
27	containing	O
28	a	O
29	single	O
30	8	O
31	-	O
32	OxoG	O
33	residue	O
34	paired	O
35	with	O
36	a	O
37	cytosine	O
38	(	O
39	8	O
40	-	O
41	OxoG	O
42	/	O
43	C	O
44	)	O
45	as	O
46	a	O
47	substrate	O
48	.	O

0	Total	O
1	body	O
2	water	O
3	,	O
4	rhodanide	O
5	space	O
6	and	O
7	I	O
8	-	O
9	131	O
10	-	O
11	albumin	B
12	space	O
13	under	O
14	the	O
15	acute	O
16	effect	O
17	of	O
18	furosemide	O

0	Cyclin	B
1	D1	I
2	promoter	I
3	activity	O
4	was	O
5	stimulated	O
6	by	O
7	overexpression	O
8	of	O
9	mitogen	B
10	-	I
11	activated	I
12	protein	I
13	kinase	I
14	(	O
15	p41MAPK	B
16	)	O
17	or	O
18	c	B
19	-	I
20	Ets	I
21	-	I
22	2	I
23	through	O
24	the	O
25	proximal	O
26	22	O
27	base	O
28	pairs	O
29	.	O

0	The	O
1	evolution	O
2	of	O
3	the	O
4	CCR5	B
5	cis	I
6	-	I
7	regulatory	I
8	region	I
9	versus	O
10	the	O
11	open	O
12	reading	O
13	frame	O
14	as	O
15	well	O
16	as	O
17	among	O
18	different	O
19	domains	O
20	of	O
21	the	O
22	open	O
23	reading	O
24	frame	O
25	differed	O
26	from	O
27	one	O
28	another	O
29	.	O

0	Deregulation	O
1	of	O
2	their	O
3	expression	O
4	may	O
5	contribute	O
6	to	O
7	malignant	O
8	transformation	O
9	associated	O
10	with	O
11	HTLV	O
12	-	O
13	1	O
14	infection	O
15	.	O

0	There	O
1	was	O
2	no	O
3	apparent	O
4	effect	O
5	of	O
6	growth	O
7	temperature	O
8	on	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	levels	O
14	of	O
15	fad7	B
16	mRNA	I
17	in	O
18	wild	O
19	type	O
20	plants	O
21	.	O

0	Sources	O
1	of	O
2	noise	O
3	in	O
4	these	O
5	signals	O
6	were	O
7	evaluated	O
8	in	O
9	preparations	O
10	stained	O
11	with	O
12	the	O
13	potentiometric	O
14	probe	O
15	RH	O
16	-	O
17	414	O
18	.	O

0	Thyroid	O
1	disease	O
2	and	O
3	pregnancy	O
4	.	O

0	The	O
1	large	O
2	subfamily	O
3	of	O
4	receptor	B
5	tyrosine	I
6	kinases	I
7	(	O
8	RTKs	B
9	)	O
10	for	O
11	which	O
12	EPH	B
13	is	O
14	the	O
15	prototype	O
16	have	O
17	likely	O
18	roles	O
19	in	O
20	intercellular	O
21	communication	O
22	during	O
23	normal	O
24	mammalian	O
25	development	O
26	,	O
27	but	O
28	the	O
29	biochemical	O
30	signalling	O
31	pathways	O
32	utilised	O
33	by	O
34	this	O
35	family	O
36	are	O
37	poorly	O
38	characterised	O
39	.	O

0	Analysis	O
1	of	O
2	the	O
3	intact	O
4	hGH	B
5	gene	I
6	or	O
7	hGH	B
8	5	O
9	'-	O
10	flanking	O
11	DNA	O
12	(	O
13	5	O
14	'-	O
15	FR	O
16	)	O
17	coupled	O
18	to	O
19	the	O
20	hGh	B
21	cDNA	I
22	or	O
23	chloramphenicol	B
24	acetyltransferase	I
25	or	O
26	luciferase	B
27	genes	O
28	,	O
29	indicated	O
30	that	O
31	cAMP	O
32	primarily	O
33	stimulated	O
34	hGH	B
35	promoter	I
36	activity	O
37	.	O

0	Autopsy	O
1	demonstrated	O
2	good	O
3	survival	O
4	of	O
5	the	O
6	transplanted	O
7	cells	O
8	with	O
9	good	O
10	integration	O
11	with	O
12	the	O
13	brain	O
14	of	O
15	the	O
16	recipient	O
17	and	O
18	traces	O
19	of	O
20	positive	O
21	immunocytochemical	O
22	reaction	O
23	for	O
24	tyrosine	B
25	hydroxylase	I
26	.	O

0	Nitrogen	O
1	balance	O
2	was	O
3	compared	O
4	,	O
5	and	O
6	metabolic	O
7	complications	O
8	were	O
9	monitored	O
10	by	O
11	evaluating	O
12	BUN	O
13	,	O
14	serum	O
15	creatinine	O
16	,	O
17	creatinine	O
18	clearance	O
19	,	O
20	serum	O
21	CO2	O
22	,	O
23	SGOT	O
24	,	O
25	SGPT	B
26	,	O
27	serum	B
28	LDH	B
29	,	O
30	and	O
31	serum	B
32	alkaline	I
33	phosphatase	I
34	.	O

0	Some	O
1	of	O
2	the	O
3	PCR	O
4	products	O
5	contained	O
6	mutations	O
7	in	O
8	ATG1	B
9	and	O
10	/	O
11	or	O
12	ATG2	B
13	.	O

0	ORF	O
1	2	O
2	potentially	O
3	encoded	O
4	a	O
5	hydrophobic	O
6	protein	O
7	of	O
8	29	O
9	,	O
10	705	O
11	Da	O
12	with	O
13	six	O
14	potential	O
15	membrane	O
16	-	O
17	spanning	O
18	regions	O
19	.	O

0	Incorporation	O
1	of	O
2	0	O
3	.	O
4	1	O
5	or	O
6	0	O
7	.	O
8	2	O
9	M	O
10	sodium	O
11	dihydrogen	O
12	phosphate	O
13	in	O
14	the	O
15	sugar	O
16	solutions	O
17	resulted	O
18	in	O
19	a	O
20	decrease	O
21	in	O
22	the	O
23	shelf	O
24	-	O
25	life	O
26	of	O
27	diltiazem	O
28	.	O

0	Morphogenesis	O
1	of	O
2	the	O
3	trochanter	O
4	produced	O
5	by	O
6	femoral	O
7	regeneration	O
8	in	O
9	the	O
10	phasmid	O
11	Carausius	O
12	morosus	O
13	Br	O

0	Two	O
1	estrogen	B
2	receptor	I
3	(	O
4	ER	B
5	)	O
6	isoforms	O
7	with	O
8	different	O
9	estrogen	O
10	dependencies	O
11	are	O
12	generated	O
13	from	O
14	the	O
15	trout	B
16	ER	I
17	gene	I
18	.	O

0	The	O
1	protein	O
2	sequence	O
3	contains	O
4	seven	O
5	potential	O
6	N	O
7	-	O
8	linked	O
9	glycosylation	O
10	sites	O
11	and	O
12	a	O
13	threonine	O
14	/	O
15	serine	O
16	-	O
17	rich	O
18	region	O
19	which	O
20	is	O
21	a	O
22	potential	O
23	site	O
24	for	O
25	attachment	O
26	of	O
27	O	O
28	-	O
29	linked	O
30	carbohydrate	O
31	.	O

0	Year	O
1	one	O
2	of	O
3	the	O
4	first	O
5	general	O
6	practitioner	O
7	medical	O
8	unit	O
9	in	O
10	the	O
11	greater	O
12	Glasgow	O
13	area	O
14	.	O

0	The	O
1	N	O
2	-	O
3	terminal	O
4	sequence	O
5	of	O
6	one	O
7	hydrophilic	O
8	peptide	O
9	of	O
10	the	O
11	FeS	B
12	protein	I
13	has	O
14	been	O
15	also	O
16	obtained	O
17	confirming	O
18	the	O
19	fbcF	B
20	reading	O
21	frame	O
22	.	O

0	We	O
1	have	O
2	previously	O
3	reported	O
4	that	O
5	depletion	O
6	of	O
7	protein	B
8	kinase	I
9	C	I
10	by	O
11	long	O
12	-	O
13	term	O
14	treatment	O
15	of	O
16	B16	O
17	mouse	O
18	melanoma	O
19	cells	O
20	with	O
21	phorbol	O
22	dibutyrate	O
23	(	O
24	PDBu	O
25	)	O
26	prevented	O
27	cell	O
28	density	O
29	-	O
30	dependent	O
31	melanogenesis	O
32	.	O

0	At	O
1	43	O
2	%	O
3	blood	O
4	pressure	O
5	reduction	O
6	,	O
7	PCO2	O
8	fell	O
9	by	O
10	0	O
11	.	O
12	53	O
13	kPa	O
14	,	O
15	a	O
16	decrease	O
17	which	O
18	could	O
19	not	O
20	explain	O
21	the	O
22	observed	O
23	CBF	O
24	fall	O
25	of	O
26	27	O
27	%.	O

0	These	O
1	genes	O
2	are	O
3	expressed	O
4	within	O
5	a	O
6	few	O
7	hours	O
8	of	O
9	the	O
10	initiation	O
11	of	O
12	development	O
13	;	O
14	their	O
15	mRNAs	O
16	accumulate	O
17	to	O
18	a	O
19	peak	O
20	at	O
21	12	O
22	hr	O
23	and	O
24	persist	O
25	until	O
26	culmination	O
27	.	O

0	20	O
1	%	O
2	of	O
3	total	O
4	HSL	B
5	transcripts	I
6	in	O
7	human	O
8	subcutaneous	O
9	adipocytes	O
10	.	O

0	Immunohistochemical	O
1	studies	O
2	revealed	O
3	positive	O
4	staining	O
5	for	O
6	S100	B
7	protein	I
8	in	O
9	all	O
10	the	O
11	granular	O
12	cell	O
13	tumors	O
14	of	O
15	the	O
16	adult	O
17	but	O
18	in	O
19	none	O
20	of	O
21	the	O
22	congenital	O
23	granular	O
24	cell	O
25	epulides	O
26	.	O

0	Based	O
1	on	O
2	our	O
3	observations	O
4	,	O
5	we	O
6	propose	O
7	a	O
8	model	O
9	whereby	O
10	inactive	O
11	precursor	O
12	molecules	O
13	produced	O
14	from	O
15	the	O
16	PEP4	B
17	gene	I
18	self	O
19	-	O
20	activate	O
21	within	O
22	the	O
23	yeast	O
24	vacuole	O
25	and	O
26	subsequently	O
27	activate	O
28	other	O
29	vacuolar	B
30	hydrolases	I
31	.	O

0	These	O
1	observations	O
2	indicate	O
3	that	O
4	there	O
5	are	O
6	multiple	O
7	mechanisms	O
8	by	O
9	which	O
10	an	O
11	individual	O
12	transcript	O
13	can	O
14	be	O
15	degraded	O
16	following	O
17	deadenylation	O
18	.	O

0	Acad	O
1	.	O

0	BACKGROUND	O
1	:	O
2	We	O
3	conducted	O
4	a	O
5	phase	O
6	I	O
7	study	O
8	with	O
9	MDL	O
10	73	O
11	,	O
12	147EF	O
13	,	O
14	a	O
15	new	O
16	5	B
17	hydroxytryptamine	I
18	3	I
19	(	I
20	5	I
21	-	I
22	HT3	I
23	)	I
24	receptor	I
25	antagonist	O
26	,	O
27	in	O
28	25	O
29	patients	O
30	requiring	O
31	emetogenic	O
32	chemotherapy	O
33	.	O

0	Formation	O
1	of	O
2	hyphae	O
3	and	O
4	chlamydospores	O
5	by	O
6	Cryptococcus	O
7	laurentii	O
8	.	O

0	L	O
1	/	O
2	H	O
3	>	O
4	0	O
5	.	O
6	61	O
7	(	O
8	chi	O
9	(	O
10	2	O
11	)=	O
12	10	O
13	.	O
14	8	O
15	;	O
16	P	O
17	:<	O
18	0	O
19	.	O
20	001	O
21	)	O
22	and	O
23	a	O
24	restrictive	O
25	filling	O
26	pattern	O
27	(	O
28	chi	O
29	(	O
30	2	O
31	)=	O
32	3	O
33	.	O
34	6	O
35	;	O
36	P	O
37	:<	O
38	0	O
39	.	O
40	05	O
41	)	O
42	were	O
43	independent	O
44	predictors	O
45	of	O
46	events	O
47	.	O

0	Articles	O
1	addressing	O
2	valvular	O
3	heart	O
4	disease	O
5	or	O
6	heart	O
7	failure	O
8	secondary	O
9	to	O
10	acute	O
11	myocardial	O
12	infarction	O
13	or	O
14	Chagas	O
15	'	O
16	disease	O
17	were	O
18	excluded	O
19	.	O

0	On	O
1	a	O
2	separate	O
3	occasion	O
4	the	O
5	T1	O
6	weighted	O
7	and	O
8	T2	O
9	weighted	O
10	sagittal	O
11	and	O
12	T2	O
13	weighted	O
14	axial	O
15	sequences	O
16	were	O
17	reported	O
18	blind	O
19	in	O
20	relation	O
21	to	O
22	the	O
23	initial	O
24	assessment	O
25	.	O

0	CONCLUSION	O
1	:	O
2	Our	O
3	results	O
4	suggest	O
5	that	O
6	AIF	B
7	peak	O
8	saturation	O
9	leads	O
10	to	O
11	a	O
12	significant	O
13	systematic	O
14	error	O
15	in	O
16	the	O
17	determination	O
18	of	O
19	CBV	O
20	and	O
21	CBF	B
22	values	O
23	and	O
24	has	O
25	necessarily	O
26	to	O
27	be	O
28	taken	O
29	into	O
30	account	O
31	for	O
32	dynamic	O
33	contrast	O
34	-	O
35	enhanced	O
36	MR	O
37	perfusion	O
38	studies	O
39	.	O

0	In	O
1	the	O
2	PMR	O
3	target	O
4	area	O
5	but	O
6	not	O
7	in	O
8	the	O
9	nontreated	O
10	area	O
11	an	O
12	improvement	O
13	in	O
14	regional	O
15	myocardial	O
16	flow	O
17	reserve	O
18	occurs	O
19	in	O
20	wall	O
21	segments	O
22	with	O
23	initially	O
24	severely	O
25	or	O
26	moderately	O
27	reduced	O
28	stress	O
29	perfusion	O
30	.	O

0	Fine	O
1	analysis	O
2	at	O
3	the	O
4	nucleotide	O
5	level	O
6	of	O
7	the	O
8	early	O
9	events	O
10	in	O
11	the	O
12	digestion	O
13	with	O
14	nuclease	B
15	S1	I
16	shows	O
17	that	O
18	the	O
19	enzyme	O
20	attacks	O
21	preferentially	O
22	the	O
23	sequence	O
24	(	O
25	G	O
26	-	O
27	A	O
28	)	O
29	12	O
30	on	O
31	the	O
32	message	O
33	complementary	O
34	strand	O
35	.	O

0	Based	O
1	on	O
2	AUC	O
3	infinity	O
4	analyses	O
5	,	O
6	the	O
7	pharmacokinetics	O
8	of	O
9	buflomedil	O
10	were	O
11	found	O
12	to	O
13	be	O
14	linear	O
15	within	O
16	the	O
17	dose	O
18	ranges	O
19	studied	O
20	(	O
21	50	O
22	to	O
23	200	O
24	mg	O
25	for	O
26	i	O
27	.	O
28	v	O
29	.	O
30	injection	O
31	and	O
32	150	O
33	to	O
34	450	O
35	mg	O
36	for	O
37	oral	O
38	administration	O
39	).	O

0	Taken	O
1	together	O
2	,	O
3	the	O
4	results	O
5	suggest	O
6	that	O
7	chlorphentermine	O
8	may	O
9	be	O
10	capable	O
11	of	O
12	producing	O
13	dual	O
14	stimulus	O
15	effects	O
16	in	O
17	animals	O
18	.	O

0	The	O
1	5	O
2	'-	O
3	flanking	O
4	region	O
5	of	O
6	the	O
7	human	B
8	lactoferrin	I
9	gene	I
10	was	O
11	isolated	O
12	from	O
13	a	O
14	human	O
15	placental	O
16	genomic	O
17	library	O
18	.	O

0	Ume6p	B
1	,	O
2	which	O
3	also	O
4	controls	O
5	the	O
6	expression	O
7	of	O
8	early	O
9	meiotic	O
10	genes	O
11	,	O
12	represses	O
13	CAR1	B
14	expression	O
15	through	O
16	a	O
17	sequence	O
18	called	O
19	URS	O
20	,	O
21	as	O
22	a	O
23	function	O
24	of	O
25	nitrogen	O
26	availability	O
27	.	O

0	Their	O
1	use	O
2	established	O
3	that	O
4	the	O
5	BrAAP	O
6	activity	O
7	catalyzed	O
8	both	O
9	a	O
10	postproline	O
11	and	O
12	a	O
13	postglutamate	O
14	cleavage	O
15	and	O
16	therefore	O
17	has	O
18	a	O
19	broader	O
20	specificity	O
21	than	O
22	previously	O
23	recognized	O
24	.	O

0	Tyrosine	O
1	phosphorylated	O
2	STATs	B
3	dimerize	O
4	and	O
5	translocate	O
6	into	O
7	the	O
8	nucleus	O
9	to	O
10	activate	O
11	specific	O
12	genes	O
13	.	O

0	The	O
1	TraD	B
2	protein	I
3	(	O
4	83	O
5	,	O
6	899	O
7	Da	O
8	)	O
9	contains	O
10	three	O
11	hydrophobic	O
12	regions	O
13	,	O
14	of	O
15	which	O
16	two	O
17	are	O
18	located	O
19	near	O
20	the	O
21	amino	O
22	-	O
23	terminal	O
24	region	O
25	.	O

0	(	O
1	1986	O
2	)	O
3	method	O
4	of	O
5	separation	O
6	of	O
7	Cryptosporidium	O
8	spp	O
9	.	O
10	oocysts	O
11	from	O
12	feces	O
13	by	O
14	using	O
15	a	O
16	percoll	O
17	discontinuous	O
18	density	O
19	gradient	O
20	appeared	O
21	a	O
22	method	O
23	of	O
24	choice	O
25	for	O
26	obtaining	O
27	large	O
28	numbers	O
29	of	O
30	oocysts	O
31	of	O
32	C	O
33	.	O
34	parvum	O
35	free	O
36	of	O
37	fecal	O
38	contamination	O
39	.	O

0	I	O
1	propose	O
2	that	O
3	their	O
4	gene	O
5	products	O
6	bind	O
7	to	O
8	the	O
9	chromatin	O
10	to	O
11	establish	O
12	or	O
13	maintain	O
14	a	O
15	proper	O
16	higher	O
17	order	O
18	structure	O
19	as	O
20	a	O
21	prerequisite	O
22	for	O
23	a	O
24	regulated	O
25	gene	O
26	expression	O
27	.	O

0	16	O
1	women	O
2	were	O
3	treated	O
4	with	O
5	methadone	O
6	to	O
7	prevent	O
8	withdrawal	O
9	symptoms	O
10	.	O

0	A	O
1	potential	O
2	binding	O
3	site	O
4	for	O
5	the	O
6	dShc	B
7	PTB	I
8	domain	I
9	is	O
10	located	O
11	at	O
12	Tyr	O
13	-	O
14	1228	O
15	of	O
16	DER	O
17	.	O

0	These	O
1	data	O
2	show	O
3	that	O
4	the	O
5	alpha	O
6	-	O
7	helix	O
8	domain	O
9	of	O
10	p57	B
11	(	O
12	Kip2	B
13	),	O
14	which	O
15	is	O
16	conserved	O
17	in	O
18	the	O
19	Cip	B
20	/	O
21	Kip	B
22	proteins	I
23	,	O
24	is	O
25	implicated	O
26	in	O
27	protein	O
28	-	O
29	protein	O
30	interaction	O
31	and	O
32	confers	O
33	a	O
34	specific	O
35	regulatory	O
36	mechanism	O
37	,	O
38	outside	O
39	of	O
40	their	O
41	Cdk	B
42	-	O
43	inhibitory	O
44	activity	O
45	,	O
46	by	O
47	which	O
48	the	O
49	p57	B
50	(	O
51	Kip2	B
52	)	O
53	family	O
54	members	O
55	positively	O
56	act	O
57	on	O
58	myogenic	O
59	differentiation	O
60	.	O

0	Another	O
1	ORF	O
2	,	O
3	dda	B
4	.	I
5	2	I
6	located	O
7	between	O
8	modA	B
9	and	O
10	dda	B
11	,	O
12	shares	O
13	sequence	O
14	similarity	O
15	with	O
16	sigma70	B
17	,	O
18	and	O
19	we	O
20	call	O
21	it	O
22	srd	B
23	.	O

0	Pao2	O
1	increased	O
2	from	O
3	15	O
4	.	O
5	5	O
6	+/-	O
7	5	O
8	.	O
9	6	O
10	kPa	O
11	(	O
12	116	O
13	+/-	O
14	42	O
15	mm	O
16	Hg	O
17	)	O
18	to	O
19	17	O
20	.	O
21	3	O
22	+/-	O
23	6	O
24	.	O
25	3	O
26	kPa	O
27	(	O
28	130	O
29	+/-	O
30	47	O
31	mm	O
32	Hg	O
33	)	O
34	(	O
35	P	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O

0	LY290181	B
1	appears	O
2	to	O
3	inhibit	O
4	uPA	B
5	promoter	I
6	activation	O
7	by	O
8	blocking	O
9	phorbol	O
10	ester	O
11	-	O
12	stimulated	O
13	binding	O
14	of	O
15	nuclear	O
16	proteins	O
17	to	O
18	the	O
19	uPA	B
20	PEA3	O
21	/	O
22	12	O
23	-	O
24	0	O
25	-	O
26	tetradecanoylphorbol	O
27	13	O
28	-	O
29	acetate	O
30	responsive	O
31	element	O
32	(	O
33	TRE	O
34	).	O

0	We	O
1	conclude	O
2	that	O
3	cAMP	O
4	,	O
5	acting	O
6	through	O
7	PKA	B
8	,	O
9	is	O
10	an	O
11	essential	O
12	regulator	O
13	of	O
14	basal	B
15	CFTR	I
16	gene	I
17	expression	O
18	and	O
19	may	O
20	mediate	O
21	an	O
22	induction	O
23	of	O
24	CFTR	B
25	in	O
26	responsive	O
27	cell	O
28	types	O
29	.	O

0	Northern	O
1	analyses	O
2	of	O
3	RNAs	O
4	from	O
5	mouse	O
6	tissues	O
7	and	O
8	cell	O
9	lines	O
10	indicated	O
11	that	O
12	p11	B
13	mRNA	I
14	levels	O
15	vary	O
16	widely	O
17	.	O

0	The	O
1	previously	O
2	described	O
3	enhanced	O
4	translation	O
5	of	O
6	spinach	B
7	L12	I
8	mRNA	I
9	from	O
10	its	O
11	two	O
12	tandem	O
13	AUG	O
14	codons	O
15	and	O
16	the	O
17	two	O
18	functional	O
19	rpl12	B
20	genes	I
21	in	O
22	Arabidopsis	O
23	probably	O
24	provide	O
25	two	O
26	mechanisms	O
27	for	O
28	generating	O
29	the	O
30	four	O
31	copies	O
32	of	O
33	L12	B
34	/	O
35	chloroplast	O
36	ribosome	O
37	,	O
38	qualitatively	O
39	different	O
40	from	O
41	those	O
42	attempted	O
43	in	O
44	eubacteria	O
45	.	O

0	Studies	O
1	on	O
2	the	O
3	pathogenicity	O
4	of	O
5	ECHO	B
6	9	I
7	(	O
8	HILL	O
9	)	O
10	virus	O
11	and	O
12	its	O
13	mutants	O
14	for	O
15	suckling	O
16	mice	O

0	In	O
1	contrast	O
2	,	O
3	dig1	B
4	dig2	I
5	cells	O
6	constitutively	O
7	invade	O
8	agar	O
9	medium	O
10	,	O
11	whereas	O
12	a	O
13	dig1	B
14	dig2	I
15	ste12	I
16	triple	I
17	mutant	I
18	does	O
19	not	O
20	,	O
21	indicating	O
22	that	O
23	Dig1	B
24	and	O
25	Dig2	B
26	share	O
27	a	O
28	role	O
29	in	O
30	negatively	O
31	regulating	O
32	the	O
33	invasive	O
34	growth	O
35	pathway	O
36	.	O

0	Efficacy	O
1	of	O
2	cervical	O
3	spine	O
4	immobilization	O
5	methods	O
6	.	O

0	As	O
1	in	O
2	Tb	B
3	,	O
4	U6	B
5	is	O
6	a	O
7	single	O
8	-	O
9	copy	O
10	gene	O
11	and	O
12	two	O
13	tRNA	O
14	genes	O
15	,	O
16	tRNAGln	B
17	and	O
18	tRNAIle	B
19	,	O
20	are	O
21	found	O
22	upstream	O
23	to	O
24	the	O
25	gene	O
26	.	O

0	The	O
1	ICBF	O
2	in	O
3	the	O
4	ischaemic	O
5	cortex	O
6	revealed	O
7	a	O
8	graded	O
9	reduction	O
10	from	O
11	the	O
12	ischaemic	O
13	centre	O
14	to	O
15	the	O
16	surrounding	O
17	tissues	O
18	.	O

0	The	O
1	appearance	O
2	of	O
3	dyskinetic	O
4	movement	O
5	disorders	O
6	in	O
7	humans	O
8	following	O
9	the	O
10	chronic	O
11	use	O
12	of	O
13	levodopa	O
14	or	O
15	amphetamine	O
16	may	O
17	be	O
18	a	O
19	manifestation	O
20	of	O
21	similarly	O
22	increased	O
23	dopamine	B
24	receptor	I
25	site	I
26	sensitivity	O
27	within	O
28	the	O
29	striatum	O
30	.	O

0	Mutation	O
1	of	O
2	the	O
3	presumptive	O
4	phosphorylated	O
5	tyrosine	O
6	and	O
7	threonine	O
8	residues	O
9	of	O
10	Mpk1p	B
11	individually	O
12	to	O
13	phenylalanine	O
14	and	O
15	alanine	O
16	,	O
17	respectively	O
18	,	O
19	severely	O
20	impaired	O
21	Mpk1p	B
22	function	O
23	.	O

0	Teratological	O
1	study	O
2	of	O
3	etoperidone	O
4	in	O
5	the	O
6	rat	O
7	and	O
8	rabbit	O
9	.	O

0	The	O
1	obtained	O
2	results	O
3	were	O
4	compared	O
5	with	O
6	control	O
7	group	O
8	(	O
9	10	O
10	female	O
11	volunteers	O
12	).	O

0	Peripheral	O
1	polyneuropathy	O
2	associated	O
3	with	O
4	multiple	O
5	myeloma	O
6	.	O

0	This	O
1	core	O
2	sequence	O
3	,	O
4	along	O
5	with	O
6	additional	O
7	nonspecific	O
8	downstream	O
9	nucleotides	O
10	,	O
11	is	O
12	sufficient	O
13	for	O
14	partial	O
15	suppression	O
16	of	O
17	spliceosome	O
18	assembly	O
19	and	O
20	splicing	O
21	of	O
22	BPV	B
23	-	I
24	1	I
25	pre	I
26	-	I
27	mRNAs	I
28	.	O

0	The	O
1	clinical	O
2	picture	O
3	and	O
4	laboratory	O
5	parameters	O
6	were	O
7	consistent	O
8	with	O
9	a	O
10	serum	O
11	sickness	O
12	reaction	O
13	.	O

0	Molecular	O
1	cloning	O
2	and	O
3	expression	O
4	of	O
5	RPE65	B
6	,	O
7	a	O
8	novel	O
9	retinal	O
10	pigment	O
11	epithelium	O
12	-	O
13	specific	O
14	microsomal	O
15	protein	O
16	that	O
17	is	O
18	post	O
19	-	O
20	transcriptionally	O
21	regulated	O
22	in	O
23	vitro	O
24	.	O

0	This	O
1	difference	O
2	may	O
3	result	O
4	from	O
5	the	O
6	lower	O
7	match	O
8	to	O
9	the	O
10	ARG	O
11	box	O
12	consensus	O
13	of	O
14	the	O
15	O	B
16	(	O
17	rocD	B
18	)	I
19	site	I
20	.	O

0	Sci	O
1	.	O

0	They	O
1	also	O
2	interact	O
3	with	O
4	GTPase	B
5	activating	I
6	proteins	I
7	encoded	O
8	by	O
9	IRA1	B
10	and	O
11	IRA2	B
12	.	O

0	The	O
1	kinetics	O
2	of	O
3	kinase	O
4	activity	O
5	within	O
6	these	O
7	complexes	O
8	compared	O
9	to	O
10	CheA	B
11	alone	O
12	indicate	O
13	approximately	O
14	a	O
15	50	O
16	%	O
17	decrease	O
18	in	O
19	the	O
20	KM	O
21	for	O
22	ATP	O
23	and	O
24	a	O
25	100	O
26	-	O
27	fold	O
28	increase	O
29	in	O
30	the	O
31	Vmax	O
32	.	O

0	In	O
1	ischemic	O
2	and	O
3	hypoxic	O
4	hypoxia	O
5	,	O
6	a	O
7	strong	O
8	correlation	O
9	was	O
10	found	O
11	between	O
12	cyt	O
13	a	O
14	,	O
15	a3	O
16	oxidation	O
17	level	O
18	and	O
19	VO2	O
20	in	O
21	both	O
22	ischemic	O
23	and	O
24	hypoxic	O
25	hypoxia	O
26	(	O
27	r2	O
28	=.	O
29	90	O
30	and	O
31	.	O
32	87	O
33	,	O
34	respectively	O
35	).	O

0	It	O
1	was	O
2	concluded	O
3	that	O
4	patients	O
5	with	O
6	acute	O
7	respiratory	O
8	failure	O
9	requiring	O
10	artificial	O
11	ventilation	O
12	have	O
13	two	O
14	componenents	O
15	of	O
16	the	O
17	pulmonary	O
18	shunt	O
19	,	O
20	one	O
21	parallel	O
22	with	O
23	and	O
24	the	O
25	other	O
26	inversely	O
27	related	O
28	with	O
29	the	O
30	PAO2	O
31	.	O

0	Amiodarone	O
1	,	O
2	seldom	O
3	used	O
4	as	O
5	first	O
6	-	O
7	line	O
8	treatment	O
9	,	O
10	appears	O
11	to	O
12	be	O
13	the	O
14	most	O
15	effective	O
16	drug	O
17	.	O

0	Oral	O
1	candidiasis	O

0	Petrous	O
1	meningioma	O
2	en	O
3	plaque	O
4	presenting	O
5	as	O
6	a	O
7	right	O
8	middle	O
9	ear	O
10	tumor	O
11	.	O

0	Chem	O
1	.	O

0	Fowlpox	O
1	virus	O
2	encodes	O
3	nonessential	O
4	homologs	O
5	of	O
6	cellular	B
7	alpha	I
8	-	I
9	SNAP	I
10	,	O
11	PC	B
12	-	I
13	1	I
14	,	O
15	and	O
16	an	O
17	orphan	O
18	human	O
19	homolog	O
20	of	O
21	a	O
22	secreted	O
23	nematode	O
24	protein	O
25	.	O

0	Only	O
1	two	O
2	of	O
3	27	O
4	participants	O
5	(	O
6	7	O
7	.	O
8	4	O
9	%)	O
10	with	O
11	definite	O
12	POAG	O
13	had	O
14	been	O
15	previously	O
16	diagnosed	O
17	and	O
18	treated	O
19	,	O
20	and	O
21	66	O
22	.	O
23	7	O
24	%	O
25	of	O
26	the	O
27	previously	O
28	undiagnosed	O
29	had	O
30	IOP	O
31	less	O
32	than	O
33	22	O
34	mmHg	O
35	.	O

0	The	O
1	coordinate	O
2	increase	O
3	in	O
4	cyclin	B
5	D1	I
6	and	O
7	p21	B
8	had	O
9	the	O
10	effect	O
11	of	O
12	decreasing	O
13	the	O
14	specific	O
15	but	O
16	not	O
17	absolute	O
18	activity	O
19	of	O
20	cyclin	B
21	D1	I
22	/	O
23	cdk4	B
24	.	O
25	p53	B
26	was	O
27	not	O
28	involved	O
29	since	O
30	CSF	B
31	-	I
32	1	I
33	induction	O
34	of	O
35	p21	B
36	was	O
37	unaffected	O
38	by	O
39	dominant	O
40	-	O
41	negative	O
42	p53	B
43	expression	O
44	.	O

0	The	O
1	two	O
2	IL6	B
3	mRNA	I
4	species	I
5	are	O
6	generated	O
7	by	O
8	alternative	O
9	polyadenylation	O
10	at	O
11	sites	O
12	separated	O
13	by	O
14	a	O
15	distance	O
16	of	O
17	1	O
18	.	O
19	2	O
20	kilobases	O
21	.	O

0	Subsequent	O
1	to	O
2	their	O
3	secretion	O
4	,	O
5	the	O
6	IGF	B
7	-	I
8	II	I
9	in	O
10	xz97	O
11	and	O
12	G11	O
13	cells	O
14	accumulated	O
15	in	O
16	the	O
17	conditioned	O
18	medium	O
19	mostly	O
20	as	O
21	two	O
22	partially	O
23	processed	O
24	species	O
25	with	O
26	appMr	O
27	,	O
28	of	O
29	17K	O
30	and	O
31	14K	O
32	,	O
33	respectively	O
34	.	O

0	The	O
1	interaction	O
2	of	O
3	caffeine	O
4	,	O
5	theophylline	O
6	and	O
7	theobromine	O
8	with	O
9	monoamine	B
10	oxidase	I
11	inhibitors	O
12	.	O

0	We	O
1	report	O
2	the	O
3	isolation	O
4	of	O
5	genomic	O
6	and	O
7	cDNA	O
8	clones	O
9	of	O
10	the	O
11	light	O
12	-	O
13	independent	O
14	Sn	B
15	:	I
16	bol3	I
17	allele	I
18	.	O

0	As	O
1	a	O
2	last	O
3	resort	O
4	,	O
5	it	O
6	may	O
7	be	O
8	possible	O
9	to	O
10	maintain	O
11	a	O
12	patient	O
13	on	O
14	dialysis	O
15	in	O
16	reasonable	O
17	health	O
18	with	O
19	a	O
20	DiaTAP	O
21	button	O
22	graft	O
23	complex	O
24	infected	O
25	with	O
26	Staphylococcus	O
27	epidermidis	O
28	and	O
29	intermittent	O
30	positive	O
31	blood	O
32	cultures	O
33	using	O
34	long	O
35	term	O
36	vancomycin	O
37	therapy	O
38	.	O

0	Re	O
1	-	O
2	examination	O
3	of	O
4	the	O
5	ED01	O
6	study	O
7	.	O

0	Neither	O
1	side	O
2	effect	O
3	nor	O
4	abnormal	O
5	laboratory	O
6	findings	O
7	due	O
8	to	O
9	this	O
10	drug	O
11	were	O
12	observed	O
13	.	O

0	Disruption	O
1	of	O
2	RB	B
3	/	O
4	E2F	B
5	-	I
6	1	I
7	interaction	O
8	by	O
9	single	O
10	point	O
11	mutations	O
12	in	O
13	E2F	B
14	-	I
15	1	I
16	enhances	O
17	S	O
18	-	O
19	phase	O
20	entry	O
21	and	O
22	apoptosis	O
23	.	O

0	Phosphopeptide	O
1	mapping	O
2	revealed	O
3	the	O
4	same	O
5	autophosphorylation	O
6	sites	O
7	utilized	O
8	by	O
9	EGFR	B
10	-	I
11	IC	I
12	as	O
13	those	O
14	identified	O
15	in	O
16	wild	B
17	-	I
18	type	I
19	EGFR	I
20	.	O

0	The	O
1	319	O
2	base	O
3	pair	O
4	region	O
5	immediately	O
6	upstream	O
7	of	O
8	the	O
9	CAP	B
10	site	I
11	is	O
12	characterized	O
13	by	O
14	the	O
15	lack	O
16	of	O
17	a	O
18	proximal	O
19	TATA	O
20	box	O
21	and	O
22	the	O
23	presence	O
24	of	O
25	sequences	O
26	similar	O
27	to	O
28	GC	O
29	boxes	O
30	,	O
31	CACCC	O
32	boxes	O
33	,	O
34	CCAAT	O
35	boxes	O
36	,	O
37	activator	B
38	protein	I
39	2	I
40	(	O
41	Ap	B
42	-	I
43	2	I
44	)	O
45	sites	O
46	,	O
47	partial	O
48	glucocorticoid	O
49	response	O
50	elements	O
51	(	O
52	GREs	O
53	),	O
54	and	O
55	partial	O
56	cyclic	O
57	AMP	O
58	response	O
59	elements	O
60	(	O
61	CREs	O
62	).	O

0	However	O
1	,	O
2	whether	O
3	or	O
4	not	O
5	nonsense	O
6	codon	O
7	recognition	O
8	within	O
9	TPI	B
10	transcripts	I
11	takes	O
12	place	O
13	prior	O
14	to	O
15	or	O
16	after	O
17	splicing	O
18	remained	O
19	unresolved	O
20	.	O

0	Human	B
1	MGP	I
2	is	O
3	a	O
4	10	O
5	-	O
6	kD	O
7	skeletal	O
8	extracellular	O
9	matrix	O
10	(	O
11	ECM	O
12	)	O
13	protein	O
14	that	O
15	consists	O
16	of	O
17	an	O
18	84	O
19	-	O
20	aa	O
21	mature	O
22	protein	O
23	and	O
24	a	O
25	19	O
26	-	O
27	aa	O
28	transmembrane	O
29	signal	O
30	peptide	O
31	.	O

0	Expression	O
1	of	O
2	a	O
3	hybrid	O
4	protein	O
5	containing	O
6	the	O
7	cytoplasmic	O
8	C	O
9	-	O
10	terminal	O
11	half	O
12	of	O
13	UhpB	B
14	fused	O
15	to	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	(	O
21	GST	B
22	)	O
23	also	O
24	interfered	O
25	with	O
26	Uhp	B
27	signaling	O
28	.	O

0	Measurement	O
1	of	O
2	anti	B
3	-	I
4	HCV	I
5	IgM	I
6	antibodies	I
7	with	O
8	an	O
9	experimental	O
10	kit	O

0	The	O
1	ipiO	B
2	genes	I
3	code	O
4	for	O
5	two	O
6	almost	O
7	identical	O
8	152	O
9	-	O
10	aa	O
11	proteins	O
12	which	O
13	do	O
14	not	O
15	have	O
16	any	O
17	homology	O
18	with	O
19	sequences	O
20	present	O
21	in	O
22	data	O
23	libraries	O
24	.	O

0	A	O
1	randomized	O
2	,	O
3	multicenter	O
4	study	O
5	comparing	O
6	the	O
7	efficacy	O
8	and	O
9	tolerability	O
10	of	O
11	tropisetron	O
12	,	O
13	a	O
14	new	O
15	5	B
16	-	I
17	HT3	I
18	receptor	I
19	antagonist	O
20	,	O
21	with	O
22	a	O
23	metoclopramide	O
24	-	O
25	containing	O
26	antiemetic	O
27	cocktail	O
28	in	O
29	the	O
30	prevention	O
31	of	O
32	cisplatin	O
33	-	O
34	induced	O
35	emesis	O
36	.	O

0	In	O
1	the	O
2	first	O
3	series	O
4	of	O
5	experiments	O
6	,	O
7	Sprague	O
8	-	O
9	Dawley	O
10	male	O
11	rats	O
12	were	O
13	implanted	O
14	unilaterally	O
15	with	O
16	guide	O
17	cannulas	O
18	aimed	O
19	at	O
20	the	O
21	lateral	O
22	ventricle	O
23	.	O

0	Furthermore	O
1	,	O
2	the	O
3	UvrA	B
4	protein	I
5	interacts	O
6	with	O
7	the	O
8	UvrB	B
9	protein	I
10	to	O
11	modulate	O
12	its	O
13	activities	O
14	,	O
15	both	O
16	in	O
17	solution	O
18	and	O
19	in	O
20	association	O
21	with	O
22	DNA	O
23	,	O
24	where	O
25	the	O
26	UvrAB	B
27	complex	I
28	possesses	O
29	a	O
30	helicase	B
31	activity	O
32	.	O

0	Interestingly	O
1	,	O
2	highly	O
3	charged	O
4	residues	O
5	were	O
6	abundantly	O
7	possessed	O
8	in	O
9	the	O
10	carboxy	O
11	-	O
12	terminal	O
13	part	O
14	of	O
15	the	O
16	MDV2	B
17	UL10	I
18	protein	I
19	.	O

0	In	O
1	a	O
2	group	O
3	of	O
4	13	O
5	patients	O
6	with	O
7	obliterative	O
8	arteriopathies	O
9	of	O
10	the	O
11	lower	O
12	limbs	O
13	the	O
14	plasma	O
15	levels	O
16	of	O
17	thrombomodulin	B
18	(	O
19	TM	B
20	),	O
21	betathromboglobulin	B
22	(	O
23	beta	B
24	-	I
25	TG	I
26	),	O
27	D	B
28	-	I
29	dimer	I
30	(	O
31	DD	B
32	)	O
33	and	O
34	plasminogen	B
35	activator	I
36	-	I
37	inhibitor	I
38	(	O
39	pAI	B
40	-	I
41	1	I
42	)	O
43	were	O
44	measured	O
45	,	O
46	and	O
47	compared	O
48	to	O
49	the	O
50	values	O
51	obtained	O
52	from	O
53	10	O
54	healthy	O
55	volunteers	O
56	.	O

0	In	O
1	this	O
2	report	O
3	,	O
4	we	O
5	focus	O
6	on	O
7	the	O
8	genetics	O
9	of	O
10	the	O
11	region	O
12	of	O
13	the	O
14	17	B
15	hep	I
16	syn	I
17	gB	I
18	gene	I
19	that	O
20	conferred	O
21	both	O
22	the	O
23	syncytial	O
24	and	O
25	pathogenic	O
26	phenotypes	O
27	to	O
28	17	O
29	syn	O
30	+.	O

0	Here	O
1	,	O
2	we	O
3	have	O
4	used	O
5	specific	O
6	antibody	O
7	to	O
8	identify	O
9	and	O
10	characterize	O
11	the	O
12	SSN6	B
13	protein	I
14	.	O

0	The	O
1	vigilance	O
2	task	O
3	and	O
4	the	O
5	measurement	O
6	of	O
7	attentional	O
8	deficits	O
9	.	O

0	Two	O
1	rare	O
2	novel	O
3	mutations	O
4	,	O
5	D811N	O
6	in	O
7	exon	O
8	20	O
9	and	O
10	R835C	O
11	in	O
12	exon	O
13	21	O
14	,	O
15	were	O
16	identified	O
17	in	O
18	the	O
19	first	O
20	nucleotide	O
21	-	O
22	binding	O
23	fold	O
24	(	O
25	NBF	O
26	),	O
27	a	O
28	functionally	O
29	important	O
30	region	O
31	of	O
32	SUR1	B
33	,	O
34	in	O
35	one	O
36	patient	O
37	each	O
38	,	O
39	both	O
40	heterozygotes	O
41	.	O

0	Electrophile	B
1	Response	I
2	Elements	I
3	(	O
4	EpREs	B
5	),	O
6	located	O
7	in	O
8	5	O
9	'-	O
10	flanking	O
11	sequences	O
12	of	O
13	both	O
14	the	O
15	GCSh	B
16	and	O
17	GCSl	B
18	subunit	I
19	genes	I
20	,	O
21	are	O
22	hypothesized	O
23	to	O
24	at	O
25	least	O
26	partially	O
27	mediate	O
28	gene	O
29	induction	O
30	following	O
31	xenobiotic	O
32	exposure	O
33	.	O

0	However	O
1	,	O
2	we	O
3	identified	O
4	a	O
5	gene	O
6	between	O
7	the	O
8	MDV2	B
9	UL54	I
10	and	O
11	UL55	B
12	genes	I
13	with	O
14	homology	O
15	to	O
16	the	O
17	first	O
18	ORF	O
19	(	O
20	ORF	O
21	-	O
22	1	O
23	)	O
24	of	O
25	equine	O
26	herpesvirus	O
27	type	O
28	1	O
29	and	O
30	corresponding	O
31	gene	O
32	identified	O
33	in	O
34	pseudorabies	O
35	virus	O
36	.	O

0	The	O
1	partial	O
2	sequence	O
3	of	O
4	the	O
5	62	O
6	-	O
7	kDa	O
8	nuclear	O
9	pore	O
10	glycoprotein	O
11	shows	O
12	little	O
13	similarity	O
14	to	O
15	other	O
16	characterized	O
17	proteins	O
18	and	O
19	elucidates	O
20	structural	O
21	features	O
22	of	O
23	a	O
24	member	O
25	of	O
26	the	O
27	family	O
28	of	O
29	nuclear	O
30	pore	O
31	glycoproteins	O
32	.	O

0	Five	O
1	different	O
2	subtypes	O
3	of	O
4	spondyloarthropathy	O
5	(	O
6	SpA	O
7	)	O
8	are	O
9	now	O
10	recognized	O
11	.	O

0	Note	O
1	on	O
2	Slot	O
3	'	O
4	s	O
5	method	O
6	for	O
7	the	O
8	specific	O
9	determination	O
10	of	O
11	creatinine	O
12	.	O

0	Toxicity	O
1	was	O
2	mild	O
3	,	O
4	mainly	O
5	consisting	O
6	of	O
7	emesis	O
8	(	O
9	81	O
10	%	O
11	of	O
12	the	O
13	patients	O
14	;	O
15	66	O
16	%	O
17	of	O
18	the	O
19	courses	O
20	),	O
21	leukopenia	O
22	of	O
23	World	O
24	Health	O
25	Organization	O
26	(	O
27	WHO	O
28	)	O
29	grade	O
30	1	O
31	to	O
32	2	O
33	(	O
34	47	O
35	%	O
36	of	O
37	the	O
38	patients	O
39	;	O
40	18	O
41	%	O
42	of	O
43	the	O
44	courses	O
45	),	O
46	and	O
47	thrombocytopenia	O
48	(	O
49	12	O
50	%	O
51	of	O
52	the	O
53	patients	O
54	;	O
55	3	O
56	%	O
57	of	O
58	the	O
59	courses	O
60	).	O

0	The	O
1	variable	O
2	phenotype	O
3	of	O
4	the	O
5	allotetraploids	O
6	could	O
7	not	O
8	be	O
9	explained	O
10	by	O
11	cytological	O
12	abnormalities	O
13	.	O

0	In	O
1	addition	O
2	,	O
3	the	O
4	R206S	B
5	HSF	I
6	substitution	O
7	exhibits	O
8	constitutive	O
9	transcriptional	O
10	activation	O
11	from	O
12	a	O
13	consensus	O
14	HSE	O
15	(	O
16	HSE2	B
17	).	O

0	Increased	O
1	blood	O
2	pressure	O
3	during	O
4	CyA	B
5	treatment	O
6	was	O
7	independent	O
8	of	O
9	circulating	O
10	ET	B
11	-	I
12	1	I
13	levels	O
14	.	O

0	The	O
1	corn	O
2	and	O
3	mineral	O
4	oil	O
5	emulsions	O
6	were	O
7	almost	O
8	as	O
9	effective	O
10	as	O
11	milk	O
12	but	O
13	less	O
14	effective	O
15	than	O
16	sucrose	O
17	(	O
18	0	O
19	.	O
20	3M	O
21	)	O
22	in	O
23	stimulating	O
24	ingestion	O
25	.	O

0	Because	O
1	the	O
2	high	B
3	-	I
4	density	I
5	lipoprotein	I
6	receptor	I
7	(	O
8	HDL	B
9	-	I
10	R	I
11	)	O
12	is	O
13	a	O
14	key	O
15	element	O
16	in	O
17	cholesterol	O
18	homeostasis	O
19	and	O
20	a	O
21	potential	O
22	therapeutic	O
23	target	O
24	for	O
25	hypercholesterolemic	O
26	drugs	O
27	,	O
28	an	O
29	understanding	O
30	of	O
31	HDL	B
32	-	I
33	R	I
34	regulation	O
35	is	O
36	essential	O
37	.	O

0	Human	B
1	neuronal	I
2	Elav	I
3	-	I
4	like	I
5	proteins	I
6	contain	O
7	three	O
8	RNP	B
9	-	I
10	type	I
11	RNA	I
12	recognition	I
13	motifs	I
14	(	O
15	RRMs	O
16	).	O

0	Pneumothorax	O
1	during	O
2	laparoscopic	O
3	dissection	O
4	of	O
5	the	O
6	diaphragmatic	O
7	hiatus	O
8	.	O

0	Bioplastique	O
1	granuloma	O
2	presents	O
3	with	O
4	irregularly	O
5	shaped	O
6	cystic	O
7	spaces	O
8	of	O
9	varying	O
10	size	O
11	containing	O
12	jagged	O
13	,	O
14	translucent	O
15	,	O
16	nonbirefringent	O
17	foreign	O
18	bodies	O
19	whereas	O
20	Artecoll	O
21	granuloma	O
22	shows	O
23	numerous	O
24	round	O
25	vacuoles	O
26	nearly	O
27	identical	O
28	in	O
29	size	O
30	and	O
31	shape	O
32	enclosing	O
33	round	O
34	and	O
35	sharply	O
36	circumscribed	O
37	,	O
38	translucent	O
39	,	O
40	nonbirefringent	O
41	foreign	O
42	bodies	O
43	.	O

0	In	O
1	14	O
2	cases	O
3	,	O
4	isolates	O
5	were	O
6	biotyped	O
7	yielding	O
8	eight	O
9	with	O
10	biotype	O
11	II	O
12	,	O
13	four	O
14	with	O
15	biotype	O
16	III	O
17	,	O
18	and	O
19	one	O
20	each	O
21	with	O
22	biotypes	O
23	IV	O
24	and	O
25	V	O
26	.	O

0	These	O
1	probable	O
2	border	O
3	sequences	O
4	are	O
5	closely	O
6	related	O
7	to	O
8	those	O
9	of	O
10	other	O
11	known	O
12	T	O
13	-	O
14	regions	O
15	and	O
16	define	O
17	a	O
18	second	O
19	T	O
20	-	O
21	region	O
22	of	O
23	pTiChry5	O
24	,	O
25	called	O
26	T	O
27	-	O
28	right	O
29	(	O
30	TR	O
31	),	O
32	that	O
33	confers	O
34	production	O
35	of	O
36	the	O
37	Amadoriopines	O
38	.	O

0	Basal	O
1	plasma	O
2	AVP	B
3	levels	O
4	and	O
5	AVP	B
6	release	O
7	after	O
8	postural	O
9	change	O
10	were	O
11	assessed	O
12	,	O
13	and	O
14	plasma	O
15	NPY	B
16	levels	O
17	were	O
18	measured	O
19	in	O
20	the	O
21	same	O
22	samples	O
23	.	O

0	Molecular	O
1	cloning	O
2	of	O
3	a	O
4	P	B
5	-	I
6	type	I
7	ATPase	I
8	gene	I
9	from	O
10	the	O
11	cyanobacterium	O
12	Synechocystis	O
13	sp	O
14	.	O

0	No	O
1	somatic	O
2	mutations	O
3	were	O
4	found	O
5	in	O
6	any	O
7	of	O
8	the	O
9	samples	O
10	,	O
11	suggesting	O
12	that	O
13	ING1	B
14	is	O
15	not	O
16	a	O
17	tumor	O
18	suppressor	O
19	gene	O
20	target	O
21	in	O
22	head	O
23	and	O
24	neck	O
25	cancer	O
26	.	O

0	Supplementing	O
1	a	O
2	soybean	O
3	protein	O
4	and	O
5	sucrose	O
6	-	O
7	based	O
8	diet	O
9	with	O
10	levels	O
11	of	O
12	2	O
13	.	O
14	2	O
15	,	O
16	11	O
17	,	O
18	and	O
19	55	O
20	ppm	O
21	of	O
22	the	O
23	antibiotic	O
24	,	O
25	from	O
26	the	O
27	two	O
28	sources	O
29	each	O
30	with	O
31	two	O
32	different	O
33	purities	O
34	,	O
35	improved	O
36	weight	O
37	gain	O
38	of	O
39	chicks	O
40	an	O
41	average	O
42	of	O
43	23	O
44	%	O
45	and	O
46	improved	O
47	feed	O
48	efficiency	O
49	an	O
50	average	O
51	of	O
52	13	O
53	%	O
54	at	O
55	the	O
56	higher	O
57	levels	O
58	(	O
59	all	O
60	P	O
61	less	O
62	than	O
63	.	O
64	01	O
65	).	O

0	When	O
1	phosphorylation	O
2	of	O
3	exogenous	O
4	peptide	O
5	substrates	O
6	was	O
7	measured	O
8	as	O
9	a	O
10	function	O
11	of	O
12	receptor	O
13	self	O
14	-	O
15	phosphorylation	O
16	,	O
17	tyrosine	B
18	kinase	I
19	activity	O
20	was	O
21	found	O
22	to	O
23	be	O
24	enhanced	O
25	two	O
26	to	O
27	threefold	O
28	at	O
29	1	O
30	-	O
31	2	O
32	mol	O
33	of	O
34	phosphate	O
35	per	O
36	mol	O
37	of	O
38	receptor	O
39	.	O

0	Phosphate	B
1	glucose	I
2	dehydrogenase	I
3	deficiency	O
4	causing	O
5	hyperbilirubinemia	O
6	in	O
7	the	O
8	newborn	O

0	Monospecific	O
1	antibodies	O
2	raised	O
3	against	O
4	rat	B
5	cytochrome	I
6	P	I
7	-	I
8	450	I
9	1A1	I
10	recognized	O
11	a	O
12	protein	O
13	in	O
14	the	O
15	hepatic	O
16	microsomes	O
17	of	O
18	the	O
19	double	O
20	-	O
21	crested	O
22	cormorant	O
23	,	O
24	and	O
25	also	O
26	in	O
27	those	O
28	of	O
29	the	O
30	great	O
31	blue	O
32	heron	O
33	(	O
34	Ardea	O
35	herodias	O
36	),	O
37	using	O
38	immunoblotting	O
39	.	O

0	Consequently	O
1	functional	O
2	mRNAs	O
3	can	O
4	be	O
5	produced	O
6	by	O
7	endogenous	B
8	RNA	I
9	polymerase	I
10	I	I
11	.	O

0	Two	O
1	putative	O
2	12	O
3	-	O
4	O	O
5	-	O
6	tetradecanoyl	O
7	-	O
8	phorbol	O
9	-	O
10	13	O
11	-	O
12	acetate	O
13	(	O
14	TPA	O
15	)	O
16	response	O
17	elements	O
18	,	O
19	that	O
20	might	O
21	serve	O
22	as	O
23	binding	O
24	sites	O
25	for	O
26	the	O
27	transcription	O
28	factor	O
29	AP	B
30	-	I
31	1	I
32	and	O
33	a	O
34	consensus	O
35	sequence	O
36	of	O
37	a	O
38	transforming	B
39	growth	I
40	factor	I
41	beta	I
42	1	I
43	(	O
44	TGF	B
45	-	I
46	beta	I
47	1	I
48	)	O
49	inhibitory	O
50	element	O
51	were	O
52	found	O
53	in	O
54	the	O
55	promoter	O
56	region	O
57	.	O

0	Marked	O
1	sedative	O
2	activity	O
3	was	O
4	observed	O
5	with	O
6	9	O
7	-	O
8	methoxy	O
9	-	O
10	5	O
11	-	O
12	phenylpyrrolo	O
13	[	O
14	2	O
15	,	O
16	1	O
17	-	O
18	d	O
19	][	O
20	1	O
21	,	O
22	5	O
23	]	O
24	benzothiazepin	O
25	-	O
26	6	O
27	,	O
28	6	O
29	-	O
30	dioxide	O
31	(	O
32	NF19	O
33	)	O
34	and	O
35	9	O
36	-	O
37	chloro	O
38	-	O
39	5	O
40	-	O
41	p	O
42	-	O
43	nitrophenylpyrrolo	O
44	[	O
45	2	O
46	,	O
47	1	O
48	-	O
49	d	O
50	][	O
51	1	O
52	,	O
53	5	O
54	]	O
55	benzothiazepin	O
56	-	O
57	6	O
58	,	O
59	6	O
60	-	O
61	dioxide	O
62	(	O
63	NF20	O
64	).	O

0	Within	O
1	the	O
2	Strep	O
3	.	O
4	mutans	O
5	group	O
6	there	O
7	was	O
8	a	O
9	highly	O
10	-	O
11	significant	O
12	difference	O
13	between	O
14	Strep	O
15	.	O
16	mutans	O
17	/	O
18	Strep	O
19	.	O
20	cricetus	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	)	O
29	with	O
30	respect	O
31	to	O
32	mean	O
33	clump	O
34	size	O
35	.	O

0	The	O
1	predicted	O
2	receptor	O
3	structure	O
4	includes	O
5	a	O
6	cysteine	O
7	-	O
8	rich	O
9	extracellular	O
10	domain	O
11	,	O
12	a	O
13	single	O
14	hydrophobic	O
15	transmembrane	O
16	domain	O
17	,	O
18	and	O
19	a	O
20	predicted	O
21	cytoplasmic	B
22	serine	I
23	/	I
24	threonine	I
25	kinase	I
26	domain	I
27	.	O

0	The	O
1	present	O
2	study	O
3	shows	O
4	that	O
5	phosphatidylinositol	B
6	3	I
7	-	I
8	kinase	I
9	-	O
10	dependent	O
11	p38	B
12	kinase	I
13	activation	O
14	regulates	O
15	Akt	B
16	phosphorylation	O
17	and	O
18	activity	O
19	in	O
20	human	O
21	neutrophils	O
22	.	O

0	Patients	O
1	with	O
2	acute	O
3	myocardial	O
4	infarction	O
5	had	O
6	higher	O
7	plasma	O
8	concentrations	O
9	of	O
10	neutrophil	B
11	elastase	I
12	and	O
13	the	O
14	non	O
15	-	O
16	peroxide	O
17	diene	O
18	conjugated	O
19	isomer	O
20	of	O
21	linoleic	O
22	acid	O
23	than	O
24	normal	O
25	volunteers	O
26	or	O
27	patients	O
28	with	O
29	stable	O
30	ischaemic	O
31	heart	O
32	disease	O
33	.	O

0	We	O
1	show	O
2	that	O
3	stabilization	O
4	of	O
5	the	O
6	hairpin	O
7	reduced	O
8	the	O
9	amount	O
10	of	O
11	tRNA	O
12	primer	O
13	that	O
14	is	O
15	annealed	O
16	to	O
17	the	O
18	PBS	O
19	.	O

0	The	O
1	interaction	O
2	of	O
3	AF	B
4	-	I
5	1	I
6	with	O
7	proteins	O
8	that	O
9	regulate	O
10	distinct	O
11	steps	O
12	of	O
13	transcription	O
14	may	O
15	provide	O
16	a	O
17	mechanism	O
18	for	O
19	synergistic	O
20	activation	O
21	of	O
22	gene	O
23	expression	O
24	by	O
25	AF	B
26	-	I
27	1	I
28	.	O

0	Thus	O
1	,	O
2	the	O
3	L45	B
4	sequence	I
5	between	O
6	kinase	O
7	subdomains	O
8	IV	O
9	and	O
10	V	O
11	specifies	O
12	TGF	B
13	-	I
14	beta	I
15	responsiveness	O
16	of	O
17	the	O
18	type	B
19	I	I
20	receptor	I
21	.	O

0	In	O
1	HeLa	O
2	x	O
3	fibroblast	O
4	cell	O
5	hybrids	O
6	its	O
7	expression	O
8	correlates	O
9	with	O
10	tumorigenicity	O
11	.	O

0	By	O
1	contrast	O
2	,	O
3	their	O
4	basal	O
5	adrenal	O
6	androgen	O
7	levels	O
8	were	O
9	significantly	O
10	decreased	O
11	compared	O
12	to	O
13	those	O
14	in	O
15	normal	O
16	subjects	O
17	on	O
18	both	O
19	the	O
20	day	O
21	on	O
22	and	O
23	the	O
24	day	O
25	off	O
26	prednisone	O
27	(	O
28	P	O
29	less	O
30	than	O
31	0	O
32	.	O
33	05	O
34	).	O

0	Raf	B
1	is	O
2	a	O
3	key	O
4	serine	B
5	-	I
6	threonine	I
7	protein	I
8	kinase	I
9	which	O
10	participates	O
11	in	O
12	the	O
13	transmission	O
14	of	O
15	growth	O
16	,	O
17	anti	O
18	-	O
19	apoptotic	O
20	and	O
21	differentiation	O
22	messages	O
23	.	O

0	Because	O
1	the	O
2	adrenergic	O
3	nervous	O
4	system	O
5	influences	O
6	cardiac	O
7	arrhythmias	O
8	and	O
9	myocardial	O
10	infarction	O
11	can	O
12	directly	O
13	affect	O
14	sympathetic	O
15	innervation	O
16	in	O
17	the	O
18	heart	O
19	,	O
20	we	O
21	investigated	O
22	the	O
23	role	O
24	of	O
25	the	O
26	sympathetic	O
27	nervous	O
28	system	O
29	on	O
30	reentry	O
31	in	O
32	the	O
33	canine	O
34	heart	O
35	4	O
36	days	O
37	after	O
38	infarction	O
39	.	O

0	In	O
1	a	O
2	second	O
3	series	O
4	of	O
5	experiments	O
6	,	O
7	the	O
8	efficacy	O
9	of	O
10	PDC	B
11	/	O
12	HDC	B
13	Ac	I
14	was	O
15	evaluated	O
16	in	O
17	both	O
18	single	O
19	and	O
20	multiple	O
21	dose	O
22	regiments	O
23	.	O

0	The	O
1	unilateral	O
2	vestibular	O
3	hypofunction	O
4	.	O

0	Isolation	O
1	of	O
2	Weeksella	O
3	virosa	O
4	(	O
5	formerly	O
6	CDC	B
7	group	I
8	IIf	I
9	)	O
10	from	O
11	a	O
12	vaginal	O
13	sample	O
14	.	O

0	Determination	O
1	of	O
2	diquat	O
3	in	O
4	biological	O
5	materials	O
6	by	O
7	electron	O
8	spin	O
9	resonance	O
10	spectroscopy	O
11	.	O

0	We	O
1	have	O
2	measured	O
3	the	O
4	MBF	O
5	on	O
6	incisors	O
7	and	O
8	its	O
9	direction	O
10	in	O
11	three	O
12	dimensions	O
13	for	O
14	different	O
15	jaw	O
16	openings	O
17	in	O
18	ten	O
19	subjects	O
20	.	O

0	Genomic	O
1	DNA	O
2	clones	O
3	containing	O
4	the	O
5	T	B
6	-	I
7	cell	I
8	-	I
9	specific	I
10	human	I
11	MAL	I
12	gene	I
13	were	O
14	isolated	O
15	.	O

0	An	O
1	ASSEMBLER	O
2	routine	O
3	for	O
4	on	O
5	-	O
6	line	O
7	graphic	O
8	display	O
9	and	O
10	averaging	O
11	of	O
12	data	O
13	acquired	O
14	on	O
15	a	O
16	personal	O
17	microcomputer	O
18	.	O

0	Elevated	O
1	maternal	B
2	alpha	I
3	fetoproteins	I
4	and	O
5	oligoamnios	O
6	:	O
7	fetal	O
8	prognosis	O

0	Advances	O
1	in	O
2	the	O
3	management	O
4	of	O
5	gynecologic	O
6	cancer	O
7	--	O
8	radiation	O
9	therapy	O
10	.	O

0	In	O
1	vitro	O
2	transcription	O
3	extracts	O
4	from	O
5	ret1	B
6	-	I
7	1	I
8	cells	O
9	terminate	O
10	less	O
11	efficiently	O
12	at	O
13	weak	O
14	transcription	O
15	termination	O
16	signals	O
17	than	O
18	those	O
19	from	O
20	RET1	O
21	cells	O
22	,	O
23	using	O
24	a	O
25	variety	O
26	of	O
27	tRNA	O
28	templates	O
29	.	O

0	We	O
1	suggest	O
2	that	O
3	sensitivity	O
4	to	O
5	photoperiod	O
6	in	O
7	pallid	O
8	bats	O
9	,	O
10	as	O
11	in	O
12	several	O
13	other	O
14	mammals	O
15	,	O
16	is	O
17	mediated	O
18	by	O
19	the	O
20	pineal	O
21	gland	O
22	.	O

0	A	O
1	comparison	O
2	of	O
3	the	O
4	predicted	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	the	O
10	two	O
11	human	B
12	PKC	I
13	-	I
14	delta	I
15	clones	I
16	with	O
17	the	O
18	rat	O
19	and	O
20	mouse	O
21	homologues	O
22	indicated	O
23	a	O
24	greater	O
25	degree	O
26	of	O
27	sequence	O
28	divergence	O
29	(	O
30	89	O
31	-	O
32	90	O
33	%	O
34	homology	O
35	)	O
36	compared	O
37	to	O
38	the	O
39	high	O
40	degree	O
41	of	O
42	sequence	O
43	conservation	O
44	observed	O
45	with	O
46	other	O
47	human	B
48	PKC	I
49	family	I
50	members	I
51	and	O
52	their	O
53	mammalian	O
54	counterparts	O
55	.	O

0	Regulation	O
1	of	O
2	avian	B
3	fibroblast	I
4	growth	I
5	factor	I
6	receptor	I
7	1	I
8	(	O
9	FGFR	B
10	-	I
11	1	I
12	)	O
13	gene	O
14	expression	O
15	during	O
16	skeletal	O
17	muscle	O
18	differentiation	O
19	.	O

0	Respondents	O
1	who	O
2	lived	O
3	with	O
4	a	O
5	spouse	O
6	/	O
7	partner	O
8	only	O
9	were	O
10	less	O
11	likely	O
12	to	O
13	have	O
14	an	O
15	unfavorable	O
16	BMI	O
17	status	O
18	than	O
19	people	O
20	in	O
21	the	O
22	other	O
23	two	O
24	groups	O
25	.	O

0	Splice	O
1	variations	O
2	in	O
3	genes	O
4	coding	O
5	for	O
6	the	O
7	transmembrane	B
8	FGF	I
9	receptor	I
10	(	O
11	FGFR	B
12	)	O
13	result	O
14	in	O
15	isoforms	O
16	that	O
17	vary	O
18	in	O
19	the	O
20	ectodomain	B
21	,	O
22	intracellular	O
23	juxtamembrane	O
24	domain	O
25	,	O
26	and	O
27	the	O
28	intracellular	B
29	kinase	O
30	domain	O
31	.	O

0	Twenty	O
1	-	O
2	nine	O
3	days	O
4	after	O
5	injection	O
6	of	O
7	5	O
8	.	O
9	8	O
10	mCi	O
11	of	O
12	Tc	O
13	-	O
14	99m	O
15	,	O
16	which	O
17	gives	O
18	28	O
19	rads	O
20	to	O
21	the	O
22	testis	O
23	,	O
24	the	O
25	number	O
26	of	O
27	sperm	O
28	hads	O
29	decreased	O
30	to	O
31	70	O
32	%	O
33	of	O
34	control	O
35	.	O

0	BCR	B
1	cross	O
2	-	O
3	linking	O
4	also	O
5	led	O
6	to	O
7	increased	O
8	MAPK	B
9	-	I
10	activated	I
11	protein	I
12	kinase	I
13	-	I
14	2	I
15	activity	O
16	,	O
17	an	O
18	enzyme	O
19	that	O
20	lies	O
21	immediately	O
22	downstream	O
23	from	O
24	p38	B
25	MAPK	I
26	;	O
27	MAPK	B
28	-	I
29	activated	I
30	protein	I
31	kinase	I
32	-	I
33	2	I
34	immune	O
35	complexes	O
36	phosphorylated	O
37	a	O
38	peptide	O
39	substrate	O
40	containing	O
41	the	O
42	CREB	B
43	serine	I
44	133	I
45	phosphoacceptor	I
46	motif	I
47	.	O

0	Liquid	O
1	chromatographic	O
2	method	O
3	for	O
4	determination	O
5	of	O
6	citreoviridin	O
7	in	O
8	corn	O
9	and	O
10	rice	O
11	.	O

0	In	O
1	cellular	O
2	supernatant	O
3	fraction	O
4	,	O
5	SHRSP	B
6	showed	O
7	a	O
8	decrease	O
9	of	O
10	magnesium	O
11	in	O
12	many	O
13	tissues	O
14	and	O
15	an	O
16	elevation	O
17	of	O
18	the	O
19	calcium	O
20	to	O
21	magnesium	O
22	ratio	O
23	when	O
24	compared	O
25	to	O
26	age	O
27	-	O
28	matched	O
29	WKY	O
30	and	O
31	SHRSR	O
32	.	O

0	Effect	O
1	of	O
2	triftazin	O
3	and	O
4	aminazin	O
5	on	O
6	hippocampal	O
7	bioelectric	O
8	activity	O

0	The	O
1	fibrinogen	B
2	,	O
3	serum	O
4	proteins	O
5	,	O
6	sodium	O
7	heparin	O
8	and	O
9	membrane	O
10	contributed	O
11	to	O
12	Cm	B
13	by	O
14	20	O
15	%,	O
16	14	O
17	%,	O
18	2	O
19	%	O
20	and	O
21	64	O
22	%,	O
23	respectively	O
24	.	O

0	Although	O
1	the	O
2	binding	O
3	of	O
4	IE2	B
5	86	I
6	to	O
7	nonphosphorylated	O
8	full	B
9	-	I
10	length	I
11	CREB	I
12	or	O
13	deltaCREB	B
14	is	O
15	minimal	O
16	,	O
17	IE2	B
18	86	I
19	does	O
20	form	O
21	complexes	O
22	with	O
23	p300	B
24	and	O
25	the	O
26	CREB	B
27	-	I
28	binding	I
29	protein	I
30	(	O
31	CBP	B
32	),	O
33	which	O
34	in	O
35	turn	O
36	bind	O
37	to	O
38	CREB	B
39	and	O
40	can	O
41	serve	O
42	as	O
43	adaptor	O
44	proteins	O
45	for	O
46	CREB	B
47	function	O
48	.	O

0	In	O
1	this	O
2	report	O
3	we	O
4	describe	O
5	the	O
6	isolation	O
7	of	O
8	a	O
9	Fab	B
10	fragment	O
11	(	O
12	Fab	B
13	A8	I
14	)	O
15	showing	O
16	a	O
17	high	O
18	relative	O
19	affinity	O
20	for	O
21	the	O
22	receptor	O
23	(	O
24	0	O
25	.	O
26	5	O
27	nM	O
28	).	O

0	The	O
1	corresponding	O
2	differences	O
3	in	O
4	FVIIa	O
5	and	O
6	PAI	B
7	-	I
8	1	I
9	were	O
10	not	O
11	statistically	O
12	significant	O
13	.	O

0	Eucaryotic	O
1	transcription	O
2	factors	O
3	that	O
4	stimulate	O
5	RNA	B
6	polymerase	I
7	II	I
8	by	O
9	increasing	O
10	the	O
11	efficiency	O
12	of	O
13	elongation	O
14	of	O
15	specifically	O
16	or	O
17	randomly	O
18	initiated	O
19	RNA	O
20	chains	O
21	have	O
22	been	O
23	isolated	O
24	and	O
25	characterized	O
26	.	O

0	We	O
1	determined	O
2	whether	O
3	the	O
4	human	B
5	StAR	I
6	promoter	I
7	is	O
8	responsive	O
9	to	O
10	sterol	B
11	regulatory	I
12	element	I
13	-	I
14	binding	I
15	proteins	I
16	(	O
17	SREBPs	B
18	).	O

0	An	O
1	immunologically	O
2	related	O
3	protein	O
4	was	O
5	detected	O
6	in	O
7	ribosome	O
8	and	O
9	membrane	O
10	fractions	O
11	of	O
12	mitochondria	O
13	from	O
14	Saccharomyces	O
15	cerevisiae	O
16	.	O

0	These	O
1	observations	O
2	of	O
3	elevated	O
4	serum	B
5	lipase	I
6	and	O
7	serum	O
8	CA	I
9	19	I
10	-	I
11	9	I
12	in	O
13	Sjogren	O
14	'	O
15	s	O
16	syndrome	O
17	without	O
18	evidence	O
19	of	O
20	malignancy	O
21	may	O
22	reflect	O
23	pancreatic	O
24	involvement	O
25	in	O
26	this	O
27	disorder	O
28	.	O

0	The	O
1	eluting	O
2	solvent	O
3	was	O
4	methanol	O
5	-	O
6	chloroform	O
7	(	O
8	10	O
9	+	O
10	90	O
11	)	O
12	at	O
13	a	O
14	flow	O
15	rate	O
16	of	O
17	2	O
18	.	O
19	0	O
20	ml	O
21	/	O
22	min	O
23	.	O

0	A	O
1	stretch	O
2	of	O
3	16	O
4	nucleotides	O
5	just	O
6	upstream	O
7	of	O
8	the	O
9	IL	B
10	-	I
11	4RE	I
12	contributed	O
13	to	O
14	IL	B
15	-	I
16	4	I
17	inducibility	O
18	and	O
19	formed	O
20	nucleoprotein	O
21	complexes	O
22	with	O
23	constitutive	O
24	factors	O
25	.	O

0	The	O
1	5	O
2	'	O
3	untranslated	O
4	and	O
5	coding	O
6	regions	O
7	are	O
8	contained	O
9	within	O
10	12	O
11	exons	O
12	,	O
13	with	O
14	the	O
15	translation	O
16	start	O
17	site	O
18	located	O
19	within	O
20	the	O
21	first	O
22	exon	O
23	.	O

0	Furthermore	O
1	,	O
2	the	O
3	potency	O
4	of	O
5	Dacarbacine	O
6	in	O
7	the	O
8	treatment	O
9	of	O
10	carcinoid	O
11	tumors	O
12	seems	O
13	to	O
14	be	O
15	underestimated	O
16	up	O
17	to	O
18	now	O
19	.	O

0	An	O
1	epidemic	O
2	of	O
3	hepatitis	O
4	B	O
5	virus	O
6	infection	O
7	among	O
8	intravenous	O
9	drug	O
10	users	O
11	in	O
12	Iceland	O
13	.	O

0	Improved	O
1	cosmesis	O
2	,	O
3	extension	O
4	of	O
5	the	O
6	scope	O
7	of	O
8	the	O
9	problems	O
10	that	O
11	can	O
12	be	O
13	addressed	O
14	with	O
15	this	O
16	repair	O
17	(	O
18	including	O
19	treatment	O
20	of	O
21	a	O
22	distal	O
23	urethrocutaneous	O
24	fistula	O
25	)	O
26	and	O
27	the	O
28	ease	O
29	with	O
30	which	O
31	the	O
32	Arap	O
33	procedure	O
34	can	O
35	be	O
36	performed	O
37	are	O
38	the	O
39	advantages	O
40	that	O
41	this	O
42	operation	O
43	has	O
44	over	O
45	other	O
46	1	O
47	-	O
48	stage	O
49	distal	O
50	hypospadias	O
51	repairs	O
52	.	O

0	R	O
1	.,	O
2	Fleischmann	O
3	,	O
4	R	O
5	.,	O
6	Venter	O
7	,	O
8	J	O
9	.	O

0	Derivatives	O
1	of	O
2	boswellic	O
3	acids	O
4	.	O

0	The	O
1	prevalence	O
2	of	O
3	hepatitis	B
4	B	I
5	surface	I
6	antigen	I
7	(	O
8	HBsAg	B
9	)	O
10	and	O
11	anti	B
12	-	I
13	HBs	I
14	was	O
15	determined	O
16	by	O
17	a	O
18	sensitive	O
19	double	O
20	-	O
21	antibody	O
22	radio	O
23	-	O
24	immunoassay	O
25	technique	O
26	in	O
27	a	O
28	series	O
29	of	O
30	patients	O
31	with	O
32	chronic	O
33	liver	O
34	diseases	O
35	.	O

0	At	O
1	maximum	O
2	photosensitivity	O
3	the	O
4	inhibitory	O
5	amino	O
6	acids	O
7	gamma	O
8	-	O
9	aminobutyric	O
10	acid	O
11	and	O
12	taurine	O
13	were	O
14	lower	O
15	,	O
16	and	O
17	those	O
18	of	O
19	asparagine	O
20	(	O
21	metabolite	O
22	of	O
23	the	O
24	excitatory	O
25	amino	O
26	acid	O
27	aspartate	O
28	)	O
29	were	O
30	higher	O
31	,	O
32	than	O
33	when	O
34	the	O
35	animals	O
36	were	O
37	not	O
38	photosensitive	O
39	.	O

0	A	O
1	protein	O
2	lacking	O
3	the	O
4	SH2	B
5	and	O
6	RING	O
7	finger	O
8	domains	O
9	has	O
10	no	O
11	activity	O
12	,	O
13	but	O
14	a	O
15	chimeric	O
16	protein	O
17	with	O
18	the	O
19	SH2	B
20	and	O
21	RING	O
22	finger	O
23	domains	O
24	of	O
25	SLI	B
26	-	I
27	1	I
28	replaced	O
29	by	O
30	the	O
31	equivalent	O
32	domains	O
33	of	O
34	c	B
35	-	I
36	Cbl	I
37	has	O
38	activity	O
39	.	O

0	IGF	B
1	I	I
2	and	O
3	insulin	B
4	receptors	I
5	are	O
6	homologous	O
7	proteins	O
8	that	O
9	function	O
10	in	O
11	distinct	O
12	physiological	O
13	pathways	O
14	.	O

0	Structure	O
1	-	O
2	function	O
3	analysis	O
4	of	O
5	the	O
6	Z	B
7	-	I
8	DNA	I
9	-	I
10	binding	I
11	domain	I
12	Zalpha	I
13	of	O
14	dsRNA	B
15	adenosine	I
16	deaminase	I
17	type	I
18	I	I
19	reveals	O
20	similarity	O
21	to	O
22	the	O
23	(	O
24	alpha	O
25	+	O
26	beta	O
27	)	O
28	family	O
29	of	O
30	helix	B
31	-	I
32	turn	I
33	-	I
34	helix	I
35	proteins	I
36	.	O

0	CD4	B
1	lymphocyte	O
2	and	O
3	viral	O
4	load	O
5	levels	O
6	suggested	O
7	an	O
8	optimal	O
9	response	O
10	to	O
11	ARV	O
12	therapy	O
13	at	O
14	the	O
15	time	O
16	LD	O
17	developed	O
18	.	O

0	A	O
1	position	O
2	-	O
3	independent	O
4	activation	O
5	domain	O
6	which	O
7	contained	O
8	conserved	O
9	regions	O
10	II	O
11	and	O
12	III	O
13	was	O
14	identified	O
15	at	O
16	the	O
17	carboxyl	O
18	terminus	O
19	of	O
20	the	O
21	HNF	B
22	-	I
23	3	I
24	beta	I
25	protein	I
26	(	O
27	amino	O
28	acids	O
29	361	O
30	to	O
31	458	O
32	).	O

0	In	O
1	this	O
2	study	O
3	26	O
4	patients	O
5	(	O
6	20	O
7	females	O
8	and	O
9	6	O
10	males	O
11	)	O
12	were	O
13	evaluated	O
14	.	O

0	The	O
1	presence	O
2	of	O
3	the	O
4	corresponding	O
5	mature	O
6	mRNA	O
7	transcripts	O
8	(	O
9	3	O
10	.	O
11	2	O
12	-	O
13	3	O
14	.	O
15	5	O
16	kilobase	O
17	pairs	O
18	(	O
19	kb	O
20	]	O
21	in	O
22	human	O
23	fibroblasts	O
24	was	O
25	shown	O
26	by	O
27	Northern	O
28	blot	O
29	hybridization	O
30	,	O
31	S1	B
32	nuclease	I
33	protection	O
34	assay	O
35	,	O
36	and	O
37	the	O
38	polymerase	O
39	chain	O
40	reaction	O
41	.	O

0	Further	O
1	studies	O
2	on	O
3	a	O
4	"	O
5	new	O
6	"	O
7	human	O
8	isoprecipitin	O
9	system	O
10	(	O
11	Australia	B
12	antigen	I
13	).	O

0	The	O
1	same	O
2	rhythmic	O
3	structure	O
4	enables	O
5	a	O
6	prediction	O
7	to	O
8	be	O
9	made	O
10	concerning	O
11	when	O
12	vowels	O
13	of	O
14	stressed	O
15	syllables	O
16	will	O
17	be	O
18	auditorily	O
19	perceived	O
20	.	O

0	"	O
1	Complex	O
2	partial	O
3	"	O
4	seizures	O
5	.	O

0	Marked	O
1	hemolysis	O
2	significantly	O
3	increased	O
4	plasma	O
5	values	O
6	of	O
7	potassium	O
8	,	O
9	phosphorus	O
10	,	O
11	total	O
12	protein	O
13	,	O
14	and	O
15	aspartate	B
16	aminotransferase	I
17	.	O

0	Deletion	O
1	analysis	O
2	showed	O
3	that	O
4	the	O
5	NF	B
6	-	I
7	4FA	I
8	,	O
9	NF	B
10	-	I
11	4FB	I
12	,	O
13	and	O
14	AP	B
15	-	I
16	1	I
17	sequences	I
18	are	O
19	each	O
20	necessary	O
21	for	O
22	full	O
23	enhancer	O
24	activity	O
25	.	O

0	Second	O
1	,	O
2	the	O
3	wild	B
4	-	I
5	type	I
6	m8	I
7	3	I
8	'	I
9	UTR	I
10	strongly	O
11	reduces	O
12	accumulation	O
13	of	O
14	heterologous	O
15	transcripts	O
16	in	O
17	vivo	O
18	,	O
19	an	O
20	activity	O
21	that	O
22	requires	O
23	its	O
24	K	O
25	box	O
26	sequences	O
27	.	O

0	The	O
1	role	O
2	of	O
3	ascorbic	O
4	acid	O
5	in	O
6	the	O
7	prevention	O
8	of	O
9	bladder	O
10	tumor	O
11	formation	O
12	.	O

0	Plasma	O
1	concentrations	O
2	of	O
3	ANF	B
4	(	O
5	pANF	O
6	),	O
7	aldosterone	O
8	(	O
9	PAC	O
10	)	O
11	and	O
12	renin	B
13	(	O
14	PRC	O
15	)	O
16	were	O
17	measured	O
18	daily	O
19	,	O
20	as	O
21	were	O
22	hemodynamic	O
23	parameters	O
24	.	O

0	Manganese	O
1	ions	O
2	were	O
3	found	O
4	to	O
5	be	O
6	essential	O
7	for	O
8	autophosphorylation	O
9	of	O
10	BGLF4	B
11	,	O
12	and	O
13	magnesium	O
14	can	O
15	stimulate	O
16	the	O
17	activity	O
18	.	O

0	Coexpression	O
1	of	O
2	mouse	B
3	PKR	I
4	(	I
5	1	I
6	-	I
7	515	I
8	)	I
9	WT	I
10	as	O
11	a	O
12	Gal4	B
13	DNA	I
14	-	I
15	binding	I
16	domain	I
17	fusion	O
18	with	O
19	either	O
20	the	O
21	catalytic	O
22	-	O
23	deficient	O
24	human	B
25	PKR	I
26	(	I
27	1	I
28	-	I
29	551	I
30	)	O
31	K296R	B
32	mutant	I
33	,	O
34	the	O
35	RNA	O
36	-	O
37	binding	O
38	-	O
39	deficient	O
40	human	B
41	PKR	I
42	(	I
43	1	I
44	-	I
45	551	I
46	)	I
47	K64E	B
48	/	O
49	K296R	B
50	double	O
51	mutant	O
52	,	O
53	or	O
54	wild	B
55	-	I
56	type	I
57	mouse	I
58	PKR	I
59	(	I
60	1	I
61	-	I
62	515	I
63	)	I
64	WT	I
65	as	O
66	full	B
67	-	I
68	length	I
69	PKR	I
70	-	O
71	Gal4	B
72	activation	I
73	domain	I
74	fusions	O
75	resulted	O
76	in	O
77	activation	O
78	of	O
79	the	O
80	HIS3	B
81	and	O
82	lacZ	B
83	reporters	O
84	.	O

0	Following	O
1	treatment	O
2	,	O
3	serum	O
4	estradiol	O
5	levels	O
6	were	O
7	higher	O
8	in	O
9	groups	O
10	E	O
11	+	O
12	T	O
13	and	O
14	E	O
15	than	O
16	in	O
17	group	O
18	C	O
19	.	O

0	Serotonin	B
1	concentration	O
2	in	O
3	the	O
4	blood	O
5	of	O
6	patients	O
7	with	O
8	hemorrhagic	O
9	fever	O
10	with	O
11	renal	O
12	syndrome	O

0	These	O
1	show	O
2	that	O
3	the	O
4	collagen	B
5	in	O
6	this	O
7	tissue	O
8	is	O
9	modified	O
10	compared	O
11	with	O
12	that	O
13	in	O
14	tendon	O
15	.	O

0	Deletion	O
1	and	O
2	mutational	O
3	analyses	O
4	revealed	O
5	two	O
6	positive	O
7	cis	O
8	-	O
9	regulatory	O
10	elements	O
11	in	O
12	this	O
13	region	O
14	that	O
15	are	O
16	essential	O
17	for	O
18	CSX1	B
19	expression	O
20	in	O
21	cardiomyocytes	O
22	.	O

0	Serum	O
1	and	O
2	peritoneal	O
3	dialysis	O
4	fluid	O
5	(	O
6	PDF	O
7	)	O
8	were	O
9	collected	O
10	for	O
11	assay	O
12	throughout	O
13	the	O
14	course	O
15	of	O
16	the	O
17	study	O
18	and	O
19	for	O
20	5	O
21	days	O
22	thereafter	O
23	.	O

0	The	O
1	molecular	O
2	mechanism	O
3	of	O
4	Tax	B
5	-	O
6	mediated	O
7	trans	O
8	-	O
9	activation	O
10	has	O
11	been	O
12	well	O
13	investigated	O
14	.	O

0	The	O
1	two	O
2	larger	O
3	peptides	O
4	,	O
5	one	O
6	containing	O
7	amino	O
8	acids	O
9	1	O
10	-	O
11	228	O
12	and	O
13	the	O
14	other	O
15	containing	O
16	amino	O
17	acids	O
18	85	O
19	-	O
20	228	O
21	,	O
22	formed	O
23	dimers	O
24	in	O
25	solution	O
26	and	O
27	bound	O
28	DNA	O
29	specifically	O
30	as	O
31	a	O
32	dimer	O
33	.	O

0	However	O
1	,	O
2	the	O
3	published	O
4	reports	O
5	consist	O
6	of	O
7	a	O
8	small	O
9	number	O
10	of	O
11	patients	O
12	and	O
13	limited	O
14	data	O
15	.	O

0	In	O
1	particular	O
2	,	O
3	changes	O
4	in	O
5	intracellular	O
6	Ca2	O
7	+	O
8	have	O
9	the	O
10	potential	O
11	to	O
12	either	O
13	inhibit	O
14	or	O
15	augment	O
16	the	O
17	ability	O
18	of	O
19	cAMP	O
20	to	O
21	stimulate	O
22	transcription	O
23	,	O
24	depending	O
25	on	O
26	the	O
27	presence	O
28	of	O
29	specific	O
30	forms	O
31	of	O
32	Ca2	B
33	+/	I
34	calmodulin	B
35	-	I
36	dependent	I
37	protein	I
38	kinases	I
39	.	O

0	Separate	O
1	experiments	O
2	measured	O
3	AIB	O
4	and	O
5	86RbCl	O
6	uptake	O
7	in	O
8	36B	O
9	-	O
10	10	O
11	cells	O
12	in	O
13	vitro	O
14	1	O
15	and	O
16	2	O
17	days	O
18	following	O
19	20	O
20	Gy	O
21	irradiation	O
22	to	O
23	assess	O
24	whether	O
25	this	O
26	radiation	O
27	dose	O
28	reduced	O
29	the	O
30	capacity	O
31	of	O
32	tumor	O
33	cells	O
34	to	O
35	trap	O
36	AIB	O
37	or	O
38	Rb	O
39	+.	O

0	The	O
1	presence	O
2	of	O
3	local	O
4	abnormalities	O
5	in	O
6	both	O
7	patients	O
8	can	O
9	support	O
10	the	O
11	hypothesis	O
12	that	O
13	the	O
14	cortex	O
15	,	O
16	especially	O
17	of	O
18	the	O
19	temporal	O
20	anterior	O
21	lobe	O
22	,	O
23	is	O
24	involved	O
25	in	O
26	the	O
27	origin	O
28	of	O
29	the	O
30	laughing	O
31	seizures	O
32	.	O

0	Incidental	O
1	findings	O
2	in	O
3	the	O
4	epidermis	O
5	and	O
6	in	O
7	the	O
8	intraepidermal	O
9	eccrine	O
10	sweat	O
11	duct	O
12	units	O
13	.	O

0	Studies	O
1	on	O
2	immunoglobulin	B
3	E	I
4	:	O
5	the	O
6	impact	O
7	of	O
8	a	O
9	sojourn	O
10	with	O
11	Professor	O
12	Dan	O
13	H	O
14	.	O

0	They	O
1	generated	O
2	ca	O
3	.	O

0	After	O
1	giving	O
2	a	O
3	survey	O
4	on	O
5	the	O
6	situation	O
7	of	O
8	antibiotic	O
9	resistance	O
10	in	O
11	the	O
12	region	O
13	of	O
14	Northern	O
15	Bavaria	O
16	during	O
17	1973	O
18	/	O
19	74	O
20	and	O
21	comparing	O
22	the	O
23	activity	O
24	of	O
25	a	O
26	sulfamethoxazole	O
27	(	O
28	SMZ	O
29	)	O
30	trimethoprim	O
31	(	O
32	TMP	O
33	)	O
34	combination	O
35	to	O
36	other	O
37	commonly	O
38	used	O
39	antibiotics	O
40	and	O
41	chemotherapeutic	O
42	agents	O
43	,	O
44	the	O
45	results	O
46	of	O
47	tests	O
48	with	O
49	the	O
50	new	O
51	combination	O
52	of	O
53	N1	O
54	-(	O
55	4	O
56	,	O
57	5	O
58	-	O
59	dimethyl	O
60	-	O
61	2	O
62	-	O
63	oxazolyl	O
64	)-	O
65	sulfanilamide	O
66	)	O
67	(	O
68	sulfamoxole	O
69	)	O
70	and	O
71	2	O
72	,	O
73	4	O
74	-	O
75	diamino	O
76	-	O
77	5	O
78	-(	O
79	3	O
80	,	O
81	4	O
82	,	O
83	5	O
84	-	O
85	trimethoxy	O
86	-	O
87	benzyl	O
88	)-	O
89	pyrimidine	O
90	(	O
91	trimethoprim	O
92	)	O
93	at	O
94	a	O
95	ratio	O
96	of	O
97	5	O
98	:	O
99	1	O
100	(	O
101	CN	O
102	3123	O
103	;	O
104	Nevin	O
105	,	O
106	Supristol	O
107	)	O
108	are	O
109	compared	O
110	to	O
111	those	O
112	of	O
113	tests	O
114	with	O
115	TMP	O
116	/	O
117	SMZ	O
118	.	O

0	During	O
1	a	O
2	disease	O
3	remission	O
4	there	O
5	was	O
6	an	O
7	increase	O
8	in	O
9	GAG	B
10	secretion	O
11	with	O
12	urine	O
13	,	O
14	linked	O
15	with	O
16	hyperheparinuria	O
17	(	O
18	13	O
19	.	O
20	1	O
21	-	O
22	fold	O
23	,	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	001	O
30	).	O

0	Mechanism	O
1	of	O
2	the	O
3	t	O
4	(	O
5	14	O
6	;	O
7	18	O
8	)	O
9	chromosomal	O
10	translocation	O
11	:	O
12	structural	O
13	analysis	O
14	of	O
15	both	O
16	derivative	O
17	14	O
18	and	O
19	18	O
20	reciprocal	O
21	partners	O
22	.	O

0	We	O
1	consider	O
2	that	O
3	DIL	O
4	-	O
5	CP	O
6	is	O
7	a	O
8	safe	O
9	and	O
10	excellent	O
11	CP	O
12	in	O
13	CABG	O
14	surgery	O
15	and	O
16	we	O
17	are	O
18	now	O
19	utilizing	O
20	this	O
21	CP	O
22	in	O
23	all	O
24	patients	O
25	requiring	O
26	CABG	O
27	surgery	O
28	.	O

0	Impaction	O
1	of	O
2	gastrostomy	O
3	tube	O
4	in	O
5	the	O
6	abdominal	O
7	wall	O
8	.	O

0	Using	O
1	lectin	B
2	-	O
3	affinity	O
4	chromatography	O
5	,	O
6	discordance	O
7	between	O
8	the	O
9	pattern	O
10	of	O
11	O	O
12	-	O
13	glycosylation	O
14	of	O
15	SSBP	B
16	and	O
17	DSBP	B
18	was	O
19	demonstrated	O
20	.	O

0	Transvenous	O
1	serial	O
2	xeroradiography	O
3	.	O

0	It	O
1	was	O
2	concluded	O
3	that	O
4	Scotchbond	O
5	2	O
6	and	O
7	Prisma	O
8	Universal	O
9	Bond	O
10	2	O
11	are	O
12	effective	O
13	and	O
14	are	O
15	the	O
16	dentine	O
17	bonding	O
18	agents	O
19	of	O
20	choice	O
21	.	O

0	Both	O
1	increasing	O
2	basal	O
3	FSH	B
4	and	O
5	age	O
6	were	O
7	associated	O
8	significantly	O
9	with	O
10	increased	O
11	total	O
12	gonadotrophin	B
13	dose	O
14	,	O
15	and	O
16	reduced	O
17	number	O
18	of	O
19	oocytes	O
20	collected	O
21	and	O
22	pregnancy	O
23	rate	O
24	.	O

0	1	O
1	,	O
2	3	O
3	-	O
4	bis	O
5	(	O
6	2	O
7	-	O
8	chloroethyl	O
9	)-	O
10	1	O
11	-	O
12	nitrosourea	O
13	(	O
14	bcnu	O
15	)	O
16	and	O
17	other	O
18	nitrosoureas	O
19	in	O
20	cancer	O
21	treatment	O
22	:	O
23	a	O
24	review	O
25	.	O

0	Cocaine	O
1	-	O
2	treated	O
3	rats	O
4	acquired	O
5	a	O
6	preference	O
7	for	O
8	cocaine	O
9	-	O
10	associated	O
11	contextual	O
12	stimuli	O
13	(	O
14	CS	O
15	)	O
16	relative	O
17	to	O
18	saline	O
19	-	O
20	injected	O
21	control	O
22	rats	O
23	.	O

0	(	O
1	1996a	O
2	)	O
3	Biochemistry	O
4	35	O
5	,	O
6	1589	O
7	-	O
8	1598	O
9	].	O

0	When	O
1	cells	O
2	were	O
3	microinjected	O
4	with	O
5	TFOs	B
6	designed	O
7	to	O
8	bind	O
9	to	O
10	a	O
11	30	O
12	-	O
13	bp	O
14	polypurine	O
15	site	O
16	situated	O
17	between	O
18	the	O
19	two	O
20	TK	B
21	genes	I
22	,	O
23	recombination	O
24	was	O
25	observed	O
26	at	O
27	frequencies	O
28	in	O
29	the	O
30	range	O
31	of	O
32	1	O
33	%,	O
34	2	O
35	,	O
36	500	O
37	-	O
38	fold	O
39	above	O
40	the	O
41	background	O
42	.	O

0	Conjugated	O
1	and	O
2	unconjugated	O
3	phenylacetic	O
4	acid	O
5	and	O
6	m	O
7	-	O
8	and	O
9	p	O
10	-	O
11	hydroxyphenylacetic	O
12	acid	O
13	have	O
14	been	O
15	determined	O
16	in	O
17	the	O
18	plasma	O
19	of	O
20	normal	O
21	,	O
22	healthy	O
23	subjects	O
24	after	O
25	fasting	O
26	,	O
27	consumption	O
28	of	O
29	a	O
30	meal	O
31	and	O
32	ingestion	O
33	of	O
34	deuterium	O
35	labelled	O
36	amine	O
37	precursors	O
38	,	O
39	by	O
40	high	O
41	-	O
42	resolution	O
43	gas	O
44	chromatography	O
45	--	O
46	high	O
47	resolution	O
48	mass	O
49	spectrometry	O
50	with	O
51	selected	O
52	ion	O
53	monitoring	O
54	of	O
55	their	O
56	trifluoroethyl	O
57	-	O
58	pentafluoropropionyl	O
59	derivatives	O
60	.	O

0	Integrated	O
1	mapping	O
2	analysis	O
3	of	O
4	the	O
5	Werner	O
6	syndrome	O
7	region	O
8	of	O
9	chromosome	O
10	8	O
11	.	O

0	The	O
1	hybridizing	O
2	clone	O
3	of	O
4	V	O
5	.	O
6	vulnificus	O
7	chromosomal	O
8	DNA	O
9	complemented	O
10	a	O
11	V	O
12	.	O
13	cholerae	O
14	fur	O
15	mutant	O
16	.	O

0	Second	O
1	,	O
2	the	O
3	transcription	O
4	factor	O
5	Gal	B
6	-	I
7	ER	I
8	was	O
9	rendered	O
10	more	O
11	potent	O
12	and	O
13	less	O
14	susceptible	O
15	to	O
16	cell	O
17	type	O
18	-	O
19	specific	O
20	variation	O
21	by	O
22	fusing	O
23	the	O
24	strong	O
25	activating	O
26	domain	O
27	of	O
28	the	O
29	herpesvirus	B
30	protein	I
31	VP16	I
32	onto	O
33	its	O
34	C	O
35	terminus	O
36	.	O

0	This	O
1	interaction	O
2	inhibits	O
3	the	O
4	histone	B
5	acetyltransferase	I
6	activity	O
7	of	O
8	p300	B
9	,	O
10	resulting	O
11	in	O
12	drastic	O
13	reduction	O
14	of	O
15	nucleosomal	O
16	histone	O
17	acetylation	O
18	and	O
19	alteration	O
20	of	O
21	chromatin	O
22	structure	O
23	.	O

0	This	O
1	brief	O
2	hypercapnic	O
3	challenge	O
4	induced	O
5	a	O
6	rapid	O
7	increase	O
8	in	O
9	CBF	B
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	change	O
16	in	O
17	MABP	B
18	.	O

0	All	O
1	patients	O
2	had	O
3	the	O
4	CA	O
5	125	O
6	assay	O
7	performed	O
8	within	O
9	one	O
10	week	O
11	before	O
12	their	O
13	second	O
14	-	O
15	look	O
16	operation	O
17	.	O

0	After	O
1	1	O
2	.	O
3	5	O
4	years	O
5	of	O
6	such	O
7	photoperiodic	O
8	control	O
9	,	O
10	all	O
11	ewes	O
12	were	O
13	blinded	O
14	by	O
15	bilateral	O
16	orbital	O
17	enucleation	O
18	.	O

0	The	O
1	amino	O
2	-	O
3	terminal	O
4	half	O
5	of	O
6	1a	O
7	is	O
8	a	O
9	distant	O
10	homolog	O
11	of	O
12	alphavirus	B
13	nonstructural	I
14	protein	I
15	nsP1	I
16	,	O
17	which	O
18	has	O
19	been	O
20	implicated	O
21	in	O
22	capping	O
23	viral	O
24	RNAs	O
25	.	O

0	The	O
1	transport	O
2	of	O
3	a	O
4	genetically	O
5	engineered	O
6	chimeric	O
7	transmembrane	O
8	protein	O
9	connected	O
10	to	O
11	this	O
12	ER	B
13	leader	I
14	sequence	I
15	was	O
16	as	O
17	efficient	O
18	as	O
19	that	O
20	of	O
21	the	O
22	original	O
23	protein	O
24	from	O
25	which	O
26	the	O
27	ER	O
28	sequence	O
29	has	O
30	been	O
31	derived	O
32	.	O

0	When	O
1	data	O
2	were	O
3	expressed	O
4	in	O
5	a	O
6	cumulative	O
7	manner	O
8	,	O
9	the	O
10	response	O
11	to	O
12	intravenous	O
13	adenosine	O
14	3	O
15	mg	O
16	,	O
17	6	O
18	mg	O
19	,	O
20	9	O
21	mg	O
22	and	O
23	12	O
24	mg	O
25	in	O
26	the	O
27	24	O
28	episodes	O
29	of	O
30	PSVT	O
31	were	O
32	5	O
33	episodes	O
34	(	O
35	21	O
36	%),	O
37	16	O
38	episodes	O
39	(	O
40	67	O
41	%),	O
42	20	O
43	episodes	O
44	(	O
45	83	O
46	%)	O
47	and	O
48	20	O
49	episodes	O
50	(	O
51	83	O
52	%)	O
53	respectively	O
54	.	O

0	All	O
1	other	O
2	ejaculate	O
3	parameters	O
4	(	O
5	density	O
6	,	O
7	motility	O
8	,	O
9	swelling	O
10	test	O
11	,	O
12	penetration	O
13	test	O
14	)	O
15	remained	O
16	unchanged	O
17	,	O
18	and	O
19	there	O
20	was	O
21	only	O
22	one	O
23	post	O
24	-	O
25	therapeutic	O
26	pregnancy	O
27	.	O

0	The	O
1	two	O
2	different	O
3	phosphoforms	O
4	of	O
5	STAT5	B
6	have	O
7	identical	O
8	in	O
9	vitro	O
10	DNA	O
11	binding	O
12	specificity	O
13	and	O
14	reactivity	O
15	with	O
16	tyrosine	O
17	phosphopeptides	O
18	,	O
19	but	O
20	differ	O
21	in	O
22	their	O
23	cellular	O
24	localization	O
25	.	O

0	Because	O
1	L	B
2	-	I
3	plastin	I
4	expression	O
5	in	O
6	tissue	O
7	-	O
8	specifically	O
9	regulated	O
10	in	O
11	both	O
12	humans	O
13	and	O
14	rodents	O
15	,	O
16	it	O
17	is	O
18	likely	O
19	that	O
20	similar	O
21	mechanisms	O
22	regulate	O
23	L	B
24	-	I
25	plastin	I
26	gene	I
27	expression	O
28	in	O
29	human	O
30	and	O
31	rodent	O
32	cells	O
33	and	O
34	that	O
35	they	O
36	could	O
37	be	O
38	identified	O
39	by	O
40	comparing	O
41	the	O
42	function	O
43	and	O
44	nucleotide	O
45	sequences	O
46	of	O
47	the	O
48	human	B
49	and	I
50	murine	I
51	L	I
52	-	I
53	plastin	I
54	gene	I
55	promoters	I
56	.	O

0	Direct	O
1	approach	O
2	to	O
3	the	O
4	study	O
5	of	O
6	soliton	O
7	perturbations	O
8	.	O

0	The	O
1	addition	O
2	of	O
3	diatrizoate	O
4	to	O
5	the	O
6	IPRK	B
7	led	O
8	to	O
9	a	O
10	dose	O
11	-	O
12	dependent	O
13	biphasic	O
14	change	O
15	in	O
16	RPF	B
17	and	O
18	GFR	B
19	characterized	O
20	by	O
21	an	O
22	initial	O
23	transient	O
24	increase	O
25	followed	O
26	by	O
27	a	O
28	marked	O
29	and	O
30	sustained	O
31	decrease	O
32	.	O

0	We	O
1	have	O
2	mutated	O
3	to	O
4	cysteine	O
5	,	O
6	one	O
7	at	O
8	a	O
9	time	O
10	,	O
11	21	O
12	consecutive	O
13	residues	O
14	in	O
15	the	O
16	fourth	O
17	TMS	O
18	(	O
19	TM4	O
20	).	O

0	The	O
1	pel	B
2	gene	I
3	from	O
4	an	O
5	Amycolata	O
6	sp	O
7	.	O
8	encoding	O
9	a	O
10	pectate	B
11	lyase	I
12	(	O
13	EC	B
14	4	I
15	.	I
16	2	I
17	.	I
18	2	I
19	.	I
20	2	I
21	)	O
22	was	O
23	isolated	O
24	by	O
25	activity	O
26	screening	O
27	a	O
28	genomic	O
29	DNA	O
30	library	O
31	in	O
32	Streptomyces	O
33	lividans	O
34	TK24	O
35	.	O

0	Identification	O
1	of	O
2	this	O
3	region	O
4	as	O
5	the	O
6	E	B
7	.	I
8	coli	I
9	tmk	I
10	gene	I
11	was	O
12	confirmed	O
13	by	O
14	functional	O
15	complementation	O
16	of	O
17	a	O
18	yeast	B
19	dTMP	I
20	kinase	I
21	temperature	O
22	-	O
23	sensitive	O
24	mutant	O
25	and	O
26	by	O
27	in	O
28	vitro	O
29	enzyme	O
30	assay	O
31	of	O
32	the	O
33	thymidylate	B
34	kinase	I
35	activity	O
36	in	O
37	cell	O
38	extracts	O
39	of	O
40	E	O
41	.	O
42	coli	O
43	by	O
44	use	O
45	of	O
46	tmk	B
47	-	O
48	overproducing	O
49	plasmids	O
50	.	O

0	Results	O
1	of	O
2	the	O
3	recognition	O
4	task	O
5	revealed	O
6	significant	O
7	effects	O
8	of	O
9	consonant	O
10	voicing	O
11	,	O
12	position	O
13	and	O
14	vowel	O
15	context	O
16	on	O
17	syllable	O
18	recognition	O
19	.	O

0	The	O
1	therapeutic	O
2	action	O
3	of	O
4	cyclosporin	O
5	A	O
6	(	O
7	Sandimmun	O
8	):	O
9	its	O
10	application	O
11	in	O
12	rheumatoid	O
13	arthritis	O
14	.	O

0	Potentiation	O
1	of	O
2	the	O
3	thrombolytic	O
4	efficacy	O
5	of	O
6	single	B
7	-	I
8	chain	I
9	urokinase	I
10	(	O
11	Pro	B
12	-	I
13	urokinase	I
14	)	O
15	by	O
16	heparin	O
17	.	O

0	The	O
1	statistical	O
2	significance	O
3	of	O
4	the	O
5	prognosis	O
6	factors	O
7	was	O
8	studied	O
9	by	O
10	uni	O
11	-	O
12	and	O
13	multivariative	O
14	methods	O
15	,	O
16	according	O
17	to	O
18	the	O
19	model	O
20	of	O
21	Cox	O
22	,	O
23	with	O
24	the	O
25	help	O
26	of	O
27	an	O
28	IMB	O
29	computer	O
30	.	O

0	Carbonic	B
1	anhydrase	I
2	V	I
3	(	O
4	CA	B
5	V	I
6	)	O
7	is	O
8	expressed	O
9	in	O
10	mitochondrial	O
11	matrix	O
12	in	O
13	liver	O
14	and	O
15	several	O
16	other	O
17	tissues	O
18	.	O

0	Patients	O
1	who	O
2	have	O
3	undergone	O
4	thyroidectomy	O
5	for	O
6	thyroid	O
7	carcinoma	O
8	are	O
9	frequently	O
10	subjected	O
11	to	O
12	periods	O
13	of	O
14	induced	O
15	severe	O
16	hypothyroidism	O
17	in	O
18	preparation	O
19	for	O
20	131I	O
21	whole	O
22	body	O
23	scanning	O
24	and	O
25	measurement	O
26	of	O
27	serum	O
28	TG	O
29	.	O

0	Here	O
1	we	O
2	report	O
3	that	O
4	Dbp5p	B
5	and	O
6	Rat7p	B
7	interact	O
8	through	O
9	their	O
10	Nterminal	O
11	domains	O
12	.	O

0	Biological	O
1	activities	O
2	of	O
3	hematopoietic	O
4	growth	I
5	factors	I
6	that	O
7	lead	O
8	to	O
9	future	O
10	clinical	O
11	application	O
12	.	O

0	Naphthalene	O
1	and	O
2	paradichlorobenzene	O
3	in	O
4	clinical	O
5	toxicology	O

0	The	O
1	requirement	O
2	for	O
3	proteolytic	O
4	activity	O
5	of	O
6	both	O
7	FVIIa	B
8	and	O
9	FXa	B
10	suggests	O
11	that	O
12	protease	O
13	-	O
14	activated	O
15	receptors	O
16	may	O
17	be	O
18	involved	O
19	.	O

0	Parasitological	O
1	and	O
2	pathological	O
3	findings	O
4	in	O
5	capuchin	O
6	monkeys	O
7	infected	O
8	with	O
9	Schistosoma	O
10	japonicum	O
11	or	O
12	Schistosoma	O
13	mansoni	O
14	.	O

0	The	O
1	overall	O
2	incidence	O
3	of	O
4	SIDS	O
5	was	O
6	1	O
7	.	O
8	43	O
9	per	O
10	1	O
11	,	O
12	000	O
13	live	O
14	births	O
15	.	O

0	Lack	O
1	of	O
2	cyclin	B
3	D	I
4	-	O
5	Cdk	B
6	complexes	O
7	in	O
8	Rb	B
9	-	O
10	negative	O
11	cells	O
12	correlates	O
13	with	O
14	high	O
15	levels	O
16	of	O
17	p16INK4	B
18	/	O
19	MTS1	B
20	tumour	I
21	suppressor	I
22	gene	I
23	product	O
24	.	O

0	Methods	O
1	included	O
2	24	O
3	-	O
4	hour	O
5	dietary	O
6	recall	O
7	,	O
8	menu	O
9	weights	O
10	,	O
11	and	O
12	recipe	O
13	analysis	O
14	.	O

0	When	O
1	the	O
2	LCx	O
3	was	O
4	partially	O
5	occluded	O
6	,	O
7	mild	O
8	PM	O
9	-	O
10	induced	O
11	tachycardia	O
12	resulted	O
13	in	O
14	decreased	O
15	AoP	O
16	(	O
17	P	O
18	=	O
19	0	O
20	.	O
21	045	O
22	)	O
23	as	O
24	well	O
25	as	O
26	in	O
27	decreased	O
28	SV	O
29	(	O
30	P	O
31	=	O
32	0	O
33	.	O
34	048	O
35	);	O
36	the	O
37	LVEDP	O
38	remained	O
39	high	O
40	(	O
41	P	O
42	=	O
43	0	O
44	.	O
45	002	O
46	).	O

0	The	O
1	Clb5	B
2	kinase	I
3	,	O
4	which	O
5	promotes	O
6	S	O
7	phase	O
8	,	O
9	remains	O
10	active	O
11	during	O
12	the	O
13	G2	O
14	-	O
15	phase	O
16	arrest	O
17	of	O
18	cells	O
19	of	O
20	the	O
21	parental	O
22	strain	O
23	,	O
24	but	O
25	its	O
26	activity	O
27	declines	O
28	rapidly	O
29	in	O
30	sim	B
31	mutants	I
32	.	O

0	In	O
1	ciliates	O
2	,	O
3	both	O
4	mechanisms	O
5	are	O
6	readily	O
7	observed	O
8	.	O

0	These	O
1	findings	O
2	suggest	O
3	that	O
4	a	O
5	range	O
6	of	O
7	microenvironmental	O
8	conditions	O
9	exist	O
10	within	O
11	purified	O
12	water	O
13	systems	O
14	,	O
15	leading	O
16	to	O
17	variable	O
18	populations	O
19	of	O
20	bacteria	O
21	.	O

0	The	O
1	first	O
2	85	O
3	nt	O
4	upstream	O
5	of	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	of	O
11	the	O
12	mouse	B
13	desmin	I
14	gene	I
15	,	O
16	which	O
17	contain	O
18	an	O
19	E	O
20	box	O
21	(	O
22	E1	O
23	),	O
24	the	O
25	binding	O
26	site	O
27	of	O
28	the	O
29	helix	O
30	-	O
31	loop	O
32	-	O
33	helix	O
34	myogenic	O
35	regulators	O
36	,	O
37	are	O
38	sufficient	O
39	to	O
40	confer	O
41	low	O
42	level	O
43	muscle	O
44	-	O
45	specific	O
46	expression	O
47	.	O

0	Three	O
1	chromosomal	B
2	crsA	I
3	mutations	I
4	,	O
5	crsA1	B
6	,	O
7	crsA4	B
8	,	O
9	and	O
10	crsA47	B
11	,	O
12	were	O
13	transferred	O
14	by	O
15	the	O
16	"	O
17	gene	O
18	conversion	O
19	"	O
20	process	O
21	to	O
22	B	O
23	.	O
24	subtilis	O
25	plasmid	O
26	pRPD11	O
27	,	O
28	which	O
29	consists	O
30	of	O
31	the	O
32	entire	O
33	wild	O
34	-	O
35	type	O
36	rpoD	O
37	coding	O
38	sequence	O
39	,	O
40	encoding	O
41	the	O
42	major	O
43	sigma	B
44	43	I
45	factor	I
46	of	I
47	B	I
48	.	I
49	subtilis	I
50	RNA	I
51	polymerase	I
52	,	O
53	and	O
54	pUB110	B
55	.	O

0	Hyaluronan	O
1	treatment	O
2	stimulated	O
3	collagen	B
4	remodeling	O
5	in	O
6	the	O
7	peripheral	O
8	region	O
9	and	O
10	inhibited	O
11	swelling	O
12	of	O
13	the	O
14	meniscus	O
15	repaired	O
16	in	O
17	the	O
18	inner	O
19	region	O
20	.	O

0	Copyright	O
1	2000	O
2	Academic	O
3	Press	O
4	.	O

0	For	O
1	the	O
2	first	O
3	group	O
4	,	O
5	the	O
6	maximal	O
7	decrease	O
8	in	O
9	plasma	O
10	potassium	O
11	elicited	O
12	by	O
13	salbutamol	O
14	was	O
15	0	O
16	.	O
17	80	O
18	+/-	O
19	0	O
20	.	O
21	19	O
22	,	O
23	0	O
24	.	O
25	48	O
26	+/-	O
27	0	O
28	.	O
29	22	O
30	,	O
31	and	O
32	0	O
33	.	O
34	78	O
35	+/-	O
36	0	O
37	.	O
38	46	O
39	mmol	O
40	/	O
41	l	O
42	,	O
43	and	O
44	for	O
45	the	O
46	second	O
47	group	O
48	,	O
49	maximal	O
50	decrement	O
51	was	O
52	1	O
53	.	O
54	31	O
55	+/-	O
56	0	O
57	.	O
58	37	O
59	,	O
60	0	O
61	.	O
62	70	O
63	+/-	O
64	0	O
65	.	O
66	24	O
67	,	O
68	and	O
69	0	O
70	.	O
71	84	O
72	+/-	O
73	0	O
74	.	O
75	17	O
76	mmol	O
77	/	O
78	l	O
79	for	O
80	the	O
81	iv	O
82	,	O
83	po	O
84	,	O
85	and	O
86	it	O
87	routes	O
88	,	O
89	respectively	O
90	.	O

0	The	O
1	human	B
2	insulin	I
3	-	I
4	like	I
5	growth	I
6	factor	I
7	II	I
8	(	O
9	IGF	B
10	-	I
11	II	I
12	)	O
13	gene	O
14	contains	O
15	four	O
16	promoters	O
17	(	O
18	P1	O
19	,	O
20	P2	O
21	,	O
22	P3	O
23	and	O
24	P4	O
25	).	O

0	Diagnosis	O
1	of	O
2	prostatic	O
3	carcinoma	O
4	:	O
5	the	O
6	yield	O
7	of	O
8	serum	B
9	prostate	I
10	specific	I
11	antigen	I
12	,	O
13	digital	O
14	rectal	O
15	examination	O
16	and	O
17	transrectal	O
18	ultrasonography	O
19	.	O

0	No	O
1	difference	O
2	in	O
3	elastin	B
4	peptide	I
5	concentration	O
6	was	O
7	observed	O
8	between	O
9	emphysematous	O
10	patients	O
11	and	O
12	control	O
13	subjects	O
14	(	O
15	mean	O
16	+/-	O
17	SD	O
18	=	O
19	2	O
20	.	O
21	39	O
22	+/-	O
23	1	O
24	.	O
25	18	O
26	micrograms	O
27	/	O
28	ml	O
29	in	O
30	patients	O
31	versus	O
32	2	O
33	.	O
34	55	O
35	+/-	O
36	1	O
37	.	O
38	34	O
39	micrograms	O
40	/	O
41	ml	O
42	in	O
43	policemen	O
44	and	O
45	2	O
46	.	O
47	59	O
48	+/-	O
49	1	O
50	.	O
51	20	O
52	micrograms	O
53	/	O
54	ml	O
55	in	O
56	coal	O
57	miners	O
58	).	O

0	However	O
1	,	O
2	the	O
3	presence	O
4	of	O
5	Tax	B
6	I	I
7	increased	O
8	the	O
9	extent	O
10	and	O
11	altered	O
12	the	O
13	profile	O
14	of	O
15	proteins	O
16	binding	O
17	TRE	B
18	-	I
19	2	I
20	in	O
21	vivo	O
22	.	O

0	1	O
1	("	O
2	long	O
3	method	O
4	")	O
5	and	O
6	the	O
7	HML	O
8	method	O
9	.	O

0	It	O
1	has	O
2	come	O
3	out	O
4	that	O
5	CAEC	O
6	is	O
7	between	O
8	CC	O
9	and	O
10	CIEC	O
11	and	O
12	that	O
13	attacks	O
14	of	O
15	biliary	O
16	fever	O
17	and	O
18	high	O
19	levels	O
20	of	O
21	alkaline	B
22	phosphatase	I
23	and	O
24	transaminases	B
25	in	O
26	the	O
27	serum	O
28	are	O
29	the	O
30	helpful	O
31	findings	O
32	for	O
33	preoperative	O
34	diagnosis	O
35	.	O

0	This	O
1	construct	O
2	,	O
3	termed	O
4	pDeltaCREC	B
5	/	O
6	EBP	B
7	,	O
8	binds	O
9	C	B
10	/	I
11	EBPalpha	I
12	and	O
13	beta	O
14	but	O
15	not	O
16	CREB	B
17	,	O
18	yet	O
19	it	O
20	confers	O
21	a	O
22	nearly	O
23	complete	O
24	glucocorticoid	O
25	response	O
26	when	O
27	transiently	O
28	transfected	O
29	into	O
30	H4IIE	O
31	rat	O
32	hepatoma	O
33	cells	O
34	.	O

0	They	O
1	were	O
2	checked	O
3	for	O
4	anti	O
5	-	I
6	HCV	I
7	(	O
8	anti	B
9	-	I
10	C100	I
11	-	I
12	3	I
13	)	O
14	with	O
15	HCV	O
16	EIA	O
17	kit	O
18	(	O
19	Abbott	O
20	Lab	O
21	.,	O
22	North	O
23	Chicago	O
24	,	O
25	IL	O
26	).	O

0	Tissue	O
1	samples	O
2	were	O
3	obtained	O
4	either	O
5	from	O
6	rats	O
7	that	O
8	had	O
9	been	O
10	exposed	O
11	to	O
12	opiate	O
13	withdrawal	O
14	following	O
15	a	O
16	seven	O
17	day	O
18	morphine	O
19	infusion	O
20	or	O
21	sham	O
22	treated	O
23	control	O
24	subjects	O
25	.	O

0	D	O
1	.	O

0	Students	O
1	,	O
2	parents	O
3	,	O
4	teachers	O
5	and	O
6	hearing	O
7	disorders	O

0	The	O
1	standard	O
2	method	O
3	for	O
4	calculating	O
5	the	O
6	composite	O
7	score	O
8	on	O
9	the	O
10	S	O
11	-	O
12	B	O
13	IV	O
14	excludes	O
15	subtests	O
16	with	O
17	a	O
18	raw	O
19	score	O
20	of	O
21	0	O
22	,	O
23	which	O
24	overestimates	O
25	cognitive	O
26	functioning	O
27	in	O
28	young	O
29	biologically	O
30	high	O
31	risk	O
32	children	O
33	.	O

0	CodY	B
1	does	O
2	not	O
3	have	O
4	any	O
5	homologues	O
6	in	O
7	the	O
8	data	O
9	-	O
10	bases	O
11	.	O

0	Members	O
1	of	O
2	the	O
3	titin	B
4	/	I
5	myosin	I
6	light	I
7	chain	I
8	kinase	I
9	family	I
10	play	O
11	an	O
12	essential	O
13	role	O
14	in	O
15	the	O
16	organization	O
17	of	O
18	the	O
19	actin	B
20	/	O
21	myosin	B
22	cytoskeleton	O
23	,	O
24	especially	O
25	in	O
26	sarcomere	O
27	assembly	O
28	and	O
29	function	O
30	.	O

0	However	O
1	,	O
2	activation	O
3	of	O
4	the	O
5	cAMP	O
6	pathway	O
7	,	O
8	which	O
9	is	O
10	known	O
11	to	O
12	regulate	O
13	inhibin	B
14	alpha	I
15	expression	O
16	,	O
17	greatly	O
18	enhanced	O
19	the	O
20	actions	O
21	of	O
22	SF	B
23	-	I
24	1	I
25	.	O

0	The	O
1	4	O
2	-	O
3	AP	O
4	(	O
5	4	O
6	-	O
7	20	O
8	mM	O
9	)	O
10	effect	O
11	resulted	O
12	in	O
13	a	O
14	decrease	O
15	of	O
16	the	O
17	sensory	O
18	activity	O
19	,	O
20	which	O
21	was	O
22	fully	O
23	restored	O
24	by	O
25	TEA	O
26	or	O
27	Ba2	O
28	+.	O

0	The	O
1	recruitment	O
2	of	O
3	constitutively	O
4	phosphorylated	O
5	p185	B
6	(	O
7	neu	B
8	)	O
9	and	O
10	the	O
11	activated	O
12	mitogenic	O
13	pathway	O
14	proteins	O
15	to	O
16	this	O
17	membrane	O
18	-	O
19	microfilament	O
20	interaction	O
21	site	O
22	provides	O
23	a	O
24	physical	O
25	model	O
26	for	O
27	integrating	O
28	the	O
29	assembly	O
30	of	O
31	the	O
32	mitogenic	O
33	pathway	O
34	with	O
35	the	O
36	transmission	O
37	of	O
38	growth	B
39	factor	I
40	signal	O
41	to	O
42	the	O
43	cytoskeleton	O
44	.	O

0	Interplane	O
1	coupling	O
2	in	O
3	the	O
4	superconductor	O
5	Y2Ba4Cu7O15	O
6	as	O
7	revealed	O
8	by	O
9	NQR	O
10	spin	O
11	-	O
12	echo	O
13	double	O
14	resonance	O
15	.	O

0	Of	O
1	the	O
2	three	O
3	known	O
4	C	B
5	/	I
6	EBP	I
7	family	I
8	inhibitors	O
9	,	O
10	Ig	B
11	/	O
12	EBP	B
13	,	O
14	LIP	B
15	and	O
16	CHOP	B
17	-	I
18	10	I
19	,	O
20	only	O
21	Ig	B
22	/	O
23	EBP	B
24	is	O
25	ubiquitously	O
26	expressed	O
27	.	O

0	The	O
1	importance	O
2	of	O
3	these	O
4	sites	O
5	for	O
6	transcriptional	O
7	activation	O
8	was	O
9	studied	O
10	by	O
11	site	O
12	-	O
13	directed	O
14	mutagenesis	O
15	followed	O
16	by	O
17	promoter	O
18	function	O
19	analysis	O
20	of	O
21	the	O
22	mutants	O
23	with	O
24	a	O
25	chloramphenicol	B
26	acetyltransferase	I
27	reporter	O
28	system	O
29	.	O

0	The	O
1	ability	O
2	of	O
3	SMRT	B
4	to	O
5	associate	O
6	with	O
7	these	O
8	transcription	O
9	factors	O
10	and	O
11	thereby	O
12	to	O
13	mediate	O
14	repression	O
15	is	O
16	strongly	O
17	inhibited	O
18	by	O
19	activation	O
20	of	O
21	tyrosine	B
22	kinase	I
23	signaling	O
24	pathways	O
25	,	O
26	such	O
27	as	O
28	that	O
29	represented	O
30	by	O
31	the	O
32	epidermal	B
33	growth	I
34	factor	I
35	receptor	I
36	.	O

0	A	O
1	candidate	O
2	gene	O
3	for	O
4	Bcg	B
5	,	O
6	designated	O
7	natural	B
8	resistance	I
9	-	I
10	associated	I
11	macrophage	I
12	protein	I
13	(	O
14	Nramp	B
15	),	O
16	has	O
17	been	O
18	isolated	O
19	and	O
20	shown	O
21	to	O
22	encode	O
23	a	O
24	novel	O
25	macrophage	O
26	-	O
27	specific	O
28	membrane	O
29	protein	O
30	,	O
31	which	O
32	is	O
33	altered	O
34	in	O
35	susceptible	O
36	animals	O
37	.	O

0	Finally	O
1	,	O
2	we	O
3	demonstrate	O
4	that	O
5	C	B
6	/	I
7	EBP	I
8	alpha	I
9	can	O
10	also	O
11	active	O
12	the	O
13	GM	B
14	-	I
15	CSF	I
16	receptor	I
17	alpha	I
18	promoter	I
19	in	O
20	nonmyeloid	O
21	cells	O
22	.	O

0	Sixty	O
1	days	O
2	after	O
3	the	O
4	intervention	O
5	,	O
6	twitch	O
7	and	O
8	tetanic	O
9	tensions	O
10	remained	O
11	dependent	O
12	upon	O
13	the	O
14	extracellular	O
15	Ca2	O
16	+	O
17	concentration	O
18	([	O
19	Ca	O
20	]	O
21	o	O
22	)	O
23	both	O
24	in	O
25	groups	O
26	A	O
27	and	O
28	B	O
29	.	O

0	Key	O
1	areas	O
2	of	O
3	the	O
4	selection	O
5	process	O
6	including	O
7	medical	O
8	and	O
9	surgical	O
10	alternatives	O
11	to	O
12	transplantation	O
13	,	O
14	the	O
15	composition	O
16	of	O
17	the	O
18	transplant	O
19	work	O
20	-	O
21	up	O
22	,	O
23	specific	O
24	inclusion	O
25	criteria	O
26	as	O
27	well	O
28	as	O
29	specific	O
30	psychosocial	O
31	factors	O
32	and	O
33	specific	O
34	disease	O
35	etiologies	O
36	and	O
37	co	O
38	-	O
39	morbidities	O
40	that	O
41	might	O
42	represent	O
43	contraindications	O
44	were	O
45	extensively	O
46	reviewed	O
47	.	O

0	In	O
1	general	O
2	lookback	O
3	,	O
4	all	O
5	patients	O
6	who	O
7	received	O
8	blood	O
9	before	O
10	being	O
11	tested	O
12	for	O
13	hepatitis	O
14	C	O
15	are	O
16	advised	O
17	to	O
18	undergo	O
19	testing	O
20	.	O

0	However	O
1	,	O
2	unlike	O
3	Bcl	B
4	-	I
5	2	I
6	and	O
7	the	O
8	E1B	B
9	19K	I
10	proteins	I
11	,	O
12	which	O
13	completely	O
14	block	O
15	apoptosis	O
16	but	O
17	not	O
18	p53	B
19	-	O
20	dependent	O
21	growth	O
22	arrest	O
23	,	O
24	H	B
25	-	I
26	ras	I
27	expression	O
28	permitted	O
29	DNA	O
30	synthesis	O
31	and	O
32	cell	O
33	proliferation	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	high	O
39	levels	O
40	of	O
41	wild	B
42	-	I
43	type	I
44	p53	I
45	.	O

0	Such	O
1	mutations	O
2	are	O
3	thought	O
4	to	O
5	exert	O
6	their	O
7	dominant	O
8	phenotype	O
9	by	O
10	sequestration	O
11	of	O
12	the	O
13	guanine	B
14	nucleotide	I
15	exchange	I
16	factor	I
17	(	O
18	GNEF	B
19	).	O

0	T	O
1	-	O
2	cell	O
3	hybridomas	O
4	,	O
5	thymocytes	O
6	,	O
7	and	O
8	T	O
9	cells	O
10	can	O
11	be	O
12	induced	O
13	to	O
14	undergo	O
15	apoptotic	O
16	cell	O
17	death	O
18	by	O
19	activation	O
20	through	O
21	the	O
22	T	B
23	-	I
24	cell	I
25	receptor	I
26	.	O

0	3	O
1	'	O
2	RNA	O
3	boundary	O
4	experiments	O
5	indicate	O
6	that	O
7	the	O
8	5	O
9	'	O
10	structure	O
11	reduces	O
12	the	O
13	number	O
14	of	O
15	(	O
16	G	O
17	/	O
18	U	O
19	)	O
20	AG	O
21	repeats	O
22	required	O
23	for	O
24	stable	O
25	TRAP	B
26	-	O
27	trp	B
28	leader	O
29	RNA	O
30	association	O
31	.	O

0	Dopamine	B
1	beta	I
2	-	I
3	hydroxylase	I
4	(	O
5	DBH	B
6	)	O
7	catalyzes	O
8	the	O
9	conversion	O
10	of	O
11	dopamine	O
12	to	O
13	noradrenaline	O
14	and	O
15	is	O
16	selectively	O
17	expressed	O
18	in	O
19	noradrenergic	O
20	and	O
21	adrenergic	O
22	neurons	O
23	and	O
24	neuroendocrine	O
25	cells	O
26	.	O

0	By	O
1	150	O
2	minutes	O
3	after	O
4	Cr2O3	O
5	inhalation	O
6	,	O
7	FEV1	O
8	.	O
9	0	O
10	had	O
11	decreased	O
12	by	O
13	32	O
14	%.	O

0	Bacteriostatic	O
1	and	O
2	bacteriacidal	O
3	activity	O
4	of	O
5	hydroxy	O
6	-	O
7	9	O
8	ellipticine	O
9	in	O
10	vitro	O

0	Control	O
1	subjects	O
2	'	O
3	evoked	O
4	potentials	O
5	(	O
6	EPs	O
7	)	O
8	were	O
9	characterized	O
10	by	O
11	an	O
12	initial	O
13	positivity	O
14	in	O
15	the	O
16	90	O
17	-	O
18	140	O
19	ms	O
20	range	O
21	(	O
22	P1	O
23	)	O
24	at	O
25	the	O
26	temporo	O
27	-	O
28	occipital	O
29	site	O
30	.	O

0	APOE	O
1	-	O
2	epsilon4	O
3	count	O
4	predicts	O
5	age	O
6	when	O
7	prevalence	O
8	of	O
9	AD	O
10	increases	O
11	,	O
12	then	O
13	declines	O
14	:	O
15	the	O
16	Cache	O
17	County	O
18	Study	O
19	.	O

0	Trial	O
1	treatment	O
2	of	O
3	schizophrenia	O
4	with	O
5	des	B
6	-	I
7	Tyr	I
8	-	I
9	gamma	I
10	-	I
11	endorphin	I

0	Extracellular	O
1	fibril	O
2	formation	O
3	by	O
4	neuroglial	O
5	cells	O
6	at	O
7	the	O
8	vitreoretinal	O
9	junction	O
10	of	O
11	the	O
12	human	O
13	eye	O
14	.	O

0	The	O
1	promoter	O
2	was	O
3	stimulated	O
4	8	O
5	-	O
6	20	O
7	-	O
8	fold	O
9	by	O
10	phorbol	O
11	esters	O
12	accounting	O
13	for	O
14	the	O
15	previously	O
16	observed	O
17	transcriptional	O
18	activation	O
19	of	O
20	protein	B
21	kinase	I
22	C	I
23	beta	I
24	.	O

0	Young	O
1	CD	O
2	-	O
3	1	O
4	mice	O
5	,	O
6	4	O
7	days	O
8	old	O
9	,	O
10	exposed	O
11	to	O
12	0	O
13	.	O
14	1	O
15	%	O
16	nicotine	O
17	sulfate	O
18	on	O
19	gestational	O
20	days	O
21	6	O
22	-	O
23	20	O
24	were	O
25	compared	O
26	with	O
27	untreated	O
28	pups	O
29	of	O
30	the	O
31	same	O
32	age	O
33	to	O
34	determine	O
35	its	O
36	effect	O
37	on	O
38	the	O
39	development	O
40	of	O
41	mandibular	O
42	first	O
43	molars	O
44	.	O

0	High	O
1	fibrinogen	B
2	levels	O
3	could	O
4	thus	O
5	be	O
6	a	O
7	risk	O
8	for	O
9	perioperative	O
10	thrombosis	O
11	.	O

0	This	O
1	scFv	B
2	was	O
3	therefore	O
4	used	O
5	as	O
6	control	O
7	in	O
8	experiments	O
9	where	O
10	another	O
11	anti	B
12	-	I
13	Ras	I
14	scFv	I
15	(	O
16	Y259	B
17	scFv	I
18	,	O
19	derived	O
20	from	O
21	the	O
22	neutralizing	O
23	anti	B
24	-	I
25	Ras	I
26	mAb	I
27	Y13	I
28	-	I
29	259	I
30	)	O
31	blocked	O
32	the	O
33	Ras	B
34	pathway	O
35	in	O
36	vitro	O
37	and	O
38	led	O
39	to	O
40	tumor	O
41	regression	O
42	in	O
43	a	O
44	nude	O
45	mouse	O
46	model	O
47	[	O
48	Cochet	O
49	,	O
50	O	O
51	.,	O
52	Kenigsberg	O
53	,	O
54	M	O
55	.,	O
56	Delumeau	O
57	,	O
58	I	O
59	.,	O
60	Virone	O
61	-	O
62	Oddos	O
63	,	O
64	A	O
65	.,	O
66	Multon	O
67	,	O
68	M	O
69	.	O
70	C	O
71	.,	O
72	Fridman	O
73	,	O
74	W	O
75	.	O
76	H	O
77	.,	O
78	Schweighoffer	O
79	,	O
80	F	O
81	.,	O
82	Teillaud	O
83	,	O
84	J	O
85	.	O
86	L	O
87	.,	O
88	Tocque	O
89	,	O
90	B	O
91	.,	O
92	1998	O
93	.	O

0	As	O
1	a	O
2	result	O
3	,	O
4	the	O
5	subendocardial	O
6	/	O
7	subepicardial	O
8	blood	O
9	flow	O
10	ratio	O
11	(	O
12	ENDO	O
13	/	O
14	EPI	O
15	)	O
16	increased	O
17	from	O
18	0	O
19	.	O
20	44	O
21	+/-	O
22	0	O
23	.	O
24	09	O
25	during	O
26	control	O
27	stenosis	O
28	to	O
29	0	O
30	.	O
31	85	O
32	+/-	O
33	0	O
34	.	O
35	13	O
36	after	O
37	ITF	O
38	1129	O
39	(	O
40	10	O
41	micrograms	O
42	/	O
43	kg	O
44	/	O
45	min	O
46	i	O
47	.	O
48	v	O
49	.)	O
50	and	O
51	to	O
52	0	O
53	.	O
54	81	O
55	+/-	O
56	0	O
57	.	O
58	12	O
59	after	O
60	NTG	O
61	.	O

0	In	O
1	this	O
2	way	O
3	it	O
4	is	O
5	possible	O
6	to	O
7	simulate	O
8	the	O
9	growth	O
10	function	O
11	of	O
12	the	O
13	embryofetal	O
14	curve	O
15	of	O
16	the	O
17	length	O
18	'	O
19	increase	O
20	of	O
21	man	O
22	and	O
23	the	O
24	curve	O
25	of	O
26	the	O
27	mass	O
28	'	O
29	increase	O
30	of	O
31	rat	O
32	.	O

0	Recent	O
1	studies	O
2	have	O
3	demonstrated	O
4	that	O
5	the	O
6	activated	O
7	GH	B
8	receptor	I
9	can	O
10	stimulate	O
11	Stat1	B
12	,	O
13	a	O
14	cytoplasmic	O
15	transcription	O
16	factor	O
17	that	O
18	becomes	O
19	tyrosine	O
20	phosphorylated	O
21	and	O
22	translocates	O
23	to	O
24	the	O
25	nucleus	O
26	,	O
27	where	O
28	it	O
29	can	O
30	interact	O
31	with	O
32	specific	O
33	DNA	O
34	sequences	O
35	to	O
36	modulate	O
37	gene	O
38	expression	O
39	.	O

0	The	O
1	final	O
2	screening	O
3	yielded	O
4	a	O
5	clone	O
6	containing	O
7	a	O
8	2	O
9	kilobase	O
10	(	O
11	kb	O
12	)	O
13	insert	O
14	.	O

0	The	O
1	human	B
2	SHBG	I
3	proximal	I
4	promoter	I
5	was	O
6	analyzed	O
7	by	O
8	DNase	B
9	I	I
10	footprinting	O
11	,	O
12	and	O
13	the	O
14	functional	O
15	significance	O
16	of	O
17	6	O
18	footprinted	O
19	regions	O
20	(	O
21	FP1	O
22	-	O
23	FP6	O
24	)	O
25	within	O
26	the	O
27	proximal	O
28	promoter	O
29	was	O
30	studied	O
31	in	O
32	human	O
33	HepG2	O
34	hepatoblastoma	O
35	cells	O
36	.	O

0	These	O
1	results	O
2	suggest	O
3	that	O
4	HAC1	B
5	may	O
6	also	O
7	be	O
8	one	O
9	of	O
10	the	O
11	meiotic	O
12	genes	O
13	.	O

0	Both	O
1	inhaled	O
2	and	O
3	superfused	O
4	isoflurane	O
5	dilated	O
6	the	O
7	baseline	O
8	vein	O
9	diameter	O
10	before	O
11	stimulation	O
12	.	O

0	LON	O
1	-	O
2	72	O
3	(	O
4	34	O
5	isolates	O
6	),	O
7	LON	O
8	-	O
9	73	O
10	(	O
11	1	O
12	),	O
13	LON	O
14	-	O
15	71	O
16	(	O
17	2	O
18	)	O
19	and	O
20	LON	O
21	-	O
22	10	O
23	(	O
24	2	O
25	)	O
26	were	O
27	found	O
28	at	O
29	altitudes	O
30	around	O
31	2000	O
32	m	O
33	,	O
34	3	O
35	of	O
36	them	O
37	in	O
38	a	O
39	single	O
40	village	O
41	.	O

0	The	O
1	recombinant	O
2	purified	O
3	protein	O
4	expressed	O
5	in	O
6	the	O
7	baculovirus	O
8	system	O
9	had	O
10	an	O
11	approximate	O
12	molecular	O
13	size	O
14	20	O
15	kDa	O
16	with	O
17	amino	O
18	-	O
19	terminal	O
20	sequence	O
21	of	O
22	AVQGP	O
23	.	O

0	On	O
1	the	O
2	basis	O
3	of	O
4	serum	O
5	alpha1AT	B
6	quantitation	O
7	,	O
8	newborn	O
9	infants	O
10	may	O
11	be	O
12	separated	O
13	into	O
14	two	O
15	groups	O
16	,	O
17	characterized	O
18	respectively	O
19	by	O
20	concentrations	O
21	above	O
22	or	O
23	below	O
24	150	O
25	mg	O
26	%.	O

0	To	O
1	study	O
2	retinoid	O
3	signalling	O
4	in	O
5	zebrafish	O
6	embryos	O
7	,	O
8	we	O
9	developed	O
10	a	O
11	novel	O
12	method	O
13	to	O
14	detect	O
15	endogenous	O
16	retinoids	O
17	in	O
18	situ	O
19	in	O
20	embryos	O
21	,	O
22	using	O
23	a	O
24	fusion	O
25	protein	O
26	of	O
27	the	O
28	ligand	O
29	inducible	O
30	transactivation	O
31	domain	O
32	of	O
33	a	O
34	retinoic	B
35	acid	I
36	receptor	I
37	and	O
38	a	O
39	heterologous	O
40	DNA	O
41	binding	O
42	domain	O
43	.	O

0	The	O
1	beta	O
2	chain	O
3	contains	O
4	five	O
5	potential	O
6	N	O
7	-	O
8	linked	O
9	glycosylation	O
10	sites	O
11	,	O
12	and	O
13	endoglycosidase	B
14	digestion	O
15	suggested	O
16	that	O
17	the	O
18	beta	O
19	chain	O
20	contained	O
21	multiple	O
22	complex	O
23	carbohydrate	O
24	side	O
25	chains	O
26	.	O

0	CONCLUSION	O
1	:	O
2	The	O
3	study	O
4	demonstrates	O
5	that	O
6	transvaginal	O
7	ultrasonography	O
8	has	O
9	an	O
10	efficiency	O
11	of	O
12	88	O
13	%	O
14	in	O
15	differentiating	O
16	endometriomas	O
17	from	O
18	other	O
19	ovarian	O
20	masses	O
21	with	O
22	a	O
23	specificity	O
24	of	O
25	90	O
26	%.	O

0	Its	O
1	interaction	O
2	with	O
3	RFX5	B
4	and	O
5	RFXAP	B
6	is	O
7	essential	O
8	for	O
9	binding	O
10	of	O
11	the	O
12	RFX	B
13	complex	I
14	to	O
15	MHC	B
16	-	I
17	II	I
18	promoters	I
19	.	O

0	Four	O
1	patients	O
2	(	O
3	group	O
4	1	O
5	)	O
6	had	O
7	type	O
8	I	O
9	basement	O
10	membrane	O
11	nephropathy	O
12	,	O
13	characterized	O
14	by	O
15	marked	O
16	thickening	O
17	and	O
18	lamellation	O
19	of	O
20	the	O
21	basement	O
22	membrane	O
23	in	O
24	a	O
25	pattern	O
26	resembling	O
27	that	O
28	of	O
29	Alport	O
30	'	O
31	s	O
32	syndrome	O
33	.	O

0	Furthermore	O
1	the	O
2	median	O
3	increase	O
4	in	O
5	cyclosporine	O
6	DR	O
7	/	O
8	C	O
9	(	O
10	SS	O
11	trough	O
12	)	O
13	was	O
14	18	O
15	l	O
16	h	O
17	-	O
18	1	O
19	(-	O
20	3	O
21	.	O
22	1	O
23	to	O
24	42	O
25	.	O
26	1	O
27	l	O
28	h	O
29	-	O
30	1	O
31	,	O
32	interquartile	O
33	range	O
34	).	O

0	There	O
1	is	O
2	no	O
3	TATA	O
4	box	O
5	appropriately	O
6	spaced	O
7	upstream	O
8	from	O
9	the	O
10	transcription	O
11	initiation	O
12	site	O
13	.	O

0	This	O
1	5	O
2	'	O
3	splice	O
4	site	O
5	sequence	O
6	was	O
7	required	O
8	for	O
9	enhanced	O
10	polyadenylation	O
11	and	O
12	was	O
13	recognized	O
14	by	O
15	both	O
16	U1	B
17	small	I
18	nuclear	I
19	ribonucleoproteins	I
20	(	O
21	snRNPs	O
22	)	O
23	and	O
24	alternative	O
25	splicing	O
26	factor	O
27	/	O
28	splicing	I
29	factor	I
30	2	I
31	(	O
32	ASF	B
33	/	O
34	SF2	B
35	).	O

0	The	O
1	receptor	O
2	for	O
3	hyaluronan	B
4	mediated	I
5	motility	I
6	(	O
7	RHAMM	B
8	)	O
9	gene	O
10	expression	O
11	is	O
12	markedly	O
13	elevated	O
14	in	O
15	fibrosarcomas	O
16	exposed	O
17	to	O
18	transforming	B
19	growth	I
20	factor	I
21	-	I
22	beta1	I
23	(	O
24	TGF	B
25	-	I
26	beta1	I
27	).	O

0	The	O
1	effects	O
2	of	O
3	mean	O
4	luminance	O
5	were	O
6	also	O
7	measured	O
8	and	O
9	a	O
10	general	O
11	expression	O
12	that	O
13	would	O
14	take	O
15	them	O
16	into	O
17	account	O
18	was	O
19	derived	O
20	.	O

0	The	O
1	clinical	O
2	picture	O
3	of	O
4	the	O
5	disease	O
6	was	O
7	significantly	O
8	different	O
9	from	O
10	anthropogenic	O
11	cutaneous	O
12	leishmaniasis	O
13	caused	O
14	by	O
15	L	O
16	.	O
17	tropica	O
18	but	O
19	similar	O
20	to	O
21	cutaneous	O
22	patterns	O
23	caused	O
24	by	O
25	L	O
26	.	O
27	infantum	O
28	which	O
29	was	O
30	a	O
31	prevalent	O
32	pattern	O
33	in	O
34	the	O
35	southern	O
36	France	O
37	.	O

0	Serum	B
1	antibody	I
2	titre	I
3	was	O
4	not	O
5	significantly	O
6	associated	O
7	with	O
8	the	O
9	recurrence	O
10	rate	O
11	or	O
12	the	O
13	duration	O
14	of	O
15	infection	O
16	.	O

0	Fourteen	O
1	healthy	O
2	male	O
3	volunteers	O
4	completed	O
5	the	O
6	study	O
7	.	O

0	Disruption	O
1	of	O
2	the	O
3	IRA2	B
4	gene	I
5	resulted	O
6	in	O
7	(	O
8	i	O
9	)	O
10	increased	O
11	sensitivity	O
12	to	O
13	heat	O
14	shock	O
15	and	O
16	nitrogen	O
17	starvation	O
18	,	O
19	(	O
20	ii	O
21	)	O
22	sporulation	O
23	defects	O
24	,	O
25	and	O
26	(	O
27	iii	O
28	)	O
29	suppression	O
30	of	O
31	the	O
32	lethality	O
33	of	O
34	the	O
35	cdc25	B
36	mutant	I
37	.	O

0	Each	O
1	recombinant	O
2	product	O
3	was	O
4	a	O
5	fusion	O
6	protein	O
7	with	O
8	a	O
9	B	O
10	domain	O
11	of	O
12	Staphylococcal	B
13	protein	I
14	A	I
15	(	O
16	SPA	B
17	).	O

0	Furthermore	O
1	,	O
2	analysis	O
3	of	O
4	the	O
5	E2	B
6	proteins	I
7	present	O
8	in	O
9	various	O
10	cell	O
11	lines	O
12	harboring	O
13	specific	O
14	BPV	B
15	-	I
16	1	I
17	mutants	I
18	,	O
19	including	O
20	the	O
21	2558	O
22	acceptor	O
23	mutant	O
24	,	O
25	proves	O
26	that	O
27	alternate	O
28	modes	O
29	of	O
30	E2	B
31	expression	O
32	exist	O
33	.	O

0	Recessive	O
1	lethal	O
2	mutations	O
3	were	O
4	isolated	O
5	based	O
6	upon	O
7	failure	O
8	to	O
9	complement	O
10	the	O
11	recessive	O
12	lethality	O
13	of	O
14	Df	B
15	(	I
16	3L	I
17	)	I
18	RR2	I
19	,	O
20	a	O
21	deletion	O
22	of	O
23	the	O
24	DRE	O
25	region	O
26	that	O
27	removes	O
28	16	O
29	-	O
30	18	O
31	polytene	O
32	chromosome	O
33	bands	O
34	.	O

0	In	O
1	vivo	O
2	,	O
3	selective	O
4	activation	O
5	of	O
6	SAPKs	B
7	stimulates	O
8	formation	O
9	of	O
10	the	O
11	ternary	O
12	complex	O
13	containing	O
14	Elk	B
15	-	I
16	1	I
17	,	O
18	serum	B
19	response	I
20	factor	I
21	and	O
22	the	O
23	serum	O
24	response	O
25	element	O
26	,	O
27	and	O
28	enhances	O
29	Elk	B
30	-	I
31	1	I
32	-	O
33	dependent	O
34	transcription	O
35	.	O

0	(	O
1	3	O
2	)	O
3	This	O
4	effect	O
5	occurs	O
6	without	O
7	removing	O
8	TRs	O
9	from	O
10	the	O
11	TRE	O
12	.	O

0	The	O
1	dichloromethane	O
2	is	O
3	removed	O
4	,	O
5	mobile	O
6	phase	O
7	solvent	O
8	is	O
9	added	O
10	,	O
11	and	O
12	aliquots	O
13	are	O
14	injected	O
15	onto	O
16	a	O
17	PRP	O
18	-	O
19	1	O
20	liquid	O
21	chromatographic	O
22	column	O
23	;	O
24	fluazifop	O
25	acid	O
26	is	O
27	separated	O
28	from	O
29	coextracted	O
30	compounds	O
31	and	O
32	detected	O
33	at	O
34	an	O
35	applied	O
36	potential	O
37	of	O
38	+	O
39	1	O
40	.	O
41	25	O
42	V	O
43	,	O
44	using	O
45	an	O
46	amperometric	O
47	electrochemical	O
48	detector	O
49	in	O
50	the	O
51	oxidation	O
52	mode	O
53	.	O

0	METHODS	O
1	:	O
2	We	O
3	retrospectively	O
4	reviewed	O
5	242	O
6	adult	O
7	cadaveric	O
8	renal	O
9	transplant	O
10	recipients	O
11	treated	O
12	between	O
13	11	O
14	/	O
15	91	O
16	and	O
17	5	O
18	/	O
19	97	O
20	.	O

0	Splicing	O
1	of	O
2	the	O
3	K	B
4	-	O
5	SAM	O
6	alternative	O
7	exon	O
8	of	O
9	the	O
10	fibroblast	B
11	growth	I
12	factor	I
13	receptor	I
14	2	I
15	gene	I
16	is	O
17	heavily	O
18	dependent	O
19	on	O
20	the	O
21	U	O
22	-	O
23	rich	O
24	sequence	O
25	IAS1	O
26	lying	O
27	immediately	O
28	downstream	O
29	from	O
30	its	O
31	5	O
32	'	O
33	splice	O
34	site	O
35	.	O

0	The	O
1	MMA	B
2	,	O
3	DMA	B
4	,	O
5	and	O
6	TMA	B
7	methyltransferases	I
8	are	O
9	not	O
10	homologs	O
11	;	O
12	however	O
13	,	O
14	like	O
15	the	O
16	MMA	B
17	methyltransferase	I
18	gene	I
19	,	O
20	the	O
21	genes	O
22	encoding	O
23	the	O
24	DMA	B
25	and	O
26	TMA	B
27	methyltransferases	I
28	each	O
29	contain	O
30	a	O
31	single	O
32	in	O
33	-	O
34	frame	O
35	amber	O
36	codon	O
37	.	O

0	Identification	O
1	of	O
2	RNase	B
3	T	I
4	as	O
5	a	O
6	high	O
7	-	O
8	copy	O
9	suppressor	O
10	of	O
11	the	O
12	UV	O
13	sensitivity	O
14	associated	O
15	with	O
16	single	B
17	-	I
18	strand	I
19	DNA	I
20	exonuclease	I
21	deficiency	O
22	in	O
23	Escherichia	O
24	coli	O
25	.	O

0	Here	O
1	we	O
2	show	O
3	that	O
4	a	O
5	novel	O
6	isoform	O
7	of	O
8	Rapl	B
9	GTPase	I
10	-	I
11	activating	I
12	protein	I
13	,	O
14	called	O
15	rap1GAPII	B
16	,	O
17	binds	O
18	specifically	O
19	to	O
20	the	O
21	alpha	O
22	-	O
23	subunits	O
24	of	O
25	the	O
26	G	B
27	(	I
28	i	I
29	)	I
30	family	I
31	of	O
32	heterotrimeric	B
33	G	I
34	-	I
35	proteins	I
36	.	O

0	Cloning	O
1	of	O
2	a	O
3	human	O
4	cDNA	O
5	encoding	O
6	a	O
7	CDC2	B
8	-	I
9	related	I
10	kinase	I
11	by	O
12	complementation	O
13	of	O
14	a	O
15	budding	B
16	yeast	I
17	cdc28	I
18	mutation	I
19	.	O

0	Here	O
1	the	O
2	cloning	O
3	and	O
4	molecular	O
5	analysis	O
6	of	O
7	the	O
8	Zm	B
9	-	I
10	ERabp1	I
11	,	O
12	Zm	B
13	-	I
14	ERabp4	I
15	,	O
16	and	O
17	Zm	B
18	-	I
19	ERabp5	I
20	genes	I
21	is	O
22	presented	O
23	.	O

0	Roizman	O
1	,	O
2	J	O
3	.	O

0	Previous	O
1	work	O
2	has	O
3	shown	O
4	that	O
5	spleen	B
6	necrosis	O
7	virus	O
8	(	O
9	SNV	O
10	)	O
11	long	O
12	terminal	O
13	repeats	O
14	(	O
15	LTRs	O
16	)	O
17	are	O
18	associated	O
19	with	O
20	Rex	B
21	/	O
22	Rex	B
23	-	O
24	responsive	O
25	element	O
26	-	O
27	independent	O
28	expression	O
29	of	O
30	bovine	O
31	leukemia	O
32	virus	O
33	RNA	O
34	and	O
35	supports	O
36	the	O
37	hypothesis	O
38	that	O
39	SNV	B
40	RNA	I
41	contains	O
42	a	O
43	cis	O
44	-	O
45	acting	O
46	element	O
47	that	O
48	interacts	O
49	with	O
50	cellular	B
51	Rex	B
52	-	I
53	like	I
54	proteins	I
55	.	O

0	Two	O
1	potential	O
2	regulatory	O
3	sequences	O
4	for	O
5	DNA	O
6	binding	O
7	proteins	O
8	were	O
9	found	O
10	in	O
11	the	O
12	non	O
13	-	O
14	coding	O
15	5	O
16	'	O
17	region	O
18	:	O
19	a	O
20	HAP2	B
21	/	O
22	HAP3	B
23	consensus	O
24	recognition	O
25	sequence	O
26	at	O
27	nucleotide	O
28	-	O
29	154	O
30	and	O
31	a	O
32	BAF1	B
33	consensus	O
34	recognition	O
35	sequence	O
36	at	O
37	nucleotide	O
38	-	O
39	136	O
40	.	O

0	The	O
1	ubiquitously	O
2	expressed	O
3	hypoxia	B
4	-	I
5	inducible	I
6	factor	I
7	-	I
8	1	I
9	(	O
10	HIF	B
11	-	I
12	1	I
13	)	O
14	is	O
15	involved	O
16	in	O
17	expression	O
18	of	O
19	a	O
20	large	O
21	number	O
22	of	O
23	oxygen	O
24	-	O
25	regulated	O
26	genes	O
27	.	O

0	A	O
1	convenient	O
2	measure	O
3	of	O
4	this	O
5	impairment	O
6	may	O
7	be	O
8	obtained	O
9	using	O
10	the	O
11	ratio	O
12	of	O
13	urine	O
14	volume	O
15	(	O
16	V	O
17	)	O
18	divided	O
19	by	O
20	lithium	O
21	clearance	O
22	(	O
23	CLi	O
24	).	O

0	All	O
1	patients	O
2	were	O
3	evaluable	O
4	for	O
5	toxicity	O
6	and	O
7	9	O
8	for	O
9	response	O
10	.	O

0	Kinetic	O
1	experiments	O
2	revealed	O
3	that	O
4	within	O
5	10	O
6	min	O
7	this	O
8	radiolabeled	O
9	precursor	O
10	protein	O
11	was	O
12	converted	O
13	in	O
14	HL	O
15	-	O
16	60	O
17	cells	O
18	into	O
19	an	O
20	Mr	O
21	approximately	O
22	150	O
23	,	O
24	000	O
25	chondroitin	O
26	sulfate	O
27	proteoglycan	O
28	intermediate	O
29	.	O

0	Strategic	O
1	change	O
2	in	O
3	the	O
4	NHS	O
5	.	O

0	One	O
1	R	O
2	-	O
3	EST	O
4	and	O
5	one	O
6	Pto	B
7	-	O
8	like	O
9	sequence	O
10	each	O
11	mapped	O
12	to	O
13	two	O
14	locations	O
15	.	O

0	Tctex	B
1	-	I
2	1	I
3	binding	O
4	required	O
5	the	O
6	first	O
7	19	O
8	amino	O
9	acids	O
10	of	O
11	Fyn	B
12	and	O
13	integrity	O
14	of	O
15	two	O
16	lysine	O
17	residues	O
18	within	O
19	this	O
20	sequence	O
21	that	O
22	were	O
23	previously	O
24	shown	O
25	to	O
26	be	O
27	important	O
28	for	O
29	Fyn	B
30	interactions	O
31	with	O
32	the	O
33	immunoreceptor	O
34	tyrosine	O
35	-	O
36	based	O
37	activation	O
38	motifs	O
39	(	O
40	ITAMs	O
41	)	O
42	of	O
43	lymphocyte	B
44	Ag	I
45	receptors	I
46	.	O

0	8	O
1	%	O
2	(	O
3	95	O
4	%	O
5	CI	O
6	,	O
7	21	O
8	.	O
9	3	O
10	-	O
11	44	O
12	.	O
13	3	O
14	%).	O

0	Partial	O
1	correction	O
2	of	O
3	anemia	O
4	with	O
5	recombinant	B
6	human	B
7	erythropoietin	I
8	likely	O
9	reduces	O
10	left	O
11	ventricular	O
12	mass	O
13	and	O
14	volume	O
15	.	O

0	These	O
1	results	O
2	further	O
3	support	O
4	an	O
5	important	O
6	role	O
7	for	O
8	CBF2	B
9	in	O
10	mediating	O
11	EBNA2	B
12	transactivation	O
13	;	O
14	they	O
15	identify	O
16	the	O
17	hnRNP	B
18	protein	I
19	AUF1	I
20	as	O
21	a	O
22	major	O
23	component	O
24	of	O
25	CBF2	B
26	and	O
27	are	O
28	also	O
29	the	O
30	first	O
31	evidence	O
32	of	O
33	a	O
34	cis	O
35	-	O
36	acting	O
37	sequence	O
38	other	O
39	than	O
40	a	O
41	CBF1	B
42	binding	I
43	element	I
44	that	O
45	is	O
46	able	O
47	to	O
48	confer	O
49	responsiveness	O
50	to	O
51	EBNA2	B
52	.	O

0	Large	O
1	genomic	O
2	constructs	O
3	integrate	O
4	at	O
5	the	O
6	endogenous	O
7	locus	O
8	by	O
9	homologous	O
10	recombination	O
11	,	O
12	but	O
13	cDNA	O
14	-	O
15	derived	O
16	sequences	O
17	lacking	O
18	long	O
19	stretches	O
20	of	O
21	contiguous	O
22	genomic	O
23	DNA	O
24	(	O
25	due	O
26	to	O
27	intron	O
28	excision	O
29	)	O
30	typically	O
31	integrate	O
32	into	O
33	chromosomal	O
34	DNA	O
35	by	O
36	nonhomologous	O
37	recombination	O
38	.	O

0	A	O
1	poor	O
2	correlation	O
3	was	O
4	found	O
5	between	O
6	a	O
7	mildly	O
8	-	O
9	atypical	O
10	(	O
11	inflammatory	O
12	)	O
13	cytological	O
14	result	O
15	(	O
16	class	O
17	2	O
18	)	O
19	and	O
20	a	O
21	benign	O
22	histological	O
23	diagnosis	O
24	:	O
25	48	O
26	%	O
27	of	O
28	class	O
29	-	O
30	2	O
31	smears	O
32	were	O
33	diagnosed	O
34	histologically	O
35	as	O
36	dysplasia	O
37	or	O
38	worse	O
39	.	O

0	In	O
1	patients	O
2	who	O
3	had	O
4	received	O
5	no	O
6	previous	O
7	drug	O
8	treatment	O
9	,	O
10	log	O
11	baseline	O
12	plasma	B
13	renin	I
14	activity	O
15	and	O
16	change	O
17	in	O
18	mean	O
19	blood	O
20	pressure	O
21	after	O
22	SQ	O
23	20881	O
24	correlated	O
25	significantly	O
26	(	O
27	r	O
28	=	O
29	0	O
30	.	O
31	651	O
32	,	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

0	The	O
1	segmental	O
2	and	O
3	regional	O
4	projections	O
5	of	O
6	the	O
7	sciatic	O
8	,	O
9	tibial	O
10	and	O
11	common	O
12	peroneal	O
13	nerves	O
14	to	O
15	the	O
16	substantia	O
17	gelatinosa	O
18	of	O
19	the	O
20	spinal	O
21	cord	O
22	in	O
23	rats	O
24	--	O
25	an	O
26	experimental	O
27	study	O
28	by	O
29	means	O
30	of	O
31	an	O
32	acid	B
33	phosphatase	I
34	(	O
35	ACP	B
36	)	O
37	method	O
38	.	O

0	In	O
1	all	O
2	sessions	O
3	under	O
4	IFN	O
5	,	O
6	the	O
7	latency	O
8	of	O
9	the	O
10	P100	O
11	component	O
12	of	O
13	the	O
14	VEP	O
15	was	O
16	shortened	O
17	as	O
18	compared	O
19	to	O
20	baseline	O
21	conditions	O
22	.	O

0	The	O
1	antibody	O
2	titer	O
3	of	O
4	202	O
5	chickens	O
6	to	O
7	SA	O
8	-	O
9	11	O
10	rotavirus	O
11	was	O
12	determined	O
13	by	O
14	enzyme	O
15	-	O
16	linked	O
17	immunosorbent	O
18	blocking	O
19	assay	O
20	.	O

0	Abstracts	O
1	.	O

0	Invited	O
1	editorial	O
2	on	O
3	"	O
4	Acute	O
5	and	O
6	chronic	O
7	effects	O
8	of	O
9	exercise	O
10	on	O
11	leptin	B
12	levels	O
13	in	O
14	humans	O
15	".	O

0	Although	O
1	L	O
2	-	O
3	threo	O
4	-	O
5	dihydroxyphenylserine	O
6	(	O
7	DOPS	O
8	),	O
9	an	O
10	artificial	O
11	norepinephrine	O
12	(	O
13	NE	O
14	)	O
15	precursor	O
16	,	O
17	did	O
18	not	O
19	change	O
20	immobility	O
21	in	O
22	intact	O
23	mice	O
24	,	O
25	DOPS	O
26	significantly	O
27	reduced	O
28	immobility	O
29	in	O
30	mice	O
31	pretreated	O
32	with	O
33	the	O
34	selective	O
35	NE	B
36	neurotoxin	I
37	DSP4	I
38	.	O

0	In	O
1	this	O
2	report	O
3	,	O
4	we	O
5	present	O
6	two	O
7	lines	O
8	of	O
9	evidence	O
10	that	O
11	all	O
12	ribosomes	O
13	which	O
14	synthesize	O
15	GCN4	B
16	have	O
17	previously	O
18	translated	O
19	uORF1	B
20	,	O
21	resumed	O
22	scanning	O
23	,	O
24	and	O
25	reinitiated	O
26	at	O
27	the	O
28	GCN4	B
29	start	O
30	site	O
31	.	O

0	Conservative	O
1	treatment	O
2	of	O
3	bladder	O
4	carcinoma	O
5	by	O
6	partial	O
7	cystectomy	O
8	and	O
9	interstitial	O
10	iridium	O
11	192	O
12	.	O

0	Acute	O
1	pancreatitis	O
2	:	O
3	a	O
4	multisystem	O
5	disease	O
6	.	O

0	The	O
1	tryptase	B
2	locus	I
3	also	O
4	contains	O
5	at	O
6	least	O
7	four	O
8	tryptase	B
9	-	I
10	like	I
11	pseudogenes	I
12	,	O
13	including	O
14	mastin	B
15	,	O
16	a	O
17	gene	O
18	expressed	O
19	in	O
20	dogs	O
21	but	O
22	not	O
23	in	O
24	humans	O
25	.	O

0	Logistic	O
1	regression	O
2	analysis	O
3	revealed	O
4	that	O
5	physicians	O
6	were	O
7	3	O
8	.	O
9	6	O
10	times	O
11	more	O
12	likely	O
13	to	O
14	detect	O
15	thin	O
16	lesions	O
17	(</=	O
18	0	O
19	.	O
20	75	O
21	mm	O
22	)	O
23	compared	O
24	with	O
25	nonphysician	O
26	detectors	O
27	(	O
28	95	O
29	%	O
30	confidence	O
31	interval	O
32	[	O
33	95	O
34	%	O
35	CI	O
36	],	O
37	2	O
38	.	O
39	1	O
40	,	O
41	6	O
42	.	O
43	5	O
44	;	O
45	P	O
46	=	O
47	0	O
48	.	O
49	0001	O
50	).	O

0	In	O
1	patients	O
2	with	O
3	complete	O
4	or	O
5	partial	O
6	remission	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	the	O
12	neopterine	O
13	excretion	O
14	dropped	O
15	to	O
16	normal	O
17	values	O
18	.	O

0	Group	O
1	psychometric	O
2	functions	O
3	for	O
4	listeners	O
5	with	O
6	hearing	O
7	loss	O
8	do	O
9	not	O
10	show	O
11	a	O
12	decrease	O
13	in	O
14	performance	O
15	at	O
16	the	O
17	largest	O
18	values	O
19	of	O
20	delta	O
21	f	O
22	included	O
23	in	O
24	this	O
25	study	O
26	.	O

0	These	O
1	results	O
2	suggest	O
3	that	O
4	Rho1p	B
5	regulates	O
6	cytoskeletal	O
7	reorganization	O
8	at	O
9	least	O
10	through	O
11	Bni1p	B
12	and	O
13	Pkc1p	B
14	.	O

0	Two	O
1	-	O
2	Channel	O
3	Kondo	O
4	Lattice	O
5	:	O
6	An	O
7	Incoherent	O
8	Metal	O
9	.	O

0	Shift	O
1	-	O
2	down	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	10	O
8	(	O
9	4	O
10	)-	O
11	to	O
12	10	O
13	(	O
14	5	O
15	)-	O
16	fold	O
17	reduction	O
18	in	O
19	virus	O
20	yield	O
21	at	O
22	the	O
23	nonpermissive	O
24	temperature	O
25	was	O
26	due	O
27	to	O
28	the	O
29	disfunction	O
30	of	O
31	alpha	B
32	TIF	I
33	late	O
34	in	O
35	infection	O
36	,	O
37	presumably	O
38	in	O
39	virion	O
40	maturation	O
41	.	O

0	The	O
1	ARX2	O
2	procedure	O
3	models	O
4	the	O
5	recorded	O
6	signal	O
7	as	O
8	the	O
9	sum	O
10	of	O
11	three	O
12	signals	O
13	:	O
14	(	O
15	a	O
16	)	O
17	the	O
18	background	O
19	EEG	O
20	activity	O
21	,	O
22	modelled	O
23	as	O
24	an	O
25	autoregressive	O
26	process	O
27	driven	O
28	by	O
29	a	O
30	white	O
31	noise	O
32	;	O
33	(	O
34	b	O
35	)	O
36	a	O
37	filtered	O
38	version	O
39	of	O
40	a	O
41	reference	O
42	signal	O
43	carrying	O
44	the	O
45	average	O
46	information	O
47	contained	O
48	in	O
49	each	O
50	sweep	O
51	;	O
52	(	O
53	c	O
54	)	O
55	a	O
56	signal	O
57	due	O
58	to	O
59	the	O
60	ocular	O
61	artefact	O
62	propagation	O
63	.	O

0	In	O
1	this	O
2	report	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	hGCN5	B
8	is	O
9	also	O
10	an	O
11	HAT	B
12	and	O
13	has	O
14	the	O
15	same	O
16	substrate	O
17	specificity	O
18	as	O
19	yGCN5	B
20	.	O

0	These	O
1	observations	O
2	,	O
3	together	O
4	with	O
5	the	O
6	occurrence	O
7	of	O
8	putative	O
9	4	O
10	'-	O
11	phosphopantetheine	O
12	-	O
13	attachment	O
14	sites	O
15	and	O
16	a	O
17	putative	O
18	thioesterase	B
19	site	I
20	,	O
21	are	O
22	discussed	O
23	with	O
24	reference	O
25	to	O
26	the	O
27	reaction	O
28	sequence	O
29	leading	O
30	to	O
31	production	O
32	of	O
33	the	O
34	ACV	B
35	tripeptide	I
36	.	O

0	We	O
1	also	O
2	examined	O
3	the	O
4	effect	O
5	of	O
6	proteolytic	O
7	processing	O
8	in	O
9	the	O
10	MVE	B
11	nonstructural	I
12	polyprotein	I
13	segment	I
14	mediated	O
15	by	O
16	the	O
17	viral	B
18	proteinase	I
19	NS3	I
20	on	O
21	antigen	O
22	processing	O
23	and	O
24	presentation	O
25	of	O
26	the	O
27	MVE	B
28	H	I
29	-	I
30	2Kk	I
31	-	O
32	restricted	O
33	T	O
34	cell	O
35	determinant	O
36	.	O

0	The	O
1	effects	O
2	of	O
3	procedural	O
4	variations	O
5	on	O
6	lateralized	O
7	Stroop	O
8	effects	O
9	.	O

0	These	O
1	adverse	O
2	effects	O
3	usually	O
4	abate	O
5	with	O
6	time	O
7	.	O

0	In	O
1	addition	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	novel	O
7	type	O
8	of	O
9	inhibitory	O
10	domain	O
11	in	O
12	the	O
13	N	O
14	-	O
15	terminal	O
16	60	O
17	amino	O
18	acids	O
19	of	O
20	IRF	B
21	-	I
22	1	I
23	which	O
24	strongly	O
25	inhibits	O
26	its	O
27	transcriptional	O
28	activity	O
29	.	O

0	In	O
1	summary	O
2	,	O
3	the	O
4	segments	O
5	of	O
6	C3	B
7	represented	O
8	by	O
9	amino	O
10	acid	O
11	residues	O
12	1082	O
13	-	O
14	1118	O
15	,	O
16	1117	O
17	-	O
18	1155	O
19	,	O
20	1234	O
21	-	O
22	1294	O
23	and	O
24	1312	O
25	-	O
26	1404	O
27	accommodate	O
28	C3	B
29	(	O
30	D	O
31	)	O
32	epitopes	O
33	that	O
34	are	O
35	expressed	O
36	by	O
37	erythrocyte	O
38	-	O
39	bound	O
40	C3	B
41	fragments	O
42	,	O
43	but	O
44	not	O
45	by	O
46	the	O
47	corresponding	O
48	fluid	O
49	-	O
50	phase	O
51	fragment	O
52	,	O
53	whereas	O
54	the	O
55	segments	O
56	spanning	O
57	residues	O
58	973	O
59	-	O
60	1026	O
61	and	O
62	1477	O
63	-	O
64	1510	O
65	contain	O
66	C3	B
67	(	O
68	D	O
69	)	O
70	epitopes	O
71	that	O
72	are	O
73	exposed	O
74	exclusively	O
75	in	O
76	denatured	O
77	C3	B
78	and	O
79	therefore	O
80	hidden	O
81	in	O
82	physiological	O
83	fragments	O
84	of	O
85	the	O
86	protein	O
87	.	O

0	Additionally	O
1	,	O
2	the	O
3	mouse	O
4	promoter	O
5	contains	O
6	22	O
7	copies	O
8	of	O
9	a	O
10	CT	O
11	dinucleotide	O
12	repeat	O
13	sequence	O
14	located	O
15	approximately	O
16	155	O
17	bp	O
18	5	O
19	'	O
20	to	O
21	exon	O
22	1	O
23	.	O

0	We	O
1	introduced	O
2	the	O
3	gel	O
4	technique	O
5	as	O
6	a	O
7	routine	O
8	assay	O
9	for	O
10	antibody	O
11	detection	O
12	and	O
13	identification	O
14	in	O
15	1993	O
16	.	O

0	The	O
1	feed	O
2	consumed	O
3	which	O
4	was	O
5	lowered	O
6	by	O
7	25	O
8	%	O
9	initially	O
10	,	O
11	did	O
12	not	O
13	alter	O
14	later	O
15	.	O

0	In	O
1	order	O
2	to	O
3	gain	O
4	deeper	O
5	insight	O
6	into	O
7	the	O
8	role	O
9	of	O
10	the	O
11	amino	O
12	-	O
13	terminal	O
14	domain	O
15	of	O
16	the	O
17	p24	B
18	(	O
19	CA	B
20	)	O
21	protein	O
22	during	O
23	viral	O
24	replication	O
25	,	O
26	eight	O
27	highly	O
28	conserved	O
29	proline	O
30	residues	O
31	known	O
32	to	O
33	promote	O
34	turns	O
35	and	O
36	to	O
37	terminate	O
38	alpha	O
39	-	O
40	helices	O
41	within	O
42	the	O
43	p24	B
44	tertiary	O
45	structure	O
46	were	O
47	replaced	O
48	by	O
49	a	O
50	leucine	O
51	residue	O
52	(	O
53	P	O
54	-	O
55	position	O
56	-	O
57	L	O
58	).	O

0	In	O
1	mammals	O
2	,	O
3	the	O
4	Rb	B
5	protein	I
6	interacts	O
7	specifically	O
8	with	O
9	D	B
10	-	I
11	type	I
12	cyclins	I
13	and	O
14	regulates	O
15	cell	O
16	proliferation	O
17	by	O
18	binding	O
19	and	O
20	inhibiting	O
21	E2F	B
22	transcription	I
23	factors	I
24	.	O

0	Northern	O
1	blot	O
2	analysis	O
3	revealed	O
4	the	O
5	expression	O
6	of	O
7	LIMK	B
8	-	I
9	1	I
10	mRNA	I
11	predominantly	O
12	in	O
13	the	O
14	brain	O
15	and	O
16	the	O
17	expression	O
18	of	O
19	LIMK	B
20	-	I
21	2	I
22	mRNA	I
23	in	O
24	various	O
25	tissues	O
26	in	O
27	the	O
28	rat	O
29	.	O

0	Recent	O
1	studies	O
2	have	O
3	revealed	O
4	unconventional	O
5	myosin	B
6	V	I
7	to	O
8	be	O
9	an	O
10	important	O
11	actin	B
12	-	O
13	based	O
14	molecular	O
15	motor	O
16	involved	O
17	in	O
18	vesicular	O
19	movement	O
20	.	O

0	Transformation	O
1	blocks	O
2	differentiation	O
3	-	O
4	induced	O
5	inhibition	O
6	of	O
7	serum	B
8	response	I
9	factor	I
10	interactions	O
11	with	O
12	serum	O
13	response	O
14	elements	O
15	.	O

0	Electrocardiographic	O
1	right	O
2	ventricular	O
3	hypertrophy	O
4	was	O
5	seen	O
6	in	O
7	4	O
8	,	O
9	and	O
10	biventricular	O
11	hypertrophy	O
12	in	O
13	5	O
14	patients	O
15	.	O

0	KAR1	B
1	encodes	O
2	an	O
3	essential	O
4	component	O
5	of	O
6	the	O
7	yeast	O
8	spindle	O
9	pole	O
10	body	O
11	(	O
12	SPB	O
13	)	O
14	that	O
15	is	O
16	required	O
17	for	O
18	karyogamy	O
19	and	O
20	SPB	B
21	duplication	O
22	.	O

0	The	O
1	importin	B
2	alpha	I
3	.	I
4	beta	I
5	heterodimer	O
6	mediates	O
7	nuclear	O
8	import	O
9	of	O
10	proteins	O
11	containing	O
12	classical	O
13	nuclear	O
14	localization	O
15	signals	O
16	.	O

0	The	O
1	glomerular	O
2	filtration	O
3	rate	O
4	did	O
5	not	O
6	change	O
7	but	O
8	lithium	O
9	clearance	O
10	fell	O
11	by	O
12	30	O
13	%.	O

0	In	O
1	gel	O
2	mobility	O
3	shift	O
4	assays	O
5	,	O
6	we	O
7	found	O
8	no	O
9	evidence	O
10	for	O
11	VDR	B
12	-	O
13	TR	B
14	heterodimer	O
15	interaction	O
16	with	O
17	any	O
18	tested	O
19	element	O
20	.	O

0	Limits	O
1	of	O
2	energy	O
3	turnover	O
4	in	O
5	relation	O
6	to	O
7	physical	O
8	performance	O
9	were	O
10	addressed	O
11	in	O
12	terms	O
13	of	O
14	upper	O
15	and	O
16	lower	O
17	limit	O
18	,	O
19	changes	O
20	during	O
21	a	O
22	training	O
23	programme	O
24	and	O
25	how	O
26	to	O
27	regulate	O
28	energy	O
29	balance	O
30	at	O
31	a	O
32	changing	O
33	energy	O
34	turnover	O
35	.	O

0	Corticosteroid	O
1	therapy	O
2	is	O
3	known	O
4	to	O
5	be	O
6	hazardous	O
7	in	O
8	patients	O
9	with	O
10	occult	O
11	infection	O
12	but	O
13	the	O
14	mechanism	O
15	by	O
16	which	O
17	the	O
18	host	O
19	parasite	O
20	relationship	O
21	is	O
22	altered	O
23	by	O
24	steroids	O
25	is	O
26	not	O
27	known	O
28	.	O
29	We	O
30	have	O
31	used	O
32	an	O
33	intestinal	O
34	protozoal	O
35	parasite	O
36	,	O
37	Giardia	O
38	muris	O
39	,	O
40	to	O
41	examine	O
42	the	O
43	effects	O
44	of	O
45	corticosteroids	O
46	on	O
47	the	O
48	number	O
49	of	O
50	parasites	O
51	in	O
52	the	O
53	intestine	O
54	in	O
55	the	O
56	course	O
57	of	O
58	a	O
59	primary	O
60	infection	O
61	.	O

0	Compensatory	O
1	renal	O
2	hypertrophy	O
3	in	O
4	parabiotic	O
5	rats	O
6	.	O

0	Activation	O
1	of	O
2	PKA	B
3	by	O
4	8	O
5	-	O
6	bromo	O
7	-	O
8	cyclic	O
9	AMP	O
10	or	O
11	forskolin	O
12	,	O
13	and	O
14	inhibition	O
15	of	O
16	PKC	B
17	by	O
18	calphostin	B
19	C	I
20	,	O
21	resulted	O
22	in	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	3TP	B
28	activity	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vitro	O
34	ERK	B
35	kinase	I
36	activity	O
37	in	O
38	CRAC	B
39	.	O

0	On	O
1	catabolism	O
2	of	O
3	aminoketones	O
4	in	O
5	climacteric	O
6	age	O

0	Hydrocortisone	O
1	caused	O
2	lymphopenia	O
3	and	O
4	inhibited	O
5	the	O
6	blastogenic	O
7	response	O
8	of	O
9	peripheral	O
10	blood	O
11	lymphocytes	O
12	to	O
13	phytohemagglutinin	B
14	and	O
15	concanavalin	B
16	A	I
17	mitogens	I
18	.	O

0	Using	O
1	transgenic	O
2	Xenopus	O
3	embryos	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	the	O
9	integrity	O
10	of	O
11	these	O
12	two	O
13	sequences	O
14	is	O
15	necessary	O
16	for	O
17	correct	O
18	spatial	O
19	expression	O
20	of	O
21	a	O
22	Xbra2	B
23	promoter	I
24	-	O
25	driven	O
26	reporter	O
27	gene	O
28	.	O

0	Significance	O
1	of	O
2	thin	O
3	glomerular	O
4	basement	O
5	membranes	O
6	in	O
7	hematuric	O
8	children	O
9	.	O

0	In	O
1	H4IIE	O
2	rat	O
3	hepatoma	O
4	cells	O
5	,	O
6	glucocorticoids	O
7	,	O
8	retinoic	O
9	acid	O
10	and	O
11	cyclic	O
12	AMP	O
13	(	O
14	cAMP	O
15	)	O
16	increase	O
17	PEPCK	B
18	gene	I
19	transcription	O
20	whereas	O
21	insulin	B
22	and	O
23	phorbol	O
24	esters	O
25	have	O
26	the	O
27	opposite	O
28	effect	O
29	.	O

0	The	O
1	multidomain	O
2	structure	O
3	includes	O
4	a	O
5	cysteine	O
6	-	O
7	rich	O
8	motif	O
9	resembling	O
10	those	O
11	of	O
12	protein	B
13	kinase	I
14	C	I
15	and	O
16	n	B
17	-	I
18	chimaerin	I
19	and	O
20	a	O
21	putative	O
22	pleckstrin	B
23	homology	I
24	domain	I
25	.	O

0	There	O
1	were	O
2	15	O
3	deaths	O
4	,	O
5	seven	O
6	of	O
7	which	O
8	were	O
9	felt	O
10	to	O
11	be	O
12	avoidable	O
13	.	O

0	Muscular	O
1	pathology	O

0	Two	O
1	patients	O
2	had	O
3	immediate	O
4	adverse	O
5	effects	O
6	from	O
7	NMF	O
8	;	O
9	one	O
10	had	O
11	a	O
12	grand	O
13	mal	O
14	seizure	O
15	and	O
16	the	O
17	other	O
18	developed	O
19	severe	O
20	abdominal	O
21	pain	O
22	.	O

0	Male	B
1	-	I
2	enhanced	I
3	antigen	I
4	gene	I
5	is	O
6	phylogenetically	O
7	conserved	O
8	and	O
9	expressed	O
10	at	O
11	late	O
12	stages	O
13	of	O
14	spermatogenesis	O
15	.	O

0	Genetic	O
1	studies	O
2	in	O
3	Drosophila	O
4	have	O
5	led	O
6	to	O
7	the	O
8	identification	O
9	of	O
10	several	O
11	components	O
12	of	O
13	the	O
14	Notch	B
15	pathway	O
16	.	O

0	All	O
1	subjects	O
2	were	O
3	submitted	O
4	to	O
5	ECG	O
6	and	O
7	arterial	O
8	blood	O
9	pressure	O
10	determination	O
11	and	O
12	were	O
13	assayed	O
14	for	O
15	TSH	B
16	,	O
17	thyroid	B
18	hormone	I
19	,	O
20	PRL	B
21	,	O
22	glucose	O
23	,	O
24	creatinine	O
25	,	O
26	nitrogen	O
27	,	O
28	glutamine	B
29	transaminase	I
30	,	O
31	cholesterol	O
32	and	O
33	triglycerides	O
34	plasma	O
35	levels	O
36	before	O
37	therapy	O
38	(	O
39	T0	O
40	),	O
41	after	O
42	30	O
43	treatment	O
44	days	O
45	(	O
46	T30	O
47	)	O
48	and	O
49	after	O
50	a	O
51	15	O
52	days	O
53	washout	O
54	(	O
55	T45	O
56	).	O

0	After	O
1	measuring	O
2	baseline	O
3	Vmca	O
4	at	O
5	a	O
6	partial	O
7	pressure	O
8	of	O
9	carbon	O
10	dioxide	O
11	in	O
12	arterial	O
13	blood	O
14	(	O
15	PaCO2	O
16	)	O
17	of	O
18	37	O
19	.	O
20	7	O
21	+/-	O
22	4	O
23	.	O
24	5	O
25	mmHg	O
26	(	O
27	mean	O
28	+/-	O
29	SD	O
30	),	O
31	measurements	O
32	were	O
33	repeated	O
34	at	O
35	a	O
36	PaCO	O
37	of	O
38	44	O
39	.	O
40	2	O
41	+/-	O
42	3	O
43	.	O
44	8	O
45	mmHg	O
46	,	O
47	and	O
48	the	O
49	carbon	O
50	dioxide	O
51	reactivity	O
52	(	O
53	absolute	O
54	value	O
55	:	O
56	cm	O
57	x	O
58	s	O
59	(-	O
60	1	O
61	)	O
62	x	O
63	mmHg	O
64	(-	O
65	1	O
66	);	O
67	relative	O
68	value	O
69	:	O
70	percentage	O
71	of	O
72	baseline	O
73	Vmca	O
74	/	O
75	mmHg	O
76	)	O
77	was	O
78	calculated	O
79	.	O

0	The	O
1	determination	O
2	of	O
3	physical	O
4	performance	O
5	capacity	O
6	was	O
7	based	O
8	on	O
9	W170	O
10	,	O
11	W85	O
12	%	O
13	and	O
14	on	O
15	predicted	O
16	VO2	O
17	max	O
18	measured	O
19	with	O
20	continuously	O
21	increasing	O
22	work	O
23	load	O
24	on	O
25	a	O
26	bicycle	O
27	ergometer	O
28	.	O

0	In	O
1	one	O
2	of	O
3	these	O
4	tumors	O
5	the	O
6	observed	O
7	rearrangement	O
8	was	O
9	not	O
10	due	O
11	to	O
12	the	O
13	insertion	O
14	of	O
15	an	O
16	intact	O
17	MoMuLV	O
18	provirus	O
19	.	O

0	Filter	O
1	and	O
2	cytocentrifuge	O
3	preparations	O
4	of	O
5	the	O
6	urine	O
7	were	O
8	studied	O
9	and	O
10	all	O
11	cases	O
12	displayed	O
13	numerous	O
14	scattered	O
15	aggregates	O
16	or	O
17	single	O
18	tumor	O
19	cells	O
20	in	O
21	an	O
22	inflammatory	O
23	background	O
24	.	O

0	On	O
1	the	O
2	other	O
3	hand	O
4	,	O
5	subjects	O
6	with	O
7	air	O
8	trapping	O
9	(	O
10	residual	O
11	volume	O
12	(	O
13	RV	O
14	)/	O
15	total	O
16	lung	O
17	capacity	O
18	(	O
19	TLC	O
20	)	O
21	>	O
22	37	O
23	%)	O
24	disclosed	O
25	not	O
26	only	O
27	a	O
28	higher	O
29	n	O
30	(	O
31	mit	O
32	)	O
33	(	O
34	0	O
35	.	O
36	63	O
37	+/-	O
38	0	O
39	.	O
40	17	O
41	versus	O
42	0	O
43	.	O
44	43	O
45	+/-	O
46	0	O
47	.	O
48	07	O
49	mt	O
50	x	O
51	microm	O
52	(-	O
53	2	O
54	),	O
55	p	O
56	<	O
57	0	O
58	.	O
59	05	O
60	)	O
61	but	O
62	shorter	O
63	sarcomeres	O
64	(	O
65	L	O
66	(	O
67	sar	O
68	))	O
69	than	O
70	subjects	O
71	without	O
72	this	O
73	functional	O
74	abnormality	O
75	(	O
76	2	O
77	.	O
78	08	O
79	+/-	O
80	0	O
81	.	O
82	16	O
83	to	O
84	2	O
85	.	O
86	27	O
87	+/-	O
88	0	O
89	.	O
90	15	O
91	microm	O
92	,	O
93	p	O
94	<	O
95	0	O
96	.	O
97	05	O
98	).	O

0	RESULT	O
1	(	O
2	S	O
3	):	O
4	In	O
5	patients	O
6	with	O
7	elevated	O
8	FSH	B
9	levels	O
10	on	O
11	cycle	O
12	day	O
13	3	O
14	,	O
15	a	O
16	low	O
17	oocyte	O
18	yield	O
19	was	O
20	achieved	O
21	(	O
22	7	O
23	versus	O
24	11	O
25	)	O
26	and	O
27	a	O
28	high	O
29	number	O
30	of	O
31	ampules	O
32	of	O
33	hMG	O
34	was	O
35	necessary	O
36	(	O
37	56	O
38	versus	O
39	33	O
40	).	O

0	An	O
1	ion	O
2	chromatographic	O
3	method	O
4	was	O
5	used	O
6	to	O
7	determine	O
8	Br	O
9	ion	O
10	in	O
11	the	O
12	urine	O
13	of	O
14	Greyhounds	O
15	.	O

0	The	O
1	physicians	O
2	in	O
3	charge	O
4	of	O
5	all	O
6	patients	O
7	with	O
8	evidence	O
9	of	O
10	acute	O
11	Q	O
12	fever	O
13	(	O
14	seroconversion	O
15	and	O
16	/	O
17	or	O
18	presence	O
19	of	O
20	IgM	B
21	)	O
22	or	O
23	chronic	O
24	Q	O
25	fever	O
26	(	O
27	prolonged	O
28	disease	O
29	and	O
30	/	O
31	or	O
32	IgG	B
33	antibody	I
34	titer	O
35	to	O
36	phase	O
37	I	O
38	of	O
39	Coxiella	O
40	burnetii	O
41	>	O
42	or	O
43	=	O
44	800	O
45	)	O
46	were	O
47	asked	O
48	to	O
49	complete	O
50	a	O
51	questionnaire	O
52	,	O
53	which	O
54	was	O
55	computerized	O
56	.	O

0	This	O
1	sequenced	O
2	region	O
3	of	O
4	the	O
5	V	B
6	beta	I
7	locus	I
8	contains	O
9	an	O
10	average	O
11	number	O
12	of	O
13	repetitive	O
14	DNA	O
15	elements	O
16	(	O
17	21	O
18	Alu	O
19	,	O
20	three	O
21	L1	O
22	,	O
23	three	O
24	MER	O
25	,	O
26	and	O
27	three	O
28	retrovirus	O
29	-	O
30	related	O
31	elements	O
32	.	O

0	Neonatal	O
1	lupus	O
2	erythematosus	O
3	is	O
4	most	O
5	often	O
6	associated	O
7	with	O
8	autoantibodies	O
9	against	O
10	Ro	B
11	and	O
12	La	B
13	antigens	I
14	.	O

0	Double	O
1	mutant	O
2	analysis	O
3	suggests	O
4	that	O
5	Rad54p	B
6	and	O
7	Mus81p	B
8	act	O
9	in	O
10	one	O
11	pathway	O
12	for	O
13	the	O
14	repair	O
15	of	O
16	,	O
17	or	O
18	tolerance	O
19	to	O
20	,	O
21	UV	O
22	-	O
23	induced	O
24	DNA	O
25	damage	O
26	.	O

0	PURPOSE	O
1	:	O
2	To	O
3	determine	O
4	the	O
5	effects	O
6	of	O
7	hypercholesterolemia	O
8	and	O
9	atherosclerosis	O
10	-	O
11	induced	O
12	chronic	O
13	cavernosal	O
14	arterial	O
15	insufficiency	O
16	on	O
17	cavernosal	O
18	smooth	O
19	muscle	O
20	tone	O
21	,	O
22	nitric	B
23	oxide	I
24	synthase	I
25	(	O
26	NOS	B
27	)	O
28	activity	O
29	and	O
30	cavernosal	O
31	tissue	O
32	synthesis	O
33	of	O
34	constrictor	O
35	eicosanoids	O
36	.	O

0	To	O
1	modulate	O
2	transcription	O
3	,	O
4	regulatory	O
5	factors	O
6	communicate	O
7	with	O
8	basal	O
9	transcription	O
10	factors	O
11	and	O
12	/	O
13	or	O
14	RNA	B
15	polymerases	I
16	in	O
17	a	O
18	variety	O
19	of	O
20	ways	O
21	.	O

0	Effect	O
1	of	O
2	ingestion	O
3	of	O
4	Norbiogest	O
5	during	O
6	the	O
7	quiescent	O
8	period	O
9	of	O
10	the	O
11	genital	O
12	organs	O

0	The	O
1	distribution	O
2	of	O
3	patients	O
4	was	O
5	as	O
6	follows	O
7	:	O
8	group	O
9	1	O
10	--	O
11	complex	O
12	gamma	O
13	-	O
14	therapy	O
15	(	O
16	55	O
17	cases	O
18	),	O
19	group	O
20	2	O
21	--	O
22	complex	O
23	gamma	O
24	-	O
25	therapy	O
26	plus	O
27	iliac	O
28	lymphadenectomy	O
29	(	O
30	50	O
31	cases	O
32	)	O
33	and	O
34	group	O
35	3	O
36	--	O
37	complex	O
38	radiation	O
39	treatment	O
40	with	O
41	megavolt	O
42	bremsstrahlung	O
43	beam	O
44	from	O
45	the	O
46	luc	O
47	type	O
48	installation	O
49	and	O
50	iliac	O
51	lymphadenectomy	O
52	(	O
53	50	O
54	cases	O
55	).	O

0	These	O
1	results	O
2	suggest	O
3	that	O
4	XAB1	B
5	is	O
6	a	O
7	novel	O
8	cytoplasmic	B
9	GTPase	I
10	involved	O
11	in	O
12	nuclear	O
13	localization	O
14	of	O
15	XPA	B
16	.	O

0	The	O
1	active	O
2	open	O
3	reading	O
4	frame	O
5	in	O
6	the	O
7	clone	O
8	maps	O
9	at	O
10	27	O
11	min	O
12	on	O
13	the	O
14	E	O
15	.	O
16	coli	O
17	chromosome	O
18	and	O
19	is	O
20	identical	O
21	in	O
22	sequence	O
23	to	O
24	a	O
25	wild	O
26	type	O
27	counterpart	O
28	.	O

0	Strain	B
1	CFN037	I
2	is	O
3	an	O
4	R	O
5	.	O
6	etli	O
7	mutant	O
8	induced	O
9	by	O
10	a	O
11	single	O
12	Tn5mob	B
13	insertion	O
14	in	O
15	the	O
16	promoter	O
17	region	O
18	of	O
19	the	O
20	thiCOGE	B
21	gene	I
22	cluster	I
23	.	O

0	Similar	O
1	observations	O
2	were	O
3	made	O
4	with	O
5	unilateral	O
6	pneumothorax	O
7	of	O
8	15	O
9	cmH2O	O
10	for	O
11	30	O
12	min	O
13	.	O

0	This	O
1	indicates	O
2	that	O
3	lipid	O
4	peroxidation	O
5	may	O
6	be	O
7	involved	O
8	in	O
9	the	O
10	development	O
11	of	O
12	senile	O
13	cataract	O
14	and	O
15	,	O
16	as	O
17	a	O
18	direct	O
19	consequence	O
20	of	O
21	retinal	O
22	damage	O
23	,	O
24	also	O
25	in	O
26	the	O
27	pathogenesis	O
28	of	O
29	cataract	O
30	in	O
31	diabetes	O
32	and	O
33	in	O
34	severe	O
35	myopia	O
36	.	O

0	ERK	B
1	MAP	I
2	kinase	I
3	links	O
4	cytokine	O
5	signals	O
6	to	O
7	activation	O
8	of	O
9	latent	O
10	HIV	O
11	-	O
12	1	O
13	infection	O
14	by	O
15	stimulating	O
16	a	O
17	cooperative	O
18	interaction	O
19	of	O
20	AP	B
21	-	I
22	1	I
23	and	O
24	NF	B
25	-	I
26	kappaB	I
27	.	O

0	Since	O
1	electrical	O
2	stimulation	O
3	of	O
4	neurones	O
5	may	O
6	activate	O
7	not	O
8	only	O
9	cell	O
10	bodies	O
11	but	O
12	also	O
13	neuronal	O
14	fibres	O
15	,	O
16	this	O
17	study	O
18	aimed	O
19	to	O
20	test	O
21	a	O
22	selectively	O
23	cholinergic	O
24	neurochemical	O
25	stimulation	O
26	of	O
27	the	O
28	rat	O
29	substantia	O
30	innominata	O
31	(	O
32	SI	O
33	)	O
34	by	O
35	the	O
36	local	O
37	microinjection	O
38	of	O
39	carbachol	O
40	;	O
41	the	O
42	effects	O
43	of	O
44	this	O
45	acetylcholine	O
46	agonist	O
47	were	O
48	compared	O
49	with	O
50	glutamate	O
51	.	O

0	The	O
1	site	O
2	-	O
3	directed	O
4	mutation	O
5	of	O
6	the	O
7	kappa	B
8	B	I
9	motif	I
10	in	O
11	IL	B
12	-	I
13	6	I
14	/	O
15	CAT	B
16	plasmid	O
17	resulted	O
18	in	O
19	the	O
20	complete	O
21	abrogation	O
22	of	O
23	IL	B
24	-	I
25	6	I
26	promoter	I
27	activity	O
28	in	O
29	these	O
30	cells	O
31	.	O

0	For	O
1	this	O
2	purpose	O
3	,	O
4	we	O
5	used	O
6	a	O
7	series	O
8	of	O
9	plasmid	O
10	constructs	O
11	encoding	O
12	different	O
13	forms	O
14	of	O
15	the	O
16	envelope	B
17	glycoprotein	I
18	E	I
19	of	O
20	the	O
21	flavivirus	O
22	tick	O
23	-	O
24	borne	O
25	encephalitis	O
26	virus	O
27	.	O

0	In	O
1	this	O
2	regard	O
3	,	O
4	it	O
5	differs	O
6	from	O
7	a	O
8	recently	O
9	reported	O
10	BFA	B
11	-	O
12	sensitive	O
13	ARF	B
14	-	O
15	GEP	I
16	that	O
17	contains	O
18	a	O
19	Sec7	B
20	domain	I
21	.	O

0	The	O
1	cis	O
2	-	O
3	acting	O
4	regulatory	O
5	properties	O
6	of	O
7	an	O
8	872	O
9	bp	O
10	promoter	O
11	fragment	O
12	of	O
13	a	O
14	B	B
15	.	I
16	napus	I
17	oleosin	I
18	gene	I
19	were	O
20	examined	O
21	by	O
22	analysis	O
23	of	O
24	beta	B
25	-	I
26	glucuronidase	I
27	(	O
28	GUS	B
29	)	O
30	expression	O
31	in	O
32	transgenic	O
33	tobacco	O
34	plants	O
35	containing	O
36	an	O
37	oleosin	B
38	promoter	I
39	-	O
40	GUS	B
41	transcriptional	O
42	fusion	O
43	.	O

0	These	O
1	two	O
2	contigs	O
3	contain	O
4	a	O
5	total	O
6	of	O
7	163	O
8	open	O
9	reading	O
10	frames	O
11	(	O
12	ORFs	O
13	)	O
14	in	O
15	26	O
16	-	O
17	29	O
18	putative	O
19	operons	O
20	;	O
21	56	O
22	ORFs	O
23	could	O
24	be	O
25	identified	O
26	with	O
27	reasonable	O
28	certainty	O
29	.	O

0	Deleting	O
1	SNF1	B
2	repressed	O
3	meiosis	O
4	at	O
5	the	O
6	same	O
7	three	O
8	steps	O
9	that	O
10	were	O
11	inhibited	O
12	by	O
13	glucose	O
14	,	O
15	suggesting	O
16	that	O
17	glucose	O
18	blocks	O
19	meiosis	O
20	by	O
21	inhibiting	O
22	Snf1	B
23	.	O

0	BACKGROUND	O
1	:	O
2	Hepatic	O
3	encephalopathy	O
4	is	O
5	a	O
6	neuropsychiatric	O
7	syndrome	O
8	associated	O
9	with	O
10	acute	O
11	liver	O
12	failure	O
13	,	O
14	chronic	O
15	parenchymal	O
16	liver	O
17	disease	O
18	or	O
19	portal	O
20	systemic	O
21	anastomosis	O
22	.	O

0	In	O
1	adherent	O
2	macrophages	O
3	,	O
4	absence	O
5	of	O
6	CD45	B
7	led	O
8	to	O
9	the	O
10	hyperphosphorylation	O
11	and	O
12	hyperactivation	O
13	of	O
14	p56	B
15	/	I
16	59	I
17	(	O
18	hck	B
19	)	O
20	and	O
21	p53	B
22	/	I
23	56	I
24	(	O
25	lyn	B
26	),	O
27	but	O
28	not	O
29	of	O
30	p58	B
31	(	O
32	c	B
33	-	I
34	fgr	I
35	).	O

0	Anastrozole	O
1	is	O
2	the	O
3	first	O
4	aromatase	B
5	inhibitor	O
6	to	O
7	show	O
8	a	O
9	significant	O
10	survival	O
11	advantage	O
12	over	O
13	megestrol	O
14	acetate	O
15	in	O
16	post	O
17	-	O
18	menopausal	O
19	women	O
20	with	O
21	advanced	O
22	breast	O
23	cancer	O
24	.	O

0	Total	O
1	cholesterol	O
2	was	O
3	also	O
4	reduced	O
5	at	O
6	week	O
7	12	O
8	by	O
9	17	O
10	.	O
11	0	O
12	%	O
13	(	O
14	20	O
15	mg	O
16	/	O
17	day	O
18	)	O
19	and	O
20	15	O
21	.	O
22	7	O
23	%	O
24	(	O
25	20	O
26	-	O
27	30	O
28	mg	O
29	/	O
30	day	O
31	),	O
32	and	O
33	at	O
34	week	O
35	52	O
36	by	O
37	20	O
38	.	O
39	4	O
40	%	O
41	(<	O
42	or	O
43	=	O
44	20	O
45	mg	O
46	/	O
47	day	O
48	)	O
49	and	O
50	19	O
51	.	O
52	2	O
53	%	O
54	(>	O
55	or	O
56	=	O
57	30	O
58	mg	O
59	/	O
60	day	O
61	).	O

0	Thyroid	O
1	lymphoma	O
2	and	O
3	its	O
4	management	O
5	.	O

0	Suppression	O
1	of	O
2	food	O
3	intake	O
4	in	O
5	the	O
6	rat	O
7	by	O
8	tung	O
9	oil	O
10	.	O

0	Efficacy	O
1	and	O
2	field	O
3	evaluation	O
4	of	O
5	Bacillus	O
6	thuringiensis	O
7	(	O
8	H	O
9	-	O
10	14	O
11	)	O
12	and	O
13	B	O
14	.	O
15	sphaericus	O
16	against	O
17	floodwater	O
18	mosquitoes	O
19	in	O
20	California	O
21	.	O

0	Groups	O
1	of	O
2	ten	O
3	dependent	O
4	and	O
5	ten	O
6	saline	O
7	mice	O
8	were	O
9	singly	O
10	tested	O
11	in	O
12	both	O
13	light	O
14	and	O
15	dark	O
16	conditions	O
17	in	O
18	each	O
19	of	O
20	five	O
21	covered	O
22	cylinders	O
23	(	O
24	2	O
25	-	O
26	23	O
27	in	O
28	high	O
29	).	O

0	Furthermore	O
1	,	O
2	we	O
3	notice	O
4	two	O
5	potential	O
6	consensus	O
7	motifs	O
8	which	O
9	are	O
10	also	O
11	found	O
12	in	O
13	corresponding	O
14	positions	O
15	in	O
16	the	O
17	genes	O
18	for	O
19	the	O
20	nerve	B
21	growth	I
22	factor	I
23	receptor	I
24	and	O
25	the	O
26	68	B
27	-	I
28	kDa	I
29	neurofilament	I
30	protein	I
31	.	O

0	Institution	O
1	of	O
2	both	O
3	intravenous	O
4	and	O
5	intracisternal	O
6	administration	O
7	of	O
8	amphotericin	O
9	B	O
10	and	O
11	possibly	O
12	concomitant	O
13	intravenous	O
14	administration	O
15	of	O
16	dexamethasone	O
17	may	O
18	be	O
19	warranted	O
20	in	O
21	situations	O
22	in	O
23	which	O
24	the	O
25	association	O
26	of	O
27	C	O
28	.	O
29	immitis	O
30	with	O
31	CNS	O
32	vasculitis	O
33	or	O
34	encephalitis	O
35	appears	O
36	likely	O
37	before	O
38	serologic	O
39	or	O
40	cultural	O
41	confirmation	O
42	of	O
43	C	O
44	.	O
45	immitis	O
46	infection	O
47	involving	O
48	the	O
49	CNS	O
50	is	O
51	available	O
52	.	O

0	Deletion	O
1	analyses	O
2	of	O
3	the	O
4	pCD41	B
5	ORF	I
6	-	I
7	A	I
8	and	O
9	the	O
10	use	O
11	of	O
12	promoter	O
13	constructs	O
14	further	O
15	mapped	O
16	an	O
17	internal	O
18	functional	O
19	promoter	O
20	within	O
21	the	O
22	pCD41	B
23	sequence	I
24	that	O
25	can	O
26	direct	O
27	the	O
28	synthesis	O
29	of	O
30	the	O
31	trans	O
32	-	O
33	activating	O
34	protein	O
35	.	O

0	In	O
1	serum	O
2	-	O
3	free	O
4	media	O
5	,	O
6	p50E4F	B
7	accelerated	O
8	E1A	B
9	-	O
10	induced	O
11	apoptosis	O
12	.	O

0	The	O
1	introduction	O
2	of	O
3	an	O
4	acidic	O
5	residue	O
6	at	O
7	the	O
8	second	O
9	site	O
10	was	O
11	essential	O
12	for	O
13	suppression	O
14	of	O
15	the	O
16	Asn	B
17	-	I
18	285	I
19	mutation	I
20	because	O
21	Lys	B
22	-	I
23	220	I
24	and	O
25	Gln	O
26	-	O
27	220	O
28	second	O
29	-	O
30	site	O
31	mutants	O
32	of	O
33	the	O
34	Asn	B
35	-	I
36	285	I
37	mutant	I
38	showed	O
39	very	O
40	low	O
41	tetracycline	O
42	resistance	O
43	.(	O
44	ABSTRACT	O
45	TRUNCATED	O
46	AT	O
47	250	O
48	WORDS	O
49	)	O

0	Control	O
1	experiments	O
2	showed	O
3	that	O
4	each	O
5	fusion	O
6	protein	O
7	had	O
8	a	O
9	high	O
10	affinity	O
11	binding	O
12	site	O
13	for	O
14	estradiol	O
15	-	O
16	17	O
17	beta	O
18	and	O
19	could	O
20	transactivate	O
21	an	O
22	ERE	B
23	-	O
24	LacZ	B
25	reporter	O
26	gene	O
27	in	O
28	yeast	O
29	similar	O
30	to	O
31	the	O
32	wild	O
33	type	O
34	ER	B
35	.	O

0	The	O
1	low	O
2	number	O
3	of	O
4	false	O
5	positives	O
6	indicates	O
7	that	O
8	our	O
9	scheme	O
10	would	O
11	not	O
12	confuse	O
13	the	O
14	radiologist	O
15	by	O
16	suggesting	O
17	normal	O
18	regions	O
19	as	O
20	suspicious	O
21	.	O

0	Here	O
1	we	O
2	demonstrate	O
3	that	O
4	another	O
5	cellular	O
6	protein	O
7	linked	O
8	to	O
9	BCR	B
10	/	O
11	ABL	B
12	through	O
13	the	O
14	CRKL	B
15	-	O
16	SH2	B
17	domain	O
18	is	O
19	p130	B
20	(	O
21	CAS	B
22	).	O
23	p130	B
24	(	O
25	CAS	B
26	)	O
27	was	O
28	found	O
29	to	O
30	be	O
31	tyrosine	O
32	phosphorylated	O
33	and	O
34	associated	O
35	with	O
36	CRKL	B
37	in	O
38	BCR	B
39	/	O
40	ABL	B
41	expressing	O
42	cell	O
43	lines	O
44	and	O
45	in	O
46	samples	O
47	obtained	O
48	from	O
49	CML	O
50	and	O
51	ALL	O
52	patients	O
53	,	O
54	but	O
55	not	O
56	in	O
57	samples	O
58	from	O
59	controls	O
60	.	O

0	Rolandic	O
1	spikes	O
2	and	O
3	cognitive	O
4	function	O
5	.	O

0	The	O
1	investigation	O
2	was	O
3	thereafter	O
4	continued	O
5	in	O
6	an	O
7	open	O
8	fashion	O
9	by	O
10	administering	O
11	a	O
12	single	O
13	10	O
14	mg	O
15	dose	O
16	of	O
17	the	O
18	MAO	B
19	-	I
20	B	I
21	inhibitor	O
22	deprenyl	O
23	to	O
24	the	O
25	same	O
26	subjects	O
27	.	O

0	The	O
1	medium	O
2	chains	O
3	of	O
4	these	O
5	complexes	O
6	,	O
7	mu1	B
8	and	O
9	mu2	B
10	,	O
11	have	O
12	been	O
13	implicated	O
14	in	O
15	two	O
16	types	O
17	of	O
18	interaction	O
19	:	O
20	assembly	O
21	with	O
22	the	O
23	beta1	B
24	and	O
25	beta2	O
26	chains	O
27	of	O
28	the	O
29	corresponding	O
30	complexes	O
31	and	O
32	recognition	O
33	of	O
34	tyrosine	O
35	-	O
36	based	O
37	sorting	O
38	signals	O
39	.	O

0	Kidney	O
1	weight	O
2	and	O
3	kidney	O
4	-	O
5	to	O
6	-	O
7	body	O
8	weight	O
9	ratio	O
10	were	O
11	significantly	O
12	elevated	O
13	at	O
14	the	O
15	highest	O
16	dose	O
17	level	O
18	after	O
19	10	O
20	weeks	O
21	and	O
22	at	O
23	the	O
24	two	O
25	higher	O
26	dose	O
27	levels	O
28	after	O
29	15	O
30	weeks	O
31	of	O
32	exposure	O
33	.	O

0	Finally	O
1	,	O
2	in	O
3	situ	O
4	RNA	O
5	hybridization	O
6	studies	O
7	revealed	O
8	a	O
9	very	O
10	specific	O
11	pattern	O
12	of	O
13	EphA8	B
14	gene	I
15	expression	O
16	restricted	O
17	to	O
18	the	O
19	rostral	O
20	region	O
21	of	O
22	midbrain	O
23	tectum	O
24	during	O
25	embryonic	O
26	development	O
27	.	O

0	CONCLUSIONS	O
1	:	O
2	Our	O
3	findings	O
4	suggest	O
5	that	O
6	pre	O
7	-	O
8	treatment	O
9	with	O
10	coenzyme	O
11	Q10	O
12	may	O
13	play	O
14	a	O
15	protective	O
16	role	O
17	during	O
18	routine	O
19	vascular	O
20	procedures	O
21	requiring	O
22	abdominal	O
23	aortic	O
24	cross	O
25	clamping	O
26	by	O
27	attenuating	O
28	the	O
29	degree	O
30	of	O
31	peroxidative	O
32	damage	O
33	.	O

0	We	O
1	previously	O
2	showed	O
3	that	O
4	the	O
5	upstream	O
6	promoter	O
7	element	O
8	of	O
9	the	O
10	yeast	B
11	RP39A	I
12	gene	I
13	consists	O
14	of	O
15	these	O
16	identical	O
17	sequence	O
18	motifs	O
19	.	O

0	Platelet	B
1	activating	I
2	factor	I
3	was	O
4	given	O
5	in	O
6	six	O
7	doses	O
8	at	O
9	15	O
10	minute	O
11	intervals	O
12	and	O
13	airway	O
14	response	O
15	measured	O
16	as	O
17	change	O
18	in	O
19	partial	O
20	expiratory	O
21	flow	O
22	at	O
23	30	O
24	%	O
25	of	O
26	vital	O
27	capacity	O
28	(	O
29	Vp30	O
30	).	O

0	Radiation	O
1	therapy	O
2	was	O
3	effective	O
4	in	O
5	controlling	O
6	symptomatic	O
7	metastasis	O
8	in	O
9	all	O
10	three	O
11	patients	O
12	.	O

0	Moreover	O
1	,	O
2	increasing	O
3	the	O
4	dosage	O
5	of	O
6	wild	B
7	-	I
8	type	I
9	Fus3	I
10	intensifies	O
11	the	O
12	inhibition	O
13	of	O
14	both	O
15	Ty1	B
16	transposition	O
17	and	O
18	invasive	O
19	growth	O
20	.	O

0	Southern	O
1	blotting	O
2	analysis	O
3	implied	O
4	the	O
5	occurrence	O
6	of	O
7	multiple	O
8	COXVb	B
9	genes	I
10	in	O
11	the	O
12	rat	O
13	genome	O
14	.	O

0	MSMS	O
1	Council	O
2	hears	O
3	new	O
4	public	O
5	health	O
6	director	O
7	.	O

0	As	O
1	predicted	O
2	by	O
3	the	O
4	Wing	O
5	and	O
6	Kristofferson	O
7	model	O
8	,	O
9	the	O
10	durations	O
11	of	O
12	successive	O
13	ISIs	O
14	tended	O
15	to	O
16	be	O
17	negatively	O
18	correlated	O
19	.	O

0	Eighteen	O
1	patients	O
2	were	O
3	untreated	O
4	,	O
5	and	O
6	8	O
7	had	O
8	been	O
9	given	O
10	previous	O
11	treatment	O
12	with	O
13	depot	O
14	testosterone	O
15	100	O
16	mg	O
17	intramuscularly	O
18	every	O
19	2	O
20	-	O
21	3	O
22	weeks	O
23	for	O
24	an	O
25	average	O
26	duration	O
27	of	O
28	4	O
29	.	O
30	7	O
31	years	O
32	.	O

0	During	O
1	conventional	O
2	hemofiltration	O
3	using	O
4	substitution	O
5	fluid	O
6	with	O
7	a	O
8	Na	O
9	+	O
10	concentration	O
11	of	O
12	140	O
13	mEq	O
14	/	O
15	L	O
16	,	O
17	a	O
18	decrease	O
19	in	O
20	extracellular	O
21	fluid	O
22	volume	O
23	was	O
24	noted	O
25	whereas	O
26	the	O
27	intracellular	O
28	fluid	O
29	volume	O
30	was	O
31	unaltered	O
32	.	O

0	An	O
1	examination	O
2	of	O
3	the	O
4	properties	O
5	of	O
6	sequences	O
7	surrounding	O
8	ARS1	B
9	left	O
10	open	O
11	the	O
12	possibility	O
13	that	O
14	ABFI	B
15	enhances	O
16	the	O
17	initiation	O
18	of	O
19	DNA	O
20	replication	O
21	at	O
22	ARS1	B
23	by	O
24	transcriptional	O
25	activation	O
26	.	O

0	Treatment	O
1	of	O
2	meat	O
3	muscle	O
4	800	O
5	V	O
6	for	O
7	45	O
8	s	O
9	reduced	O
10	weeping	O
11	but	O
12	increased	O
13	slightly	O
14	the	O
15	rate	O
16	of	O
17	autoxidation	O
18	of	O
19	lipids	O
20	.	O

0	RNA	O
1	blot	O
2	hybridizations	O
3	identified	O
4	an	O
5	1	O
6	.	O
7	8	O
8	-	O
9	kb	O
10	mRNA	O
11	common	O
12	to	O
13	cytochrome	B
14	b6	I
15	and	O
16	subunit	B
17	IV	I
18	,	O
19	and	O
20	an	O
21	intensely	O
22	hybridizing	O
23	0	O
24	.	O
25	8	O
26	-	O
27	kb	O
28	mRNA	O
29	specific	O
30	to	O
31	the	O
32	subunit	B
33	IV	I
34	gene	I
35	probe	I
36	.	O

0	The	O
1	amplitude	O
2	of	O
3	detrusor	O
4	contractions	O
5	at	O
6	6	O
7	,	O
8	12	O
9	,	O
10	and	O
11	24	O
12	hours	O
13	showed	O
14	no	O
15	significant	O
16	difference	O
17	from	O
18	that	O
19	in	O
20	the	O
21	controls	O
22	.	O

0	N	O
1	-	O
2	Substituted	O
3	trimethylsilylcarbamates	O
4	were	O
5	tested	O
6	as	O
7	derivatizing	O
8	reagents	O
9	for	O
10	gas	O
11	chromatographic	O
12	analysis	O
13	.	O

0	The	O
1	observation	O
2	of	O
3	late	O
4	effects	O
5	after	O
6	irradiations	O
7	or	O
8	after	O
9	space	O
10	flights	O
11	show	O
12	the	O
13	difficulties	O
14	encountered	O
15	in	O
16	assessing	O
17	radiative	O
18	risks	O
19	during	O
20	long	O
21	duration	O
22	space	O
23	flights	O
24	.	O

0	High	O
1	resolution	O
2	computed	O
3	tomography	O
4	of	O
5	the	O
6	lungs	O
7	in	O
8	patients	O
9	with	O
10	rheumatoid	O
11	arthritis	O
12	.	O

0	Amino	O
1	acid	O
2	residues	O
3	147	O
4	-	O
5	167	O
6	of	O
7	the	O
8	previously	O
9	reported	O
10	sequence	O
11	are	O
12	replaced	O
13	by	O
14	new	O
15	residues	O
16	147	O
17	to	O
18	150	O
19	.	O

0	These	O
1	results	O
2	indicate	O
3	that	O
4	baculovirus	O
5	-	O
6	expressed	O
7	TR	B
8	mediates	O
9	transcriptional	O
10	activation	O
11	and	O
12	repression	O
13	in	O
14	a	O
15	promoter	O
16	-	O
17	specific	O
18	manner	O
19	in	O
20	vitro	O
21	.	O

0	The	O
1	concentrations	O
2	of	O
3	vitamin	O
4	A	O
5	precursors	O
6	and	O
7	vitamin	O
8	E	O
9	in	O
10	the	O
11	hay	O
12	were	O
13	below	O
14	currently	O
15	recommended	O
16	dietary	O
17	levels	O
18	for	O
19	llamas	O
20	,	O
21	and	O
22	alfalfa	O
23	hay	O
24	appears	O
25	to	O
26	provide	O
27	an	O
28	unreliable	O
29	source	O
30	of	O
31	vitamins	O
32	A	O
33	and	O
34	E	O
35	in	O
36	this	O
37	species	O
38	.	O

0	Hypoglycemic	O
1	and	O
2	antidiabetic	O
3	properties	O

0	To	O
1	determine	O
2	if	O
3	CYC2	B
4	is	O
5	found	O
6	in	O
7	a	O
8	complex	O
9	with	O
10	previously	O
11	identified	O
12	trypanosome	B
13	cdc2	I
14	-	I
15	related	I
16	kinases	I
17	(	O
18	CRKs	B
19	),	O
20	the	O
21	CYC2	B
22	gene	I
23	was	O
24	fused	O
25	to	O
26	the	O
27	TY	B
28	epitope	I
29	tag	I
30	,	O
31	integrated	O
32	into	O
33	the	O
34	trypanosome	O
35	genome	O
36	,	O
37	and	O
38	expressed	O
39	under	O
40	inducible	O
41	control	O
42	.	O

0	Methyl	O
1	formate	O
2	was	O
3	used	O
4	as	O
5	the	O
6	solvent	O
7	of	O
8	biodegradable	O
9	oligoesters	O
10	for	O
11	the	O
12	fabrication	O
13	of	O
14	microspheres	O
15	with	O
16	encapsulated	O
17	bovine	B
18	serum	I
19	albumin	I
20	(	O
21	BSA	B
22	).	O

0	G	B
1	-	I
2	CSF	I
3	was	O
4	started	O
5	on	O
6	day	O
7	3	O
8	of	O
9	each	O
10	cycle	O
11	(	O
12	5	O
13	microg	O
14	/	O
15	kg	O
16	/	O
17	day	O
18	)	O
19	and	O
20	was	O
21	stopped	O
22	the	O
23	day	O
24	before	O
25	the	O
26	last	O
27	apheresis	O
28	or	O
29	when	O
30	absolute	O
31	neutrophil	O
32	count	O
33	was	O
34	above	O
35	0	O
36	.	O
37	5	O
38	x	O
39	10	O
40	(	O
41	9	O
42	)/	O
43	l	O
44	.	O

0	Peripheral	O
1	visual	O
2	stimuli	O
3	and	O
4	monoaural	O
5	auditory	O
6	stimuli	O
7	were	O
8	used	O
9	as	O
10	targets	O
11	.	O

0	The	O
1	full	B
2	-	I
3	length	I
4	N	I
5	gene	I
6	,	O
7	encoded	O
8	by	O
9	open	O
10	reading	O
11	frame	O
12	7	O
13	,	O
14	was	O
15	cloned	O
16	from	O
17	the	O
18	Canadian	O
19	PRRS	O
20	virus	O
21	,	O
22	PA	O
23	-	O
24	8	O
25	.	O

0	Biological	O
1	evaluation	O
2	of	O
3	mibolerone	B
4	in	O
5	the	O
6	female	O
7	Beagle	O
8	.	O

0	Implication	O
1	of	O
2	PAF	B
3	and	O
4	acetylhydrolase	B
5	(	O
6	PAF	B
7	-	O
8	AH	I
9	)	O
10	activity	O
11	in	O
12	periodontal	O
13	disease	O
14	.	O

0	Conversely	O
1	,	O
2	the	O
3	central	O
4	regions	O
5	are	O
6	highly	O
7	variable	O
8	.	O

0	Both	O
1	mu	B
2	and	O
3	gamma	B
4	2b	I
5	heavy	I
6	chain	I
7	genes	I
8	cause	O
9	this	O
10	feedback	O
11	inhibition	O
12	of	O
13	heavy	O
14	chain	O
15	gene	O
16	rearrangement	O
17	.	O

0	Me	B
1	(	I
2	2	I
3	)	O
4	SO	B
5	-	O
6	induced	O
7	neuronal	O
8	differentiation	O
9	of	O
10	N1E	O
11	-	O
12	115	O
13	neuroblastoma	O
14	cells	O
15	increased	O
16	both	O
17	the	O
18	expression	O
19	of	O
20	the	O
21	endogenous	B
22	Ntr	I
23	-	I
24	1	I
25	gene	I
26	and	O
27	reporter	O
28	genes	O
29	driven	O
30	by	O
31	NTR	B
32	-	I
33	1	I
34	promoter	I
35	sequences	I
36	by	O
37	3	O
38	-	O
39	4	O
40	-	O
41	fold	O
42	.	O

0	This	O
1	gene	O
2	encodes	O
3	a	O
4	putative	O
5	transcription	O
6	factor	O
7	with	O
8	regions	O
9	of	O
10	homology	O
11	to	O
12	several	O
13	other	O
14	proteins	O
15	including	O
16	the	O
17	zinc	O
18	fingers	O
19	and	O
20	other	O
21	domains	O
22	of	O
23	the	O
24	Drosophila	B
25	trithorax	I
26	gene	I
27	product	I
28	,	O
29	and	O
30	the	O
31	"	O
32	AT	B
33	-	I
34	hook	I
35	"	O
36	DNA	O
37	-	O
38	binding	O
39	motif	O
40	of	O
41	high	B
42	mobility	I
43	group	I
44	proteins	I
45	.	O

0	Electrophoretic	O
1	mobility	O
2	shift	O
3	assays	O
4	and	O
5	competition	O
6	experiments	O
7	showed	O
8	that	O
9	site	O
10	A	O
11	is	O
12	recognized	O
13	by	O
14	an	O
15	NF1	B
16	protein	I
17	.	O

0	RESULTS	O
1	:	O
2	Looking	O
3	at	O
4	the	O
5	question	O
6	of	O
7	its	O
8	benefits	O
9	,	O
10	we	O
11	were	O
12	unable	O
13	to	O
14	find	O
15	any	O
16	methodologically	O
17	sound	O
18	studies	O
19	that	O
20	have	O
21	shown	O
22	efficacy	O
23	for	O
24	EMDR	O
25	in	O
26	eating	O
27	disorders	O
28	,	O
29	or	O
30	,	O
31	indeed	O
32	,	O
33	any	O
34	psychiatric	O
35	disorder	O
36	.	O

0	Of	O
1	848	O
2	patients	O
3	,	O
4	819	O
5	cases	O
6	with	O
7	complete	O
8	description	O
9	of	O
10	patient	O
11	'	O
12	s	O
13	background	O
14	were	O
15	evaluable	O
16	:	O
17	Group	O
18	A	O
19	(	O
20	surgery	O
21	+	O
22	MMC	O
23	+	O
24	5	O
25	-	O
26	FU	O
27	:	O
28	chemotherapy	O
29	)	O
30	253	O
31	cases	O
32	,	O
33	group	O
34	B	O
35	(	O
36	surgery	O
37	+	O
38	MMC	O
39	+	O
40	5	O
41	-	O
42	FU	O
43	+	O
44	OK	O
45	-	O
46	432	O
47	or	O
48	PSK	O
49	:	O
50	immunochemotherapy	O
51	)	O
52	282	O
53	and	O
54	group	O
55	C	O
56	(	O
57	surgery	O
58	alone	O
59	)	O
60	284	O
61	.	O

0	The	O
1	intron	O
2	is	O
3	capable	O
4	of	O
5	splicing	O
6	despite	O
7	the	O
8	fact	O
9	that	O
10	both	O
11	the	O
12	EBS1	B
13	/	O
14	IBS1	B
15	and	O
16	the	O
17	EBS2	B
18	/	O
19	IBS2	B
20	sequence	O
21	motifs	O
22	,	O
23	thought	O
24	to	O
25	be	O
26	necessary	O
27	for	O
28	correct	O
29	splicing	O
30	,	O
31	extend	O
32	over	O
33	5	O
34	instead	O
35	of	O
36	6	O
37	bp	O
38	.	O

0	Recombinant	B
1	human	I
2	erythropoietin	I
3	(	O
4	epoetin	B
5	)	O
6	is	O
7	approved	O
8	to	O
9	be	O
10	administered	O
11	by	O
12	the	O
13	intravenous	O
14	(	O
15	i	O
16	.	O
17	v	O
18	.)	O
19	or	O
20	subcutaneous	O
21	(	O
22	SC	O
23	)	O
24	route	O
25	.	O

0	Basal	O
1	components	O
2	of	O
3	the	O
4	transcription	O
5	apparatus	O
6	(	O
7	RNA	B
8	polymerase	I
9	II	I
10	,	O
11	TATA	B
12	-	I
13	binding	I
14	protein	I
15	)	O
16	contain	O
17	activation	O
18	domains	O
19	:	O
20	is	O
21	the	O
22	repetitive	O
23	C	O
24	-	O
25	terminal	O
26	domain	O
27	(	O
28	CTD	O
29	)	O
30	of	O
31	RNA	B
32	polymerase	I
33	II	I
34	a	O
35	"	O
36	portable	O
37	enhancer	O
38	domain	O
39	"?	O
40	Regions	O
41	rich	O
42	in	O
43	serine	O
44	,	O
45	threonine	O
46	,	O
47	and	O
48	proline	O
49	residues	O
50	can	O
51	be	O
52	found	O
53	in	O
54	transcriptional	O
55	activation	O
56	domains	O
57	,	O
58	as	O
59	well	O
60	as	O
61	in	O
62	the	O
63	N	O
64	-	O
65	terminal	O
66	parts	O
67	of	O
68	mammalian	B
69	TATA	I
70	-	I
71	binding	I
72	proteins	I
73	,	O
74	where	O
75	they	O
76	are	O
77	interrupted	O
78	by	O
79	polyglutamine	O
80	stretches	O
81	.	O

0	Topics	O
1	reviewed	O
2	here	O
3	include	O
4	:	O
5	data	O
6	supporting	O
7	the	O
8	association	O
9	of	O
10	myositis	O
11	with	O
12	cancer	O
13	and	O
14	the	O
15	appropriate	O
16	evaluations	O
17	for	O
18	malignancy	O
19	in	O
20	a	O
21	myositis	O
22	patient	O
23	;	O
24	an	O
25	approach	O
26	to	O
27	the	O
28	assessment	O
29	of	O
30	patients	O
31	with	O
32	dermatomyositis	O
33	sine	O
34	myositis	O
35	;	O
36	the	O
37	usefulness	O
38	of	O
39	the	O
40	clinicopathological	O
41	and	O
42	serological	O
43	classifications	O
44	;	O
45	a	O
46	discussion	O
47	of	O
48	whether	O
49	childhood	O
50	and	O
51	adult	O
52	myositis	O
53	are	O
54	the	O
55	same	O
56	or	O
57	different	O
58	entities	O
59	;	O
60	a	O
61	review	O
62	of	O
63	those	O
64	prognostic	O
65	factors	O
66	to	O
67	consider	O
68	in	O
69	the	O
70	clinical	O
71	management	O
72	of	O
73	myositis	O
74	patients	O
75	;	O
76	current	O
77	approaches	O
78	and	O
79	their	O
80	limitations	O
81	for	O
82	assessing	O
83	disease	O
84	activity	O
85	and	O
86	damage	O
87	.	O

0	The	O
1	defect	O
2	in	O
3	these	O
4	proteins	O
5	was	O
6	also	O
7	uniformly	O
8	suppressed	O
9	by	O
10	either	O
11	Mn2	O
12	+,	O
13	or	O
14	the	O
15	Mu	B
16	B	I
17	protein	I
18	in	O
19	the	O
20	presence	O
21	of	O
22	ATP	O
23	and	O
24	target	O
25	DNA	O
26	.	O

0	Furthermore	O
1	,	O
2	this	O
3	study	O
4	demonstrates	O
5	that	O
6	reduced	O
7	inotropy	O
8	with	O
9	timolol	O
10	helped	O
11	uniform	O
12	local	O
13	contraction	O
14	as	O
15	estimated	O
16	by	O
17	the	O
18	increased	O
19	LONG	O
20	/	O
21	CIRC	O
22	ratio	O
23	,	O
24	a	O
25	transition	O
26	that	O
27	could	O
28	improve	O
29	contraction	O
30	efficacy	O
31	.	O

0	In	O
1	both	O
2	shoots	O
3	and	O
4	roots	O
5	,	O
6	GT	B
7	-	I
8	2	I
9	protein	I
10	is	O
11	undetectable	O
12	in	O
13	meristematic	O
14	tissue	O
15	but	O
16	becomes	O
17	expressed	O
18	at	O
19	later	O
20	stages	O
21	of	O
22	cellular	O
23	development	O
24	,	O
25	consistent	O
26	with	O
27	a	O
28	role	O
29	in	O
30	contributing	O
31	to	O
32	the	O
33	pattern	O
34	of	O
35	phytochrome	B
36	A	I
37	gene	I
38	expression	O
39	.	O

0	[	O
1	82Br	O
2	]	O
3	MISO	O
4	was	O
5	prepared	O
6	by	O
7	irradiating	O
8	samples	O
9	of	O
10	Br	O
11	-	O
12	MISO	O
13	in	O
14	a	O
15	SLOWPOKE	O
16	reactor	O
17	for	O
18	2	O
19	h	O
20	at	O
21	a	O
22	thermal	O
23	neutron	O
24	flux	O
25	of	O
26	10	O
27	(	O
28	12	O
29	)	O
30	n	O
31	cm	O
32	-	O
33	2	O
34	s	O
35	-	O
36	1	O
37	.	O

0	The	O
1	epidemic	O
2	occurred	O
3	in	O
4	a	O
5	group	O
6	of	O
7	26	O
8	community	O
9	members	O
10	(	O
11	23	O
12	men	O
13	and	O
14	3	O
15	women	O
16	,	O
17	mean	O
18	age	O
19	,	O
20	28	O
21	.	O
22	9	O
23	--	O
24	3	O
25	years	O
26	)	O
27	living	O
28	and	O
29	working	O
30	together	O
31	,	O
32	who	O
33	underwent	O
34	acute	O
35	and	O
36	convalescent	O
37	serologic	O
38	tests	O
39	for	O
40	Mycoplasma	O
41	pneumoniae	O
42	,	O
43	Legionella	O
44	pneumophila	O
45	,	O
46	cytomegalovirus	O
47	,	O
48	adenovirus	O
49	,	O
50	Coxiella	O
51	burnetii	O
52	,	O
53	and	O
54	Chlamydia	O
55	pneumoniae	O
56	.	O

0	Restriction	O
1	analysis	O
2	and	O
3	Southern	O
4	hybridization	O
5	revealed	O
6	the	O
7	presence	O
8	of	O
9	Tn5422	O
10	in	O
11	all	O
12	the	O
13	plasmid	O
14	-	O
15	mediated	O
16	cadmium	O
17	-	O
18	resistant	O
19	L	O
20	.	O
21	monocytogenes	O
22	strains	O
23	tested	O
24	but	O
25	not	O
26	in	O
27	strains	O
28	encoding	O
29	cadmium	O
30	resistance	O
31	on	O
32	the	O
33	chromosome	O
34	.	O

0	Gene	O
1	silencing	O
2	associated	O
3	with	O
4	repeated	O
5	DNA	O
6	sequences	O
7	has	O
8	been	O
9	reported	O
10	for	O
11	many	O
12	eukaryotes	O
13	,	O
14	including	O
15	plants	O
16	.	O

0	The	O
1	sites	O
2	targeted	O
3	for	O
4	mutagenesis	O
5	,	O
6	residues	O
7	60	O
8	,	O
9	61	O
10	,	O
11	and	O
12	66	O
13	,	O
14	are	O
15	located	O
16	within	O
17	a	O
18	putative	O
19	helical	O
20	loop	O
21	structure	O
22	which	O
23	may	O
24	be	O
25	involved	O
26	in	O
27	substrate	O
28	recognition	O
29	by	O
30	the	O
31	enzyme	O
32	.	O

0	Secondary	O
1	pancreatic	O
2	involvement	O
3	of	O
4	mycosis	O
5	fungoides	O
6	detected	O
7	by	O
8	a	O
9	clinically	O
10	palpable	O
11	mass	O
12	.	O

0	A	O
1	comparison	O
2	of	O
3	physical	O
4	and	O
5	cytogenetic	O
6	estimates	O
7	of	O
8	radiation	O
9	dose	O
10	in	O
11	patients	O
12	treated	O
13	with	O
14	iodine	O
15	-	O
16	131	O
17	for	O
18	thyroid	O
19	carcinoma	O
20	.	O

0	As	O
1	the	O
2	length	O
3	of	O
4	the	O
5	fatty	O
6	acid	O
7	decreased	O
8	,	O
9	the	O
10	binding	O
11	affinity	O
12	was	O
13	reduced	O
14	;	O
15	myristic	O
16	acid	O
17	(	O
18	14	O
19	:	O
20	0	O
21	)	O
22	bound	O
23	with	O
24	a	O
25	K	O
26	(	O
27	d	O
28	)	O
29	of	O
30	1409	O
31	+/-	O
32	423	O
33	nM	O
34	,	O
35	but	O
36	medium	O
37	-	O
38	chain	O
39	(	O
40	decanoic	O
41	acid	O
42	,	O
43	10	O
44	:	O
45	0	O
46	)	O
47	and	O
48	short	O
49	-	O
50	chain	O
51	(	O
52	octanoic	O
53	acid	O
54	,	O
55	8	O
56	:	O
57	0	O
58	)	O
59	lipids	O
60	were	O
61	not	O
62	bound	O
63	at	O
64	all	O
65	.	O

0	The	O
1	relative	O
2	tumor	O
3	FDG	O
4	-	O
5	uptake	O
6	(	O
7	Q	O
8	-	O
9	MRGlu	O
10	)	O
11	(	O
12	tumor	O
13	/	O
14	contralateral	O
15	cortex	O
16	)	O
17	of	O
18	all	O
19	meningiomas	O
20	was	O
21	calculated	O
22	with	O
23	0	O
24	.	O
25	73	O
26	+/-	O
27	0	O
28	.	O
29	37	O
30	(	O
31	0	O
32	.	O
33	24	O
34	-	O
35	1	O
36	.	O
37	79	O
38	).	O

0	Grasso	O
1	,	O
2	and	O
3	A	O
4	.	O

0	We	O
1	have	O
2	elucidated	O
3	the	O
4	exon	O
5	-	O
6	intron	O
7	organization	O
8	of	O
9	the	O
10	entire	O
11	human	B
12	CD58	I
13	gene	I
14	,	O
15	including	O
16	approximately	O
17	2	O
18	.	O
19	5	O
20	kilobases	O
21	(	O
22	kb	O
23	)	O
24	of	O
25	5	O
26	'-	O
27	flanking	O
28	DNA	O
29	.	O

0	An	O
1	IgG	B
2	monoclonal	O
3	gammopathy	O
4	was	O
5	present	O
6	in	O
7	the	O
8	serum	O
9	of	O
10	4	O
11	patients	O
12	and	O
13	Bence	O
14	-	O
15	Joanes	O
16	proteinuria	O
17	was	O
18	found	O
19	in	O
20	1	O
21	patient	O
22	.	O

0	TBP	B
1	can	O
2	be	O
3	phosphorylated	O
4	in	O
5	vitro	O
6	by	O
7	extracts	O
8	of	O
9	U937	O
10	cells	O
11	or	O
12	by	O
13	bacterially	O
14	expressed	O
15	activated	O
16	ERK2	B
17	;	O
18	the	O
19	phosphorylation	O
20	sites	O
21	were	O
22	mapped	O
23	to	O
24	ERK	B
25	kinase	I
26	consensus	I
27	sites	I
28	in	O
29	the	O
30	TBP	B
31	amino	I
32	-	I
33	terminal	I
34	domain	I
35	.	O

0	The	O
1	statistical	O
2	analysis	O
3	of	O
4	data	O
5	of	O
6	TRH	O
7	test	O
8	on	O
9	a	O
10	sample	O
11	of	O
12	57	O
13	healthy	O
14	volunteers	O
15	has	O
16	permitted	O
17	an	O
18	evaluation	O
19	of	O
20	the	O
21	upper	O
22	limits	O
23	of	O
24	the	O
25	normal	O
26	thyrotropin	B
27	response	O
28	;	O
29	the	O
30	secretory	O
31	area	O
32	(	O
33	As	O
34	)	O
35	was	O
36	shown	O
37	to	O
38	be	O
39	more	O
40	discriminating	O
41	.	O

0	To	O
1	search	O
2	for	O
3	transcriptional	O
4	regulators	O
5	,	O
6	we	O
7	used	O
8	a	O
9	fragment	O
10	of	O
11	the	O
12	SpHE	B
13	promoter	I
14	containing	O
15	several	O
16	individual	O
17	elements	O
18	instead	O
19	of	O
20	the	O
21	conventional	O
22	bait	O
23	that	O
24	contains	O
25	a	O
26	multimerized	O
27	cis	O
28	element	O
29	.	O

0	Zinc	B
1	fingers	I
2	(	O
3	Zf	B
4	)	O
5	are	O
6	a	O
7	common	O
8	structural	O
9	motif	O
10	found	O
11	in	O
12	many	O
13	nucleic	B
14	acid	I
15	-	I
16	binding	I
17	proteins	I
18	.	O

0	Consistent	O
1	with	O
2	our	O
3	model	O
4	,	O
5	CTCF	B
6	binding	O
7	is	O
8	abolished	O
9	by	O
10	DNA	O
11	methylation	O
12	.	O

0	Marked	O
1	thrombocytopenia	O
2	,	O
3	depletion	O
4	of	O
5	serum	O
6	fibrinogen	B
7	and	O
8	prolonged	O
9	prothrombin	B
10	and	O
11	activated	O
12	partial	O
13	thromboplastin	B
14	time	O
15	,	O
16	were	O
17	recorded	O
18	at	O
19	5	O
20	to	O
21	10	O
22	and	O
23	30	O
24	to	O
25	40	O
26	minutes	O
27	after	O
28	intravenous	O
29	envenomation	O
30	.	O

0	The	O
1	murine	B
2	facilitative	I
3	glucose	I
4	transporter	I
5	isoform	I
6	3	I
7	(	O
8	Glut	B
9	3	I
10	)	O
11	is	O
12	developmentally	O
13	regulated	O
14	and	O
15	is	O
16	predominantly	O
17	expressed	O
18	in	O
19	neurons	O
20	and	O
21	trophoblasts	O
22	.	O

0	Nucleotide	O
1	sequence	O
2	analysis	O
3	of	O
4	the	O
5	Pseudomonas	B
6	putida	I
7	PpG7	I
8	salicylate	I
9	hydroxylase	I
10	gene	I
11	(	O
12	nahG	B
13	)	O
14	and	O
15	its	O
16	3	O
17	'-	O
18	flanking	O
19	region	O
20	.	O

0	High	O
1	-	O
2	level	O
3	expression	O
4	in	O
5	Escherichia	O
6	coli	O
7	of	O
8	selenocysteine	B
9	-	I
10	containing	I
11	rat	I
12	thioredoxin	I
13	reductase	I
14	utilizing	O
15	gene	O
16	fusions	O
17	with	O
18	engineered	O
19	bacterial	O
20	-	O
21	type	O
22	SECIS	O
23	elements	O
24	and	O
25	co	O
26	-	O
27	expression	O
28	with	O
29	the	O
30	selA	B
31	,	O
32	selB	B
33	and	O
34	selC	B
35	genes	I
36	.	O

0	Repair	O
1	of	O
2	double	O
3	-	O
4	strand	O
5	breaks	O
6	(	O
7	DSBs	O
8	)	O
9	in	O
10	chromosomal	O
11	DNA	O
12	by	O
13	nonhomologous	O
14	end	O
15	-	O
16	joining	O
17	(	O
18	NHEJ	O
19	)	O
20	is	O
21	not	O
22	well	O
23	characterized	O
24	in	O
25	the	O
26	yeast	O
27	Saccharomyces	O
28	cerevisiae	O
29	.	O

0	The	O
1	transcriptional	O
2	unit	O
3	spans	O
4	a	O
5	chromosomal	O
6	region	O
7	of	O
8	about	O
9	55	O
10	kilobase	O
11	pairs	O
12	(	O
13	kbp	O
14	).	O

0	The	O
1	early	O
2	dg	O
3	.	O
4	of	O
5	rejection	O
6	and	O
7	especially	O
8	acute	O
9	rejection	O
10	,	O
11	it	O
12	'	O
13	s	O
14	adequate	O
15	management	O
16	,	O
17	decreased	O
18	risk	O
19	for	O
20	the	O
21	future	O
22	chronic	O
23	rejection	O
24	nephropathy	O
25	.	O

0	Interestingly	O
1	,	O
2	segment	O
3	nesting	O
4	differentially	O
5	increases	O
6	the	O
7	copy	O
8	number	O
9	of	O
10	genes	O
11	encoded	O
12	by	O
13	segment	O
14	W	O
15	,	O
16	suggesting	O
17	that	O
18	the	O
19	unusual	O
20	genomic	O
21	organization	O
22	of	O
23	PDVs	O
24	may	O
25	be	O
26	directly	O
27	linked	O
28	to	O
29	the	O
30	unique	O
31	functions	O
32	of	O
33	this	O
34	virus	O
35	in	O
36	its	O
37	obligate	O
38	mutualistic	O
39	association	O
40	with	O
41	parasitic	O
42	wasps	O
43	.	O

0	Sp1	B
1	binds	O
2	the	O
3	CTC	O
4	repeat	O
5	with	O
6	an	O
7	affinity	O
8	,	O
9	KD	O
10	=	O
11	0	O
12	.	O
13	37	O
14	nM	O
15	,	O
16	at	O
17	least	O
18	as	O
19	high	O
20	as	O
21	the	O
22	consensus	O
23	GC	O
24	box	O
25	.	O

0	These	O
1	results	O
2	demonstrate	O
3	Ras	B
4	-	O
5	and	O
6	Raf	B
7	-	O
8	independent	O
9	ERK	B
10	MAPK	I
11	activation	O
12	maintains	O
13	cell	O
14	viability	O
15	following	O
16	heat	O
17	shock	O
18	.	O

0	This	O
1	study	O
2	confirms	O
3	,	O
4	although	O
5	individual	O
6	reaction	O
7	is	O
8	remarkably	O
9	different	O
10	,	O
11	transportation	O
12	as	O
13	a	O
14	potent	O
15	stressor	O
16	for	O
17	Beagle	O
18	dogs	O
19	.	O

0	It	O
1	consists	O
2	of	O
3	2185	O
4	amino	O
5	acid	O
6	residues	O
7	encoded	O
8	by	O
9	a	O
10	9	O
11	-	O
12	kilobase	O
13	pair	O
14	mRNA	O
15	;	O
16	several	O
17	splice	O
18	variants	O
19	have	O
20	been	O
21	detected	O
22	in	O
23	human	O
24	and	O
25	rat	O
26	cDNA	O
27	libraries	O
28	.	O

0	Despite	O
1	the	O
2	presence	O
3	of	O
4	one	O
5	additional	O
6	ribonucleotide	B
7	reductase	I
8	,	O
9	the	O
10	nrdAB	B
11	-	I
12	encoded	I
13	enzyme	I
14	is	O
15	essential	O
16	to	O
17	the	O
18	aerobic	O
19	growth	O
20	of	O
21	the	O
22	cell	O
23	because	O
24	nrdAB	B
25	-	I
26	defective	I
27	mutants	I
28	of	O
29	both	O
30	species	O
31	are	O
32	not	O
33	viable	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	oxygen	O
39	.	O

0	The	O
1	Harleco	O
2	apparatus	O
3	is	O
4	a	O
5	simple	O
6	,	O
7	useful	O
8	,	O
9	cost	O
10	-	O
11	effective	O
12	adjunct	O
13	to	O
14	the	O
15	diagnosis	O
16	and	O
17	treatment	O
18	of	O
19	this	O
20	life	O
21	-	O
22	threatening	O
23	condition	O
24	.	O

0	BACKGROUND	O
1	AND	O
2	DESIGN	O
3	:	O
4	Fifty	O
5	-	O
6	nine	O
7	melanocytic	O
8	nevi	O
9	with	O
10	eccentric	O
11	foci	O
12	of	O
13	hyperpigmentation	O
14	("	O
15	small	O
16	dark	O
17	dots	O
18	")	O
19	that	O
20	measured	O
21	primarily	O
22	1	O
23	to	O
24	2	O
25	mm	O
26	in	O
27	diameter	O
28	were	O
29	prospectively	O
30	examined	O
31	to	O
32	determine	O
33	the	O
34	histologic	O
35	correlates	O
36	of	O
37	the	O
38	dark	O
39	dots	O
40	.	O

0	Laboratory	O
1	exam	O
2	:	O
3	IDR	O
4	of	O
5	the	O
6	tuberculin	O
7	was	O
8	high	O
9	positive	O
10	,	O
11	chest	O
12	radiography	O
13	shows	O
14	hilar	O
15	bilateral	O
16	calcifications	O
17	,	O
18	ORL	O
19	exam	O
20	shows	O
21	a	O
22	tumor	O
23	at	O
24	the	O
25	foot	O
26	of	O
27	the	O
28	epiglottis	O
29	and	O
30	anatomopathological	O
31	exam	O
32	shows	O
33	low	O
34	differentiated	O
35	epidermoid	O
36	carcinoma	O
37	.	O

0	Histochemical	O
1	localization	O
2	of	O
3	GUS	B
4	revealed	O
5	promoter	O
6	function	O
7	in	O
8	leaf	O
9	epidermis	O
10	,	O
11	mesophyll	O
12	and	O
13	vascular	O
14	bundles	O
15	,	O
16	in	O
17	the	O
18	cortex	O
19	and	O
20	vascular	O
21	cylinder	O
22	of	O
23	the	O
24	root	O
25	.	O

0	Structure	O
1	and	O
2	localization	O
3	of	O
4	the	O
5	human	O
6	gene	O
7	encoding	O
8	SR	B
9	-	I
10	BI	I
11	/	O
12	CLA	B
13	-	I
14	1	I
15	.	O

0	The	O
1	similar	O
2	phenotypes	O
3	of	O
4	bur6	B
5	and	O
6	bur3	B
7	(	O
8	mot1	B
9	)	O
10	mutations	O
11	suggest	O
12	that	O
13	Bur6p	B
14	and	O
15	Mot1p	B
16	have	O
17	related	O
18	,	O
19	but	O
20	not	O
21	identical	O
22	,	O
23	functions	O
24	in	O
25	modulating	O
26	the	O
27	activity	O
28	of	O
29	the	O
30	general	O
31	transcription	O
32	machinery	O
33	in	O
34	vivo	O
35	.	O

0	In	O
1	PC12	O
2	cells	O
3	,	O
4	nerve	B
5	growth	I
6	factor	I
7	induces	O
8	neuronal	O
9	differentiation	O
10	and	O
11	repressed	O
12	expression	O
13	of	O
14	nrg	B
15	-	I
16	1	I
17	.	O

0	Lipoprotein	B
1	lipase	I
2	(	O
3	LPL	B
4	),	O
5	a	O
6	key	O
7	enzyme	O
8	in	O
9	normal	O
10	lipoprotein	O
11	metabolism	O
12	,	O
13	has	O
14	a	O
15	complex	O
16	pattern	O
17	of	O
18	regulation	O
19	and	O
20	tissue	O
21	-	O
22	specific	O
23	expression	O
24	.	O

0	A	O
1	receptor	B
2	-	I
3	like	I
4	protein	I
5	kinase	I
6	,	O
7	OsPK10	B
8	,	O
9	has	O
10	been	O
11	cloned	O
12	from	O
13	rice	O
14	(	O
15	Oryza	O
16	sativa	O
17	).	O

0	Age	O
1	>/=	O
2	50	O
3	years	O
4	(	O
5	odds	O
6	ratio	O
7	[	O
8	OR	O
9	],	O
10	14	O
11	.	O
12	1	O
13	),	O
14	BMI	O
15	>/=	O
16	28	O
17	kg	O
18	/	O
19	m	O
20	(	O
21	2	O
22	)	O
23	(	O
24	OR	O
25	,	O
26	5	O
27	.	O
28	7	O
29	),	O
30	triglycerides	O
31	>/=	O
32	1	O
33	.	O
34	7	O
35	mmol	O
36	/	O
37	L	O
38	(	O
39	OR	O
40	,	O
41	5	O
42	),	O
43	and	O
44	alanine	B
45	aminotransferase	I
46	(	O
47	ALT	B
48	)	O
49	>/=	O
50	2N	O
51	(	O
52	OR	O
53	,	O
54	4	O
55	.	O
56	6	O
57	)	O
58	were	O
59	independently	O
60	associated	O
61	with	O
62	septal	O
63	fibrosis	O
64	.	O

0	Thrombolytic	O
1	therapy	O
2	in	O
3	spontaneous	O
4	coronary	O
5	artery	O
6	dissection	O
7	.	O

0	These	O
1	CTD	B
2	kinases	I
3	,	O
4	designated	O
5	CTDK1	B
6	and	O
7	CTDK2	B
8	,	O
9	are	O
10	fractionated	O
11	by	O
12	chromatography	O
13	on	O
14	Mono	O
15	Q	O
16	.	O

0	The	O
1	concentrations	O
2	of	O
3	apo	B
4	A	I
5	-	I
6	I	I
7	and	O
8	apo	B
9	A	I
10	-	I
11	II	I
12	of	O
13	abstainers	O
14	decreased	O
15	significantly	O
16	compared	O
17	with	O
18	the	O
19	corresponding	O
20	changes	O
21	in	O
22	controls	O
23	.	O

0	Hantaan	O
1	virus	O
2	.	O

0	CIITA	B
1	mRNA	I
2	is	O
3	normally	O
4	inducible	O
5	by	O
6	IFN	B
7	-	I
8	gamma	I
9	in	O
10	class	O
11	II	O
12	non	O
13	-	O
14	inducible	O
15	,	O
16	RB	B
17	-	O
18	defective	O
19	lines	O
20	,	O
21	and	O
22	in	O
23	one	O
24	line	O
25	,	O
26	re	O
27	-	O
28	expression	O
29	of	O
30	RB	B
31	has	O
32	no	O
33	effect	O
34	on	O
35	CIITA	B
36	mRNA	I
37	induction	O
38	levels	O
39	.	O

0	Our	O
1	analysis	O
2	suggests	O
3	that	O
4	Upf1p	B
5	is	O
6	a	O
7	multifunctional	O
8	protein	O
9	with	O
10	separable	O
11	activities	O
12	that	O
13	can	O
14	affect	O
15	mRNA	O
16	turnover	O
17	and	O
18	nonsense	O
19	suppression	O
20	.	O

0	While	O
1	blood	O
2	pressure	O
3	and	O
4	noradrenergic	O
5	activity	O
6	,	O
7	assessed	O
8	as	O
9	changes	O
10	in	O
11	the	O
12	plasma	O
13	levels	O
14	and	O
15	urinary	O
16	excretion	O
17	of	O
18	norepinephrine	O
19	,	O
20	remained	O
21	unaffected	O
22	in	O
23	the	O
24	Pl	O
25	group	O
26	,	O
27	a	O
28	significant	O
29	drop	O
30	in	O
31	the	O
32	supine	O
33	systolic	O
34	and	O
35	diastolic	O
36	blood	O
37	pressures	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	resting	O
45	venous	O
46	norepinephrine	O
47	level	O
48	and	O
49	in	O
50	urinary	O
51	norepinephrine	O
52	excretion	O
53	was	O
54	found	O
55	after	O
56	the	O
57	first	O
58	month	O
59	of	O
60	dF	B
61	administration	O
62	.	O

0	The	O
1	Pro	O
2	-	O
3	258	O
4	-->	O
5	Leu	O
6	(	O
7	P258L	O
8	)	O
9	mutation	O
10	caused	O
11	constitutive	O
12	receptor	O
13	signaling	O
14	that	O
15	was	O
16	equivalent	O
17	to	O
18	about	O
19	45	O
20	%	O
21	of	O
22	the	O
23	maximum	O
24	level	O
25	observed	O
26	in	O
27	wild	O
28	-	O
29	type	O
30	cells	O
31	stimulated	O
32	with	O
33	alpha	B
34	-	I
35	factor	I
36	.	O

0	Furthermore	O
1	,	O
2	upstream	O
3	insertion	O
4	of	O
5	the	O
6	GSTP1	B
7	silencer	I
8	element	I
9	failed	O
10	to	O
11	inhibit	O
12	activity	O
13	of	O
14	a	O
15	heterologous	O
16	promoter	O
17	in	O
18	MCF7	O
19	cells	O
20	.	O

0	Peptide	O
1	sequences	O
2	of	O
3	the	O
4	zinc	B
5	finger	I
6	protein	I
7	Ttk	I
8	and	O
9	the	O
10	transcription	B
11	factor	I
12	Adf	I
13	-	I
14	1	I
15	were	O
16	obtained	O
17	.	O

0	Interestingly	O
1	,	O
2	these	O
3	response	O
4	elements	O
5	display	O
6	dramatically	O
7	reduced	O
8	affinity	O
9	for	O
10	retinoic	B
11	acid	I
12	receptor	I
13	-	O
14	retinoid	B
15	-	I
16	X	I
17	receptor	I
18	heterodimers	O
19	.	O

0	Taken	O
1	together	O
2	,	O
3	our	O
4	results	O
5	indicate	O
6	that	O
7	thrombin	B
8	-	O
9	stimulated	O
10	vascular	O
11	smooth	O
12	muscle	O
13	proliferation	O
14	is	O
15	delayed	O
16	and	O
17	requires	O
18	the	O
19	de	O
20	novo	O
21	expression	O
22	of	O
23	one	O
24	or	O
25	more	O
26	autocrine	O
27	mitogens	O
28	.	O

0	USA	O
1	80	O
2	,	O
3	802	O
4	-	O
5	806	O
6	]	O
7	was	O
8	used	O
9	to	O
10	isolate	O
11	a	O
12	genomic	O
13	clone	O
14	lambda	O
15	PGK	O
16	-	O
17	1	O
18	containing	O
19	a	O
20	portion	O
21	of	O
22	an	O
23	autosomal	O
24	locus	O
25	for	O
26	phosphoglycerate	B
27	kinase	I
28	(	O
29	PGK	B
30	).	O

0	First	O
1	,	O
2	each	O
3	lung	O
4	was	O
5	cut	O
6	into	O
7	slices	O
8	,	O
9	from	O
10	which	O
11	primary	O
12	disectors	O
13	were	O
14	sampled	O
15	systematically	O
16	with	O
17	a	O
18	known	O
19	sampling	O
20	fraction	O
21	.	O

0	In	O
1	patients	O
2	with	O
3	type	O
4	IA	O
5	maple	O
6	syrup	O
7	urine	O
8	disease	O
9	,	O
10	the	O
11	E1alpha	B
12	subunit	I
13	is	O
14	affected	O
15	,	O
16	resulting	O
17	in	O
18	the	O
19	loss	O
20	of	O
21	E1	B
22	and	O
23	branched	B
24	-	I
25	chain	I
26	ketoacid	I
27	dehydrogenase	I
28	catalytic	O
29	activities	O
30	.	O

0	METHODS	O
1	:	O
2	109	O
3	suspected	O
4	cases	O
5	with	O
6	SS	O
7	underwent	O
8	the	O
9	biopsies	O
10	.	O

0	Promoter	O
1	region	O
2	of	O
3	the	O
4	transcriptional	O
5	unit	O
6	for	O
7	human	B
8	alpha	I
9	1	I
10	-	I
11	chimaerin	I
12	,	O
13	a	O
14	neuron	B
15	-	O
16	specific	O
17	GTPase	B
18	-	I
19	activating	I
20	protein	I
21	for	O
22	p21rac	B
23	.	O
24	alpha	B
25	1	I
26	-	I
27	chimaerin	I
28	is	O
29	a	O
30	neuron	B
31	-	O
32	specific	O
33	GTPase	B
34	-	I
35	activating	I
36	protein	I
37	for	O
38	p21rac	B
39	,	O
40	a	O
41	protein	O
42	involved	O
43	in	O
44	morphological	O
45	events	O
46	.	O

0	Domain	O
1	II	O
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	the	O
7	LDL	B
8	receptor	I
9	and	O
10	contains	O
11	four	O
12	repeats	O
13	with	O
14	perfect	O
15	conservation	O
16	of	O
17	all	O
18	6	O
19	consecutive	O
20	cysteines	O
21	.	O

0	Reactivities	O
1	to	O
2	horse	B
3	anti	I
4	-	I
5	lymphocyte	I
6	globulin	I
7	.	O

0	The	O
1	exogenous	O
2	fos	B
3	gene	I
4	was	O
5	rapidly	O
6	induced	O
7	to	O
8	maximal	O
9	levels	O
10	within	O
11	1	O
12	-	O
13	2	O
14	hr	O
15	of	O
16	estrogen	O
17	addition	O
18	.	O

0	This	O
1	article	O
2	will	O
3	briefly	O
4	review	O
5	the	O
6	published	O
7	data	O
8	on	O
9	the	O
10	morphology	O
11	,	O
12	function	O
13	,	O
14	and	O
15	biochemistry	O
16	of	O
17	the	O
18	normal	O
19	renal	O
20	medulla	O
21	and	O
22	the	O
23	pathology	O
24	associated	O
25	with	O
26	RPN	O
27	,	O
28	together	O
29	with	O
30	the	O
31	secondary	O
32	changes	O
33	which	O
34	give	O
35	rise	O
36	to	O
37	cortical	O
38	degeneration	O
39	or	O
40	epithelial	O
41	carcinoma	O
42	.	O

0	This	O
1	activity	O
2	is	O
3	stimulated	O
4	by	O
5	complex	O
6	formation	O
7	with	O
8	the	O
9	other	O
10	eIF2B	B
11	subunits	I
12	.	O

0	Streptococcal	O
1	preparation	O
2	(	O
3	OK	O
4	-	O
5	432	O
6	),	O
7	a	O
8	new	O
9	type	O
10	of	O
11	anti	O
12	-	O
13	cancer	O
14	agent	O
15	,	O
16	was	O
17	given	O
18	to	O
19	the	O
20	patients	O
21	with	O
22	advanced	O
23	cancer	O
24	in	O
25	combination	O
26	with	O
27	Mitomycin	O
28	-	O
29	C	O
30	,	O
31	5	O
32	-	O
33	FU	O
34	and	O
35	Cytosine	O
36	arabinoside	O
37	.	O

0	The	O
1	mouse	B
2	M	I
3	-	I
4	lysozyme	I
5	downstream	I
6	enhancer	I
7	has	O
8	been	O
9	previously	O
10	characterized	O
11	on	O
12	several	O
13	levels	O
14	of	O
15	gene	O
16	regulation	O
17	.	O

0	CONCLUSION	O
1	:	O
2	Presence	O
3	of	O
4	APOE	B
5	epsilon4	I
6	/*	I
7	seems	O
8	to	O
9	increase	O
10	the	O
11	risk	O
12	for	O
13	dementia	O
14	and	O
15	AD	O
16	independently	O
17	of	O
18	its	O
19	effect	O
20	on	O
21	dyslipidemia	O
22	and	O
23	atherogenesis	O
24	.	O

0	Plants	O
1	transformed	O
2	with	O
3	the	O
4	35S	O
5	-	O
6	1	O
7	-	O
8	sst	O
9	construct	O
10	accumulated	O
11	the	O
12	oligofructans	B
13	1	O
14	-	O
15	kestose	O
16	(	O
17	GF2	O
18	),	O
19	1	O
20	,	O
21	1	O
22	-	O
23	nystose	O
24	(	O
25	GF3	O
26	)	O
27	and	O
28	1	O
29	,	O
30	1	O
31	,	O
32	1	O
33	-	O
34	fructosylnystose	O
35	(	O
36	GF4	O
37	).	O

0	Correlation	O
1	coefficients	O
2	between	O
3	the	O
4	reference	O
5	methods	O
6	and	O
7	NIT	O
8	were	O
9	>	O
10	or	O
11	=	O
12	0	O
13	.	O
14	95	O
15	for	O
16	water	O
17	,	O
18	fat	O
19	,	O
20	crude	O
21	protein	O
22	and	O
23	connective	O
24	-	O
25	tissue	O
26	-	O
27	protein	O
28	frei	O
29	meat	O
30	protein	O
31	,	O
32	and	O
33	>	O
34	or	O
35	=	O
36	0	O
37	.	O
38	86	O
39	for	O
40	connective	O
41	-	O
42	tissue	O
43	-	O
44	protein	O
45	.	O

0	Bifunctionality	O
1	of	O
2	the	O
3	AcMNPV	B
4	homologous	I
5	region	I
6	sequence	I
7	(	O
8	hr1	B
9	):	O
10	enhancer	O
11	and	O
12	ori	O
13	functions	O
14	have	O
15	different	O
16	sequence	O
17	requirements	O
18	.	O

0	Laser	O
1	ablation	O
2	has	O
3	been	O
4	employed	O
5	as	O
6	a	O
7	therapeutic	O
8	measure	O
9	for	O
10	chronic	O
11	pulmonary	O
12	emphysema	O
13	.	O

0	"	O
1	In	O
2	vitro	O
3	"	O
4	study	O
5	of	O
6	dentin	O
7	adhesion	O
8	to	O
9	adhesives	O
10	made	O
11	from	O
12	urethane	O
13	molecules	O
14	with	O
15	free	O
16	groups	O
17	of	O
18	isocyanate	O

0	Protein	B
1	kinase	I
2	A	I
3	-	O
4	Ialpha	B
5	subunit	O
6	-	O
7	directed	O
8	antisense	O
9	inhibition	O
10	of	O
11	ovarian	O
12	cancer	O
13	cell	O
14	growth	O
15	:	O
16	crosstalk	O
17	with	O
18	tyrosine	B
19	kinase	I
20	signaling	O
21	pathway	O
22	.	O

0	Fundus	O
1	changes	O
2	in	O
3	(	O
4	type	O
5	II	O
6	)	O
7	mesangiocapillary	O
8	glomerulonephritis	O
9	simulating	O
10	drusen	O
11	:	O
12	a	O
13	histopathological	O
14	report	O
15	.	O

0	Quantitative	O
1	evaluation	O
2	of	O
3	the	O
4	steady	O
5	state	O
6	kinetics	O
7	of	O
8	MEK	B
9	inhibition	O
10	by	O
11	these	O
12	compounds	O
13	reveals	O
14	that	O
15	U0126	O
16	has	O
17	approximately	O
18	100	O
19	-	O
20	fold	O
21	higher	O
22	affinity	O
23	for	O
24	deltaN3	B
25	-	O
26	S218E	O
27	/	O
28	S222D	B
29	MEK	B
30	than	O
31	does	O
32	PD098059	O
33	.	O

0	The	O
1	problem	O
2	of	O
3	disablement	O
4	due	O
5	to	O
6	pulmonary	O
7	tuberculosis	O
8	,	O
9	on	O
10	the	O
11	basis	O
12	of	O
13	an	O
14	analysis	O
15	of	O
16	the	O
17	history	O
18	of	O
19	395	O
20	cases	O
21	as	O
22	observed	O
23	in	O
24	Gdansk	O
25	in	O
26	the	O
27	years	O
28	1946	O
29	-	O
30	1965	O

0	French	O
1	bean	O
2	contains	O
3	a	O
4	small	O
5	family	O
6	of	O
7	genes	O
8	encoding	O
9	PAL	B
10	and	O
11	two	O
12	of	O
13	these	O
14	genes	O
15	,	O
16	PAL2	B
17	and	O
18	PAL3	B
19	,	O
20	have	O
21	been	O
22	shown	O
23	to	O
24	be	O
25	differentially	O
26	expressed	O
27	at	O
28	the	O
29	mRNA	O
30	level	O
31	in	O
32	bean	O
33	tissues	O
34	.	O

0	An	O
1	unusual	O
2	complication	O
3	in	O
4	an	O
5	unsuitable	O
6	patient	O
7	.	O

0	The	O
1	nucleosomal	O
2	arrays	O
3	detected	O
4	by	O
5	MPE	O
6	X	O
7	Fe	O
8	(	O
9	II	O
10	)	O
11	were	O
12	characterized	O
13	by	O
14	a	O
15	considerable	O
16	loss	O
17	of	O
18	detail	O
19	and	O
20	significantly	O
21	enhanced	O
22	accessibility	O
23	,	O
24	the	O
25	extent	O
26	of	O
27	which	O
28	probably	O
29	reflected	O
30	the	O
31	relative	O
32	transcription	O
33	rate	O
34	of	O
35	each	O
36	gene	O
37	.	O

0	The	O
1	first	O
2	identification	O
3	of	O
4	the	O
5	active	B
6	37LRP	B
7	/	O
8	p40	B
9	gene	I
10	presented	O
11	in	O
12	this	O
13	study	O
14	is	O
15	a	O
16	critical	O
17	step	O
18	toward	O
19	the	O
20	isolation	O
21	of	O
22	the	O
23	corresponding	O
24	human	O
25	gene	O
26	and	O
27	the	O
28	understanding	O
29	of	O
30	the	O
31	molecular	O
32	mechanisms	O
33	involved	O
34	in	O
35	the	O
36	up	O
37	-	O
38	regulation	O
39	of	O
40	its	O
41	expression	O
42	during	O
43	tumor	O
44	invasion	O
45	and	O
46	metastasis	O
47	.	O

0	NF	B
1	-	I
2	kappa	I
3	B	I
4	p65	I
5	,	O
6	p50	B
7	,	O
8	and	O
9	Rel	B
10	functionally	O
11	synergize	O
12	with	O
13	C	B
14	/	I
15	EBP	I
16	alpha	I
17	,	O
18	C	B
19	/	I
20	EBP	I
21	beta	I
22	,	O
23	and	O
24	C	B
25	/	I
26	EBP	I
27	delta	I
28	.	O

0	Thus	O
1	,	O
2	quantitative	O
3	analysis	O
4	of	O
5	thallium	O
6	-	O
7	201	O
8	uptake	O
9	and	O
10	washout	O
11	provided	O
12	objective	O
13	evidence	O
14	for	O
15	improved	O
16	myocardial	O
17	perfusion	O
18	after	O
19	coronary	O
20	angioplasty	O
21	.	O

0	Plasma	O
1	ion	O
2	changes	O
3	in	O
4	venous	O
5	blood	O
6	incubated	O
7	with	O
8	beta	B
9	receptor	I
10	blockers	I
11	and	O
12	subjected	O
13	to	O
14	tonometry	O
15	in	O
16	vitro	O
17	.	O

0	The	O
1	accuracies	O
2	of	O
3	presence	O
4	or	O
5	absence	O
6	of	O
7	neuroblastoma	O
8	were	O
9	compared	O
10	between	O
11	131I	O
12	-	O
13	MIBG	O
14	imaging	O
15	and	O
16	several	O
17	tumor	O
18	markers	O
19	.	O

0	Lack	O
1	of	O
2	sufficient	O
3	data	O
4	on	O
5	vibration	O
6	measurements	O
7	and	O
8	employment	O
9	durations	O
10	add	O
11	to	O
12	the	O
13	uncertainty	O
14	,	O
15	as	O
16	do	O
17	variations	O
18	in	O
19	tool	O
20	conditions	O
21	(	O
22	grinder	O
23	wheels	O
24	,	O
25	etc	O
26	)	O
27	and	O
28	inherent	O
29	difficulties	O
30	in	O
31	measurement	O
32	.	O

0	The	O
1	mean	O
2	(+/-	O
3	sd	O
4	)	O
5	intra	O
6	-	O
7	vesicular	O
8	pressure	O
9	(	O
10	IVP	O
11	)	O
12	and	O
13	maximal	O
14	urethral	O
15	closure	O
16	pressures	O
17	(	O
18	MUCP	O
19	)	O
20	were	O
21	10	O
22	.	O
23	3	O
24	(+/-	O
25	1	O
26	.	O
27	7	O
28	)	O
29	and	O
30	129	O
31	.	O
32	8	O
33	(+/-	O
34	19	O
35	.	O
36	6	O
37	)	O
38	cmH2O	O
39	,	O
40	respectively	O
41	,	O
42	and	O
43	the	O
44	ratio	O
45	between	O
46	MUCP	O
47	and	O
48	IVP	O
49	was	O
50	13	O
51	.	O
52	2	O
53	(+/-	O
54	2	O
55	.	O
56	5	O
57	).	O

0	The	O
1	ORs	O
2	of	O
3	GC	O
4	,	O
5	adjusted	O
6	for	O
7	age	O
8	and	O
9	sex	O
10	,	O
11	varied	O
12	from	O
13	17	O
14	.	O
15	1	O
16	,	O
17	for	O
18	those	O
19	with	O
20	baseline	O
21	diagnoses	O
22	of	O
23	superficial	O
24	intestinal	O
25	metaplasia	O
26	(	O
27	IM	O
28	),	O
29	to	O
30	29	O
31	.	O
32	3	O
33	,	O
34	for	O
35	those	O
36	with	O
37	deep	O
38	IM	O
39	or	O
40	mild	O
41	dysplasia	O
42	(	O
43	DYS	O
44	)	O
45	or	O
46	IM	O
47	with	O
48	glandular	O
49	atrophy	O
50	and	O
51	neck	O
52	hyperplasia	O
53	,	O
54	to	O
55	104	O
56	.	O
57	2	O
58	,	O
59	for	O
60	those	O
61	with	O
62	moderate	O
63	or	O
64	severe	O
65	DYS	O
66	,	O
67	as	O
68	compared	O
69	with	O
70	subjects	O
71	with	O
72	superficial	O
73	gastritis	O
74	(	O
75	SG	O
76	)	O
77	or	O
78	chronic	O
79	atrophic	O
80	gastritis	O
81	(	O
82	CAG	O
83	)	O
84	at	O
85	baseline	O
86	.	O

0	Endonuclease	B
1	III	I
2	(	O
3	Nth	B
4	)	I
5	of	I
6	Escherichia	I
7	coli	O
8	is	O
9	a	O
10	DNA	B
11	glycosylase	I
12	essential	O
13	for	O
14	the	O
15	removal	O
16	of	O
17	oxidised	O
18	pyrimidine	O
19	base	O
20	residues	O
21	from	O
22	DNA	O
23	.	O

0	Unlike	O
1	the	O
2	introns	O
3	of	O
4	other	O
5	duplicated	B
6	ribosomal	B
7	protein	I
8	genes	I
9	which	O
10	are	O
11	highly	O
12	diverged	O
13	,	O
14	the	O
15	duplicated	O
16	S13	B
17	genes	I
18	have	O
19	two	O
20	nearly	O
21	identical	O
22	DNA	O
23	sequences	O
24	of	O
25	25	O
26	and	O
27	31	O
28	bp	O
29	in	O
30	length	O
31	within	O
32	their	O
33	introns	O
34	.	O

0	The	O
1	yeast	O
2	gene	O
3	that	O
4	encodes	O
5	eIF	B
6	-	I
7	5	I
8	,	O
9	designated	O
10	TIF5	B
11	,	O
12	has	O
13	been	O
14	isolated	O
15	and	O
16	expressed	O
17	in	O
18	Escherichia	O
19	coli	O
20	to	O
21	yield	O
22	a	O
23	catalytically	O
24	active	O
25	eIF	B
26	-	I
27	5	I
28	protein	I
29	.	O

0	The	O
1	average	O
2	backscatter	O
3	coefficient	O
4	was	O
5	six	O
6	time	O
7	larger	O
8	in	O
9	regions	O
10	of	O
11	infarct	O
12	studied	O
13	8	O
14	--	O
15	10	O
16	weeks	O
17	after	O
18	occlusion	O
19	than	O
20	that	O
21	in	O
22	regions	O
23	of	O
24	infarct	O
25	studied	O
26	5	O
27	--	O
28	6	O
29	weeks	O
30	after	O
31	occlusion	O
32	.	O

0	Similarly	O
1	,	O
2	PCDFs	O
3	/	O
4	PCDDs	O
5	ratio	O
6	in	O
7	ESP	O
8	ash	O
9	was	O
10	lower	O
11	than	O
12	that	O
13	in	O
14	boiler	O
15	ash	O
16	.	O

0	High	O
1	levels	O
2	of	O
3	IC	O
4	coincided	O
5	with	O
6	relative	O
7	hypocomplementemia	O
8	.	O

0	Complex	O
1	repetitive	O
2	discharges	O
3	were	O
4	observed	O
5	in	O
6	muscles	O
7	of	O
8	mdx	O
9	mice	O
10	but	O
11	no	O
12	complex	O
13	repetitive	O
14	discharges	O
15	or	O
16	other	O
17	abnormalities	O
18	were	O
19	observed	O
20	in	O
21	muscles	O
22	of	O
23	normal	O
24	control	O
25	mice	O
26	.	O

0	Regulation	O
1	of	O
2	Gax	B
3	homeobox	I
4	gene	I
5	transcription	O
6	by	O
7	a	O
8	combination	O
9	of	O
10	positive	O
11	factors	O
12	including	O
13	myocyte	B
14	-	I
15	specific	I
16	enhancer	I
17	factor	I
18	2	I
19	.	O

0	There	O
1	are	O
2	two	O
3	immunogenic	O
4	sites	O
5	on	O
6	the	O
7	type	O
8	A	O
9	influenza	O
10	A	O
11	/	O
12	Japan	O
13	/	O
14	57	O
15	(	O
16	H2N2	O
17	)	O
18	hemagglutinin	B
19	(	O
20	HA	B
21	)	O
22	that	O
23	can	O
24	be	O
25	recognized	O
26	by	O
27	class	B
28	I	I
29	major	I
30	histocompatibility	I
31	complex	I
32	(	O
33	MHC	B
34	),	O
35	H	B
36	-	I
37	2Kd	I
38	-	O
39	restricted	O
40	cytolytic	O
41	T	O
42	lymphocytes	O
43	(	O
44	CTLs	O
45	).	O

0	The	O
1	primary	O
2	pancreatic	O
3	insult	O
4	seemed	O
5	to	O
6	be	O
7	unaffected	O
8	by	O
9	the	O
10	treatment	O
11	,	O
12	because	O
13	neither	O
14	the	O
15	rise	O
16	in	O
17	plasma	B
18	lipase	I
19	nor	O
20	the	O
21	development	O
22	of	O
23	ascites	O
24	or	O
25	the	O
26	extension	O
27	of	O
28	the	O
29	pancreatic	O
30	necrosis	O
31	were	O
32	diminished	O
33	.	O

0	Chernoff	O
1	,	O
2	submitted	O
3	for	O
4	publication	O
5	).	O

0	The	O
1	DNA	O
2	binding	O
3	domain	O
4	of	O
5	NirA	B
6	was	O
7	expressed	O
8	as	O
9	a	O
10	fusion	O
11	protein	O
12	with	O
13	the	O
14	glutathione	B
15	S	I
16	-	I
17	transferase	I
18	of	I
19	Schistosoma	I
20	japonicum	I
21	.	O

0	The	O
1	cDNA	O
2	clone	O
3	was	O
4	used	O
5	as	O
6	a	O
7	homologous	O
8	probe	O
9	to	O
10	isolate	O
11	a	O
12	truncated	O
13	genomic	O
14	clone	O
15	encoding	O
16	H2A1	B
17	.	O

0	This	O
1	dependence	O
2	,	O
3	however	O
4	,	O
5	can	O
6	be	O
7	overcome	O
8	to	O
9	a	O
10	large	O
11	extent	O
12	by	O
13	dividing	O
14	min	O
15	LVdP	O
16	/	O
17	dt	O
18	by	O
19	mean	O
20	aortic	O
21	pressure	O
22	.	O

0	Treatment	O
1	of	O
2	ovarian	O
3	neoplasms	O

0	Nucleoprotein	O
1	(	O
2	N	O
3	)	O
4	expressed	O
5	by	O
6	both	O
7	recombinant	O
8	vaccinia	O
9	virus	O
10	and	O
11	TGEV	O
12	had	O
13	a	O
14	relative	O
15	molecular	O
16	mass	O
17	(	O
18	Mr	O
19	)	O
20	of	O
21	47	O
22	,	O
23	000	O
24	and	O
25	was	O
26	susceptible	O
27	to	O
28	degradation	O
29	at	O
30	the	O
31	C	O
32	-	O
33	terminus	O
34	yielding	O
35	discrete	O
36	breakdown	O
37	products	O
38	.	O

0	Thus	O
1	the	O
2	present	O
3	data	O
4	also	O
5	suggest	O
6	that	O
7	BP	O
8	and	O
9	HR	O
10	measurements	O
11	are	O
12	influenced	O
13	not	O
14	only	O
15	by	O
16	state	O
17	-	O
18	dependent	O
19	factors	O
20	but	O
21	also	O
22	by	O
23	at	O
24	least	O
25	three	O
26	different	O
27	factors	O
28	that	O
29	are	O
30	each	O
31	independent	O
32	of	O
33	the	O
34	state	O
35	:	O
36	one	O
37	leads	O
38	to	O
39	BP	O
40	and	O
41	HR	O
42	values	O
43	that	O
44	are	O
45	influenced	O
46	by	O
47	the	O
48	cycle	O
49	the	O
50	animal	O
51	is	O
52	in	O
53	and	O
54	the	O
55	other	O
56	two	O
57	influence	O
58	,	O
59	respectively	O
60	,	O
61	the	O
62	ranking	O
63	of	O
64	the	O
65	individual	O
66	'	O
67	s	O
68	BP	O
69	and	O
70	HR	O
71	levels	O
72	within	O
73	the	O
74	population	O
75	.	O

0	CM	B
1	-	O
2	ACO3	O
3	is	O
4	expressed	O
5	in	O
6	flowers	O
7	and	O
8	is	O
9	not	O
10	induced	O
11	by	O
12	any	O
13	of	O
14	the	O
15	stimuli	O
16	tested	O
17	.	O

0	In	O
1	a	O
2	second	O
3	experiment	O
4	involving	O
5	an	O
6	18	O
7	-	O
8	h	O
9	lung	O
10	clearance	O
11	assay	O
12	,	O
13	we	O
14	used	O
15	the	O
16	mAb	B
17	3	I
18	.	I
19	2	I
20	.	I
21	3	I
22	to	O
23	deplete	O
24	rats	O
25	of	O
26	LGL	B
27	/	O
28	NK	O
29	cells	O
30	with	O
31	the	O
32	following	O
33	rationale	O
34	:	O
35	if	O
36	LGL	B
37	/	O
38	NK	B
39	cells	O
40	are	O
41	necessary	O
42	to	O
43	mediate	O
44	an	O
45	event	O
46	,	O
47	then	O
48	in	O
49	their	O
50	absence	O
51	,	O
52	that	O
53	event	O
54	should	O
55	not	O
56	occur	O
57	.	O

0	Production	O
1	of	O
2	C	B
3	mu	I
4	RNAs	I
5	,	O
6	unlike	O
7	mu	B
8	mRNAs	I
9	,	O
10	does	O
11	not	O
12	require	O
13	recombination	O
14	with	O
15	the	O
16	joining	O
17	region	O
18	(	O
19	JH	B
20	)	I
21	locus	I
22	.	O

0	Gab2	B
1	,	O
2	a	O
3	new	O
4	pleckstrin	B
5	homology	I
6	domain	I
7	-	I
8	containing	I
9	adapter	I
10	protein	I
11	,	O
12	acts	O
13	to	O
14	uncouple	O
15	signaling	O
16	from	O
17	ERK	B
18	kinase	I
19	to	O
20	Elk	B
21	-	I
22	1	I
23	.	O

0	Dipetalonema	O
1	(	O
2	Alafilaria	O
3	)	O
4	hydrochoerus	O
5	subgen	O
6	.	O
7	et	O
8	sp	O
9	.	O
10	n	O
11	.	O

0	The	O
1	skin	O
2	site	O
3	,	O
4	6	O
5	-	O
6	cm	O
7	-	O
8	distal	O
9	and	O
10	-	O
11	proximal	O
12	subcutaneous	O
13	segments	O
14	of	O
15	the	O
16	catheter	O
17	,	O
18	exudates	O
19	,	O
20	and	O
21	blood	O
22	were	O
23	cultured	O
24	.	O

0	It	O
1	is	O
2	concluded	O
3	that	O
4	suppression	O
5	of	O
6	elevated	O
7	prolactin	B
8	levels	O
9	in	O
10	progressive	O
11	metastatic	O
12	breast	O
13	cancer	O
14	patients	O
15	is	O
16	not	O
17	effective	O
18	in	O
19	restoring	O
20	tumor	O
21	sensitivity	O
22	to	O
23	chemotherapy	O
24	.	O

0	Proposals	O
1	on	O
2	authorization	O
3	;	O
4	by	O
5	a	O
6	group	O
7	of	O
8	nurses	O
9	from	O
10	psychiatric	O
11	hospitals	O

0	Patient	O
1	characteristics	O
2	associated	O
3	with	O
4	deep	O
5	wounds	O
6	as	O
7	well	O
8	as	O
9	patient	O
10	and	O
11	wound	O
12	characteristics	O
13	predictive	O
14	of	O
15	the	O
16	extent	O
17	of	O
18	healing	O
19	and	O
20	time	O
21	required	O
22	for	O
23	healing	O
24	were	O
25	identified	O
26	.	O

0	Semidominant	O
1	mutations	O
2	in	O
3	the	O
4	yeast	B
5	Rad51	I
6	protein	I
7	and	O
8	their	O
9	relationships	O
10	with	O
11	the	O
12	Srs2	B
13	helicase	I
14	.	O

0	The	O
1	domain	O
2	structure	O
3	of	O
4	bovine	B
5	LTBP	I
6	-	I
7	2	I
8	is	O
9	very	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	the	O
15	human	B
16	LTBP	I
17	-	I
18	2	I
19	,	O
20	containing	O
21	20	O
22	examples	O
23	of	O
24	6	B
25	-	I
26	cysteine	I
27	epidermal	I
28	growth	I
29	factor	I
30	-	I
31	like	I
32	repeats	I
33	,	O
34	16	O
35	of	O
36	which	O
37	have	O
38	the	O
39	consensus	O
40	sequence	O
41	for	O
42	calcium	O
43	binding	O
44	,	O
45	together	O
46	with	O
47	4	O
48	examples	O
49	of	O
50	8	O
51	-	O
52	cysteine	O
53	motifs	O
54	characteristic	O
55	of	O
56	fibrillins	B
57	and	O
58	LTBP	B
59	-	I
60	1	I
61	.	O

0	We	O
1	have	O
2	previously	O
3	demonstrated	O
4	that	O
5	expression	O
6	of	O
7	the	O
8	gene	O
9	for	O
10	the	O
11	reproductive	O
12	neuropeptide	O
13	,	O
14	GnRH	B
15	,	O
16	is	O
17	repressed	O
18	by	O
19	the	O
20	glutamate	O
21	/	O
22	NO	O
23	/	O
24	cyclic	O
25	GMP	O
26	(	O
27	cGMP	O
28	)	O
29	signal	O
30	transduction	O
31	pathway	O
32	through	O
33	cGMP	B
34	-	I
35	dependent	I
36	protein	I
37	kinase	I
38	in	O
39	the	O
40	hypothalamic	O
41	GnRH	B
42	-	O
43	secreting	O
44	neuronal	O
45	cell	O
46	line	O
47	GT1	O
48	-	O
49	7	O
50	.	O

0	Several	O
1	authors	O
2	have	O
3	recently	O
4	reported	O
5	interference	O
6	in	O
7	theophylline	O
8	analysis	O
9	by	O
10	paraxanthine	O
11	(	O
12	1	O
13	,	O
14	7	O
15	-	O
16	dimethylxanthine	O
17	),	O
18	an	O
19	important	O
20	metabolite	O
21	of	O
22	caffeine	O
23	.	O

0	The	O
1	levels	O
2	of	O
3	galactosyltransferase	B
4	activity	O
5	in	O
6	sera	O
7	from	O
8	normal	O
9	children	O
10	and	O
11	patients	O
12	with	O
13	cystic	O
14	fibrosis	O
15	.	O

0	Ecthyma	O
1	,	O
2	a	O
3	known	O
4	disease	O
5	,	O
6	of	O
7	which	O
8	little	O
9	is	O
10	known	O

0	The	O
1	mechanism	O
2	of	O
3	peroxisome	O
4	proliferation	O
5	is	O
6	poorly	O
7	understood	O
8	.	O

0	METHODS	O
1	:	O
2	T2	O
3	*-	O
4	weighted	O
5	,	O
6	three	O
7	-	O
8	dimensional	O
9	gradient	O
10	-	O
11	echo	O
12	images	O
13	were	O
14	acquired	O
15	by	O
16	exploiting	O
17	the	O
18	magnetic	O
19	susceptibility	O
20	difference	O
21	between	O
22	oxygenated	O
23	and	O
24	deoxygenated	O
25	hemoglobin	B
26	in	O
27	the	O
28	vasculature	O
29	and	O
30	microvasculature	O
31	.	O

0	In	O
1	293	O
2	cells	O
3	,	O
4	expression	O
5	of	O
6	the	O
7	NF	B
8	-	I
9	kappa	I
10	B	I
11	inhibitor	I
12	,	O
13	I	B
14	kappa	I
15	B	I
16	-	I
17	alpha	I
18	,	O
19	reduced	O
20	the	O
21	stimulatory	O
22	activity	O
23	of	O
24	LMP	B
25	.	O

0	The	O
1	method	O
2	described	O
3	may	O
4	prove	O
5	useful	O
6	in	O
7	studying	O
8	the	O
9	physiology	O
10	of	O
11	the	O
12	nasal	O
13	cycle	O
14	.	O

0	Effect	O
1	of	O
2	the	O
3	methods	O
4	of	O
5	cutaneous	O
6	administration	O
7	of	O
8	methyl	O
9	isobutyl	O
10	ketone	O
11	on	O
12	its	O
13	toxicity	O

0	We	O
1	show	O
2	also	O
3	that	O
4	RA	B
5	represses	O
6	the	O
7	transcriptional	O
8	activity	O
9	of	O
10	a	O
11	reporter	O
12	gene	O
13	containing	O
14	a	O
15	TPA	B
16	responding	O
17	AP1	B
18	binding	I
19	site	I
20	driving	O
21	the	O
22	HSV	B
23	tk	I
24	promoter	I
25	.	O

0	The	O
1	results	O
2	showed	O
3	that	O
4	MIP	O
5	,	O
6	MMIF	O
7	,	O
8	FIC	O
9	,	O
10	Wimax	O
11	,	O
12	P0	O
13	.	O
14	1	O
15	and	O
16	minute	O
17	ventilation	O
18	(	O
19	Vr	O
20	)	O
21	were	O
22	significantly	O
23	increased	O
24	after	O
25	administration	O
26	of	O
27	methylphenidatum	O
28	and	O
29	aminophylline	O
30	.	O

0	Polyadenylation	O
1	of	O
2	B4	B
3	RNA	I
4	,	O
5	which	O
6	occurs	O
7	very	O
8	early	O
9	during	O
10	maturation	O
11	,	O
12	is	O
13	limited	O
14	to	O
15	150	O
16	residues	O
17	,	O
18	and	O
19	it	O
20	is	O
21	this	O
22	number	O
23	that	O
24	is	O
25	required	O
26	for	O
27	polysomal	O
28	recruitment	O
29	.	O

0	BACKGROUND	O
1	:	O
2	Delineation	O
3	of	O
4	the	O
5	morphologic	O
6	aspects	O
7	of	O
8	age	O
9	-	O
10	related	O
11	macular	O
12	degeneration	O
13	(	O
14	ARMD	O
15	)	O
16	is	O
17	helpful	O
18	in	O
19	correlation	O
20	with	O
21	the	O
22	clinical	O
23	features	O
24	and	O
25	may	O
26	contribute	O
27	to	O
28	understanding	O
29	the	O
30	pathogenesis	O
31	.	O

0	The	O
1	yeast	B
2	SSS1	I
3	gene	I
4	is	O
5	essential	O
6	for	O
7	secretory	O
8	protein	O
9	translocation	O
10	and	O
11	encodes	O
12	a	O
13	conserved	O
14	protein	O
15	of	O
16	the	O
17	endoplasmic	O
18	reticulum	O
19	.	O

0	Analysis	O
1	of	O
2	promoter	O
3	and	O
4	androgen	O
5	regulatory	O
6	sequences	O
7	required	O
8	for	O
9	optimal	O
10	transcription	O
11	of	O
12	the	O
13	rat	B
14	androgen	I
15	-	I
16	binding	I
17	protein	I
18	gene	I
19	.	O

0	GAL4	B
1	-	O
2	VP16	B
3	-	O
4	mediated	O
5	antirepression	O
6	required	O
7	an	O
8	auxiliary	O
9	factor	O
10	,	O
11	denoted	O
12	as	O
13	a	O
14	co	O
15	-	O
16	antirepressor	O
17	,	O
18	which	O
19	was	O
20	partially	O
21	purified	O
22	from	O
23	Drosophila	O
24	embryos	O
25	.	O

0	Results	O
1	have	O
2	surprisingly	O
3	revealed	O
4	the	O
5	presence	O
6	of	O
7	three	O
8	U14	B
9	snRNA	I
10	-	I
11	homologous	I
12	regions	I
13	positioned	O
14	within	O
15	introns	O
16	5	O
17	,	O
18	6	O
19	,	O
20	and	O
21	8	O
22	of	O
23	the	O
24	mouse	O
25	cognate	O
26	hsc70	B
27	heat	I
28	shock	I
29	gene	I
30	.	O

0	This	O
1	structure	O
2	interconnects	O
3	specific	O
4	triplets	O
5	of	O
6	the	O
7	basal	O
8	bodies	O
9	with	O
10	the	O
11	microtubular	O
12	bundles	O
13	that	O
14	emerge	O
15	from	O
16	the	O
17	basal	O
18	apparatus	O
19	.	O

0	The	O
1	enteric	O
2	route	O
3	is	O
4	the	O
5	principal	O
6	mode	O
7	of	O
8	transmission	O
9	for	O
10	hepatitis	O
11	A	O
12	,	O
13	but	O
14	maximal	O
15	levels	O
16	of	O
17	hepatitis	O
18	A	O
19	virus	O
20	excretion	O
21	occur	O
22	before	O
23	the	O
24	onset	O
25	of	O
26	jaundice	O
27	.	O

0	Biochemical	O
1	analysis	O
2	reveals	O
3	that	O
4	KS1	B
5	is	O
6	a	O
7	nuclear	O
8	protein	O
9	containing	O
10	two	O
11	transcriptional	O
12	repressor	O
13	domains	O
14	,	O
15	R1	O
16	and	O
17	R2	O
18	.	O

0	Compensative	O
1	justice	O
2	and	O
3	moral	O
4	investment	O
5	among	O
6	Japanese	O
7	,	O
8	Chinese	O
9	,	O
10	and	O
11	Koreans	O
12	.	O

0	The	O
1	strong	O
2	conservation	O
3	of	O
4	the	O
5	inverted	O
6	terminal	O
7	repeat	O
8	sequence	O
9	may	O
10	reflect	O
11	a	O
12	common	O
13	integration	O
14	mechanism	O
15	for	O
16	VL30	B
17	elements	O
18	and	O
19	MuLV	O
20	proviruses	O
21	.	O

0	A	O
1	note	O
2	on	O
3	some	O
4	consequences	O
5	of	O
6	UV	O
7	vision	O
8	in	O
9	birds	O
10	.	O

0	Changes	O
1	in	O
2	dopamine	B
3	receptor	I
4	sensitivity	O
5	in	O
6	humans	O
7	after	O
8	heavy	O
9	alcohol	O
10	intake	O
11	.	O

0	To	O
1	minimize	O
2	reflux	O
3	into	O
4	the	O
5	blind	O
6	loop	O
7	,	O
8	a	O
9	number	O
10	of	O
11	technical	O
12	steps	O
13	are	O
14	considered	O
15	indispensable	O
16	:	O
17	1	O
18	)	O
19	fluted	O
20	section	O
21	of	O
22	the	O
23	jejunal	O
24	stump	O
25	;	O
26	2	O
27	)	O
28	isoperistaltic	O
29	construction	O
30	of	O
31	the	O
32	anastomosis	O
33	and	O
34	,	O
35	particularly	O
36	,	O
37	3	O
38	)	O
39	the	O
40	creation	O
41	of	O
42	a	O
43	single	O
44	or	O
45	double	O
46	valve	O
47	system	O
48	upstream	O
49	from	O
50	the	O
51	anastomosis	O
52	by	O
53	spiral	O
54	introflexion	O
55	of	O
56	the	O
57	mucosa	O
58	using	O
59	seroserous	O
60	stitches	O
61	parallel	O
62	and	O
63	perpendicular	O
64	to	O
65	the	O
66	ileal	O
67	lumen	O
68	.	O

0	The	O
1	enzyme	O
2	displays	O
3	optimal	O
4	activity	O
5	at	O
6	about	O
7	0	O
8	.	O
9	5	O
10	mM	O
11	pantoate	O
12	(	O
13	k	O
14	(	O
15	cat	O
16	)	O
17	0	O
18	.	O
19	63	O
20	s	O
21	(-	O
22	1	O
23	))	O
24	and	O
25	at	O
26	pH	O
27	7	O
28	.	O
29	8	O
30	.	O

0	Comparison	O
1	of	O
2	three	O
3	different	O
4	preparations	O
5	of	O
6	disodium	O
7	cromoglycate	O
8	in	O
9	the	O
10	prevention	O
11	of	O
12	exercise	O
13	-	O
14	induced	O
15	bronchospasm	O
16	:	O
17	a	O
18	double	O
19	-	O
20	blind	O
21	study	O
22	.	O

0	A	O
1	case	O
2	of	O
3	Goodpasture	O
4	'	O
5	s	O
6	syndrome	O
7	.	O

0	Incidence	O
1	rate	O
2	ranging	O
3	between	O
4	122	O
5	/	O
6	100	O
7	,	O
8	000	O
9	/	O
10	year	O
11	and	O
12	190	O
13	/	O
14	100	O
15	,	O
16	000	O
17	/	O
18	year	O
19	were	O
20	found	O
21	(	O
22	minimum	O
23	,	O
24	estimated	O
25	and	O
26	raw	O
27	datasets	O
28	).	O

0	E	O
1	.,	O
2	Scott	O
3	,	O
4	J	O
5	.	O

0	This	O
1	accurate	O
2	and	O
3	rapid	O
4	method	O
5	makes	O
6	the	O
7	MLPA	O
8	test	O
9	logistically	O
10	feasible	O
11	for	O
12	large	O
13	-	O
14	scale	O
15	screening	O
16	.	O

0	Use	O
1	of	O
2	serum	O
3	thyroglobulin	I
4	determination	O
5	in	O
6	the	O
7	follow	O
8	-	O
9	up	O
10	of	O
11	differentiated	O
12	carcinomas	O
13	of	O
14	the	O
15	thyroid	O

0	This	O
1	distribution	O
2	implies	O
3	that	O
4	the	O
5	polycistronic	O
6	precursor	O
7	is	O
8	imported	O
9	into	O
10	the	O
11	nucleolus	O
12	for	O
13	processing	O
14	to	O
15	the	O
16	mature	O
17	snoRNAs	O
18	,	O
19	and	O
20	that	O
21	the	O
22	import	O
23	or	O
24	processing	O
25	pathway	O
26	involves	O
27	coiled	O
28	bodies	O
29	.	O

0	Functional	O
1	analysis	O
2	of	O
3	DNase	B
4	-	I
5	I	I
6	hypersensitive	O
7	sites	O
8	at	O
9	the	O
10	mouse	B
11	porphobilinogen	I
12	deaminase	I
13	gene	I
14	locus	I
15	.	O

0	A	O
1	high	O
2	efficacy	O
3	of	O
4	the	O
5	combined	O
6	use	O
7	of	O
8	nontoxic	O
9	doses	O
10	of	O
11	two	O
12	pharmaceuticals	O
13	:	O
14	cystamine	O
15	(	O
16	50	O
17	mg	O
18	/	O
19	kg	O
20	)	O
21	and	O
22	mexamine	O
23	(	O
24	25	O
25	mg	O
26	/	O
27	kg	O
28	)	O
29	under	O
30	the	O
31	conditions	O
32	of	O
33	short	O
34	-	O
35	term	O
36	exogenous	O
37	hypoxia	O
38	(	O
39	7	O
40	.	O
41	5	O
42	%	O
43	O2	O
44	)	O
45	was	O
46	found	O
47	in	O
48	(	O
49	CBA	O
50	X	O
51	C57Bl	O
52	)	O
53	F1	O
54	mice	O
55	.	O

0	Cytogenetic	O
1	and	O
2	molecular	O
3	characterization	O
4	of	O
5	random	O
6	chromosomal	O
7	rearrangements	O
8	activating	O
9	the	O
10	drug	O
11	resistance	O
12	gene	I
13	,	O
14	MDR1	B
15	/	O
16	P	B
17	-	I
18	glycoprotein	I
19	,	O
20	in	O
21	drug	O
22	-	O
23	selected	O
24	cell	O
25	lines	O
26	and	O
27	patients	O
28	with	O
29	drug	O
30	refractory	O
31	ALL	O
32	.	O

0	Because	O
1	all	O
2	PDGFbetaR	B
3	fusions	I
4	described	O
5	thus	O
6	far	O
7	result	O
8	in	O
9	splicing	O
10	to	O
11	a	O
12	common	O
13	exon	O
14	of	O
15	this	O
16	gene	O
17	,	O
18	we	O
19	performed	O
20	5	O
21	'-	O
22	rapid	O
23	amplification	O
24	of	O
25	cDNA	O
26	ends	O
27	PCR	O
28	on	O
29	patient	O
30	RNA	O
31	.	O

0	Furthermore	O
1	,	O
2	experiments	O
3	with	O
4	32D	O
5	temperature	O
6	-	O
7	sensitive	O
8	p53	B
9	cells	O
10	indicate	O
11	that	O
12	aberrant	O
13	tal	B
14	-	I
15	1	I
16	expression	O
17	at	O
18	the	O
19	permissive	O
20	temperature	O
21	does	O
22	not	O
23	exert	O
24	a	O
25	proliferative	O
26	effect	O
27	but	O
28	causes	O
29	p53	B
30	-	O
31	mediated	O
32	apoptosis	O
33	,	O
34	i	O
35	.	O
36	e	O
37	.,	O
38	the	O
39	tal	B
40	-	I
41	1	I
42	proliferative	O
43	effect	O
44	depends	O
45	on	O
46	the	O
47	integrity	O
48	of	O
49	the	O
50	cell	O
51	cycle	O
52	checkpoints	O
53	of	O
54	the	O
55	host	O
56	cell	O
57	,	O
58	as	O
59	observed	O
60	for	O
61	c	B
62	-	I
63	myc	I
64	and	O
65	other	O
66	oncogenes	O
67	.	O
68	tal	B
69	-	I
70	1	I
71	mutant	I
72	experiments	O
73	indicate	O
74	that	O
75	ectopic	B
76	tal	B
77	-	I
78	1	I
79	effects	O
80	are	O
81	mediated	O
82	by	O
83	both	O
84	the	O
85	DNA	O
86	-	O
87	binding	O
88	and	O
89	the	O
90	heterodimerization	O
91	domains	O
92	,	O
93	while	O
94	the	O
95	N	O
96	-	O
97	terminally	O
98	truncated	O
99	tal	B
100	-	I
101	1	I
102	variant	I
103	(	O
104	M3	O
105	)	O
106	expressed	O
107	in	O
108	T	O
109	-	O
110	ALL	O
111	malignant	O
112	cells	O
113	mimics	O
114	the	O
115	effects	O
116	of	O
117	the	O
118	wild	O
119	-	O
120	type	O
121	protein	O
122	.	O

0	The	O
1	N3	O
2	wave	O
3	of	O
4	the	O
5	SSEP	O
6	'	O
7	s	O
8	,	O
9	which	O
10	has	O
11	been	O
12	found	O
13	to	O
14	correlate	O
15	best	O
16	with	O
17	neurological	O
18	recovery	O
19	,	O
20	returned	O
21	to	O
22	65	O
23	%	O
24	+/-	O
25	48	O
26	%	O
27	of	O
28	the	O
29	preischemia	O
30	amplitude	O
31	in	O
32	the	O
33	insulin	O
34	-	O
35	treated	O
36	animals	O
37	,	O
38	compared	O
39	to	O
40	40	O
41	%	O
42	+/-	O
43	34	O
44	%	O
45	in	O
46	the	O
47	fasted	O
48	group	O
49	and	O
50	26	O
51	%	O
52	+/-	O
53	24	O
54	%	O
55	in	O
56	the	O
57	control	O
58	animals	O
59	.	O

0	Disruption	O
1	mutations	O
2	have	O
3	been	O
4	constructed	O
5	in	O
6	the	O
7	SLK1	B
8	gene	I
9	.	O
10	slk1	B
11	null	I
12	mutants	I
13	cannot	O
14	grow	O
15	at	O
16	37	O
17	degrees	O
18	C	O
19	,	O
20	but	O
21	many	O
22	cells	O
23	can	O
24	grow	O
25	at	O
26	30	O
27	,	O
28	24	O
29	,	O
30	and	O
31	17	O
32	degrees	O
33	C	O
34	.	O

0	This	O
1	sequence	O
2	possessed	O
3	homology	O
4	with	O
5	a	O
6	methylation	O
7	-	O
8	sensitive	O
9	promoter	O
10	element	O
11	,	O
12	Enh2	B
13	,	O
14	present	O
15	in	O
16	the	O
17	LTR	O
18	of	O
19	mouse	O
20	intractisternal	O
21	A	O
22	-	O
23	particles	O
24	.	O

0	Continued	O
1	development	O
2	of	O
3	the	O
4	rat	O
5	conditioning	O
6	paradigm	O
7	is	O
8	especially	O
9	warranted	O
10	because	O
11	of	O
12	the	O
13	ability	O
14	to	O
15	record	O
16	sympathetic	O
17	nerve	O
18	activity	O
19	in	O
20	intact	O
21	,	O
22	awake	O
23	subjects	O
24	and	O
25	the	O
26	large	O
27	number	O
28	of	O
29	readily	O
30	available	O
31	genetic	O
32	strains	O
33	,	O
34	which	O
35	model	O
36	human	O
37	pathological	O
38	states	O
39	.	O

0	Muscle	B
1	GSH	B
2	-	I
3	Px	I
4	activity	O
5	after	O
6	prolonged	O
7	exercise	O
8	,	O
9	training	O
10	,	O
11	and	O
12	selenium	O
13	supplementation	O
14	.	O

0	An	O
1	intralobar	O
2	change	O
3	in	O
4	temperature	O
5	above	O
6	or	O
7	below	O
8	36	O
9	degrees	O
10	C	O
11	decreases	O
12	only	O
13	the	O
14	lobar	O
15	bronchial	O
16	blood	O
17	flow	O
18	and	O
19	does	O
20	not	O
21	influence	O
22	blood	O
23	flow	O
24	to	O
25	other	O
26	nearby	O
27	tissues	O
28	including	O
29	those	O
30	vascularized	O
31	by	O
32	the	O
33	bronchial	O
34	circulation	O
35	.	O

0	Avian	O
1	reproductive	O
2	system	O
3	:	O
4	daily	O
5	variations	O
6	in	O
7	responses	O
8	to	O
9	hormones	O
10	.	O

0	The	O
1	maximum	O
2	period	O
3	of	O
4	treatment	O
5	was	O
6	73	O
7	(	O
8	oral	O
9	),	O
10	73	O
11	(	O
12	intraperitoneal	O
13	)	O
14	or	O
15	75	O
16	(	O
17	dermal	O
18	)	O
19	weeks	O
20	.	O

0	Whereas	O
1	p82	B
2	expression	O
3	had	O
4	no	O
5	effect	O
6	on	O
7	ERK2	B
8	activation	O
9	by	O
10	p126	B
11	,	O
12	p70	B
13	completely	O
14	abrogated	O
15	this	O
16	activity	O
17	.	O

0	The	O
1	carboxy	O
2	terminus	O
3	of	O
4	Mbp1	B
5	is	O
6	sufficient	O
7	for	O
8	interaction	O
9	with	O
10	Swi6	B
11	,	O
12	and	O
13	the	O
14	carboxy	O
15	terminus	O
16	of	O
17	Swi6	B
18	is	O
19	required	O
20	for	O
21	interaction	O
22	with	O
23	Mbp1	B
24	.	O

0	The	O
1	isolated	O
2	POT1	B
3	clones	O
4	hybridized	O
5	to	O
6	a	O
7	1	O
8	.	O
9	4	O
10	kb	O
11	RNA	O
12	species	O
13	,	O
14	which	O
15	was	O
16	induced	O
17	approximately	O
18	30	O
19	-	O
20	fold	O
21	when	O
22	oleate	O
23	was	O
24	the	O
25	carbon	O
26	source	O
27	.	O

0	BACKGROUND	O
1	:	O
2	Chemicals	O
3	vary	O
4	considerably	O
5	in	O
6	their	O
7	intrinsic	O
8	ability	O
9	to	O
10	cause	O
11	allergic	O
12	contact	O
13	dermatitis	O
14	.	O

0	Surprisingly	O
1	,	O
2	the	O
3	RXR	B
4	-	O
5	specific	O
6	ligand	O
7	9	O
8	-	O
9	cis	O
10	-	O
11	retinoic	O
12	acid	O
13	induced	O
14	binding	O
15	of	O
16	SRC	B
17	-	I
18	1	I
19	to	O
20	the	O
21	RXR	B
22	component	O
23	of	O
24	the	O
25	TRE	O
26	-	O
27	bound	O
28	heterodimer	O
29	.	O

0	Certain	O
1	spt10	B
2	spontaneous	I
3	alleles	I
4	are	O
5	good	O
6	suppressors	O
7	but	O
8	have	O
9	a	O
10	normal	O
11	growth	O
12	rate	O
13	,	O
14	suggesting	O
15	that	O
16	the	O
17	SPT10	B
18	protein	I
19	may	O
20	have	O
21	two	O
22	distinct	O
23	functions	O
24	.	O

0	We	O
1	established	O
2	that	O
3	the	O
4	2	O
5	.	O
6	6	O
7	kb	O
8	mRNA	I
9	V	I
10	-	I
11	1	I
12	and	O
13	the	O
14	2	B
15	.	I
16	3	I
17	kb	I
18	GGT	I
19	mRNA	I
20	V	I
21	-	I
22	2	I
23	derive	O
24	,	O
25	by	O
26	alternate	O
27	splicing	O
28	,	O
29	from	O
30	a	O
31	primary	O
32	transcript	O
33	initiated	O
34	on	O
35	a	O
36	distal	O
37	promoter	O
38	on	O
39	the	O
40	rat	B
41	GGT	I
42	gene	I
43	.	O

0	The	O
1	standard	O
2	dosage	O
3	of	O
4	anti	O
5	-	O
6	D	O
7	currently	O
8	given	O
9	at	O
10	all	O
11	gestational	O
12	ages	O
13	is	O
14	1	O
15	ampoule	O
16	containing	O
17	125	O
18	micrograms	O
19	of	O
20	anti	O
21	-	O
22	D	O
23	.	O

0	Furthermore	O
1	,	O
2	the	O
3	identification	O
4	of	O
5	a	O
6	Dr1	B
7	-	I
8	like	I
9	protein	I
10	in	O
11	A	O
12	.	O
13	thaliana	O
14	strongly	O
15	argues	O
16	for	O
17	the	O
18	ubiquity	O
19	of	O
20	this	O
21	protein	O
22	among	O
23	eukaryotic	O
24	genera	O
25	and	O
26	for	O
27	a	O
28	conserved	O
29	mechanism	O
30	to	O
31	regulate	O
32	transcription	O
33	initiation	O
34	that	O
35	involves	O
36	Dr1	B
37	.	O

0	Recurrence	O
1	of	O
2	bladder	O
3	tumors	O
4	among	O
5	the	O
6	original	O
7	9	O
8	cases	O
9	has	O
10	occurred	O
11	only	O
12	among	O
13	the	O
14	5	O
15	whose	O
16	properdin	B
17	levels	O
18	remained	O
19	below	O
20	the	O
21	median	O
22	.	O

0	Results	O
1	of	O
2	the	O
3	long	O
4	-	O
5	term	O
6	observation	O
7	and	O
8	treatment	O
9	of	O
10	patients	O
11	with	O
12	arterial	O
13	hypertension	O

0	Amongst	O
1	other	O
2	qualities	O
3	,	O
4	the	O
5	book	O
6	'	O
7	s	O
8	importance	O
9	lies	O
10	in	O
11	the	O
12	fact	O
13	that	O
14	it	O
15	associates	O
16	an	O
17	elaborate	O
18	theoretical	O
19	construction	O
20	with	O
21	the	O
22	empirical	O
23	data	O
24	,	O
25	working	O
26	within	O
27	the	O
28	possibilities	O
29	provided	O
30	by	O
31	late	O
32	19th	O
33	-	O
34	century	O
35	moral	O
36	statistics	O
37	.	O

0	Thus	O
1	,	O
2	we	O
3	have	O
4	identified	O
5	an	O
6	activation	O
7	target	O
8	of	O
9	a	O
10	human	O
11	activator	O
12	,	O
13	Oct	B
14	-	I
15	1	I
16	,	O
17	within	O
18	its	O
19	cognate	O
20	basal	O
21	transcription	O
22	complex	O
23	.	O

0	Two	O
1	mutants	O
2	,	O
3	each	O
4	representative	O
5	of	O
6	a	O
7	separate	O
8	pet	O
9	complementation	O
10	group	O
11	,	O
12	have	O
13	been	O
14	analyzed	O
15	.	O

0	Anti	B
1	-	I
2	NPROSP	I
3	-	I
4	C	I
5	also	O
6	exclusively	O
7	detected	O
8	time	O
9	-	O
10	dependent	O
11	appearances	O
12	of	O
13	5	B
14	-	I
15	10	I
16	-	I
17	kDa	I
18	proSP	I
19	-	I
20	C	I
21	forms	O
22	in	O
23	lamellar	O
24	bodies	O
25	and	O
26	homogenates	O
27	.	O

0	Sings	O
1	which	O
2	are	O
3	indicative	O
4	of	O
5	metaplastic	O
6	erythropoiesis	O
7	are	O
8	absent	O
9	.	O

0	Mutations	O
1	in	O
2	UPF1	B
3	lead	O
4	to	O
5	the	O
6	selective	O
7	stabilization	O
8	of	O
9	mRNAs	O
10	containing	O
11	early	O
12	nonsense	O
13	mutations	O
14	without	O
15	affecting	O
16	the	O
17	decay	O
18	rates	O
19	of	O
20	most	O
21	other	O
22	mRNAs	O
23	.	O

0	3	O
1	.	O
2	04	O
3	+/-	O
4	1	O
5	.	O
6	2	O
7	,	O
8	P	O
9	<	O
10	0	O
11	.	O
12	0001	O
13	),	O
14	large	O
15	accelerations	O
16	/	O
17	30	O
18	min	O
19	(	O
20	1	O
21	.	O
22	46	O
23	+/-	O
24	1	O
25	.	O
26	96	O
27	vs	O
28	.	O

0	This	O
1	interaction	O
2	occurs	O
3	over	O
4	a	O
5	wide	O
6	range	O
7	of	O
8	both	O
9	parameters	O
10	;	O
11	for	O
12	charge	O
13	density	O
14	from	O
15	at	O
16	least	O
17	10	O
18	to	O
19	800	O
20	microC	O
21	/	O
22	cm2	O
23	and	O
24	,	O
25	for	O
26	charge	O
27	per	O
28	phase	O
29	,	O
30	from	O
31	at	O
32	least	O
33	0	O
34	.	O
35	05	O
36	to	O
37	5	O
38	.	O
39	0	O
40	microC	O
41	per	O
42	phase	O
43	.	O

0	In	O
1	the	O
2	diabetics	O
3	,	O
4	Ca2	O
5	+	O
6	infusions	O
7	induced	O
8	a	O
9	rise	O
10	of	O
11	plasma	O
12	Ca2	O
13	+	O
14	up	O
15	to	O
16	3	O
17	.	O
18	2	O
19	+/-	O
20	0	O
21	.	O
22	1	O
23	mmol	O
24	/	O
25	1	O
26	and	O
27	a	O
28	fall	O
29	of	O
30	circulating	O
31	glucagon	O
32	(-	O
33	26	O
34	.	O
35	4	O
36	+/-	O
37	5	O
38	.	O
39	7	O
40	%;	O
41	p	O
42	less	O
43	than	O
44	0	O
45	.	O
46	001	O
47	)	O
48	and	O
49	glucose	O
50	(-	O
51	23	O
52	.	O
53	3	O
54	+/-	O
55	3	O
56	.	O
57	6	O
58	%;	O
59	p	O
60	less	O
61	than	O
62	0	O
63	.	O
64	05	O
65	).	O

0	Specifically	O
1	,	O
2	they	O
3	were	O
4	performed	O
5	to	O
6	determine	O
7	whether	O
8	detection	O
9	of	O
10	envelope	O
11	phase	O
12	disparity	O
13	was	O
14	consistent	O
15	with	O
16	processing	O
17	within	O
18	a	O
19	single	O
20	channel	O
21	in	O
22	which	O
23	the	O
24	AM	O
25	tones	O
26	were	O
27	simply	O
28	added	O
29	.	O

0	All	O
1	patients	O
2	had	O
3	abnormal	O
4	von	B
5	Willebrand	I
6	factor	I
7	(	O
8	vWF	B
9	)	O
10	fragmentation	O
11	as	O
12	reflected	O
13	by	O
14	decreased	O
15	high	O
16	molecular	O
17	weight	O
18	and	O
19	increased	O
20	low	O
21	molecular	O
22	weight	O
23	vWF	B
24	multimers	I
25	in	O
26	the	O
27	circulation	O
28	.	O

0	Typical	O
1	configurations	O
2	of	O
3	psychosocial	O
4	stress	O
5	factors	O
6	of	O
7	psychiatrically	O
8	conspicuous	O
9	children	O
10	and	O
11	adolescents	O

0	Using	O
1	a	O
2	MOS	O
3	-	O
4	Hypersil	O
5	reversed	O
6	-	O
7	phase	O
8	column	O
9	with	O
10	a	O
11	phosphate	O
12	buffer	O
13	--	O
14	acetonitrile	O
15	mobile	O
16	phase	O
17	,	O
18	baseline	O
19	separation	O
20	of	O
21	antipyrine	O
22	,	O
23	its	O
24	metabolites	O
25	3	O
26	-	O
27	hydroxymethylantipyrine	O
28	,	O
29	norantipyrine	O
30	and	O
31	4	O
32	-	O
33	hydroxyantipyrine	O
34	,	O
35	and	O
36	the	O
37	internal	O
38	standard	O
39	,	O
40	phenacetin	O
41	,	O
42	was	O
43	achieved	O
44	within	O
45	6	O
46	min	O
47	.	O

0	METHODS	O
1	:	O
2	Millipore	O
3	ultrafiltration	O
4	membranes	O
5	of	O
6	three	O
7	different	O
8	pore	O
9	sizes	O
10	were	O
11	used	O
12	as	O
13	model	O
14	lenticule	O
15	materials	O
16	.	O
17	The	O
18	nominal	O
19	membrane	O
20	pore	O
21	sizes	O
22	were	O
23	0	O
24	.	O
25	1	O
26	microm	O
27	,	O
28	0	O
29	.	O
30	45	O
31	microm	O
32	,	O
33	and	O
34	3	O
35	microm	O
36	;	O
37	the	O
38	surface	O
39	roughness	O
40	increased	O
41	in	O
42	the	O
43	same	O
44	order	O
45	The	O
46	membranes	O
47	were	O
48	coated	O
49	with	O
50	a	O
51	thin	O
52	layer	O
53	of	O
54	collagen	B
55	I	I
56	and	O
57	implanted	O
58	in	O
59	a	O
60	circular	O
61	pocket	O
62	of	O
63	the	O
64	anterior	O
65	cornea	O
66	of	O
67	adult	O
68	cats	O
69	,	O
70	and	O
71	were	O
72	clinically	O
73	evaluated	O
74	for	O
75	the	O
76	extent	O
77	of	O
78	epithelialization	O
79	and	O
80	the	O
81	persistence	O
82	of	O
83	epithelial	O
84	attachment	O
85	.	O

0	Decreased	O
1	levels	O
2	of	O
3	alpha2	B
4	-	I
5	antiplasmin	I
6	were	O
7	also	O
8	observed	O
9	in	O
10	the	O
11	mediastinum	O
12	(	O
13	0	O
14	.	O
15	50	O
16	versus	O
17	0	O
18	.	O
19	61	O
20	U	O
21	/	O
22	mL	O
23	;	O
24	p	O
25	<	O
26	0	O
27	.	O
28	05	O
29	).	O

0	Consistent	O
1	with	O
2	this	O
3	interpretation	O
4	,	O
5	a	O
6	mutant	O
7	form	O
8	of	O
9	XRN1	B
10	,	O
11	which	O
12	encodes	O
13	a	O
14	5	B
15	'-	I
16	3	I
17	'	I
18	exonuclease	I
19	,	O
20	was	O
21	identified	O
22	as	O
23	an	O
24	extragenic	O
25	suppressor	O
26	that	O
27	increases	O
28	the	O
29	half	O
30	-	O
31	life	O
32	of	O
33	rhis4	B
34	mRNA	I
35	,	O
36	leading	O
37	to	O
38	a	O
39	10	O
40	-	O
41	fold	O
42	increase	O
43	in	O
44	steady	O
45	-	O
46	state	O
47	mRNA	O
48	levels	O
49	compared	O
50	to	O
51	the	O
52	wild	B
53	-	I
54	type	I
55	HIS4	I
56	mRNA	I
57	level	O
58	.	O

0	Our	O
1	results	O
2	implicate	O
3	TGF	B
4	-	I
5	beta	I
6	RII	I
7	as	O
8	a	O
9	direct	O
10	target	O
11	of	O
12	EWS	B
13	-	O
14	FLI1	B
15	.	O

0	Mycotoxins	O
1	in	O
2	feeds	O
3	and	O
4	foods	O
5	.	O

0	From	O
1	the	O
2	15	O
3	-	O
4	kb	O
5	clone	O
6	a	O
7	4	O
8	-	O
9	kb	O
10	EcoRI	B
11	fragment	I
12	containing	O
13	the	O
14	first	O
15	two	O
16	exons	O
17	and	O
18	2	O
19	.	O
20	6	O
21	kb	O
22	of	O
23	the	O
24	5	O
25	'	O
26	flanking	O
27	region	O
28	of	O
29	the	O
30	opn	B
31	gene	I
32	was	O
33	sequenced	O
34	,	O
35	and	O
36	the	O
37	transcriptional	O
38	start	O
39	site	O
40	determined	O
41	by	O
42	primer	O
43	extension	O
44	analysis	O
45	and	O
46	S1	B
47	nuclease	I
48	mapping	O
49	.	O

0	Regulation	O
1	of	O
2	yeast	B
3	LEU2	I
4	.	O

0	As	O
1	it	O
2	had	O
3	been	O
4	previously	O
5	reported	O
6	that	O
7	the	O
8	18	O
9	-	O
10	bp	O
11	palindrome	O
12	contains	O
13	sufficient	O
14	nucleotide	O
15	sequence	O
16	information	O
17	for	O
18	E1	B
19	binding	O
20	,	O
21	we	O
22	speculate	O
23	that	O
24	a	O
25	minimal	O
26	E1	B
27	recognition	I
28	motif	I
29	is	O
30	presented	O
31	in	O
32	each	O
33	half	O
34	site	O
35	.	O

0	Diltiazem	O
1	decreased	O
2	the	O
3	total	O
4	body	O
5	clearance	O
6	from	O
7	34	O
8	.	O
9	0	O
10	+/-	O
11	8	O
12	.	O
13	0	O
14	to	O
15	28	O
16	.	O
17	6	O
18	+/-	O
19	6	O
20	.	O
21	1	O
22	mL	O
23	/	O
24	min	O
25	(	O
26	P	O
27	less	O
28	than	O
29	.	O
30	01	O
31	),	O
32	and	O
33	prolonged	O
34	the	O
35	elimination	O
36	half	O
37	-	O
38	life	O
39	from	O
40	12	O
41	.	O
42	6	O
43	+/-	O
44	3	O
45	.	O
46	0	O
47	to	O
48	14	O
49	.	O
50	3	O
51	+/-	O
52	2	O
53	.	O
54	5	O
55	hours	O
56	(	O
57	P	O
58	less	O
59	than	O
60	.	O
61	01	O
62	)	O
63	of	O
64	antipyrine	O
65	without	O
66	any	O
67	changes	O
68	in	O
69	volume	O
70	of	O
71	distribution	O
72	.	O

0	A	O
1	novel	O
2	,	O
3	testis	O
4	-	O
5	specific	O
6	mRNA	O
7	transcript	O
8	encoding	O
9	an	O
10	NH2	B
11	-	I
12	terminal	I
13	truncated	I
14	nitric	I
15	-	I
16	oxide	I
17	synthase	I
18	.	O
19	mRNA	O
20	diversity	O
21	represents	O
22	a	O
23	major	O
24	theme	O
25	of	O
26	neuronal	B
27	nitric	I
28	-	I
29	oxide	I
30	synthase	I
31	(	O
32	nNOS	B
33	)	O
34	gene	O
35	expression	O
36	in	O
37	somatic	O
38	cells	O
39	/	O
40	tissues	O
41	.	O

0	There	O
1	was	O
2	however	O
3	,	O
4	no	O
5	significant	O
6	difference	O
7	in	O
8	the	O
9	prevalence	O
10	of	O
11	chronic	O
12	respiratory	O
13	symptoms	O
14	between	O
15	animal	O
16	food	O
17	workers	O
18	with	O
19	positive	O
20	and	O
21	negative	O
22	skin	O
23	tests	O
24	to	O
25	house	O
26	dust	O
27	or	O
28	to	O
29	fish	O
30	flour	O
31	or	O
32	among	O
33	those	O
34	with	O
35	increased	O
36	or	O
37	normal	O
38	IgE	B
39	(	O
40	except	O
41	for	O
42	dyspnea	O
43	).	O

0	Further	O
1	support	O
2	for	O
3	a	O
4	direct	O
5	interaction	O
6	of	O
7	Tub4p	B
8	,	O
9	Spc98p	B
10	and	O
11	Spc97p	B
12	comes	O
13	from	O
14	the	O
15	toxicity	O
16	of	O
17	strong	O
18	SPC97	B
19	overexpression	O
20	which	O
21	is	O
22	suppressed	O
23	by	O
24	co	O
25	-	O
26	overexpression	O
27	of	O
28	TUB4	B
29	or	O
30	SPC98	B
31	.	O

0	HS	B
1	inducibility	O
2	required	O
3	the	O
4	HSE	B
5	which	O
6	was	O
7	bound	O
8	by	O
9	HS	B
10	transcription	I
11	factor	I
12	-	I
13	1	I
14	(	O
15	HSF	B
16	-	I
17	1	I
18	)	O
19	present	O
20	in	O
21	extracts	O
22	prepared	O
23	from	O
24	cells	O
25	exposed	O
26	to	O
27	HS	B
28	.	O

0	This	O
1	last	O
2	region	O
3	contains	O
4	two	O
5	sites	O
6	that	O
7	bind	O
8	Ets	B
9	-	I
10	related	I
11	proteins	I
12	present	O
13	in	O
14	liver	O
15	nuclear	O
16	extracts	O
17	as	O
18	well	O
19	as	O
20	recombinant	O
21	purified	O
22	Ets	B
23	-	I
24	1	I
25	protein	I
26	.	O

0	The	O
1	transit	O
2	time	O
3	was	O
4	significantly	O
5	shortened	O
6	.	O

0	Although	O
1	it	O
2	has	O
3	two	O
4	potential	O
5	binding	O
6	sites	O
7	,	O
8	the	O
9	purified	O
10	MerR	B
11	homodimer	I
12	binds	O
13	only	O
14	one	O
15	Hg	O
16	(	O
17	II	O
18	)	O
19	ion	O
20	,	O
21	employing	O
22	Cys82	O
23	from	O
24	one	O
25	monomer	O
26	and	O
27	Cys117	O
28	and	O
29	Cys126	O
30	from	O
31	the	O
32	other	O
33	.	O

0	Echinococcus	O
1	granulosus	O
2	was	O
3	diagnosed	O
4	by	O
5	fine	O
6	-	O
7	needle	O
8	aspiration	O
9	cytology	O
10	of	O
11	a	O
12	lung	O
13	cyst	O
14	in	O
15	a	O
16	6	O
17	-	O
18	yr	O
19	-	O
20	old	O
21	white	O
22	female	O
23	in	O
24	central	O
25	Missouri	O
26	.	O

0	Enhancement	O
1	of	O
2	the	O
3	immune	O
4	response	O
5	by	O
6	aspecific	O
7	action	O
8	of	O
9	vaccine	O
10	additives	O
11	in	O
12	the	O
13	aerogenic	O
14	immunization	O
15	of	O
16	swine	O
17	against	O
18	swine	O
19	plague	O

0	A	O
1	reduction	O
2	of	O
3	the	O
4	aspartate	B
5	aminotransferase	I
6	activity	O
7	was	O
8	observed	O
9	from	O
10	800	O
11	mg	O
12	/	O
13	kg	O
14	b	O
15	.	O
16	w	O
17	./	O
18	d	O
19	onwards	O
20	.	O

0	The	O
1	S229A	O
2	variant	O
3	can	O
4	better	O
5	flip	O
6	modified	O
7	bases	O
8	but	O
9	does	O
10	not	O
11	tightly	O
12	lock	O
13	the	O
14	flipped	O
15	base	O
16	into	O
17	the	O
18	adenine	O
19	-	O
20	binding	O
21	pocket	O
22	,	O
23	suggesting	O
24	that	O
25	Ser229	O
26	could	O
27	form	O
28	a	O
29	contact	O
30	to	O
31	the	O
32	flipped	O
33	adenine	O
34	.	O

0	Deletion	O
1	of	O
2	the	O
3	RVH	B
4	domain	I
5	resulted	O
6	in	O
7	loss	O
8	of	O
9	Ca	O
10	(	O
11	2	O
12	+)-	O
13	dependent	O
14	activation	O
15	.	O

0	Roles	O
1	of	O
2	the	O
3	Candida	B
4	albicans	I
5	mitogen	I
6	-	I
7	activated	I
8	protein	I
9	kinase	I
10	homolog	I
11	,	O
12	Cek1p	B
13	,	O
14	in	O
15	hyphal	O
16	development	O
17	and	O
18	systemic	O
19	candidiasis	O
20	.	O

0	Group	O
1	A	O
2	(	O
3	68	O
4	.	O
5	7	O
6	+/-	O
7	2	O
8	.	O
9	7	O
10	years	O
11	)	O
12	consisted	O
13	of	O
14	patients	O
15	with	O
16	0	O
17	or	O
18	1	O
19	risk	O
20	factors	O
21	;	O
22	B	O
23	(	O
24	68	O
25	.	O
26	3	O
27	+/-	O
28	4	O
29	.	O
30	2	O
31	years	O
32	)	O
33	those	O
34	with	O
35	2	O
36	risk	O
37	factors	O
38	;	O
39	and	O
40	C	O
41	(	O
42	69	O
43	.	O
44	2	O
45	+/-	O
46	3	O
47	.	O
48	6	O
49	years	O
50	)	O
51	those	O
52	with	O
53	3	O
54	or	O
55	more	O
56	risk	O
57	factors	O
58	.	O

0	Chem	O
1	.,	O
2	270	O
3	:	O
4	7117	O
5	-	O
6	7124	O
7	,	O
8	1995	O
9	;	O
10	and	O
11	MT	O
12	Hartsough	O
13	et	O
14	al	O
15	.,	O
16	J	O
17	.	O

0	Dentalplaque	O
1	was	O
2	controlled	O
3	by	O
4	the	O
5	oral	O
6	higienic	O
7	index	O
8	of	O
9	the	O
10	whole	O
11	dentition	O
12	daily	O
13	,	O
14	after	O
15	staining	O
16	with	O
17	1	O
18	per	O
19	cent	O
20	alkaline	O
21	fuxin	O
22	.	O

0	The	O
1	amino	O
2	acid	O
3	sequences	O
4	of	O
5	the	O
6	known	O
7	largest	O
8	subunits	O
9	of	O
10	DdRPs	B
11	from	O
12	different	O
13	species	O
14	contain	O
15	highly	O
16	conserved	O
17	regions	O
18	.	O

0	Breast	O
1	-	O
2	fed	O
3	newborn	O
4	infants	O
5	synthesize	O
6	n	O
7	-	O
8	6	O
9	long	O
10	-	O
11	chain	O
12	polyunsaturated	O
13	fatty	O
14	acids	O
15	already	O
16	during	O
17	the	O
18	first	O
19	week	O
20	of	O
21	life	O
22	,	O
23	but	O
24	the	O
25	contribution	O
26	of	O
27	endogenous	O
28	synthesis	O
29	to	O
30	the	O
31	total	O
32	plasma	O
33	long	O
34	-	O
35	chain	O
36	polyunsaturated	O
37	pool	O
38	is	O
39	small	O
40	.	O

0	Mature	O
1	and	O
2	old	O
3	B6AF1	O
4	and	O
5	B6D2F1	O
6	mice	O
7	were	O
8	given	O
9	acidified	O
10	tap	O
11	water	O
12	or	O
13	promethazine	O
14	HCl	O
15	(	O
16	a	O
17	phenothiazine	O
18	with	O
19	H1	B
20	receptor	I
21	blocking	O
22	activity	O
23	),	O
24	chlorpheniramine	O
25	(	O
26	an	O
27	H1	O
28	blocker	O
29	)	O
30	or	O
31	trifluoperazine	O
32	(	O
33	a	O
34	phenothiazine	O
35	with	O
36	no	O
37	H1	O
38	blocking	O
39	activity	O
40	)	O
41	in	O
42	their	O
43	drinking	O
44	water	O
45	,	O
46	and	O
47	the	O
48	effects	O
49	of	O
50	these	O
51	agents	O
52	on	O
53	bone	O
54	mineral	O
55	content	O
56	were	O
57	assessed	O
58	by	O
59	intermittently	O
60	measuring	O
61	the	O
62	24	O
63	-	O
64	h	O
65	whole	O
66	body	O
67	retention	O
68	of	O
69	Tc	O
70	99m	O
71	methylene	O
72	diphosphonate	O
73	(	O
74	Tc	O
75	99m	O
76	MDP	O
77	,	O
78	an	O
79	indicator	O
80	of	O
81	bone	O
82	metabolism	O
83	)	O
84	and	O
85	at	O
86	the	O
87	end	O
88	of	O
89	the	O
90	studies	O
91	by	O
92	determining	O
93	ash	O
94	weights	O
95	of	O
96	femur	O
97	,	O
98	ilium	O
99	and	O
100	sacrum	O
101	.	O

0	Measurement	O
1	of	O
2	gastric	O
3	acid	O
4	secretion	O
5	by	O
6	conductivity	O
7	.	O

0	Little	O
1	is	O
2	known	O
3	about	O
4	the	O
5	mechanism	O
6	,	O
7	but	O
8	the	O
9	availability	O
10	of	O
11	rapid	O
12	facile	O
13	assays	O
14	for	O
15	monitoring	O
16	immunoglobulin	B
17	hypermutation	O
18	would	O
19	greatly	O
20	aid	O
21	the	O
22	development	O
23	of	O
24	culture	O
25	systems	O
26	for	O
27	hypermutating	O
28	B	O
29	cells	O
30	as	O
31	well	O
32	as	O
33	the	O
34	screening	O
35	for	O
36	individuals	O
37	deficient	O
38	in	O
39	the	O
40	process	O
41	.	O

0	Because	O
1	there	O
2	is	O
3	great	O
4	need	O
5	for	O
6	iron	O
7	in	O
8	the	O
9	EPO	B
10	-	O
11	stimulated	O
12	erythroid	O
13	progenitors	O
14	,	O
15	it	O
16	is	O
17	essential	O
18	that	O
19	serum	O
20	ferritin	B
21	and	O
22	transferrin	B
23	saturation	O
24	levels	O
25	should	O
26	be	O
27	maintained	O
28	over	O
29	300	O
30	microg	O
31	/	O
32	liter	O
33	and	O
34	30	O
35	%,	O
36	respectively	O
37	.	O

0	Comparison	O
1	of	O
2	the	O
3	plant	B
4	nuclear	I
5	tRNA	I
6	3	I
7	'	I
8	processing	I
9	enzyme	I
10	with	O
11	the	O
12	plant	O
13	mitochondrial	O
14	one	O
15	suggests	O
16	that	O
17	both	O
18	activities	O
19	are	O
20	different	O
21	enzymes	O
22	.	O

0	In	O
1	addition	O
2	to	O
3	the	O
4	bZIP	B
5	protein	I
6	Opaque2	I
7	(	O
8	O2	B
9	),	O
10	there	O
11	are	O
12	other	O
13	maize	O
14	endosperm	I
15	nuclear	I
16	proteins	I
17	that	O
18	recognize	O
19	the	O
20	O2	O
21	box	O
22	in	O
23	22	B
24	kDa	I
25	zein	I
26	gene	I
27	promoters	I
28	.	O

0	The	O
1	effect	O
2	of	O
3	CBZ	B
4	and	O
5	DPH	B
6	can	O
7	be	O
8	explained	O
9	by	O
10	interference	O
11	with	O
12	thyroid	O
13	hormone	O
14	binding	O
15	to	O
16	TBG	B
17	combined	O
18	with	O
19	enzyme	O
20	-	O
21	induced	O
22	increased	O
23	metabolic	O
24	clearance	O
25	rate	O
26	of	O
27	thyroid	O
28	hormones	O
29	without	O
30	homeostatic	O
31	maintenance	O
32	of	O
33	premedication	O
34	levels	O
35	of	O
36	FT4	B
37	and	O
38	FT3	B
39	.	O

0	A	O
1	third	O
2	one	O
3	is	O
4	homologous	O
5	in	O
6	half	O
7	of	O
8	its	O
9	length	O
10	to	O
11	the	O
12	prokaryotic	B
13	hydantoinase	B
14	HyuA	I
15	and	O
16	in	O
17	the	O
18	other	O
19	half	O
20	to	O
21	hydatoinase	B
22	HyuB	I
23	.	O

0	All	O
1	six	O
2	genes	O
3	were	O
4	cloned	O
5	and	O
6	characterised	O
7	.	O

0	Similar	O
1	synergistic	O
2	activation	O
3	was	O
4	observed	O
5	in	O
6	the	O
7	IL	B
8	-	I
9	8	I
10	promoter	I
11	,	O
12	which	O
13	also	O
14	contains	O
15	both	O
16	NF	B
17	-	I
18	IL6	I
19	and	O
20	NF	B
21	-	I
22	kappa	I
23	B	I
24	binding	I
25	sites	I
26	.	O

0	Indoor	O
1	concentrations	O
2	were	O
3	only	O
4	weakly	O
5	correlated	O
6	with	O
7	outdoor	O
8	concentrations	O
9	,	O
10	however	O
11	,	O
12	and	O
13	personal	O
14	exposures	O
15	were	O
16	even	O
17	more	O
18	poorly	O
19	correlated	O
20	with	O
21	outdoor	O
22	concentrations	O
23	.	O

0	In	O
1	transient	O
2	assays	O
3	,	O
4	using	O
5	rice	O
6	suspension	O
7	-	O
8	cultured	O
9	cells	O
10	transformed	O
11	by	O
12	particle	O
13	bombardment	O
14	,	O
15	we	O
16	showed	O
17	previously	O
18	that	O
19	Oshox1	B
20	can	O
21	transcriptionally	O
22	repress	O
23	the	O
24	activity	O
25	of	O
26	reporter	O
27	gene	O
28	constructs	O
29	with	O
30	upstream	O
31	HD	B
32	-	O
33	Zip	O
34	binding	O
35	sites	O
36	.	O

0	Escherichia	O
1	coli	O
2	JRG582	O
3	is	O
4	an	O
5	ampD	B
6	ampE	I
7	deletion	O
8	derivative	O
9	of	O
10	strain	O
11	HfrH	O
12	and	O
13	accordingly	O
14	it	O
15	is	O
16	derepressed	O
17	for	O
18	expression	O
19	of	O
20	the	O
21	cloned	O
22	inducible	O
23	beta	B
24	-	I
25	lactamase	I
26	gene	I
27	of	I
28	Citrobacter	I
29	freundii	I
30	,	O
31	carried	O
32	on	O
33	plasmid	O
34	pNU305	O
35	.	O

0	Strains	O
1	bearing	O
2	the	O
3	drs2	B
4	mutation	I
5	process	O
6	the	O
7	20S	B
8	precursor	I
9	of	O
10	the	O
11	mature	O
12	18S	B
13	rRNA	I
14	slowly	O
15	and	O
16	are	O
17	deficient	O
18	in	O
19	40S	B
20	ribosomal	I
21	subunits	I
22	.	O

0	Epithelial	O
1	damage	O
2	was	O
3	not	O
4	observed	O
5	in	O
6	any	O
7	controls	O
8	but	O
9	was	O
10	in	O
11	all	O
12	tissues	O
13	exposed	O
14	to	O
15	SO2	O
16	.	O

0	On	O
1	the	O
2	basis	O
3	of	O
4	size	O
5	,	O
6	the	O
7	CRS	O
8	sequence	O
9	to	O
10	which	O
11	it	O
12	binds	O
13	,	O
14	and	O
15	its	O
16	tentative	O
17	identification	O
18	as	O
19	a	O
20	zinc	B
21	finger	I
22	protein	I
23	,	O
24	Adx	B
25	factor	I
26	has	O
27	been	O
28	identified	O
29	as	O
30	a	O
31	Kruppel	B
32	-	I
33	like	I
34	zinc	I
35	finger	I
36	protein	I
37	(	O
38	a	O
39	mouse	B
40	ZBP	I
41	-	I
42	89	I
43	homologue	I
44	).	O

0	Whereas	O
1	the	O
2	muscle	O
3	isoform	O
4	consists	O
5	of	O
6	997	O
7	amino	O
8	acids	O
9	and	O
10	terminates	O
11	with	O
12	the	O
13	sequence	O
14	Ala	O
15	-	O
16	Ile	O
17	-	O
18	Leu	O
19	-	O
20	Glu	O
21	,	O
22	the	O
23	second	O
24	isoform	O
25	is	O
26	1043	O
27	amino	O
28	acids	O
29	in	O
30	length	O
31	due	O
32	to	O
33	the	O
34	replacement	O
35	of	O
36	these	O
37	last	O
38	4	O
39	amino	O
40	acids	O
41	with	O
42	a	O
43	50	O
44	-	O
45	amino	O
46	acid	O
47	sequence	O
48	that	O
49	contains	O
50	a	O
51	potential	O
52	transmembrane	O
53	domain	O
54	followed	O
55	by	O
56	a	O
57	consensus	O
58	sequence	O
59	for	O
60	an	O
61	N	O
62	-	O
63	linked	O
64	glycosylation	O
65	site	O
66	.	O

0	OBJECTIVE	O
1	:	O
2	To	O
3	evaluate	O
4	the	O
5	overall	O
6	performance	O
7	of	O
8	a	O
9	new	O
10	oscillometric	O
11	wrist	O
12	blood	O
13	pressure	O
14	monitor	O
15	(	O
16	Braun	O
17	PrecisionSensor	O
18	,	O
19	Braun	O
20	GmbH	O
21	,	O
22	Kronberg	O
23	,	O
24	Germany	O
25	)	O
26	as	O
27	defined	O
28	by	O
29	the	O
30	ANSI	O
31	/	O
32	AAMI	O
33	SP10	O
34	-	O
35	1992	O
36	guidelines	O
37	,	O
38	and	O
39	to	O
40	analyze	O
41	the	O
42	data	O
43	for	O
44	the	O
45	optimized	O
46	selection	O
47	of	O
48	the	O
49	algorithm	O
50	that	O
51	derives	O
52	the	O
53	blood	O
54	pressure	O
55	values	O
56	from	O
57	the	O
58	oscillometric	O
59	blood	O
60	pressure	O
61	curves	O
62	.	O

0	Sputum	O
1	IL	B
2	-	I
3	8	I
4	and	O
5	MPO	O
6	were	O
7	significantly	O
8	increased	O
9	after	O
10	BPT	O
11	in	O
12	both	O
13	TDI	O
14	-	O
15	and	O
16	grain	O
17	dust	O
18	-	O
19	asthma	O
20	(	O
21	P	O
22	<	O
23	0	O
24	.	O
25	05	O
26	).	O

0	The	O
1	various	O
2	available	O
3	data	O
4	strongly	O
5	suggesting	O
6	an	O
7	environmental	O
8	toxic	O
9	origin	O
10	for	O
11	the	O
12	"	O
13	sperm	O
14	fall	O
15	"	O
16	will	O
17	be	O
18	presented	O
19	as	O
20	well	O
21	as	O
22	the	O
23	most	O
24	frequently	O
25	suspected	O
26	class	O
27	of	O
28	substances	O
29	,	O
30	the	O
31	xenoestrogens	O
32	.	O

0	Sterol	O
1	-	O
2	mediated	O
3	suppression	O
4	of	O
5	cleavage	O
6	of	O
7	SREBP	B
8	-	I
9	1	I
10	was	O
11	found	O
12	to	O
13	be	O
14	dependent	O
15	on	O
16	the	O
17	extreme	O
18	COOH	O
19	-	O
20	terminal	O
21	region	O
22	(	O
23	residue	O
24	1034	O
25	to	O
26	the	O
27	COOH	O
28	terminus	O
29	),	O
30	which	O
31	exists	O
32	in	O
33	two	O
34	forms	O
35	as	O
36	a	O
37	result	O
38	of	O
39	alternative	O
40	splicing	O
41	.	O

0	YAC	O
1	and	O
2	cosmid	O
3	contigs	O
4	spanning	O
5	the	O
6	Batten	O
7	disease	O
8	(	O
9	CLN3	B
10	)	O
11	region	O
12	at	O
13	16p12	O
14	.	O
15	1	O
16	-	O
17	p11	O
18	.	O
19	2	O
20	.	O

0	These	O
1	changes	O
2	were	O
3	the	O
4	result	O
5	of	O
6	a	O
7	decrease	O
8	in	O
9	afterload	O
10	:	O
11	mean	O
12	aortic	O
13	pressure	O
14	fell	O
15	from	O
16	85	O
17	+/-	O
18	11	O
19	.	O
20	8	O
21	to	O
22	68	O
23	+/-	O
24	19	O
25	.	O
26	6	O
27	mmHg	O
28	(	O
29	p	O
30	less	O
31	than	O
32	0	O
33	.	O
34	01	O
35	)	O
36	and	O
37	systemic	O
38	arterial	O
39	resistance	O
40	fell	O
41	from	O
42	2	O
43	886	O
44	+/-	O
45	745	O
46	to	O
47	2	O
48	010	O
49	+/-	O
50	610	O
51	dynes	O
52	/	O
53	cm	O
54	-	O
55	5	O
56	/	O
57	sec	O
58	/	O
59	m	O
60	-	O
61	2	O
62	(	O
63	p	O
64	less	O
65	than	O
66	0	O
67	.	O
68	01	O
69	).	O

0	Stromelysin	B
1	-	I
2	1	I
3	,	O
4	matrix	B
5	metalloproteinase	I
6	-	I
7	3	I
8	(	O
9	MMP	B
10	-	I
11	3	I
12	),	O
13	is	O
14	an	O
15	important	O
16	endopeptidase	B
17	selectively	O
18	expressed	O
19	by	O
20	somatic	O
21	cells	O
22	in	O
23	organ	O
24	tissues	O
25	.	O

0	A	O
1	potential	O
2	TATA	O
3	box	O
4	is	O
5	located	O
6	29	O
7	base	O
8	pairs	O
9	upstream	O
10	of	O
11	the	O
12	first	O
13	transcription	O
14	initiation	O
15	site	O
16	.	O

0	Binding	O
1	to	O
2	sulphatides	O
3	and	O
4	the	O
5	alpha	B
6	-	I
7	dystroglycan	I
8	receptor	I
9	was	O
10	much	O
11	stronger	O
12	and	O
13	required	O
14	at	O
15	least	O
16	two	O
17	LG	O
18	modules	O
19	.	O

0	In	O
1	a	O
2	recent	O
3	measles	O
4	epidemic	O
5	in	O
6	El	O
7	Paso	O
8	,	O
9	TX	O
10	,	O
11	120	O
12	,	O
13	000	O
14	records	O
15	were	O
16	screened	O
17	using	O
18	these	O
19	criteria	O
20	,	O
21	and	O
22	as	O
23	a	O
24	result	O
25	13	O
26	,	O
27	000	O
28	students	O
29	were	O
30	vaccinated	O
31	.	O

0	The	O
1	seventh	O
2	cysteine	O
3	residue	O
4	of	O
5	CTSE	B
6	is	O
7	located	O
8	within	O
9	the	O
10	activation	O
11	peptide	O
12	region	O
13	of	O
14	the	O
15	proenzyme	O
16	.	O

0	Northern	O
1	blotting	O
2	showed	O
3	that	O
4	MDMX	B
5	,	O
6	like	O
7	MDM2	B
8	,	O
9	is	O
10	expressed	O
11	in	O
12	all	O
13	tissues	O
14	tested	O
15	,	O
16	and	O
17	that	O
18	several	O
19	mRNAs	O
20	for	O
21	MDMX	B
22	can	O
23	be	O
24	detected	O
25	.	O

0	The	O
1	nucleotide	O
2	sequence	O
3	of	O
4	the	O
5	region	O
6	upstream	O
7	from	O
8	M	O
9	.	O
10	voltae	O
11	ORFtrpA	O
12	was	O
13	determined	O
14	and	O
15	revealed	O
16	the	O
17	presence	O
18	of	O
19	an	O
20	ORF	O
21	of	O
22	1227	O
23	nucleotides	O
24	(	O
25	ORFtrpB	O
26	)	O
27	encoding	O
28	a	O
29	409	O
30	amino	O
31	acid	O
32	polypeptide	O
33	of	O
34	mol	O
35	.	O
36	wt	O
37	.	O

0	Epitopes	O
1	of	O
2	adhesion	O
3	-	O
4	perturbing	O
5	monoclonal	O
6	antibodies	O
7	map	O
8	within	O
9	a	O
10	predicted	O
11	alpha	O
12	-	O
13	helical	O
14	domain	O
15	of	O
16	the	O
17	integrin	B
18	beta	I
19	1	I
20	subunit	I
21	.	O

0	Human	B
1	MN	I
2	/	O
3	CA9	B
4	gene	O
5	,	O
6	a	O
7	novel	O
8	member	O
9	of	O
10	the	O
11	carbonic	B
12	anhydrase	I
13	family	I
14	:	O
15	structure	O
16	and	O
17	exon	O
18	to	O
19	protein	O
20	domain	O
21	relationships	O
22	.	O

0	Comprising	O
1	a	O
2	126	O
3	-	O
4	nucleotide	O
5	5	O
6	'	O
7	untranscribed	O
8	genomic	O
9	sequence	O
10	and	O
11	a	O
12	466	O
13	-	O
14	nucleotide	O
15	5	O
16	'	O
17	noncoding	O
18	cDNA	O
19	sequence	O
20	,	O
21	the	O
22	592	O
23	-	O
24	nucleotide	O
25	5	O
26	'	O
27	CpG	O
28	island	O
29	lacked	O
30	TATA	O
31	and	O
32	CAAT	O
33	boxes	O
34	but	O
35	displayed	O
36	a	O
37	high	O
38	G	O
39	+	O
40	C	O
41	content	O
42	,	O
43	was	O
44	enriched	O
45	for	O
46	CpG	O
47	dinucleotides	O
48	,	O
49	and	O
50	contained	O
51	a	O
52	potential	O
53	Sp1	B
54	-	I
55	binding	I
56	site	I
57	,	O
58	i	O
59	.	O
60	e	O
61	.,	O
62	features	O
63	compatible	O
64	with	O
65	a	O
66	housekeeping	O
67	gene	O
68	.	O

0	Molecular	O
1	cloning	O
2	of	O
3	Elk	B
4	-	I
5	3	I
6	,	O
7	a	O
8	new	O
9	member	O
10	of	O
11	the	O
12	Ets	B
13	family	I
14	expressed	O
15	during	O
16	mouse	O
17	embryogenesis	O
18	and	O
19	analysis	O
20	of	O
21	its	O
22	transcriptional	O
23	repression	O
24	activity	O
25	.	O

0	Delineating	O
1	the	O
2	molecular	O
3	basis	O
4	for	O
5	agonist	O
6	-	O
7	induced	O
8	destabilization	O
9	of	O
10	mRNA	O
11	of	O
12	G	B
13	-	I
14	protein	I
15	-	I
16	linked	I
17	receptors	I
18	that	O
19	contributes	O
20	to	O
21	receptor	O
22	down	O
23	-	O
24	regulation	O
25	is	O
26	fundamental	O
27	to	O
28	our	O
29	understanding	O
30	of	O
31	long	O
32	-	O
33	term	O
34	regulation	O
35	of	O
36	receptors	O
37	by	O
38	agonist	O
39	.	O

0	Expression	O
1	of	O
2	thiamin	O
3	biosynthetic	O
4	genes	O
5	(	O
6	thiCOGE	B
7	)	O
8	and	O
9	production	O
10	of	O
11	symbiotic	O
12	terminal	B
13	oxidase	I
14	cbb3	I
15	in	O
16	Rhizobium	O
17	etli	O
18	.	O

0	Thus	O
1	,	O
2	the	O
3	multidomained	O
4	ROK	B
5	alpha	I
6	appears	O
7	to	O
8	be	O
9	involved	O
10	in	O
11	reorganization	O
12	of	O
13	the	O
14	cytoskeleton	O
15	,	O
16	with	O
17	the	O
18	N	O
19	and	O
20	C	O
21	termini	O
22	acting	O
23	as	O
24	positive	O
25	and	O
26	negative	O
27	regulators	O
28	,	O
29	respectively	O
30	,	O
31	of	O
32	the	O
33	kinase	O
34	domain	O
35	whose	O
36	activity	O
37	is	O
38	crucial	O
39	for	O
40	formation	O
41	of	O
42	stress	O
43	fibers	O
44	and	O
45	focal	O
46	adhesion	O
47	complexes	O
48	.	O

0	The	O
1	serum	B
2	insulin	I
3	response	O
4	cannot	O
5	.	O

0	Max	B
1	was	O
2	constantly	O
3	transcribed	O
4	at	O
5	a	O
6	relatively	O
7	low	O
8	level	O
9	during	O
10	cell	O
11	cycle	O
12	progression	O
13	.	O

0	In	O
1	a	O
2	blind	O
3	controlled	O
4	trial	O
5	,	O
6	15	O
7	patients	O
8	with	O
9	COCM	O
10	(	O
11	NYHA	O
12	II	O
13	-	O
14	III	O
15	)	O
16	with	O
17	sinus	O
18	rhythm	O
19	and	O
20	a	O
21	left	O
22	ventricular	O
23	ejection	O
24	fraction	O
25	(	O
26	LV	O
27	-	O
28	EF	O
29	)	O
30	of	O
31	34	O
32	.	O
33	5	O
34	+/-	O
35	2	O
36	.	O
37	6	O
38	%	O
39	received	O
40	consecutively	O
41	D	O
42	(	O
43	0	O
44	.	O
45	25	O
46	-	O
47	0	O
48	.	O
49	5	O
50	mg	O
51	/	O
52	d	O
53	),	O
54	placebo	O
55	(	O
56	PLAC	O
57	),	O
58	P	O
59	(	O
60	slow	O
61	releases	O
62	=	O
63	SR	O
64	)	O
65	(	O
66	80	O
67	mg	O
68	/	O
69	d	O
70	SR	O
71	)	O
72	and	O
73	both	O
74	drugs	O
75	combined	O
76	in	O
77	respective	O
78	doses	O
79	.	O

0	The	O
1	RNA	O
2	genome	O
3	of	O
4	rabbit	O
5	hemorrhagic	O
6	disease	O
7	virus	O
8	(	O
9	RHDV	O
10	)	O
11	was	O
12	molecularly	O
13	cloned	O
14	.	O

0	Moreover	O
1	,	O
2	we	O
3	observed	O
4	that	O
5	the	O
6	function	O
7	of	O
8	T3R	B
9	-	O
10	RXR	B
11	heterodimers	O
12	on	O
13	response	O
14	elements	O
15	composed	O
16	of	O
17	two	O
18	half	O
19	-	O
20	sites	O
21	in	O
22	a	O
23	directly	O
24	repeated	O
25	orientation	O
26	spaced	O
27	by	O
28	4	O
29	nucleotides	O
30	is	O
31	determined	O
32	in	O
33	major	O
34	parts	O
35	by	O
36	the	O
37	5	O
38	'-	O
39	flanking	O
40	sequence	O
41	of	O
42	the	O
43	upstream	O
44	half	O
45	-	O
46	site	O
47	.	O

0	The	O
1	entire	O
2	human	B
3	teneurin	I
4	-	I
5	1	I
6	(	O
7	TEN1	B
8	)	O
9	gene	O
10	is	O
11	contained	O
12	in	O
13	eight	O
14	PAC	B
15	clones	O
16	representing	O
17	part	O
18	of	O
19	the	O
20	chromosomal	O
21	locus	O
22	Xq25	O
23	.	O

0	The	O
1	cDNA	O
2	has	O
3	an	O
4	open	O
5	reading	O
6	frame	O
7	of	O
8	900	O
9	amino	O
10	acids	O
11	capable	O
12	of	O
13	encoding	O
14	a	O
15	97	O
16	-	O
17	kDa	O
18	protein	O
19	.	O

0	The	O
1	encoded	O
2	protein	O
3	has	O
4	a	O
5	leader	O
6	sequence	O
7	of	O
8	27	O
9	amino	O
10	acids	O
11	.	O

0	These	O
1	findings	O
2	indicate	O
3	that	O
4	hypergastrinemia	O
5	induced	O
6	by	O
7	surgical	O
8	removal	O
9	of	O
10	acid	O
11	-	O
12	producing	O
13	mucosa	O
14	in	O
15	the	O
16	rat	O
17	has	O
18	the	O
19	same	O
20	effects	O
21	on	O
22	oxyntical	O
23	mucosal	O
24	HDC	B
25	activity	O
26	,	O
27	histamine	O
28	concentration	O
29	and	O
30	ECL	O
31	cell	O
32	density	O
33	as	O
34	hypergastrinemia	O
35	induced	O
36	by	O
37	continuous	O
38	gastrin	O
39	infusion	O
40	or	O
41	by	O
42	long	O
43	-	O
44	term	O
45	treatment	O
46	with	O
47	effective	O
48	antisecretagogues	O
49	.	O

0	Sequence	O
1	analysis	O
2	of	O
3	the	O
4	isolated	O
5	genomic	O
6	clone	O
7	revealed	O
8	that	O
9	the	O
10	DNA	O
11	binding	O
12	domain	O
13	of	O
14	this	O
15	orphan	O
16	receptor	O
17	is	O
18	most	O
19	homologous	O
20	to	O
21	the	O
22	human	B
23	TR2	I
24	receptor	I
25	.	O

0	Two	O
1	related	O
2	studies	O
3	conducted	O
4	over	O
5	a	O
6	five	O
7	week	O
8	period	O
9	measured	O
10	and	O
11	typed	O
12	HLA	B
13	-	I
14	DQA1	I
15	from	O
16	accumulated	O
17	DNA	O
18	on	O
19	autopsy	O
20	room	O
21	and	O
22	Forensic	O
23	DNA	O
24	Laboratory	O
25	structures	O
26	.	O

0	Prevention	O
1	by	O
2	a	O
3	heparin	O
4	-	O
5	antithrombin	B
6	III	I
7	combination	O

0	It	O
1	is	O
2	mainly	O
3	transcribed	O
4	in	O
5	neural	O
6	structures	O
7	and	O
8	in	O
9	developing	O
10	organs	O
11	characterized	O
12	by	O
13	epithelial	O
14	-	O
15	mesenchymal	O
16	interactions	O
17	.	O

0	Antimicrobial	O
1	Susceptibility	O
2	of	O
3	Klebsiella	O
4	pneumoniae	O
5	Producing	O
6	Extended	B
7	-	I
8	Spectrum	I
9	beta	I
10	-	I
11	lactamase	I
12	(	O
13	ESBL	B
14	)	O
15	Isolated	O
16	in	O
17	Hospitals	O
18	in	O
19	Brazil	O
20	.	O

0	IV	O
1	.	O

0	Both	O
1	BG	O
2	and	O
3	IRI	O
4	concentrations	O
5	during	O
6	the	O
7	OGTT	O
8	were	O
9	the	O
10	lowest	O
11	in	O
12	body	O
13	builders	O
14	,	O
15	medium	O
16	in	O
17	controls	O
18	,	O
19	and	O
20	the	O
21	highest	O
22	in	O
23	obese	O
24	men	O
25	.	O

0	Ultimate	O
1	strengthes	O
2	seem	O
3	to	O
4	be	O
5	reached	O
6	for	O
7	cast	O
8	cobalt	O
9	alloys	O
10	,	O
11	whereas	O
12	titanium	O
13	alloys	O
14	,	O
15	such	O
16	as	O
17	Ta	O
18	6	O
19	V	O
20	,	O
21	present	O
22	very	O
23	high	O
24	fatigue	O
25	limit	O
26	under	O
27	corrosion	O
28	.	O

0	Among	O
1	these	O
2	,	O
3	ACT1	B
4	was	O
5	isolated	O
6	four	O
7	times	O
8	,	O
9	and	O
10	NSR1	B
11	three	O
12	times	O
13	.	O

0	From	O
1	transient	O
2	expression	O
3	studies	O
4	,	O
5	we	O
6	could	O
7	demonstrate	O
8	that	O
9	the	O
10	SH3	B
11	domain	I
12	of	O
13	PLC	B
14	-	I
15	gamma1	I
16	is	O
17	necessary	O
18	for	O
19	the	O
20	association	O
21	with	O
22	SOS1	B
23	in	O
24	vivo	O
25	.	O

0	Substitutions	O
1	introduced	O
2	at	O
3	bases	O
4	surrounding	O
5	the	O
6	ICR2	B
7	motif	I
8	yielded	O
9	levels	O
10	of	O
11	pRNA	O
12	replication	O
13	that	O
14	differed	O
15	,	O
16	depending	O
17	on	O
18	the	O
19	maintenance	O
20	of	O
21	a	O
22	putative	O
23	5	O
24	'	O
25	stem	O
26	-	O
27	loop	O
28	structure	O
29	in	O
30	the	O
31	positive	O
32	strand	O
33	of	O
34	the	O
35	viral	O
36	genome	O
37	.	O

0	Clones	O
1	that	O
2	expressed	O
3	DBD	O
4	exhibited	O
5	a	O
6	dominant	O
7	negative	O
8	phenotype	O
9	and	O
10	did	O
11	not	O
12	elicit	O
13	antiviral	O
14	activity	O
15	against	O
16	vesicular	O
17	stomatitis	O
18	virus	O
19	(	O
20	VSV	O
21	)	O
22	infection	O
23	upon	O
24	IFN	B
25	treatment	O
26	.	O

0	The	O
1	priming	O
2	activity	O
3	of	O
4	DNA	O
5	incised	O
6	by	O
7	either	O
8	of	O
9	the	O
10	Drosophila	O
11	enzymes	O
12	can	O
13	be	O
14	enhanced	O
15	,	O
16	however	O
17	,	O
18	by	O
19	an	O
20	additional	O
21	incubation	O
22	with	O
23	E	B
24	.	I
25	coli	I
26	endonuclease	I
27	IV	I
28	,	O
29	which	O
30	is	O
31	known	O
32	to	O
33	cleave	O
34	depurinated	O
35	DNA	O
36	on	O
37	the	O
38	5	O
39	'-	O
40	side	O
41	of	O
42	an	O
43	apurinic	O
44	site	O
45	.	O

0	Although	O
1	the	O
2	Src	B
3	tyrosine	I
4	kinase	I
5	induces	O
6	constitutive	O
7	Stat3	B
8	phosphorylation	O
9	on	O
10	tyrosine	O
11	,	O
12	activation	O
13	of	O
14	Stat3	B
15	-	O
16	mediated	O
17	gene	O
18	regulation	O
19	requires	O
20	both	O
21	tyrosine	O
22	and	O
23	serine	O
24	phosphorylation	O
25	of	O
26	Stat3	B
27	.	O

0	The	O
1	sequence	O
2	of	O
3	four	O
4	clones	O
5	was	O
6	sufficient	O
7	to	O
8	construct	O
9	a	O
10	3018	O
11	-	O
12	bp	O
13	BAL	O
14	cDNA	O
15	structure	O
16	.	O

0	Sequence	O
1	analysis	O
2	identified	O
3	some	O
4	of	O
5	these	O
6	cDNA	O
7	clones	O
8	as	O
9	Dlc	B
10	-	I
11	1	I
12	,	O
13	a	O
14	sequence	O
15	encoding	O
16	a	O
17	small	O
18	,	O
19	9	O
20	-	O
21	kDa	O
22	human	O
23	homolog	O
24	of	O
25	the	O
26	outer	B
27	-	I
28	arm	I
29	dynein	I
30	light	I
31	-	I
32	chain	I
33	protein	I
34	.	O

0	Disorders	O
1	of	O
2	platelet	O
3	function	O
4	in	O
5	chronic	O
6	myeloid	O
7	leukemias	O

0	Our	O
1	data	O
2	therefore	O
3	indicate	O
4	that	O
5	it	O
6	is	O
7	possible	O
8	to	O
9	engineer	O
10	the	O
11	HA	B
12	envelope	I
13	glycoprotein	I
14	by	O
15	fusing	O
16	ligands	O
17	to	O
18	its	O
19	amino	O
20	-	O
21	terminal	O
22	end	O
23	without	O
24	affecting	O
25	its	O
26	fusion	O
27	activity	O
28	.	O

0	The	O
1	highest	O
2	decrease	O
3	in	O
4	mutagenic	O
5	activity	O
6	was	O
7	observed	O
8	when	O
9	enzymatic	O
10	bleaching	O
11	was	O
12	used	O
13	together	O
14	with	O
15	chlorine	O
16	.	O

0	Unfolding	O
1	can	O
2	be	O
3	described	O
4	by	O
5	a	O
6	two	O
7	-	O
8	state	O
9	process	O
10	since	O
11	a	O
12	ratio	O
13	of	O
14	delta	O
15	Hcalorimetric	O
16	to	O
17	delta	O
18	Hvan	O
19	'	O
20	t	O
21	Hoff	O
22	equals	O
23	0	O
24	.	O
25	96	O
26	.	O

0	Indeed	O
1	,	O
2	significant	O
3	level	O
4	of	O
5	CAT	B
6	activity	O
7	was	O
8	observed	O
9	in	O
10	human	O
11	lung	O
12	adenocarcinoma	O
13	(	O
14	A549	O
15	-	O
16	1	O
17	)	O
18	cells	O
19	which	O
20	had	O
21	been	O
22	incubated	O
23	with	O
24	a	O
25	complex	O
26	of	O
27	T7	B
28	RNA	I
29	polymerase	I
30	,	O
31	pT7	B
32	-	O
33	EMC	B
34	-	O
35	CAT	O
36	DNA	O
37	and	O
38	DC	O
39	-	O
40	chol	O
41	cationic	O
42	liposomes	O
43	.	O

0	Novel	O
1	8	O
2	-	O
3	base	O
4	pair	O
5	sequence	O
6	(	O
7	Drosophila	O
8	DNA	O
9	replication	O
10	-	O
11	related	O
12	element	O
13	)	O
14	and	O
15	specific	O
16	binding	O
17	factor	O
18	involved	O
19	in	O
20	the	O
21	expression	O
22	of	O
23	Drosophila	O
24	genes	O
25	for	O
26	DNA	B
27	polymerase	I
28	alpha	I
29	and	O
30	proliferating	B
31	cell	B
32	nuclear	I
33	antigen	I
34	.	O

0	The	O
1	3	O
2	-	O
3	hour	O
4	test	O
5	iodine	O
6	(	O
7	I	O
8	-	O
9	132	O
10	)	O
11	uptake	O
12	by	O
13	the	O
14	thyroid	O
15	in	O
16	children	O
17	with	O
18	growth	O
19	deficiency	O

0	The	O
1	RET	B
2	/	O
3	PTC3	B
4	rearrangement	O
5	is	O
6	formed	O
7	by	O
8	fusion	O
9	of	O
10	the	O
11	ELE1	B
12	and	O
13	RET	B
14	genes	I
15	,	O
16	and	O
17	is	O
18	highly	O
19	prevalent	O
20	in	O
21	radiation	O
22	-	O
23	induced	O
24	post	O
25	-	O
26	Chernobyl	O
27	papillary	O
28	thyroid	O
29	carcinomas	O
30	.	O

0	Leukemia	O
1	in	O
2	twins	O
3	:	O
4	world	O
5	-	O
6	wide	O
7	review	O
8	of	O
9	clinical	O
10	cases	O
11	.	O

0	The	O
1	effect	O
2	of	O
3	salmon	O
4	calcitonin	I
5	nasal	O
6	spray	O
7	in	O
8	women	O
9	with	O
10	established	O
11	osteoporosis	O
12	has	O
13	also	O
14	been	O
15	studied	O
16	.	O

0	Toxicity	O
1	was	O
2	significant	O
3	in	O
4	selected	O
5	cases	O
6	;	O
7	three	O
8	patients	O
9	developed	O
10	WBC	O
11	counts	O
12	less	O
13	than	O
14	1	O
15	,	O
16	000	O
17	/	O
18	mm3	O
19	and	O
20	one	O
21	of	O
22	these	O
23	patients	O
24	died	O
25	with	O
26	sepsis	O
27	.	O

0	Adult	O
1	H	O
2	,	O
3	but	O
4	not	O
5	R	O
6	,	O
7	manifested	O
8	the	O
9	burrowing	O
10	preference	O
11	whenever	O
12	offered	O
13	the	O
14	opportunity	O
15	.	O

0	The	O
1	gene	O
2	pairs	O
3	psbB	B
4	-	O
5	psbT	B
6	and	O
7	psbH	B
8	-	O
9	psbN	B
10	are	O
11	cotranscribed	O
12	from	O
13	opposite	O
14	strands	O
15	.	O

0	Other	O
1	hemostatic	O
2	values	O
3	evaluated	O
4	were	O
5	activated	O
6	partial	O
7	thromboplastin	B
8	times	O
9	,	O
10	prothrombin	B
11	times	O
12	,	O
13	thrombin	B
14	times	O
15	,	O
16	fibrinogen	B
17	,	O
18	platelet	O
19	counts	O
20	,	O
21	and	O
22	fibrin	B
23	/	O
24	fibrinogen	B
25	degradation	O
26	products	O
27	.	O

0	The	O
1	bovine	O
2	papillomavirus	O
3	E2	I
4	protein	I
5	can	O
6	inhibit	O
7	the	O
8	proliferation	O
9	of	O
10	HT	O
11	-	O
12	3	O
13	cells	O
14	,	O
15	a	O
16	p53	B
17	-	O
18	negative	O
19	cervical	O
20	carcinoma	O
21	cell	O
22	line	O
23	containing	O
24	integrated	O
25	human	O
26	papillomavirus	O
27	type	O
28	30	O
29	DNA	O
30	.	O

0	Twenty	O
1	-	O
2	four	O
3	hours	O
4	later	O
5	,	O
6	the	O
7	animals	O
8	were	O
9	randomized	O
10	to	O
11	subretinal	O
12	treatment	O
13	with	O
14	2	O
15	.	O
16	5	O
17	micrograms	O
18	of	O
19	tissue	B
20	plasminogen	I
21	activator	I
22	or	O
23	a	O
24	similar	O
25	volume	O
26	of	O
27	physiologic	O
28	saline	O
29	.	O

0	A	O
1	randomized	O
2	clinical	O
3	trial	O
4	in	O
5	sixty	O
6	-	O
7	two	O
8	adult	O
9	patients	O
10	suffering	O
11	from	O
12	typhoid	O
13	fever	O
14	,	O
15	proved	O
16	by	O
17	blood	O
18	and	O
19	marrow	O
20	culture	O
21	,	O
22	showed	O
23	that	O
24	amoxycillin	O
25	in	O
26	a	O
27	dosage	O
28	schedule	O
29	of	O
30	1	O
31	g	O
32	8	O
33	-	O
34	hourly	O
35	orally	O
36	for	O
37	fourteen	O
38	days	O
39	was	O
40	better	O
41	than	O
42	chloramphenicol	O
43	with	O
44	regard	O
45	to	O
46	clinical	O
47	and	O
48	temperature	O
49	response	O
50	and	O
51	in	O
52	respect	O
53	of	O
54	carriers	O
55	and	O
56	relapse	O
57	rates	O
58	.	O

0	The	O
1	histological	O
2	grading	O
3	was	O
4	certified	O
5	in	O
6	68	O
7	cases	O
8	:	O
9	12	O
10	G1	O
11	,	O
12	39	O
13	G2	O
14	,	O
15	17	O
16	G3	O
17	;	O
18	extracapsular	O
19	spread	O
20	was	O
21	found	O
22	in	O
23	20	O
24	/	O
25	54	O
26	cases	O
27	(	O
28	37	O
29	%).	O

0	Our	O
1	data	O
2	suggest	O
3	that	O
4	it	O
5	may	O
6	be	O
7	possible	O
8	to	O
9	individualize	O
10	hCG	B
11	administration	O
12	at	O
13	midcycle	O
14	by	O
15	determining	O
16	the	O
17	number	O
18	of	O
19	follicles	O
20	greater	O
21	than	O
22	1	O
23	cm	O
24	by	O
25	ultrasound	O
26	on	O
27	cycle	O
28	day	O
29	12	O
30	or	O
31	13	O
32	and	O
33	giving	O
34	hCG	B
35	when	O
36	serum	O
37	E2	O
38	levels	O
39	reach	O
40	1100	O
41	to	O
42	1200	O
43	pmol	O
44	/	O
45	l	O
46	per	O
47	follicle	O
48	.	O

0	The	O
1	Siglecs	B
2	are	O
3	a	O
4	subfamily	O
5	of	O
6	I	B
7	-	I
8	type	I
9	lectins	I
10	(	O
11	immunoglobulin	B
12	superfamily	I
13	proteins	I
14	that	O
15	bind	O
16	sugars	O
17	)	O
18	that	O
19	specifically	O
20	recognize	O
21	sialic	O
22	acids	O
23	.	O

0	High	O
1	concentrations	O
2	of	O
3	tumor	O
4	-	O
5	associated	O
6	trypsin	B
7	inhibitor	O
8	in	O
9	hemodialyzed	O
10	patients	O
11	.	O

0	Feeding	O
1	behavior	O
2	,	O
3	circannual	O
4	body	O
5	weight	O
6	and	O
7	hibernation	O
8	rhythms	O
9	in	O
10	European	O
11	hamsters	O
12	lesioned	O
13	in	O
14	the	O
15	noradrenergic	O
16	ascending	O
17	bundles	O

0	Parkinsonian	O
1	patients	O
2	had	O
3	a	O
4	significantly	O
5	lower	O
6	prevalence	O
7	of	O
8	alcohol	O
9	use	O
10	.	O

0	Thirty	O
1	of	O
2	the	O
3	clones	O
4	contained	O
5	a	O
6	complete	O
7	340	O
8	base	O
9	-	O
10	pair	O
11	dimer	O
12	unit	O
13	of	O
14	the	O
15	repeat	O
16	.	O

0	Pentobarbital	O
1	(	O
2	1	O
3	,	O
4	3	O
5	,	O
6	10	O
7	,	O
8	and	O
9	17	O
10	.	O
11	5	O
12	mg	O
13	/	O
14	kg	O
15	)	O
16	was	O
17	also	O
18	tested	O
19	in	O
20	combination	O
21	with	O
22	rate	O
23	-	O
24	decreasing	O
25	doses	O
26	of	O
27	normeperidine	O
28	(	O
29	17	O
30	.	O
31	5	O
32	mg	O
33	/	O
34	kg	O
35	),	O
36	anileridine	O
37	(	O
38	10	O
39	mg	O
40	/	O
41	kg	O
42	),	O
43	alphaprodine	O
44	(	O
45	10	O
46	mg	O
47	/	O
48	kg	O
49	),	O
50	and	O
51	fentanyl	O
52	(	O
53	0	O
54	.	O
55	3	O
56	mg	O
57	/	O
58	kg	O
59	).	O

0	The	O
1	patient	O
2	'	O
3	s	O
4	role	O
5	,	O
6	organized	O
7	by	O
8	the	O
9	prerequisites	O
10	of	O
11	expressive	O
12	freedom	O
13	,	O
14	is	O
15	counter	O
16	posed	O
17	with	O
18	the	O
19	psychoanalyst	O
20	'	O
21	s	O
22	,	O
23	which	O
24	is	O
25	structured	O
26	to	O
27	empower	O
28	listening	O
29	and	O
30	understanding	O
31	.	O

0	Montelukast	O
1	reduces	O
2	airway	O
3	eosinophilic	O
4	inflammation	O
5	in	O
6	asthma	O
7	:	O
8	a	O
9	randomized	O
10	,	O
11	controlled	O
12	trial	O
13	.	O

0	Functional	O
1	analysis	O
2	of	O
3	the	O
4	sGTH	B
5	alpha	I
6	subunit	I
7	promoter	I
8	by	O
9	the	O
10	transient	O
11	transfection	O
12	of	O
13	several	O
14	sGTH	B
15	alpha	I
16	/	O
17	CAT	B
18	chimeric	O
19	plasmids	O
20	into	O
21	rainbow	O
22	trout	O
23	pituitary	O
24	cells	O
25	suggests	O
26	that	O
27	its	O
28	pituitary	O
29	-	O
30	specific	O
31	expression	O
32	is	O
33	GSE	O
34	-	O
35	dependent	O
36	.	O

0	Additionally	O
1	,	O
2	observations	O
3	that	O
4	patients	O
5	with	O
6	mitral	O
7	versus	O
8	aortic	O
9	regurgitation	O
10	respond	O
11	differently	O
12	to	O
13	valve	O
14	replacement	O
15	suggest	O
16	that	O
17	differences	O
18	exist	O
19	preoperatively	O
20	between	O
21	these	O
22	two	O
23	types	O
24	of	O
25	volume	O
26	overload	O
27	.	O

0	Sensory	O
1	evoked	O
2	field	O
3	potentials	O
4	were	O
5	recorded	O
6	from	O
7	the	O
8	mesencephalic	O
9	reticular	O
10	formation	O
11	(	O
12	MRF	O
13	),	O
14	central	O
15	gray	O
16	(	O
17	CG	O
18	)	O
19	and	O
20	somatosensory	O
21	cortex	O
22	(	O
23	SCX	O
24	),	O
25	following	O
26	incremental	O
27	doses	O
28	of	O
29	halothane	O
30	in	O
31	freely	O
32	-	O
33	moving	O
34	rats	O
35	.	O

0	Both	O
1	normal	O
2	and	O
3	transforming	O
4	PCPH	B
5	proteins	I
6	have	O
7	guanosine	B
8	diphosphatase	I
9	activity	O
10	but	O
11	only	O
12	the	O
13	oncoprotein	O
14	cooperates	O
15	with	O
16	Ras	B
17	in	O
18	activating	O
19	extracellular	O
20	signal	O
21	-	O
22	regulated	O
23	kinase	O
24	ERK1	B
25	.	O

0	The	O
1	etiology	O
2	,	O
3	pathology	O
4	,	O
5	brain	O
6	CT	O
7	scan	O
8	features	O
9	,	O
10	clinical	O
11	manifestations	O
12	and	O
13	treatment	O
14	of	O
15	these	O
16	accidents	O
17	were	O
18	discussed	O
19	.	O

0	The	O
1	oral	O
2	temperature	O
3	rose	O
4	and	O
5	the	O
6	serum	B
7	creatine	I
8	kinase	I
9	levels	O
10	fell	O
11	only	O
12	in	O
13	those	O
14	patients	O
15	who	O
16	were	O
17	actively	O
18	warmed	O
19	.	O

0	Sodium	O
1	restriction	O
2	in	O
3	cardiac	O
4	failure	O
5	.	O

0	To	O
1	study	O
2	the	O
3	regulation	O
4	of	O
5	mdr2	B
6	expression	O
7	,	O
8	the	O
9	promoter	O
10	of	O
11	the	O
12	mdr2	B
13	gene	I
14	has	O
15	been	O
16	isolated	O
17	from	O
18	a	O
19	murine	O
20	vinblastine	O
21	-	O
22	resistant	O
23	cell	O
24	line	O
25	,	O
26	J7	O
27	.	O
28	V2	O
29	-	O
30	1	O
31	,	O
32	and	O
33	characterized	O
34	.	O

0	The	O
1	product	O
2	of	O
3	the	O
4	vpr	B
5	open	I
6	reading	I
7	frame	I
8	of	O
9	human	O
10	immunodeficiency	O
11	virus	O
12	type	O
13	1	O
14	(	O
15	HIV	O
16	-	O
17	1	O
18	)	O
19	is	O
20	a	O
21	15	O
22	-	O
23	kDa	O
24	,	O
25	arginine	O
26	-	O
27	rich	O
28	protein	O
29	that	O
30	is	O
31	present	O
32	in	O
33	virions	O
34	in	O
35	molar	O
36	quantities	O
37	equivalent	O
38	to	O
39	that	O
40	of	O
41	Gag	B
42	.	O

0	Thus	O
1	,	O
2	the	O
3	system	O
4	can	O
5	be	O
6	used	O
7	to	O
8	detect	O
9	and	O
10	study	O
11	dynamic	O
12	perfusion	O
13	changes	O
14	from	O
15	the	O
16	brain	O
17	surface	O
18	with	O
19	minimal	O
20	tissue	O
21	damage	O
22	.	O

0	To	O
1	lower	O
2	the	O
3	current	O
4	high	O
5	incidence	O
6	of	O
7	NANB	O
8	-	O
9	induced	O
10	PTH	O
11	,	O
12	in	O
13	1986	O
14	,	O
15	the	O
16	American	O
17	Association	O
18	of	O
19	Blood	O
20	Banks	O
21	(	O
22	AABB	O
23	)	O
24	recommended	O
25	testing	O
26	for	O
27	these	O
28	PTH	B
29	-	O
30	associated	O
31	"	O
32	surrogate	O
33	"	O
34	markers	O
35	on	O
36	all	O
37	donated	O
38	units	O
39	of	O
40	blood	O
41	.	O

0	Endo16	B
1	transcripts	I
2	are	O
3	confined	O
4	to	O
5	the	O
6	definitive	O
7	vegetal	O
8	plate	O
9	in	O
10	blastula	O
11	stage	O
12	embryos	O
13	;	O
14	at	O
15	gastrula	O
16	stage	O
17	this	O
18	gene	O
19	is	O
20	expressed	O
21	throughout	O
22	the	O
23	archenteron	O
24	,	O
25	but	O
26	later	O
27	only	O
28	in	O
29	the	O
30	midgut	O
31	.	O

0	In	O
1	assays	O
2	with	O
3	purified	O
4	enzymes	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	but	O
10	not	O
11	PTPS	B
12	-	I
13	S19A	I
14	was	O
15	a	O
16	specific	O
17	substrate	O
18	for	O
19	the	O
20	cGMP	B
21	-	I
22	dependent	I
23	protein	I
24	kinase	I
25	(	O
26	cGK	B
27	)	O
28	type	I
29	I	I
30	and	I
31	II	I
32	.	O

0	The	O
1	E1	B
2	replication	I
3	protein	I
4	of	O
5	bovine	O
6	papillomavirus	O
7	type	O
8	1	O
9	contains	O
10	an	O
11	extended	O
12	nuclear	O
13	localization	O
14	signal	O
15	that	O
16	includes	O
17	a	O
18	p34cdc2	B
19	phosphorylation	O
20	site	O
21	.	O

0	This	O
1	multimodality	O
2	treatment	O
3	for	O
4	locally	O
5	advanced	O
6	gynecologic	O
7	tumors	O
8	appears	O
9	feasible	O
10	with	O
11	modification	O
12	,	O
13	and	O
14	continued	O
15	work	O
16	exploring	O
17	this	O
18	approach	O
19	is	O
20	encouraged	O
21	.	O

0	Promoter	O
1	activities	O
2	were	O
3	estimated	O
4	using	O
5	beta	B
6	-	I
7	glucuronidase	I
8	and	O
9	neomycin	B
10	phosphotransferase	I
11	II	I
12	reporter	O
13	gene	O
14	systems	O
15	.	O

0	CONCLUSION	O
1	:	O
2	Treatment	O
3	of	O
4	sepsis	O
5	with	O
6	the	O
7	platelet	B
8	-	I
9	activating	I
10	factor	I
11	antagonist	O
12	BB	O
13	-	O
14	882	O
15	offers	O
16	no	O
17	advantage	O
18	over	O
19	placebo	O
20	on	O
21	survival	O
22	,	O
23	hemodynamic	O
24	status	O
25	,	O
26	respiratory	O
27	function	O
28	,	O
29	or	O
30	organ	O
31	failure	O
32	scores	O
33	.	O

0	The	O
1	drug	O
2	sensitivity	O
3	was	O
4	100	O
5	%	O
6	for	O
7	vancomycin	O
8	(	O
9	VCM	O
10	),	O
11	30	O
12	%	O
13	for	O
14	imipenam	O
15	(	O
16	IMP	O
17	),	O
18	31	O
19	%	O
20	for	O
21	minomycin	O
22	(	O
23	MINO	O
24	),	O
25	31	O
26	%	O
27	for	O
28	amikacin	O
29	(	O
30	AMK	O
31	),	O
32	and	O
33	7	O
34	%	O
35	for	O
36	fosfomycin	O
37	(	O
38	FOM	O
39	).	O

0	The	O
1	26S	B
2	rRNA	I
3	binding	I
4	ribosomal	I
5	protein	I
6	equivalent	O
7	to	O
8	bacterial	B
9	protein	I
10	L11	I
11	is	O
12	encoded	O
13	by	O
14	unspliced	O
15	duplicated	O
16	genes	O
17	in	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

0	The	O
1	use	O
2	of	O
3	primary	O
4	GE	O
5	cells	O
6	thus	O
7	provides	O
8	a	O
9	convenient	O
10	in	O
11	vitro	O
12	system	O
13	for	O
14	further	O
15	study	O
16	of	O
17	the	O
18	endocrine	O
19	,	O
20	paracrine	O
21	,	O
22	and	O
23	autocrine	O
24	factors	O
25	regulating	O
26	endometrial	O
27	gene	O
28	expression	O
29	during	O
30	pregnancy	O
31	.	O

0	We	O
1	demonstrate	O
2	that	O
3	the	O
4	protein	O
5	is	O
6	a	O
7	murine	O
8	homologue	O
9	of	O
10	SAF	B
11	-	I
12	A	I
13	which	O
14	has	O
15	been	O
16	shown	O
17	to	O
18	bind	O
19	selectively	O
20	to	O
21	MARs	B
22	and	O
23	is	O
24	responsible	O
25	for	O
26	the	O
27	satMa	O
28	-	O
29	binding	O
30	activity	O
31	in	O
32	the	O
33	chromatographic	O
34	fractions	O
35	.	O

0	Study	O
1	of	O
2	the	O
3	alterations	O
4	of	O
5	intestinal	O
6	absorption	O
7	,	O
8	by	O
9	means	O
10	of	O
11	I	O
12	-	O
13	131	O
14	-	O
15	triolein	O
16	,	O
17	in	O
18	the	O
19	whole	O
20	body	O
21	irradiated	O
22	rat	O

0	Childhood	O
1	misbehavior	O
2	and	O
3	the	O
4	risk	O
5	of	O
6	injecting	O
7	drug	O
8	use	O
9	.	O

0	This	O
1	study	O
2	utilizes	O
3	the	O
4	mammalian	O
5	two	O
6	-	O
7	hybrid	O
8	system	O
9	to	O
10	examine	O
11	the	O
12	role	O
13	of	O
14	ligand	O
15	in	O
16	the	O
17	dimerization	O
18	of	O
19	human	B
20	progesterone	I
21	receptor	I
22	(	O
23	hPR	B
24	).	O

0	In	O
1	vitro	O
2	interaction	O
3	studies	O
4	,	O
5	using	O
6	proteins	O
7	fused	O
8	to	O
9	glutathione	B
10	-	I
11	S	I
12	-	I
13	transferase	I
14	,	O
15	showed	O
16	that	O
17	RBP	B
18	-	I
19	J	I
20	kappa	I
21	and	O
22	Su	B
23	(	I
24	H	I
25	)	I
26	bind	O
27	directly	O
28	to	O
29	the	O
30	RAM23	B
31	regions	I
32	of	O
33	mouse	B
34	Notch1	I
35	and	O
36	Drosophila	B
37	Notch	I
38	,	O
39	respectively	O
40	.	O

0	Among	O
1	100	O
2	cases	O
3	of	O
4	post	O
5	-	O
6	transfusion	O
7	hepatitis	O
8	,	O
9	10	O
10	are	O
11	due	O
12	to	O
13	the	O
14	hepatitis	O
15	B	O
16	virus	O
17	(	O
18	despite	O
19	systematic	O
20	search	O
21	for	O
22	HBs	O
23	Ag	O
24	),	O
25	89	O
26	are	O
27	due	O
28	to	O
29	one	O
30	of	O
31	the	O
32	non	O
33	-	O
34	A	O
35	non	O
36	-	O
37	B	O
38	viruses	O
39	(	O
40	not	O
41	detectable	O
42	by	O
43	specific	O
44	serological	O
45	tests	O
46	)	O
47	and	O
48	1	O
49	to	O
50	several	O
51	viruses	O
52	,	O
53	specially	O
54	CMV	O
55	.	O

0	Oxfendazole	O
1	,	O
2	which	O
3	was	O
4	active	O
5	for	O
6	the	O
7	shortest	O
8	time	O
9	(	O
10	about	O
11	65	O
12	days	O
13	)	O
14	from	O
15	the	O
16	start	O
17	of	O
18	grazing	O
19	(	O
20	May	O
21	1	O
22	),	O
23	produced	O
24	a	O
25	78	O
26	.	O
27	1	O
28	per	O
29	cent	O
30	reduction	O
31	in	O
32	Ostertagia	O
33	species	O
34	and	O
35	an	O
36	84	O
37	.	O
38	4	O
39	per	O
40	cent	O
41	reduction	O
42	in	O
43	D	O
44	viviparus	O
45	.	O

0	RESULTS	O
1	:	O
2	Transpulmonary	O
3	passage	O
4	of	O
5	contrast	O
6	occurred	O
7	in	O
8	sufficient	O
9	amounts	O
10	to	O
11	enhance	O
12	the	O
13	intensity	O
14	of	O
15	the	O
16	Doppler	O
17	signal	O
18	significantly	O
19	,	O
20	but	O
21	the	O
22	duration	O
23	of	O
24	this	O
25	effect	O
26	was	O
27	short	O
28	.	O

0	For	O
1	each	O
2	night	O
3	,	O
4	the	O
5	diary	O
6	allowed	O
7	the	O
8	subjective	O
9	measurement	O
10	of	O
11	bedtime	O
12	,	O
13	wake	O
14	time	O
15	,	O
16	time	O
17	in	O
18	bed	O
19	(	O
20	TIB	O
21	),	O
22	sleep	O
23	efficiency	O
24	,	O
25	number	O
26	of	O
27	minutes	O
28	of	O
29	wake	O
30	after	O
31	sleep	O
32	onset	O
33	(	O
34	WASO	O
35	),	O
36	alertness	O
37	on	O
38	awakening	O
39	,	O
40	and	O
41	percentage	O
42	of	O
43	morning	O
44	needing	O
45	an	O
46	alarm	O
47	(	O
48	or	O
49	a	O
50	person	O
51	functioning	O
52	as	O
53	one	O
54	).	O

0	Poly	O
1	(	O
2	dT	O
3	)	O
4	and	O
5	denatured	O
6	calf	O
7	thymus	O
8	DNA	O
9	were	O
10	more	O
11	effective	O
12	than	O
13	were	O
14	other	O
15	polynucleotides	O
16	tested	O
17	in	O
18	promoting	O
19	accumulation	O
20	of	O
21	19	O
22	HDP	O
23	*;	O
24	(	O
25	dT	O
26	)	O
27	8	O
28	was	O
29	as	O
30	effective	O
31	as	O
32	were	O
33	longer	O
34	molecules	O
35	of	O
36	(	O
37	dT	O
38	)	O
39	n	O
40	,	O
41	but	O
42	(	O
43	dT	O
44	)	O
45	4	O
46	and	O
47	(	O
48	dT	O
49	)	O
50	6	O
51	were	O
52	much	O
53	less	O
54	effective	O
55	,	O
56	indicating	O
57	that	O
58	the	O
59	binding	O
60	site	O
61	involved	O
62	in	O
63	19	O
64	HDP	O
65	*	O
66	accumulation	O
67	covered	O
68	between	O
69	6	O
70	and	O
71	8	O
72	residues	O
73	of	O
74	(	O
75	dT	O
76	)	O
77	n	O
78	.	O

0	The	O
1	enzyme	O
2	activities	O
3	studied	O
4	are	O
5	important	O
6	elements	O
7	in	O
8	the	O
9	pathophysiology	O
10	of	O
11	dental	O
12	caries	O
13	and	O
14	may	O
15	even	O
16	be	O
17	addressed	O
18	as	O
19	virulence	O
20	factors	O
21	.	O

0	Most	O
1	of	O
2	the	O
3	expressed	O
4	human	B
5	E3	I
6	polypeptides	I
7	(	O
8	five	O
9	bands	O
10	)	O
11	were	O
12	found	O
13	in	O
14	the	O
15	insoluble	O
16	pellet	O
17	while	O
18	primarily	O
19	full	O
20	-	O
21	length	O
22	mature	O
23	E3	B
24	was	O
25	found	O
26	in	O
27	the	O
28	soluble	O
29	fraction	O
30	.	O

0	A	O
1	stochastic	O
2	version	O
3	of	O
4	Kernell	O
5	'	O
6	s	O
7	(	O
8	1968	O
9	,	O
10	1972	O
11	)	O
12	model	O
13	with	O
14	cumulative	O
15	afterhyperpolarization	O
16	(	O
17	AHP	O
18	)	O
19	was	O
20	simulated	O
21	.	O

0	Histopathology	O
1	and	O
2	pathogenesis	O
3	of	O
4	exanthematous	O
5	viroses	O

0	Ciprofloxacin	O
1	:	O
2	an	O
3	overview	O
4	of	O
5	adverse	O
6	experiences	O
7	.	O

0	The	O
1	Myc	B
2	LZ	I
3	was	O
4	found	O
5	to	O
6	prevent	O
7	homodimeric	O
8	interactions	O
9	,	O
10	thus	O
11	explaining	O
12	Myc	B
13	inability	O
14	to	O
15	homodimerize	O
16	efficiently	O
17	.	O

0	Each	O
1	of	O
2	these	O
3	genes	O
4	contains	O
5	a	O
6	putative	O
7	upstream	O
8	ORF	O
9	,	O
10	while	O
11	STA2	B
12	has	O
13	two	O
14	additional	O
15	in	O
16	-	O
17	frame	O
18	AUG	O
19	codons	O
20	5	O
21	'	O
22	to	O
23	the	O
24	major	O
25	cistron	O
26	.	O

0	Synovial	O
1	cysts	O
2	of	O
3	the	O
4	hip	O
5	joint	O

0	When	O
1	the	O
2	degree	O
3	of	O
4	exercise	O
5	was	O
6	maximal	O
7	,	O
8	mPAP	O
9	was	O
10	maintained	O
11	,	O
12	SVI	O
13	decreased	O
14	,	O
15	HR	O
16	was	O
17	unchanged	O
18	,	O
19	and	O
20	CO	O
21	and	O
22	VO2	O
23	decreased	O
24	.	O

0	C3	B
1	toxin	I
2	completely	O
3	inhibited	O
4	RhoA	B
5	function	O
6	,	O
7	partially	O
8	inhibited	O
9	SRE	B
10	:	O
11	Luc	B
12	activity	O
13	,	O
14	but	O
15	had	O
16	no	O
17	effect	O
18	on	O
19	LPA	B
20	-	O
21	stimulated	O
22	c	B
23	-	I
24	Fos	I
25	expression	O
26	.	O

0	In	O
1	Experiment	O
2	1	O
3	,	O
4	pups	O
5	that	O
6	had	O
7	received	O
8	an	O
9	injection	O
10	of	O
11	the	O
12	noncompetitive	O
13	N	B
14	-	I
15	methyl	I
16	-	I
17	D	I
18	-	I
19	aspartate	I
20	receptor	I
21	antagonist	O
22	MK	O
23	-	O
24	801	O
25	(	O
26	0	O
27	.	O
28	1	O
29	mg	O
30	/	O
31	kg	O
32	,	O
33	i	O
34	.	O
35	p	O
36	.)	O
37	either	O
38	30	O
39	min	O
40	before	O
41	or	O
42	immediately	O
43	after	O
44	conditioning	O
45	spent	O
46	less	O
47	time	O
48	over	O
49	the	O
50	conditioned	O
51	odor	O
52	than	O
53	saline	O
54	-	O
55	treated	O
56	controls	O
57	.	O

0	Tobramycin	O
1	-	O
2	loaded	O
3	SLN	B
4	administered	O
5	i	O
6	.	O
7	v	O
8	.	O
9	showed	O
10	a	O
11	prolonged	O
12	circulation	O
13	time	O
14	compared	O
15	to	O
16	the	O
17	i	O
18	.	O
19	v	O
20	.	O
21	administered	O
22	tobramycin	O
23	solution	O
24	.	O

0	Previous	O
1	investigators	O
2	have	O
3	suggested	O
4	that	O
5	subretinal	O
6	blood	O
7	damages	O
8	the	O
9	retina	O
10	in	O
11	part	O
12	because	O
13	of	O
14	its	O
15	solid	O
16	fibrin	B
17	meshwork	O
18	.	O

0	Pax	B
1	-	I
2	3	I
3	is	O
4	a	O
5	paired	B
6	-	I
7	type	I
8	homeobox	I
9	gene	I
10	that	O
11	is	O
12	specifically	O
13	expressed	O
14	in	O
15	the	O
16	dorsal	O
17	and	O
18	posterior	O
19	neural	O
20	tube	O
21	.	O

0	A	O
1	study	O
2	of	O
3	human	O
4	genes	O
5	coding	O
6	for	O
7	U4	B
8	small	I
9	nuclear	I
10	RNA	I
11	is	O
12	presented	O
13	.	O

0	Antisense	O
1	transcription	O
2	of	O
3	a	O
4	murine	B
5	FGFR	B
6	-	I
7	3	I
8	psuedogene	I
9	during	O
10	fetal	O
11	developement	O
12	.	O

0	Biol	O
1	.	O

0	Expression	O
1	of	O
2	a	O
3	dominant	B
4	-	I
5	negative	I
6	ras	I
7	gene	I
8	also	O
9	blocks	O
10	TIS10	B
11	/	O
12	PGS2	B
13	induction	O
14	by	O
15	v	B
16	-	I
17	src	I
18	.	O

0	In	O
1	this	O
2	study	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	BOX	O
8	DNA	O
9	enhances	O
10	transcription	O
11	from	O
12	the	O
13	thymidine	B
14	kinase	I
15	(	O
16	TK	B
17	)	O
18	promoter	O
19	in	O
20	various	O
21	EC	O
22	cells	O
23	.	O

0	The	O
1	calcium	O
2	requirement	O
3	for	O
4	hypothermic	O
5	storage	O
6	of	O
7	the	O
8	cardiac	O
9	explant	O
10	.	O

0	99mTc	O
1	-	O
2	HMPAO	O
3	was	O
4	distributed	O
5	in	O
6	the	O
7	territories	O
8	of	O
9	the	O
10	ACA	O
11	and	O
12	MCA	O
13	in	O
14	the	O
15	two	O
16	patients	O
17	who	O
18	were	O
19	treated	O
20	with	O
21	intraarterial	O
22	infusion	O
23	of	O
24	papaverine	O
25	from	O
26	the	O
27	C4	O
28	segment	O
29	,	O
30	but	O
31	was	O
32	distributed	O
33	only	O
34	to	O
35	the	O
36	territory	O
37	of	O
38	the	O
39	ACA	O
40	in	O
41	four	O
42	patients	O
43	who	O
44	were	O
45	treated	O
46	with	O
47	intraarterial	O
48	infusion	O
49	of	O
50	papaverine	O
51	from	O
52	the	O
53	C1	O
54	segment	O
55	at	O
56	1	O
57	ml	O
58	/	O
59	min	O
60	.	O

0	Thirty	O
1	-	O
2	two	O
3	rats	O
4	were	O
5	divided	O
6	into	O
7	four	O
8	groups	O
9	.	O

0	PPD	B
1	-	O
2	specific	O
3	IgG	B
4	subclass	I
5	responses	O
6	were	O
7	evident	O
8	to	O
9	all	O
10	four	O
11	IgG	B
12	subclasses	I
13	.	O

0	Mechanism	O
1	of	O
2	enhancement	O
3	of	O
4	DNA	O
5	expression	O
6	consequent	O
7	to	O
8	cointernalization	O
9	of	O
10	a	O
11	replication	O
12	-	O
13	deficient	O
14	adenovirus	O
15	and	O
16	unmodified	O
17	plasmid	O
18	DNA	O
19	.	O

0	Induction	O
1	of	O
2	the	O
3	CINC	B
4	promoter	I
5	by	O
6	IL	B
7	-	I
8	17	I
9	in	O
10	IEC	O
11	-	O
12	6	O
13	cells	O
14	was	O
15	TNF	B
16	receptor	I
17	-	I
18	associated	I
19	factor	I
20	-	I
21	6	I
22	(	O
23	TRAF6	B
24	),	O
25	but	O
26	not	O
27	TRAF2	B
28	,	O
29	dependent	O
30	.	O

0	Schwab	O
1	and	O
2	England	O
3	ADL	O
4	scores	O
5	in	O
6	the	O
7	"	O
8	off	O
9	"	O
10	state	O
11	were	O
12	improved	O
13	by	O
14	18	O
15	%	O
16	and	O
17	in	O
18	the	O
19	"	O
20	on	O
21	"	O
22	state	O
23	the	O
24	scores	O
25	declined	O
26	by	O
27	2	O
28	%.	O

0	Commutative	O
1	saccadic	O
2	generator	O
3	is	O
4	sufficient	O
5	to	O
6	control	O
7	a	O
8	3	O
9	-	O
10	D	O
11	ocular	O
12	plant	O
13	with	O
14	pulleys	O
15	.	O

0	The	O
1	reconstituted	O
2	RNA	B
3	polymerases	I
4	containing	O
5	the	O
6	mutant	B
7	alpha	I
8	subunits	I
9	were	O
10	examined	O
11	for	O
12	their	O
13	response	O
14	to	O
15	transcription	O
16	activation	O
17	by	O
18	cAMP	B
19	-	I
20	CRP	I
21	and	O
22	the	O
23	rrnBP1	B
24	UP	I
25	element	I
26	.	O

0	Variation	O
1	in	O
2	the	O
3	temporal	O
4	-	O
5	spatial	O
6	distribution	O
7	of	O
8	228Ra	O
9	and	O
10	224Ra	O
11	in	O
12	the	O
13	RES	O
14	and	O
15	marrow	O
16	-	O
17	free	O
18	skeleton	O
19	after	O
20	incorporation	O
21	of	O
22	colloidal	O
23	ThO2	O

0	UDP	O
1	-	O
2	GlcNAc	O
3	:	O
4	alpha	B
5	-	I
6	6	I
7	-	I
8	D	I
9	-	I
10	mannoside	I
11	beta	I
12	-	I
13	1	I
14	,	I
15	2	I
16	-	I
17	N	I
18	-	I
19	acetylglucosaminyltransferase	I
20	II	I
21	(	O
22	GnT	B
23	II	I
24	;	O
25	EC	B
26	2	I
27	.	I
28	4	I
29	.	I
30	1	I
31	.	I
32	143	I
33	)	O
34	is	O
35	essential	O
36	for	O
37	the	O
38	normal	O
39	assembly	O
40	of	O
41	complex	O
42	Asn	O
43	-	O
44	linked	O
45	glycans	O
46	.	O

0	The	O
1	cycle	O
2	length	O
3	of	O
4	induced	O
5	VT	O
6	(	O
7	n	O
8	=	O
9	10	O
10	VTs	O
11	)	O
12	was	O
13	380	O
14	+/-	O
15	41	O
16	msec	O
17	.	O

0	Generally	O
1	ILC	O
2	and	O
3	ILVF	O
4	values	O
5	decreased	O
6	with	O
7	increasing	O
8	exposure	O
9	time	O
10	with	O
11	rate	O
12	constants	O
13	ranging	O
14	from	O
15	0	O
16	.	O
17	03	O
18	to	O
19	0	O
20	.	O
21	33	O
22	day	O
23	-	O
24	1	O
25	(	O
26	wet	O
27	and	O
28	lipid	O
29	weight	O
30	)	O
31	for	O
32	ILC	O
33	and	O
34	0	O
35	.	O
36	03	O
37	to	O
38	0	O
39	.	O
40	31	O
41	day	O
42	-	O
43	1	O
44	for	O
45	ILVF	O
46	.	O

0	Gel	O
1	retardation	O
2	assays	O
3	combined	O
4	with	O
5	DNase	B
6	I	I
7	footprinting	O
8	and	O
9	diethyl	O
10	pyrocarbonate	O
11	interference	O
12	showed	O
13	that	O
14	a	O
15	nuclear	O
16	factor	O
17	from	O
18	differentiated	O
19	C2	O
20	myotubes	O
21	and	O
22	BC3H1	O
23	myocytes	O
24	recognized	O
25	a	O
26	conserved	O
27	A	O
28	+	O
29	T	O
30	-	O
31	rich	O
32	sequence	O
33	within	O
34	the	O
35	peripheral	O
36	activating	O
37	region	O
38	.	O

0	Plasma	B
1	leptin	B
2	concentrations	O
3	were	O
4	higher	O
5	in	O
6	women	O
7	than	O
8	men	O
9	,	O
10	even	O
11	after	O
12	the	O
13	adjustment	O
14	for	O
15	differences	O
16	in	O
17	fat	O
18	mass	O
19	(	O
20	28	O
21	+/-	O
22	3	O
23	ng	O
24	/	O
25	ml	O
26	for	O
27	women	O
28	vs	O
29	.	O

0	Involvement	O
1	of	O
2	AP1	B
3	and	O
4	PEA3	B
5	binding	O
6	sites	O
7	in	O
8	the	O
9	regulation	O
10	of	O
11	murine	O
12	tissue	O
13	inhibitor	O
14	of	B
15	metalloproteinases	B
16	-	I
17	1	I
18	(	O
19	TIMP	B
20	-	I
21	1	I
22	)	O
23	transcription	O
24	.	O

0	To	O
1	characterize	O
2	this	O
3	effect	O
4	,	O
5	we	O
6	looked	O
7	for	O
8	targets	O
9	of	O
10	NS1	B
11	influenza	I
12	virus	I
13	protein	I
14	among	O
15	cellular	O
16	translation	O
17	factors	O
18	.	O

0	The	O
1	specific	O
2	electrical	O
3	resistance	O
4	of	O
5	the	O
6	cerebrospinal	O
7	fluid	O
8	was	O
9	measured	O
10	by	O
11	means	O
12	of	O
13	conductometry	O
14	in	O
15	14	O
16	cases	O
17	of	O
18	meningitis	O
19	purulenta	O
20	,	O
21	17	O
22	cases	O
23	of	O
24	meningitis	O
25	serosa	O
26	,	O
27	10	O
28	cases	O
29	of	O
30	encephalitis	O
31	and	O
32	in	O
33	32	O
34	control	O
35	subjects	O
36	.	O

0	Such	O
1	marked	O
2	differences	O
3	are	O
4	found	O
5	occasionally	O
6	in	O
7	the	O
8	literature	O
9	:	O
10	heterophile	O
11	antibodies	O
12	against	O
13	bovine	B
14	gammaglobulin	I
15	are	O
16	regarded	O
17	as	O
18	responsible	O
19	for	O
20	the	O
21	interference	O
22	in	O
23	the	O
24	Sephadex	O
25	system	O
26	of	O
27	RIST	O
28	.	O

0	In	O
1	the	O
2	DNA	O
3	recognition	O
4	helix	O
5	of	O
6	finger	O
7	II	O
8	,	O
9	the	O
10	conserved	O
11	Arg	O
12	at	O
13	position	O
14	62	O
15	(	O
16	N	O
17	-	O
18	terminal	O
19	side	O
20	of	O
21	the	O
22	first	O
23	zinc	O
24	-	O
25	coordinating	O
26	histidine	O
27	)	O
28	was	O
29	changed	O
30	to	O
31	a	O
32	Leu	O
33	or	O
34	Gln	O
35	.	O

0	Vaccinia	O
1	virus	O
2	-	O
3	expressed	O
4	,	O
5	purified	O
6	full	B
7	-	I
8	length	I
9	HPV	I
10	-	I
11	16	I
12	and	I
13	BPV	B
14	-	I
15	1	I
16	E2	I
17	proteins	I
18	bound	O
19	a	O
20	consensus	O
21	E2	B
22	site	I
23	with	O
24	high	O
25	specific	O
26	affinities	O
27	(	O
28	Kd	O
29	=	O
30	approximately	O
31	10	O
32	(-	O
33	9	O
34	)	O
35	M	O
36	)	O
37	and	O
38	stimulated	O
39	in	O
40	vitro	O
41	transcription	O
42	up	O
43	to	O
44	six	O
45	-	O
46	to	O
47	eightfold	O
48	.	O

0	We	O
1	present	O
2	here	O
3	a	O
4	detailed	O
5	genomic	O
6	sequencing	O
7	analysis	O
8	of	O
9	the	O
10	cytosine	O
11	methylation	O
12	patterns	O
13	of	O
14	the	O
15	transposase	B
16	binding	O
17	sites	O
18	within	O
19	both	O
20	Ac	B
21	ends	O
22	in	O
23	the	O
24	wx	B
25	-	I
26	m9	I
27	::	O
28	Ac	B
29	allele	I
30	,	O
31	where	O
32	Ac	B
33	is	O
34	inserted	O
35	into	O
36	the	O
37	tenth	O
38	exon	O
39	of	O
40	the	O
41	Waxy	B
42	gene	I
43	.	O

0	Using	O
1	varying	O
2	conditions	O
3	,	O
4	three	O
5	distinct	O
6	complexes	O
7	were	O
8	shown	O
9	to	O
10	interact	O
11	specifically	O
12	with	O
13	the	O
14	NIP	B
15	region	I
16	,	O
17	although	O
18	only	O
19	one	O
20	correlates	O
21	with	O
22	repressor	O
23	activity	O
24	.	O

0	Mutations	O
1	affecting	O
2	only	O
3	CD4	B
4	regulation	O
5	mapped	O
6	to	O
7	residues	O
8	previously	O
9	shown	O
10	to	O
11	mediate	O
12	the	O
13	binding	O
14	of	O
15	Nef	B
16	to	O
17	this	O
18	receptor	O
19	,	O
20	such	O
21	as	O
22	W57	O
23	and	O
24	L58	O
25	,	O
26	as	O
27	well	O
28	as	O
29	to	O
30	an	O
31	AP	B
32	-	O
33	recruiting	O
34	dileucine	O
35	motif	O
36	and	O
37	to	O
38	an	O
39	acidic	O
40	dipeptide	O
41	in	O
42	the	O
43	C	O
44	-	O
45	terminal	O
46	region	O
47	of	O
48	the	O
49	protein	O
50	.	O

0	The	O
1	other	O
2	is	O
3	located	O
4	at	O
5	-	O
6	1335	O
7	,	O
8	outside	O
9	this	O
10	highly	O
11	conserved	O
12	region	O
13	.	O

0	Interestingly	O
1	,	O
2	the	O
3	IR5	O
4	ORF	O
5	of	O
6	EHV	O
7	-	O
8	1	O
9	possesses	O
10	a	O
11	sequence	O
12	of	O
13	13	O
14	amino	O
15	acids	O
16	(	O
17	CAYWCCLGHAFAC	O
18	)	O
19	that	O
20	is	O
21	a	O
22	perfect	O
23	match	O
24	to	O
25	the	O
26	consensus	O
27	zinc	O
28	finger	O
29	motif	O
30	(	O
31	C	O
32	-	O
33	X2	O
34	-	O
35	4	O
36	-	O
37	C	O
38	-	O
39	X2	O
40	-	O
41	15	O
42	-	O
43	C	O
44	/	O
45	H	O
46	-	O
47	X2	O
48	-	O
49	4	O
50	-	O
51	C	O
52	/	O
53	H	O
54	).	O

0	Cross	O
1	reactivity	O
2	in	O
3	theophylline	O
4	RIA	O
5	kit	O
6	decreased	O
7	.	O

0	Bacterial	O
1	metabolism	O
2	of	O
3	4	O
4	-	O
5	chlorophenoxyacetate	O
6	.	O

0	Silencing	O
1	can	O
2	be	O
3	restored	O
4	by	O
5	creation	O
6	of	O
7	a	O
8	telomere	O
9	at	O
10	13	O
11	kb	O
12	from	O
13	the	O
14	reporter	O
15	construct	O
16	,	O
17	or	O
18	by	O
19	insertion	O
20	of	O
21	340	O
22	bp	O
23	of	O
24	yeast	O
25	telomeric	O
26	repeat	O
27	sequence	O
28	at	O
29	this	O
30	site	O
31	without	O
32	chromosomal	O
33	truncation	O
34	.	O

0	Vacuolar	O
1	membrane	O
2	vesicles	O
3	from	O
4	hum1	B
5	mutants	I
6	lack	O
7	all	O
8	Ca2	O
9	+/	O
10	H	O
11	+	O
12	antiport	O
13	activity	O
14	,	O
15	demonstrating	O
16	that	O
17	Hum1p	B
18	catalyzes	O
19	the	O
20	exchange	O
21	of	O
22	Ca2	O
23	+	O
24	for	O
25	H	O
26	+	O
27	across	O
28	the	O
29	yeast	O
30	vacuolar	O
31	membrane	O
32	.	O

0	A	O
1	prospective	O
2	trial	O
3	was	O
4	carried	O
5	out	O
6	in	O
7	156	O
8	unselected	O
9	patients	O
10	(	O
11	41	O
12	men	O
13	,	O
14	mean	O
15	age	O
16	67	O
17	.	O
18	5	O
19	years	O
20	,	O
21	115	O
22	women	O
23	,	O
24	mean	O
25	age	O
26	71	O
27	.	O
28	4	O
29	years	O
30	)	O
31	who	O
32	had	O
33	undergone	O
34	total	O
35	hip	O
36	joint	O
37	replacement	O
38	because	O
39	of	O
40	degenerative	O
41	or	O
42	inflammatory	O
43	arthritis	O
44	or	O
45	fracture	O
46	of	O
47	the	O
48	neck	O
49	of	O
50	the	O
51	femur	O
52	.	O

0	Total	O
1	serum	O
2	calcium	O
3	was	O
4	7	O
5	.	O
6	8	O
7	+/-	O
8	0	O
9	.	O
10	8	O
11	mg	O
12	/	O
13	dl	O
14	,	O
15	whereas	O
16	ionized	O
17	calcium	O
18	was	O
19	5	O
20	.	O
21	7	O
22	+/-	O
23	0	O
24	.	O
25	7	O
26	mg	O
27	/	O
28	dl	O
29	,	O
30	phosphorus	O
31	3	O
32	.	O
33	2	O
34	+/-	O
35	1	O
36	.	O
37	2	O
38	mg	O
39	/	O
40	dl	O
41	,	O
42	and	O
43	alkaline	B
44	phosphatase	I
45	149	O
46	+/-	O
47	48	O
48	.	O
49	6	O
50	U	O
51	/	O
52	liter	O
53	.	O

0	A	O
1	synthetic	O
2	oligonucleotide	O
3	containing	O
4	the	O
5	SRE	O
6	sequence	O
7	from	O
8	the	O
9	mouse	B
10	c	I
11	-	I
12	fos	I
13	gene	I
14	promoter	I
15	(-	O
16	299	O
17	to	O
18	-	O
19	322	O
20	)	O
21	was	O
22	radioactively	O
23	labeled	O
24	,	O
25	used	O
26	as	O
27	a	O
28	probe	O
29	for	O
30	the	O
31	mobility	O
32	shift	O
33	assay	O
34	and	O
35	Southwestern	O
36	(	O
37	DNA	O
38	-	O
39	protein	O
40	)	O
41	blotting	O
42	,	O
43	and	O
44	also	O
45	used	O
46	for	O
47	sequence	O
48	-	O
49	specific	O
50	affinity	O
51	chromatography	O
52	.	O

0	The	O
1	2	O
2	kb	O
3	of	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	and	O
9	the	O
10	1	O
11	.	O
12	1	O
13	kb	O
14	of	O
15	the	O
16	entire	O
17	sGTH	B
18	alpha	I
19	subunit	I
20	coding	I
21	region	I
22	were	O
23	sequenced	O
24	from	O
25	the	O
26	genomic	O
27	clone	O
28	,	O
29	sGTH	B
30	alpha	I
31	-	I
32	G1	I
33	.	O

0	Despite	O
1	this	O
2	DNA	O
3	binding	O
4	activity	O
5	,	O
6	AP	B
7	-	I
8	1	I
9	reporter	I
10	activity	O
11	was	O
12	suppressed	O
13	in	O
14	these	O
15	cells	O
16	.	O

0	Transcervical	O
1	amnioinfusion	O
2	.	O

0	CONCLUSION	O
1	:	O
2	Monitoring	O
3	SpO2	O
4	at	O
5	the	O
6	nasal	O
7	septum	O
8	site	O
9	is	O
10	more	O
11	reliable	O
12	than	O
13	monitoring	O
14	it	O
15	at	O
16	the	O
17	finger	O
18	site	O
19	in	O
20	hypothermic	O
21	patients	O
22	.	O

0	Thus	O
1	,	O
2	the	O
3	association	O
4	of	O
5	PS1	B
6	fragments	I
7	may	O
8	be	O
9	maintained	O
10	during	O
11	cycles	O
12	of	O
13	phosphorylation	O
14	/	O
15	dephosphorylation	O
16	of	O
17	the	O
18	PS1	B
19	CTF	I
20	.	O

0	Tobramycin	O
1	60	O
2	mg	O
3	did	O
4	not	O
5	show	O
6	any	O
7	remarkable	O
8	effect	O
9	,	O
10	but	O
11	dibecacin	O
12	100	O
13	mg	O
14	produced	O
15	a	O
16	slight	O
17	potentiating	O
18	effect	O
19	on	O
20	the	O
21	action	O
22	of	O
23	d	O
24	-	O
25	tubocurarine	O
26	.	O

0	Possible	O
1	pathogenetic	O
2	mechanisms	O
3	of	O
4	hemopoietic	O
5	changes	O
6	in	O
7	response	O
8	to	O
9	space	O
10	flight	O
11	effects	O
12	are	O
13	described	O
14	.	O

0	Human	O
1	thyroid	O
2	stimulator	O
3	(	O
4	HTS	O
5	)	O
6	in	O
7	thyroid	O
8	diseases	O

0	In	O
1	turn	O
2	,	O
3	assembly	O
4	of	O
5	this	O
6	complex	O
7	mediates	O
8	the	O
9	enzymatic	O
10	activation	O
11	of	O
12	the	O
13	p21	B
14	-	I
15	activated	I
16	protein	I
17	kinase	I
18	1	I
19	and	O
20	facilitates	O
21	actin	B
22	polymerization	O
23	.	O

0	In	O
1	addition	O
2	,	O
3	lexical	O
4	priming	O
5	was	O
6	examined	O
7	by	O
8	presenting	O
9	an	O
10	identity	O
11	prime	O
12	earlier	O
13	in	O
14	the	O
15	text	O
16	.	O

0	W	O
1	.	O

0	These	O
1	data	O
2	are	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	in	O
8	which	O
9	GATA	B
10	-	I
11	5	I
12	performs	O
13	a	O
14	unique	O
15	temporally	O
16	and	O
17	spatially	O
18	restricted	O
19	function	O
20	in	O
21	the	O
22	embryonic	O
23	heart	O
24	and	O
25	lung	O
26	.	O

0	The	O
1	duration	O
2	and	O
3	the	O
4	amplitude	O
5	of	O
6	the	O
7	negative	O
8	potential	O
9	were	O
10	greatest	O
11	for	O
12	completely	O
13	regenerating	O
14	ears	O
15	with	O
16	overgrowth	O
17	,	O
18	smaller	O
19	for	O
20	partially	O
21	regenerating	O
22	ears	O
23	,	O
24	and	O
25	smallest	O
26	for	O
27	the	O
28	nonregenerating	O
29	ears	O
30	.	O

0	In	O
1	Experiment	O
2	2	O
3	scopolamine	O
4	hydrobromide	O
5	,	O
6	0	O
7	.	O
8	5	O
9	and	O
10	1	O
11	.	O
12	0	O
13	mg	O
14	/	O
15	kg	O
16	i	O
17	.	O
18	p	O
19	.,	O
20	was	O
21	administered	O
22	1	O
23	h	O
24	before	O
25	each	O
26	electrical	O
27	stimulation	O
28	until	O
29	each	O
30	rat	O
31	showed	O
32	the	O
33	stage	O
34	-	O
35	3	O
36	seizure	O
37	.	O

0	The	O
1	TTG	B
2	-	I
3	2	I
4	gene	I
5	has	O
6	been	O
7	identified	O
8	at	O
9	the	O
10	site	O
11	of	O
12	chromosomal	O
13	translocations	O
14	in	O
15	acute	O
16	T	O
17	-	O
18	cell	O
19	leukemia	O
20	'	O
21	s	O
22	(	O
23	T	O
24	-	O
25	ALL	O
26	).	O

0	The	O
1	aim	O
2	of	O
3	this	O
4	study	O
5	was	O
6	to	O
7	assess	O
8	the	O
9	reproducibility	O
10	of	O
11	a	O
12	number	O
13	of	O
14	simplified	O
15	clearance	O
16	methods	O
17	using	O
18	chromium	O
19	-	O
20	51	O
21	ethylenediamine	O
22	tetraacetic	O
23	acid	O
24	(	O
25	51Cr	O
26	-	O
27	EDTA	O
28	)	O
29	and	O
30	to	O
31	compare	O
32	these	O
33	with	O
34	the	O
35	multiple	O
36	blood	O
37	sample	O
38	technique	O
39	.	O

0	Factors	O
1	involved	O
2	in	O
3	specific	O
4	transcription	O
5	by	O
6	mammalian	B
7	RNA	I
8	polymerase	I
9	II	I
10	:	O
11	purification	O
12	,	O
13	genetic	O
14	specificity	O
15	,	O
16	and	O
17	TATA	O
18	box	O
19	-	O
20	promoter	O
21	interactions	O
22	of	O
23	TFIID	B
24	.	O

0	Insulin	B
1	regulation	O
2	of	O
3	mitogen	B
4	-	I
5	activated	I
6	protein	I
7	kinase	I
8	kinase	I
9	(	O
10	MEK	B
11	),	O
12	mitogen	B
13	-	I
14	activated	I
15	protein	I
16	kinase	I
17	and	O
18	casein	B
19	kinase	I
20	in	O
21	the	O
22	cell	O
23	nucleus	O
24	:	O
25	a	O
26	possible	O
27	role	O
28	in	O
29	the	O
30	regulation	O
31	of	O
32	gene	O
33	expression	O
34	.	O

0	The	O
1	FAS	B
2	promoter	I
3	was	O
4	up	O
5	-	O
6	regulated	O
7	by	O
8	insulin	B
9	through	O
10	the	O
11	proximal	O
12	insulin	B
13	response	O
14	sequence	O
15	containing	O
16	an	O
17	E	O
18	-	O
19	box	O
20	motif	O
21	at	O
22	the	O
23	-	O
24	65	O
25	-	O
26	base	O
27	pair	O
28	position	O
29	.	O

0	Although	O
1	MAP	B
2	(	O
3	mitogen	B
4	-	I
5	activated	I
6	protein	I
7	)	I
8	kinases	I
9	are	O
10	implicated	O
11	in	O
12	cell	O
13	proliferation	O
14	and	O
15	differentiation	O
16	in	O
17	many	O
18	cell	O
19	types	O
20	,	O
21	the	O
22	role	O
23	of	O
24	MAP	B
25	kinases	I
26	in	O
27	cardiac	O
28	hypertrophy	O
29	remains	O
30	unclear	O
31	.	O

0	Interestingly	O
1	,	O
2	a	O
3	portion	O
4	of	O
5	the	O
6	tail	O
7	domain	O
8	(	O
9	aa	O
10	,	O
11	1	O
12	,	O
13	094	O
14	-	O
15	1	O
16	,	O
17	830	O
18	)	O
19	shares	O
20	58	O
21	%	O
22	amino	O
23	acid	O
24	sequence	O
25	identity	O
26	with	O
27	a	O
28	723	O
29	-	O
30	aa	O
31	protein	O
32	from	O
33	mouse	O
34	brain	O
35	reported	O
36	to	O
37	be	O
38	a	O
39	glutamic	B
40	acid	I
41	decarboxylase	I
42	.	O

0	To	O
1	investigate	O
2	the	O
3	requirements	O
4	for	O
5	CBF2	B
6	binding	O
7	,	O
8	we	O
9	synthesized	O
10	a	O
11	series	O
12	of	O
13	oligonucleotides	O
14	carrying	O
15	double	O
16	transversion	O
17	mutations	O
18	spanning	O
19	both	O
20	the	O
21	conserved	O
22	core	O
23	sequence	O
24	and	O
25	outside	O
26	flanking	O
27	sequences	O
28	.	O

0	A	O
1	sharp	O
2	outbreak	O
3	of	O
4	influenza	O
5	A	O
6	occurred	O
7	on	O
8	the	O
9	base	O
10	during	O
11	February	O
12	that	O
13	was	O
14	due	O
15	to	O
16	an	O
17	A	O
18	/	O
19	Texas	O
20	/	O
21	1	O
22	/	O
23	77	O
24	-	O
25	like	O
26	virus	O
27	,	O
28	a	O
29	variant	O
30	of	O
31	the	O
32	A	O
33	/	O
34	Victoria	O
35	/	O
36	3	O
37	/	O
38	75	O
39	prototpye	O
40	.	O

0	Circulatory	O
1	arrest	O
2	in	O
3	the	O
4	operating	O
5	room	O
6	.	O

0	Some	O
1	mutations	O
2	affected	O
3	Dhfr	B
4	in	O
5	a	O
6	qualitative	O
7	manner	O
8	,	O
9	such	O
10	as	O
11	by	O
12	changing	O
13	the	O
14	startpoint	O
15	of	O
16	one	O
17	of	O
18	the	O
19	major	O
20	Dhfr	B
21	transcripts	I
22	or	O
23	changing	O
24	the	O
25	relative	O
26	abundance	O
27	of	O
28	the	O
29	two	O
30	major	O
31	Dhfr	B
32	transcripts	I
33	.	O

0	Antibodies	O
1	against	O
2	this	O
3	purified	O
4	protein	O
5	localize	O
6	RIM1	B
7	to	O
8	mitochondria	O
9	.	O

0	Trypanosoma	O
1	cruzi	O
2	.	O

0	Transplantation	O
1	of	O
2	kidneys	O
3	of	O
4	juvenile	O
5	donors	O
6	in	O
7	adult	O
8	recipients	O
9	.	O

0	Thus	O
1	,	O
2	the	O
3	characterization	O
4	of	O
5	the	O
6	promoter	O
7	region	O
8	should	O
9	help	O
10	to	O
11	define	O
12	regulatory	O
13	elements	O
14	that	O
15	control	O
16	neuron	O
17	-	O
18	specific	O
19	and	O
20	developmental	O
21	expression	O
22	of	O
23	the	O
24	MAP1B	B
25	gene	I
26	.	O

0	The	O
1	brackets	O
2	were	O
3	bonded	O
4	to	O
5	100	O
6	freshly	O
7	extracted	O
8	bovine	O
9	incisors	O
10	,	O
11	and	O
12	,	O
13	after	O
14	storage	O
15	in	O
16	tap	O
17	water	O
18	at	O
19	room	O
20	temperature	O
21	for	O
22	24	O
23	hours	O
24	,	O
25	they	O
26	were	O
27	subsequently	O
28	tested	O
29	in	O
30	a	O
31	shear	O
32	mode	O
33	using	O
34	a	O
35	universal	O
36	testing	O
37	machine	O
38	.	O

0	Adhesion	O
1	,	O
2	phagocytosis	O
3	,	O
4	chemotactic	O
5	and	O
6	random	O
7	migration	O
8	,	O
9	nitroblue	O
10	tetrazolium	O
11	dye	O
12	reduction	O
13	of	O
14	peritoneal	O
15	exudate	O
16	neutrophils	O
17	and	O
18	macrophages	O
19	,	O
20	fibrinogen	B
21	level	O
22	,	O
23	gelation	O
24	of	O
25	soluble	O
26	fibrin	B
27	and	O
28	serial	O
29	dilution	O
30	protamine	O
31	sulfate	O
32	test	O
33	were	O
34	investigated	O
35	in	O
36	115	O
37	New	O
38	Zealand	O
39	white	O
40	rabbits	O
41	with	O
42	experimentally	O
43	induced	O
44	Shwartzman	O
45	phenomenon	O
46	in	O
47	the	O
48	colon	O
49	,	O
50	and	O
51	in	O
52	control	O
53	animals	O
54	.	O

0	The	O
1	data	O
2	obtained	O
3	up	O
4	to	O
5	now	O
6	only	O
7	suggest	O
8	the	O
9	future	O
10	potentiality	O
11	of	O
12	Bestatin	B
13	treatment	O
14	for	O
15	these	O
16	types	O
17	of	O
18	malignancy	O
19	.	O

0	Effects	O
1	of	O
2	repeated	O
3	exposures	O
4	of	O
5	hydrogen	O
6	sulphide	O
7	on	O
8	rat	O
9	hippocampal	O
10	EEG	O
11	.	O

0	For	O
1	an	O
2	unsupervised	O
3	program	O
4	,	O
5	the	O
6	costs	O
7	were	O
8	estimated	O
9	at	O
10	$	O
11	311	O
12	for	O
13	the	O
14	first	O
15	year	O
16	and	O
17	$	O
18	73	O
19	for	O
20	all	O
21	additional	O
22	years	O
23	.	O

0	Paralemmin	B
1	is	O
2	also	O
3	phosphorylated	O
4	,	O
5	and	O
6	its	O
7	mRNA	O
8	is	O
9	differentially	O
10	spliced	O
11	in	O
12	a	O
13	tissue	O
14	-	O
15	specific	O
16	and	O
17	developmentally	O
18	regulated	O
19	manner	O
20	.	O

0	Coliphage	B
1	186	I
2	B	I
3	is	O
4	a	O
5	72	O
6	-	O
7	amino	O
8	acid	O
9	protein	O
10	belonging	O
11	to	O
12	the	O
13	Ogr	B
14	family	I
15	of	O
16	analogous	O
17	transcription	O
18	factors	O
19	present	O
20	in	O
21	P2	O
22	-	O
23	like	O
24	phage	O
25	,	O
26	which	O
27	contain	O
28	a	O
29	Cys	O
30	-	O
31	X2	O
32	-	O
33	Cys	O
34	-	O
35	X22	O
36	-	O
37	Cys	O
38	-	O
39	X4	O
40	-	O
41	Cys	O
42	presumptive	O
43	zinc	O
44	-	O
45	finger	O
46	motif	O
47	.	O

0	Spatial	O
1	zones	O
2	for	O
3	muscle	O
4	coactivation	O
5	and	O
6	the	O
7	control	O
8	of	O
9	postural	O
10	stability	O
11	.	O

0	Ketanserin	O
1	,	O
2	a	O
3	hypotensive	O
4	drug	O
5	with	O
6	5	B
7	-	I
8	HT2	I
9	receptor	I
10	antagonism	O
11	,	O
12	when	O
13	administered	O
14	by	O
15	topical	O
16	infusion	O
17	of	O
18	a	O
19	0	O
20	.	O
21	25	O
22	%	O
23	w	O
24	/	O
25	v	O
26	solution	O
27	by	O
28	corneal	O
29	and	O
30	scleral	O
31	applications	O
32	,	O
33	was	O
34	found	O
35	to	O
36	lower	O
37	intraocular	O
38	pressure	O
39	with	O
40	four	O
41	times	O
42	more	O
43	activity	O
44	than	O
45	its	O
46	metabolite	O
47	,	O
48	ketanserinol	O
49	.	O

0	Obesity	O
1	was	O
2	strongly	O
3	associated	O
4	with	O
5	the	O
6	proportions	O
7	of	O
8	nonprotein	O
9	-	O
10	bound	O
11	and	O
12	albumin	B
13	-	O
14	bound	O
15	estradiol	O
16	,	O
17	and	O
18	inversely	O
19	associated	O
20	with	O
21	sex	B
22	hormone	I
23	binding	I
24	globulin	I
25	(	O
26	SHBG	B
27	)	O
28	levels	O
29	and	O
30	the	O
31	proportion	O
32	of	O
33	SHBG	B
34	-	O
35	bound	O
36	estradiol	O
37	.	O

0	Characterization	O
1	of	O
2	the	O
3	promoter	O
4	for	O
5	the	O
6	human	B
7	85	I
8	kDa	I
9	cytosolic	I
10	phospholipase	I
11	A2	I
12	gene	I
13	.	O

0	This	O
1	implies	O
2	that	O
3	the	O
4	groups	O
5	do	O
6	not	O
7	just	O
8	differ	O
9	along	O
10	one	O
11	dimension	O
12	,	O
13	but	O
14	along	O
15	three	O
16	dimensions	O
17	.	O

0	The	O
1	results	O
2	of	O
3	a	O
4	quantitative	O
5	study	O
6	of	O
7	vasculosyncytial	O
8	membranes	O
9	in	O
10	123	O
11	placentas	O
12	are	O
13	presented	O
14	.	O

0	The	O
1	highest	O
2	prevalence	O
3	of	O
4	reported	O
5	pet	O
6	allergy	O
7	,	O
8	chronic	O
9	cough	O
10	,	O
11	wheeze	O
12	,	O
13	attacks	O
14	of	O
15	shortness	O
16	of	O
17	breath	O
18	with	O
19	wheezing	O
20	,	O
21	and	O
22	doctor	O
23	-	O
24	diagnosed	O
25	asthma	O
26	was	O
27	found	O
28	in	O
29	children	O
30	who	O
31	had	O
32	pets	O
33	in	O
34	the	O
35	past	O
36	but	O
37	not	O
38	anymore	O
39	.	O

0	In	O
1	concept	O
2	II	O
3	62	O
4	patients	O
5	were	O
6	treated	O
7	with	O
8	selective	O
9	vagotomy	O
10	and	O
11	pyloroplasty	O
12	.	O

0	We	O
1	also	O
2	compared	O
3	the	O
4	sequence	O
5	with	O
6	the	O
7	partly	O
8	homologous	O
9	products	O
10	of	O
11	the	O
12	S	B
13	.	I
14	cerevisiae	I
15	genes	I
16	TPS2	I
17	and	O
18	TSL1	B
19	which	O
20	code	O
21	for	O
22	the	O
23	larger	O
24	subunits	O
25	of	O
26	the	O
27	trehalose	B
28	synthase	I
29	complex	I
30	and	O
31	with	O
32	a	O
33	TSL1	B
34	homologue	I
35	,	O
36	TPS3	B
37	,	O
38	of	O
39	unknown	O
40	function	O
41	.	O

0	Drug	O
1	inhibition	O
2	of	O
3	whole	B
4	blood	I
5	aspirin	I
6	esterase	I
7	.	O

0	Heterogeneous	O
1	nuclear	O
2	ribonucleoprotein	I
3	A1	I
4	binds	O
5	to	O
6	the	O
7	transcription	O
8	-	O
9	regulatory	O
10	region	O
11	of	O
12	mouse	B
13	hepatitis	I
14	virus	I
15	RNA	I
16	.	O

0	Paf1p	B
1	may	O
2	therefore	O
3	be	O
4	required	O
5	for	O
6	both	O
7	positive	O
8	and	O
9	negative	O
10	regulation	O
11	of	O
12	subsets	O
13	of	O
14	yeast	O
15	genes	O
16	.	O

0	A	O
1	simple	O
2	analytical	O
3	method	O
4	for	O
5	l	O
6	-	O
7	menthol	O
8	by	O
9	high	O
10	-	O
11	performance	O
12	liquid	O
13	chromatography	O
14	with	O
15	a	O
16	polarized	O
17	photometric	O
18	detector	O
19	was	O
20	established	O
21	.	O

0	The	O
1	apparatus	O
2	consists	O
3	of	O
4	an	O
5	Am	O
6	-	O
7	241	O
8	exciting	O
9	source	O
10	(	O
11	300	O
12	mCi	O
13	)	O
14	and	O
15	pure	O
16	Ge	O
17	detector	O
18	(	O
19	50	O
20	mm2	O
21	X	O
22	5	O
23	mm	O
24	)	O
25	for	O
26	measuring	O
27	K	O
28	alpha	O
29	fluorescent	O
30	x	O
31	-	O
32	rays	O
33	(	O
34	28	O
35	.	O
36	3	O
37	and	O
38	28	O
39	.	O
40	6	O
41	KeV	O
42	)	O
43	emitted	O
44	from	O
45	exited	O
46	iodine	O
47	.	O

0	The	O
1	T	O
2	-	O
3	box	O
4	motif	O
5	is	O
6	present	O
7	in	O
8	a	O
9	family	O
10	of	O
11	genes	O
12	whose	O
13	structural	O
14	features	O
15	and	O
16	expression	O
17	patterns	O
18	support	O
19	their	O
20	involvement	O
21	in	O
22	developmental	O
23	gene	O
24	regulation	O
25	.	O

0	Toxicities	O
1	included	O
2	:	O
3	nausea	O
4	/	O
5	vomiting	O
6	(	O
7	69	O
8	%),	O
9	headache	O
10	(	O
11	25	O
12	%),	O
13	chills	O
14	(	O
15	69	O
16	%),	O
17	pain	O
18	at	O
19	tumor	O
20	sites	O
21	(	O
22	63	O
23	%),	O
24	hypotension	O
25	(	O
26	31	O
27	%),	O
28	and	O
29	hypertension	O
30	(	O
31	38	O
32	%).	O

0	Our	O
1	studies	O
2	also	O
3	excluded	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	phosphorylation	O
9	of	O
10	Ser	O
11	-	O
12	2	O
13	,	O
14	Ser	O
15	-	O
16	123	O
17	,	O
18	or	O
19	Ser	O
20	-	O
21	210	O
22	,	O
23	had	O
24	roles	O
25	in	O
26	the	O
27	trans	O
28	-	O
29	suppression	O
30	activity	O
31	of	O
32	the	O
33	large	O
34	HDAg	B
35	,	O
36	in	O
37	the	O
38	assembly	O
39	of	O
40	empty	O
41	virus	O
42	-	I
43	like	I
44	HDAg	I
45	particle	I
46	,	O
47	and	O
48	in	O
49	the	O
50	nuclear	O
51	transport	O
52	of	O
53	HDAgs	B
54	.	O

0	The	O
1	bcl	B
2	-	I
3	2	I
4	gene	I
5	can	O
6	potentially	O
7	encode	O
8	26	O
9	-	O
10	and	O
11	22	O
12	-	O
13	kDa	O
14	proteins	O
15	that	O
16	differ	O
17	only	O
18	in	O
19	their	O
20	carboxyl	O
21	tails	O
22	because	O
23	of	O
24	an	O
25	alternative	O
26	splicing	O
27	mechanism	O
28	.	O

0	Examination	O
1	of	O
2	the	O
3	mitochondrial	B
4	bc1	I
5	complex	I
6	crystal	O
7	structure	O
8	[	O
9	Zhang	O
10	,	O
11	Z	O
12	.,	O
13	Huang	O
14	,	O
15	L	O
16	.,	O
17	Shulmeister	O
18	,	O
19	V	O
20	.	O

0	Deltamethrin	O
1	was	O
2	most	O
3	effective	O
4	on	O
5	the	O
6	thatched	O
7	surface	O
8	and	O
9	produced	O
10	100	O
11	%	O
12	mortality	O
13	of	O
14	An	O
15	.	O
16	culicifacies	O
17	adults	O
18	up	O
19	to	O
20	12	O
21	weeks	O
22	,	O
23	even	O
24	when	O
25	exposed	O
26	at	O
27	the	O
28	lowest	O
29	dose	O
30	/	O
31	12	O
32	.	O
33	5	O
34	mg	O
35	/	O
36	m2	O
37	.	O

0	Consciousness	O
1	is	O
2	connected	O
3	with	O
4	attention	O
5	,	O
6	working	O
7	memory	O
8	and	O
9	perception	O
10	.	O

0	The	O
1	Psc2	B
2	cDNA	I
3	contained	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	homologous	O
9	to	O
10	CP2	B
11	family	I
12	proteins	I
13	.	O

0	Regulatory	O
1	regions	O
2	in	O
3	the	O
4	promoter	O
5	and	O
6	third	O
7	intron	O
8	of	O
9	the	O
10	growth	B
11	hormone	I
12	gene	I
13	in	O
14	rainbow	O
15	trout	O
16	,	O
17	Oncorhynchus	O
18	mykiss	O
19	walbaum	O
20	.	O

0	The	O
1	second	O
2	transcriptional	O
3	unit	O
4	,	O
5	designated	O
6	UL26	B
7	.	I
8	5	I
9	,	O
10	predicted	O
11	to	O
12	specify	O
13	a	O
14	protein	O
15	of	O
16	329	O
17	amino	O
18	acids	O
19	,	O
20	encodes	O
21	the	O
22	family	B
23	35	I
24	proteins	I
25	;	O
26	it	O
27	is	O
28	transcribed	O
29	by	O
30	an	O
31	mRNA	O
32	which	O
33	initiates	O
34	at	O
35	approximately	O
36	nucleotide	O
37	+	O
38	1000	O
39	of	O
40	the	O
41	UL26	B
42	transcription	I
43	initiation	I
44	site	I
45	and	O
46	is	O
47	translated	O
48	from	O
49	the	O
50	methionine	O
51	initiation	O
52	codon	O
53	located	O
54	at	O
55	position	O
56	+	O
57	1099	O
58	of	O
59	the	O
60	UL26	B
61	transcriptional	O
62	unit	O
63	.	O

0	Taken	O
1	together	O
2	,	O
3	we	O
4	provide	O
5	evidence	O
6	for	O
7	the	O
8	existence	O
9	of	O
10	an	O
11	activator	O
12	,	O
13	NFE	B
14	,	O
15	which	O
16	in	O
17	combination	O
18	with	O
19	the	O
20	p50	B
21	and	O
22	c	B
23	-	I
24	Rel	I
25	proteins	I
26	,	O
27	are	O
28	part	O
29	of	O
30	the	O
31	transcription	O
32	factor	O
33	machinery	O
34	that	O
35	regulates	O
36	3	O
37	'	O
38	enhancer	O
39	activity	O
40	,	O
41	and	O
42	thus	O
43	the	O
44	control	O
45	of	O
46	the	O
47	IgH	B
48	locus	I
49	in	O
50	late	O
51	B	O
52	lymphocyte	O
53	development	O
54	.	O

0	The	O
1	aim	O
2	of	O
3	this	O
4	study	O
5	was	O
6	to	O
7	investigate	O
8	the	O
9	spontaneous	O
10	reports	O
11	of	O
12	suspected	O
13	adverse	O
14	drug	O
15	reactions	O
16	,	O
17	observed	O
18	in	O
19	elderly	O
20	patients	O
21	(	O
22	over	O
23	65	O
24	years	O
25	of	O
26	age	O
27	)	O
28	in	O
29	Sicily	O
30	(	O
31	Italy	O
32	)	O
33	during	O
34	the	O
35	period	O
36	from	O
37	1	O
38	January	O
39	1995	O
40	to	O
41	31	O
42	December	O
43	1997	O
44	.	O

0	Ventral	O
1	rhinotomy	O
2	is	O
3	no	O
4	more	O
5	difficult	O
6	than	O
7	dorsal	O
8	rhinotomy	O
9	,	O
10	has	O
11	less	O
12	patient	O
13	morbidity	O
14	and	O
15	fewer	O
16	postoperative	O
17	complications	O
18	,	O
19	and	O
20	is	O
21	more	O
22	cosmetically	O
23	acceptable	O
24	.	O

0	Further	O
1	outbreaks	O
2	of	O
3	ocular	O
4	disease	O
5	in	O
6	farmed	O
7	red	O
8	deer	O
9	calves	O
10	caused	O
11	by	O
12	HVC	O
13	-	O
14	1	O
15	were	O
16	investigated	O
17	.	O

0	These	O
1	data	O
2	confirm	O
3	the	O
4	existence	O
5	of	O
6	hyperlipemic	O
7	abdominal	O
8	crisis	O
9	as	O
10	a	O
11	distinct	O
12	entity	O
13	and	O
14	testify	O
15	to	O
16	the	O
17	importance	O
18	of	O
19	recognizing	O
20	this	O
21	syndrome	O
22	in	O
23	order	O
24	to	O
25	avoid	O
26	the	O
27	occurrence	O
28	of	O
29	acute	O
30	pancreatitis	O
31	and	O
32	the	O
33	performance	O
34	of	O
35	unnecessary	O
36	and	O
37	potentially	O
38	harmful	O
39	surgery	O
40	.	O

0	We	O
1	describe	O
2	a	O
3	novel	O
4	cytoplasmic	B
5	tyrosine	I
6	kinase	I
7	,	O
8	termed	O
9	BPK	B
10	(	O
11	B	B
12	cell	I
13	progenitor	I
14	kinase	I
15	),	O
16	which	O
17	is	O
18	expressed	O
19	in	O
20	all	O
21	stages	O
22	of	O
23	the	O
24	B	O
25	lineage	O
26	and	O
27	in	O
28	myeloid	O
29	cells	O
30	.	O

0	Testing	O
1	gravity	O
2	to	O
3	second	O
4	post	O
5	-	O
6	Newtonian	O
7	order	O
8	:	O
9	A	O
10	field	O
11	-	O
12	theory	O
13	approach	O
14	.	O

0	In	O
1	the	O
2	formalin	O
3	test	O
4	,	O
5	however	O
6	,	O
7	naloxone	O
8	attenuated	O
9	morphine	O
10	analgesia	O
11	at	O
12	the	O
13	lower	O
14	doses	O
15	(	O
16	0	O
17	.	O
18	1	O
19	and	O
20	0	O
21	.	O
22	3	O
23	mg	O
24	/	O
25	kg	O
26	)	O
27	and	O
28	potentiated	O
29	morphine	O
30	analgesia	O
31	at	O
32	the	O
33	highest	O
34	dose	O
35	(	O
36	10	O
37	mg	O
38	/	O
39	kg	O
40	).	O

0	Examination	O
1	of	O
2	ANCA	O
3	is	O
4	not	O
5	only	O
6	a	O
7	significant	O
8	contribution	O
9	towards	O
10	a	O
11	more	O
12	accurate	O
13	diagnosis	O
14	of	O
15	renal	O
16	vasculitis	O
17	,	O
18	but	O
19	also	O
20	an	O
21	indicator	O
22	of	O
23	the	O
24	activity	O
25	of	O
26	the	O
27	disease	O
28	and	O
29	thus	O
30	of	O
31	the	O
32	effectiveness	O
33	of	O
34	immunosuppressive	O
35	treatment	O
36	.	O

0	Platelet	O
1	function	O
2	and	O
3	platelet	O
4	-	O
5	polymorphonuclear	O
6	-	O
7	neutrophil	O
8	interaction	O
9	in	O
10	patients	O
11	with	O
12	deficient	O
13	platelet	B
14	lipoxygenase	I
15	activity	O
16	.	O

0	The	O
1	present	O
2	findings	O
3	revealed	O
4	that	O
5	the	O
6	rib	B
7	-	I
8	2	I
9	protein	I
10	was	O
11	a	O
12	unique	O
13	alpha1	B
14	,	I
15	4	I
16	-	I
17	N	I
18	-	I
19	acetylglucosaminyltransferase	I
20	involved	O
21	in	O
22	the	O
23	biosynthetic	O
24	initiation	O
25	and	O
26	elongation	O
27	of	O
28	heparan	O
29	sulfate	O
30	.	O

0	Although	O
1	IL	B
2	-	I
3	2	I
4	and	O
5	IFN	B
6	-	I
7	alpha	I
8	activated	O
9	STAT1	B
10	alpha	I
11	and	O
12	STAT5	B
13	,	O
14	IL	B
15	-	I
16	2	I
17	predominantly	O
18	activated	O
19	STAT5	B
20	,	O
21	while	O
22	IFN	B
23	-	I
24	alpha	I
25	predominantly	O
26	activated	O
27	STAT1	B
28	alpha	I
29	.	O

0	In	O
1	particular	O
2	,	O
3	the	O
4	S1	B
5	'	I
6	specificity	I
7	site	I
8	is	O
9	a	O
10	deep	O
11	and	O
12	highly	O
13	hydrophobic	O
14	cavity	O
15	.	O

0	Since	O
1	GAGs	B
2	are	O
3	the	O
4	components	O
5	of	O
6	cartilage	O
7	matrix	O
8	,	O
9	the	O
10	depletion	O
11	of	O
12	which	O
13	is	O
14	associated	O
15	with	O
16	osteoarthrosis	O
17	,	O
18	a	O
19	method	O
20	for	O
21	measuring	O
22	sulphated	O
23	GAG	B
24	synthesis	O
25	in	O
26	culture	O
27	has	O
28	been	O
29	investigated	O
30	.	O

0	Two	O
1	US	O
2	commercial	O
3	cultivars	O
4	(	O
5	Tehama	O
6	and	O
7	Vina	O
8	),	O
9	three	O
10	European	O
11	commercial	O
12	cultivars	O
13	(	O
14	Esterhazy	O
15	,	O
16	139	O
17	,	O
18	G120	O
19	)	O
20	and	O
21	five	O
22	New	O
23	Zealand	O
24	selections	O
25	(	O
26	Rex	O
27	,	O
28	Dublin	O
29	'	O
30	s	O
31	Glory	O
32	,	O
33	Meyric	O
34	,	O
35	McKinster	O
36	,	O
37	Stanley	O
38	)	O
39	were	O
40	evaluated	O
41	.	O

0	This	O
1	suggests	O
2	roles	O
3	for	O
4	both	O
5	the	O
6	CE1	O
7	and	O
8	CE2	O
9	elements	O
10	in	O
11	regulating	O
12	Hoxb1	B
13	gene	I
14	expression	O
15	during	O
16	development	O
17	.	O

0	Molecular	O
1	cloning	O
2	and	O
3	characterization	O
4	of	O
5	two	O
6	genes	O
7	encoding	O
8	gp138	B
9	,	O
10	a	O
11	cell	O
12	surface	O
13	glycoprotein	O
14	involved	O
15	in	O
16	the	O
17	sexual	O
18	cell	O
19	fusion	O
20	of	O
21	Dictyostelium	O
22	discoideum	O
23	.	O

0	The	O
1	RS447	B
2	human	I
3	megasatellite	I
4	tandem	I
5	repetitive	I
6	sequence	I
7	encodes	O
8	a	O
9	novel	O
10	deubiquitinating	O
11	enzyme	O
12	with	O
13	a	O
14	functional	O
15	promoter	O
16	.	O

0	The	O
1	IE13	O
2	.	O
3	1	O
4	cell	O
5	line	O
6	was	O
7	able	O
8	to	O
9	complement	O
10	a	O
11	recombinant	O
12	virus	O
13	in	O
14	which	O
15	both	O
16	copies	O
17	of	O
18	the	O
19	IE	B
20	gene	I
21	were	O
22	replaced	O
23	by	O
24	insertion	O
25	of	O
26	the	O
27	Escherichia	B
28	coli	I
29	lacZ	I
30	gene	I
31	.	O

0	Immunophenotyping	O
1	in	O
2	four	O
3	cases	O
4	,	O
5	demonstrated	O
6	non	O
7	-	O
8	B	O
9	,	O
10	non	O
11	-	O
12	T	O
13	cell	O
14	origin	O
15	in	O
16	three	O
17	and	O
18	pre	O
19	-	O
20	B	O
21	cell	O
22	origin	O
23	in	O
24	one	O
25	.	O

0	Of	O
1	these	O
2	179	O
3	samples	O
4	,	O
5	Mobiluncus	O
6	SP	O
7	was	O
8	observed	O
9	in	O
10	35	O
11	(	O
12	19	O
13	.	O
14	6	O
15	%)	O
16	using	O
17	Gram	O
18	staining	O
19	and	O
20	in	O
21	18	O
22	(	O
23	10	O
24	.	O
25	1	O
26	%)	O
27	this	O
28	microorganism	O
29	was	O
30	isolated	O
31	in	O
32	agar	O
33	RLK	O
34	and	O
35	anaerobic	O
36	atmosphere	O
37	.	O

0	A	O
1	short	O
2	sequence	O
3	surrounding	O
4	the	O
5	major	O
6	JNK	B
7	phosphorylation	O
8	site	O
9	of	O
10	c	B
11	-	I
12	Jun	I
13	is	O
14	conserved	O
15	in	O
16	c	B
17	-	I
18	Fos	I
19	and	O
20	is	O
21	part	O
22	of	O
23	its	O
24	activation	O
25	domain	O
26	,	O
27	suggesting	O
28	that	O
29	c	B
30	-	I
31	Fos	I
32	may	O
33	be	O
34	similarly	O
35	regulated	O
36	.	O

0	Irradiation	O
1	of	O
2	human	O
3	blood	O
4	platelets	O
5	with	O
6	UV	O
7	-	O
8	A	O
9	in	O
10	vitro	O
11	impairs	O
12	their	O
13	ability	O
14	to	O
15	aggregate	O
16	after	O
17	challenge	O
18	with	O
19	collagen	B
20	.	O

0	To	O
1	determine	O
2	whether	O
3	the	O
4	NTP	B
5	-	I
6	binding	I
7	motif	I
8	is	O
9	important	O
10	for	O
11	Rad24	B
12	function	O
13	,	O
14	we	O
15	mutated	O
16	the	O
17	conserved	O
18	lysine	O
19	(	O
20	115	O
21	)	O
22	residue	O
23	in	O
24	this	O
25	motif	O
26	.	O

0	The	O
1	NIT2	B
2	protein	I
3	is	O
4	localised	O
5	in	O
6	nuclei	O
7	and	O
8	could	O
9	not	O
10	be	O
11	detected	O
12	in	O
13	the	O
14	cytoplasmic	O
15	fraction	O
16	of	O
17	cells	O
18	subjected	O
19	to	O
20	nitrogen	O
21	derepression	O
22	or	O
23	nitrogen	O
24	repression	O
25	,	O
26	indicating	O
27	that	O
28	the	O
29	nuclear	O
30	import	O
31	of	O
32	NIT2	B
33	is	O
34	not	O
35	regulated	O
36	.	O

0	The	O
1	role	O
2	of	O
3	saliva	O
4	in	O
5	sour	O
6	taste	O
7	perception	O
8	was	O
9	investigated	O
10	in	O
11	a	O
12	series	O
13	of	O
14	4	O
15	experiments	O
16	.	O

0	The	O
1	sense	O
2	of	O
3	self	O
4	.	O

0	Mutation	O
1	of	O
2	TTF	B
3	-	I
4	1	I
5	-	I
6	binding	I
7	sites	I
8	(	O
9	TBE	B
10	)	I
11	1	I
12	,	I
13	3	O
14	,	O
15	and	O
16	4	O
17	in	O
18	combination	O
19	markedly	O
20	decreased	O
21	transcriptional	O
22	activity	O
23	of	O
24	SP	B
25	-	I
26	A	I
27	promoter	I
28	-	O
29	chloramphenicol	B
30	acetyltransferase	I
31	constructs	O
32	containing	O
33	SP	B
34	-	I
35	A	I
36	gene	I
37	sequences	I
38	from	O
39	-	O
40	256	O
41	to	O
42	+	O
43	45	O
44	.	O

0	This	O
1	R	O
2	-	O
3	domain	O
4	may	O
5	modulate	O
6	the	O
7	interaction	O
8	with	O
9	SRF	B
10	,	O
11	providing	O
12	a	O
13	mechanism	O
14	that	O
15	would	O
16	be	O
17	unique	O
18	to	O
19	FLI1	B
20	and	O
21	EWS	B
22	-	O
23	FLI1	B
24	,	O
25	thus	O
26	implicating	O
27	a	O
28	novel	O
29	function	O
30	for	O
31	these	O
32	ETS	B
33	transcription	I
34	factors	I
35	in	O
36	the	O
37	regulation	O
38	of	O
39	the	O
40	Egr1	B
41	gene	I
42	.	O

0	The	O
1	C4BP	B
2	alpha	I
3	gene	I
4	is	O
5	organized	O
6	as	O
7	follows	O
8	:	O
9	the	O
10	first	O
11	exon	O
12	codes	O
13	for	O
14	the	O
15	first	O
16	198	O
17	nucleotides	O
18	of	O
19	the	O
20	5	O
21	'	O
22	UTR	O
23	.	O

0	The	O
1	growth	O
2	of	O
3	Aer	O
4	.	O
5	hydrophila	O
6	in	O
7	filter	O
8	-	O
9	sterilized	O
10	lettuce	O
11	extract	O
12	was	O
13	completely	O
14	inhibited	O
15	by	O
16	0	O
17	.	O
18	1	O
19	%	O
20	(	O
21	v	O
22	/	O
23	v	O
24	)	O
25	BMC	O
26	whereas	O
27	that	O
28	of	O
29	Ps	O
30	.	O
31	fluorescens	O
32	was	O
33	not	O
34	significantly	O
35	affected	O
36	by	O
37	1	O
38	%	O
39	(	O
40	v	O
41	/	O
42	v	O
43	)	O
44	BMC	O
45	.	O

0	The	O
1	mean	O
2	value	O
3	of	O
4	the	O
5	CD79b	B
6	to	O
7	the	O
8	CD79b	B
9	internally	I
10	deleted	I
11	ratio	O
12	was	O
13	0	O
14	.	O
15	64	O
16	+/-	O
17	0	O
18	.	O
19	20	O
20	SD	O
21	in	O
22	normal	O
23	donors	O
24	and	O
25	0	O
26	.	O
27	44	O
28	+/-	O
29	0	O
30	.	O
31	27	O
32	SD	O
33	in	O
34	B	O
35	-	O
36	CLL	O
37	(	O
38	P	O
39	=.	O
40	01	O
41	).	O

0	AMDA	O
1	white	O
2	paper	O
3	identifies	O
4	ways	O
5	to	O
6	improve	O
7	pharmaceutical	O
8	care	O
9	in	O
10	SNFs	O
11	.	O

0	On	O
1	admission	O
2	to	O
3	our	O
4	department	O
5	in	O
6	September	O
7	,	O
8	1987	O
9	,	O
10	the	O
11	patient	O
12	was	O
13	alert	O
14	and	O
15	had	O
16	spastic	O
17	paraparesis	O
18	,	O
19	the	O
20	impairment	O
21	of	O
22	all	O
23	sensory	O
24	modalities	O
25	below	O
26	the	O
27	level	O
28	of	O
29	Th	O
30	10	O
31	and	O
32	urinary	O
33	disturbance	O
34	.	O

0	Such	O
1	a	O
2	concept	O
3	is	O
4	crucial	O
5	to	O
6	our	O
7	understanding	O
8	of	O
9	the	O
10	pathology	O
11	of	O
12	ageing	O
13	in	O
14	general	O
15	.	O

0	Comparison	O
1	with	O
2	the	O
3	crystal	O
4	structure	O
5	of	O
6	Desulfovibrio	O
7	gigas	O
8	,	O
9	Dg	B
10	,	O
11	Fd	O
12	(	O
13	Kissinger	O
14	et	O
15	al	O
16	.,	O
17	1991	O
18	)	O
19	reveals	O
20	a	O
21	very	O
22	similar	O
23	folding	O
24	topology	O
25	,	O
26	although	O
27	several	O
28	secondary	O
29	structural	O
30	elements	O
31	are	O
32	extended	O
33	in	O
34	Pf	O
35	relative	O
36	to	O
37	Dg	B
38	Fd	O
39	.	O

0	Simple	O
1	method	O
2	for	O
3	determination	O
4	of	O
5	the	O
6	cephalosporin	O
7	DQ	O
8	-	O
9	2556	O
10	in	O
11	biological	O
12	fluids	O
13	by	O
14	high	O
15	-	O
16	performance	O
17	liquid	O
18	chromatography	O
19	.	O

0	Analysis	O
1	of	O
2	cell	O
3	cycle	O
4	regulation	O
5	in	O
6	the	O
7	budding	O
8	yeast	O
9	Saccharomyces	O
10	cerevisiae	O
11	has	O
12	shown	O
13	that	O
14	a	O
15	central	O
16	regulatory	O
17	protein	O
18	kinase	O
19	,	O
20	Cdc28	B
21	,	O
22	undergoes	O
23	changes	O
24	in	O
25	activity	O
26	through	O
27	the	O
28	cell	O
29	cycle	O
30	by	O
31	associating	O
32	with	O
33	distinct	O
34	groups	O
35	of	O
36	cyclins	B
37	that	O
38	accumulate	O
39	at	O
40	different	O
41	times	O
42	.	O

0	RESULTS	O
1	:	O
2	Statistically	O
3	significant	O
4	differences	O
5	were	O
6	obtained	O
7	between	O
8	group	O
9	I	O
10	and	O
11	II	O
12	concerning	O
13	the	O
14	number	O
15	of	O
16	patients	O
17	in	O
18	whom	O
19	induced	O
20	atrial	O
21	fibrillation	O
22	with	O
23	conduction	O
24	by	O
25	the	O
26	accessory	O
27	pathway	O
28	and	O
29	RR	O
30	<	O
31	or	O
32	=	O
33	250	O
34	msec	O
35	was	O
36	found	O
37	(	O
38	0	O
39	vs	O
40	6	O
41	,	O
42	p	O
43	=	O
44	0	O
45	.	O
46	0045	O
47	).	O

0	XXI	O
1	.	O

0	Although	O
1	it	O
2	is	O
3	well	O
4	known	O
5	that	O
6	calcium	O
7	channel	O
8	blockers	O
9	can	O
10	influence	O
11	contraction	O
12	of	O
13	vascular	O
14	smooth	O
15	muscle	O
16	,	O
17	there	O
18	is	O
19	less	O
20	knowledge	O
21	on	O
22	its	O
23	effect	O
24	on	O
25	excitation	O
26	contraction	O
27	coupling	O
28	in	O
29	the	O
30	endocrine	O
31	glands	O
32	and	O
33	more	O
34	specifically	O
35	on	O
36	insulin	B
37	and	O
38	glucagon	B
39	release	O
40	.	O

0	Biological	O
1	properties	O
2	of	O
3	sumithion	O
4	.	O

0	Drosophila	B
1	UbcD1	I
2	encodes	O
3	a	O
4	highly	O
5	conserved	O
6	ubiquitin	B
7	-	I
8	conjugating	I
9	enzyme	I
10	involved	O
11	in	O
12	selective	O
13	protein	O
14	degradation	O
15	.	O

0	We	O
1	have	O
2	identified	O
3	two	O
4	overlapping	O
5	expressed	O
6	sequence	O
7	tag	O
8	clones	O
9	,	O
10	which	O
11	contain	O
12	the	O
13	missing	O
14	4	O
15	.	O
16	4	O
17	-	O
18	kb	O
19	3	O
20	'-	O
21	UTR	O
22	of	O
23	the	O
24	human	B
25	D2	I
26	(	O
27	hD2	B
28	)	O
29	cDNA	O
30	.	O

0	The	O
1	modalities	O
2	for	O
3	using	O
4	reference	O
5	values	O
6	for	O
7	individual	O
8	subjects	O
9	as	O
10	well	O
11	as	O
12	for	O
13	groups	O
14	are	O
15	then	O
16	discussed	O
17	and	O
18	the	O
19	main	O
20	points	O
21	of	O
22	research	O
23	which	O
24	must	O
25	be	O
26	faced	O
27	in	O
28	the	O
29	near	O
30	future	O
31	regarding	O
32	reference	O
33	values	O
34	are	O
35	highlighted	O
36	.	O

0	Baseline	O
1	data	O
2	were	O
3	obtained	O
4	from	O
5	10	O
6	adults	O
7	.	O

0	Of	O
1	these	O
2	carriers	O
3	149	O
4	were	O
5	diagnosed	O
6	to	O
7	be	O
8	asymptomatic	O
9	clinically	O
10	,	O
11	biochemically	O
12	and	O
13	echographically	O
14	.	O

0	The	O
1	encoded	O
2	amino	O
3	acid	O
4	sequences	O
5	in	O
6	the	O
7	full	O
8	-	O
9	length	O
10	bovine	O
11	and	O
12	porcine	O
13	cDNAs	O
14	were	O
15	identical	O
16	,	O
17	consisting	O
18	of	O
19	209	O
20	amino	O
21	acid	O
22	residues	O
23	,	O
24	and	O
25	were	O
26	nearly	O
27	the	O
28	same	O
29	as	O
30	the	O
31	published	O
32	sequence	O
33	determined	O
34	by	O
35	Edman	O
36	degradation	O
37	.	O

0	Collectively	O
1	,	O
2	these	O
3	data	O
4	indicate	O
5	that	O
6	HIP	B
7	is	O
8	a	O
9	membrane	O
10	-	O
11	associated	O
12	HP	B
13	-	I
14	binding	I
15	protein	I
16	expressed	O
17	on	O
18	the	O
19	surface	O
20	of	O
21	normal	O
22	human	O
23	uterine	O
24	epithelia	O
25	and	O
26	uterine	O
27	epithelial	O
28	cell	O
29	lines	O
30	.	O

0	The	O
1	alpha	B
2	4	I
3	gene	I
4	5	I
5	'	I
6	flanking	I
7	region	I
8	acted	O
9	as	O
10	a	O
11	promoter	O
12	in	O
13	transfection	O
14	assays	O
15	.	O

0	The	O
1	1	B
2	.	I
3	9	I
4	-	I
5	kb	I
6	C	I
7	mu	I
8	RNA	I
9	contains	O
10	the	O
11	3	O
12	'	O
13	sequence	O
14	characteristic	O
15	of	O
16	secreted	O
17	mu	B
18	chain	I
19	,	O
20	whereas	O
21	the	O
22	longer	O
23	species	O
24	bear	O
25	that	O
26	of	O
27	membrane	O
28	-	O
29	bound	O
30	mu	B
31	chin	I
32	.	O

0	Differential	O
1	activation	O
2	of	O
3	the	O
4	extracellular	O
5	signal	O
6	-	O
7	regulated	O
8	kinase	O
9	,	O
10	Jun	B
11	kinase	I
12	and	O
13	Janus	B
14	kinase	I
15	-	O
16	Stat	B
17	pathways	O
18	by	O
19	oncostatin	B
20	M	I
21	and	O
22	basic	B
23	fibroblast	I
24	growth	I
25	factor	I
26	in	O
27	AIDS	O
28	-	O
29	derived	O
30	Kaposi	O
31	'	O
32	s	O
33	sarcoma	O
34	cells	O
35	.	O

0	Rho	B
1	GDP	I
2	/	I
3	GTP	I
4	exchange	I
5	inhibitor	O
6	,	O
7	Rho	B
8	GDI	B
9	,	O
10	comigrated	O
11	with	O
12	Rac2	B
13	and	O
14	RhoA	B
15	,	O
16	but	O
17	not	O
18	Rac1	B
19	.	O

0	What	O
1	young	O
2	people	O
3	think	O
4	and	O
5	do	O
6	when	O
7	the	O
8	option	O
9	for	O
10	cystic	O
11	fibrosis	O
12	carrier	O
13	testing	O
14	is	O
15	available	O
16	.	O

0	A	O
1	role	O
2	for	O
3	the	O
4	small	B
5	GTPase	I
6	Rac	I
7	in	I
8	polyomavirus	B
9	middle	I
10	-	I
11	T	I
12	antigen	I
13	-	O
14	mediated	O
15	activation	O
16	of	O
17	the	O
18	serum	O
19	response	O
20	element	O
21	and	O
22	in	O
23	cell	O
24	transformation	O
25	.	O

0	The	O
1	catenins	B
2	bind	O
3	to	O
4	APC	B
5	and	O
6	E	B
7	-	I
8	cadherin	I
9	in	O
10	a	O
11	similar	O
12	fashion	O
13	,	O
14	but	O
15	APC	B
16	and	O
17	E	B
18	-	I
19	cadherin	I
20	do	O
21	not	O
22	associate	O
23	with	O
24	each	O
25	other	O
26	either	O
27	in	O
28	the	O
29	presence	O
30	or	O
31	absence	O
32	of	O
33	catenins	B
34	.	O

0	Current	O
1	status	O
2	of	O
3	telepathology	O
4	.	O

0	The	O
1	final	O
2	sigma54	B
3	-	I
4	dependent	I
5	DmpR	B
6	activator	I
7	regulates	O
8	transcription	O
9	of	O
10	the	O
11	dmp	B
12	operon	I
13	that	O
14	encodes	O
15	the	O
16	enzymes	O
17	for	O
18	catabolism	O
19	of	O
20	(	O
21	methyl	O
22	)	O
23	phenols	O
24	.	O

0	Recently	O
1	,	O
2	an	O
3	electrical	O
4	-	O
5	mechanical	O
6	analog	O
7	model	O
8	of	O
9	heat	O
10	flow	O
11	within	O
12	the	O
13	brain	O
14	has	O
15	been	O
16	developed	O
17	from	O
18	which	O
19	an	O
20	expression	O
21	for	O
22	CBF	B
23	has	O
24	been	O
25	derived	O
26	:	O
27	CBF	B
28	=	O
29	Cb	O
30	/(	O
31	tau	O
32	rho	O
33	c	O
34	)	O
35	where	O
36	tau	O
37	is	O
38	the	O
39	thermal	O
40	decay	O
41	constant	O
42	,	O
43	rho	O
44	is	O
45	the	O
46	density	O
47	of	O
48	blood	O
49	,	O
50	and	O
51	c	O
52	is	O
53	its	O
54	specific	O
55	heat	O
56	.	O

0	Experiments	O
1	were	O
2	performed	O
3	in	O
4	which	O
5	brain	O
6	-	O
7	stem	O
8	auditory	O
9	-	O
10	evoked	O
11	responses	O
12	(	O
13	BAERs	O
14	)	O
15	were	O
16	elicited	O
17	by	O
18	two	O
19	types	O
20	of	O
21	pseudorandom	O
22	pulse	O
23	trains	O
24	:	O
25	maximum	O
26	length	O
27	sequences	O
28	(	O
29	MLS	O
30	)	O
31	and	O
32	Legendre	O
33	sequences	O
34	(	O
35	LGS	O
36	).	O

0	Most	O
1	strains	O
2	(	O
3	95	O
4	%)	O
5	of	O
6	S	O
7	.	O
8	lugdunensis	O
9	produced	O
10	a	O
11	delta	B
12	hemolysin	I
13	like	O
14	that	O
15	seen	O
16	with	O
17	nine	O
18	other	O
19	species	O
20	of	O
21	CNS	O
22	.	O

0	The	O
1	authors	O
2	present	O
3	the	O
4	only	O
5	two	O
6	studies	O
7	that	O
8	have	O
9	proved	O
10	successful	O
11	in	O
12	treating	O
13	animal	O
14	models	O
15	of	O
16	osteoarthritis	O
17	using	O
18	gene	O
19	therapy	O
20	,	O
21	and	O
22	propose	O
23	an	O
24	overview	O
25	of	O
26	several	O
27	strategies	O
28	for	O
29	the	O
30	development	O
31	of	O
32	gene	O
33	therapy	O
34	in	O
35	osteoarthritis	O
36	treatment	O
37	in	O
38	the	O
39	future	O
40	.	O

0	A	O
1	recombinant	O
2	derivative	O
3	harboring	O
4	the	O
5	pMJ101	O
6	replication	O
7	region	O
8	proved	O
9	to	O
10	be	O
11	compatible	O
12	with	O
13	pJM1	O
14	,	O
15	a	O
16	plasmid	O
17	containing	O
18	the	O
19	iron	O
20	acquisition	O
21	system	O
22	required	O
23	for	O
24	the	O
25	virulence	O
26	of	O
27	V	O
28	.	O
29	anguillarum	O
30	775	O
31	,	O
32	another	O
33	important	O
34	pathogen	O
35	that	O
36	causes	O
37	vibriosis	O
38	.	O

0	Therapeutic	O
1	use	O
2	of	O
3	continuous	O
4	subcutaneous	O
5	infusion	O
6	of	O
7	recombinant	B
8	human	B
9	erythropoietin	I
10	in	O
11	malnourished	O
12	predialysis	O
13	anemic	O
14	patients	O
15	with	O
16	diabetic	O
17	nephropathy	O
18	.	O

0	The	O
1	paper	O
2	is	O
3	concerned	O
4	with	O
5	the	O
6	data	O
7	on	O
8	change	O
9	in	O
10	the	O
11	blood	O
12	level	O
13	of	O
14	ACTH	B
15	,	O
16	STH	B
17	,	O
18	TSH	B
19	,	O
20	cortisol	B
21	,	O
22	T3	B
23	,	O
24	insulin	B
25	,	O
26	C	B
27	-	I
28	peptide	I
29	during	O
30	a	O
31	25	O
32	-	O
33	minute	O
34	session	O
35	of	O
36	respiration	O
37	using	O
38	a	O
39	gaseous	O
40	hypoxic	O
41	mixture	O
42	with	O
43	10	O
44	%	O
45	oxygen	O
46	(	O
47	GHM	O
48	-	O
49	10	O
50	).	O

0	Generally	O
1	the	O
2	differences	O
3	between	O
4	short	O
5	gut	O
6	and	O
7	sham	O
8	operation	O
9	animals	O
10	disappeared	O
11	when	O
12	the	O
13	data	O
14	were	O
15	normalised	O
16	for	O
17	mucosal	O
18	weight	O
19	.	O

0	These	O
1	techniques	O
2	have	O
3	been	O
4	used	O
5	by	O
6	many	O
7	people	O
8	for	O
9	many	O
10	years	O
11	and	O
12	no	O
13	claim	O
14	is	O
15	being	O
16	made	O
17	for	O
18	any	O
19	innovation	O
20	in	O
21	this	O
22	regard	O
23	.	O

0	Diagnostic	O
1	value	O
2	of	O
3	serum	B
4	myoglobin	I
5	in	O
6	cases	O
7	of	O
8	neuromuscular	O
9	disease	O

0	CKbeta4GT	B
1	-	I
2	II	I
3	is	O
4	predicted	O
5	to	O
6	encode	O
7	a	O
8	type	O
9	II	O
10	transmembrane	O
11	glycoprotein	O
12	of	O
13	43	O
14	kDa	O
15	with	O
16	five	O
17	potential	O
18	N	O
19	-	O
20	linked	O
21	glycosylation	O
22	sites	O
23	.	O

0	Both	O
1	methods	O
2	were	O
3	employed	O
4	for	O
5	various	O
6	focal	O
7	-	O
8	film	O
9	distances	O
10	,	O
11	image	O
12	intensifier	O
13	tube	O
14	modes	O
15	and	O
16	laser	O
17	printer	O
18	formats	O
19	.	O

0	This	O
1	strategy	O
2	was	O
3	used	O
4	to	O
5	place	O
6	both	O
7	the	O
8	Tn903	B
9	neo	I
10	gene	I
11	and	O
12	the	O
13	Rhodosporidium	B
14	toruloides	I
15	phenylalanine	I
16	ammonia	I
17	lyase	I
18	(	O
19	PAL	B
20	)-	O
21	encoding	O
22	gene	O
23	under	O
24	the	O
25	transcriptional	O
26	control	O
27	of	O
28	pPGK	B
29	::	O
30	REP2	B
31	.	O

0	Patients	O
1	were	O
2	randomly	O
3	assigned	O
4	to	O
5	treatment	O
6	with	O
7	the	O
8	ACE	B
9	inhibitor	O
10	perindopril	O
11	(	O
12	and	O
13	the	O
14	diuretic	O
15	indapamide	O
16	for	O
17	those	O
18	with	O
19	no	O
20	definite	O
21	indication	O
22	for	O
23	or	O
24	contraindication	O
25	to	O
26	treatment	O
27	with	O
28	a	O
29	diuretic	O
30	)	O
31	or	O
32	matching	O
33	placebo	O
34	(	O
35	s	O
36	).	O

0	Immuno	O
1	-	O
2	cytochemistry	O
3	,	O
4	using	O
5	antisera	O
6	against	O
7	Campylobacter	O
8	jejuni	O
9	,	O
10	showed	O
11	that	O
12	the	O
13	positive	O
14	staining	O
15	in	O
16	altered	O
17	epithelial	O
18	cells	O
19	were	O
20	restricted	O
21	to	O
22	intracellular	O
23	organisms	O
24	having	O
25	a	O
26	structure	O
27	resembling	O
28	Campylobacter	O
29	spp	O
30	.	O

0	The	O
1	lytic	O
2	cycle	O
3	of	O
4	KSHV	O
5	,	O
6	probably	O
7	under	O
8	the	O
9	initial	O
10	control	O
11	of	O
12	the	O
13	KSHV	B
14	/	O
15	Rta	B
16	gene	I
17	,	O
18	may	O
19	directly	O
20	contribute	O
21	to	O
22	tumor	O
23	pathogenesis	O
24	.	O

0	Closeup	O
1	:	O
2	a	O
3	resource	O
4	for	O
5	nurses	O
6	who	O
7	smoke	O
8	.	O

0	Factors	O
1	associated	O
2	with	O
3	intrafamilial	O
4	transmission	O
5	of	O
6	hepatitis	O
7	B	O
8	virus	O
9	infection	O
10	in	O
11	Korea	O
12	.	O

0	These	O
1	observed	O
2	drug	O
3	interactions	O
4	,	O
5	plus	O
6	the	O
7	known	O
8	effect	O
9	of	O
10	probenecid	O
11	to	O
12	block	O
13	secretion	O
14	of	O
15	PZA	O
16	,	O
17	have	O
18	to	O
19	be	O
20	considered	O
21	in	O
22	evaluating	O
23	the	O
24	effect	O
25	of	O
26	the	O
27	two	O
28	drugs	O
29	given	O
30	together	O
31	,	O
32	compared	O
33	to	O
34	the	O
35	effect	O
36	of	O
37	each	O
38	drug	O
39	given	O
40	separately	O
41	.	O

0	It	O
1	is	O
2	concluded	O
3	that	O
4	in	O
5	patients	O
6	with	O
7	first	O
8	-	O
9	attack	O
10	genital	O
11	herpes	O
12	,	O
13	the	O
14	type	O
15	of	O
16	HSV	O
17	is	O
18	the	O
19	most	O
20	important	O
21	determinant	O
22	of	O
23	subsequent	O
24	recurrences	O
25	and	O
26	that	O
27	intravenous	O
28	acyclovir	O
29	has	O
30	little	O
31	effect	O
32	on	O
33	subsequent	O
34	recurrences	O
35	.	O

0	PDGF	B
1	A	I
2	-	I
3	chain	I
4	levels	O
5	increase	O
6	in	O
7	cultured	O
8	vascular	O
9	smooth	O
10	muscle	O
11	cells	O
12	(	O
13	SMCs	O
14	)	O
15	exposed	O
16	to	O
17	ATII	B
18	.	O

0	N	O
1	.	O
2	van	O
3	Hoek	O
4	,	O
5	and	O
6	M	O
7	.	O

0	The	O
1	RAP74	B
2	subunit	I
3	of	O
4	TFIIF	B
5	alone	O
6	contained	O
7	the	O
8	stimulatory	O
9	activity	O
10	and	O
11	the	O
12	minimal	O
13	region	O
14	sufficient	O
15	for	O
16	stimulation	O
17	corresponds	O
18	to	O
19	COOH	O
20	-	O
21	terminal	O
22	residues	O
23	358	O
24	-	O
25	517	O
26	.	O

0	Ime1	B
1	plays	O
2	a	O
3	pivotal	O
4	role	O
5	in	O
6	the	O
7	initiation	O
8	of	O
9	meiosis	O
10	in	O
11	a	O
12	/	O
13	alpha	O
14	diploid	O
15	cells	O
16	of	O
17	Saccharomyces	O
18	cerevisiae	O
19	.	O

0	An	O
1	inverted	O
2	Alu	B
3	repeat	I
4	element	I
5	,	O
6	flanked	O
7	by	O
8	nonamer	O
9	direct	O
10	repeats	O
11	,	O
12	was	O
13	identified	O
14	within	O
15	the	O
16	region	O
17	-	O
18	913	O
19	/-	O
20	620	O
21	,	O
22	relative	O
23	to	O
24	the	O
25	cap	O
26	site	O
27	.	O

0	Badcock	O
1	and	O
2	Westheimer	O
3	(	O
4	Spatial	O
5	Vision	O
6	1	O
7	(	O
8	1	O
9	),	O
10	3	O
11	-	O
12	11	O
13	,	O
14	1985	O
15	)	O
16	showed	O
17	that	O
18	a	O
19	thin	O
20	vertical	O
21	line	O
22	induces	O
23	nearby	O
24	zones	O
25	of	O
26	attraction	O
27	and	O
28	repulsion	O
29	;	O
30	this	O
31	study	O
32	extends	O
33	those	O
34	results	O
35	by	O
36	more	O
37	closely	O
38	examining	O
39	the	O
40	horizontal	O
41	and	O
42	vertical	O
43	extents	O
44	of	O
45	the	O
46	repulsion	O
47	zone	O
48	and	O
49	by	O
50	using	O
51	an	O
52	illusory	O
53	contour	O
54	to	O
55	induce	O
56	repulsion	O
57	.	O

0	Rifabutin	O
1	has	O
2	substantial	O
3	efficacy	O
4	when	O
5	combined	O
6	with	O
7	other	O
8	agents	O
9	.	O

0	In	O
1	cell	O
2	lines	O
3	transformed	O
4	by	O
5	BCR	B
6	/	O
7	ABL	B
8	,	O
9	CRKL	B
10	was	O
11	tyrosine	O
12	phosphorylated	O
13	,	O
14	while	O
15	CRK	B
16	was	O
17	not	O
18	.	O

0	Thus	O
1	,	O
2	the	O
3	induction	O
4	of	O
5	E2F	B
6	binding	O
7	to	O
8	the	O
9	E2F	B
10	-	I
11	1	I
12	promoter	I
13	by	O
14	the	O
15	E4	B
16	-	I
17	6	I
18	/	I
19	7	I
20	protein	I
21	observed	O
22	in	O
23	vitro	O
24	correlates	O
25	with	O
26	transactivation	O
27	of	O
28	E2F	B
29	-	I
30	1	I
31	promoter	I
32	activity	O
33	in	O
34	vivo	O
35	.	O

0	Four	O
1	cases	O
2	of	O
3	synovial	O
4	chondromatosis	O
5	are	O
6	presented	O
7	.	O

0	The	O
1	promoter	O
2	for	O
3	HMG	B
4	-	I
5	CoA	I
6	synthase	I
7	contains	O
8	two	O
9	binding	O
10	sites	O
11	for	O
12	the	O
13	sterol	B
14	regulatory	I
15	element	I
16	-	I
17	binding	I
18	proteins	I
19	(	O
20	SREBPs	B
21	).	O

0	Inactivation	O
1	of	O
2	p53	B
3	but	O
4	not	O
5	p73	B
6	by	O
7	adenovirus	B
8	type	I
9	5	I
10	E1B	I
11	55	I
12	-	I
13	kilodalton	I
14	and	O
15	E4	B
16	34	I
17	-	I
18	kilodalton	I
19	oncoproteins	I
20	.	O

0	On	O
1	admission	O
2	to	O
3	the	O
4	ICU	O
5	,	O
6	117	O
7	patients	O
8	(	O
9	61	O
10	percent	O
11	)	O
12	had	O
13	hypomagnesemia	O
14	(	O
15	serum	O
16	Mg	O
17	less	O
18	than	O
19	1	O
20	.	O
21	5	O
22	mEq	O
23	/	O
24	dl	O
25	),	O
26	66	O
27	patients	O
28	(	O
29	34	O
30	percent	O
31	)	O
32	had	O
33	normomagnesemia	O
34	(	O
35	1	O
36	.	O
37	5	O
38	to	O
39	2	O
40	.	O
41	0	O
42	mEq	O
43	/	O
44	dl	O
45	),	O
46	and	O
47	ten	O
48	patients	O
49	(	O
50	5	O
51	percent	O
52	)	O
53	had	O
54	hypermagnesemia	O
55	(	O
56	greater	O
57	than	O
58	2	O
59	.	O
60	0	O
61	mEq	O
62	/	O
63	dl	O
64	).	O

0	The	O
1	most	O
2	frequent	O
3	risk	O
4	factor	O
5	for	O
6	ischaemic	O
7	was	O
8	hypertension	O
9	.	O

0	The	O
1	morphological	O
2	effects	O
3	of	O
4	two	O
5	snake	O
6	venoms	O
7	,	O
8	N	O
9	.	O
10	naja	O
11	and	O
12	A	O
13	.	O
14	piscivorus	O
15	,	O
16	and	O
17	of	O
18	the	O
19	Direct	B
20	Lytic	I
21	Factor	I
22	and	O
23	Phospholipase	B
24	-	I
25	A	I
26	,	O
27	compounds	O
28	purified	O
29	from	O
30	N	O
31	.	O
32	naja	O
33	crude	O
34	venom	O
35	,	O
36	were	O
37	investigated	O
38	on	O
39	lung	O
40	and	O
41	cremaster	O
42	vessels	O
43	of	O
44	rats	O
45	.	O

0	We	O
1	propose	O
2	that	O
3	the	O
4	reduced	O
5	responsiveness	O
6	of	O
7	CYP3A2	B
8	is	O
9	the	O
10	result	O
11	of	O
12	preferential	O
13	binding	O
14	of	O
15	COUP	B
16	-	I
17	TF	I
18	at	O
19	the	O
20	CYP3A2	B
21	DexRE	I
22	-	I
23	1	I
24	site	I
25	.	O

0	Using	O
1	anchored	O
2	PCR	O
3	,	O
4	a	O
5	VL	O
6	element	O
7	rearranged	O
8	to	O
9	CL2	O
10	was	O
11	isolated	O
12	.	O

0	Macroscopic	O
1	researches	O
2	on	O
3	heart	O
4	vascularization	O
5	have	O
6	indicated	O
7	that	O
8	the	O
9	angioarchitecture	O
10	of	O
11	the	O
12	conducting	O
13	system	O
14	differs	O
15	from	O
16	that	O
17	of	O
18	the	O
19	normal	O
20	myocardium	O
21	.	O

0	An	O
1	increase	O
2	in	O
3	bone	O
4	mineral	O
5	density	O
6	at	O
7	the	O
8	spine	O
9	,	O
10	total	O
11	hip	O
12	,	O
13	and	O
14	total	O
15	body	O
16	has	O
17	been	O
18	reported	O
19	with	O
20	raloxifene	O
21	but	O
22	seems	O
23	to	O
24	be	O
25	less	O
26	than	O
27	that	O
28	seen	O
29	with	O
30	estrogen	O
31	or	O
32	alendronate	O
33	therapy	O
34	.	O

0	Overexpressing	O
1	the	O
2	coactivator	O
3	,	O
4	SRC1a	B
5	or	O
6	GRIP1	B
7	,	O
8	further	O
9	enhances	O
10	ERRalpha1	B
11	-	O
12	induced	O
13	transcriptional	O
14	activity	O
15	.	O

0	E	O
1	.,	O
2	Hession	O
3	,	O
4	C	O
5	.,	O
6	Goff	O
7	,	O
8	D	O
9	.,	O
10	Griffiths	O
11	,	O
12	B	O
13	.,	O
14	Tizard	O
15	,	O
16	R	O
17	.,	O
18	Newman	O
19	,	O
20	B	O
21	.,	O
22	Chi	O
23	-	O
24	Rosso	O
25	,	O
26	G	O
27	.,	O
28	and	O
29	Lobb	O
30	,	O
31	R	O
32	.,	O
33	(	O
34	1990	O
35	)	O
36	Cell	O
37	63	O
38	,	O
39	1349	O
40	-	O
41	1356	O
42	).	O

0	Regressing	O
1	microaneurysms	O
2	in	O
3	5	O
4	cases	O
5	of	O
6	hepatitis	O
7	B	O
8	virus	O
9	related	O
10	polyarteritis	O
11	nodosa	O
12	.	O

0	For	O
1	228	O
2	of	O
3	425	O
4	deaths	O
5	(	O
6	54	O
7	%)	O
8	occurring	O
9	among	O
10	26	O
11	100	O
12	people	O
13	of	O
14	known	O
15	age	O
16	in	O
17	the	O
18	Malumfashi	O
19	area	O
20	of	O
21	northern	O
22	Nigeria	O
23	,	O
24	data	O
25	were	O
26	collected	O
27	on	O
28	symptoms	O
29	present	O
30	prior	O
31	to	O
32	death	O
33	.	O

0	Adjustment	O
1	for	O
2	age	O
3	,	O
4	total	O
5	cholesterol	O
6	,	O
7	HDL	B
8	cholesterol	I
9	,	O
10	triglycerides	O
11	,	O
12	current	O
13	smoking	O
14	,	O
15	and	O
16	systolic	O
17	pressure	O
18	slightly	O
19	reduced	O
20	the	O
21	association	O
22	between	O
23	fibrinogen	B
24	and	O
25	atherosclerosis	O
26	.	O

0	Curing	O
1	shrinkage	O
2	and	O
3	volumetric	O
4	changes	O
5	of	O
6	resin	O
7	-	O
8	modified	O
9	glass	O
10	ionomer	O
11	restorative	O
12	materials	O
13	.	O

0	Because	O
1	the	O
2	mutant	O
3	defective	O
4	in	O
5	DNA	O
6	binding	O
7	also	O
8	fails	O
9	to	O
10	stimulate	O
11	Abf1	B
12	ARS1	I
13	DNA	O
14	-	O
15	binding	O
16	activity	O
17	,	O
18	our	O
19	results	O
20	suggest	O
21	that	O
22	Cdc6	B
23	DNA	O
24	-	O
25	binding	O
26	activity	O
27	may	O
28	play	O
29	a	O
30	pivotal	O
31	role	O
32	in	O
33	the	O
34	initiation	O
35	of	O
36	DNA	O
37	replication	O
38	.	O

0	Each	O
1	trial	O
2	consisted	O
3	of	O
4	light	O
5	and	O
6	buzzer	O
7	for	O
8	five	O
9	seconds	O
10	as	O
11	conditioned	O
12	stimuli	O
13	and	O
14	electric	O
15	shock	O
16	for	O
17	five	O
18	seconds	O
19	as	O
20	an	O
21	unconditioned	O
22	stimulus	O
23	.	O

0	Two	O
1	new	O
2	glucosidase	B
3	inhibitors	O
4	(	O
5	BAY	O
6	m	O
7	1099	O
8	and	O
9	BAY	O
10	o	O
11	1248	O
12	)	O
13	were	O
14	studied	O
15	in	O
16	volunteers	O
17	and	O
18	type	O
19	II	O
20	diabetics	O
21	under	O
22	various	O
23	conditions	O
24	.	O

0	Determined	O
1	as	O
2	migration	O
3	differentials	O
4	,	O
5	chemotactic	O
6	and	O
7	chemokinetic	O
8	responsiveness	O
9	tended	O
10	to	O
11	be	O
12	higher	O
13	in	O
14	the	O
15	neutropenic	O
16	group	O
17	.	O

0	Sequence	O
1	analysis	O
2	indicates	O
3	that	O
4	in	O
5	addition	O
6	to	O
7	an	O
8	ATA	O
9	and	O
10	GC	O
11	box	O
12	,	O
13	this	O
14	region	O
15	contains	O
16	domains	O
17	that	O
18	have	O
19	been	O
20	implicated	O
21	in	O
22	the	O
23	regulation	O
24	of	O
25	other	O
26	muscle	O
27	-	O
28	specific	O
29	genes	O
30	:	O
31	a	O
32	CArG	O
33	box	O
34	at	O
35	-	O
36	91	O
37	bp	O
38	;	O
39	myocyte	B
40	-	I
41	specific	I
42	enhancer	I
43	-	I
44	binding	I
45	nuclear	I
46	factor	I
47	1	I
48	binding	I
49	site	I
50	homologies	O
51	at	O
52	-	O
53	58	O
54	,	O
55	-	O
56	535	O
57	,	O
58	and	O
59	-	O
60	583	O
61	bp	O
62	;	O
63	and	O
64	a	O
65	muscle	O
66	-	O
67	CAAT	O
68	consensus	O
69	sequence	O
70	at	O
71	-	O
72	394	O
73	bp	O
74	relative	O
75	to	O
76	the	O
77	cap	O
78	site	O
79	.	O

0	Bilateral	O
1	basal	O
2	arteries	O
3	were	O
4	measured	O
5	by	O
6	the	O
7	transtemporal	O
8	approach	O
9	with	O
10	a	O
11	2	O
12	MHz	O
13	pulsed	O
14	Doppler	O
15	instrument	O
16	(	O
17	TC	O
18	-	O
19	2	O
20	64B	O
21	EME	O
22	).	O

0	Twenty	O
1	-	O
2	three	O
3	sequence	O
4	-	O
5	tagged	O
6	sites	O
7	(	O
8	STSs	O
9	)	O
10	were	O
11	mapped	O
12	within	O
13	the	O
14	contig	O
15	,	O
16	a	O
17	density	O
18	of	O
19	approximately	O
20	1	O
21	per	O
22	200	O
23	kb	O
24	.	O

0	RESULTS	O
1	:	O
2	During	O
3	the	O
4	7	O
5	-	O
6	year	O
7	period	O
8	,	O
9	10	O
10	,	O
11	331	O
12	symptomatic	O
13	duodenal	O
14	ulcer	O
15	diseases	O
16	were	O
17	diagnosed	O
18	.	O

0	The	O
1	results	O
2	point	O
3	to	O
4	the	O
5	effectiveness	O
6	of	O
7	the	O
8	educational	O
9	intervention	O
10	.	O

0	Malaria	O
1	had	O
2	diminished	O
3	significantly	O
4	by	O
5	the	O
6	early	O
7	1940s	O
8	,	O
9	and	O
10	this	O
11	paper	O
12	queries	O
13	whether	O
14	that	O
15	reduction	O
16	was	O
17	due	O
18	to	O
19	the	O
20	control	O
21	projects	O
22	of	O
23	the	O
24	thirties	O
25	,	O
26	and	O
27	,	O
28	if	O
29	so	O
30	,	O
31	whether	O
32	such	O
33	projects	O
34	should	O
35	be	O
36	a	O
37	model	O
38	for	O
39	the	O
40	current	O
41	developing	O
42	world	O
43	,	O
44	where	O
45	malaria	O
46	is	O
47	a	O
48	growing	O
49	problem	O
50	today	O
51	.	O

0	The	O
1	protein	O
2	was	O
3	associated	O
4	with	O
5	purified	O
6	vaccinia	O
7	virus	O
8	particles	O
9	and	O
10	with	O
11	membranes	O
12	of	O
13	immature	O
14	and	O
15	mature	O
16	virions	O
17	that	O
18	were	O
19	visualized	O
20	by	O
21	electron	O
22	microscopy	O
23	of	O
24	infected	O
25	cells	O
26	.	O

0	The	O
1	RNA	O
2	transcripts	O
3	structurally	O
4	equivalent	O
5	to	O
6	I	B
7	(	I
8	2	I
9	)	I
10	sgRNAs	I
11	of	O
12	TMV	O
13	U1	O
14	and	O
15	crTMV	O
16	,	O
17	but	O
18	containing	O
19	a	O
20	hairpin	O
21	structure	O
22	(	O
23	H	O
24	)	O
25	immediately	O
26	upstream	O
27	of	O
28	IRES	O
29	(	O
30	MP	O
31	,	O
32	75	O
33	)	O
34	(	O
35	HIRES	O
36	(	O
37	MP	O
38	),	O
39	(	O
40	75	O
41	)(	O
42	CR	O
43	)-	O
44	MP	O
45	-	O
46	CP	O
47	-	O
48	3	O
49	'	O
50	UTR	O
51	;	O
52	HIRES	O
53	(	O
54	MP	O
55	,	O
56	75	O
57	)(	O
58	U1	O
59	)-	O
60	MP	O
61	-	O
62	CP	O
63	-	O
64	3	O
65	'	O
66	UTR	O
67	),	O
68	were	O
69	able	O
70	to	O
71	express	O
72	the	O
73	MP	B
74	gene	I
75	in	O
76	vitro	O
77	.	O

0	Two	O
1	soybean	O
2	cDNA	O
3	clones	O
4	,	O
5	SPK	B
6	-	I
7	3	I
8	and	O
9	SPK	B
10	-	I
11	4	I
12	,	O
13	encoding	O
14	putative	O
15	protein	O
16	kinases	O
17	were	O
18	isolated	O
19	and	O
20	characterized	O
21	.	O

0	The	O
1	variability	O
2	is	O
3	most	O
4	likely	O
5	a	O
6	result	O
7	of	O
8	alternative	O
9	splicing	O
10	of	O
11	exons	O
12	from	O
13	the	O
14	primary	O
15	elastin	B
16	transcripts	I
17	.	O

0	SBF	B
1	binds	O
2	to	O
3	the	O
4	promoter	O
5	prior	O
6	to	O
7	the	O
8	activation	O
9	of	O
10	transcription	O
11	in	O
12	late	O
13	G1	O
14	,	O
15	suggesting	O
16	that	O
17	Cln	B
18	/	O
19	Cdc28	B
20	kinase	O
21	regulates	O
22	the	O
23	ability	O
24	of	O
25	previously	O
26	bound	O
27	SBF	B
28	to	O
29	activate	O
30	transcription	O
31	.	O

0	DPA	O
1	attenuated	O
2	the	O
3	increase	O
4	of	O
5	the	O
6	intensity	O
7	of	O
8	the	O
9	ischemic	O
10	and	O
11	pressure	O
12	pain	O
13	components	O
14	with	O
15	increasing	O
16	ischemia	O
17	duration	O
18	,	O
19	but	O
20	only	O
21	the	O
22	effect	O
23	on	O
24	the	O
25	pressure	O
26	pain	O
27	component	O
28	was	O
29	significant	O
30	.	O

0	These	O
1	mutants	O
2	grow	O
3	normally	O
4	in	O
5	3T6	O
6	mouse	O
7	fibroblast	O
8	cells	O
9	,	O
10	and	O
11	they	O
12	do	O
13	not	O
14	complement	O
15	the	O
16	wild	O
17	-	O
18	type	O
19	virus	O
20	in	O
21	coinfection	O
22	experiments	O
23	of	O
24	C2	O
25	myoblasts	O
26	.	O

0	All	O
1	groups	O
2	were	O
3	challenged	O
4	subsequently	O
5	with	O
6	naloxone	O
7	(	O
8	0	O
9	.	O
10	4	O
11	mg	O
12	/	O
13	kg	O
14	)	O
15	in	O
16	the	O
17	distinctive	O
18	environment	O
19	and	O
20	then	O
21	observed	O
22	for	O
23	signs	O
24	of	O
25	opiate	O
26	withdrawal	O
27	.	O

0	Chlorambucil	B
1	and	O
2	interferon	B
3	for	O
4	low	O
5	grade	O
6	non	O
7	-	O
8	Hodgkin	O
9	'	O
10	s	O
11	lymphoma	O
12	.	O

0	Estrogen	O
1	replacement	O
2	,	O
3	either	O
4	as	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	or	O
10	beta	O
11	-	O
12	estradiol	O
13	-	O
14	3	O
15	-	O
16	benzoate	O
17	via	O
18	subcutaneous	O
19	Silastic	O
20	capsules	O
21	,	O
22	was	O
23	associated	O
24	with	O
25	elevated	O
26	rates	O
27	of	O
28	heat	O
29	production	O
30	and	O
31	dry	O
32	heat	O
33	loss	O
34	relative	O
35	to	O
36	untreated	O
37	ovariectomized	O
38	controls	O
39	.	O

0	One	O
1	hundred	O
2	fifty	O
3	patients	O
4	were	O
5	reviewed	O
6	at	O
7	1	O
8	year	O
9	after	O
10	arthroplasty	O
11	.	O

0	Effect	O
1	of	O
2	noise	O
3	on	O
4	CO	O
5	-	O
6	induced	O
7	increases	O
8	of	O
9	LAP	B
10	and	O
11	GPT	B
12	activity	O
13	in	O
14	the	O
15	plasma	O
16	of	O
17	rats	O

0	Marrow	O
1	dysplasia	O
2	is	O
3	a	O
4	major	O
5	characteristic	O
6	of	O
7	patients	O
8	with	O
9	myelodysplastic	O
10	syndrome	O
11	(	O
12	MDS	O
13	),	O
14	along	O
15	with	O
16	marrow	O
17	blastosis	O
18	,	O
19	cytopenia	O
20	and	O
21	cytogenetic	O
22	anomalies	O
23	.	O

0	VaI	B
1	and	O
2	VaII	B
3	co	O
4	-	O
5	immunoprecipitated	O
6	with	O
7	ErbB2	B
8	,	O
9	but	O
10	not	O
11	with	O
12	ErbB1	B
13	,	O
14	ErbB3	B
15	,	O
16	or	O
17	ErbB4	B
18	.	O

0	This	O
1	technique	O
2	was	O
3	employed	O
4	in	O
5	12	O
6	patients	O
7	with	O
8	a	O
9	unicameral	O
10	bone	O
11	cyst	O
12	.	O

0	To	O
1	address	O
2	these	O
3	questions	O
4	,	O
5	a	O
6	recombinant	B
7	FRAP	B
8	/	I
9	mTOR	I
10	protein	I
11	and	O
12	a	O
13	FRAP	B
14	/	I
15	mTOR	I
16	immunoprecipitate	O
17	were	O
18	utilized	O
19	in	O
20	in	O
21	vitro	O
22	kinase	O
23	assays	O
24	to	O
25	phosphorylate	O
26	4E	B
27	-	O
28	BP1	O
29	.	O

0	A	O
1	population	O
2	pharmacokinetic	O
3	study	O
4	of	O
5	cyclosporin	O
6	in	O
7	organ	O
8	transplant	O
9	patients	O
10	,	O
11	including	O
12	elderly	O
13	allograft	O
14	recipients	O
15	up	O
16	to	O
17	75	O
18	years	O
19	of	O
20	age	O
21	,	O
22	did	O
23	not	O
24	identify	O
25	age	O
26	as	O
27	a	O
28	covariable	O
29	influencing	O
30	cyclosporin	O
31	pharmacokinetics	O
32	.	O

0	When	O
1	excluding	O
2	children	O
3	with	O
4	ocular	O
5	and	O
6	cerebral	O
7	pathology	O
8	,	O
9	32	O
10	matched	O
11	pairs	O
12	of	O
13	premature	O
14	and	O
15	control	O
16	children	O
17	remained	O
18	.	O

0	Direct	O
1	binding	O
2	and	O
3	competition	O
4	assays	O
5	using	O
6	30	O
7	-	O
8	mer	O
9	oligonucleotide	O
10	probes	O
11	representing	O
12	the	O
13	individual	O
14	CBF1	B
15	binding	I
16	sites	I
17	indicated	O
18	that	O
19	CBF1	B
20	bound	O
21	less	O
22	efficiently	O
23	to	O
24	the	O
25	CD23	B
26	promoter	I
27	and	O
28	the	O
29	EBV	B
30	LMP	B
31	-	I
32	1	I
33	promoter	I
34	sites	I
35	than	O
36	to	O
37	the	O
38	Cp	B
39	site	I
40	.	O

0	Therefore	O
1	,	O
2	the	O
3	molecular	O
4	mechanisms	O
5	of	O
6	the	O
7	estrogen	O
8	action	O
9	that	O
10	govern	O
11	the	O
12	lactoferrin	B
13	gene	I
14	expression	O
15	differ	O
16	between	O
17	mouse	O
18	and	O
19	human	O
20	.	O

0	EIAV	B
1	LTR	I
2	sequence	I
3	variability	O
4	is	O
5	confined	O
6	mostly	O
7	to	O
8	a	O
9	small	O
10	portion	O
11	of	O
12	the	O
13	enhancer	O
14	within	O
15	the	O
16	U3	O
17	segment	O
18	of	O
19	the	O
20	LTR	O
21	.	O

0	The	O
1	c	B
2	-	I
3	myc	I
4	/	O
5	TGF	B
6	-	I
7	alpha	I
8	HCCs	I
9	were	O
10	also	O
11	characterized	O
12	by	O
13	a	O
14	particularly	O
15	strong	O
16	expression	O
17	of	O
18	TGF	B
19	-	I
20	alpha	I
21	and	O
22	very	O
23	low	O
24	apoptotic	O
25	index	O
26	in	O
27	contrast	O
28	to	O
29	high	O
30	levels	O
31	of	O
32	apoptosis	O
33	in	O
34	peritumorous	O
35	tissues	O
36	and	O
37	c	B
38	-	I
39	myc	I
40	HCCs	I
41	.	O

0	This	O
1	L	B
2	-	I
3	myc	I
4	sequence	I
5	is	O
6	amplified	O
7	10	O
8	-	O
9	20	O
10	-	O
11	fold	O
12	in	O
13	four	O
14	SCLC	O
15	cell	O
16	line	O
17	DNAs	O
18	and	O
19	in	O
20	one	O
21	SCLC	O
22	tumour	O
23	specimen	O
24	taken	O
25	directly	O
26	from	O
27	a	O
28	patient	O
29	.	O

0	Viscosity	O
1	experiments	O
2	on	O
3	the	O
4	catalytic	O
5	fragment	O
6	kinase	O
7	reaction	O
8	demonstrated	O
9	that	O
10	the	O
11	chemical	O
12	(	O
13	phosphoryl	O
14	transfer	O
15	)	O
16	step	O
17	had	O
18	a	O
19	reduced	O
20	rate	O
21	.	O

0	Two	O
1	other	O
2	peptides	O
3	,	O
4	either	O
5	partially	O
6	or	O
7	totally	O
8	lacking	O
9	the	O
10	basic	O
11	region	O
12	,	O
13	but	O
14	containing	O
15	the	O
16	intact	O
17	leucine	O
18	zipper	O
19	domain	O
20	,	O
21	readily	O
22	form	O
23	dimers	O
24	but	O
25	do	O
26	not	O
27	bind	O
28	to	O
29	the	O
30	CRE	O
31	.	O

0	These	O
1	results	O
2	suggest	O
3	that	O
4	different	O
5	models	O
6	of	O
7	intestinal	O
8	ischemia	O
9	have	O
10	different	O
11	cytokine	O
12	profiles	O
13	and	O
14	that	O
15	the	O
16	early	B
17	TNF	B
18	response	O
19	associated	O
20	with	O
21	SMA	O
22	occlusion	O
23	model	O
24	is	O
25	primarily	O
26	due	O
27	to	O
28	the	O
29	laparotomy	O
30	.	O

0	These	O
1	contain	O
2	a	O
3	single	O
4	1977	O
5	-	O
6	bp	O
7	exon	O
8	that	O
9	encodes	O
10	900	O
11	bp	O
12	of	O
13	the	O
14	5	O
15	'	O
16	and	O
17	3	O
18	'	O
19	untranslated	O
20	sequences	O
21	in	O
22	addition	O
23	to	O
24	a	O
25	1077	O
26	-	O
27	bp	O
28	open	O
29	reading	O
30	frame	O
31	identical	O
32	to	O
33	that	O
34	found	O
35	in	O
36	vascular	B
37	smooth	I
38	muscle	I
39	cell	I
40	AT1a	I
41	receptor	I
42	cDNAs	I
43	.	O

0	Transient	O
1	,	O
2	high	O
3	-	O
4	level	O
5	Ras	B
6	-	O
7	expression	O
8	induces	O
9	transcriptional	O
10	activation	O
11	of	O
12	p21	B
13	mediated	O
14	by	O
15	a	O
16	GC	O
17	-	O
18	rich	O
19	region	O
20	in	O
21	p21	B
22	promoter	I
23	-	O
24	83	O
25	-	O
26	54	O
27	bp	O
28	relative	O
29	to	O
30	the	O
31	transcription	O
32	initiation	O
33	site	O
34	containing	O
35	binding	O
36	sites	O
37	for	O
38	Sp1	B
39	-	I
40	family	I
41	transcription	I
42	factors	I
43	.	O

0	An	O
1	anchored	O
2	AFLP	O
3	-	O
4	and	O
5	retrotransposon	O
6	-	O
7	based	O
8	map	O
9	of	O
10	diploid	O
11	Avena	O
12	.	O

0	When	O
1	10	O
2	fields	O
3	were	O
4	analysed	O
5	,	O
6	a	O
7	strong	O
8	relationship	O
9	was	O
10	found	O
11	between	O
12	the	O
13	presence	O
14	of	O
15	bacteria	O
16	on	O
17	Gram	O
18	staining	O
19	and	O
20	the	O
21	final	O
22	diagnosis	O
23	of	O
24	VAP	O
25	(	O
26	for	O
27	PSB	O
28	and	O
29	PTC	O
30	respectively	O
31	:	O
32	sensitivity	O
33	74	O
34	and	O
35	81	O
36	%,	O
37	specificity	O
38	94	O
39	and	O
40	100	O
41	%,	O
42	positive	O
43	predictive	O
44	value	O
45	91	O
46	and	O
47	100	O
48	%,	O
49	negative	O
50	predictive	O
51	value	O
52	82	O
53	and	O
54	88	O
55	%).	O

0	Analysis	O
1	of	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	rightmost	O
7	43	O
8	kbp	O
9	of	O
10	herpesvirus	O
11	saimiri	O
12	(	O
13	HVS	O
14	)	O
15	L	O
16	-	O
17	DNA	O
18	:	O
19	general	O
20	conservation	O
21	of	O
22	genetic	O
23	organization	O
24	between	O
25	HVS	O
26	and	O
27	Epstein	O
28	-	O
29	Barr	O
30	virus	O
31	.	O

0	Despite	O
1	the	O
2	favourable	O
3	natural	O
4	history	O
5	of	O
6	acute	O
7	BI	O
8	,	O
9	mild	O
10	,	O
11	moderate	O
12	,	O
13	and	O
14	severe	O
15	posttraumatic	O
16	changes	O
17	were	O
18	shown	O
19	to	O
20	appear	O
21	as	O
22	cicatricial	O
23	-	O
24	adhesive	O
25	and	O
26	atrophic	O
27	processes	O
28	,	O
29	intracerebral	O
30	cysts	O
31	,	O
32	porencephaly	O
33	,	O
34	which	O
35	result	O
36	in	O
37	posttraumatic	O
38	epilepsy	O
39	,	O
40	hydrocephalus	O
41	,	O
42	etc	O
43	.	O

0	The	O
1	experimental	O
2	design	O
3	represents	O
4	a	O
5	2	O
6	x	O
7	3	O
8	factorial	O
9	arrangement	O
10	of	O
11	treatments	O
12	with	O
13	three	O
14	dietary	O
15	levels	O
16	of	O
17	incorporation	O
18	of	O
19	RSB	O
20	(	O
21	0	O
22	,	O
23	50	O
24	,	O
25	and	O
26	100	O
27	%),	O
28	and	O
29	chickens	O
30	either	O
31	infected	O
32	or	O
33	uninfected	O
34	.	O

0	Significantly	O
1	greater	O
2	improvement	O
3	(	O
4	p	O
5	<	O
6	0	O
7	.	O
8	05	O
9	)	O
10	in	O
11	the	O
12	sertraline	O
13	group	O
14	first	O
15	became	O
16	apparent	O
17	by	O
18	the	O
19	end	O
20	of	O
21	week	O
22	3	O
23	on	O
24	the	O
25	Y	O
26	-	O
27	BOCS	O
28	and	O
29	the	O
30	CGI	O
31	Improvement	O
32	scale	O
33	,	O
34	and	O
35	by	O
36	the	O
37	end	O
38	of	O
39	weeks	O
40	6	O
41	and	O
42	8	O
43	,	O
44	respectively	O
45	,	O
46	on	O
47	the	O
48	NIMH	O
49	and	O
50	CGI	O
51	Severity	O
52	scale	O
53	.	O

0	The	O
1	UV	O
2	induction	O
3	of	O
4	c	B
5	-	I
6	jun	I
7	is	O
8	mediated	O
9	by	O
10	two	O
11	UV	O
12	response	O
13	elements	O
14	consisting	O
15	of	O
16	AP	B
17	-	I
18	1	I
19	-	I
20	like	I
21	sequences	I
22	within	O
23	its	O
24	5	O
25	'	O
26	control	O
27	region	O
28	.	O

0	These	O
1	children	O
2	were	O
3	grouped	O
4	into	O
5	four	O
6	diagnostic	O
7	categories	O
8	:	O
9	1	O
10	)	O
11	idiopathic	O
12	GH	B
13	deficiency	O
14	(	O
15	n	O
16	=	O
17	10	O
18	);	O
19	2	O
20	)	O
21	organic	O
22	hypopituitarism	O
23	(	O
24	n	O
25	=	O
26	7	O
27	);	O
28	3	O
29	)	O
30	intrauterine	O
31	growth	O
32	retardation	O
33	(	O
34	n	O
35	=	O
36	5	O
37	);	O
38	and	O
39	4	O
40	)	O
41	constitutional	O
42	delay	O
43	of	O
44	growth	O
45	and	O
46	/	O
47	or	O
48	familial	O
49	short	O
50	stature	O
51	(	O
52	n	O
53	=	O
54	18	O
55	),	O
56	by	O
57	standard	O
58	clinical	O
59	criteria	O
60	and	O
61	physiological	O
62	and	O
63	pharmacological	O
64	tests	O
65	of	O
66	GH	B
67	reserve	O
68	.	O

0	Linking	O
1	continuous	O
2	community	O
3	-	O
4	based	O
5	morbidity	O
6	recording	O
7	of	O
8	influenza	O
9	-	O
10	like	O
11	illness	O
12	(	O
13	ILI	O
14	)	O
15	with	O
16	virological	O
17	sampling	O
18	has	O
19	consistently	O
20	proved	O
21	its	O
22	value	O
23	as	O
24	one	O
25	of	O
26	the	O
27	earliest	O
28	indicators	O
29	of	O
30	circulating	O
31	influenza	O
32	activity	O
33	.	O

0	Taste	O
1	reactivity	O
2	tests	O
3	were	O
4	used	O
5	to	O
6	examine	O
7	the	O
8	orofacial	O
9	responses	O
10	of	O
11	alcohol	O
12	preferring	O
13	(	O
14	P	O
15	)	O
16	rats	O
17	and	O
18	alcohol	O
19	nonpreferring	O
20	(	O
21	NP	O
22	)	O
23	rats	O
24	to	O
25	the	O
26	taste	O
27	of	O
28	alcohol	O
29	.	O

0	Derivatives	O
1	of	O
2	fluorene	O
3	.	O

0	The	O
1	abscess	O
2	was	O
3	debrided	O
4	and	O
5	the	O
6	septum	O
7	was	O
8	patched	O
9	with	O
10	a	O
11	single	O
12	layer	O
13	of	O
14	autologous	O
15	pericardium	O
16	.	O

0	Combined	O
1	therapy	O
2	with	O
3	MK	O
4	-	O
5	801	O
6	and	O
7	nimodipine	O
8	for	O
9	protection	O
10	of	O
11	ischemic	O
12	brain	O
13	damage	O
14	.	O

0	The	O
1	temporal	O
2	component	O
3	lacked	O
4	a	O
5	mandibular	O
6	fossa	O
7	as	O
8	well	O
9	as	O
10	articular	O
11	eminence	O
12	.	O

0	Molecular	O
1	cloning	O
2	of	O
3	mouse	B
4	glycolate	I
5	oxidase	I
6	.	O

0	Enterococcus	O
1	faecium	O
2	strains	O
3	with	O
4	vanA	B
5	-	O
6	mediated	O
7	glycopeptide	O
8	resistance	O
9	were	O
10	isolated	O
11	by	O
12	enrichment	O
13	culture	O
14	from	O
15	the	O
16	intestines	O
17	and	O
18	feces	O
19	of	O
20	several	O
21	animal	O
22	species	O
23	,	O
24	mainly	O
25	horses	O
26	and	O
27	dogs	O
28	(	O
29	8	O
30	%	O
31	positive	O
32	),	O
33	chickens	O
34	(	O
35	7	O
36	%	O
37	positive	O
38	),	O
39	and	O
40	pigs	O
41	(	O
42	6	O
43	%	O
44	positive	O
45	).	O

0	Furthermore	O
1	,	O
2	binding	O
3	of	O
4	recombinant	B
5	Myb	I
6	and	O
7	Ets	B
8	-	I
9	2	I
10	protein	I
11	to	O
12	these	O
13	fragments	O
14	could	O
15	be	O
16	competed	O
17	with	O
18	an	O
19	excess	O
20	of	O
21	double	O
22	stranded	O
23	oligodeoxynucleotides	O
24	containing	O
25	canonical	O
26	,	O
27	but	O
28	not	O
29	mutated	O
30	,	O
31	Myb	B
32	-	O
33	or	O
34	Ets	B
35	-	I
36	binding	I
37	sites	I
38	.	O

0	These	O
1	six	O
2	districts	O
3	have	O
4	an	O
5	area	O
6	of	O
7	34	O
8	,	O
9	000	O
10	km2	O
11	and	O
12	hold	O
13	a	O
14	population	O
15	of	O
16	30	O
17	million	O
18	.	O

0	Ultrastructural	O
1	and	O
2	morphometric	O
3	study	O
4	of	O
5	the	O
6	myeloid	O
7	parenchyma	O
8	cells	O
9	of	O
10	mice	O
11	prior	O
12	and	O
13	after	O
14	X	O
15	-	O
16	ray	O
17	exposure	O

0	The	O
1	mature	O
2	chromosome	B
3	4	I
4	FRG1	I
5	transcript	I
6	is	O
7	1042	O
8	bp	O
9	in	O
10	length	O
11	and	O
12	contains	O
13	nine	O
14	exons	O
15	which	O
16	encode	O
17	a	O
18	putative	O
19	protein	O
20	of	O
21	258	O
22	amino	O
23	acid	O
24	residues	O
25	.	O

0	Based	O
1	on	O
2	the	O
3	comparison	O
4	of	O
5	the	O
6	predicted	O
7	amino	O
8	acid	O
9	sequences	O
10	of	O
11	1	O
12	-	O
13	sst	O
14	and	O
15	1	O
16	-	O
17	fft	O
18	with	O
19	those	O
20	of	O
21	other	O
22	plant	B
23	fructosyl	I
24	transferase	I
25	genes	I
26	,	O
27	we	O
28	postulate	O
29	that	O
30	both	O
31	plant	B
32	fructan	I
33	genes	I
34	have	O
35	evolved	O
36	from	O
37	plant	B
38	invertase	I
39	genes	I
40	.	O

0	T7	B
1	transcription	O
2	could	O
3	be	O
4	manipulated	O
5	to	O
6	achieve	O
7	different	O
8	levels	O
9	of	O
10	constitutive	O
11	expression	O
12	,	O
13	through	O
14	the	O
15	use	O
16	of	O
17	promoter	O
18	mutations	O
19	.	O

0	Retroviral	O
1	transduction	O
2	of	O
3	T	O
4	/	O
5	T	O
6	(	O
7	L	O
8	)	O
9	causes	O
10	a	O
11	rapidly	O
12	fatal	O
13	myeloproliferative	O
14	disease	O
15	in	O
16	a	O
17	murine	O
18	bone	O
19	marrow	O
20	transplant	O
21	(	O
22	BMT	O
23	)	O
24	model	O
25	,	O
26	whereas	O
27	T	O
28	/	O
29	T	O
30	(	O
31	F	O
32	)	O
33	causes	O
34	a	O
35	long	O
36	-	O
37	latency	O
38	,	O
39	pre	O
40	-	O
41	B	O
42	-	O
43	cell	O
44	lymphoblastic	O
45	lymphoma	O
46	.	O

0	The	O
1	comparisons	O
2	revealed	O
3	that	O
4	female	O
5	homicide	O
6	-	O
7	suicide	O
8	perpetrators	O
9	were	O
10	more	O
11	likely	O
12	than	O
13	female	O
14	homicide	O
15	-	O
16	suicide	O
17	victims	O
18	to	O
19	live	O
20	in	O
21	mobile	O
22	homes	O
23	,	O
24	kill	O
25	their	O
26	lover	O
27	or	O
28	ex	O
29	-	O
30	lover	O
31	,	O
32	have	O
33	their	O
34	crime	O
35	accidentally	O
36	discovered	O
37	,	O
38	leave	O
39	a	O
40	suicide	O
41	note	O
42	,	O
43	kill	O
44	on	O
45	a	O
46	weekend	O
47	,	O
48	and	O
49	be	O
50	depressed	O
51	,	O
52	but	O
53	are	O
54	less	O
55	likely	O
56	than	O
57	female	O
58	homicide	O
59	-	O
60	suicide	O
61	victims	O
62	to	O
63	live	O
64	with	O
65	a	O
66	spouse	O
67	.	O

0	Dorsal	O
1	foot	O
2	TcpO2	O
3	was	O
4	measured	O
5	by	O
6	using	O
7	oxygen	O
8	-	O
9	sensing	O
10	electrodes	O
11	with	O
12	surface	O
13	temperatures	O
14	of	O
15	42	O
16	degrees	O
17	C	O
18	and	O
19	45	O
20	degrees	O
21	C	O
22	;	O
23	in	O
24	theory	O
25	,	O
26	changes	O
27	in	O
28	sympathetic	O
29	activity	O
30	should	O
31	affect	O
32	vasomotor	O
33	tone	O
34	and	O
35	TcpO2	O
36	in	O
37	skin	O
38	beneath	O
39	an	O
40	electrode	O
41	at	O
42	42	O
43	degrees	O
44	C	O
45	(	O
46	submaximal	O
47	vasodilation	O
48	),	O
49	but	O
50	not	O
51	at	O
52	45	O
53	degrees	O
54	C	O
55	(	O
56	maximal	O
57	vasodilation	O
58	).	O

0	Cotransfection	O
1	of	O
2	the	O
3	coactivator	O
4	CREB	B
5	-	I
6	binding	I
7	protein	I
8	relieved	O
9	the	O
10	transcriptional	O
11	repression	O
12	of	O
13	PPARalphawt	B
14	by	O
15	PPARalphatr	B
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	dominant	O
21	negative	O
22	effect	O
23	of	O
24	PPARalphatr	B
25	might	O
26	occur	O
27	through	O
28	competition	O
29	for	O
30	essential	O
31	coactivators	O
32	.	O

0	Alveolar	O
1	lymphocytes	O
2	were	O
3	surprisingly	O
4	increased	O
5	in	O
6	most	O
7	patients	O
8	with	O
9	AIDS	O
10	(	O
11	mean	O
12	26	O
13	.	O
14	1	O
15	+/-	O
16	21	O
17	.	O
18	9	O
19	%;	O
20	range	O
21	1	O
22	-	O
23	76	O
24	%)	O
25	and	O
26	CGL	O
27	(	O
28	mean	O
29	26	O
30	.	O
31	6	O
32	+/-	O
33	22	O
34	.	O
35	6	O
36	%;	O
37	range	O
38	3	O
39	-	O
40	76	O
41	%)	O
42	with	O
43	criteria	O
44	of	O
45	activation	O
46	contrasting	O
47	with	O
48	the	O
49	blood	O
50	lymphopenia	O
51	.	O

0	During	O
1	the	O
2	period	O
3	from	O
4	May	O
5	to	O
6	August	O
7	,	O
8	1978	O
9	,	O
10	an	O
11	epidemic	O
12	of	O
13	hand	O
14	,	O
15	foot	O
16	and	O
17	mouth	O
18	disease	O
19	(	O
20	HFMD	O
21	)	O
22	occurred	O
23	in	O
24	Gifu	O
25	prefecture	O
26	.	O

0	Two	O
1	BASIC	O
2	computer	O
3	programs	O
4	using	O
5	logit	O
6	transformation	O
7	for	O
8	the	O
9	analysis	O
10	of	O
11	S	O
12	-	O
13	shaped	O
14	curves	O
15	are	O
16	presented	O
17	.	O

0	In	O
1	a	O
2	retrospective	O
3	analysis	O
4	of	O
5	data	O
6	from	O
7	35	O
8	cases	O
9	with	O
10	malignant	O
11	lymphoma	O
12	from	O
13	a	O
14	cohort	O
15	of	O
16	2017	O
17	HIV	O
18	-	O
19	infected	O
20	patients	O
21	,	O
22	the	O
23	stage	O
24	of	O
25	HIV	O
26	-	O
27	disease	O
28	,	O
29	the	O
30	CD4	B
31	counts	O
32	at	O
33	the	O
34	time	O
35	of	O
36	diagnosis	O
37	,	O
38	and	O
39	the	O
40	use	O
41	of	O
42	antineoplastic	O
43	agents	O
44	or	O
45	radiotherapy	O
46	were	O
47	correlated	O
48	with	O
49	outcome	O
50	.	O

0	Mature	O
1	mRNA	O
2	for	O
3	cytosolic	B
4	phosphoenolpyruvate	I
5	carboxykinase	I
6	of	I
7	the	I
8	chicken	O
9	is	O
10	2	O
11	.	O
12	8	O
13	kilobases	O
14	in	O
15	length	O
16	,	O
17	similar	O
18	to	O
19	that	O
20	previously	O
21	noted	O
22	for	O
23	mRNA	O
24	coding	O
25	for	O
26	the	O
27	same	O
28	enzyme	O
29	in	O
30	the	O
31	rat	O
32	.	O

0	With	O
1	aging	O
2	,	O
3	many	O
4	aspects	O
5	of	O
6	immune	O
7	function	O
8	change	O
9	.	O

0	Therefore	O
1	,	O
2	with	O
3	a	O
4	biopsy	O
5	from	O
6	the	O
7	stoma	O
8	site	O
9	there	O
10	is	O
11	a	O
12	risk	O
13	of	O
14	missing	O
15	early	O
16	rejection	O
17	.	O

0	Sequence	O
1	conservation	O
2	is	O
3	greatest	O
4	for	O
5	residues	O
6	located	O
7	near	O
8	the	O
9	active	O
10	centers	O
11	of	O
12	the	O
13	exo	B
14	and	O
15	pol	B
16	domains	O
17	of	O
18	the	O
19	E	B
20	.	I
21	coli	I
22	DNA	I
23	polymerase	I
24	I	I
25	structure	O
26	.	O

0	IgE	B
1	levels	O
2	showed	O
3	higher	O
4	values	O
5	compared	O
6	to	O
7	normal	O
8	individuals	O
9	and	O
10	IgE	B
11	levels	O
12	were	O
13	higher	O
14	in	O
15	children	O
16	groups	O
17	than	O
18	in	O
19	adults	O
20	regardless	O
21	of	O
22	the	O
23	intensity	O
24	of	O
25	infection	O
26	.	O

0	The	O
1	tyrosine	O
2	-	O
3	phosphorylated	O
4	state	O
5	of	O
6	CAK	B
7	beta	I
8	was	O
9	not	O
10	reduced	O
11	on	O
12	trypsinization	O
13	,	O
14	nor	O
15	enhanced	O
16	in	O
17	response	O
18	to	O
19	plating	O
20	3Y1	O
21	cells	O
22	onto	O
23	fibronectin	B
24	.	O

0	Survey	O
1	on	O
2	antibody	O
3	against	O
4	egg	O
5	drop	O
6	syndrome	O
7	-	O
8	1976	O
9	virus	O
10	among	O
11	chicken	O
12	flocks	O
13	in	O
14	Japan	O
15	.	O

0	Oligonucleotide	O
1	mutagenesis	O
2	of	O
3	these	O
4	binding	O
5	domains	O
6	indicated	O
7	their	O
8	importance	O
9	in	O
10	the	O
11	transcriptional	O
12	regulation	O
13	of	O
14	the	O
15	E3	B
16	promoter	I
17	in	O
18	yeast	O
19	cells	O
20	.	O

0	We	O
1	also	O
2	examined	O
3	the	O
4	relationship	O
5	between	O
6	the	O
7	side	O
8	of	O
9	sinusitis	O
10	and	O
11	the	O
12	cleft	O
13	side	O
14	in	O
15	patients	O
16	with	O
17	unilateral	O
18	cleft	O
19	palate	O
20	.	O

0	Perceptions	O
1	of	O
2	illness	O
3	intrusiveness	O
4	were	O
5	significantly	O
6	higher	O
7	when	O
8	both	O
9	muscle	O
10	cramp	O
11	and	O
12	headache	O
13	symptoms	O
14	occurred	O
15	during	O
16	one	O
17	or	O
18	more	O
19	assessment	O
20	intervals	O
21	as	O
22	compared	O
23	to	O
24	when	O
25	muscle	O
26	cramps	O
27	or	O
28	headaches	O
29	,	O
30	only	O
31	,	O
32	occurred	O
33	.	O

0	Comparison	O
1	with	O
2	alkaline	B
3	phosphatases	I
4	and	O
5	5	B
6	-	I
7	nucleotidase	I
8	.	O

0	Pharmacologic	O
1	properties	O
2	of	O
3	serotonergic	O
4	agents	O
5	and	O
6	antidepressant	O
7	drugs	O
8	.	O

0	RESULTS	O
1	:	O
2	The	O
3	cardiac	O
4	index	O
5	significantly	O
6	changed	O
7	with	O
8	varying	O
9	PaCO2	O
10	levels	O
11	(	O
12	hypocapnia	O
13	,	O
14	-	O
15	9	O
16	%;	O
17	hypercapnia	O
18	,	O
19	13	O
20	%).	O

0	Guiding	O
1	patients	O
2	in	O
3	the	O
4	decision	O
5	should	O
6	involve	O
7	a	O
8	multidisciplinary	O
9	team	O
10	composed	O
11	of	O
12	a	O
13	surgical	O
14	oncologist	O
15	,	O
16	geneticist	O
17	,	O
18	pathologist	O
19	,	O
20	psychotherapist	O
21	and	O
22	plastic	O
23	surgeon	O
24	.	O

0	Proximal	O
1	CBD	O
2	was	O
3	inversely	O
4	correlated	O
5	with	O
6	bone	B
7	alkaline	I
8	phosphatase	I
9	(	O
10	r	O
11	=	O
12	-	O
13	0	O
14	.	O
15	71	O
16	,	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	and	O
24	intact	O
25	PTH	B
26	(	O
27	r	O
28	=	O
29	-	O
30	0	O
31	.	O
32	59	O
33	,	O
34	p	O
35	<	O
36	0	O
37	.	O
38	05	O
39	).	O

0	The	O
1	recently	O
2	developed	O
3	gamma	B
4	-	I
5	interferon	I
6	(	O
7	IFN	B
8	-	I
9	gamma	I
10	)	O
11	assay	O
12	system	O
13	for	O
14	the	O
15	diagnosis	O
16	of	O
17	bovine	O
18	tuberculosis	O
19	in	O
20	cattle	O
21	has	O
22	been	O
23	accredited	O
24	by	O
25	the	O
26	Standing	O
27	Committee	O
28	on	O
29	Agriculture	O
30	for	O
31	use	O
32	in	O
33	Australia	O
34	.	O

0	Propranolol	O
1	(	O
2	Inderal	O
3	)	O
4	administered	O
5	in	O
6	a	O
7	dose	O
8	which	O
9	blocks	O
10	the	O
11	beta	O
12	-	O
13	adrenergic	O
14	apparatus	O
15	of	O
16	the	O
17	heart	O
18	prevents	O
19	the	O
20	development	O
21	of	O
22	the	O
23	positive	O
24	inotropic	O
25	effect	O
26	of	O
27	therapeutic	O
28	doses	O
29	of	O
30	strophanthin	O
31	K	O
32	on	O
33	a	O
34	hypodynamic	O
35	left	O
36	ventricular	O
37	myocardium	O
38	.	O

0	At	O
1	temperatures	O
2	permissive	O
3	for	O
4	transformation	O
5	,	O
6	6m2	O
7	cells	O
8	contain	O
9	P58gag	B
10	produced	O
11	from	O
12	the	O
13	4	O
14	.	O
15	0	O
16	-	O
17	kilobase	O
18	(	O
19	kb	O
20	)	O
21	viral	O
22	RNA	O
23	genome	O
24	and	O
25	P85gag	B
26	-	O
27	mos	B
28	translated	O
29	from	O
30	a	O
31	3	O
32	.	O
33	5	O
34	-	O
35	kb	O
36	spliced	O
37	mRNA	O
38	.	O

0	In	O
1	controls	O
2	,	O
3	most	O
4	of	O
5	the	O
6	output	O
7	from	O
8	the	O
9	conduit	O
10	occurred	O
11	during	O
12	type	O
13	I	O
14	activity	O
15	(	O
16	73	O
17	+/-	O
18	14	O
19	%).	O

0	These	O
1	results	O
2	support	O
3	a	O
4	model	O
5	in	O
6	which	O
7	p53	B
8	protein	I
9	contributes	O
10	to	O
11	the	O
12	maintenance	O
13	of	O
14	genomic	O
15	integrity	O
16	through	O
17	recombinational	O
18	repair	O
19	.	O

0	Evolutive	O
1	morphology	O
2	of	O
3	the	O
4	olfactory	O
5	bulb	O
6	in	O
7	man	O
8	and	O
9	certain	O
10	non	O
11	-	O
12	human	O
13	mammals	O

0	Reperfusion	O
1	caused	O
2	a	O
3	transient	O
4	reduction	O
5	in	O
6	lactate	O
7	production	O
8	and	O
9	a	O
10	significant	O
11	increase	O
12	in	O
13	LDH	B
14	release	O
15	.	O

0	Human	O
1	papillomavirus	O
2	type	O
3	31b	O
4	late	O
5	gene	O
6	expression	O
7	is	O
8	regulated	O
9	through	O
10	protein	B
11	kinase	I
12	C	I
13	-	O
14	mediated	O
15	changes	O
16	in	O
17	RNA	O
18	processing	O
19	.	O

0	It	O
1	seems	O
2	that	O
3	the	O
4	way	O
5	in	O
6	which	O
7	drugs	O
8	modify	O
9	a	O
10	patient	O
11	'	O
12	s	O
13	serum	O
14	chemistry	O
15	may	O
16	be	O
17	used	O
18	to	O
19	assess	O
20	the	O
21	efficacy	O
22	with	O
23	which	O
24	they	O
25	control	O
26	the	O
27	inflammatory	O
28	process	O
29	.	O

0	Standard	O
1	reference	O
2	sources	O
3	indicate	O
4	that	O
5	an	O
6	able	O
7	-	O
8	bodied	O
9	11	O
10	-	O
11	year	O
12	-	O
13	old	O
14	child	O
15	of	O
16	comparable	O
17	height	O
18	requires	O
19	1	O
20	,	O
21	493	O
22	kcal	O
23	/	O
24	d	O
25	for	O
26	support	O
27	of	O
28	basal	O
29	metabolic	O
30	functions	O
31	.	O

0	Diagnostic	O
1	importance	O
2	of	O
3	determining	O
4	the	O
5	complement	O
6	constituents	O
7	in	O
8	children	O
9	with	O
10	autoimmune	O
11	thyroiditis	O

0	The	O
1	Cr	O
2	.	O
3	psbA	O
4	-	O
5	4	O
6	ORF	O
7	contains	O
8	an	O
9	H	O
10	-	O
11	N	O
12	-	O
13	H	O
14	motif	O
15	,	O
16	and	O
17	possibly	O
18	a	O
19	GIY	O
20	-	O
21	YIG	O
22	motif	O
23	.	O

0	Effects	O
1	of	O
2	early	O
3	monocular	O
4	deprivation	O
5	on	O
6	development	O
7	of	O
8	cortico	O
9	-	O
10	geniculate	O
11	projections	O
12	in	O
13	the	O
14	cat	O
15	.	O

0	The	O
1	'	O
2	field	O
3	of	O
4	stress	O
5	'	O
6	of	O
7	the	O
8	supervisory	O
9	nurse	O

0	Incorporation	O
1	of	O
2	the	O
3	polyene	O
4	antibiotic	O
5	amphotericin	O
6	B	O
7	(	O
8	AMB	O
9	)	O
10	in	O
11	liposomes	O
12	results	O
13	in	O
14	a	O
15	marked	O
16	reduction	O
17	in	O
18	drug	O
19	toxicity	O
20	with	O
21	no	O
22	loss	O
23	of	O
24	antifungal	O
25	potency	O
26	.	O

0	Post	O
1	-	O
2	operative	O
3	functional	O
4	outcome	O
5	is	O
6	related	O
7	to	O
8	pre	O
9	-	O
10	operative	O
11	functional	O
12	status	O
13	.	O

0	This	O
1	approach	O
2	enables	O
3	the	O
4	sources	O
5	of	O
6	error	O
7	in	O
8	the	O
9	calculation	O
10	of	O
11	nutrient	O
12	utilization	O
13	to	O
14	be	O
15	readily	O
16	identified	O
17	,	O
18	and	O
19	their	O
20	effect	O
21	on	O
22	precision	O
23	to	O
24	be	O
25	assessed	O
26	in	O
27	different	O
28	nutritional	O
29	and	O
30	metabolic	O
31	states	O
32	.	O

0	Statement	O
1	of	O
2	the	O
3	American	O
4	Academy	O
5	of	O
6	Implant	O
7	Dentistry	O
8	.	O

0	Following	O
1	the	O
2	injection	O
3	of	O
4	PGF2	O
5	alpha	O
6	,	O
7	heifers	O
8	were	O
9	observed	O
10	visually	O
11	for	O
12	signs	O
13	of	O
14	estrus	O
15	at	O
16	0730	O
17	and	O
18	1630	O
19	(	O
20	45	O
21	min	O
22	each	O
23	).	O

0	Further	O
1	characterization	O
2	of	O
3	these	O
4	putative	O
5	Hoxa	B
6	-	I
7	1	I
8	target	I
9	genes	I
10	will	O
11	aid	O
12	in	O
13	delineating	O
14	the	O
15	functions	O
16	of	O
17	the	O
18	Hoxa	B
19	-	I
20	1	I
21	protein	I
22	in	O
23	the	O
24	differentiation	O
25	processes	O
26	which	O
27	occur	O
28	during	O
29	embryogenesis	O
30	.	O

0	A	O
1	prospective	O
2	observational	O
3	study	O
4	was	O
5	conducted	O
6	to	O
7	identify	O
8	early	O
9	indicators	O
10	of	O
11	acute	O
12	dengue	O
13	virus	O
14	infection	O
15	.	O

0	Transactivation	O
1	of	O
2	naturally	O
3	occurring	O
4	HIV	O
5	-	O
6	1	O
7	long	O
8	terminal	O
9	repeats	O
10	by	O
11	the	O
12	JNK	B
13	signaling	O
14	pathway	O
15	.	O

0	A	O
1	rather	O
2	similar	O
3	pattern	O
4	of	O
5	results	O
6	was	O
7	obtained	O
8	with	O
9	respect	O
10	to	O
11	LMP2B	B
12	mRNA	I
13	expression	O
14	,	O
15	such	O
16	transcripts	O
17	being	O
18	detectable	O
19	only	O
20	in	O
21	a	O
22	subset	O
23	of	O
24	tumors	O
25	,	O
26	and	O
27	then	O
28	at	O
29	apparently	O
30	low	O
31	levels	O
32	.	O

0	The	O
1	mean	O
2	values	O
3	of	O
4	the	O
5	first	O
6	three	O
7	components	O
8	were	O
9	not	O
10	significantly	O
11	different	O
12	in	O
13	ARVD	O
14	patients	O
15	and	O
16	control	O
17	subjects	O
18	.	O

0	We	O
1	have	O
2	isolated	O
3	a	O
4	binding	O
5	partner	O
6	for	O
7	the	O
8	Fanconi	B
9	anemia	B
10	group	I
11	C	I
12	protein	I
13	(	O
14	FANCC	B
15	)	O
16	by	O
17	yeast	O
18	two	O
19	-	O
20	hybrid	O
21	screening	O
22	.	O

0	In	O
1	addition	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	production	O
8	of	O
9	active	O
10	recombinant	B
11	telomerase	I
12	requires	O
13	a	O
14	factor	O
15	in	O
16	rabbit	O
17	reticulocyte	O
18	lysate	O
19	that	O
20	promotes	O
21	ribonucleoprotein	O
22	assembly	O
23	.	O

0	From	O
1	all	O
2	clinically	O
3	important	O
4	yeasts	O
5	species	O
6	,	O
7	a	O
8	total	O
9	of	O
10	96	O
11	%	O
12	were	O
13	identified	O
14	by	O
15	ATB	O
16	method	O
17	according	O
18	to	O
19	conventional	O
20	methods	O
21	.	O

0	This	O
1	element	O
2	,	O
3	termed	O
4	CREsp	B
5	-	O
6	a	O
7	(	O
8	TGACCTCA	O
9	),	O
10	differs	O
11	by	O
12	one	O
13	nucleotide	O
14	from	O
15	a	O
16	palindromic	O
17	CRE	O
18	(	O
19	CREpal	O
20	,	O
21	TGACGTCA	O
22	),	O
23	which	O
24	is	O
25	known	O
26	to	O
27	bind	O
28	CREB	B
29	as	O
30	a	O
31	homodimer	O
32	.	O

0	In	O
1	addition	O
2	,	O
3	both	O
4	the	O
5	exon	O
6	1	O
7	-	O
8	and	O
9	exon	O
10	2	O
11	-	O
12	initiated	O
13	forms	O
14	of	O
15	the	O
16	c	B
17	-	I
18	Myc	I
19	protein	I
20	stimulated	O
21	transcription	O
22	of	O
23	a	O
24	Myc	B
25	/	O
26	Max	B
27	-	O
28	responsive	O
29	reporter	O
30	construct	O
31	to	O
32	a	O
33	similar	O
34	level	O
35	.	O

0	74	O
1	,	O
2	193	O
3	-	O
4	197	O
5	).	O

0	Two	O
1	evolutionarily	O
2	conserved	O
3	kinases	O
4	,	O
5	the	O
6	cyclin	B
7	B	I
8	(	O
9	Clb	B
10	)/	O
11	cyclin	B
12	-	I
13	dependent	I
14	kinase	I
15	(	O
16	Cdk	B
17	/	O
18	Cdc28p	B
19	)	O
20	and	O
21	Cdc7p	B
22	along	O
23	with	O
24	its	O
25	interacting	O
26	factor	O
27	Dbf4p	B
28	,	O
29	are	O
30	required	O
31	late	O
32	in	O
33	G1	O
34	to	O
35	initiate	O
36	DNA	O
37	replication	O
38	.	O

0	Thus	O
1	,	O
2	the	O
3	effects	O
4	of	O
5	father	O
6	absence	O
7	under	O
8	routine	O
9	conditions	O
10	in	O
11	relatively	O
12	healthy	O
13	samples	O
14	may	O
15	exert	O
16	no	O
17	significant	O
18	effects	O
19	independent	O
20	of	O
21	intervening	O
22	family	O
23	stressors	O
24	or	O
25	maternal	O
26	psychopathology	O
27	.	O

0	In	O
1	previous	O
2	work	O
3	(	O
4	E	O
5	.	O

0	Perturbation	O
1	of	O
2	dNTP	O
3	pools	O
4	also	O
5	affected	O
6	the	O
7	frameshift	O
8	fidelity	O
9	of	O
10	the	O
11	replicative	O
12	yeast	B
13	DNA	I
14	polymerase	I
15	alpha	I
16	.	O

0	We	O
1	obtained	O
2	quantitative	O
3	evidence	O
4	on	O
5	the	O
6	coding	O
7	of	O
8	interaural	O
9	time	O
10	differences	O
11	(	O
12	ITDs	O
13	)	O
14	of	O
15	click	O
16	stimuli	O
17	by	O
18	40	O
19	single	O
20	neurons	O
21	in	O
22	the	O
23	auditory	O
24	cortex	O
25	of	O
26	anesthetized	O
27	albino	O
28	rats	O
29	.	O

0	The	O
1	mechanism	O
2	by	O
3	which	O
4	large	O
5	molecules	O
6	,	O
7	such	O
8	as	O
9	the	O
10	diphosphonate	O
11	99mTc	O
12	-	O
13	labeled	O
14	EHDP	O
15	or	O
16	99mTc	O
17	-	O
18	labeled	O
19	pyrophosphate	O
20	,	O
21	pass	O
22	through	O
23	capillaries	O
24	in	O
25	bone	O
26	is	O
27	by	O
28	passive	O
29	diffusion	O
30	.	O

0	No	O
1	homology	O
2	was	O
3	found	O
4	between	O
5	the	O
6	36K	B
7	protein	I
8	and	O
9	known	O
10	structures	O
11	of	O
12	proteins	O
13	.	O

0	In	O
1	contrast	O
2	to	O
3	the	O
4	wild	O
5	-	O
6	type	O
7	protein	O
8	,	O
9	expression	O
10	of	O
11	p45	B
12	NF	I
13	-	I
14	E2	I
15	lacking	O
16	this	O
17	activation	O
18	domain	O
19	in	O
20	an	O
21	NF	B
22	-	I
23	E2	I
24	null	O
25	cell	O
26	line	O
27	fails	O
28	to	O
29	support	O
30	enhancer	O
31	-	O
32	dependent	O
33	transcription	O
34	in	O
35	transient	O
36	assays	O
37	.	O

0	Taken	O
1	together	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	Mif2	B
9	protein	I
10	interacts	O
11	with	O
12	Cep1p	B
13	at	O
14	the	O
15	centromere	O
16	and	O
17	that	O
18	the	O
19	yeast	O
20	centromere	O
21	indeed	O
22	exists	O
23	as	O
24	a	O
25	higher	O
26	order	O
27	protein	O
28	-	O
29	DNA	O
30	complex	O
31	.	O

0	Moreover	O
1	,	O
2	the	O
3	same	O
4	mutations	O
5	alter	O
6	the	O
7	structure	O
8	of	O
9	junB	B
10	5	I
11	'	O
12	flanking	O
13	DNA	O
14	within	O
15	chromatin	O
16	.	O

0	Five	O
1	women	O
2	(	O
3	15	O
4	.	O
5	6	O
6	%)	O
7	met	O
8	criteria	O
9	for	O
10	PMS	O
11	.	O

0	The	O
1	first	O
2	contains	O
3	ATF	B
4	/	O
5	CRE	B
6	and	O
7	TBP	B
8	/	O
9	TATA	O
10	sequence	O
11	motifs	O
12	within	O
13	an	O
14	87	O
15	-	O
16	bp	O
17	region	O
18	.	O

0	Differential	O
1	expression	O
2	was	O
3	confirmed	O
4	by	O
5	Northern	O
6	blot	O
7	analysis	O
8	employing	O
9	multiple	O
10	normal	O
11	and	O
12	tumor	O
13	cell	O
14	lines	O
15	.	O

0	Kinase	B
1	-	O
2	deficient	O
3	erbB	B
4	proteins	I
5	reduced	O
6	epidermal	B
7	growth	I
8	factor	I
9	(	O
10	EGF	B
11	)-	O
12	induced	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	endogenous	B
17	Shc	I
18	proteins	I
19	and	O
20	also	O
21	reduced	O
22	immediate	O
23	and	O
24	sustained	O
25	EGF	B
26	-	O
27	induced	O
28	ERK	B
29	MAPK	I
30	activities	O
31	in	O
32	human	O
33	glioblastoma	O
34	cells	O
35	,	O
36	although	O
37	basal	O
38	ERK	B
39	MAPK	I
40	activities	O
41	were	O
42	unaffected	O
43	.	O

0	The	O
1	zona	O
2	pellucida	O
3	(	O
4	ZP	O
5	),	O
6	the	O
7	extracellular	O
8	glycocalyx	O
9	that	O
10	surrounds	O
11	the	O
12	oocyte	O
13	,	O
14	is	O
15	well	O
16	known	O
17	to	O
18	mediate	O
19	homologous	O
20	gamete	O
21	interaction	O
22	.	O

0	Flurazepam	O
1	thus	O
2	appears	O
3	to	O
4	be	O
5	an	O
6	effective	O
7	hypnotic	O
8	drug	O
9	with	O
10	the	O
11	optimum	O
12	dose	O
13	for	O
14	use	O
15	in	O
16	general	O
17	practice	O
18	being	O
19	15	O
20	mg	O
21	at	O
22	night	O
23	.	O

0	Variables	O
1	evaluated	O
2	were	O
3	number	O
4	of	O
5	weekly	O
6	anginal	O
7	events	O
8	,	O
9	data	O
10	from	O
11	ergometric	O
12	exercise	O
13	testing	O
14	with	O
15	simultaneous	O
16	electrocardiographic	O
17	registration	O
18	,	O
19	semiquantitative	O
20	evaluation	O
21	of	O
22	Tc	O
23	-	O
24	99m	O
25	2	O
26	-	O
27	methoxy	O
28	isobutyl	O
29	isonitrile	O
30	(	O
31	MIBI	O
32	)	O
33	scans	O
34	and	O
35	rheologic	O
36	variables	O
37	.	O

0	CONCLUSION	O
1	:	O
2	In	O
3	Cdks	B
4	functioning	O
5	throughout	O
6	the	O
7	cell	O
8	cycle	O
9	,	O
10	tyrosine	O
11	phosphorylation	O
12	is	O
13	inhibitory	O
14	to	O
15	the	O
16	activation	O
17	of	O
18	kinase	O
19	,	O
20	whereas	O
21	the	O
22	phosphorylation	O
23	of	O
24	threonine	O
25	in	O
26	the	O
27	T	O
28	-	O
29	loop	O
30	is	O
31	essential	O
32	for	O
33	activation	O
34	.	O

0	TGF	B
1	beta	I
2	1	I
3	expression	O
4	is	O
5	largely	O
6	governed	O
7	by	O
8	three	O
9	AP	B
10	-	I
11	1	I
12	binding	I
13	sites	I
14	located	O
15	in	O
16	two	O
17	different	O
18	promoters	O
19	of	O
20	this	O
21	gene	O
22	.	O

0	References	O
1	for	O
2	occupational	O
3	fitness	O
4	of	O
5	adolescents	O
6	with	O
7	diseases	O
8	of	O
9	the	O
10	respiratory	O
11	tract	O
12	and	O
13	lungs	O

0	In	O
1	the	O
2	rat	B
3	rnu	I
4	allele	I
5	described	O
6	here	O
7	,	O
8	a	O
9	nonsense	O
10	mutation	O
11	in	O
12	exon	O
13	8	O
14	of	O
15	the	O
16	whn	B
17	gene	I
18	was	O
19	identified	O
20	.	O

0	A	O
1	total	O
2	of	O
3	1060	O
4	clones	O
5	were	O
6	randomly	O
7	selected	O
8	for	O
9	sequencing	O
10	of	O
11	one	O
12	end	O
13	.	O

0	However	O
1	,	O
2	the	O
3	same	O
4	U1A	B
5	peptide	I
6	,	O
7	when	O
8	conjugated	O
9	to	O
10	BSA	B
11	,	O
12	inhibits	O
13	vertebrate	O
14	PAP	B
15	.	O

0	Intron	B
1	8	I
2	harbored	O
3	a	O
4	strong	O
5	erythroid	O
6	-	O
7	specific	O
8	enhancer	O
9	activity	O
10	which	O
11	was	O
12	orientation	O
13	-	O
14	dependent	O
15	.	O

0	Orientation	O
1	of	O
2	the	O
3	nuclear	O
4	spin	O
5	system	O
6	by	O
7	optical	O
8	pumping	O
9	causes	O
10	an	O
11	Overhauser	O
12	shift	O
13	of	O
14	the	O
15	excitonic	O
16	energy	O
17	levels	O
18	proportional	O
19	to	O
20	the	O
21	degree	O
22	of	O
23	nuclear	O
24	orientation	O
25	.	O

0	Class	B
1	I	I
2	alpha1	I
3	,	I
4	2	I
5	-	I
6	mannosidases	I
7	play	O
8	an	O
9	essential	O
10	role	O
11	in	O
12	the	O
13	elaboration	O
14	of	O
15	complex	O
16	and	O
17	hybrid	O
18	N	O
19	-	O
20	glycans	O
21	in	O
22	mammalian	O
23	cells	O
24	.	O

0	The	O
1	effects	O
2	of	O
3	tap	O
4	(	O
5	TW	O
6	)	O
7	or	O
8	carbonated	O
9	(	O
10	CW	O
11	)	O
12	water	O
13	on	O
14	arterial	O
15	pH	O
16	,	O
17	partial	O
18	pressure	O
19	of	O
20	carbon	O
21	dioxide	O
22	(	O
23	PCO2	O
24	)	O
25	and	O
26	plasma	O
27	lactate	O
28	were	O
29	determined	O
30	in	O
31	heat	O
32	-	O
33	stressed	O
34	broilers	O
35	.	O

0	These	O
1	results	O
2	suggest	O
3	an	O
4	increased	O
5	risk	O
6	of	O
7	developing	O
8	cancer	O
9	among	O
10	polyp	O
11	patients	O
12	and	O
13	the	O
14	possibility	O
15	of	O
16	prophylactic	O
17	effect	O
18	of	O
19	polypectomy	O
20	against	O
21	subsequent	O
22	cancer	O
23	.	O

0	OKA	B
1	and	O
2	calyculin	B
3	A	I
4	do	O
5	not	O
6	decrease	O
7	OCFRE	O
8	DNA	O
9	-	O
10	protein	O
11	interactions	O
12	,	O
13	suggesting	O
14	that	O
15	important	O
16	protein	O
17	-	O
18	protein	O
19	interactions	O
20	are	O
21	phosphatase	O
22	regulated	O
23	.	O

0	Mean	O
1	total	O
2	lung	O
3	capacity	O
4	,	O
5	functional	O
6	residual	O
7	capacity	O
8	,	O
9	and	O
10	residual	O
11	volume	O
12	increased	O
13	significantly	O
14	,	O
15	and	O
16	the	O
17	mean	O
18	closing	O
19	volume	O
20	,	O
21	the	O
22	lung	O
23	volume	O
24	above	O
25	residual	O
26	volume	O
27	at	O
28	which	O
29	phase	O
30	IV	O
31	begins	O
32	,	O
33	decreased	O
34	significantly	O
35	with	O
36	11	O
37	cm	O
38	H20	O
39	continuous	O
40	positive	O
41	airway	O
42	pressure	O
43	;	O
44	differences	O
45	at	O
46	5	O
47	cm	O
48	H20	O
49	were	O
50	not	O
51	significant	O
52	.	O

0	Wnt	B
1	-	I
2	1	I
3	(	O
4	int	B
5	-	I
6	1	I
7	)	O
8	is	O
9	a	O
10	cellular	O
11	oncogene	O
12	often	O
13	activated	O
14	by	O
15	insertion	O
16	of	O
17	proviral	O
18	DNA	O
19	of	O
20	the	O
21	mouse	O
22	mammary	O
23	tumor	O
24	virus	O
25	.	O

0	Differential	O
1	expression	O
2	of	O
3	the	O
4	"	O
5	B	O
6	"	O
7	subunit	O
8	of	O
9	the	O
10	vacuolar	B
11	H	I
12	(+)-	I
13	ATPase	I
14	in	O
15	bovine	O
16	tissues	O
17	.	O

0	Role	O
1	of	O
2	the	O
3	infectious	O
4	-	O
5	disease	O
6	specialist	O
7	of	O
8	a	O
9	polyclinic	O
10	in	O
11	reducing	O
12	the	O
13	incidence	O
14	of	O
15	communicable	O
16	diseases	O

0	For	O
1	Al	O
2	,	O
3	the	O
4	exposure	O
5	to	O
6	1	O
7	.	O
8	36	O
9	mg	O
10	/	O
11	m3	O
12	during	O
13	the	O
14	shift	O
15	corresponded	O
16	to	O
17	a	O
18	urinary	O
19	concentration	O
20	at	O
21	the	O
22	end	O
23	of	O
24	the	O
25	shift	O
26	of	O
27	200	O
28	microgram	O
29	/	O
30	g	O
31	creatinine	O
32	.	O

0	Current	O
1	status	O
2	of	O
3	chemotherapy	O
4	for	O
5	Hodgkin	O
6	'	O
7	s	O
8	disease	O

0	Thus	O
1	,	O
2	the	O
3	predicted	O
4	CD30v	B
5	protein	I
6	retains	O
7	most	O
8	of	O
9	the	O
10	cytoplasmic	O
11	region	O
12	,	O
13	but	O
14	lacks	O
15	the	O
16	extracellular	O
17	and	O
18	transmembrane	O
19	domains	O
20	.	O

0	The	O
1	predicted	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	the	O
7	SGC1	B
8	gene	I
9	product	I
10	includes	O
11	a	O
12	region	O
13	with	O
14	substantial	O
15	similarity	O
16	to	O
17	the	O
18	basic	O
19	-	O
20	helix	O
21	-	O
22	loop	O
23	-	O
24	helix	O
25	domain	O
26	of	O
27	the	O
28	Myc	B
29	family	I
30	of	O
31	DNA	O
32	-	O
33	binding	O
34	proteins	O
35	.	O

0	Splice	O
1	-	O
2	junction	O
3	elements	O
4	and	O
5	intronic	O
6	sequences	O
7	regulate	O
8	alternative	O
9	splicing	O
10	of	O
11	the	O
12	Drosophila	B
13	myosin	I
14	heavy	I
15	chain	I
16	gene	I
17	transcript	I
18	.	O

0	A	O
1	5	O
2	.	O
3	0	O
4	-	O
5	kb	O
6	transcript	O
7	detected	O
8	by	O
9	the	O
10	differential	O
11	display	O
12	amplicon	O
13	3G1	O
14	was	O
15	found	O
16	to	O
17	correlate	O
18	strongly	O
19	with	O
20	RAG1	B
21	mRNA	I
22	expression	O
23	in	O
24	various	O
25	human	O
26	cell	O
27	lines	O
28	.	O

0	Umweltchem	O
1	.	O

0	No	O
1	difference	O
2	in	O
3	telomere	O
4	length	O
5	was	O
6	seen	O
7	in	O
8	mutants	O
9	affected	O
10	in	O
11	the	O
12	regulation	O
13	of	O
14	Cdc2	B
15	,	O
16	whereas	O
17	some	O
18	of	O
19	the	O
20	DNA	O
21	repair	O
22	mutants	O
23	examined	O
24	had	O
25	slightly	O
26	longer	O
27	telomeres	O
28	than	O
29	did	O
30	the	O
31	wild	O
32	type	O
33	.	O

0	Toxicity	O
1	during	O
2	the	O
3	therapeutic	O
4	period	O
5	was	O
6	not	O
7	significant	O
8	in	O
9	the	O
10	study	O
11	group	O
12	compared	O
13	with	O
14	the	O
15	historical	O
16	control	O
17	,	O
18	treated	O
19	with	O
20	the	O
21	same	O
22	regimen	O
23	without	O
24	G	B
25	-	I
26	CSF	I
27	.	O

0	They	O
1	suggest	O
2	that	O
3	decreased	O
4	steady	O
5	-	O
6	state	O
7	levels	O
8	of	O
9	IME1	B
10	and	O
11	IME2	B
12	mRNA	I
13	were	O
14	not	O
15	merely	O
16	the	O
17	result	O
18	of	O
19	non	O
20	-	O
21	specific	O
22	adverse	O
23	affects	O
24	on	O
25	nucleic	O
26	acid	O
27	metabolism	O
28	caused	O
29	by	O
30	the	O
31	yvh1	B
32	disruption	O
33	.	O

0	This	O
1	vector	O
2	transfected	O
3	into	O
4	the	O
5	yeast	O
6	Saccharomyces	O
7	cerevisiae	O
8	directs	O
9	expression	O
10	of	O
11	a	O
12	secreted	O
13	mature	O
14	protein	O
15	at	O
16	levels	O
17	up	O
18	to	O
19	200	O
20	mg	O
21	of	O
22	LAPP	O
23	/	O
24	liter	O
25	of	O
26	culture	O
27	medium	O
28	.	O

0	Here	O
1	we	O
2	investigate	O
3	the	O
4	role	O
5	of	O
6	c	B
7	-	I
8	Cbl	I
9	in	O
10	development	O
11	and	O
12	homeostasis	O
13	in	O
14	mice	O
15	by	O
16	targeted	O
17	disruption	O
18	of	O
19	the	O
20	c	B
21	-	I
22	Cbl	I
23	locus	I
24	.	O
25	c	B
26	-	I
27	Cbl	I
28	-	O
29	deficient	O
30	mice	O
31	were	O
32	viable	O
33	,	O
34	fertile	O
35	,	O
36	and	O
37	outwardly	O
38	normal	O
39	in	O
40	appearance	O
41	.	O

0	Lars	O
1	has	O
2	AIDS	O
3	--	O
4	a	O
5	more	O
6	dignified	O
7	life	O
8	with	O
9	care	O
10	at	O
11	home	O
12	.	O

0	Between	O
1	the	O
2	subgroups	O
3	of	O
4	dementia	O
5	disorders	O
6	there	O
7	were	O
8	no	O
9	significant	O
10	differences	O
11	in	O
12	basal	O
13	cortisol	O
14	levels	O
15	.	O

0	Compared	O
1	to	O
2	controls	O
3	,	O
4	both	O
5	UB	O
6	and	O
7	OCS	O
8	rats	O
9	showed	O
10	a	O
11	small	O
12	but	O
13	significant	O
14	post	O
15	-	O
16	operative	O
17	reduction	O
18	in	O
19	the	O
20	nocturnality	O
21	of	O
22	drinking	O
23	.	O

0	The	O
1	frequency	O
2	of	O
3	integrations	O
4	that	O
5	led	O
6	to	O
7	transcription	O
8	of	O
9	the	O
10	lacZ	B
11	gene	I
12	was	O
13	estimated	O
14	to	O
15	be	O
16	0	O
17	.	O
18	5	O
19	%	O
20	of	O
21	all	O
22	integrations	O
23	,	O
24	of	O
25	which	O
26	14	O
27	%	O
28	were	O
29	downregulated	O
30	on	O
31	differentiation	O
32	of	O
33	32D	O
34	cells	O
35	towards	O
36	neutrophils	O
37	.	O

0	We	O
1	identify	O
2	the	O
3	"	O
4	M	O
5	region	O
6	"	O
7	of	O
8	the	O
9	muscle	B
10	-	I
11	specific	I
12	Xenopus	I
13	cardiac	I
14	actin	I
15	gene	I
16	promoter	I
17	from	O
18	-	O
19	282	O
20	to	O
21	-	O
22	348	O
23	as	O
24	necessary	O
25	for	O
26	the	O
27	embryonic	O
28	expression	O
29	of	O
30	a	O
31	cardiac	B
32	actin	I
33	-	I
34	beta	I
35	-	I
36	globin	I
37	reporter	O
38	gene	O
39	injected	O
40	into	O
41	fertilized	O
42	eggs	O
43	.	O

0	The	O
1	average	O
2	coefficients	O
3	of	O
4	correlation	O
5	were	O
6	0	O
7	.	O
8	9998	O
9	and	O
10	0	O
11	.	O
12	9993	O
13	for	O
14	the	O
15	QMF	O
16	and	O
17	the	O
18	QIT	O
19	system	O
20	,	O
21	respectively	O
22	.	O

0	The	O
1	conservation	O
2	of	O
3	both	O
4	the	O
5	G	O
6	-	O
7	box	O
8	and	O
9	H	O
10	-	O
11	box	O
12	in	O
13	different	O
14	CHS	B
15	promoters	I
16	emphasizes	O
17	their	O
18	importance	O
19	as	O
20	regulatory	O
21	motifs	O
22	.	O

0	Pituitary	B
1	adenylate	I
2	cyclase	I
3	-	I
4	activating	I
5	polypeptide	I
6	regulates	O
7	prolactin	B
8	promoter	I
9	activity	O
10	via	O
11	a	O
12	protein	B
13	kinase	I
14	A	I
15	-	O
16	mediated	O
17	pathway	O
18	that	O
19	is	O
20	independent	O
21	of	O
22	the	O
23	transcriptional	O
24	pathway	O
25	employed	O
26	by	O
27	thyrotropin	B
28	-	I
29	releasing	I
30	hormone	I
31	.	O

0	A	O
1	portion	O
2	of	O
3	p193	B
4	is	O
5	nuclear	O
6	and	O
7	localizes	O
8	to	O
9	the	O
10	mitotic	O
11	spindle	O
12	.	O

0	Nevertheless	O
1	,	O
2	protein	B
3	kinase	I
4	A	I
5	stimulation	O
6	induces	O
7	CREMalpha	B
8	to	O
9	activate	O
10	the	O
11	complex	O
12	native	O
13	promoter	O
14	in	O
15	the	O
16	phosphoenolpyruvate	B
17	carboxykinase	I
18	(	O
19	PEPCK	B
20	)	O
21	gene	O
22	.	O

0	Treatment	O
1	is	O
2	instituted	O
3	with	O
4	prednisone	O
5	and	O
6	cyclophosphamide	O
7	.	O

0	Habituation	O
1	of	O
2	completely	O
3	isolated	O
4	neurons	O
5	of	O
6	the	O
7	edible	O
8	snail	O
9	to	O
10	electrical	O
11	stimulation	O
12	.	O

0	Sestamibi	O
1	scintigraphy	O
2	,	O
3	performed	O
4	in	O
5	70	O
6	patients	O
7	,	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	ultrasonography	O
13	(	O
14	80	O
15	%).	O

0	RESULTS	O
1	:	O
2	Fournier	O
3	'	O
4	s	O
5	gangrene	O
6	occurs	O
7	worldwide	O
8	.	O

0	The	O
1	complement	B
2	C3a	I
3	anaphylatoxin	I
4	receptor	I
5	(	O
6	C3aR	B
7	)	O
8	is	O
9	a	O
10	seven	B
11	-	I
12	transmembrane	I
13	G	I
14	-	I
15	protein	I
16	coupled	I
17	chemoattractant	I
18	receptor	I
19	that	O
20	on	O
21	binding	O
22	the	O
23	C3a	B
24	peptide	O
25	ligand	O
26	mediates	O
27	numerous	O
28	cellular	O
29	responses	O
30	,	O
31	including	O
32	histamine	O
33	release	O
34	from	O
35	mast	O
36	cells	O
37	.	O
38	smooth	O
39	muscle	O
40	contraction	O
41	,	O
42	and	O
43	the	O
44	directed	O
45	migration	O
46	of	O
47	eosinophils	O
48	.	O

0	Based	O
1	on	O
2	these	O
3	results	O
4	,	O
5	a	O
6	new	O
7	model	O
8	for	O
9	the	O
10	regulation	O
11	of	O
12	nif	B
13	/	O
14	fix	B
15	gene	I
16	expression	O
17	in	O
18	A	O
19	.	O
20	caulinodans	O
21	is	O
22	proposed	O
23	.	O

0	Persistent	O
1	activation	O
2	of	O
3	mitogen	B
4	-	I
5	activated	I
6	protein	I
7	kinases	I
8	p42	I
9	and	O
10	p44	B
11	and	O
12	ets	B
13	-	I
14	2	I
15	phosphorylation	O
16	in	O
17	response	O
18	to	O
19	colony	B
20	-	I
21	stimulating	I
22	factor	I
23	1	I
24	/	O
25	c	B
26	-	I
27	fms	I
28	signaling	O
29	.	O

0	To	O
1	clarify	O
2	whether	O
3	seizure	O
4	-	O
5	offset	O
6	patterns	O
7	are	O
8	reliable	O
9	in	O
10	predicting	O
11	seizure	O
12	outcome	O
13	,	O
14	we	O
15	studied	O
16	SEEG	O
17	/	O
18	ECoG	O
19	in	O
20	a	O
21	similar	O
22	group	O
23	of	O
24	patients	O
25	with	O
26	temporal	O
27	lobe	O
28	epilepsy	O
29	(	O
30	TLE	O
31	).	O

0	A	O
1	case	O
2	of	O
3	AIDS	O
4	-	O
5	related	O
6	complex	O
7	(	O
8	ARC	O
9	/	O
10	LAS	O
11	)	O
12	in	O
13	a	O
14	health	O
15	worker	O

0	The	O
1	matrix	O
2	surrounding	O
3	the	O
4	clusters	O
5	either	O
6	showed	O
7	a	O
8	normal	O
9	morphology	O
10	or	O
11	a	O
12	homogeneous	O
13	appearance	O
14	,	O
15	within	O
16	which	O
17	faint	O
18	cross	O
19	striations	O
20	but	O
21	no	O
22	distinctly	O
23	fibrillar	O
24	outlines	O
25	could	O
26	be	O
27	identified	O
28	.	O

0	When	O
1	cotransfected	O
2	in	O
3	fibroblasts	O
4	with	O
5	a	O
6	C	B
7	/	I
8	EBP	I
9	alpha	I
10	expression	O
11	vector	O
12	,	O
13	reporter	O
14	gene	O
15	expression	O
16	increased	O
17	3	O
18	-	O
19	fold	O
20	only	O
21	in	O
22	the	O
23	wild	O
24	-	O
25	type	O
26	constructs	O
27	.	O

0	The	O
1	TATA	B
2	box	I
3	-	I
4	binding	I
5	protein	I
6	(	O
7	TBP	B
8	)	O
9	plays	O
10	an	O
11	essential	O
12	role	O
13	in	O
14	transcription	O
15	by	O
16	all	O
17	three	O
18	eukaryotic	B
19	nuclear	I
20	RNA	I
21	polymerases	I
22	,	O
23	polymerases	B
24	(	O
25	Pol	B
26	)	I
27	I	I
28	,	I
29	II	I
30	,	I
31	and	I
32	III	I
33	.	O

0	Rats	O
1	with	O
2	one	O
3	olfactory	O
4	bulb	O
5	removed	O
6	and	O
7	the	O
8	contralateral	O
9	naris	O
10	closed	O
11	can	O
12	detect	O
13	odors	O
14	.	O

0	In	O
1	connective	O
2	tissue	O
3	,	O
4	cell	O
5	structure	O
6	contributes	O
7	to	O
8	type	B
9	I	I
10	collagen	I
11	expression	O
12	.	O

0	Repression	O
1	of	O
2	glucocorticoid	B
3	receptor	I
4	-	O
5	mediated	O
6	transcriptional	O
7	activation	O
8	by	O
9	unliganded	O
10	thyroid	B
11	hormone	I
12	receptor	I
13	(	O
14	TR	B
15	)	O
16	is	O
17	TR	B
18	isoform	O
19	-	O
20	specific	O
21	.	O

0	Sterols	O
1	in	O
2	pollen	O
3	.	O

0	Coronary	O
1	flow	O
2	was	O
3	reduced	O
4	by	O
5	10	O
6	%	O
7	in	O
8	the	O
9	phosphocreatine	O
10	and	O
11	by	O
12	18	O
13	%	O
14	in	O
15	the	O
16	control	O
17	group	O
18	.	O

0	Mutations	O
1	in	O
2	seven	O
3	other	O
4	lts	B
5	genes	I
6	do	O
7	not	O
8	result	O
9	in	O
10	the	O
11	mak	B
12	-	I
13	phenotype	I
14	.	O

0	ALT	O
1	levels	O
2	in	O
3	responders	O
4	were	O
5	lowered	O
6	by	O
7	46	O
8	%	O
9	and	O
10	AST	O
11	levels	O
12	were	O
13	lowered	O
14	by	O
15	35	O
16	%	O
17	after	O
18	12	O
19	weeks	O
20	of	O
21	vitamin	O
22	E	O
23	treatment	O
24	.	O

0	The	O
1	background	O
2	processes	O
3	depending	O
4	on	O
5	the	O
6	etiological	O
7	factor	O
8	and	O
9	the	O
10	character	O
11	of	O
12	lesion	O
13	of	O
14	the	O
15	epithelium	O
16	are	O
17	divided	O
18	into	O
19	dyshormonal	O
20	,	O
21	inflammatory	O
22	,	O
23	and	O
24	posttraumatic	O
25	.	O

0	Isolation	O
1	and	O
2	identification	O
3	of	O
4	genes	O
5	activating	O
6	UAS2	B
7	-	O
8	dependent	O
9	ADH2	B
10	expression	O
11	in	O
12	Saccharomyces	O
13	cerevisiae	O
14	.	O

0	Overall	O
1	,	O
2	lesions	O
3	infiltrating	O
4	the	O
5	deep	O
6	lamina	O
7	propria	O
8	do	O
9	not	O
10	exhibit	O
11	a	O
12	reduced	O
13	frequency	O
14	of	O
15	occurrence	O
16	compared	O
17	to	O
18	lesions	O
19	infiltrating	O
20	the	O
21	skeletal	O
22	muscle	O
23	;	O
24	however	O
25	,	O
26	carcinomas	O
27	affecting	O
28	other	O
29	oral	O
30	sites	O
31	showed	O
32	a	O
33	reduced	O
34	frequency	O
35	of	O
36	deeply	O
37	infiltrating	O
38	lesions	O
39	in	O
40	comparison	O
41	to	O
42	more	O
43	superficial	O
44	lesions	O
45	.	O

0	Movement	O
1	time	O
2	and	O
3	kinematic	O
4	characteristics	O
5	were	O
6	analyzed	O
7	together	O
8	with	O
9	the	O
10	magnitude	O
11	of	O
12	cerebral	O
13	blood	O
14	flow	O
15	to	O
16	identify	O
17	areas	O
18	of	O
19	brain	O
20	activity	O
21	proportionate	O
22	to	O
23	task	O
24	and	O
25	movement	O
26	variables	O
27	.	O

0	Model	O
1	of	O
2	spatiotemporal	O
3	dynamics	O
4	of	O
5	stick	O
6	-	O
7	slip	O
8	motion	O
9	.	O

0	Receptor	B
1	protein	I
2	tyrosine	I
3	phosphatases	I
4	(	O
5	RPTPs	B
6	)	O
7	comprise	O
8	a	O
9	family	O
10	of	O
11	proteins	O
12	that	O
13	feature	O
14	intracellular	O
15	phosphatase	O
16	domains	O
17	and	O
18	an	O
19	ectodomain	B
20	with	O
21	putative	O
22	ligand	O
23	-	O
24	binding	O
25	motifs	O
26	.	O

0	Validation	O
1	of	O
2	the	O
3	survey	O
4	of	O
5	work	O
6	styles	O
7	:	O
8	a	O
9	profile	O
10	measure	O
11	of	O
12	the	O
13	type	O
14	A	O
15	behaviour	O
16	pattern	O
17	.	O

0	The	O
1	relative	O
2	toxicity	O
3	of	O
4	nickel	O
5	oxide	O
6	(	O
7	NiO	O
8	),	O
9	nickel	O
10	sulfate	O
11	hexahydrate	O
12	(	O
13	NiSO4	O
14	.	O
15	6H2O	O
16	),	O
17	and	O
18	nickel	O
19	subsulfide	O
20	(	O
21	Ni3S2	O
22	)	O
23	was	O
24	studied	O
25	in	O
26	F344	O
27	/	O
28	N	O
29	rats	O
30	and	O
31	B6C3F1	O
32	mice	O
33	after	O
34	inhalation	O
35	exposure	O
36	for	O
37	6	O
38	hr	O
39	/	O
40	day	O
41	,	O
42	5	O
43	days	O
44	/	O
45	week	O
46	,	O
47	for	O
48	13	O
49	weeks	O
50	.	O

0	Cloning	O
1	of	O
2	individual	O
3	ZI	B
4	domains	I
5	upstream	O
6	of	O
7	a	O
8	minimal	O
9	promoter	O
10	demonstrated	O
11	that	O
12	the	O
13	ZIA	B
14	,	O
15	ZIC	B
16	,	O
17	and	O
18	ZID	B
19	domains	I
20	,	O
21	but	O
22	not	O
23	the	O
24	ZIB	B
25	domain	I
26	,	O
27	are	O
28	TPA	O
29	responsive	O
30	.	O

0	Serine	O
1	phosphorylation	O
2	of	O
3	STAT3	B
4	was	O
5	only	O
6	apparent	O
7	after	O
8	somatostatin	B
9	treatment	O
10	and	O
11	was	O
12	abolished	O
13	by	O
14	pertussis	B
15	toxin	I
16	or	O
17	PD	B
18	98059	I
19	,	O
20	together	O
21	with	O
22	the	O
23	associated	O
24	increases	O
25	in	O
26	proliferation	O
27	.	O

0	Utilizing	O
1	transient	O
2	transfection	O
3	studies	O
4	in	O
5	HepG2	O
6	cells	O
7	,	O
8	we	O
9	have	O
10	shown	O
11	that	O
12	deletion	O
13	of	O
14	the	O
15	factor	B
16	VIII	I
17	promoter	I
18	sequences	I
19	distal	O
20	to	O
21	nucleotide	O
22	-	O
23	44	O
24	results	O
25	in	O
26	a	O
27	significant	O
28	but	O
29	small	O
30	increase	O
31	in	O
32	promoter	O
33	activity	O
34	.	O

0	Presently	O
1	four	O
2	unique	O
3	variants	O
4	carrying	O
5	distinct	O
6	GAF	B
7	sequences	I
8	in	O
9	the	O
10	N	O
11	-	O
12	terminal	O
13	region	O
14	have	O
15	been	O
16	identified	O
17	.	O

0	Upstream	O
1	activation	O
2	sites	O
3	of	O
4	the	O
5	CYC1	B
6	gene	I
7	of	I
8	Saccharomyces	I
9	cerevisiae	O
10	are	O
11	active	O
12	when	O
13	inverted	O
14	but	O
15	not	O
16	when	O
17	placed	O
18	downstream	O
19	of	O
20	the	O
21	"	O
22	TATA	O
23	box	O
24	".	O

0	The	O
1	epitope	O
2	-	O
3	protected	O
4	lysine	O
5	(	O
6	K	O
7	)	O
8	was	O
9	present	O
10	in	O
11	a	O
12	30	O
13	-	O
14	aa	O
15	TPO	O
16	fragment	O
17	that	O
18	,	O
19	by	O
20	N	O
21	-	O
22	terminal	O
23	sequencing	O
24	,	O
25	was	O
26	found	O
27	to	O
28	be	O
29	K713	O
30	.	O

0	Significant	O
1	GMBF	O
2	reductions	O
3	occurred	O
4	in	O
5	early	O
6	shock	O
7	in	O
8	both	O
9	treatment	O
10	groups	O
11	.	O

0	One	O
1	of	O
2	these	O
3	factors	O
4	,	O
5	IRF	B
6	-	I
7	2	I
8	,	O
9	was	O
10	initially	O
11	cloned	O
12	as	O
13	an	O
14	antagonistic	O
15	counterpart	O
16	to	O
17	IRF	B
18	-	I
19	1	I
20	with	O
21	oncogenic	O
22	potential	O
23	.	O

0	To	O
1	elucidate	O
2	whether	O
3	potential	O
4	endocrine	O
5	changes	O
6	resulted	O
7	from	O
8	acute	O
9	hypoxaemia	O
10	alone	O
11	,	O
12	the	O
13	underlying	O
14	disease	O
15	,	O
16	or	O
17	unspecific	O
18	influences	O
19	connected	O
20	with	O
21	the	O
22	ICU	O
23	setting	O
24	,	O
25	all	O
26	measurements	O
27	were	O
28	compared	O
29	to	O
30	those	O
31	of	O
32	a	O
33	completely	O
34	healthy	O
35	reference	O
36	group	O
37	(	O
38	REF	O
39	)	O
40	with	O
41	comparable	O
42	acute	O
43	experimental	O
44	hypoxaemia	O
45	.	O

0	In	O
1	budding	O
2	yeast	O
3	,	O
4	the	O
5	protein	B
6	Skp1p	B
7	,	O
8	the	O
9	cullin	B
10	-	I
11	family	I
12	member	I
13	Cdc53p	B
14	,	O
15	and	O
16	the	O
17	F	B
18	-	I
19	box	I
20	/	I
21	WD	I
22	-	I
23	repeat	I
24	protein	I
25	Cdc4p	I
26	form	O
27	the	O
28	SCFCdc4p	B
29	ubiquitin	I
30	ligase	I
31	complex	I
32	,	O
33	which	O
34	targets	O
35	the	O
36	cyclin	B
37	-	I
38	dependent	I
39	kinase	I
40	(	O
41	Cdk	B
42	)	O
43	inhibitor	O
44	Sic1p	B
45	for	O
46	proteolysis	O
47	[	O
48	3	O
49	]	O
50	[	O
51	4	O
52	]	O
53	[	O
54	5	O
55	]	O
56	[	O
57	6	O
58	]	O
59	[	O
60	7	O
61	]	O
62	[	O
63	8	O
64	].	O

0	Bilateral	O
1	Charnley	O
2	arthroplasty	O
3	as	O
4	a	O
5	single	O
6	procedure	O
7	.	O

0	They	O
1	self	O
2	-	O
3	completed	O
4	the	O
5	SF	O
6	-	O
7	36	O
8	questionnaire	O
9	and	O
10	their	O
11	QoL	O
12	was	O
13	described	O
14	and	O
15	retrospectively	O
16	compared	O
17	to	O
18	that	O
19	of	O
20	historical	O
21	controls	O
22	.	O

0	Mild	O
1	orbital	O
2	discomfort	O
3	occurred	O
4	in	O
5	some	O
6	patients	O
7	.	O

0	Five	O
1	-	O
2	year	O
3	prospective	O
4	study	O
5	of	O
6	peripheral	O
7	white	O
8	blood	O
9	cells	O
10	in	O
11	infectious	O
12	mononucleosis	O
13	.	O

0	Alanine	B
1	aminotransferase	I
2	in	O
3	clinical	O
4	practice	O
5	.	O

0	2	O
1	.	O

0	The	O
1	Dax	B
2	-	I
3	1	I
4	gene	I
5	encodes	O
6	a	O
7	protein	O
8	that	O
9	is	O
10	structurally	O
11	related	O
12	to	O
13	members	O
14	of	O
15	the	O
16	orphan	B
17	nuclear	I
18	receptor	I
19	superfamily	I
20	.	O

0	IRF	B
1	-	I
2	1	I
3	acts	O
4	as	O
5	a	O
6	transcriptional	O
7	activator	O
8	,	O
9	while	O
10	IRF	B
11	-	I
12	2	I
13	acts	O
14	as	O
15	a	O
16	repressor	O
17	.	O

0	We	O
1	report	O
2	herein	O
3	the	O
4	case	O
5	of	O
6	a	O
7	30	O
8	-	O
9	year	O
10	-	O
11	old	O
12	man	O
13	in	O
14	whom	O
15	ectopic	O
16	mediastinal	O
17	parathyroid	O
18	adenoma	O
19	was	O
20	detected	O
21	by	O
22	99mTc	O
23	-	O
24	methoxyisobutylisonitrile	O
25	scintigraphy	O
26	(	O
27	99mTc	O
28	-	O
29	MIBI	O
30	).	O

0	These	O
1	results	O
2	confirmed	O
3	that	O
4	cleavage	O
5	of	O
6	the	O
7	leader	O
8	peptide	O
9	is	O
10	the	O
11	last	O
12	step	O
13	in	O
14	nisin	B
15	maturation	O
16	and	O
17	is	O
18	necessary	O
19	to	O
20	generate	O
21	a	O
22	biologically	O
23	active	O
24	peptide	O
25	.	O

0	Heterogeneous	B
1	nuclear	I
2	ribonucleoprotein	I
3	(	O
4	hnRNP	B
5	)	I
6	core	I
7	protein	I
8	A1	I
9	is	O
10	a	O
11	major	O
12	component	O
13	of	O
14	mammalian	B
15	hnRNP	I
16	40	I
17	S	I
18	particles	I
19	.	O

0	Mean	O
1	fluorosis	O
2	scores	O
3	,	O
4	however	O
5	,	O
6	were	O
7	similar	O
8	.	O

0	In	O
1	both	O
2	cities	O
3	,	O
4	HTLV	O
5	-	O
6	I	O
7	/	O
8	II	O
9	prevalence	O
10	increased	O
11	significantly	O
12	with	O
13	age	O
14	,	O
15	and	O
16	the	O
17	New	O
18	Orleans	O
19	age	O
20	-	O
21	and	O
22	sex	O
23	-	O
24	adjusted	O
25	HTLV	O
26	-	O
27	I	O
28	/	O
29	II	O
30	prevalence	O
31	was	O
32	significantly	O
33	higher	O
34	than	O
35	that	O
36	of	O
37	Baltimore	O
38	(	O
39	P	O
40	less	O
41	than	O
42	.	O
43	001	O
44	).	O

0	Estral	O
1	cycle	O
2	in	O
3	white	O
4	rats	O
5	in	O
6	the	O
7	low	O
8	and	O
9	high	O
10	mountains	O
11	of	O
12	Kirghizia	O

0	Analysis	O
1	of	O
2	Msy2	B
3	mRNA	I
4	expression	O
5	in	O
6	prepubertal	O
7	and	O
8	adult	O
9	mouse	O
10	testes	O
11	,	O
12	and	O
13	in	O
14	isolated	O
15	populations	O
16	of	O
17	germ	O
18	cells	O
19	,	O
20	reveals	O
21	maximal	O
22	expression	O
23	in	O
24	postmeiotic	O
25	round	O
26	spermatids	O
27	,	O
28	a	O
29	cell	O
30	type	O
31	with	O
32	abundant	O
33	amounts	O
34	of	O
35	stored	O
36	messenger	O
37	ribonucleoproteins	O
38	.	O

0	Conversely	O
1	,	O
2	E1A	B
3	binding	O
4	to	O
5	only	O
6	p300	B
7	/	O
8	CBP	B
9	results	O
10	in	O
11	an	O
12	increase	O
13	in	O
14	PARP	B
15	enzyme	I
16	activity	O
17	and	O
18	consequently	O
19	in	O
20	cell	O
21	death	O
22	susceptibility	O
23	to	O
24	irradiation	O
25	,	O
26	which	O
27	is	O
28	effectively	O
29	counteracted	O
30	by	O
31	the	O
32	PARP	B
33	chemical	O
34	inhibitor	O
35	3	O
36	-	O
37	aminobenzamide	O
38	.	O

0	(	O
1	1998	O
2	)	O
3	FASEB	O
4	J	O
5	.	O

0	These	O
1	offspring	O
2	of	O
3	the	O
4	alpha	B
5	-	I
6	MSH	I
7	treated	O
8	mothers	O
9	were	O
10	less	O
11	sensitive	O
12	to	O
13	pain	O
14	and	O
15	as	O
16	adults	O
17	showed	O
18	a	O
19	reduced	O
20	analgesic	O
21	response	O
22	to	O
23	morphine	O
24	.	O

0	In	O
1	the	O
2	absence	O
3	of	O
4	enhancer	O
5	sequences	O
6	,	O
7	the	O
8	adenovirus	B
9	E1A	I
10	gene	I
11	can	O
12	not	O
13	stimulate	O
14	CATase	B
15	synthesis	O
16	.	O

0	Despite	O
1	the	O
2	reported	O
3	detrimental	O
4	effects	O
5	on	O
6	CNS	O
7	development	O
8	,	O
9	a	O
10	number	O
11	of	O
12	animal	O
13	studies	O
14	have	O
15	shown	O
16	that	O
17	pretreatment	O
18	with	O
19	corticosteroids	O
20	nevertheless	O
21	protect	O
22	the	O
23	brain	O
24	from	O
25	hypoxia	O
26	-	O
27	ischemic	O
28	injury	O
29	;	O
30	however	O
31	,	O
32	clinically	O
33	such	O
34	treatment	O
35	is	O
36	no	O
37	longer	O
38	favored	O
39	.	O

0	The	O
1	N	O
2	-	O
3	terminal	O
4	115	O
5	amino	O
6	acids	O
7	correspond	O
8	to	O
9	a	O
10	putative	O
11	DNA	O
12	-	O
13	binding	O
14	domain	O
15	and	O
16	show	O
17	significant	O
18	sequence	O
19	similarity	O
20	with	O
21	other	O
22	cloned	O
23	IFN	B
24	response	I
25	factors	I
26	(	O
27	IRF	B
28	-	I
29	1	I
30	and	O
31	IRF	B
32	-	I
33	2	I
34	).	O

0	The	O
1	different	O
2	holoenzyme	B
3	RNA	I
4	polymerases	I
5	generated	O
6	upon	O
7	reconstituting	O
8	these	O
9	mutants	O
10	independently	O
11	with	O
12	core	B
13	RNA	I
14	polymerase	I
15	(	O
16	alpha2beta	B
17	beta	I
18	')	I
19	have	O
20	shown	O
21	reduced	O
22	transcriptional	O
23	activity	O
24	in	O
25	comparison	O
26	to	O
27	the	O
28	enzyme	O
29	containing	O
30	wild	B
31	-	I
32	type	I
33	sigma	I
34	factor	I
35	.	O

0	However	O
1	,	O
2	in	O
3	a	O
4	new	O
5	experiment	O
6	in	O
7	which	O
8	the	O
9	deletion	O
10	task	O
11	was	O
12	presented	O
13	as	O
14	a	O
15	puppet	O
16	game	O
17	,	O
18	and	O
19	with	O
20	pretraining	O
21	and	O
22	selection	O
23	on	O
24	vowel	O
25	deletion	O
26	,	O
27	a	O
28	significantly	O
29	higher	O
30	level	O
31	of	O
32	success	O
33	was	O
34	achieved	O
35	by	O
36	the	O
37	children	O
38	working	O
39	with	O
40	the	O
41	CVCC	O
42	material	O
43	.	O

0	M	B
1	-	I
2	Ras	I
3	interacted	O
4	poorly	O
5	in	O
6	a	O
7	yeast	O
8	two	O
9	-	O
10	hybrid	O
11	assay	O
12	with	O
13	multiple	O
14	Ras	B
15	effectors	O
16	,	O
17	including	O
18	c	B
19	-	I
20	Raf	I
21	-	I
22	1	I
23	,	O
24	A	B
25	-	I
26	Raf	I
27	,	O
28	B	B
29	-	I
30	Raf	I
31	,	O
32	phosphoinositol	B
33	-	I
34	3	I
35	kinase	I
36	delta	I
37	,	O
38	RalGDS	B
39	,	O
40	and	O
41	Rin1	B
42	.	O

0	Hence	O
1	,	O
2	the	O
3	uPA	B
4	promoter	I
5	contains	O
6	multiple	O
7	weak	O
8	cis	O
9	-	O
10	acting	O
11	elements	O
12	distributed	O
13	over	O
14	7	O
15	.	O
16	0	O
17	kb	O
18	5	O
19	'	O
20	to	O
21	the	O
22	translation	O
23	start	O
24	site	O
25	.	O

0	Histiocytic	O
1	panniculitis	O
2	was	O
3	observed	O
4	in	O
5	biopsy	O
6	specimens	O
7	with	O
8	cytophagocytosis	O
9	.	O

0	In	O
1	an	O
2	effort	O
3	to	O
4	contribute	O
5	to	O
6	the	O
7	transcript	O
8	map	O
9	of	O
10	human	O
11	chromosome	O
12	21	O
13	and	O
14	the	O
15	understanding	O
16	of	O
17	the	O
18	pathophysiology	O
19	of	O
20	trisomy	O
21	21	O
22	,	O
23	we	O
24	have	O
25	used	O
26	exon	O
27	trapping	O
28	to	O
29	identify	O
30	fragments	O
31	of	O
32	chromosome	O
33	21	O
34	genes	O
35	.	O

0	Toxicity	O
1	was	O
2	very	O
3	mild	O
4	with	O
5	both	O
6	regimens	O
7	,	O
8	although	O
9	sedation	O
10	was	O
11	significantly	O
12	higher	O
13	in	O
14	arm	O
15	B	O
16	(	O
17	p	O
18	less	O
19	than	O
20	0	O
21	.	O
22	001	O
23	).	O

0	Restoration	O
1	of	O
2	opponens	O
3	function	O
4	with	O
5	transplantation	O
6	of	O
7	free	O
8	composites	O
9	dorsal	O
10	pedal	O
11	skin	O
12	flap	O
13	containing	O
14	m	O
15	.	O
16	extensor	O
17	hallucis	O
18	brevis	O

0	The	O
1	antilog	O
2	transformation	O
3	of	O
4	pH	O
5	did	O
6	not	O
7	improve	O
8	the	O
9	results	O
10	.	O

0	We	O
1	show	O
2	that	O
3	these	O
4	three	O
5	gain	O
6	-	O
7	of	O
8	-	O
9	function	O
10	mutants	O
11	differ	O
12	considerably	O
13	in	O
14	their	O
15	ability	O
16	to	O
17	bypass	O
18	the	O
19	sex	O
20	determination	O
21	signal	O
22	,	O
23	with	O
24	SxlM4	B
25	being	O
26	the	O
27	strongest	O
28	and	O
29	SxlM1	B
30	the	O
31	weakest	O
32	.	O

0	All	O
1	problems	O
2	were	O
3	associated	O
4	with	O
5	fractured	O
6	or	O
7	lost	O
8	screws	O
9	.	O

0	A	O
1	Y	B
2	.	I
3	lipolytica	I
4	Kar2p	I
5	mutant	I
6	was	O
7	isolated	O
8	that	O
9	restored	O
10	interaction	O
11	with	O
12	an	O
13	Sls1p	B
14	mutant	I
15	,	O
16	suggesting	O
17	that	O
18	the	O
19	interaction	O
20	with	O
21	Sls1p	B
22	could	O
23	be	O
24	nucleotide	O
25	and	O
26	/	O
27	or	O
28	conformation	O
29	dependent	O
30	.	O

0	51	O
1	.	O
2	9	O
3	%	O
4	(	O
5	P	O
6	=	O
7	0	O
8	.	O
9	0006	O
10	)	O
11	in	O
12	the	O
13	MMF	O
14	versus	O
15	the	O
16	AZA	O
17	groups	O
18	,	O
19	respectively	O
20	.	O

0	On	O
1	the	O
2	third	O
3	occasion	O
4	water	O
5	(	O
6	W	O
7	)	O
8	was	O
9	ingested	O
10	throughout	O
11	the	O
12	run	O
13	.	O

0	Using	O
1	PRL	B
2	-	I
3	R	I
4	tagged	O
5	both	O
6	in	O
7	the	O
8	N	O
9	-	O
10	terminal	O
11	or	O
12	C	O
13	-	O
14	terminal	O
15	regions	O
16	of	O
17	the	O
18	mature	O
19	receptor	O
20	excludes	O
21	the	O
22	possibility	O
23	of	O
24	a	O
25	cleaved	O
26	fragment	O
27	which	O
28	could	O
29	have	O
30	been	O
31	subsequently	O
32	imported	O
33	into	O
34	the	O
35	nucleus	O
36	.	O

0	METHOD	O
1	:	O
2	The	O
3	sample	O
4	of	O
5	subjects	O
6	was	O
7	drawn	O
8	from	O
9	the	O
10	Suffolk	O
11	County	O
12	Mental	O
13	Health	O
14	Project	O
15	,	O
16	a	O
17	longitudinal	O
18	epidemiologic	O
19	study	O
20	of	O
21	first	O
22	-	O
23	hospitalized	O
24	subjects	O
25	with	O
26	psychotic	O
27	disorders	O
28	;	O
29	the	O
30	present	O
31	study	O
32	focused	O
33	on	O
34	patients	O
35	with	O
36	schizophrenic	O
37	disorders	O
38	.	O

0	OBJECTIVE	O
1	:	O
2	To	O
3	evaluate	O
4	the	O
5	accuracy	O
6	of	O
7	working	O
8	casts	O
9	for	O
10	crown	O
11	and	O
12	bridge	O
13	restorations	O
14	made	O
15	from	O
16	twin	O
17	mix	O
18	putty	O
19	/	O
20	wash	O
21	silicone	O
22	elastomeric	O
23	impression	O
24	materials	O
25	using	O
26	different	O
27	types	O
28	of	O
29	stock	O
30	tray	O
31	.	O

0	To	O
1	facilitate	O
2	the	O
3	investigation	O
4	of	O
5	parameters	O
6	that	O
7	govern	O
8	selective	O
9	export	O
10	in	O
11	adenovirus	O
12	-	O
13	infected	O
14	cells	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	marked	O
20	human	B
21	beta	I
22	-	I
23	actin	I
24	minigene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	glucocorticoid	O
31	-	O
32	inducible	O
33	enhancer	O
34	-	O
35	promoter	O
36	of	O
37	mouse	O
38	mammary	O
39	tumor	O
40	virus	O
41	and	O
42	introduced	O
43	it	O
44	into	O
45	the	O
46	left	O
47	end	O
48	of	O
49	the	O
50	adenovirus	O
51	type	O
52	5	O
53	(	O
54	Ad5	O
55	)	O
56	genome	O
57	.	O

0	Upstream	O
1	of	O
2	the	O
3	dra	B
4	gene	I
5	an	O
6	open	O
7	reading	O
8	frame	O
9	of	O
10	313	O
11	amino	O
12	acids	O
13	was	O
14	identified	O
15	.	O

0	Subjects	O
1	with	O
2	a	O
3	short	O
4	postexposure	O
5	time	O
6	and	O
7	a	O
8	dioxin	O
9	burden	O
10	>	O
11	0	O
12	.	O
13	6	O
14	pg	O
15	/	O
16	m3	O
17	had	O
18	a	O
19	significantly	O
20	higher	O
21	risk	O
22	of	O
23	hypoergy	O
24	than	O
25	unexposed	O
26	subjects	O
27	(	O
28	hypoergy	O
29	I	O
30	:	O
31	OR	O
32	=	O
33	9	O
34	.	O
35	51	O
36	,	O
37	95	O
38	%	O
39	CI	O
40	=	O
41	1	O
42	.	O
43	96	O
44	-	O
45	42	O
46	.	O
47	02	O
48	;	O
49	hypoergy	O
50	II	O
51	:	O
52	OR	O
53	=	O
54	2	O
55	.	O
56	92	O
57	,	O
58	95	O
59	%	O
60	CI	O
61	=	O
62	1	O
63	.	O
64	14	O
65	-	O
66	7	O
67	.	O
68	5	O
69	).	O

0	Truncated	B
1	ICSBP	I
2	lacking	O
3	the	O
4	first	O
5	33	O
6	amino	O
7	-	O
8	terminal	O
9	amino	O
10	acids	O
11	fails	O
12	to	O
13	bind	O
14	to	O
15	the	O
16	ICS	B
17	,	O
18	indicating	O
19	that	O
20	at	O
21	least	O
22	part	O
23	of	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	is	O
29	located	O
30	within	O
31	the	O
32	well	O
33	conserved	O
34	amino	O
35	terminus	O
36	.	O

0	Number	O
1	of	O
2	patients	O
3	infected	O
4	with	O
5	nontuberculous	O
6	mycobacteria	O
7	(	O
8	NTM	O
9	)	O
10	is	O
11	increasing	O
12	world	O
13	-	O
14	wide	O
15	in	O
16	recent	O
17	years	O
18	.	O

0	32Pi	O
1	labeling	O
2	or	O
3	isoelectric	O
4	focusing	O
5	analysis	O
6	of	O
7	eIF	B
8	-	I
9	2	I
10	alpha	I
11	from	O
12	conditional	B
13	casein	B
14	kinase	I
15	II	I
16	mutants	I
17	indicated	O
18	that	O
19	phosphorylation	O
20	of	O
21	eIF	B
22	-	I
23	2	I
24	alpha	I
25	is	O
26	abolished	O
27	or	O
28	dephosphorylated	O
29	forms	O
30	of	O
31	eIF	B
32	-	I
33	2	I
34	alpha	I
35	are	O
36	detected	O
37	when	O
38	these	O
39	strains	O
40	are	O
41	grown	O
42	at	O
43	the	O
44	restrictive	O
45	growth	O
46	conditions	O
47	.	O

0	Radiolabelled	O
1	palmitate	O
2	was	O
3	not	O
4	incorporated	O
5	into	O
6	the	O
7	mutated	O
8	protein	O
9	,	O
10	showing	O
11	that	O
12	lipid	O
13	modification	O
14	occurs	O
15	at	O
16	the	O
17	Cys	O
18	-	O
19	22	O
20	residue	O
21	.	O

0	Effects	O
1	of	O
2	beta	B
3	-	I
4	adrenergic	I
5	receptor	I
6	blockade	O
7	on	O
8	airway	O
9	conductance	O
10	and	O
11	lung	O
12	volume	O
13	in	O
14	normal	O
15	and	O
16	asthmatic	O
17	subjects	O
18	.	O

0	The	O
1	physical	O
2	and	O
3	chemical	O
4	stability	O
5	of	O
6	a	O
7	combination	O
8	of	O
9	drugs	O
10	commonly	O
11	administered	O
12	into	O
13	the	O
14	epidural	O
15	or	O
16	intrathecal	O
17	space	O
18	for	O
19	the	O
20	treatment	O
21	of	O
22	chronic	O
23	pain	O
24	was	O
25	investigated	O
26	.	O

0	In	O
1	particular	O
2	,	O
3	Western	O
4	,	O
5	supershift	O
6	,	O
7	and	O
8	promoter	O
9	deletion	O
10	analyses	O
11	suggested	O
12	a	O
13	role	O
14	for	O
15	CCAAT	B
16	/	I
17	enhancer	I
18	-	I
19	binding	I
20	protein	I
21	-	I
22	beta	I
23	(	O
24	C	B
25	/	I
26	EBP	I
27	-	I
28	beta	I
29	)	O
30	binding	O
31	site	O
32	between	O
33	-	O
34	2010	O
35	and	O
36	-	O
37	1954	O
38	in	O
39	regulating	O
40	transcription	O
41	of	O
42	collagenase	B
43	-	I
44	1	I
45	in	O
46	monocytic	O
47	cells	O
48	.	O

0	Identity	O
1	elements	O
2	in	O
3	tRNA	B
4	for	O
5	mono	O
6	-	O
7	and	O
8	dimethylation	O
9	reactions	O
10	by	O
11	the	O
12	recombinant	O
13	pfTrm1p	I
14	were	O
15	identified	O
16	using	O
17	in	O
18	vitro	O
19	T7	B
20	transcripts	I
21	of	O
22	33	O
23	variants	O
24	of	O
25	tRNA	B
26	(	O
27	Asp	B
28	)	O
29	and	O
30	tRNA	B
31	(	O
32	Phe	B
33	)	O
34	from	O
35	yeast	O
36	.	O

0	The	O
1	effect	O
2	of	O
3	emotional	O
4	-	O
5	painful	O
6	stress	O
7	(	O
8	EPS	O
9	)	O
10	on	O
11	myocardial	O
12	extensibility	O
13	and	O
14	contractility	O
15	was	O
16	studied	O
17	on	O
18	an	O
19	isolated	O
20	rat	O
21	atrium	O
22	.	O

0	In	O
1	the	O
2	absence	O
3	of	O
4	Mg2	O
5	+,	O
6	a	O
7	hydrophobic	O
8	exonuclease	O
9	site	O
10	dominates	O
11	over	O
12	the	O
13	polymerase	O
14	site	O
15	for	O
16	possession	O
17	of	O
18	the	O
19	primer	O
20	terminus	O
21	.	O

0	Gag	B
1	protein	I
2	sequence	I
3	motifs	I
4	of	O
5	the	O
6	NC	B
7	domain	I
8	of	O
9	primate	O
10	foamy	O
11	viruses	O
12	assumed	O
13	to	O
14	be	O
15	involved	O
16	in	O
17	genome	O
18	encapsidation	O
19	are	O
20	not	O
21	conserved	O
22	in	O
23	FeFV	O
24	.	O

0	The	O
1	Saccharomyces	B
2	cerevisiae	I
3	14DM	I
4	gene	I
5	,	O
6	encoding	O
7	cytochrome	B
8	P450	I
9	lanosterol	I
10	14	I
11	alpha	I
12	-	I
13	demethylase	I
14	(	O
15	14DM	B
16	),	O
17	was	O
18	overexpressed	O
19	in	O
20	various	O
21	S	O
22	.	O
23	cerevisiae	O
24	strains	O
25	under	O
26	the	O
27	control	O
28	of	O
29	three	O
30	strong	O
31	heterologous	O
32	yeast	O
33	transcription	O
34	promoters	O
35	(	O
36	pADC1	B
37	,	O
38	pGPD	B
39	,	O
40	pPHO5	B
41	)	O
42	and	O
43	under	O
44	the	O
45	control	O
46	of	O
47	its	O
48	own	O
49	promoter	O
50	.	O

0	Ammonia	O
1	concentration	O
2	dropped	O
3	significantly	O
4	in	O
5	all	O
6	treatments	O
7	,	O
8	a	O
9	finding	O
10	which	O
11	suggests	O
12	a	O
13	protective	O
14	effect	O
15	on	O
16	protein	O
17	nitrogen	O
18	degradation	O
19	to	O
20	non	O
21	-	O
22	protein	O
23	nitrogen	O
24	(	O
25	NH3	O
26	).	O

0	Bupropion	O
1	to	O
2	aid	O
3	smoking	O
4	cessation	O
5	.	O

0	Northern	O
1	and	O
2	RT	O
3	-	O
4	PCR	O
5	analysis	O
6	of	O
7	Ube3a	B
8	expression	O
9	in	O
10	mouse	O
11	tissues	O
12	from	O
13	animals	O
14	with	O
15	segmental	O
16	,	O
17	paternal	O
18	uniparental	O
19	disomy	O
20	failed	O
21	to	O
22	detect	O
23	substantially	O
24	reduced	O
25	or	O
26	absent	O
27	expression	O
28	compared	O
29	to	O
30	control	O
31	animals	O
32	,	O
33	failing	O
34	to	O
35	provide	O
36	any	O
37	evidence	O
38	for	O
39	maternal	O
40	-	O
41	specific	O
42	expression	O
43	from	O
44	this	O
45	locus	O
46	.	O

0	A	O
1	role	O
2	for	O
3	glycogen	B
4	synthase	I
5	kinase	I
6	-	I
7	3	I
8	in	O
9	the	O
10	control	O
11	of	O
12	gene	O
13	expression	O
14	.	O

0	These	O
1	characteristics	O
2	of	O
3	N22	O
4	/	O
5	P22	O
6	indicate	O
7	that	O
8	it	O
9	is	O
10	a	O
11	localized	O
12	synaptically	O
13	dependent	O
14	event	O
15	conforming	O
16	to	O
17	a	O
18	transverse	O
19	dipole	O
20	with	O
21	dorsal	O
22	negativity	O
23	and	O
24	a	O
25	simultaneous	O
26	anterior	O
27	positivity	O
28	.	O

0	The	O
1	patient	O
2	initially	O
3	attained	O
4	complete	O
5	remission	O
6	(	O
7	CR1	O
8	)	O
9	with	O
10	conventional	O
11	chemotherapy	O
12	and	O
13	then	O
14	relapsed	O
15	14	O
16	months	O
17	later	O
18	.	O

0	Clinical	O
1	course	O
2	and	O
3	nursing	O
4	care	O
5	of	O
6	patients	O
7	with	O
8	decubitus	O
9	ulcer	O
10	--	O
11	use	O
12	of	O
13	pillows	O
14	stuffed	O
15	with	O
16	buckwheat	O
17	chaff	O

0	The	O
1	optimum	O
2	technique	O
3	for	O
4	the	O
5	pathological	O
6	examination	O
7	of	O
8	sentinel	O
9	lymph	O
10	nodes	O
11	(	O
12	SLNs	O
13	)	O
14	is	O
15	still	O
16	under	O
17	debate	O
18	.	O

0	In	O
1	about	O
2	one	O
3	third	O
4	of	O
5	the	O
6	cases	O
7	this	O
8	operation	O
9	results	O
10	in	O
11	tonal	O
12	and	O
13	vocal	O
14	improvement	O
15	for	O
16	patients	O
17	suffering	O
18	from	O
19	progressive	O
20	perceptive	O
21	deafness	O
22	.	O

0	Thus	O
1	,	O
2	diamide	O
3	treatment	O
4	of	O
5	nuclear	O
6	extracts	O
7	strongly	O
8	reduces	O
9	the	O
10	binding	O
11	of	O
12	NFI	B
13	proteins	I
14	,	O
15	and	O
16	the	O
17	addition	O
18	of	O
19	higher	O
20	concentrations	O
21	of	O
22	dithiothreitol	O
23	to	O
24	nuclear	O
25	extracts	O
26	from	O
27	TG	O
28	-	O
29	treated	O
30	cells	O
31	restores	O
32	NFI	B
33	-	I
34	DNA	I
35	binding	O
36	to	O
37	levels	O
38	in	O
39	extracts	O
40	from	O
41	untreated	O
42	cells	O
43	.	O

0	However	O
1	,	O
2	three	O
3	Hm1	B
4	mutants	I
5	that	O
6	were	O
7	moderately	O
8	deficient	O
9	in	O
10	stimulating	O
11	PI	O
12	turnover	O
13	displayed	O
14	normal	O
15	sequestration	O
16	,	O
17	suggesting	O
18	distinct	O
19	mechanisms	O
20	.	O

0	In	O
1	Salmo	O
2	gairdneri	O
3	,	O
4	no	O
5	specialized	O
6	system	O
7	of	O
8	portal	O
9	vessels	O
10	appears	O
11	to	O
12	exist	O
13	between	O
14	the	O
15	pineal	O
16	organ	O
17	and	O
18	other	O
19	portions	O
20	of	O
21	the	O
22	brain	O
23	.	O

0	Some	O
1	of	O
2	these	O
3	targets	O
4	were	O
5	reported	O
6	to	O
7	code	O
8	for	O
9	molecules	O
10	involved	O
11	in	O
12	cell	O
13	-	O
14	cell	O
15	interactions	O
16	,	O
17	whereas	O
18	no	O
19	relationship	O
20	has	O
21	yet	O
22	been	O
23	demonstrated	O
24	between	O
25	Hox	B
26	genes	I
27	and	O
28	other	O
29	transcription	O
30	factors	O
31	involved	O
32	in	O
33	determining	O
34	and	O
35	/	O
36	or	O
37	maintaining	O
38	tissue	O
39	specificity	O
40	.	O

0	Gal4	B
1	-	O
2	Eed	B
3	fusion	O
4	protein	O
5	represses	O
6	transcription	O
7	of	O
8	a	O
9	reporter	O
10	gene	O
11	driven	O
12	by	O
13	a	O
14	promoter	O
15	that	O
16	contains	O
17	Gal4	B
18	-	I
19	binding	I
20	DNA	I
21	elements	I
22	.	O

0	Degradation	O
1	of	O
2	the	O
3	soybean	B
4	ribulose	I
5	-	I
6	1	I
7	,	I
8	5	I
9	-	I
10	bisphosphate	I
11	carboxylase	I
12	small	I
13	-	I
14	subunit	I
15	mRNA	I
16	,	O
17	SRS4	B
18	,	O
19	initiates	O
20	with	O
21	endonucleolytic	O
22	cleavage	O
23	.	O

0	Basal	O
1	plasma	B
2	renin	I
3	activity	O
4	(	O
5	PRA	O
6	)	O
7	was	O
8	slightly	O
9	raised	O
10	prior	O
11	to	O
12	training	O
13	(	O
14	P	O
15	<	O
16	0	O
17	.	O
18	07	O
19	)	O
20	compared	O
21	to	O
22	the	O
23	controls	O
24	and	O
25	post	O
26	-	O
27	training	O
28	.	O

0	Conjugated	O
1	estrogens	O
2	shorten	O
3	bleeding	O
4	time	O
5	in	O
6	uraemia	O
7	:	O
8	a	O
9	possible	O
10	role	O
11	of	O
12	serotonin	O
13	?	O

0	Like	O
1	DNA	O
2	binding	O
3	,	O
4	transcriptional	O
5	enhancement	O
6	required	O
7	amino	O
8	-	O
9	terminally	O
10	located	O
11	basic	O
12	amino	O
13	acid	O
14	residues	O
15	but	O
16	not	O
17	the	O
18	carboxyl	O
19	-	O
20	terminal	O
21	portion	O
22	of	O
23	Hap46	B
24	known	O
25	to	O
26	participate	O
27	in	O
28	hsp70	B
29	interaction	O
30	.	O

0	Neither	O
1	CES1	B
2	nor	O
3	CES4	B
4	is	O
5	essential	O
6	for	O
7	cell	O
8	growth	O
9	,	O
10	and	O
11	a	O
12	double	O
13	deletion	O
14	mutant	O
15	is	O
16	viable	O
17	.	O

0	Uses	O
1	of	O
2	orthoclone	O
3	OKT3	O
4	for	O
5	prophylaxis	O
6	of	O
7	rejection	O
8	and	O
9	induction	O
10	in	O
11	initial	O
12	nonfunction	O
13	in	O
14	kidney	O
15	transplantation	O
16	.	O

0	Regulation	O
1	of	O
2	the	O
3	Raf	B
4	kinase	I
5	in	O
6	T	O
7	cells	O
8	differs	O
9	from	O
10	findings	O
11	with	O
12	a	O
13	variety	O
14	of	O
15	cell	O
16	lines	O
17	that	O
18	the	O
19	catalytic	O
20	domain	O
21	of	O
22	Raf	B
23	(	O
24	Raf	B
25	(	I
26	delta26	I
27	-	I
28	303	I
29	))	O
30	shows	O
31	no	O
32	activity	O
33	.	O

0	CONCLUSIONS	O
1	:	O
2	In	O
3	essential	O
4	hypertension	O
5	an	O
6	acute	O
7	protein	O
8	load	O
9	induces	O
10	a	O
11	decrease	O
12	in	O
13	GFR	B
14	that	O
15	may	O
16	normalize	O
17	under	O
18	antihypertensive	O
19	treatment	O
20	.	O

0	Light	O
1	microscopical	O
2	and	O
3	routine	O
4	immunohistochemical	O
5	studies	O
6	of	O
7	a	O
8	cervical	O
9	neoplasm	O
10	in	O
11	a	O
12	32	O
13	year	O
14	old	O
15	woman	O
16	initially	O
17	suggested	O
18	a	O
19	histiocytic	O
20	lymphoma	O
21	,	O
22	but	O
23	histochemical	O
24	staining	O
25	for	O
26	chloroacetate	B
27	esterase	I
28	established	O
29	the	O
30	correct	O
31	diagnosis	O
32	.	O

0	Essentially	O
1	,	O
2	2	O
3	'-	O
4	O	O
5	-	O
6	methyl	O
7	oligoribonucleotides	O
8	(	O
9	2	O
10	'	O
11	OMeRNA	O
12	)	O
13	were	O
14	delivered	O
15	to	O
16	the	O
17	nuclei	O
18	of	O
19	primary	O
20	mdx	O
21	myoblasts	O
22	in	O
23	culture	O
24	.	O

0	Mammalian	B
1	M	I
2	-	I
3	Ras	I
4	and	O
5	a	O
6	Caenorhabditis	O
7	elegans	O
8	orthologue	O
9	exhibit	O
10	conserved	O
11	structural	O
12	features	O
13	,	O
14	and	O
15	these	O
16	are	O
17	likely	O
18	to	O
19	mediate	O
20	activation	O
21	of	O
22	distinctive	O
23	signaling	O
24	paths	O
25	that	O
26	function	O
27	in	O
28	parallel	O
29	to	O
30	those	O
31	downstream	O
32	of	O
33	p21	B
34	Ras	I
35	.	O

0	Nickel	O
1	is	O
2	the	O
3	most	O
4	common	O
5	cause	O
6	of	O
7	allergic	O
8	contact	O
9	dermatitis	O
10	in	O
11	Singapore	O
12	,	O
13	resulting	O
14	in	O
15	positive	O
16	reactions	O
17	in	O
18	patch	O
19	tests	O
20	between	O
21	7	O
22	and	O
23	14	O
24	%.	O

0	It	O
1	has	O
2	been	O
3	shown	O
4	in	O
5	experiments	O
6	in	O
7	vitro	O
8	that	O
9	the	O
10	hepatotrophic	O
11	organic	O
12	anions	O
13	,	O
14	the	O
15	radiographic	O
16	contrast	O
17	agent	O
18	(	O
19	RCA	O
20	)	O
21	bilignost	O
22	used	O
23	in	O
24	cholecystography	O
25	and	O
26	Bengal	O
27	pink	O
28	,	O
29	have	O
30	an	O
31	affinity	O
32	,	O
33	unlike	O
34	the	O
35	urographic	O
36	RCA	B
37	triombrin	I
38	and	O
39	renotrophic	O
40	dye	O
41	indigo	O
42	-	O
43	carmine	O
44	,	O
45	for	O
46	the	O
47	plasmatic	O
48	membranes	O
49	(	O
50	PM	O
51	)	O
52	of	O
53	liver	O
54	cells	O
55	.	O

0	At	O
1	baseline	O
2	,	O
3	serum	O
4	levels	O
5	of	O
6	lycopene	O
7	and	O
8	FLOP	O
9	were	O
10	abnormally	O
11	high	O
12	and	O
13	serum	O
14	FLOP	O
15	was	O
16	correlated	O
17	significantly	O
18	with	O
19	plasma	O
20	cyclosporine	O
21	levels	O
22	(	O
23	r	O
24	=	O
25	0	O
26	.	O
27	646	O
28	,	O
29	p	O
30	=	O
31	0	O
32	.	O
33	016	O
34	).	O

0	Serial	O
1	levels	O
2	of	O
3	troponin	B
4	T	I
5	and	O
6	the	O
7	activity	O
8	of	O
9	CK	B
10	-	I
11	MB	I
12	were	O
13	measured	O
14	6	O
15	,	O
16	12	O
17	,	O
18	24	O
19	and	O
20	48	O
21	h	O
22	after	O
23	aortic	O
24	unclamping	O
25	.	O

0	Furthermore	O
1	,	O
2	the	O
3	3	O
4	'-	O
5	untranslated	O
6	regions	O
7	of	O
8	pmGT10	B
9	display	O
10	a	O
11	marked	O
12	degree	O
13	of	O
14	homology	O
15	to	O
16	the	O
17	3	O
18	'	O
19	region	O
20	of	O
21	the	O
22	rat	B
23	Yb1	I
24	gene	I
25	,	O
26	while	O
27	this	O
28	region	O
29	of	O
30	pmGT2	B
31	displays	O
32	marked	O
33	homology	O
34	to	O
35	the	O
36	corresponding	O
37	region	O
38	of	O
39	the	O
40	rat	B
41	Yb2	I
42	gene	I
43	.	O

0	Despite	O
1	its	O
2	requirement	O
3	for	O
4	enhancer	O
5	-	O
6	dependent	O
7	splicing	O
8	activity	O
9	in	O
10	vitro	O
11	,	O
12	the	O
13	dU2AF38	B
14	RS	I
15	domain	I
16	was	O
17	also	O
18	inessential	O
19	in	O
20	vivo	O
21	.	O

0	Diagnosis	O
1	and	O
2	treatment	O
3	of	O
4	insulin	B
5	-	O
6	secreting	O
7	tumours	O
8	.	O

0	The	O
1	baroreflex	O
2	latency	O
3	(	O
4	from	O
5	the	O
6	ECG	O
7	R	O
8	-	O
9	wave	O
10	to	O
11	the	O
12	integrated	O
13	MSNA	O
14	burst	O
15	peak	O
16	)	O
17	was	O
18	constant	O
19	at	O
20	approximately	O
21	1	O
22	.	O
23	20	O
24	s	O
25	during	O
26	sleep	O
27	,	O
28	suggesting	O
29	that	O
30	pulse	O
31	-	O
32	synchronicity	O
33	was	O
34	maintained	O
35	.	O

0	These	O
1	temperature	O
2	-	O
3	and	O
4	cold	O
5	-	O
6	sensitive	O
7	strains	O
8	were	O
9	used	O
10	to	O
11	prepare	O
12	extracts	O
13	deficient	O
14	in	O
15	BRF1	B
16	activity	O
17	and	O
18	were	O
19	tested	O
20	for	O
21	transcriptional	O
22	activity	O
23	by	O
24	RNA	B
25	polymerases	I
26	I	I
27	,	I
28	II	I
29	,	I
30	and	I
31	III	I
32	in	O
33	vitro	O
34	.	O

0	Mutations	O
1	in	O
2	the	O
3	yeast	B
4	RNA14	I
5	and	O
6	RNA15	B
7	genes	I
8	result	O
9	in	O
10	an	O
11	abnormal	O
12	mRNA	O
13	decay	O
14	rate	O
15	;	O
16	sequence	O
17	analysis	O
18	reveals	O
19	an	O
20	RNA	O
21	-	O
22	binding	O
23	domain	O
24	in	O
25	the	O
26	RNA15	B
27	protein	I
28	.	O

0	Dual	O
1	roles	O
2	of	O
3	p82	B
4	,	O
5	the	O
6	clam	B
7	CPEB	I
8	homolog	I
9	,	O
10	in	O
11	cytoplasmic	O
12	polyadenylation	O
13	and	O
14	translational	O
15	masking	O
16	.	O

0	A	O
1	value	O
2	of	O
3	1	O
4	.	O
5	1	O
6	l	O
7	/	O
8	kg	O
9	was	O
10	used	O
11	for	O
12	V	O
13	in	O
14	calculating	O
15	all	O
16	single	O
17	sample	O
18	estimates	O
19	of	O
20	clearance	O
21	(	O
22	CL	O
23	),	O
24	and	O
25	a	O
26	value	O
27	of	O
28	4	O
29	.	O
30	3	O
31	l	O
32	/	O
33	kg	O
34	was	O
35	used	O
36	to	O
37	calculate	O
38	single	O
39	sample	O
40	estimates	O
41	of	O
42	clearance	O
43	of	O
44	plasma	O
45	unbound	O
46	drug	O
47	(	O
48	CLunb	O
49	).	O

0	In	O
1	order	O
2	to	O
3	better	O
4	characterize	O
5	the	O
6	distribution	O
7	of	O
8	ML	O
9	and	O
10	MAP	O
11	estimates	O
12	under	O
13	these	O
14	conditions	O
15	,	O
16	we	O
17	derive	O
18	a	O
19	point	O
20	approximation	O
21	to	O
22	density	O
23	values	O
24	of	O
25	the	O
26	conditional	O
27	distribution	O
28	of	O
29	such	O
30	estimates	O
31	.	O

0	An	O
1	8	O
2	-	O
3	h	O
4	exposure	O
5	to	O
6	10	O
7	mg	O
8	DMEA	O
9	/	O
10	m3	O
11	corresponds	O
12	to	O
13	a	O
14	postexposure	O
15	plasma	O
16	concentration	O
17	and	O
18	2	O
19	-	O
20	h	O
21	postexposure	O
22	urinary	O
23	excretion	O
24	of	O
25	4	O
26	.	O
27	9	O
28	mumol	O
29	/	O
30	l	O
31	and	O
32	75	O
33	mmol	O
34	/	O
35	mol	O
36	creatinine	O
37	,	O
38	respectively	O
39	.	O

0	[	O
1	18F	O
2	](+)-	O
3	4	O
4	-	O
5	fluorobenzyltrozamicol	O
6	(	O
7	FBT	O
8	),	O
9	which	O
10	selectively	O
11	binds	O
12	to	O
13	the	O
14	vesicular	O
15	acetylcholine	O
16	transporter	O
17	in	O
18	the	O
19	presynaptic	O
20	cholinergic	O
21	neuron	O
22	,	O
23	has	O
24	previously	O
25	been	O
26	shown	O
27	to	O
28	be	O
29	a	O
30	useful	O
31	ligand	O
32	for	O
33	the	O
34	study	O
35	of	O
36	cholinergic	O
37	terminal	O
38	density	O
39	in	O
40	the	O
41	basal	O
42	ganglia	O
43	with	O
44	PET	O
45	.	O

0	Static	O
1	lung	O
2	function	O
3	in	O
4	puppies	O
5	after	O
6	pneumonectomy	O
7	.	O

0	At	O
1	each	O
2	level	O
3	of	O
4	PaO2	O
5	we	O
6	obtained	O
7	simultaneous	O
8	measures	O
9	of	O
10	arterial	O
11	and	O
12	venous	O
13	blood	O
14	gases	O
15	,	O
16	venous	O
17	lactate	O
18	concentration	O
19	,	O
20	and	O
21	changes	O
22	in	O
23	the	O
24	relative	O
25	concentrations	O
26	of	O
27	inorganic	O
28	phosphate	O
29	,	O
30	phosphocreatine	O
31	,	O
32	and	O
33	ATP	O
34	measured	O
35	with	O
36	31P	O
37	magnetic	O
38	resonance	O
39	spectroscopy	O
40	.	O

0	Both	O
1	fusion	O
2	proteins	O
3	form	O
4	stable	O
5	specific	O
6	complexes	O
7	with	O
8	a	O
9	short	O
10	DNA	O
11	duplex	O
12	harboring	O
13	the	O
14	CTGT	B
15	(	O
16	at	O
17	)	O
18	4ACAG	O
19	consensus	O
20	sequence	O
21	of	O
22	the	O
23	LexA	B
24	repressor	I
25	.	O

0	Kodak	O
1	XV	O
2	-	O
3	2	O
4	film	O
5	is	O
6	wrapped	O
7	around	O
8	a	O
9	cylindrical	O
10	water	O
11	-	O
12	filled	O
13	phantom	O
14	and	O
15	the	O
16	dose	O
17	distribution	O
18	is	O
19	recorded	O
20	.	O

0	Transcription	O
1	of	O
2	these	O
3	genes	O
4	was	O
5	also	O
6	elevated	O
7	in	O
8	gut	O
9	and	O
10	lung	O
11	during	O
12	freezing	O
13	,	O
14	but	O
15	mRNA	O
16	levels	O
17	in	O
18	these	O
19	tissues	O
20	were	O
21	lower	O
22	than	O
23	in	O
24	liver	O
25	.	O

0	In	O
1	all	O
2	trials	O
3	,	O
4	antigen	O
5	challenge	O
6	followed	O
7	1	O
8	h	O
9	after	O
10	the	O
11	last	O
12	treatment	O
13	.	O

0	Finally	O
1	,	O
2	a	O
3	complementary	O
4	footprinting	O
5	analysis	O
6	of	O
7	the	O
8	upstream	O
9	region	O
10	of	O
11	the	O
12	constitutively	O
13	expressed	O
14	HSC82	B
15	gene	I
16	reveals	O
17	the	O
18	presence	O
19	of	O
20	three	O
21	discrete	O
22	protein	O
23	complexes	O
24	.	O

0	Abnormalities	O
1	of	O
2	plasma	O
3	cholecystokinin	B
4	were	O
5	observed	O
6	only	O
7	in	O
8	patients	O
9	with	O
10	delayed	O
11	gastric	O
12	emptying	O
13	.	O

0	These	O
1	data	O
2	suggest	O
3	that	O
4	RPF	B
5	-	I
6	1	I
7	is	O
8	likely	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	early	O
14	steps	O
15	in	O
16	the	O
17	differentiation	O
18	of	O
19	amacrine	O
20	and	O
21	ganglion	O
22	cells	O
23	.	O

0	We	O
1	observed	O
2	abundant	O
3	levels	O
4	of	O
5	Rev	B
6	-	I
7	erbA	I
8	alpha	I
9	mRNA	I
10	in	O
11	dividing	O
12	C2C12	O
13	myoblasts	O
14	,	O
15	which	O
16	were	O
17	suppressed	O
18	when	O
19	the	O
20	cells	O
21	differentiated	O
22	into	O
23	postmitotic	O
24	multinucleated	O
25	myotubes	O
26	.	O

0	The	O
1	11	O
2	;	O
3	22	O
4	chromosomal	O
5	translocation	O
6	specifically	O
7	linked	O
8	to	O
9	Ewing	O
10	sarcoma	O
11	and	O
12	primitive	O
13	neuroectodermal	O
14	tumor	O
15	results	O
16	in	O
17	a	O
18	chimeric	O
19	molecule	O
20	fusing	O
21	the	O
22	amino	O
23	-	O
24	terminal	O
25	-	O
26	encoding	O
27	portion	O
28	of	O
29	the	O
30	EWS	B
31	gene	I
32	to	O
33	the	O
34	carboxyl	O
35	-	O
36	terminal	O
37	DNA	O
38	-	O
39	binding	O
40	domain	O
41	encoded	O
42	by	O
43	the	O
44	FLI1	B
45	gene	I
46	.	O

0	Particularly	O
1	striking	O
2	was	O
3	the	O
4	conservation	O
5	of	O
6	an	O
7	AP	B
8	-	I
9	4	I
10	binding	I
11	site	I
12	within	O
13	100	O
14	nucleotides	O
15	upstream	O
16	of	O
17	the	O
18	transcription	O
19	initiation	O
20	site	O
21	in	O
22	both	O
23	Aal	B
24	-	I
25	rpL34	I
26	and	O
27	Aal	B
28	-	I
29	rpL8	I
30	genes	I
31	.	O

0	We	O
1	sought	O
2	to	O
3	determine	O
4	whether	O
5	such	O
6	differences	O
7	in	O
8	polyadenylation	O
9	affect	O
10	the	O
11	steady	O
12	-	O
13	state	O
14	levels	O
15	of	O
16	DHFR	B
17	and	O
18	mRNAs	O
19	expressed	O
20	from	O
21	either	O
22	allele	O
23	and	O
24	,	O
25	in	O
26	a	O
27	more	O
28	general	O
29	sense	O
30	,	O
31	to	O
32	ask	O
33	whether	O
34	differences	O
35	in	O
36	3	O
37	'	O
38	end	O
39	RNA	O
40	processing	O
41	in	O
42	a	O
43	gene	O
44	containing	O
45	multiple	O
46	poly	O
47	(	O
48	A	O
49	)	O
50	sites	O
51	affects	O
52	the	O
53	final	O
54	level	O
55	of	O
56	gene	O
57	expression	O
58	.	O

0	In	O
1	our	O
2	previous	O
3	studies	O
4	,	O
5	transcriptional	O
6	activation	O
7	was	O
8	shown	O
9	to	O
10	correlate	O
11	with	O
12	IEP86	B
13	binding	O
14	to	O
15	both	O
16	the	O
17	TATA	B
18	-	I
19	box	I
20	binding	I
21	protein	I
22	(	O
23	TBP	B
24	)	O
25	and	O
26	the	O
27	transcription	O
28	factor	O
29	bound	O
30	upstream	O
31	.	O

0	Sterol	O
1	analysis	O
2	of	O
3	the	O
4	disrupted	O
5	mutant	O
6	demonstrated	O
7	the	O
8	accumulation	O
9	of	O
10	ignosterol	O
11	,	O
12	indicating	O
13	a	O
14	loss	O
15	of	O
16	Erg24p	B
17	activity	O
18	.	O

0	Immunohistochemical	O
1	staining	O
2	with	O
3	MIB	B
4	-	I
5	1	I
6	and	O
7	p53	B
8	antibodies	I
9	showed	O
10	low	O
11	(<	O
12	1	O
13	%)	O
14	and	O
15	negative	O
16	reaction	O
17	.	O

0	Moreover	O
1	,	O
2	the	O
3	major	O
4	site	O
5	of	O
6	transcriptional	O
7	initiation	O
8	,	O
9	which	O
10	was	O
11	localized	O
12	by	O
13	primer	O
14	extension	O
15	250	O
16	bp	O
17	upstream	O
18	of	O
19	the	O
20	5	O
21	'	O
22	end	O
23	of	O
24	the	O
25	Ets	B
26	-	I
27	1	I
28	cDNA	I
29	clone	I
30	,	O
31	was	O
32	shown	O
33	to	O
34	be	O
35	identical	O
36	in	O
37	normal	O
38	cells	O
39	and	O
40	tumors	O
41	carrying	O
42	a	O
43	provirus	O
44	in	O
45	the	O
46	Tpl	B
47	-	I
48	1	I
49	locus	I
50	.	O

0	Because	O
1	the	O
2	Pit	B
3	-	I
4	1	I
5	sites	I
6	in	O
7	the	O
8	hGH	B
9	-	I
10	N	I
11	gene	I
12	promoter	I
13	are	O
14	insufficient	O
15	for	O
16	such	O
17	gene	O
18	activation	O
19	in	O
20	vivo	O
21	,	O
22	these	O
23	data	O
24	suggested	O
25	a	O
26	unique	O
27	chromatin	O
28	-	O
29	mediated	O
30	developmental	O
31	role	O
32	for	O
33	Pit	B
34	-	I
35	1	I
36	in	O
37	the	O
38	hGH	B
39	LCR	I
40	.	O

0	A	O
1	new	O
2	bioencapsulation	O
3	technology	O
4	for	O
5	microbial	O
6	inoculants	O
7	.	O

0	Ischaemia	O
1	was	O
2	induced	O
3	by	O
4	a	O
5	low	O
6	flow	O
7	rate	O
8	of	O
9	0	O
10	.	O
11	8	O
12	mL	O
13	min	O
14	-	O
15	1	O
16	for	O
17	30	O
18	min	O
19	,	O
20	and	O
21	was	O
22	followed	O
23	by	O
24	a	O
25	40	O
26	-	O
27	minute	O
28	reperfusion	O
29	.	O

0	In	O
1	contrast	O
2	,	O
3	the	O
4	action	O
5	of	O
6	GLP	B
7	-	I
8	1	I
9	at	O
10	the	O
11	CRE	O
12	was	O
13	not	O
14	blocked	O
15	by	O
16	cotransfection	O
17	with	O
18	M1	B
19	-	O
20	CREB	B
21	,	O
22	an	O
23	isoform	O
24	that	O
25	lacks	O
26	a	O
27	consensus	O
28	serine	O
29	residue	O
30	serving	O
31	as	O
32	substrate	O
33	for	O
34	PKA	B
35	-	O
36	mediated	O
37	phosphorylation	O
38	.	O

0	The	O
1	murine	O
2	mutation	O
3	dominant	O
4	white	O
5	spotting	O
6	(	O
7	W	O
8	)	O
9	is	O
10	in	O
11	the	O
12	proto	O
13	-	O
14	oncogene	O
15	,	O
16	c	B
17	-	I
18	kit	I
19	.	O

0	Studies	O
1	suggest	O
2	that	O
3	the	O
4	DGOR	O
5	without	O
6	acid	O
7	reflux	O
8	may	O
9	result	O
10	in	O
11	symptoms	O
12	but	O
13	unless	O
14	acid	O
15	reflux	O
16	is	O
17	present	O
18	simultaneously	O
19	,	O
20	it	O
21	does	O
22	not	O
23	cause	O
24	oesophagitis	O
25	.	O

0	The	O
1	high	B
2	density	I
3	lipoprotein	I
4	(	O
5	HDL	B
6	)	I
7	receptor	I
8	mediates	O
9	the	O
10	uptake	O
11	of	O
12	cholesterol	O
13	and	O
14	cholesteryl	O
15	esters	O
16	,	O
17	substrates	O
18	for	O
19	steroidogenesis	O
20	,	O
21	from	O
22	an	O
23	HDL	B
24	particle	O
25	in	O
26	the	O
27	adrenal	O
28	gland	O
29	and	O
30	gonads	O
31	.	O

0	These	O
1	results	O
2	indicate	O
3	that	O
4	mutL	B
5	,	O
6	miaA	B
7	,	O
8	and	O
9	hfq	B
10	expression	O
11	could	O
12	be	O
13	regulated	O
14	by	O
15	multiple	O
16	mechanisms	O
17	,	O
18	including	O
19	degree	O
20	of	O
21	cotranscription	O
22	from	O
23	upstream	O
24	genes	O
25	,	O
26	modulation	O
27	of	O
28	internal	O
29	promoter	O
30	strength	O
31	,	O
32	and	O
33	by	O
34	RNase	B
35	E	I
36	activity	O
37	.	O

0	These	O
1	results	O
2	demonstrate	O
3	that	O
4	endogenous	O
5	N	O
6	-	O
7	methylation	O
8	of	O
9	salsolinol	O
10	into	O
11	N	O
12	-	O
13	methylsalsolinol	O
14	occurs	O
15	in	O
16	the	O
17	brain	O
18	in	O
19	vivo	O
20	.	O

0	Comparable	O
1	amounts	O
2	of	O
3	alpha	B
4	5	I
5	beta	I
6	1	I
7	integrin	I
8	were	O
9	isolated	O
10	from	O
11	these	O
12	cells	O
13	by	O
14	chromatography	O
15	of	O
16	detergent	O
17	extracts	O
18	on	O
19	a	O
20	fibronectin	B
21	cell	O
22	-	O
23	binding	O
24	fragment	O
25	affinity	O
26	column	O
27	and	O
28	elution	O
29	with	O
30	EDTA	O
31	.	O

0	Double	O
1	-	O
2	staining	O
3	confirmed	O
4	that	O
5	there	O
6	were	O
7	separate	O
8	populations	O
9	of	O
10	CD68	B
11	-	O
12	positive	O
13	macrophages	O
14	and	O
15	XIIIa	O
16	-	O
17	positive	O
18	dendrocytes	O
19	.	O

0	Since	O
1	1968	O
2	,	O
3	a	O
4	steep	O
5	decrease	O
6	in	O
7	the	O
8	number	O
9	of	O
10	strains	O
11	resistant	O
12	to	O
13	three	O
14	or	O
15	more	O
16	antibiotics	O
17	(	O
18	multiple	O
19	-	O
20	resistant	O
21	)	O
22	and	O
23	in	O
24	strains	O
25	of	O
26	the	O
27	83A	O
28	complex	O
29	was	O
30	noticed	O
31	.	O

0	Using	O
1	the	O
2	rap1t	B
3	alleles	I
4	to	O
5	generate	O
6	wild	O
7	-	O
8	type	O
9	cells	O
10	differing	O
11	only	O
12	in	O
13	telomere	O
14	tract	O
15	lengths	O
16	,	O
17	we	O
18	also	O
19	show	O
20	that	O
21	telomere	O
22	position	O
23	effects	O
24	are	O
25	highly	O
26	sensitive	O
27	to	O
28	changes	O
29	in	O
30	the	O
31	size	O
32	(	O
33	or	O
34	structure	O
35	)	O
36	of	O
37	the	O
38	telomeric	O
39	tract	O
40	.	O

0	A511	O
1	is	O
2	a	O
3	broad	O
4	-	O
5	host	O
6	-	O
7	range	O
8	,	O
9	virulent	O
10	myovirus	O
11	for	O
12	Listeria	O
13	monocytogenes	O
14	.	O

0	Closure	O
1	of	O
2	an	O
3	open	O
4	high	O
5	below	O
6	-	O
7	knee	O
8	guillotine	O
9	amputation	O
10	wound	O
11	using	O
12	a	O
13	skin	O
14	-	O
15	stretching	O
16	device	O
17	.	O

0	Experiment	O
1	3	O
2	showed	O
3	that	O
4	the	O
5	long	O
6	-	O
7	term	O
8	analgesic	O
9	reaction	O
10	could	O
11	also	O
12	be	O
13	reduced	O
14	by	O
15	administration	O
16	of	O
17	naltrexone	O
18	prior	O
19	to	O
20	reexposure	O
21	to	O
22	shock	O
23	.	O

0	The	O
1	zta	B
2	transactivator	I
3	involved	O
4	in	O
5	induction	O
6	of	O
7	lytic	O
8	cycle	O
9	gene	O
10	expression	O
11	in	O
12	Epstein	O
13	-	O
14	Barr	O
15	virus	O
16	-	O
17	infected	O
18	lymphocytes	O
19	binds	O
20	to	O
21	both	O
22	AP	B
23	-	I
24	1	I
25	and	O
26	ZRE	B
27	sites	I
28	in	O
29	target	O
30	promoter	O
31	and	O
32	enhancer	O
33	regions	O
34	.	O

0	Purified	O
1	spleen	O
2	GAP	O
3	accelerated	O
4	hydrolysis	O
5	of	O
6	GTP	O
7	bound	O
8	to	O
9	recombinant	B
10	ARF1	I
11	,	O
12	ARF3	B
13	,	O
14	ARF5	B
15	,	O
16	and	O
17	ARF6	B
18	;	O
19	no	O
20	effect	O
21	of	O
22	NH2	O
23	-	O
24	terminal	O
25	myristoylation	O
26	was	O
27	observed	O
28	.	O

0	The	O
1	absence	O
2	of	O
3	H4PteGlun	B
4	bound	O
5	to	O
6	the	O
7	T	B
8	protein	I
9	in	O
10	our	O
11	experimental	O
12	conditions	O
13	demonstrates	O
14	that	O
15	H4PteGlun	B
16	is	O
17	not	O
18	covalently	O
19	linked	O
20	to	O
21	the	O
22	T	B
23	protein	I
24	.	O

0	A	O
1	cDNA	O
2	encoding	O
3	a	O
4	putative	O
5	RNA	B
6	and	I
7	/	I
8	or	I
9	DNA	B
10	helicase	I
11	has	O
12	been	O
13	isolated	O
14	from	O
15	Arabidopsis	O
16	thaliana	O
17	cDNA	O
18	libraries	O
19	.	O

0	Echosismography	O
1	enables	O
2	to	O
3	improve	O
4	the	O
5	diagnosis	O
6	when	O
7	compared	O
8	with	O
9	classical	O
10	sonography	O
11	in	O
12	about	O
13	20	O
14	%	O
15	of	O
16	cases	O
17	.	O

0	Transfer	O
1	also	O
2	correlated	O
3	inversely	O
4	with	O
5	gastric	O
6	juice	O
7	pH	O
8	(	O
9	r	O
10	=	O
11	-	O
12	0	O
13	.	O
14	619	O
15	,	O
16	P	O
17	<	O
18	0	O
19	.	O
20	02	O
21	).	O

0	However	O
1	,	O
2	there	O
3	was	O
4	a	O
5	difference	O
6	in	O
7	the	O
8	quality	O
9	of	O
10	immunity	O
11	:	O
12	fever	O
13	and	O
14	body	O
15	weight	O
16	loss	O
17	were	O
18	seen	O
19	in	O
20	hamsters	O
21	vaccinated	O
22	with	O
23	the	O
24	killed	O
25	-	O
26	toxoplasma	O
27	vaccine	O
28	after	O
29	they	O
30	were	O
31	challenge	O
32	exposed	O
33	with	O
34	T	O
35	-	O
36	1	O
37	strain	O
38	,	O
39	whereas	O
40	these	O
41	changes	O
42	were	O
43	rarely	O
44	seen	O
45	in	O
46	hamsters	O
47	given	O
48	the	O
49	live	O
50	-	O
51	toxoplasma	O
52	vaccine	O
53	and	O
54	then	O
55	challenge	O
56	exposed	O
57	with	O
58	RH	O
59	strain	O
60	.	O

0	CONCLUSION	O
1	:	O
2	The	O
3	authors	O
4	emphasize	O
5	that	O
6	the	O
7	initial	O
8	management	O
9	of	O
10	primary	O
11	STS	O
12	should	O
13	be	O
14	adequate	O
15	and	O
16	suggest	O
17	that	O
18	safty	O
19	margin	O
20	of	O
21	>	O
22	or	O
23	=	O
24	2	O
25	cm	O
26	should	O
27	be	O
28	adhered	O
29	to	O
30	.	O

0	A	O
1	clinically	O
2	useful	O
3	diagnostic	O
4	method	O
5	has	O
6	been	O
7	developed	O
8	for	O
9	detecting	O
10	and	O
11	quantitating	O
12	periods	O
13	of	O
14	apnea	O
15	in	O
16	pediatric	O
17	patients	O
18	.	O

0	Five	O
1	healthy	O
2	male	O
3	subjects	O
4	inspired	O
5	air	O
6	for	O
7	20	O
8	min	O
9	and	O
10	then	O
11	5	O
12	%	O
13	CO2	O
14	/	O
15	95	O
16	%	O
17	O2	O
18	for	O
19	30	O
20	min	O
21	,	O
22	of	O
23	which	O
24	the	O
25	first	O
26	10	O
27	min	O
28	was	O
29	used	O
30	to	O
31	achieve	O
32	a	O
33	steady	O
34	-	O
35	state	O
36	end	O
37	-	O
38	tidal	O
39	CO2	O
40	measurement	O
41	.	O

0	In	O
1	most	O
2	cases	O
3	of	O
4	acute	O
5	transmural	O
6	infarction	O
7	,	O
8	the	O
9	reciprocal	O
10	ST	O
11	segment	O
12	depressions	O
13	observed	O
14	in	O
15	contralateral	O
16	leads	O
17	are	O
18	less	O
19	marked	O
20	than	O
21	the	O
22	primary	O
23	ST	O
24	segment	O
25	elevations	O
26	.	O

0	Tests	O
1	showed	O
2	that	O
3	an	O
4	overall	O
5	impression	O
6	of	O
7	the	O
8	force	O
9	applied	O
10	could	O
11	be	O
12	obtained	O
13	from	O
14	a	O
15	laboratory	O
16	simulation	O
17	,	O
18	but	O
19	that	O
20	clearing	O
21	cement	O
22	and	O
23	testing	O
24	cement	O
25	were	O
26	not	O
27	modelled	O
28	by	O
29	this	O
30	method	O
31	.	O

0	Kinetic	O
1	coupling	O
2	and	O
3	requirement	O
4	for	O
5	ATP	O
6	hydrolysis	O
7	.	O

0	We	O
1	show	O
2	here	O
3	that	O
4	v	B
5	-	I
6	Rel	I
7	specifically	O
8	increased	O
9	expression	O
10	from	O
11	a	O
12	reporter	O
13	plasmid	O
14	containing	O
15	multiple	O
16	Sp1	B
17	binding	I
18	sites	I
19	approximately	O
20	sixfold	O
21	in	O
22	chicken	O
23	embryo	O
24	fibroblasts	O
25	(	O
26	CEFs	O
27	),	O
28	even	O
29	though	O
30	v	B
31	-	I
32	Rel	I
33	did	O
34	not	O
35	bind	O
36	directly	O
37	to	O
38	these	O
39	sites	O
40	.	O
41	v	B
42	-	I
43	Rel	I
44	also	O
45	increased	O
46	expression	O
47	from	O
48	a	O
49	reporter	O
50	plasmid	O
51	containing	O
52	a	O
53	human	O
54	immunodeficiency	O
55	virus	O
56	type	O
57	1	O
58	(	O
59	HIV	O
60	-	O
61	1	O
62	)	O
63	long	O
64	terminal	O
65	repeat	O
66	(	O
67	LTR	O
68	)	O
69	in	O
70	which	O
71	the	O
72	kappa	B
73	B	I
74	binding	I
75	sites	I
76	were	O
77	mutated	O
78	but	O
79	which	O
80	still	O
81	contained	O
82	intact	O
83	Sp1	B
84	binding	I
85	sites	I
86	.	O

0	For	O
1	the	O
2	first	O
3	time	O
4	we	O
5	describe	O
6	deletion	O
7	and	O
8	point	O
9	mutations	O
10	within	O
11	the	O
12	plasma	O
13	membrane	O
14	family	O
15	of	O
16	guanylyl	B
17	cyclase	I
18	receptors	I
19	that	O
20	result	O
21	in	O
22	the	O
23	formation	O
24	of	O
25	effective	O
26	dominant	O
27	negative	O
28	proteins	O
29	.	O

0	These	O
1	factors	O
2	belong	O
3	to	O
4	a	O
5	set	O
6	of	O
7	genetically	O
8	distinct	O
9	molecules	O
10	,	O
11	including	O
12	AP	B
13	-	I
14	4	I
15	and	O
16	MLTF	B
17	,	O
18	that	O
19	bind	O
20	to	O
21	the	O
22	CACCTGTC	O
23	motif	O
24	or	O
25	related	O
26	sequences	O
27	.	O

0	To	O
1	study	O
2	the	O
3	regulation	O
4	of	O
5	its	O
6	expression	O
7	,	O
8	the	O
9	human	B
10	aldehyde	I
11	reductase	I
12	gene	I
13	and	O
14	promoter	O
15	were	O
16	cloned	O
17	and	O
18	characterized	O
19	.	O

0	This	O
1	paper	O
2	presents	O
3	the	O
4	reasons	O
5	why	O
6	countries	O
7	to	O
8	which	O
9	Chagas	O
10	disease	O
11	is	O
12	endemic	O
13	should	O
14	carry	O
15	out	O
16	the	O
17	relevant	O
18	research	O
19	themselves	O
20	.	O

0	These	O
1	findings	O
2	suggest	O
3	that	O
4	both	O
5	in	O
6	the	O
7	early	O
8	stages	O
9	(	O
10	0T	O
11	,	O
12	0N	O
13	)	O
14	and	O
15	in	O
16	more	O
17	severe	O
18	stages	O
19	of	O
20	VWF	O
21	(	O
22	stages	O
23	1	O
24	-	O
25	2	O
26	)	O
27	cold	O
28	induced	O
29	hyperreactivity	O
30	in	O
31	the	O
32	digital	O
33	vessels	O
34	and	O
35	Raynaud	O
36	'	O
37	s	O
38	syndrome	O
39	are	O
40	vascular	O
41	disorders	O
42	of	O
43	functional	O
44	origin	O
45	occurring	O
46	without	O
47	any	O
48	prethrombotic	O
49	alterations	O
50	.	O

0	The	O
1	ventilation	O
2	did	O
3	not	O
4	increase	O
5	when	O
6	PACO2	O
7	was	O
8	increased	O
9	.	O

0	The	O
1	linear	O
2	plasmid	O
3	pCLU1	O
4	from	O
5	the	O
6	yeast	O
7	Kluyveromyces	O
8	lactis	O
9	normally	O
10	replicates	O
11	in	O
12	the	O
13	cytoplasm	O
14	,	O
15	with	O
16	the	O
17	aid	O
18	of	O
19	the	O
20	helper	O
21	linear	O
22	plasmid	O
23	pGKL2	O
24	,	O
25	using	O
26	terminal	O
27	protein	O
28	(	O
29	TP	O
30	)	O
31	as	O
32	a	O
33	primer	O
34	.	O

0	In	O
1	a	O
2	112	O
3	-	O
4	d	O
5	feedlot	O
6	trial	O
7	,	O
8	105	O
9	heifers	O
10	were	O
11	assigned	O
12	to	O
13	light	O
14	,	O
15	medium	O
16	and	O
17	heavy	O
18	weight	O
19	blocks	O
20	on	O
21	five	O
22	treatments	O
23	:	O
24	dietary	O
25	MGA	O
26	(.	O
27	5	O
28	mg	O
29	.	O
30	hd	O
31	-	O
32	1	O
33	.	O
34	d	O
35	-	O
36	1	O
37	),	O
38	control	O
39	(	O
40	no	O
41	MGA	O
42	)	O
43	or	O
44	DEPO	O
45	-	O
46	MGA	O
47	on	O
48	d	O
49	1	O
50	at	O
51	.	O
52	5	O
53	,	O
54	1	O
55	.	O
56	0	O
57	or	O
58	1	O
59	.	O
60	5	O
61	ml	O
62	/	O
63	hd	O
64	(	O
65	30	O
66	,	O
67	60	O
68	or	O
69	90	O
70	mg	O
71	MGA	O
72	/	O
73	hd	O
74	,	O
75	respectively	O
76	).	O

0	Identification	O
1	of	O
2	Ets	B
3	-	I
4	and	I
5	notch	I
6	-	I
7	related	I
8	subunits	I
9	in	O
10	GA	B
11	binding	I
12	protein	I
13	.	O

0	The	O
1	addition	O
2	of	O
3	a	O
4	Paf	B
5	-	O
6	containing	O
7	extract	O
8	does	O
9	not	O
10	lead	O
11	to	O
12	significant	O
13	protein	O
14	binding	O
15	to	O
16	these	O
17	two	O
18	hly	B
19	target	I
20	sequences	I
21	in	O
22	the	O
23	absence	O
24	of	O
25	PrfA	B
26	but	O
27	converts	O
28	the	O
29	complex	O
30	(	O
31	CIII	B
32	)	O
33	consisting	O
34	of	O
35	PrfA	B
36	and	O
37	the	O
38	109	O
39	bp	O
40	hly	O
41	DNA	O
42	fragment	O
43	to	O
44	a	O
45	slower	O
46	migrating	O
47	PrfA	B
48	-	O
49	Paf	B
50	-	I
51	DNA	I
52	complex	I
53	(	O
54	CI	B
55	).	O

0	The	O
1	HMG	B
2	CoA	I
3	reductase	I
4	inhibitors	O
5	are	O
6	the	O
7	most	O
8	effective	O
9	cholesterol	O
10	-	O
11	lowering	O
12	agents	O
13	currently	O
14	available	O
15	.	O

0	Changing	O
1	and	O
2	predicting	O
3	doses	O
4	of	O
5	Cs137	O
6	irradiation	O

0	The	O
1	levels	O
2	of	O
3	fibrinogen	B
4	as	O
5	well	O
6	as	O
7	antithrombin	B
8	III	I
9	(	O
10	ATIII	B
11	)	O
12	and	O
13	heparin	B
14	cofactor	I
15	II	I
16	(	O
17	HCII	B
18	)	O
19	activities	O
20	were	O
21	steadily	O
22	increased	O
23	in	O
24	loop	O
25	-	O
26	bearing	O
27	animals	O
28	.	O

0	In	O
1	this	O
2	study	O
3	,	O
4	we	O
5	have	O
6	cloned	O
7	the	O
8	human	B
9	DSG3	I
10	gene	I
11	and	O
12	examined	O
13	the	O
14	transcriptional	O
15	regulation	O
16	of	O
17	its	O
18	expression	O
19	.	O

0	We	O
1	have	O
2	found	O
3	that	O
4	the	O
5	expression	O
6	of	O
7	GTPase	B
8	-	O
9	deficient	O
10	mutants	O
11	of	O
12	alpha	O
13	12	O
14	(	O
15	alpha	O
16	12Q229L	O
17	)	O
18	or	O
19	alpha	O
20	13	O
21	(	O
22	alpha	O
23	13Q226L	O
24	)	O
25	leads	O
26	to	O
27	robust	O
28	activation	O
29	of	O
30	the	O
31	Jun	B
32	kinase	I
33	/	O
34	stress	B
35	-	I
36	activated	I
37	protein	I
38	kinase	I
39	(	O
40	JNK	B
41	/	O
42	SAPK	B
43	)	O
44	pathway	O
45	.	O

0	CONCLUSIONS	O
1	:	O
2	Two	O
3	consecutive	O
4	sets	O
5	of	O
6	transrectal	O
7	ultrasound	O
8	guided	O
9	sextant	O
10	biopsies	O
11	of	O
12	the	O
13	prostate	O
14	performed	O
15	in	O
16	a	O
17	single	O
18	office	O
19	visit	O
20	represent	O
21	a	O
22	cost	O
23	-	O
24	effective	O
25	biopsy	O
26	strategy	O
27	for	O
28	men	O
29	presenting	O
30	with	O
31	an	O
32	abnormal	O
33	digital	O
34	rectal	O
35	examination	O
36	and	O
37	/	O
38	or	O
39	elevated	O
40	serum	O
41	PSA	O
42	.	O

0	The	O
1	histopathology	O
2	and	O
3	neovascularization	O
4	did	O
5	not	O
6	appreciably	O
7	differ	O
8	between	O
9	xenograft	O
10	tumors	O
11	derived	O
12	from	O
13	FGF4	B
14	over	O
15	-	O
16	expressing	O
17	versus	O
18	control	O
19	transfectants	O
20	.	O

0	ORFA	O
1	and	O
2	ccdA	B
3	were	O
4	constitutively	O
5	cotranscribed	O
6	as	O
7	determined	O
8	by	O
9	primer	O
10	extension	O
11	analysis	O
12	.	O

0	To	O
1	get	O
2	further	O
3	insights	O
4	into	O
5	the	O
6	molecular	O
7	mechanisms	O
8	that	O
9	control	O
10	tal	B
11	-	I
12	1	I
13	expression	O
14	,	O
15	we	O
16	have	O
17	isolated	O
18	5	O
19	'	O
20	sequences	O
21	of	O
22	the	O
23	murine	O
24	gene	O
25	and	O
26	compared	O
27	them	O
28	to	O
29	their	O
30	human	O
31	counterparts	O
32	.	O

0	HL	B
1	-	I
2	A	I
3	antibodies	I
4	in	O
5	polytransfused	O
6	patients	O

0	Hemodynamic	O
1	assessment	O
2	was	O
3	obtained	O
4	before	O
5	and	O
6	following	O
7	administration	O
8	of	O
9	digoxin	O
10	10	O
11	micrograms	O
12	/	O
13	kg	O
14	IV	O
15	or	O
16	dopamine	O
17	,	O
18	5	O
19	to	O
20	12	O
21	micrograms	O
22	/	O
23	kg	O
24	/	O
25	min	O
26	IV	O
27	.	O

0	Thirty	O
1	-	O
2	five	O
3	strains	O
4	of	O
5	Legionnaires	O
6	'	O
7	disease	O
8	bacteria	O
9	were	O
10	shown	O
11	to	O
12	belong	O
13	in	O
14	four	O
15	distinct	O
16	serologic	O
17	groups	O
18	on	O
19	the	O
20	basis	O
21	of	O
22	findings	O
23	obtained	O
24	with	O
25	direct	O
26	fluorescent	O
27	antibody	O
28	testing	O
29	.	O

0	Previous	O
1	analysis	O
2	of	O
3	the	O
4	98	O
5	-	O
6	bp	O
7	sequence	O
8	has	O
9	delineated	O
10	several	O
11	protein	O
12	-	O
13	binding	O
14	domains	O
15	that	O
16	are	O
17	recognized	O
18	by	O
19	nuclear	O
20	factors	O
21	present	O
22	in	O
23	human	O
24	brain	O
25	cells	O
26	.	O

0	STUDY	O
1	DESIGN	O
2	.	O

0	Members	O
1	of	O
2	the	O
3	C	B
4	/	I
5	EBP	I
6	family	I
7	of	O
8	basic	B
9	-	I
10	leucine	I
11	zipper	I
12	(	I
13	bZip	I
14	)	I
15	transcription	I
16	factors	I
17	form	O
18	heterodimers	O
19	and	O
20	bind	O
21	to	O
22	the	O
23	CAAT	O
24	box	O
25	and	O
26	other	O
27	sequence	O
28	-	O
29	related	O
30	enhancer	O
31	motifs	O
32	.	O

0	Enhancer	O
1	activity	O
2	requires	O
3	both	O
4	the	O
5	AP	B
6	-	I
7	1	I
8	site	I
9	and	O
10	these	O
11	adjacent	O
12	sequences	O
13	.	O

0	Thrombotic	O
1	thrombocytopenic	O
2	purpura	O
3	in	O
4	systemic	O
5	lupus	O
6	erythematosus	O
7	.	O

0	Both	O
1	groups	O
2	rejected	O
3	pops	O
4	with	O
5	added	O
6	SOA	O
7	,	O
8	decreasing	O
9	mouthing	O
10	times	O
11	as	O
12	SOA	O
13	concentration	O
14	increased	O
15	.	O

0	Greater	O
1	attenuation	O
2	of	O
3	the	O
4	N1	O
5	-	O
6	P2	O
7	and	O
8	baseline	O
9	-	O
10	P2	O
11	amplitude	O
12	of	O
13	the	O
14	probe	O
15	EPs	O
16	was	O
17	observed	O
18	when	O
19	the	O
20	probe	O
21	stimulus	O
22	was	O
23	presented	O
24	to	O
25	the	O
26	right	O
27	ear	O
28	and	O
29	the	O
30	verbal	O
31	material	O
32	presented	O
33	to	O
34	the	O
35	left	O
36	ear	O
37	than	O
38	when	O
39	the	O
40	opposite	O
41	stimulation	O
42	arrangement	O
43	was	O
44	used	O
45	.	O

0	The	O
1	TIMP	B
2	(-	O
3	59	O
4	/	O
5	-	I
6	53	I
7	)	I
8	AP1	I
9	site	I
10	is	O
11	a	O
12	promiscuous	O
13	motif	O
14	that	O
15	binds	O
16	c	B
17	-	I
18	Fos	I
19	/	O
20	c	B
21	-	I
22	Jun	I
23	AP1	I
24	translated	O
25	in	O
26	vitro	O
27	and	O
28	is	O
29	an	O
30	effective	O
31	competitor	O
32	for	O
33	binding	O
34	of	O
35	nuclear	B
36	AP1	I
37	factors	I
38	to	O
39	the	O
40	consensus	O
41	TRE	O
42	,	O
43	but	O
44	in	O
45	addition	O
46	it	O
47	binds	O
48	factors	O
49	that	O
50	do	O
51	not	O
52	associate	O
53	with	O
54	the	O
55	consensus	O
56	TRE	O
57	.	O

0	EXERCISE	O
1	IN	O
2	THE	O
3	TERRESTRIAL	O
4	CHRISTMAS	O
5	ISLAND	O
6	RED	O
7	CRAB	O
8	GECARCOIDEA	O
9	NATALIS	O
10	-	O
11	ENERGETICS	O
12	OF	O
13	LOCOMOTION	O

0	Commun	O
1	.	O

0	Histopathologically	O
1	,	O
2	a	O
3	cystic	O
4	lymphangioma	O
5	was	O
6	diagnosed	O
7	because	O
8	of	O
9	the	O
10	morphological	O
11	features	O
12	and	O
13	the	O
14	immunohistochemical	O
15	stainings	O
16	of	O
17	CD34	B
18	and	O
19	Factor	B
20	VIII	I
21	related	I
22	antigen	I
23	which	O
24	were	O
25	observed	O
26	positive	O
27	reactions	O
28	in	O
29	endothelial	O
30	cells	O
31	of	O
32	the	O
33	cysts	O
34	.	O

0	It	O
1	is	O
2	concluded	O
3	that	O
4	the	O
5	plasma	B
6	prolactin	B
7	response	O
8	to	O
9	12	O
10	.	O
11	5	O
12	micrograms	O
13	i	O
14	.	O
15	v	O
16	.	O

0	Proprotein	O
1	processing	O
2	occurs	O
3	intracellularly	O
4	.	O

0	Since	O
1	proteins	O
2	containing	O
3	TPR	O
4	elements	O
5	are	O
6	typically	O
7	involved	O
8	in	O
9	multiple	O
10	protein	O
11	-	O
12	protein	O
13	interactions	O
14	,	O
15	we	O
16	suggest	O
17	that	O
18	the	O
19	102kD	B
20	protein	I
21	interacts	O
22	within	O
23	the	O
24	tri	O
25	-	O
26	snRNP	O
27	with	O
28	both	O
29	the	O
30	U5	B
31	and	O
32	U4	B
33	/	O
34	U6	B
35	snRNPs	I
36	,	O
37	thus	O
38	bridging	O
39	the	O
40	two	O
41	particles	O
42	.	O

0	Thus	O
1	,	O
2	cibenzoline	O
3	is	O
4	an	O
5	effective	O
6	antiarrhythmic	O
7	agent	O
8	with	O
9	a	O
10	favourable	O
11	pharmacokinetic	O
12	profile	O
13	that	O
14	may	O
15	be	O
16	considered	O
17	with	O
18	other	O
19	class	O
20	I	O
21	drugs	O
22	in	O
23	patients	O
24	requiring	O
25	therapy	O
26	for	O
27	high	O
28	risk	O
29	arrhythmias	O
30	.	O

0	Disulfiram	O
1	and	O
2	the	O
3	drug	O
4	-	O
5	induced	O
6	effects	O
7	on	O
8	motility	O
9	.	O

0	In	O
1	myometrial	O
2	SMC	O
3	,	O
4	both	O
5	isoforms	O
6	of	O
7	the	O
8	progesterone	B
9	receptor	I
10	,	O
11	PR	B
12	-	I
13	B	I
14	and	O
15	PR	B
16	-	I
17	A	I
18	,	O
19	caused	O
20	a	O
21	ligand	O
22	-	O
23	dependent	O
24	activation	O
25	of	O
26	PGDH	B
27	-	I
28	2368	I
29	/	O
30	luc3	B
31	.	O

0	These	O
1	results	O
2	imply	O
3	that	O
4	the	O
5	GCN3	B
6	product	I
7	can	O
8	promote	O
9	either	O
10	repression	O
11	or	O
12	activation	O
13	of	O
14	GCN4	B
15	expression	O
16	depending	O
17	on	O
18	amino	O
19	acid	O
20	availability	O
21	.	O

0	Animal	O
1	studies	O
2	showed	O
3	that	O
4	beam	O
5	equalization	O
6	significantly	O
7	improved	O
8	fluoroscopic	O
9	and	O
10	angiographic	O
11	image	O
12	quality	O
13	.	O

0	All	O
1	were	O
2	experienced	O
3	hearing	O
4	aid	O
5	users	O
6	who	O
7	wore	O
8	linear	O
9	Class	O
10	D	O
11	instruments	O
12	with	O
13	input	O
14	compression	O
15	limiting	O
16	at	O
17	the	O
18	time	O
19	of	O
20	their	O
21	enrollment	O
22	in	O
23	this	O
24	study	O
25	.	O

0	The	O
1	activity	O
2	of	O
3	the	O
4	minimal	O
5	promoter	O
6	was	O
7	found	O
8	to	O
9	be	O
10	controlled	O
11	by	O
12	a	O
13	combination	O
14	of	O
15	the	O
16	activities	O
17	of	O
18	the	O
19	transcription	O
20	factors	O
21	Sp1	B
22	,	O
23	Sp3	B
24	,	O
25	and	O
26	NF	B
27	-	I
28	Y	I
29	.	O

0	Serotonin	B
1	5	I
2	-	I
3	HT2	I
4	receptor	I
5	binding	O
6	on	O
7	blood	O
8	platelets	O
9	as	O
10	a	O
11	state	O
12	dependent	O
13	marker	O
14	in	O
15	major	O
16	affective	O
17	disorder	O
18	.	O

0	Type	O
1	I	O
2	position	O
3	-	O
4	vestibular	O
5	-	O
6	pause	O
7	(	O
8	PVP	O
9	I	O
10	)	O
11	and	O
12	vestibular	O
13	-	O
14	only	O
15	(	O
16	V	O
17	I	O
18	)	O
19	neurons	O
20	,	O
21	as	O
22	well	O
23	as	O
24	a	O
25	smaller	O
26	number	O
27	of	O
28	other	O
29	type	O
30	I	O
31	and	O
32	type	O
33	II	O
34	eye	O
35	-	O
36	plus	O
37	-	O
38	vestibular	O
39	neurons	O
40	were	O
41	studied	O
42	.	O

0	Nonsynonymous	O
1	substitution	O
2	in	O
3	abalone	O
4	sperm	O
5	fertilization	O
6	genes	O
7	exceeds	O
8	substitution	O
9	in	O
10	introns	O
11	and	O
12	mitochondrial	O
13	DNA	O
14	.	O

0	A	O
1	comparative	O
2	study	O
3	was	O
4	undertaken	O
5	between	O
6	an	O
7	enzymatic	O
8	immunohistochemical	O
9	technique	O
10	(	O
11	EIT	O
12	)	O
13	developed	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	human	O
19	trichinellosis	O
20	and	O
21	the	O
22	indirect	O
23	immunofluorescence	O
24	test	O
25	(	O
26	IIF	O
27	),	O
28	analysing	O
29	sera	O
30	from	O
31	outbreaks	O
32	of	O
33	human	O
34	trichinellosis	O
35	in	O
36	Argentina	O
37	.	O

0	In	O
1	an	O
2	effort	O
3	to	O
4	separate	O
5	domains	O
6	of	O
7	FadR	B
8	required	O
9	for	O
10	DNA	O
11	binding	O
12	,	O
13	dimerization	O
14	,	O
15	and	O
16	ligand	O
17	binding	O
18	,	O
19	chimeric	O
20	protein	O
21	fusions	O
22	between	O
23	the	O
24	DNA	O
25	binding	O
26	domain	O
27	of	O
28	LexA	B
29	and	O
30	different	O
31	regions	O
32	of	O
33	FadR	B
34	were	O
35	constructed	O
36	.	O

0	The	O
1	concentration	O
2	of	O
3	mite	O
4	allergen	O
5	was	O
6	very	O
7	low	O
8	(	O
9	mean	O
10	0	O
11	.	O
12	18	O
13	micrograms	O
14	Der	O
15	p	O
16	milligrams	O
17	sieved	O
18	house	O
19	dust	O
20	),	O
21	whereas	O
22	that	O
23	of	O
24	cat	B
25	allergen	I
26	was	O
27	high	O
28	in	O
29	homes	O
30	with	O
31	a	O
32	cat	O
33	(	O
34	80	O
35	.	O
36	8	O
37	micrograms	O
38	Fel	O
39	d	O
40	milligrams	O
41	)	O
42	but	O
43	also	O
44	in	O
45	homes	O
46	with	O
47	no	O
48	cat	O
49	(	O
50	3	O
51	.	O
52	2	O
53	micrograms	O
54	Fel	O
55	d	O
56	milligrams	O
57	).	O

0	Ultrastructural	O
1	studies	O
2	of	O
3	retinopathy	O
4	of	O
5	premature	O
6	infants	O

0	RVR	B
1	'	O
2	loss	O
3	of	O
4	function	O
5	'	O
6	studies	O
7	by	O
8	constitutive	O
9	over	O
10	-	O
11	expression	O
12	of	O
13	a	O
14	dominant	B
15	negative	I
16	RVR	I
17	delta	I
18	E	I
19	resulted	O
20	in	O
21	increased	O
22	levels	O
23	of	O
24	p21Cip1	B
25	/	O
26	Waf1	B
27	and	O
28	myogenin	B
29	mRNAs	I
30	after	O
31	serum	O
32	withdrawal	O
33	.	O

0	Natl	O
1	.	O

0	However	O
1	,	O
2	the	O
3	increase	O
4	in	O
5	biliary	O
6	excretion	O
7	did	O
8	not	O
9	compensate	O
10	for	O
11	the	O
12	reduced	O
13	elimination	O
14	of	O
15	bretylium	O
16	and	O
17	hexylsalicylic	O
18	acid	O
19	via	O
20	the	O
21	kidney	O
22	.	O

0	This	O
1	-	O
2	2485	O
3	/-	O
4	2458	O
5	element	O
6	bound	O
7	PPARalpha	B
8	and	O
9	PPARgamma	B
10	from	O
11	brown	O
12	fat	O
13	nuclei	O
14	.	O

0	The	O
1	recommendation	O
2	is	O
3	made	O
4	that	O
5	specific	O
6	sub	O
7	-	O
8	groups	O
9	of	O
10	attempters	O
11	need	O
12	to	O
13	be	O
14	identified	O
15	and	O
16	may	O
17	warrant	O
18	specialized	O
19	intervention	O
20	strategies	O
21	.	O

0	Baseline	O
1	measurements	O
2	of	O
3	forced	O
4	expiratory	O
5	volume	O
6	in	O
7	1	O
8	s	O
9	(	O
10	FEV1	O
11	),	O
12	specific	O
13	airway	O
14	conductance	O
15	(	O
16	SGaw	O
17	)	O
18	and	O
19	the	O
20	provocative	O
21	dose	O
22	of	O
23	carbachol	O
24	causing	O
25	a	O
26	35	O
27	%	O
28	reduction	O
29	in	O
30	SGaw	O
31	(	O
32	PD35	O
33	),	O
34	and	O
35	a	O
36	20	O
37	%	O
38	reduction	O
39	in	O
40	FEV1	O
41	(	O
42	PD20	O
43	)	O
44	were	O
45	established	O
46	on	O
47	entry	O
48	while	O
49	each	O
50	subject	O
51	was	O
52	still	O
53	smoking	O
54	.	O

0	Continued	O
1	absorption	O
2	of	O
3	amino	O
4	acids	O
5	by	O
6	the	O
7	NBB	B
8	carrier	I
9	(	O
10	for	O
11	neutral	O
12	amino	O
13	acids	O
14	),	O
15	the	O
16	Y	O
17	+	O
18	system	O
19	(	O
20	for	O
21	dibasic	O
22	amino	O
23	acids	O
24	),	O
25	and	O
26	the	O
27	PHE	B
28	carrier	I
29	were	O
30	operative	O
31	even	O
32	during	O
33	the	O
34	actively	O
35	purging	O
36	stage	O
37	of	O
38	watery	O
39	diarrhoea	O
40	due	O
41	to	O
42	cholera	O
43	.	O

0	It	O
1	contains	O
2	binding	O
3	sites	O
4	for	O
5	several	O
6	transcription	O
7	factors	O
8	,	O
9	for	O
10	example	O
11	:	O
12	(	O
13	i	O
14	)	O
15	a	O
16	well	O
17	-	O
18	characterized	O
19	binding	O
20	site	O
21	for	O
22	rel	B
23	/	O
24	NF	B
25	-	I
26	kappaB	I
27	transcription	I
28	factors	I
29	in	O
30	its	O
31	3	O
32	'-	O
33	end	O
34	(	O
35	the	O
36	H2TF1	B
37	or	O
38	kappaB1	B
39	element	O
40	),	O
41	(	O
42	ii	O
43	)	O
44	a	O
45	second	O
46	kappaB	B
47	site	I
48	(	O
49	the	O
50	kappaB2	B
51	element	O
52	),	O
53	which	O
54	is	O
55	located	O
56	immediately	O
57	adjacent	O
58	5	O
59	'	O
60	to	O
61	the	O
62	H2TF1	B
63	element	O
64	and	O
65	which	O
66	is	O
67	recognized	O
68	by	O
69	p65	B
70	/	O
71	relA	B
72	in	O
73	the	O
74	human	O
75	HLA	O
76	system	O
77	,	O
78	and	O
79	(	O
80	iii	O
81	)	O
82	an	O
83	AP	B
84	-	I
85	1	I
86	/	O
87	ATF	B
88	recognition	O
89	sequence	O
90	in	O
91	the	O
92	5	O
93	'	O
94	end	O
95	(	O
96	EnA	O
97	-	O
98	TRE	O
99	).	O

0	Based	O
1	on	O
2	previous	O
3	mapping	O
4	of	O
5	the	O
6	G	B
7	beta	I
8	gamma	I
9	binding	I
10	region	I
11	of	O
12	beta	B
13	ARK	I
14	,	O
15	and	O
16	conserved	O
17	residues	O
18	within	O
19	the	O
20	PH	B
21	domain	I
22	,	O
23	we	O
24	have	O
25	constructed	O
26	a	O
27	series	O
28	of	O
29	mutants	O
30	in	O
31	the	O
32	carboxyl	O
33	terminus	O
34	of	O
35	beta	B
36	ARK	I
37	in	O
38	order	O
39	to	O
40	determine	O
41	important	O
42	residues	O
43	involved	O
44	in	O
45	G	B
46	beta	I
47	gamma	I
48	and	O
49	PIP2	B
50	binding	O
51	.	O

0	There	O
1	was	O
2	no	O
3	correlation	O
4	between	O
5	secretor	O
6	status	O
7	and	O
8	clinical	O
9	status	O
10	,	O
11	spirometry	O
12	measurements	O
13	,	O
14	salivary	O
15	and	O
16	serum	B
17	lysozyme	I
18	levels	O
19	or	O
20	rates	O
21	of	O
22	respiratory	O
23	tract	O
24	colonization	O
25	with	O
26	P	O
27	.	O
28	aeruginosa	O
29	and	O
30	S	O
31	.	O
32	aureus	O
33	.	O

0	The	O
1	RMRI	O
2	was	O
3	tested	O
4	for	O
5	interrater	O
6	reliability	O
7	using	O
8	three	O
9	simulated	O
10	and	O
11	10	O
12	actual	O
13	patients	O
14	.	O

0	The	O
1	SUP44	B
2	suppressor	I
3	mutation	I
4	occurs	O
5	near	O
6	a	O
7	region	O
8	of	O
9	the	O
10	protein	O
11	that	O
12	corresponds	O
13	to	O
14	the	O
15	known	O
16	positions	O
17	of	O
18	alterations	O
19	in	O
20	E	O
21	.	O
22	coli	O
23	S5	O
24	ram	O
25	mutations	O
26	.	O

0	16	O
1	percent	O
2	,	O
3	P	O
4	<	O
5	0	O
6	.	O
7	001	O
8	),	O
9	and	O
10	sustained	O
11	normalization	O
12	of	O
13	serum	B
14	alanine	I
15	aminotransferase	I
16	levels	O
17	(	O
18	41	O
19	percent	O
20	vs	O
21	.	O

0	In	O
1	concert	O
2	with	O
3	the	O
4	coactivator	O
5	CREB	B
6	binding	I
7	protein	I
8	/	O
9	p300	B
10	,	O
11	which	O
12	interacts	O
13	with	O
14	GABPalpha	B
15	,	O
16	the	O
17	binding	O
18	of	O
19	GABPalpha	B
20	and	I
21	-	I
22	beta	I
23	to	O
24	the	O
25	dyad	O
26	symmetry	O
27	element	O
28	controls	O
29	the	O
30	induction	O
31	of	O
32	IL	B
33	-	I
34	16	I
35	promoter	I
36	in	O
37	T	O
38	cells	O
39	.	O

0	MZF	B
1	-	I
2	1	I
3	represses	O
4	CAT	B
5	reporter	I
6	gene	I
7	expression	O
8	via	O
9	GAL4	B
10	binding	I
11	sites	I
12	in	O
13	the	O
14	nonhematopoietic	O
15	cell	O
16	lines	O
17	NIH	O
18	3T3	O
19	and	O
20	293	O
21	.	O

0	This	O
1	paper	O
2	describes	O
3	the	O
4	advantages	O
5	and	O
6	limitations	O
7	of	O
8	the	O
9	main	O
10	study	O
11	approaches	O
12	used	O
13	.	O

0	Results	O
1	of	O
2	electron	O
3	therapy	O
4	of	O
5	tumors	O
6	in	O
7	different	O
8	sites	O

0	The	O
1	latency	O
2	time	O
3	for	O
4	the	O
5	lactate	O
6	concentration	O
7	to	O
8	reach	O
9	the	O
10	top	O
11	values	O
12	was	O
13	reduced	O
14	by	O
15	aerobic	O
16	training	O
17	(	O
18	T2	O
19	).	O

0	Northern	O
1	blot	O
2	analyses	O
3	show	O
4	that	O
5	the	O
6	hBub1	B
7	mRNA	I
8	level	O
9	is	O
10	abundantly	O
11	expressed	O
12	in	O
13	tissues	O
14	or	O
15	cells	O
16	with	O
17	a	O
18	high	O
19	mitotic	O
20	index	O
21	.	O

0	In	O
1	conclusion	O
2	,	O
3	the	O
4	disposition	O
5	of	O
6	venlafaxine	O
7	and	O
8	O	O
9	-	O
10	desmethylvenlafaxine	O
11	is	O
12	markedly	O
13	altered	O
14	in	O
15	renal	O
16	disease	O
17	;	O
18	therefore	O
19	dosage	O
20	adjustment	O
21	is	O
22	warranted	O
23	for	O
24	patients	O
25	with	O
26	creatinine	O
27	clearance	O
28	values	O
29	below	O
30	30	O
31	ml	O
32	/	O
33	min	O
34	.	O

0	Furthermore	O
1	,	O
2	both	O
3	rhHR23	B
4	proteins	I
5	function	O
6	in	O
7	a	O
8	defined	O
9	NER	B
10	system	O
11	reconstituted	O
12	with	O
13	purified	O
14	proteins	O
15	,	O
16	indicating	O
17	direct	O
18	involvement	O
19	of	O
20	hHR23	B
21	proteins	I
22	in	O
23	the	O
24	DNA	O
25	repair	O
26	reaction	O
27	via	O
28	interaction	O
29	with	O
30	XPC	B
31	.	O

0	BIM	O
1	130	O
2	.	O

0	The	O
1	existence	O
2	of	O
3	these	O
4	two	O
5	categories	O
6	of	O
7	strains	O
8	offers	O
9	a	O
10	new	O
11	genetic	O
12	system	O
13	in	O
14	which	O
15	the	O
16	properties	O
17	of	O
18	a	O
19	potential	O
20	invertebrate	O
21	retrovirus	O
22	can	O
23	be	O
24	tested	O
25	.	O

0	Re	O
1	-	O
2	evaluation	O
3	of	O
4	the	O
5	biopsy	O
6	specimen	O
7	from	O
8	the	O
9	right	O
10	hip	O
11	taken	O
12	at	O
13	the	O
14	time	O
15	of	O
16	the	O
17	initial	O
18	operation	O
19	showed	O
20	areas	O
21	of	O
22	chondrosarcoma	O
23	arising	O
24	in	O
25	the	O
26	background	O
27	of	O
28	synovial	O
29	chondromatosis	O
30	.	O

0	As	O
1	in	O
2	mammals	O
3	,	O
4	considerable	O
5	nucleotide	O
6	diversity	O
7	was	O
8	observed	O
9	at	O
10	the	O
11	junctions	O
12	of	O
13	the	O
14	variable	O
15	,	O
16	diversity	O
17	,	O
18	and	O
19	joining	O
20	elements	O
21	in	O
22	chicken	B
23	TCR	I
24	beta	I
25	cDNAs	I
26	.	O

0	Within	O
1	-	O
2	subject	O
3	BP	O
4	differences	O
5	between	O
6	fish	O
7	oil	O
8	and	O
9	corn	O
10	oil	O
11	treatment	O
12	were	O
13	similar	O
14	for	O
15	Dinamap	O
16	(	O
17	3	O
18	.	O
19	2	O
20	+/-	O
21	1	O
22	.	O
23	8	O
24	/	O
25	2	O
26	.	O
27	5	O
28	+/-	O
29	1	O
30	.	O
31	0	O
32	mm	O
33	Hg	O
34	)	O
35	and	O
36	for	O
37	24	O
38	-	O
39	h	O
40	ABP	O
41	(	O
42	2	O
43	.	O
44	5	O
45	+/-	O
46	1	O
47	.	O
48	0	O
49	/	O
50	2	O
51	.	O
52	3	O
53	+/-	O
54	0	O
55	.	O
56	8	O
57	mm	O
58	Hg	O
59	),	O
60	but	O
61	were	O
62	more	O
63	significant	O
64	with	O
65	the	O
66	latter	O
67	.	O

0	Salient	O
1	applications	O
2	of	O
3	PB	O
4	-	O
5	PK	O
6	modeling	O
7	to	O
8	toxicological	O
9	problems	O
10	are	O
11	illustrated	O
12	with	O
13	examples	O
14	.	O

0	Dopamine	O
1	neurons	O
2	in	O
3	subjects	O
4	that	O
5	received	O
6	6	O
7	-	O
8	OHDA	O
9	were	O
10	protected	O
11	by	O
12	pre	O
13	-	O
14	treatment	O
15	with	O
16	GBR	O
17	-	O
18	12909	O
19	.	O

0	Agonist	O
1	-	O
2	induced	O
3	receptor	O
4	internalization	O
5	,	O
6	determined	O
7	as	O
8	the	O
9	percent	O
10	of	O
11	total	O
12	[	O
13	125I	O
14	]	O
15	Tyr0	B
16	-	I
17	oCRF	I
18	bound	O
19	located	O
20	in	O
21	the	O
22	acid	O
23	-	O
24	resistant	O
25	fraction	O
26	of	O
27	transfected	O
28	Cos	O
29	7	O
30	cells	O
31	,	O
32	increased	O
33	with	O
34	time	O
35	(	O
36	0	O
37	-	O
38	60	O
39	min	O
40	at	O
41	37	O
42	degrees	O
43	C	O
44	)	O
45	for	O
46	both	O
47	wild	O
48	-	O
49	type	O
50	and	O
51	variant	O
52	oCRF1	O
53	.	O

0	We	O
1	inserted	O
2	genes	O
3	or	O
4	gene	O
5	segments	O
6	,	O
7	that	O
8	code	O
9	for	O
10	the	O
11	bacterial	B
12	chloramphenicol	I
13	acetyltransferase	I
14	,	O
15	the	O
16	bacterial	O
17	gene	O
18	conferring	O
19	resistance	O
20	against	O
21	hygromycin	O
22	,	O
23	and	O
24	the	O
25	ORF	O
26	E7	O
27	of	O
28	the	O
29	human	O
30	papillomavirus	O
31	type	O
32	18	O
33	into	O
34	these	O
35	vectors	O
36	.	O

0	We	O
1	found	O
2	that	O
3	the	O
4	expression	O
5	of	O
6	the	O
7	protein	O
8	was	O
9	maximum	O
10	in	O
11	mitosis	O
12	and	O
13	minimum	O
14	in	O
15	G1	O
16	,	O
17	which	O
18	correlated	O
19	with	O
20	the	O
21	expression	O
22	of	O
23	its	O
24	messenger	O
25	RNA	O
26	.	O

0	Acute	O
1	pancreatitis	O
2	as	O
3	a	O
4	complication	O
5	of	O
6	polyarteritis	O
7	nodosa	O
8	.	O

0	Patterns	O
1	defined	O
2	by	O
3	combinations	O
4	of	O
5	normal	O
6	and	O
7	abnormal	O
8	laboratory	O
9	results	O
10	had	O
11	decreased	O
12	the	O
13	likelihood	O
14	of	O
15	PEM	O
16	from	O
17	an	O
18	all	O
19	-	O
20	2	O
21	to	O
22	all	O
23	-	O
24	0	O
25	pattern	O
26	.	O

0	Association	O
1	of	O
2	human	B
3	Pur	I
4	alpha	I
5	with	O
6	the	O
7	retinoblastoma	B
8	protein	I
9	,	O
10	Rb	B
11	,	O
12	regulates	O
13	binding	O
14	to	O
15	the	O
16	single	O
17	-	O
18	stranded	O
19	DNA	O
20	Pur	I
21	alpha	I
22	recognition	I
23	element	I
24	.	O

0	The	O
1	results	O
2	indicate	O
3	considerable	O
4	flexibility	O
5	in	O
6	the	O
7	spacing	O
8	between	O
9	DH	B
10	regulatory	I
11	sites	I
12	.	O

0	The	O
1	12S	B
2	E1A	I
3	product	I
4	does	O
5	not	O
6	activate	O
7	a	O
8	TRE	O
9	sequence	O
10	,	O
11	but	O
12	cotransfection	O
13	with	O
14	c	B
15	-	I
16	jun	I
17	circumvents	O
18	this	O
19	lack	O
20	of	O
21	stimulation	O
22	.	O

0	Interaction	O
1	was	O
2	apparently	O
3	determined	O
4	by	O
5	the	O
6	N	O
7	-	O
8	terminal	O
9	splice	O
10	region	O
11	of	O
12	RPDE	B
13	-	I
14	6	I
15	,	O
16	as	O
17	the	O
18	PDE4A	B
19	splice	O
20	variant	O
21	RPDE	B
22	-	I
23	39	I
24	,	O
25	which	O
26	differs	O
27	from	O
28	RPDE	B
29	-	I
30	6	I
31	at	O
32	the	O
33	extreme	O
34	N	O
35	-	O
36	terminus	O
37	,	O
38	failed	O
39	to	O
40	associate	O
41	with	O
42	v	B
43	-	I
44	Src	I
45	-	I
46	SH3	I
47	;	O
48	met26RD1	B
49	(	O
50	where	O
51	RD1	B
52	is	O
53	rat	B
54	'	I
55	dunc	I
56	-	I
57	like	I
58	'	I
59	PDE	I
60	),	O
61	which	O
62	has	O
63	the	O
64	N	O
65	-	O
66	terminal	O
67	splice	O
68	region	O
69	deleted	O
70	,	O
71	failed	O
72	to	O
73	associate	O
74	with	O
75	v	B
76	-	I
77	Src	I
78	-	I
79	SH3	I
80	,	O
81	and	O
82	the	O
83	association	O
84	of	O
85	RPDE	B
86	-	I
87	6	I
88	and	O
89	v	B
90	-	I
91	Src	I
92	-	I
93	SH3	I
94	was	O
95	blocked	O
96	by	O
97	a	O
98	fusion	O
99	protein	O
100	formed	O
101	from	O
102	the	O
103	N	O
104	-	O
105	terminal	O
106	splice	O
107	region	O
108	.	O

0	The	O
1	structural	O
2	genes	O
3	encoding	O
4	glyceraldehyde	B
5	-	I
6	3	I
7	-	I
8	phosphate	I
9	dehydrogenase	I
10	(	O
11	GAPDH	B
12	),	O
13	3	B
14	-	I
15	phosphoglycerate	I
16	kinase	I
17	(	O
18	PGK	B
19	)	O
20	and	O
21	the	O
22	N	B
23	-	I
24	terminal	O
25	part	O
26	of	O
27	triosephosphate	B
28	isomerase	I
29	(	O
30	TIM	B
31	)	O
32	from	O
33	mesophilic	O
34	Bacillus	O
35	megaterium	O
36	DSM319	O
37	have	O
38	been	O
39	cloned	O
40	as	O
41	a	O
42	gene	O
43	cluster	O
44	(	O
45	gap	O
46	operon	O
47	)	O
48	by	O
49	complementation	O
50	of	O
51	an	O
52	Escherichia	B
53	coli	I
54	gap	I
55	amber	I
56	mutant	I
57	.	O

0	Late	O
1	mRNA	O
2	selected	O
3	by	O
4	a	O
5	cDNA	O
6	homologous	O
7	to	O
8	the	O
9	HindIII	B
10	-	I
11	P	I
12	/	O
13	EcoRI	B
14	-	I
15	B	I
16	region	O
17	of	O
18	the	O
19	AcNPV	O
20	map	O
21	directed	O
22	the	O
23	synthesis	O
24	of	O
25	31K	O
26	and	O
27	30K	O
28	proteins	O
29	which	O
30	comigrated	O
31	with	O
32	the	O
33	31K	O
34	and	O
35	30K	O
36	proteins	O
37	translated	O
38	from	O
39	RNA	O
40	selected	O
41	by	O
42	the	O
43	HindIII	B
44	-	I
45	A	I
46	/	O
47	EcoRI	B
48	-	I
49	C	I
50	/	O
51	SstI	B
52	-	I
53	G	I
54	cDNA	O
55	.	O

0	Complete	O
1	nucleotide	O
2	sequence	O
3	of	O
4	the	O
5	bacteriophage	B
6	K1F	I
7	tail	I
8	gene	I
9	encoding	O
10	endo	B
11	-	I
12	N	I
13	-	I
14	acylneuraminidase	I
15	(	O
16	endo	B
17	-	I
18	N	I
19	)	O
20	and	O
21	comparison	O
22	to	O
23	an	O
24	endo	B
25	-	I
26	N	I
27	homolog	I
28	in	O
29	bacteriophage	O
30	PK1E	O
31	.	O

0	Substituting	O
1	a	O
2	Ser	O
3	for	O
4	Gly69	O
5	or	O
6	a	O
7	Glu	O
8	for	O
9	Lys	O
10	71	O
11	in	O
12	the	O
13	conserved	O
14	TGEK	B
15	tetrapeptide	I
16	in	O
17	finger	O
18	II	O
19	of	O
20	TFIIIA	B
21	resulted	O
22	in	O
23	the	O
24	loss	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

0	The	O
1	nucleotide	O
2	sequence	O
3	of	O
4	22	O
5	,	O
6	846	O
7	bp	O
8	of	O
9	the	O
10	left	O
11	arm	O
12	of	O
13	chromosome	O
14	IV	O
15	is	O
16	described	O
17	.	O

0	We	O
1	present	O
2	evidence	O
3	that	O
4	YY1	B
5	,	O
6	a	O
7	ubiquitously	O
8	expressed	O
9	DNA	O
10	-	O
11	binding	O
12	protein	O
13	,	O
14	regulates	O
15	the	O
16	activity	O
17	of	O
18	the	O
19	c	B
20	-	I
21	fos	I
22	promoter	I
23	primarily	O
24	through	O
25	an	O
26	effect	O
27	on	O
28	DNA	O
29	structure	O
30	.	O

0	This	O
1	is	O
2	the	O
3	first	O
4	report	O
5	that	O
6	an	O
7	in	O
8	vitro	O
9	-	O
10	synthesized	O
11	alphavirus	O
12	RNA	O
13	lacking	O
14	a	O
15	poly	O
16	(	O
17	A	O
18	)	O
19	tail	O
20	can	O
21	initiate	O
22	infection	O
23	and	O
24	produce	O
25	3	O
26	'	O
27	polyadenylated	O
28	viral	O
29	genome	O
30	in	O
31	vivo	O
32	.	O

0	ICP4	B
1	has	O
2	been	O
3	shown	O
4	to	O
5	form	O
6	tripartite	O
7	complexes	O
8	cooperatively	O
9	with	O
10	the	O
11	TATA	B
12	box	I
13	-	I
14	binding	I
15	protein	I
16	and	O
17	TFIIB	B
18	on	O
19	DNA	O
20	containing	O
21	an	O
22	ICP4	B
23	binding	I
24	site	I
25	and	O
26	a	O
27	TATA	O
28	box	O
29	(	O
30	C	O
31	.	O

0	Functional	O
1	analysis	O
2	of	O
3	promoter	O
4	activity	O
5	of	O
6	the	O
7	5	O
8	'-	O
9	flanking	O
10	region	O
11	of	O
12	cyclin	B
13	D2	I
14	suggested	O
15	that	O
16	the	O
17	region	O
18	-	O
19	1	O
20	,	O
21	100	O
22	to	O
23	-	O
24	805	O
25	including	O
26	C	B
27	/	I
28	EBP	I
29	,	O
30	PEA3	B
31	,	O
32	AP2	B
33	,	O
34	NF	B
35	-	I
36	Y	I
37	,	O
38	c	B
39	-	I
40	Myc	I
41	,	O
42	and	O
43	Sp1	B
44	may	O
45	have	O
46	a	O
47	major	O
48	positive	O
49	regulatory	O
50	activity	O
51	for	O
52	expression	O
53	of	O
54	cyclin	B
55	D2	I
56	.	O

0	In	O
1	this	O
2	report	O
3	we	O
4	describe	O
5	for	O
6	the	O
7	first	O
8	time	O
9	the	O
10	complete	O
11	primary	O
12	structure	O
13	of	O
14	type	B
15	X	I
16	collagen	I
17	,	O
18	based	O
19	on	O
20	cloning	O
21	and	O
22	sequencing	O
23	of	O
24	cDNA	O
25	and	O
26	genomic	O
27	DNA	O
28	.	O

0	To	O
1	examine	O
2	the	O
3	basis	O
4	for	O
5	the	O
6	apparent	O
7	differences	O
8	in	O
9	postsegregational	O
10	killing	O
11	between	O
12	the	O
13	two	O
14	E	O
15	.	O
16	coli	O
17	strains	O
18	,	O
19	transformation	O
20	assays	O
21	were	O
22	carried	O
23	out	O
24	to	O
25	determine	O
26	the	O
27	relative	O
28	sensitivities	O
29	of	O
30	the	O
31	strains	O
32	to	O
33	the	O
34	ParE	B
35	toxin	I
36	protein	I
37	.	O

0	These	O
1	data	O
2	suggest	O
3	that	O
4	combined	O
5	lesions	O
6	of	O
7	cholinergic	O
8	and	O
9	serotonergic	O
10	neurons	O
11	in	O
12	the	O
13	rat	O
14	brain	O
15	do	O
16	not	O
17	alter	O
18	olfactory	O
19	perception	O
20	or	O
21	olfactory	O
22	short	O
23	-	O
24	term	O
25	memory	O
26	.	O

0	Cloning	O
1	and	O
2	sequence	O
3	analyses	O
4	revealed	O
5	a	O
6	second	O
7	cDNA	O
8	with	O
9	a	O
10	95	O
11	-	O
12	nt	O
13	deletion	O
14	in	O
15	the	O
16	region	O
17	coding	O
18	for	O
19	the	O
20	putative	O
21	second	O
22	intracellular	O
23	loop	O
24	and	O
25	the	O
26	fourth	O
27	transmembrane	O
28	domain	O
29	of	O
30	the	O
31	5	B
32	-	I
33	HT2C	I
34	-	I
35	R	I
36	.	O

0	We	O
1	have	O
2	also	O
3	tested	O
4	Src	B
5	SH2	I
6	mutants	I
7	for	O
8	their	O
9	binding	O
10	properties	O
11	and	O
12	have	O
13	interpreted	O
14	our	O
15	results	O
16	in	O
17	light	O
18	of	O
19	the	O
20	recent	O
21	crystal	O
22	structure	O
23	solution	O
24	for	O
25	the	O
26	Src	B
27	SH2	I
28	domain	I
29	.	O

0	The	O
1	triple	O
2	combination	O
3	of	O
4	nizatidine	O
5	,	O
6	clarithromycin	O
7	,	O
8	and	O
9	bismuth	O
10	subcitrate	O
11	resulted	O
12	in	O
13	an	O
14	ulcer	O
15	healing	O
16	rate	O
17	of	O
18	98	O
19	%	O
20	and	O
21	an	O
22	H	O
23	.	O
24	pylori	O
25	eradication	O
26	rate	O
27	of	O
28	90	O
29	%.	O

0	Expression	O
1	of	O
2	Bcl	B
3	-	I
4	XL	I
5	inhibited	O
6	the	O
7	association	O
8	of	O
9	Apaf	B
10	-	I
11	1	I
12	with	O
13	caspase	B
14	-	I
15	9	I
16	in	O
17	mammalian	O
18	cells	O
19	.	O

0	Treatment	O
1	and	O
2	staining	O
3	of	O
4	smears	O
5	and	O
6	sections	O
7	for	O
8	detection	O
9	of	O
10	microorganisms	O

0	In	O
1	short	O
2	-	O
3	term	O
4	cotransfections	O
5	,	O
6	a	O
7	pFRTK	B
8	-	O
9	CAT	B
10	target	O
11	containing	O
12	EBNA	B
13	-	I
14	1	I
15	-	I
16	binding	I
17	sites	I
18	from	O
19	the	O
20	EBV	O
21	origin	O
22	of	O
23	plasmid	O
24	replication	O
25	,	O
26	ori	O
27	-	O
28	P	O
29	,	O
30	was	O
31	transactivated	O
32	by	O
33	a	O
34	carboxy	O
35	-	O
36	terminal	O
37	EBNA	B
38	-	I
39	1	I
40	construction	O
41	(	O
42	amino	O
43	acids	O
44	450	O
45	to	O
46	641	O
47	)	O
48	that	O
49	also	O
50	carried	O
51	a	O
52	c	B
53	-	I
54	myc	I
55	nuclear	O
56	localization	O
57	signal	O
58	.	O

0	A	O
1	patient	O
2	with	O
3	an	O
4	infected	O
5	wound	O
6	or	O
7	one	O
8	on	O
9	a	O
10	primary	O
11	area	O
12	(	O
13	hands	O
14	,	O
15	feet	O
16	,	O
17	face	O
18	,	O
19	or	O
20	perineum	O
21	)	O
22	may	O
23	have	O
24	to	O
25	be	O
26	hospitalized	O
27	to	O
28	ensure	O
29	proper	O
30	care	O
31	.	O

0	Cestode	O
1	invasion	O
2	in	O
3	irradiated	O
4	host	O
5	organism	O
6	increases	O
7	the	O
8	negative	O
9	effect	O
10	of	O
11	ionizing	O
12	radiation	O
13	on	O
14	the	O
15	hamster	O
16	immune	O
17	system	O
18	.	O

0	Cheung	O
1	and	O
2	S	O
3	.	O

0	This	O
1	survey	O
2	included	O
3	3000	O
4	randomly	O
5	selected	O
6	Norwegians	O
7	above	O
8	18	O
9	years	O
10	of	O
11	age	O
12	who	O
13	received	O
14	the	O
15	European	O
16	Organization	O
17	for	O
18	Research	O
19	and	O
20	Treatment	O
21	of	O
22	Cancer	O
23	Core	O
24	Quality	O
25	of	O
26	Life	O
27	Questionnaire	O
28	(	O
29	EORTC	O
30	QLQ	O
31	-	O
32	C30	O
33	(+	O
34	3	O
35	)	O
36	by	O
37	mail	O
38	.	O

0	Cosmid	O
1	clones	O
2	containing	O
3	both	O
4	VNTR	O
5	sequences	O
6	were	O
7	identified	O
8	,	O
9	and	O
10	restriction	O
11	mapping	O
12	showed	O
13	them	O
14	to	O
15	be	O
16	less	O
17	than	O
18	15	O
19	kb	O
20	apart	O
21	.	O

0	Elevated	O
1	IOP	O
2	developed	O
3	in	O
4	35	O
5	patients	O
6	(	O
7	44	O
8	eyes	O
9	)	O
10	during	O
11	the	O
12	study	O
13	.	O

0	The	O
1	characterized	O
2	Y	O
3	'	O
4	repeated	O
5	sequence	O
6	families	O
7	provide	O
8	an	O
9	experimental	O
10	system	O
11	in	O
12	which	O
13	repeated	O
14	sequence	O
15	interactions	O
16	and	O
17	subsequent	O
18	evolution	O
19	can	O
20	be	O
21	studied	O
22	.	O

0	The	O
1	outer	O
2	diameter	O
3	and	O
4	the	O
5	thickness	O
6	of	O
7	the	O
8	rotor	O
9	are	O
10	60	O
11	mm	O
12	and	O
13	8	O
14	mm	O
15	,	O
16	respectively	O
17	.	O

0	Progressive	O
1	100	O
2	-	O
3	mmHg	O
4	stepwise	O
5	decreases	O
6	in	O
7	superfusate	O
8	oxygen	O
9	partial	O
10	pressure	O
11	(	O
12	PO2	O
13	)	O
14	from	O
15	control	O
16	(	O
17	95	O
18	%	O
19	O2	O
20	aeration	O
21	,	O
22	PO2	O
23	,	O
24	620	O
25	-	O
26	650	O
27	mmHg	O
28	)	O
29	were	O
30	produced	O
31	,	O
32	and	O
33	subsequent	O
34	changes	O
35	in	O
36	isometric	O
37	active	O
38	and	O
39	resting	O
40	tension	O
41	were	O
42	measured	O
43	.	O

0	255	O
1	-	O
2	61	O
3	.	O

0	Urinary	O
1	LTE4	O
2	increased	O
3	after	O
4	both	O
5	challenges	O
6	the	O
7	rise	O
8	being	O
9	higher	O
10	following	O
11	oral	O
12	as	O
13	compared	O
14	to	O
15	inhalation	O
16	provocation	O
17	(	O
18	p	O
19	=	O
20	0	O
21	.	O
22	0001	O
23	).	O

0	Experiments	O
1	with	O
2	epitope	O
3	-	O
4	tagged	O
5	proteins	O
6	show	O
7	that	O
8	UEV1A	B
9	is	O
10	a	O
11	nuclear	O
12	protein	O
13	,	O
14	whereas	O
15	both	O
16	Kua	B
17	and	O
18	Kua	B
19	-	O
20	UEV	B
21	localize	O
22	to	O
23	cytoplasmic	O
24	structures	O
25	,	O
26	indicating	O
27	that	O
28	the	O
29	Kua	B
30	domain	I
31	determines	O
32	the	O
33	cytoplasmic	O
34	localization	O
35	of	O
36	Kua	B
37	-	O
38	UEV	B
39	.	O

0	Surprisingly	O
1	,	O
2	however	O
3	,	O
4	TCR	B
5	-	O
6	mediated	O
7	tyrosine	O
8	phosphorylation	O
9	of	O
10	phospholipase	B
11	C	I
12	gamma	I
13	1	I
14	remains	O
15	intact	O
16	in	O
17	the	O
18	Jurkat	O
19	cells	O
20	expressing	O
21	the	O
22	A2	O
23	/	O
24	HCP	O
25	chimera	O
26	.	O

0	RT	O
1	-	O
2	PCR	O
3	indicated	O
4	that	O
5	p21	B
6	mRNA	I
7	was	O
8	induced	O
9	1	O
10	.	O
11	4	O
12	-,	O
13	2	O
14	.	O
15	0	O
16	-,	O
17	and	O
18	3	O
19	.	O
20	1	O
21	-	O
22	fold	O
23	in	O
24	the	O
25	2	O
26	-	O
27	day	O
28	neonatal	O
29	,	O
30	7	O
31	-	O
32	day	O
33	neonatal	O
34	,	O
35	and	O
36	adult	O
37	stages	O
38	,	O
39	respectively	O
40	,	O
41	compared	O
42	to	O
43	the	O
44	17	O
45	-	O
46	day	O
47	fetal	O
48	stage	O
49	.	O

0	Most	O
1	important	O
2	,	O
3	infection	O
4	of	O
5	the	O
6	cells	O
7	with	O
8	an	O
9	adenoviral	O
10	construct	O
11	expressing	O
12	this	O
13	mutant	O
14	inhibited	O
15	the	O
16	induction	O
17	of	O
18	VEGF	B
19	mRNA	I
20	under	O
21	conditions	O
22	that	O
23	mimic	O
24	hypoxia	O
25	.	O

0	A	O
1	recent	O
2	index	O
3	(	O
4	Fluorosis	O
5	Risk	O
6	Index	O
7	)	O
8	developed	O
9	by	O
10	Pendrys	O
11	(	O
12	1990	O
13	)	O
14	is	O
15	also	O
16	included	O
17	in	O
18	this	O
19	review	O
20	.	O

0	Standard	O
1	curve	O
2	correlation	O
3	coefficients	O
4	of	O
5	0	O
6	.	O
7	995	O
8	or	O
9	greater	O
10	were	O
11	obtained	O
12	during	O
13	validation	O
14	experiments	O
15	and	O
16	analysis	O
17	of	O
18	study	O
19	samples	O
20	.	O

0	A	O
1	promising	O
2	new	O
3	cement	O
4	,	O
5	4	O
6	-	O
7	META	O
8	/	O
9	MMA	O
10	-	O
11	TBB	O
12	opaque	O
13	resin	O
14	,	O
15	has	O
16	shown	O
17	remarkable	O
18	adhesive	O
19	properties	O
20	as	O
21	a	O
22	bone	O
23	cement	O
24	in	O
25	vivo	O
26	.	O

0	Molecular	O
1	neurochemistry	O
2	of	O
3	addictive	O
4	drugs	O
5	.	O

0	In	O
1	gel	O
2	mobility	O
3	shift	O
4	assays	O
5	,	O
6	low	O
7	binding	O
8	activity	O
9	of	O
10	CBF	B
11	to	O
12	the	O
13	wild	B
14	-	I
15	type	I
16	AtpC	I
17	promoter	I
18	sequence	I
19	was	O
20	observed	O
21	with	O
22	nuclear	O
23	extracts	O
24	from	O
25	tissue	O
26	with	O
27	low	O
28	AtpC	B
29	expression	O
30	levels	O
31	,	O
32	i	O
33	.	O
34	e	O
35	.	O
36	extracts	O
37	from	O
38	etiolated	O
39	and	O
40	photobleached	O
41	seedlings	O
42	,	O
43	whereas	O
44	high	O
45	binding	O
46	activity	O
47	was	O
48	detectable	O
49	with	O
50	extracts	O
51	from	O
52	tissues	O
53	with	O
54	high	O
55	AtpC	B
56	expression	O
57	levels	O
58	,	O
59	i	O
60	.	O
61	e	O
62	.	O
63	extracts	O
64	from	O
65	light	O
66	-	O
67	grown	O
68	seedlings	O
69	and	O
70	etiolated	O
71	seedlings	O
72	treated	O
73	with	O
74	cytokinin	B
75	.	O

0	Typical	O
1	and	O
2	atypical	O
3	clinical	O
4	features	O
5	of	O
6	this	O
7	lacrimal	O
8	sac	O
9	cyst	O
10	are	O
11	emphasized	O
12	.	O

0	BACKGROUND	O
1	:	O
2	The	O
3	c	B
4	-	I
5	myc	I
6	proto	I
7	-	I
8	oncogene	I
9	has	O
10	been	O
11	suggested	O
12	to	O
13	play	O
14	key	O
15	roles	O
16	in	O
17	cell	O
18	proliferation	O
19	,	O
20	differentiation	O
21	,	O
22	transformation	O
23	and	O
24	apoptosis	O
25	.	O

0	Studies	O
1	on	O
2	swine	O
3	enteroviruses	O
4	.	O

0	Behcet	O
1	'	O
2	s	O
3	syndrome	O

0	Improvement	O
1	of	O
2	nursing	O
3	instruction	O
4	to	O
5	be	O
6	given	O
7	at	O
8	the	O
9	time	O
10	of	O
11	discharge	O
12	from	O
13	the	O
14	ward	O
15	for	O
16	premature	O
17	infants	O

0	It	O
1	is	O
2	now	O
3	recognized	O
4	that	O
5	essentially	O
6	all	O
7	eukaryotic	O
8	and	O
9	prokaryotic	O
10	genes	O
11	whose	O
12	5	O
13	'-	O
14	flanking	O
15	regions	O
16	are	O
17	known	O
18	and	O
19	that	O
20	encode	O
21	barbiturate	O
22	-	O
23	inducible	O
24	proteins	O
25	contain	O
26	the	O
27	Barbie	O
28	box	O
29	element	O
30	.	O

0	The	O
1	orf61	B
2	gene	I
3	product	I
4	,	O
5	when	O
6	expressed	O
7	from	O
8	an	O
9	exogenous	O
10	promoter	O
11	,	O
12	inhibited	O
13	int	B
14	-	O
15	mediated	O
16	integration	O
17	at	O
18	the	O
19	chromosomal	B
20	attB	B
21	site	I
22	.	O

0	The	O
1	salient	O
2	clinical	O
3	features	O
4	,	O
5	the	O
6	problems	O
7	of	O
8	management	O
9	and	O
10	the	O
11	modern	O
12	approaches	O
13	to	O
14	the	O
15	reconstruction	O
16	of	O
17	facial	O
18	deformities	O
19	seen	O
20	in	O
21	this	O
22	disease	O
23	are	O
24	described	O
25	.	O

0	This	O
1	conclusion	O
2	was	O
3	confirmed	O
4	by	O
5	Northern	O
6	blotting	O
7	analysis	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	of	O
15	CAD	B
16	gene	I
17	.	O

0	Self	O
1	-	O
2	emasculation	O
3	is	O
4	the	O
5	end	O
6	result	O
7	of	O
8	an	O
9	unusual	O
10	psychiatric	O
11	disorder	O
12	,	O
13	which	O
14	initially	O
15	requires	O
16	surgical	O
17	treatment	O
18	.	O

0	Differentiation	O
1	was	O
2	not	O
3	observed	O
4	after	O
5	cellular	O
6	expression	O
7	of	O
8	GTPase	B
9	-	O
10	deficient	O
11	forms	O
12	of	O
13	alpha	B
14	i2	I
15	or	O
16	alpha	B
17	0	I
18	,	O
19	indicating	O
20	selectivity	O
21	for	O
22	the	O
23	Gq	B
24	family	I
25	of	O
26	G	B
27	proteins	I
28	.	O

0	The	O
1	early	O
2	lethality	O
3	of	O
4	the	O
5	left	O
6	-	O
7	sided	O
8	resectio	O
9	was	O
10	0	O
11	%	O
12	and	O
13	the	O
14	postoperative	O
15	survival	O
16	--	O
17	5	O
18	-	O
19	10	O
20	months	O
21	.	O

0	In	O
1	patients	O
2	with	O
3	osteomyelitis	O
4	and	O
5	joint	O
6	empyema	O
7	(	O
8	n	O
9	=	O
10	48	O
11	)	O
12	PMN	B
13	elastase	I
14	had	O
15	a	O
16	sensitivity	O
17	of	O
18	77	O
19	%,	O
20	which	O
21	was	O
22	only	O
23	exceeded	O
24	by	O
25	that	O
26	of	O
27	the	O
28	unspecific	O
29	erythrocyte	O
30	sedimentation	O
31	rate	O
32	(	O
33	sensitivity	O
34	89	O
35	%).	O

0	The	O
1	5	O
2	'	O
3	flanking	O
4	region	O
5	of	O
6	the	O
7	mouse	B
8	Met	I
9	-	I
10	ase	I
11	-	I
12	1	I
13	gene	I
14	also	O
15	shares	O
16	considerable	O
17	regions	O
18	of	O
19	identity	O
20	with	O
21	the	O
22	5	O
23	'	O
24	flanking	O
25	region	O
26	of	O
27	the	O
28	rat	B
29	Met	I
30	-	I
31	ase	I
32	-	I
33	1	I
34	gene	I
35	.	O

0	Topical	O
1	1	O
2	percent	O
3	isoproterenol	O
4	in	O
5	the	O
6	presence	O
7	of	O
8	the	O
9	phosphodiesterase	O
10	inhibitor	O
11	theophylline	O
12	was	O
13	tested	O
14	for	O
15	its	O
16	ability	O
17	to	O
18	stimulate	O
19	the	O
20	rate	O
21	of	O
22	aqueous	O
23	humor	O
24	flow	O
25	through	O
26	the	O
27	anterior	O
28	chamber	O
29	of	O
30	the	O
31	normal	O
32	and	O
33	the	O
34	partially	O
35	adrenergically	O
36	denervated	O
37	human	O
38	eye	O
39	(	O
40	Horner	O
41	'	O
42	s	O
43	syndrome	O
44	).	O

0	The	O
1	quantitative	O
2	determination	O
3	of	O
4	HBSAG	O
5	--	O
6	a	O
7	valuable	O
8	aid	O
9	in	O
10	evaluating	O
11	the	O
12	infectiousness	O
13	of	O
14	hepatitis	O
15	B	O
16	virus	O
17	carriers	O

0	We	O
1	have	O
2	measured	O
3	the	O
4	kinetics	O
5	of	O
6	the	O
7	recovery	O
8	of	O
9	mRNA	O
10	synthesis	O
11	in	O
12	the	O
13	inducible	O
14	GAL10	B
15	and	O
16	RNR3	B
17	genes	I
18	after	O
19	exposure	O
20	of	O
21	yeast	O
22	cells	O
23	to	O
24	ultraviolet	O
25	(	O
26	UV	O
27	)	O
28	radiation	O
29	.	O

0	The	O
1	qualitative	O
2	concentrations	O
3	of	O
4	HCG	O
5	had	O
6	a	O
7	sensitivity	O
8	of	O
9	37	O
10	.	O
11	5	O
12	%	O
13	and	O
14	a	O
15	specificity	O
16	of	O
17	100	O
18	%.	O

0	In	O
1	64	O
2	%	O
3	a	O
4	small	O
5	cardiac	O
6	vein	O
7	does	O
8	not	O
9	exist	O
10	,	O
11	but	O
12	its	O
13	origin	O
14	,	O
15	the	O
16	right	O
17	marginal	O
18	vein	O
19	,	O
20	joins	O
21	the	O
22	system	O
23	of	O
24	anterior	O
25	cardiac	O
26	veins	O
27	.	O

0	Pol32Delta	B
1	strains	O
2	are	O
3	weak	O
4	antimutators	O
5	and	O
6	are	O
7	defective	O
8	for	O
9	damage	O
10	-	O
11	induced	O
12	mutagenesis	O
13	.	O

0	European	O
1	Community	O
2	Huntington	O
3	'	O
4	s	O
5	Disease	O
6	Collaborative	O
7	Study	O
8	Group	O
9	.	O

0	Using	O
1	a	O
2	previously	O
3	published	O
4	two	O
5	-	O
6	frequency	O
7	(	O
8	AC	O
9	excitation	O
10	)	O
11	three	O
12	-	O
13	electrode	O
14	method	O
15	,	O
16	the	O
17	admittance	O
18	locus	O
19	plot	O
20	(	O
21	ALP	O
22	)	O
23	in	O
24	the	O
25	low	O
26	-	O
27	frequency	O
28	region	O
29	(<	O
30	1000	O
31	Hz	O
32	)	O
33	has	O
34	been	O
35	shown	O
36	to	O
37	be	O
38	very	O
39	well	O
40	approximated	O
41	by	O
42	a	O
43	straight	O
44	line	O
45	and	O
46	can	O
47	be	O
48	described	O
49	with	O
50	frequency	O
51	-	O
52	independent	O
53	parameters	O
54	;	O
55	phase	O
56	angle	O
57	alpha	O
58	pi	O
59	/	O
60	2	O
61	,	O
62	conductance	O
63	at	O
64	extrapolated	O
65	zero	O
66	frequency	O
67	G0	O
68	=	O
69	1	O
70	/	O
71	R0	O
72	,	O
73	and	O
74	ion	O
75	relaxation	O
76	time	O
77	tau	O
78	.	O

0	Several	O
1	particular	O
2	features	O
3	of	O
4	this	O
5	polypeptide	O
6	fragment	O
7	from	O
8	the	O
9	hamster	B
10	lysyl	I
11	-	I
12	tRNA	I
13	synthetase	I
14	suggest	O
15	that	O
16	it	O
17	is	O
18	implicated	O
19	in	O
20	the	O
21	assembly	O
22	of	O
23	that	O
24	enzyme	O
25	within	O
26	the	O
27	multisynthetase	B
28	complex	O
29	.	O

0	Point	O
1	mutations	O
2	of	O
3	the	O
4	site	O
5	that	O
6	suppressed	O
7	Pit	B
8	-	I
9	1	I
10	binding	O
11	in	O
12	vitro	O
13	restored	O
14	full	O
15	tiGH	B
16	promoter	I
17	activity	O
18	.	O

0	Serine	O
1	528	O
2	is	O
3	phosphorylated	O
4	in	O
5	vivo	O
6	in	O
7	several	O
8	cell	O
9	lines	O
10	,	O
11	and	O
12	substitution	O
13	of	O
14	serine	O
15	528	O
16	to	O
17	alanine	O
18	(	O
19	S528A	O
20	)	O
21	resulted	O
22	in	O
23	an	O
24	increased	O
25	ability	O
26	of	O
27	Myb	B
28	to	O
29	transactivate	O
30	a	O
31	synthetic	O
32	promoter	O
33	containing	O
34	five	O
35	copies	O
36	of	O
37	the	O
38	mim	B
39	-	I
40	1A	I
41	Myb	I
42	-	I
43	responsive	I
44	element	I
45	and	O
46	a	O
47	minimal	O
48	herpes	B
49	tk	I
50	promoter	I
51	.	O

0	The	O
1	LAMMER	B
2	protein	I
3	kinase	I
4	encoded	O
5	by	O
6	the	O
7	Doa	B
8	locus	I
9	of	I
10	Drosophila	I
11	is	O
12	required	O
13	in	O
14	both	O
15	somatic	O
16	and	O
17	germline	O
18	cells	O
19	and	O
20	is	O
21	expressed	O
22	as	O
23	both	O
24	nuclear	O
25	and	O
26	cytoplasmic	O
27	isoforms	O
28	throughout	O
29	development	O
30	.	O

0	Biohydrogenation	O
1	of	O
2	linoleic	O
3	acid	O
4	into	O
5	octadecenoic	O
6	acid	O
7	was	O
8	observed	O
9	.	O

0	A	O
1	system	O
2	is	O
3	described	O
4	in	O
5	which	O
6	the	O
7	volume	O
8	flow	O
9	rate	O
10	of	O
11	blood	O
12	in	O
13	a	O
14	vessel	O
15	is	O
16	determined	O
17	using	O
18	transverse	O
19	colour	O
20	Doppler	O
21	ultrasound	O
22	imaging	O
23	.	O

0	Isolation	O
1	of	O
2	T	O
3	.	O
4	gambiense	O
5	strains	O
6	in	O
7	Zaire	O
8	and	O
9	their	O
10	adaptation	O
11	to	O
12	laboratory	O
13	animals	O

0	Expression	O
1	of	O
2	thymidine	B
3	kinase	I
4	gene	I
5	in	O
6	normal	O
7	human	O
8	diploid	O
9	cells	O
10	is	O
11	both	O
12	cell	O
13	cycle	O
14	-	O
15	and	O
16	age	O
17	-	O
18	dependent	O
19	and	O
20	appears	O
21	to	O
22	be	O
23	transcriptionally	O
24	regulated	O
25	.	O

0	We	O
1	show	O
2	here	O
3	that	O
4	these	O
5	Jun	B
6	/	O
7	eb1	B
8	chimeras	I
9	are	O
10	potent	O
11	transactivators	O
12	of	O
13	AP1	B
14	sites	I
15	and	O
16	that	O
17	they	O
18	can	O
19	cooperate	O
20	with	O
21	c	B
22	-	I
23	Ha	I
24	-	I
25	Ras	I
26	to	O
27	induce	O
28	foci	O
29	.	O

0	SL1	B
1	trans	O
2	-	O
3	splicing	O
4	specified	O
5	by	O
6	AU	O
7	-	O
8	rich	O
9	synthetic	O
10	RNA	O
11	inserted	O
12	at	O
13	the	O
14	5	O
15	'	O
16	end	O
17	of	O
18	Caenorhabditis	O
19	elegans	O
20	pre	O
21	-	O
22	mRNA	O
23	.	O

0	A	O
1	cDNA	O
2	for	O
3	a	O
4	newly	O
5	discovered	O
6	pseudogene	O
7	,	O
8	closely	O
9	related	O
10	to	O
11	the	O
12	mouse	B
13	mast	I
14	cell	I
15	chymases	I
16	was	O
17	isolated	O
18	by	O
19	polymerase	O
20	chain	O
21	reaction	O
22	amplification	O
23	from	O
24	a	O
25	mouse	O
26	connective	O
27	tissue	O
28	-	O
29	like	O
30	mast	O
31	cell	O
32	line	O
33	.	O

0	The	O
1	effects	O
2	of	O
3	systemic	O
4	glucose	O
5	concentration	O
6	on	O
7	brain	O
8	metabolism	O
9	following	O
10	repeated	O
11	brain	O
12	ischemia	O
13	.	O

0	Although	O
1	the	O
2	molecular	O
3	mechanisms	O
4	involved	O
5	in	O
6	this	O
7	regulation	O
8	are	O
9	currently	O
10	being	O
11	elucidated	O
12	,	O
13	very	O
14	little	O
15	is	O
16	known	O
17	about	O
18	the	O
19	trans	O
20	-	O
21	acting	O
22	factors	O
23	that	O
24	allow	O
25	expression	O
26	of	O
27	the	O
28	nitrate	B
29	and	I
30	nitrite	I
31	reductase	I
32	genes	I
33	which	O
34	code	O
35	for	O
36	the	O
37	first	O
38	enzymes	O
39	in	O
40	the	O
41	pathway	O
42	.	O

0	It	O
1	is	O
2	related	O
3	to	O
4	a	O
5	variety	O
6	of	O
7	mammalian	B
8	Golgi	I
9	-	I
10	associated	I
11	proteins	I
12	and	O
13	to	O
14	the	O
15	yeast	B
16	Uso1p	I
17	,	O
18	an	O
19	essential	O
20	protein	O
21	involved	O
22	in	O
23	docking	O
24	of	O
25	endoplasmic	O
26	reticulum	O
27	-	O
28	derived	O
29	vesicles	O
30	to	O
31	the	O
32	cis	O
33	-	O
34	Golgi	O
35	.	O

0	Diminished	O
1	forearm	O
2	arteriolar	O
3	dilator	O
4	capacity	O
5	produced	O
6	by	O
7	mineralocorticoid	O
8	-	O
9	induced	O
10	salt	O
11	retention	O
12	in	O
13	man	O
14	.	O

0	Using	O
1	homology	O
2	cloning	O
3	techniques	O
4	,	O
5	we	O
6	identified	O
7	a	O
8	mouse	O
9	homologue	O
10	of	O
11	E	B
12	(	O
13	Pc	B
14	),	O
15	termed	O
16	Epc1	B
17	,	O
18	a	O
19	yeast	O
20	protein	O
21	that	O
22	we	O
23	name	O
24	EPL1	B
25	,	O
26	and	O
27	as	O
28	well	O
29	as	O
30	additional	O
31	ESTs	O
32	from	O
33	Caenorhabditis	O
34	elegans	O
35	,	O
36	mice	O
37	and	O
38	humans	O
39	.	O

0	RNA	O
1	of	O
2	GBV	B
3	-	I
4	C	I
5	was	O
6	detected	O
7	in	O
8	14	O
9	(	O
10	18	O
11	%)	O
12	patients	O
13	before	O
14	BMT	O
15	.	O

0	Moreover	O
1	,	O
2	promoters	O
3	containing	O
4	a	O
5	TATA	O
6	box	O
7	in	O
8	the	O
9	absence	O
10	of	O
11	Sp1	B
12	sites	I
13	or	O
14	Sp1	B
15	sites	I
16	in	O
17	the	O
18	absence	O
19	of	O
20	a	O
21	TATA	O
22	box	O
23	were	O
24	equally	O
25	inducible	O
26	in	O
27	vitro	O
28	,	O
29	as	O
30	was	O
31	an	O
32	RNA	B
33	polymerase	I
34	III	I
35	promoter	I
36	.	O

0	We	O
1	describe	O
2	a	O
3	genetic	O
4	system	O
5	for	O
6	further	O
7	characterizing	O
8	the	O
9	role	O
10	of	O
11	the	O
12	extreme	O
13	C	O
14	-	O
15	terminus	O
16	of	O
17	the	O
18	beta	O
19	subunit	O
20	of	O
21	E	B
22	.	I
23	coli	I
24	RNA	I
25	polymerase	I
26	.	O

0	Human	B
1	SRF	I
2	-	I
3	related	I
4	proteins	I
5	:	O
6	DNA	O
7	-	O
8	binding	O
9	properties	O
10	and	O
11	potential	O
12	regulatory	O
13	targets	O
14	.	O

0	Patients	O
1	at	O
2	risk	O
3	of	O
4	hypothyroidism	O
5	.	O

0	The	O
1	cause	O
2	of	O
3	death	O
4	is	O
5	often	O
6	quite	O
7	apparent	O
8	from	O
9	the	O
10	pathological	O
11	and	O
12	toxicological	O
13	findings	O
14	;	O
15	however	O
16	,	O
17	the	O
18	manner	O
19	of	O
20	death	O
21	often	O
22	gives	O
23	the	O
24	examining	O
25	official	O
26	some	O
27	difficulty	O
28	.	O

0	Such	O
1	a	O
2	change	O
3	may	O
4	involve	O
5	increased	O
6	mammary	O
7	utilization	O
8	of	O
9	pre	O
10	-	O
11	formed	O
12	long	O
13	-	O
14	chain	O
15	fatty	O
16	acid	O
17	and	O
18	increased	O
19	metabolism	O
20	of	O
21	glucose	O
22	via	O
23	glycolysis	O
24	.	O

0	Phylogenetic	O
1	position	O
2	of	O
3	the	O
4	Phacotaceae	O
5	within	O
6	the	O
7	Chlamydophyceaeas	O
8	revealed	O
9	by	O
10	analysis	O
11	of	O
12	18S	B
13	rDNA	O
14	and	O
15	rbcL	B
16	sequences	O
17	.	O

0	T	B
1	-	I
2	cell	I
3	receptor	I
4	beta	I
5	(	O
6	TCR	B
7	beta	I
8	)	O
9	gene	O
10	rearrangements	O
11	occur	O
12	in	O
13	a	O
14	third	O
15	of	O
16	early	O
17	B	O
18	-	O
19	cell	O
20	acute	O
21	lymphoblastic	O
22	leukemias	O
23	(	O
24	ALLs	O
25	).	O

0	The	O
1	alpha	B
2	inhibin	I
3	promoter	I
4	containing	O
5	a	O
6	mutated	O
7	CRE	O
8	was	O
9	not	O
10	regulated	O
11	by	O
12	forskolin	B
13	in	O
14	granulosa	O
15	cells	O
16	and	O
17	did	O
18	not	O
19	bind	O
20	the	O
21	CREB	B
22	protein	I
23	.	O

0	All	O
1	ribosomal	B
2	protein	I
3	(	I
4	rp	I
5	)	O
6	gene	O
7	promoters	O
8	from	O
9	Saccharomyces	O
10	cerevisiae	O
11	studied	O
12	so	O
13	far	O
14	contain	O
15	either	O
16	(	O
17	usually	O
18	two	O
19	)	O
20	binding	O
21	sites	O
22	for	O
23	the	O
24	global	O
25	gene	O
26	regulator	O
27	Rap1p	B
28	or	O
29	one	O
30	binding	O
31	site	O
32	for	O
33	another	O
34	global	O
35	factor	O
36	,	O
37	Abf1p	B
38	.	O

0	We	O
1	have	O
2	overexpressed	O
3	,	O
4	purified	O
5	,	O
6	characterized	O
7	,	O
8	and	O
9	crystallized	O
10	the	O
11	BTB	B
12	/	O
13	POZ	B
14	domain	O
15	from	O
16	PLZF	B
17	(	O
18	PLZF	B
19	-	O
20	BTB	B
21	/	O
22	POZ	B
23	).	O

0	The	O
1	prevalence	O
2	of	O
3	malnutrition	O
4	was	O
5	30	O
6	%	O
7	in	O
8	the	O
9	47	O
10	patients	O
11	without	O
12	CVD	O
13	and	O
14	was	O
15	significantly	O
16	higher	O
17	(	O
18	70	O
19	%,	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	)	O
26	in	O
27	the	O
28	70	O
29	patients	O
30	with	O
31	CVD	O
32	,	O
33	who	O
34	also	O
35	had	O
36	lower	O
37	tHcy	B
38	,	O
39	SAlb	B
40	,	O
41	plasma	B
42	IGF	I
43	-	I
44	1	I
45	,	O
46	serum	O
47	creatinine	O
48	(	O
49	SCr	B
50	),	O
51	and	O
52	blood	B
53	hemoglobin	I
54	.	O

0	The	O
1	nature	O
2	of	O
3	the	O
4	process	O
5	formed	O
6	by	O
7	the	O
8	successive	O
9	occurrences	O
10	of	O
11	this	O
12	arrhythmia	O
13	was	O
14	studied	O
15	in	O
16	8	O
17	patients	O
18	with	O
19	a	O
20	history	O
21	of	O
22	symptomatic	O
23	paroxysmal	O
24	AF	O
25	.	O

0	The	O
1	structure	O
2	of	O
3	digiprogenin	B
4	.	O

0	The	O
1	C	O
2	-	O
3	terminal	O
4	region	O
5	of	O
6	the	O
7	150	O
8	-	O
9	kDa	O
10	protein	O
11	contains	O
12	an	O
13	NTP	B
14	-	I
15	binding	I
16	helicase	I
17	motif	I
18	and	O
19	the	O
20	readthrough	O
21	region	O
22	,	O
23	an	O
24	RNA	B
25	polymerase	I
26	motif	I
27	,	O
28	indicating	O
29	that	O
30	these	O
31	two	O
32	overlapping	O
33	proteins	O
34	may	O
35	form	O
36	an	O
37	RNA	O
38	replication	O
39	complex	O
40	similar	O
41	to	O
42	those	O
43	of	O
44	tobamo	O
45	-	O
46	and	O
47	tobraviruses	O
48	.	O

0	The	O
1	active	O
2	derivatives	O
3	of	O
4	the	O
5	present	O
6	series	O
7	were	O
8	also	O
9	tested	O
10	for	O
11	their	O
12	analgesic	O
13	activity	O
14	against	O
15	aconitine	O
16	-	O
17	induced	O
18	writhing	O
19	in	O
20	albino	O
21	mice	O
22	and	O
23	ulcerogenic	O
24	activity	O
25	in	O
26	albino	O
27	rats	O
28	.	O

0	When	O
1	examined	O
2	as	O
3	adults	O
4	(	O
5	8	O
6	weeks	O
7	old	O
8	),	O
9	the	O
10	external	O
11	genitalia	O
12	of	O
13	TA	O
14	-	O
15	exposed	O
16	offspring	O
17	were	O
18	normal	O
19	.	O

0	The	O
1	clinical	O
2	and	O
3	laboratory	O
4	features	O
5	of	O
6	72	O
7	children	O
8	with	O
9	Henoch	O
10	-	O
11	Schonlein	O
12	purpura	O
13	(	O
14	HSP	O
15	)	O
16	were	O
17	examined	O
18	to	O
19	determine	O
20	if	O
21	there	O
22	were	O
23	associations	O
24	between	O
25	the	O
26	laboratory	O
27	indices	O
28	--	O
29	including	O
30	white	O
31	blood	O
32	cell	O
33	(	O
34	WBC	O
35	)	O
36	counts	O
37	,	O
38	serum	B
39	C	I
40	-	I
41	reactive	I
42	protein	I
43	(	O
44	CRP	B
45	)	O
46	levels	O
47	,	O
48	platelet	O
49	(	O
50	PLT	O
51	)	O
52	counts	O
53	--	O
54	and	O
55	the	O
56	clinical	O
57	manifestations	O
58	of	O
59	acute	O
60	HSP	O
61	.	O

0	CDK4	B
1	kinase	I
2	activities	O
3	were	O
4	unaffected	O
5	,	O
6	as	O
7	were	O
8	the	O
9	levels	O
10	of	O
11	the	O
12	CDK	B
13	inhibitor	O
14	p21Cip1	B
15	present	O
16	in	O
17	cyclin	B
18	E	O
19	immunocomplexes	O
20	.	O

0	The	O
1	P	B
2	-	I
3	wr	I
4	and	O
5	P	B
6	-	I
7	rr	I
8	cDNA	O
9	sequences	O
10	are	O
11	very	O
12	similar	O
13	in	O
14	their	O
15	5	O
16	'	O
17	regions	O
18	.	O

0	In	O
1	the	O
2	first	O
3	,	O
4	homologous	O
5	sequences	O
6	were	O
7	deleted	O
8	from	O
9	a	O
10	mouse	O
11	enhancer	O
12	,	O
13	resulting	O
14	in	O
15	a	O
16	tissue	O
17	-	O
18	specific	O
19	loss	O
20	of	O
21	activity	O
22	when	O
23	assayed	O
24	in	O
25	transgenic	O
26	mice	O
27	.	O

0	A	O
1	major	O
2	pool	O
3	of	O
4	Dsg	B
5	-	O
6	plakoglobin	B
7	complexes	O
8	sedimented	O
9	at	O
10	8S	O
11	and	O
12	exhibited	O
13	a	O
14	1	O
15	:	O
16	1	O
17	stoichiometry	O
18	.	O

0	In	O
1	contrast	O
2	to	O
3	the	O
4	myoD	B
5	promoter	I
6	,	O
7	the	O
8	myoD	B
9	enhancer	I
10	shows	O
11	striking	O
12	conservation	O
13	between	O
14	humans	O
15	and	O
16	mice	O
17	both	O
18	in	O
19	its	O
20	sequence	O
21	and	O
22	its	O
23	distal	O
24	position	O
25	.	O

0	These	O
1	results	O
2	indicate	O
3	that	O
4	HIV	B
5	-	I
6	1	I
7	Gag	I
8	sequences	I
9	can	O
10	influence	O
11	the	O
12	viral	O
13	PR	O
14	-	O
15	mediated	O
16	processing	O
17	of	O
18	the	O
19	MuLV	B
20	TM	I
21	Env	I
22	protein	I
23	p15	I
24	(	I
25	E	I
26	).	O

0	The	O
1	pattern	O
2	and	O
3	timing	O
4	of	O
5	CARP	B
6	mRNA	I
7	expression	O
8	,	O
9	including	O
10	transient	O
11	expression	O
12	in	O
13	the	O
14	tongue	O
15	at	O
16	14	O
17	.	O
18	5	O
19	days	O
20	p	O
21	.	O
22	c	O
23	.,	O
24	coincides	O
25	with	O
26	that	O
27	of	O
28	Nkx2	B
29	.	I
30	5	I
31	/	O
32	Csx	B
33	(	O
34	a	O
35	putative	O
36	homolog	O
37	of	O
38	tinman	B
39	,	O
40	the	O
41	Drosophila	B
42	melanogaster	I
43	gene	I
44	responsible	O
45	for	O
46	cardiac	O
47	development	O
48	).	O

0	The	O
1	distribution	O
2	of	O
3	the	O
4	various	O
5	repeats	O
6	suggests	O
7	its	O
8	organization	O
9	is	O
10	similar	O
11	to	O
12	the	O
13	beta	O
14	-	O
15	heterochromatic	O
16	regions	O
17	near	O
18	the	O
19	base	O
20	of	O
21	the	O
22	major	O
23	chromosome	O
24	arms	O
25	.	O

0	It	O
1	has	O
2	been	O
3	shown	O
4	in	O
5	an	O
6	animal	O
7	experiment	O
8	that	O
9	alterations	O
10	of	O
11	the	O
12	renal	O
13	vasculature	O
14	and	O
15	parenchyma	O
16	after	O
17	hemostasis	O
18	performed	O
19	by	O
20	Infrared	O
21	-	O
22	Contact	O
23	-	O
24	Coagulation	O
25	are	O
26	best	O
27	shown	O
28	by	O
29	intravital	O
30	magnification	O
31	angiography	O
32	(	O
33	magnification	B
34	factor	I
35	2	I
36	.	I
37	22	I
38	).	O

0	A	O
1	high	O
2	-	O
3	frequency	O
4	restriction	O
5	fragment	O
6	length	O
7	polymorphism	O
8	was	O
9	evident	O
10	in	O
11	the	O
12	DNA	O
13	from	O
14	29	O
15	unrelated	O
16	individuals	O
17	using	O
18	the	O
19	enzyme	O
20	BglII	B
21	.	O

0	Evolutionary	O
1	relationships	O
2	among	O
3	putative	O
4	RNA	B
5	-	I
6	dependent	I
7	RNA	I
8	polymerases	I
9	encoded	O
10	by	O
11	a	O
12	mitochondrial	O
13	virus	O
14	-	O
15	like	O
16	RNA	O
17	in	O
18	the	O
19	Dutch	O
20	elm	O
21	disease	O
22	fungus	O
23	,	O
24	Ophiostoma	O
25	novo	O
26	-	O
27	ulmi	O
28	,	O
29	by	O
30	other	O
31	viruses	O
32	and	O
33	virus	O
34	-	O
35	like	O
36	RNAs	O
37	and	O
38	by	O
39	the	O
40	Arabidopsis	O
41	mitochondrial	O
42	genome	O
43	.	O

0	Transfer	B
1	RNA	I
2	genes	I
3	from	O
4	Dictyostelium	O
5	discoideum	O
6	are	O
7	frequently	O
8	associated	O
9	with	O
10	repetitive	O
11	elements	O
12	and	O
13	contain	O
14	consensus	O
15	boxes	O
16	in	O
17	their	O
18	5	O
19	'	O
20	and	O
21	3	O
22	'-	O
23	flanking	O
24	regions	O
25	.	O

0	The	O
1	grandfather	O
2	and	O
3	the	O
4	granddaughter	O
5	both	O
6	had	O
7	microtia	O
8	and	O
9	meatal	O
10	atresia	O
11	,	O
12	whereas	O
13	the	O
14	daughter	O
15	had	O
16	a	O
17	normal	O
18	outer	O
19	ear	O
20	except	O
21	for	O
22	a	O
23	narrow	O
24	meatus	O
25	and	O
26	auricular	O
27	appendages	O
28	.	O

0	Effect	O
1	of	O
2	hyperglycemia	O
3	on	O
4	pain	O
5	threshold	O
6	in	O
7	alloxan	O
8	-	O
9	diabetic	O
10	rats	O
11	.	O

0	Role	O
1	of	O
2	superoxide	B
3	dismutase	I
4	in	O
5	cellular	O
6	oxidative	O
7	processes	O
8	and	O
9	method	O
10	of	O
11	its	O
12	determination	O
13	in	O
14	biological	O
15	materials	O

0	A	O
1	general	O
2	model	O
3	for	O
4	ARE	B
5	-	O
6	mediated	O
7	mRNA	O
8	degradation	O
9	involving	O
10	a	O
11	potential	O
12	role	O
13	for	O
14	certain	O
15	heterogeneous	O
16	nuclear	O
17	ribonucleoproteins	O
18	and	O
19	ARE	B
20	-	I
21	binding	I
22	proteins	I
23	is	O
24	proposed	O
25	.	O

0	In	O
1	addition	O
2	,	O
3	narZ	B
4	expression	O
5	was	O
6	induced	O
7	approximately	O
8	20	O
9	-	O
10	fold	O
11	intracellularly	O
12	in	O
13	Madin	O
14	-	O
15	Darby	O
16	canine	O
17	kidney	O
18	epithelial	O
19	cells	O
20	and	O
21	16	O
22	-	O
23	fold	O
24	in	O
25	intracellular	O
26	salts	O
27	medium	O
28	,	O
29	which	O
30	is	O
31	believed	O
32	to	O
33	mimic	O
34	the	O
35	intracellular	O
36	milieu	O
37	.	O

0	Postglucose	B
1	serum	I
2	insulin	I
3	levels	O
4	showed	O
5	no	O
6	significant	O
7	correlations	O
8	with	O
9	systolic	O
10	or	O
11	diastolic	O
12	blood	O
13	pressure	O
14	levels	O
15	in	O
16	men	O
17	,	O
18	but	O
19	in	O
20	female	O
21	diabetic	O
22	and	O
23	non	O
24	-	O
25	diabetic	O
26	subjects	O
27	significant	O
28	correlations	O
29	were	O
30	found	O
31	in	O
32	particular	O
33	with	O
34	systolic	O
35	blood	O
36	pressure	O
37	level	O
38	.	O

0	All	O
1	13	O
2	patients	O
3	showed	O
4	endoscopic	O
5	evidence	O
6	of	O
7	oesophagitis	O
8	,	O
9	moderate	O
10	in	O
11	4	O
12	and	O
13	severe	O
14	in	O
15	9	O
16	.	O

0	Activation	O
1	of	O
2	T	O
3	cells	O
4	via	O
5	the	O
6	TCR	B
7	and	O
8	other	O
9	costimulatory	O
10	receptors	O
11	triggers	O
12	a	O
13	number	O
14	of	O
15	signaling	O
16	cascades	O
17	.	O

0	To	O
1	characterize	O
2	the	O
3	expression	O
4	of	O
5	this	O
6	DNA	O
7	repair	O
8	enzyme	O
9	,	O
10	we	O
11	have	O
12	isolated	O
13	the	O
14	corresponding	O
15	genomic	O
16	clone	O
17	.	O

0	The	O
1	aim	O
2	of	O
3	the	O
4	study	O
5	was	O
6	to	O
7	correlate	O
8	the	O
9	responsiveness	O
10	to	O
11	bronchoprovocation	O
12	with	O
13	methacholine	O
14	in	O
15	subjects	O
16	a	O
17	with	O
18	allergic	O
19	rhinitis	O
20	during	O
21	and	O
22	out	O
23	of	O
24	the	O
25	pollen	O
26	season	O
27	with	O
28	total	O
29	serum	O
30	IgE	B
31	and	O
32	blood	O
33	eosinophils	O
34	.	O

0	Derepression	O
1	of	O
2	gene	O
3	expression	O
4	mediated	O
5	by	O
6	the	O
7	5	O
8	'	O
9	upstream	O
10	region	O
11	of	O
12	the	O
13	isocitrate	B
14	lyase	I
15	gene	I
16	of	I
17	Candida	I
18	tropicalis	I
19	is	O
20	controlled	O
21	by	O
22	two	O
23	distinct	O
24	regulatory	O
25	pathways	O
26	in	O
27	Saccharomyces	O
28	cerevisiae	O
29	.	O

0	METHODS	O
1	:	O
2	Ten	O
3	influenza	O
4	A	O
5	(	O
6	H3N2	O
7	)	O
8	viruses	O
9	isolated	O
10	during	O
11	the	O
12	outbreaks	O
13	were	O
14	examined	O
15	for	O
16	resistance	O
17	to	O
18	amantadine	O
19	and	O
20	rimantadine	O
21	by	O
22	means	O
23	of	O
24	an	O
25	enzyme	O
26	immunoassay	O
27	and	O
28	by	O
29	sequencing	O
30	of	O
31	the	O
32	viral	O
33	nucleic	O
34	acid	O
35	that	O
36	encodes	O
37	the	O
38	transmembrane	O
39	domain	O
40	of	O
41	the	O
42	M2	B
43	protein	I
44	.	O

0	Four	O
1	possible	O
2	isoforms	O
3	(	O
4	hGli2	B
5	alpha	I
6	,	O
7	beta	O
8	,	O
9	gamma	O
10	,	O
11	and	O
12	delta	O
13	)	O
14	are	O
15	formed	O
16	by	O
17	combinations	O
18	of	O
19	two	O
20	independent	O
21	alternative	O
22	splicings	O
23	,	O
24	and	O
25	all	O
26	the	O
27	isoforms	O
28	could	O
29	bind	O
30	to	O
31	a	O
32	DNA	O
33	motif	O
34	,	O
35	TRE2S	B
36	,	O
37	in	O
38	the	O
39	LTR	O
40	.	O

0	Encompassing	O
1	tamponade	O
2	and	O
3	pericardiocentesis	O
4	data	O
5	,	O
6	left	O
7	ventricular	O
8	stroke	O
9	work	O
10	index	O
11	showed	O
12	positive	O
13	correlation	O
14	with	O
15	TMFP1	O
16	(	O
17	r	O
18	=	O
19	.	O
20	59	O
21	)	O
22	and	O
23	TMFP2	O
24	(	O
25	r	O
26	=	O
27	.	O
28	52	O
29	)	O
30	but	O
31	not	O
32	with	O
33	TMFP3	O
34	.	O

0	Efforts	O
1	were	O
2	made	O
3	to	O
4	determine	O
5	the	O
6	amount	O
7	of	O
8	time	O
9	required	O
10	for	O
11	kidney	O
12	lesions	O
13	to	O
14	develop	O
15	and	O
16	,	O
17	if	O
18	possible	O
19	,	O
20	to	O
21	delineate	O
22	the	O
23	potential	O
24	site	O
25	of	O
26	action	O
27	of	O
28	PBB	O
29	.	O

0	Blood	O
1	serum	O
2	erythropoietin	B
3	level	O
4	and	O
5	basic	O
6	hematological	O
7	indices	O
8	during	O
9	the	O
10	adaptation	O
11	of	O
12	healthy	O
13	newborn	O
14	infants	O

0	The	O
1	main	O
2	causes	O
3	of	O
4	liver	O
5	disease	O
6	in	O
7	the	O
8	patients	O
9	with	O
10	HCC	O
11	were	O
12	hepatitis	O
13	C	O
14	virus	O
15	(	O
16	HCV	O
17	)	O
18	(	O
19	77	O
20	%),	O
21	alcohol	O
22	abuse	O
23	(	O
24	73	O
25	%),	O
26	and	O
27	the	O
28	combination	O
29	of	O
30	HCV	O
31	and	O
32	alcohol	O
33	abuse	O
34	(	O
35	50	O
36	%).	O

0	No	O
1	significant	O
2	differences	O
3	between	O
4	the	O
5	substituted	O
6	and	O
7	wild	O
8	type	O
9	peptides	O
10	were	O
11	observed	O
12	,	O
13	suggesting	O
14	that	O
15	this	O
16	substitution	O
17	in	O
18	the	O
19	intact	O
20	protein	O
21	may	O
22	cause	O
23	disruption	O
24	of	O
25	global	O
26	rather	O
27	than	O
28	local	O
29	structures	O
30	.	O

0	Molecule	O
1	(	O
2	s	O
3	)	O
4	secreted	O
5	by	O
6	neuronal	O
7	cultures	O
8	contribute	O
9	to	O
10	this	O
11	induction	O
12	of	O
13	GLT	B
14	-	I
15	1	I
16	,	O
17	but	O
18	little	O
19	is	O
20	known	O
21	about	O
22	the	O
23	signaling	O
24	pathways	O
25	mediating	O
26	this	O
27	regulation	O
28	.	O

0	Members	O
1	of	O
2	the	O
3	mitogen	B
4	activated	I
5	protein	I
6	(	I
7	MAP	I
8	)	I
9	kinase	I
10	family	I
11	,	O
12	extracellular	B
13	signal	I
14	-	I
15	regulated	I
16	kinase	I
17	,	O
18	stress	B
19	-	I
20	activated	I
21	protein	I
22	kinase	I
23	-	I
24	1	I
25	/	O
26	c	B
27	-	I
28	Jun	I
29	NH2	I
30	-	I
31	terminal	I
32	kinase	I
33	,	O
34	and	O
35	p38	B
36	,	O
37	are	O
38	central	O
39	elements	O
40	that	O
41	transduce	O
42	the	O
43	signal	O
44	generated	O
45	by	O
46	growth	O
47	factors	O
48	,	O
49	cytokines	O
50	,	O
51	and	O
52	stressing	O
53	agents	O
54	.	O

0	This	O
1	gene	O
2	joins	O
3	the	O
4	group	O
5	of	O
6	genes	O
7	whose	O
8	members	O
9	are	O
10	rapidly	O
11	transcribed	O
12	in	O
13	response	O
14	to	O
15	insulin	B
16	and	O
17	other	O
18	mitogens	O
19	.	O

0	This	O
1	investigation	O
2	was	O
3	undertaken	O
4	to	O
5	determine	O
6	whether	O
7	consuming	O
8	several	O
9	small	O
10	feedings	O
11	of	O
12	preexercise	O
13	carbohydrate	O
14	(	O
15	CHO	O
16	),	O
17	rather	O
18	than	O
19	a	O
20	single	O
21	bolus	O
22	,	O
23	would	O
24	affect	O
25	blood	O
26	glucose	O
27	and	O
28	insulin	B
29	responses	O
30	during	O
31	rest	O
32	and	O
33	exercise	O
34	.	O

0	Significant	O
1	clinical	O
2	differences	O
3	between	O
4	the	O
5	patients	O
6	treated	O
7	with	O
8	and	O
9	without	O
10	AMB	O
11	were	O
12	longer	O
13	survival	O
14	time	O
15	following	O
16	diagnosis	O
17	of	O
18	illness	O
19	(	O
20	P	O
21	less	O
22	than	O
23	0	O
24	.	O
25	05	O
26	)	O
27	and	O
28	more	O
29	frequent	O
30	cranial	O
31	nerve	O
32	signs	O
33	in	O
34	the	O
35	treated	O
36	patients	O
37	(	O
38	P	O
39	=	O
40	0	O
41	.	O
42	089	O
43	).	O

0	Therefore	O
1	the	O
2	prevalences	O
3	of	O
4	total	O
5	diabetes	O
6	and	O
7	GDM	O
8	were	O
9	1	O
10	.	O
11	19	O
12	%	O
13	and	O
14	0	O
15	.	O
16	56	O
17	%,	O
18	respectively	O
19	.	O

0	Previous	O
1	studies	O
2	have	O
3	shown	O
4	[	O
5	Hisanaga	O
6	,	O
7	S	O
8	.,	O
9	Kusubata	O
10	,	O
11	M	O
12	.,	O
13	Okumura	O
14	,	O
15	E	O
16	.	O
17	&	O
18	Kishimoto	O
19	,	O
20	T	O
21	.	O

0	We	O
1	critically	O
2	assess	O
3	current	O
4	systematic	O
5	uncertainties	O
6	and	O
7	determine	O
8	the	O
9	primordial	O
10	Li	O
11	abundance	O
12	within	O
13	new	O
14	,	O
15	much	O
16	tighter	O
17	limits	O
18	:	O
19	&	O
20	amp	O
21	;	O
22	parl0	O
23	;	O
24	Li	O
25	&	O
26	amp	O
27	;	O
28	solm0	O
29	;	O
30	H	O
31	&	O
32	amp	O
33	;	O
34	parr0	O
35	;	O
36	p	O
37	=	O
38	1	O
39	.	O
40	23	O
41	+	O
42	0	O
43	.	O
44	68	O
45	-	O
46	0	O
47	.	O
48	32x10	O
49	-	O
50	10	O
51	.	O

0	The	O
1	rad9	B
2	.	I
3	192	I
4	DNA	I
5	repair	I
6	mutant	I
7	from	O
8	the	O
9	fission	O
10	yeast	O
11	,	O
12	Schizosaccharomyces	O
13	pombe	O
14	,	O
15	is	O
16	sensitive	O
17	to	O
18	both	O
19	UV	O
20	and	O
21	ionising	O
22	radiation	O
23	.	O

0	Estimated	O
1	nucleic	O
2	acid	O
3	N	O
4	absorption	O
5	is	O
6	7	O
7	-	O
8	8	O
9	%	O
10	of	O
11	N	O
12	intake	O
13	.	O

0	The	O
1	purpose	O
2	of	O
3	the	O
4	study	O
5	reported	O
6	here	O
7	was	O
8	to	O
9	investigate	O
10	whether	O
11	differences	O
12	in	O
13	T1	O
14	and	O
15	T2	O
16	between	O
17	tumors	O
18	are	O
19	mainly	O
20	a	O
21	consequence	O
22	of	O
23	differences	O
24	in	O
25	the	O
26	fractional	O
27	volume	O
28	of	O
29	the	O
30	extracellular	O
31	compartment	O
32	.	O

0	Practical	O
1	interest	O
2	of	O
3	such	O
4	studies	O
5	is	O
6	limited	O
7	since	O
8	the	O
9	pharmacokinetic	O
10	parameters	O
11	are	O
12	systematically	O
13	evaluated	O
14	in	O
15	man	O
16	during	O
17	phase	O
18	I	O
19	trials	O
20	.	O

0	We	O
1	report	O
2	here	O
3	that	O
4	in	O
5	cultured	O
6	Jurkat	O
7	T	O
8	cells	O
9	,	O
10	Cbl	B
11	is	O
12	coprecipitated	O
13	with	O
14	antibody	O
15	against	O
16	the	O
17	adapter	B
18	protein	I
19	Grb2	I
20	.	O

0	In	O
1	conclusion	O
2	,	O
3	these	O
4	studies	O
5	indicate	O
6	that	O
7	LiCl	O
8	(	O
9	1	O
10	)	O
11	decreases	O
12	histamine	O
13	-	O
14	stimulated	O
15	gastric	O
16	acid	O
17	secretion	O
18	,	O
19	and	O
20	(	O
21	2	O
22	)	O
23	diminishes	O
24	bile	O
25	-	O
26	induced	O
27	disruption	O
28	of	O
29	the	O
30	gastric	O
31	mucosal	O
32	barrier	O
33	in	O
34	the	O
35	canine	O
36	Heidenhain	O
37	pouch	O
38	.	O

0	Recombination	O
1	and	O
2	transcription	O
3	of	O
4	the	O
5	endogenous	B
6	Ig	I
7	heavy	I
8	chain	I
9	locus	I
10	is	O
11	effected	O
12	by	O
13	the	O
14	Ig	B
15	heavy	I
16	chain	I
17	intronic	I
18	enhancer	I
19	core	I
20	region	I
21	in	O
22	the	O
23	absence	O
24	of	O
25	the	O
26	matrix	O
27	attachment	O
28	regions	O
29	.	O

0	The	O
1	class	B
2	II	I
3	Escherichia	I
4	coli	I
5	alanine	I
6	tRNA	I
7	synthetase	I
8	aminoacylates	O
9	RNA	O
10	miniduplexes	O
11	,	O
12	which	O
13	reconstruct	O
14	the	O
15	acceptor	O
16	end	O
17	of	O
18	alanine	O
19	tRNA	O
20	with	O
21	the	O
22	critical	O
23	G3	O
24	:	O
25	U70	O
26	base	O
27	pair	O
28	.	O

0	The	O
1	contraceptive	O
2	pattern	O
3	of	O
4	157	O
5	women	O
6	was	O
7	analysed	O
8	and	O
9	13	O
10	.	O
11	8	O
12	percent	O
13	were	O
14	using	O
15	inefficient	O
16	methods	O
17	.	O

0	Autorosette	O
1	-	O
2	forming	O
3	cells	O
4	are	O
5	characterized	O
6	by	O
7	a	O
8	high	O
9	activity	O
10	of	O
11	alkaline	B
12	and	I
13	acid	I
14	phosphatases	I
15	and	O
16	low	O
17	NBT	O
18	-	O
19	test	O
20	values	O
21	.	O

0	We	O
1	conclude	O
2	that	O
3	sequences	O
4	outside	O
5	of	O
6	the	O
7	hLEF	B
8	HMG	I
9	box	I
10	mediate	O
11	cell	O
12	-	O
13	and	O
14	context	O
15	-	O
16	specific	O
17	activation	O
18	of	O
19	the	O
20	TCR	B
21	alpha	I
22	enhancer	I
23	and	O
24	may	O
25	facilitate	O
26	interactions	O
27	between	O
28	hLEF	B
29	and	O
30	other	O
31	T	O
32	-	O
33	cell	O
34	-	O
35	specific	O
36	factors	O
37	recruited	O
38	to	O
39	the	O
40	enhancer	O
41	.	O

0	Patients	O
1	were	O
2	subclassified	O
3	into	O
4	age	O
5	-	O
6	matched	O
7	groups	O
8	of	O
9	primary	O
10	untreated	O
11	cancer	O
12	(	O
13	21	O
14	),	O
15	recurrent	O
16	cancer	O
17	(	O
18	18	O
19	),	O
20	and	O
21	"	O
22	cured	O
23	"	O
24	patients	O
25	who	O
26	had	O
27	been	O
28	free	O
29	of	O
30	disease	O
31	for	O
32	at	O
33	least	O
34	9	O
35	months	O
36	(	O
37	16	O
38	).	O

0	The	O
1	harpin	B
2	-	I
3	encoding	I
4	hrpZ	I
5	gene	I
6	is	O
7	located	O
8	in	O
9	an	O
10	operon	O
11	that	O
12	also	O
13	encodes	O
14	Hrp	B
15	secretion	O
16	pathway	O
17	components	O
18	and	O
19	is	O
20	part	O
21	of	O
22	the	O
23	functional	O
24	cluster	O
25	of	O
26	hrp	B
27	genes	I
28	carried	O
29	on	O
30	cosmid	O
31	pHIR11	O
32	that	O
33	enables	O
34	saprophytic	O
35	bacteria	O
36	like	O
37	Escherichia	O
38	coli	O
39	and	O
40	Pseudomonas	O
41	fluorescens	O
42	to	O
43	elicit	O
44	the	O
45	HR	B
46	in	O
47	tobacco	O
48	leaves	O
49	.	O

0	Deletion	O
1	of	O
2	an	O
3	intergenic	O
4	DNA	O
5	-	O
6	binding	O
7	site	O
8	for	O
9	this	O
10	complex	O
11	from	O
12	a	O
13	human	B
14	beta	I
15	-	I
16	globin	I
17	locus	I
18	construct	O
19	results	O
20	in	O
21	delayed	O
22	human	B
23	gamma	I
24	-	I
25	to	I
26	beta	I
27	-	I
28	globin	I
29	switching	O
30	in	O
31	transgenic	O
32	mice	O
33	,	O
34	suggesting	O
35	that	O
36	the	O
37	PYR	B
38	complex	I
39	acts	O
40	to	O
41	facilitate	O
42	the	O
43	switch	O
44	.	O

0	We	O
1	used	O
2	oligonucleotide	O
3	-	O
4	directed	O
5	mutagenesis	O
6	to	O
7	alter	O
8	a	O
9	site	O
10	in	O
11	MucA	B
12	homologous	I
13	to	O
14	the	O
15	Ala	O
16	-	O
17	Gly	O
18	cleavage	O
19	site	O
20	of	O
21	LexA	B
22	.	O

0	In	O
1	contrast	O
2	,	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	a	O
10	second	O
11	family	O
12	(	O
13	ART5	B
14	)	O
15	of	O
16	transferases	B
17	,	O
18	cloned	O
19	from	O
20	murine	O
21	lymphoma	O
22	cells	O
23	and	O
24	expressed	O
25	in	O
26	high	O
27	abundance	O
28	in	O
29	testis	O
30	,	O
31	displays	O
32	a	O
33	hydrophobic	O
34	amino	O
35	terminus	O
36	,	O
37	consistent	O
38	with	O
39	a	O
40	signal	O
41	sequence	O
42	,	O
43	but	O
44	lacks	O
45	a	O
46	hydrophobic	O
47	signal	O
48	sequence	O
49	at	O
50	its	O
51	carboxyl	O
52	terminus	O
53	,	O
54	suggesting	O
55	that	O
56	the	O
57	protein	O
58	is	O
59	destined	O
60	for	O
61	export	O
62	.	O

0	The	O
1	carboxyl	O
2	-	O
3	terminal	O
4	proline	O
5	-	O
6	rich	O
7	domain	O
8	of	O
9	SOS1	B
10	is	O
11	involved	O
12	in	O
13	the	O
14	interaction	O
15	with	O
16	the	O
17	PLC	B
18	-	I
19	gamma1	I
20	SH3	I
21	domain	O
22	.	O

0	Additional	O
1	exonuclease	B
2	III	I
3	protection	O
4	was	O
5	observed	O
6	beyond	O
7	the	O
8	core	O
9	region	O
10	on	O
11	both	O
12	the	O
13	5	O
14	'	O
15	and	O
16	3	O
17	'	O
18	sides	O
19	,	O
20	suggesting	O
21	that	O
22	E1	B
23	interacted	O
24	with	O
25	more	O
26	distal	O
27	sequences	O
28	as	O
29	well	O
30	.	O

0	The	O
1	wild	O
2	-	O
3	type	O
4	and	O
5	altered	O
6	forms	O
7	of	O
8	the	O
9	F	B
10	protein	I
11	were	O
12	expressed	O
13	in	O
14	BHK	O
15	-	O
16	21	O
17	and	O
18	HeLa	O
19	T4	O
20	cells	O
21	by	O
22	use	O
23	of	O
24	the	O
25	recombinant	B
26	vaccinia	I
27	virus	I
28	-	I
29	encoding	I
30	T7	I
31	polymerase	I
32	system	O
33	.	O

0	Sequences	O
1	needed	O
2	for	O
3	iron	O
4	-	O
5	regulated	O
6	expression	O
7	of	O
8	sid1	B
9	were	O
10	localized	O
11	to	O
12	a	O
13	306	O
14	bp	O
15	region	O
16	mapping	O
17	2	O
18	.	O
19	3	O
20	and	O
21	2	O
22	.	O
23	6	O
24	kb	O
25	upstream	O
26	of	O
27	the	O
28	ATG	O
29	.	O

0	D3S1261	B
1	is	O
2	physically	O
3	located	O
4	at	O
5	or	O
6	near	O
7	the	O
8	MITF	B
9	locus	I
10	,	O
11	while	O
12	D3S2465	B
13	and	O
14	D3S1766	B
15	are	O
16	flanking	O
17	the	O
18	locus	O
19	at	O
20	about	O
21	17	O
22	.	O
23	5	O
24	cM	O
25	genetic	O
26	distance	O
27	each	O
28	side	O
29	.	O

0	Glomerular	O
1	mesangial	O
2	cells	O
3	expressed	O
4	an	O
5	abundant	O
6	1	O
7	.	O
8	1	O
9	kb	O
10	mRNA	O
11	transcript	O
12	for	O
13	Id1	B
14	,	O
15	but	O
16	in	O
17	contrast	O
18	to	O
19	other	O
20	cell	O
21	types	O
22	Id1	B
23	mRNA	I
24	was	O
25	expressed	O
26	in	O
27	both	O
28	randomly	O
29	cycling	O
30	cells	O
31	and	O
32	in	O
33	serum	O
34	-	O
35	deprived	O
36	,	O
37	quiescent	O
38	cultures	O
39	.	O

0	Early	O
1	-	O
2	onset	O
3	scleral	O
4	necrosis	O
5	after	O
6	iodine	O
7	I	O
8	125	O
9	plaque	O
10	radiotherapy	O
11	for	O
12	ciliochoroidal	O
13	melanoma	O
14	.	O

0	Canadian	O
1	survey	O
2	reveals	O
3	widespread	O
4	dissatisfaction	O
5	among	O
6	physicians	O
7	.	O

0	NH2	O
1	-	O
2	and	O
3	COOH	O
4	-	O
5	terminal	O
6	deletion	O
7	analysis	O
8	revealed	O
9	that	O
10	both	O
11	the	O
12	PH	B
13	and	O
14	putative	O
15	guanine	B
16	nucleotide	I
17	exchange	I
18	factor	I
19	domains	I
20	are	O
21	required	O
22	,	O
23	but	O
24	the	O
25	zinc	O
26	butterfly	O
27	is	O
28	dispensable	O
29	,	O
30	for	O
31	transformation	O
32	.	O

0	In	O
1	this	O
2	study	O
3	,	O
4	we	O
5	identified	O
6	Sp1	B
7	and	O
8	Sp3	B
9	as	O
10	major	O
11	factors	O
12	binding	O
13	to	O
14	the	O
15	Sp1	B
16	sites	I
17	of	O
18	the	O
19	p21	B
20	/	O
21	WAF1	B
22	/	O
23	Cip1	B
24	promoter	O
25	in	O
26	MG63	O
27	cells	O
28	through	O
29	electrophoretic	O
30	mobility	O
31	shift	O
32	assays	O
33	and	O
34	showed	O
35	that	O
36	TSA	O
37	treatment	O
38	did	O
39	not	O
40	change	O
41	their	O
42	binding	O
43	activities	O
44	.	O

0	Mucin	B
1	gene	I
2	expression	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	be	O
8	altered	O
9	in	O
10	many	O
11	intestinal	O
12	diseases	O
13	and	O
14	especially	O
15	cancers	O
16	of	O
17	the	O
18	gastrointestinal	O
19	tract	O
20	.	O

0	All	O
1	nuclear	O
2	receptors	O
3	have	O
4	several	O
5	well	O
6	-	O
7	characterized	O
8	structural	O
9	domains	O
10	,	O
11	including	O
12	a	O
13	conserved	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	,	O
19	and	O
20	a	O
21	ligand	O
22	binding	O
23	domain	O
24	at	O
25	the	O
26	carboxyl	O
27	terminus	O
28	of	O
29	the	O
30	receptor	O
31	.	O

0	Characterization	O
1	of	O
2	CR1	B
3	repeat	O
4	random	O
5	PCR	O
6	markers	O
7	for	O
8	mapping	O
9	the	O
10	chicken	O
11	genome	O
12	.	O

0	Effect	O
1	of	O
2	corticosteroid	O
3	-	O
4	containing	O
5	antirheumatic	O
6	combination	O
7	drugs	O
8	on	O
9	endogenous	O
10	ACTH	B
11	and	O
12	cortisol	O
13	production	O
14	.	O

0	The	O
1	SH2	B
2	-	I
3	containing	I
4	adapter	I
5	protein	I
6	GRB10	I
7	interacts	O
8	with	O
9	BCR	B
10	-	I
11	ABL	I
12	.	O

0	An	O
1	additional	O
2	advantage	O
3	is	O
4	that	O
5	the	O
6	resin	O
7	can	O
8	be	O
9	removed	O
10	and	O
11	the	O
12	immunoperoxidase	B
13	technique	O
14	carried	O
15	out	O
16	on	O
17	thin	O
18	sections	O
19	.	O

0	Some	O
1	of	O
2	the	O
3	mutations	O
4	obtained	O
5	do	O
6	not	O
7	contain	O
8	a	O
9	copy	O
10	of	O
11	the	O
12	Ulysses	B
13	element	I
14	at	O
15	the	O
16	mutant	O
17	locus	O
18	,	O
19	suggesting	O
20	that	O
21	a	O
22	different	O
23	transposable	O
24	element	O
25	may	O
26	be	O
27	responsible	O
28	for	O
29	the	O
30	mutation	O
31	.	O

0	Recording	O
1	of	O
2	the	O
3	digital	O
4	sphygmic	O
5	activity	O
6	in	O
7	the	O
8	lower	O
9	extremities	O
10	with	O
11	the	O
12	photoplethysmographic	O
13	and	O
14	strain	O
15	-	O
16	gauge	O
17	methods	O
18	.	O

0	Comparisons	O
1	of	O
2	the	O
3	four	O
4	operon	O
5	control	O
6	regions	O
7	studied	O
8	indicate	O
9	that	O
10	the	O
11	NarL	B
12	heptamers	I
13	are	O
14	arranged	O
15	with	O
16	diverse	O
17	orientations	O
18	and	O
19	spacing	O
20	.	O

0	Acute	O
1	inhalation	O
2	toxicity	O
3	of	O
4	T	O
5	-	O
6	2	O
7	mycotoxin	O
8	in	O
9	mice	O
10	.	O

0	To	O
1	overcome	O
2	this	O
3	problem	O
4	,	O
5	we	O
6	have	O
7	overexpressed	O
8	Kex2p	B
9	using	O
10	the	O
11	baculovirus	O
12	/	O
13	insect	O
14	cell	O
15	expression	O
16	system	O
17	.	O

0	RNase	B
1	protection	O
2	and	O
3	primer	O
4	extension	O
5	assays	O
6	confirmed	O
7	that	O
8	the	O
9	5	O
10	'	O
11	non	O
12	-	O
13	coding	O
14	exon	O
15	is	O
16	included	O
17	in	O
18	the	O
19	DDT1	B
20	aFGF	I
21	mRNA	I
22	and	O
23	that	O
24	a	O
25	major	O
26	transcription	O
27	start	O
28	site	O
29	is	O
30	approximately	O
31	136	O
32	bp	O
33	upstream	O
34	of	O
35	the	O
36	5	O
37	'	O
38	non	O
39	-	O
40	coding	O
41	splice	O
42	junction	O
43	of	O
44	this	O
45	exon	O
46	.	O

0	Additionally	O
1	in	O
2	seven	O
3	subjects	O
4	adrenaline	O
5	(	O
6	A	O
7	)	O
8	and	O
9	noradrenaline	O
10	(	O
11	NA	O
12	)	O
13	concentrations	O
14	were	O
15	determined	O
16	.	O

0	The	O
1	distribution	O
2	and	O
3	organization	O
4	of	O
5	projections	O
6	from	O
7	the	O
8	spinal	O
9	cervical	O
10	enlargement	O
11	to	O
12	subnucleus	O
13	reticularis	O
14	dorsalis	O
15	(	O
16	SRD	O
17	)	O
18	and	O
19	the	O
20	neighbouring	O
21	Cuneate	O
22	nucleus	O
23	(	O
24	Cu	O
25	)	O
26	area	O
27	was	O
28	studied	O
29	in	O
30	the	O
31	rat	O
32	by	O
33	using	O
34	microinjections	O
35	of	O
36	Phaseolus	B
37	vulgaris	I
38	leucoagglutinin	I
39	(	O
40	PHA	B
41	-	I
42	L	I
43	)	O
44	into	O
45	different	O
46	laminae	O
47	around	O
48	the	O
49	C7	O
50	level	O
51	.	O

0	Thus	O
1	in	O
2	this	O
3	region	O
4	of	O
5	the	O
6	vessel	O
7	pyridinoline	O
8	represents	O
9	the	O
10	major	O
11	stabilising	O
12	crosslink	O
13	of	O
14	collagen	B
15	.	O

0	An	O
1	experiment	O
2	was	O
3	carried	O
4	on	O
5	133	O
6	grown	O
7	up	O
8	fowls	O
9	and	O
10	broilers	O
11	from	O
12	4	O
13	industrial	O
14	farms	O
15	,	O
16	vaccinated	O
17	with	O
18	spray	O
19	lento	O
20	and	O
21	mesogenic	O
22	vaccines	O
23	for	O
24	straining	O
25	the	O
26	immunity	O
27	against	O
28	pseodopest	O
29	through	O
30	RIHA	O
31	and	O
32	provoking	O
33	pseudoplague	O
34	with	O
35	a	O
36	pathogenic	O
37	virus	O
38	.	O

0	We	O
1	have	O
2	cloned	O
3	and	O
4	sequenced	O
5	the	O
6	mouse	B
7	NMO1	I
8	cDNA	I
9	,	O
10	which	O
11	encodes	O
12	the	O
13	NAD	B
14	(	I
15	P	I
16	)	I
17	H	I
18	:	I
19	menadione	I
20	oxidoreductase	I
21	[	O
22	also	O
23	called	O
24	NAD	B
25	(	I
26	P	I
27	)	I
28	H	I
29	:(	I
30	quinone	I
31	acceptor	I
32	)	I
33	oxidoreductase	I
34	;	O
35	quinone	B
36	reductase	I
37	;	O
38	azo	B
39	dye	I
40	reductase	I
41	;	O
42	DT	B
43	diaphorase	I
44	;	O
45	EC	B
46	1	I
47	.	I
48	6	I
49	.	I
50	99	I
51	.	I
52	2	I
53	].	O

0	Three	O
1	high	O
2	mobility	O
3	group	O
4	-	O
5	like	O
6	sequences	O
7	within	O
8	a	O
9	48	O
10	-	O
11	base	O
12	pair	O
13	enhancer	O
14	of	O
15	the	O
16	Col2a1	B
17	gene	I
18	are	O
19	required	O
20	for	O
21	cartilage	O
22	-	O
23	specific	O
24	expression	O
25	in	O
26	vivo	O
27	.	O

0	Transcriptional	O
1	regulation	O
2	of	O
3	SUP35	B
4	and	O
5	SUP45	B
6	in	O
7	Saccharomyces	O
8	cerevisiae	O
9	.	O

0	Moreover	O
1	,	O
2	it	O
3	is	O
4	the	O
5	assumptions	O
6	behind	O
7	steady	O
8	-	O
9	state	O
10	O2	O
11	uptake	O
12	that	O
13	do	O
14	not	O
15	permit	O
16	proper	O
17	interpretation	O
18	of	O
19	energy	O
20	expenditure	O
21	during	O
22	EPOC	O
23	;	O
24	1	O
25	l	O
26	O2	O
27	not	O
28	=	O
29	20	O
30	.	O
31	9	O
32	kJ	O
33	.	O

0	The	O
1	amino	O
2	acid	O
3	sequence	O
4	of	O
5	the	O
6	protein	O
7	in	O
8	the	O
9	region	O
10	of	O
11	the	O
12	specificity	O
13	pocket	O
14	is	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	S	B
20	.	I
21	griseus	I
22	proteases	I
23	A	I
24	,	I
25	B	I
26	,	I
27	and	I
28	C	I
29	.	O

0	Accumulated	O
1	evidence	O
2	indicates	O
3	that	O
4	,	O
5	upon	O
6	stimulation	O
7	with	O
8	interferon	B
9	-	I
10	gamma	I
11	(	O
12	IFN	B
13	-	I
14	gamma	I
15	),	O
16	three	O
17	beta	O
18	-	O
19	type	O
20	subunits	O
21	,	O
22	designated	O
23	LMP2	B
24	,	O
25	LMP7	B
26	,	O
27	and	O
28	PSMB10	B
29	,	O
30	are	O
31	incorporated	O
32	into	O
33	the	O
34	20S	B
35	proteasome	I
36	by	O
37	displacing	O
38	the	O
39	housekeeping	O
40	beta	O
41	-	O
42	type	O
43	subunits	O
44	designated	O
45	PSMB6	B
46	,	O
47	PSMB5	B
48	,	O
49	and	O
50	PSMB7	B
51	,	O
52	respectively	O
53	.	O

0	The	O
1	granules	O
2	grew	O
3	as	O
4	the	O
5	melted	O
6	material	O
7	immersed	O
8	into	O
9	the	O
10	void	O
11	space	O
12	among	O
13	the	O
14	adhered	O
15	particles	O
16	.	O

0	The	O
1	inhibitory	O
2	response	O
3	to	O
4	taps	O
5	is	O
6	essentially	O
7	a	O
8	protective	O
9	reflex	O
10	which	O
11	probably	O
12	serves	O
13	to	O
14	reduce	O
15	the	O
16	activity	O
17	of	O
18	the	O
19	jaw	O
20	-	O
21	closing	O
22	muscles	O
23	when	O
24	one	O
25	bites	O
26	unexpectedly	O
27	on	O
28	hard	O
29	objects	O
30	.	O

0	The	O
1	experimentally	O
2	mapped	O
3	regions	O
4	of	O
5	RPB5	B
6	involved	O
7	in	O
8	these	O
9	interactions	O
10	correspond	O
11	to	O
12	distinct	O
13	and	O
14	surface	O
15	-	O
16	exposed	O
17	alpha	O
18	-	O
19	helical	O
20	structures	O
21	.	O

0	Tributyltin	O
1	and	O
2	its	O
3	breakdown	O
4	products	O
5	,	O
6	mono	O
7	-	O
8	and	O
9	di	O
10	-	O
11	butyltin	O
12	,	O
13	were	O
14	determined	O
15	in	O
16	water	O
17	birds	O
18	collected	O
19	from	O
20	Lake	O
21	Huron	O
22	(	O
23	the	O
24	Great	O
25	Lakes	O
26	),	O
27	marine	O
28	coastal	O
29	United	O
30	States	O
31	,	O
32	and	O
33	the	O
34	west	O
35	coast	O
36	of	O
37	British	O
38	Columbia	O
39	,	O
40	Canada	O
41	.	O

0	Aviators	O
1	from	O
2	the	O
3	Light	O
4	Attack	O
5	Wing	O
6	,	O
7	Pacific	O
8	were	O
9	surveyed	O
10	and	O
11	the	O
12	results	O
13	were	O
14	categorized	O
15	by	O
16	aircraft	O
17	type	O
18	.	O

0	OBJECTIVES	O
1	:	O
2	To	O
3	assess	O
4	the	O
5	ability	O
6	of	O
7	pretreatment	O
8	and	O
9	post	O
10	-	O
11	treatment	O
12	prostate	B
13	-	I
14	specific	I
15	antigen	I
16	(	O
17	PSA	B
18	)	O
19	measurements	O
20	,	O
21	clinical	O
22	tumor	O
23	stage	O
24	,	O
25	tumor	O
26	grade	O
27	,	O
28	Gleason	O
29	sum	O
30	,	O
31	race	O
32	,	O
33	age	O
34	,	O
35	and	O
36	radiation	O
37	dose	O
38	to	O
39	predict	O
40	the	O
41	recurrence	O
42	of	O
43	prostate	O
44	cancer	O
45	following	O
46	external	O
47	beam	O
48	radiation	O
49	therapy	O
50	(	O
51	XRT	O
52	)	O
53	since	O
54	the	O
55	introduction	O
56	of	O
57	PSA	O
58	as	O
59	a	O
60	tumor	O
61	marker	O
62	at	O
63	one	O
64	tertiary	O
65	care	O
66	center	O
67	.	O

0	Mutagenesis	O
1	of	O
2	IM1	B
3	enhances	O
4	the	O
5	ability	O
6	of	O
7	c	B
8	-	I
9	Fos	I
10	to	O
11	activate	O
12	an	O
13	AP1	B
14	bearing	I
15	promoter	I
16	.	O

0	Mesial	O
1	temporal	O
2	sclerosis	O
3	was	O
4	characterized	O
5	by	O
6	severe	O
7	neuronal	O
8	loss	O
9	accompanied	O
10	by	O
11	gliosis	O
12	occurring	O
13	in	O
14	the	O
15	CA1	O
16	/	O
17	prosubiculum	O
18	(	O
19	27	O
20	patients	O
21	,	O
22	100	O
23	%),	O
24	focally	O
25	in	O
26	the	O
27	dentate	O
28	gyrus	O
29	(	O
30	12	O
31	patients	O
32	,	O
33	44	O
34	%),	O
35	and	O
36	in	O
37	the	O
38	CA4	O
39	region	O
40	(	O
41	11	O
42	patients	O
43	,	O
44	41	O
45	%).	O

0	All	O
1	corneal	O
2	buttons	O
3	were	O
4	processed	O
5	for	O
6	histopathologic	O
7	and	O
8	electron	O
9	microscopic	O
10	studies	O
11	.	O

0	These	O
1	risk	O
2	factors	O
3	can	O
4	be	O
5	divided	O
6	into	O
7	2	O
8	groups	O
9	:	O
10	local	O
11	vessel	O
12	wall	O
13	-	O
14	related	O
15	factors	O
16	,	O
17	and	O
18	local	O
19	(	O
20	focal	O
21	action	O
22	)	O
23	systemic	O
24	factors	O
25	.	O

0	Cooperative	O
1	roles	O
2	of	O
3	Bozozok	B
4	/	O
5	Dharma	B
6	and	O
7	Nodal	B
8	-	I
9	related	I
10	proteins	I
11	in	O
12	the	O
13	formation	O
14	of	O
15	the	O
16	dorsal	O
17	organizer	O
18	in	O
19	zebrafish	O
20	.	O

0	Identification	O
1	and	O
2	estimation	O
3	of	O
4	monosaccharides	O
5	and	O
6	disaccharides	O
7	in	O
8	urine	O
9	by	O
10	gas	O
11	-	O
12	liquid	O
13	chromatography	O
14	.	O

0	On	O
1	the	O
2	constituents	O
3	of	O
4	Dryopteris	O
5	polylepis	O

0	In	O
1	addition	O
2	,	O
3	they	O
4	display	O
5	common	O
6	features	O
7	that	O
8	make	O
9	them	O
10	strikingly	O
11	related	O
12	to	O
13	snoRNA	B
14	U14	I
15	.	O

0	The	O
1	Ishasha	O
2	samples	O
3	show	O
4	a	O
5	range	O
6	encompassing	O
7	three	O
8	trophic	O
9	levels	O
10	.	O

0	Halothane	O
1	is	O
2	metabolized	O
3	by	O
4	an	O
5	oxidative	O
6	pathway	O
7	to	O
8	stable	O
9	,	O
10	nonvolatile	O
11	end	O
12	products	O
13	,	O
14	trifluoroacetic	O
15	acid	O
16	(	O
17	TFAA	O
18	)	O
19	and	O
20	bromide	O
21	(	O
22	Br	O
23	-),	O
24	and	O
25	by	O
26	reductive	O
27	pathways	O
28	to	O
29	Br	O
30	-	O
31	and	O
32	inorganic	O
33	fluoride	O
34	(	O
35	F	O
36	-).	O

0	Variety	O
1	of	O
2	cows	O
3	and	O
4	sires	O
5	according	O
6	to	O
7	types	O
8	of	O
9	dermatoglyphics	O
10	(	O
11	patterns	O
12	)	O
13	of	O
14	the	O
15	nose	O
16	-	O
17	labial	O
18	mirror	O
19	of	O
20	cattle	O

0	II	O
1	.	O

0	The	O
1	present	O
2	study	O
3	examined	O
4	the	O
5	dependence	O
6	of	O
7	difference	O
8	tone	O
9	level	O
10	[	O
11	L	O
12	(	O
13	f2	O
14	-	O
15	f1	O
16	)]	O
17	on	O
18	the	O
19	following	O
20	parameters	O
21	of	O
22	the	O
23	two	O
24	-	O
25	tone	O
26	input	O
27	:	O
28	f1	O
29	,	O
30	f2	O
31	/	O
32	f1	O
33	(	O
34	f2	O
35	greater	O
36	than	O
37	f1	O
38	),	O
39	L1	O
40	,	O
41	L2	O
42	,	O
43	and	O
44	L1	O
45	=	O
46	L2	O
47	.	O

0	The	O
1	most	O
2	frequent	O
3	causes	O
4	of	O
5	the	O
6	meningitis	O
7	was	O
8	the	O
9	external	O
10	ventricular	O
11	drainage	O
12	(	O
13	14	O
14	.	O
15	8	O
16	%),	O
17	post	O
18	-	O
19	neurosurgical	O
20	(	O
21	0	O
22	.	O
23	8	O
24	%)	O
25	and	O
26	head	O
27	injury	O
28	(	O
29	0	O
30	.	O
31	0007	O
32	%).	O

0	When	O
1	given	O
2	the	O
3	choice	O
4	between	O
5	an	O
6	estrous	O
7	female	O
8	and	O
9	a	O
10	sexually	O
11	active	O
12	male	O
13	in	O
14	the	O
15	AOF	O
16	,	O
17	flutamide	O
18	females	O
19	,	O
20	as	O
21	well	O
22	as	O
23	controls	O
24	,	O
25	preferred	O
26	the	O
27	male	O
28	partner	O
29	.	O

0	Examination	O
1	of	O
2	the	O
3	sequence	O
4	of	O
5	the	O
6	Punta	B
7	Toro	I
8	M	I
9	gene	I
10	product	I
11	reveals	O
12	the	O
13	presence	O
14	of	O
15	multiple	O
16	hydrophobic	O
17	sequences	O
18	including	O
19	a	O
20	19	O
21	-	O
22	amino	O
23	acid	O
24	,	O
25	carboxy	O
26	-	O
27	proximal	O
28	,	O
29	hydrophobic	O
30	region	O
31	(	O
32	G2	O
33	).	O

0	GN101	B
1	,	O
2	YC819	B
3	-	I
4	9	I
5	,	O
6	and	O
7	SB3	B
8	.	O

0	The	O
1	subunit	O
2	protein	O
3	of	O
4	curli	B
5	was	O
6	highly	O
7	homologous	O
8	at	O
9	its	O
10	amino	O
11	terminus	O
12	to	O
13	SEF	B
14	-	I
15	17	I
16	,	O
17	the	O
18	subunit	O
19	protein	O
20	of	O
21	thin	O
22	,	O
23	aggregative	O
24	fimbriae	O
25	of	O
26	Salmonella	O
27	enteritidis	O
28	27655	O
29	strain	O
30	3b	O
31	,	O
32	suggesting	O
33	that	O
34	these	O
35	fibres	O
36	form	O
37	a	O
38	novel	O
39	class	O
40	of	O
41	surface	O
42	organelles	O
43	on	O
44	enterobacteria	O
45	.	O

0	Furthermore	O
1	,	O
2	we	O
3	have	O
4	identified	O
5	a	O
6	43	O
7	-	O
8	bp	O
9	region	O
10	of	O
11	the	O
12	24p3	B
13	promoter	I
14	required	O
15	for	O
16	the	O
17	Dex	O
18	responsiveness	O
19	.	O

0	Inclusion	O
1	in	O
2	this	O
3	family	O
4	of	O
5	proteins	O
6	suggests	O
7	that	O
8	FliQ	B
9	and	O
10	FliR	B
11	may	O
12	participate	O
13	in	O
14	an	O
15	export	O
16	pathway	O
17	required	O
18	for	O
19	flagellum	O
20	assembly	O
21	.	O

0	The	O
1	mRNA	O
2	expression	O
3	of	O
4	RFX1	B
5	,	O
6	RFX2	B
7	,	O
8	and	O
9	RFX3	B
10	was	O
11	detected	O
12	ubiquitously	O
13	,	O
14	but	O
15	in	O
16	transient	O
17	-	O
18	transfection	O
19	assays	O
20	,	O
21	multimerized	O
22	RFX	B
23	binding	I
24	sites	I
25	in	O
26	front	O
27	of	O
28	a	O
29	basal	O
30	promoter	O
31	efficiently	O
32	functioned	O
33	in	O
34	a	O
35	tissue	O
36	-	O
37	and	O
38	lineage	O
39	-	O
40	specific	O
41	manner	O
42	.	O

0	Identical	O
1	results	O
2	were	O
3	obtained	O
4	when	O
5	transfections	O
6	and	O
7	mobility	O
8	shift	O
9	assays	O
10	were	O
11	performed	O
12	in	O
13	primary	O
14	rat	O
15	hepatocytes	O
16	in	O
17	which	O
18	the	O
19	endogenous	B
20	ALS	I
21	gene	I
22	is	O
23	expressed	O
24	.	O

0	In	O
1	addition	O
2	,	O
3	we	O
4	identified	O
5	two	O
6	mutations	O
7	,	O
8	Delta	O
9	M1281	O
10	and	O
11	IVS51	O
12	+	O
13	5G	O
14	-->	O
15	A	O
16	,	O
17	in	O
18	a	O
19	German	O
20	USH1	O
21	patient	O
22	.	O

0	These	O
1	mutations	O
2	alter	O
3	two	O
4	regions	O
5	of	O
6	GAL4	B
7	protein	I
8	:	O
9	the	O
10	DNA	O
11	binding	O
12	domain	O
13	,	O
14	and	O
15	the	O
16	transcription	O
17	activation	O
18	domain	O
19	.	O

0	Sequence	O
1	analysis	O
2	of	O
3	the	O
4	sMtCK	B
5	genomic	I
6	upstream	I
7	sequences	I
8	reveals	O
9	a	O
10	typical	O
11	TATAA	O
12	box	O
13	within	O
14	the	O
15	80	O
16	base	O
17	pairs	O
18	(	O
19	bp	O
20	)	O
21	that	O
22	,	O
23	by	O
24	transfection	O
25	experiments	O
26	,	O
27	are	O
28	sufficient	O
29	to	O
30	promote	O
31	expression	O
32	of	O
33	chimeric	O
34	plasmids	O
35	with	O
36	the	O
37	chloramphenicol	B
38	acetyltransferase	I
39	reporter	O
40	.	O

0	In	O
1	an	O
2	effort	O
3	to	O
4	identify	O
5	the	O
6	USH1C	B
7	disease	I
8	gene	I
9	we	O
10	have	O
11	isolated	O
12	the	O
13	region	O
14	between	O
15	these	O
16	markers	O
17	in	O
18	yeast	O
19	artificial	O
20	chromosomes	O
21	(	O
22	YACs	O
23	)	O
24	using	O
25	a	O
26	combination	O
27	of	O
28	STS	O
29	content	O
30	mapping	O
31	and	O
32	Alu	O
33	-	O
34	PCR	O
35	hybridization	O
36	.	O

0	The	O
1	results	O
2	obtained	O
3	tend	O
4	to	O
5	prove	O
6	that	O
7	the	O
8	reticuloendothelial	O
9	system	O
10	mainly	O
11	participated	O
12	in	O
13	beryllium	O
14	retention	O
15	.	O

0	Use	O
1	of	O
2	Medi	O
3	-	O
4	Jector	O
5	EZ	O
6	dermojet	O
7	for	O
8	anesthesia	O
9	in	O
10	minor	O
11	surgery	O

0	Brain	B
1	cholinesterase	I
2	activity	O
3	of	O
4	nestling	O
5	great	O
6	egrets	O
7	,	O
8	snowy	O
9	egrets	O
10	and	O
11	black	O
12	-	O
13	crowned	O
14	night	O
15	-	O
16	herons	O
17	.	O
18	inhibition	O
19	of	O
20	brain	B
21	cholinesterase	I
22	(	O
23	ChE	B
24	)	O
25	activity	O
26	in	O
27	birds	O
28	is	O
29	often	O
30	used	O
31	to	O
32	diagnose	O
33	exposure	O
34	or	O
35	death	O
36	from	O
37	organophosphorus	O
38	or	O
39	carbamate	O
40	pesticides	O
41	.	O

0	Gng3lg	B
1	transcripts	I
2	are	O
3	expressed	O
4	in	O
5	a	O
6	variety	O
7	of	O
8	tissues	O
9	including	O
10	both	O
11	brain	O
12	and	O
13	testes	O
14	.	O

0	Heterodimers	O
1	of	O
2	myogenin	B
3	and	O
4	E12	B
5	(	O
6	or	O
7	MyoD	B
8	and	O
9	E12	B
10	)	O
11	specifically	O
12	bound	O
13	a	O
14	restriction	O
15	fragment	O
16	extending	O
17	from	O
18	-	O
19	200	O
20	to	O
21	-	O
22	103	O
23	relative	O
24	to	O
25	the	O
26	start	O
27	of	O
28	cardiac	B
29	alpha	I
30	-	I
31	actin	I
32	transcription	O
33	.	O

0	Additional	O
1	information	O
2	including	O
3	echocardiographic	O
4	sequences	O
5	,	O
6	perioperative	O
7	video	O
8	sequences	O
9	,	O
10	x	O
11	-	O
12	ray	O
13	analysis	O
14	,	O
15	angiograms	O
16	,	O
17	etc	O
18	.	O
19	is	O
20	represented	O
21	in	O
22	the	O
23	program	O
24	.	O

0	INTERVENTIONS	O
1	:	O
2	Study	O
3	patients	O
4	were	O
5	randomly	O
6	divided	O
7	into	O
8	four	O
9	parallel	O
10	groups	O
11	to	O
12	receive	O
13	either	O
14	terbinafine	O
15	250	O
16	mg	O
17	a	O
18	day	O
19	for	O
20	12	O
21	or	O
22	16	O
23	weeks	O
24	(	O
25	groups	O
26	T12	O
27	and	O
28	T16	O
29	)	O
30	or	O
31	itraconazole	O
32	400	O
33	mg	O
34	a	O
35	day	O
36	for	O
37	1	O
38	week	O
39	in	O
40	every	O
41	4	O
42	weeks	O
43	for	O
44	12	O
45	or	O
46	16	O
47	weeks	O
48	(	O
49	groups	O
50	I3	O
51	and	O
52	I4	O
53	).	O

0	Rather	O
1	,	O
2	usp	B
3	is	O
4	required	O
5	in	O
6	late	O
7	third	O
8	instar	O
9	larvae	O
10	for	O
11	appropriate	O
12	developmental	O
13	and	O
14	transcriptional	O
15	responses	O
16	to	O
17	the	O
18	ecdysone	O
19	pulse	O
20	that	O
21	triggers	O
22	puparium	O
23	formation	O
24	.	O

0	AIDS	O
1	-	O
2	related	O
3	disseminated	O
4	histoplasmosis	O
5	in	O
6	San	O
7	Francisco	O
8	,	O
9	California	O
10	.	O

0	After	O
1	an	O
2	initial	O
3	titration	O
4	period	O
5	and	O
6	adjustment	O
7	of	O
8	the	O
9	therapeutic	O
10	dose	O
11	,	O
12	the	O
13	individual	O
14	doses	O
15	were	O
16	from	O
17	21	O
18	to	O
19	500	O
20	micrograms	O
21	/	O
22	24	O
23	hrs	O
24	(	O
25	mean	O
26	160	O
27	micrograms	O
28	/	O
29	24	O
30	hrs	O
31	).	O

0	Among	O
1	eight	O
2	graminaceous	O
3	species	O
4	tested	O
5	,	O
6	Ids3	B
7	expression	O
8	was	O
9	observed	O
10	only	O
11	in	O
12	Fe	O
13	-	O
14	deficient	O
15	roots	O
16	of	O
17	H	O
18	.	O
19	vulgare	O
20	and	O
21	Secale	O
22	cereale	O
23	.	O
24	which	O
25	not	O
26	only	O
27	secrete	O
28	2	O
29	'-	O
30	deoxymugineic	O
31	acid	O
32	(	O
33	DMA	O
34	),	O
35	but	O
36	also	O
37	mugineic	O
38	acid	O
39	(	O
40	MA	O
41	)	O
42	and	O
43	3	O
44	-	O
45	epihydroxymugineic	O
46	acid	O
47	(	O
48	epiHMA	O
49	,	O
50	H	O
51	.	O
52	vulgare	O
53	),	O
54	and	O
55	3	O
56	-	O
57	hydroxymugineic	O
58	acid	O
59	(	O
60	HMA	O
61	,	O
62	S	O
63	.	O
64	cereale	O
65	).	O

0	We	O
1	conclude	O
2	that	O
3	(	O
4	i	O
5	)	O
6	we	O
7	have	O
8	identified	O
9	several	O
10	candidate	O
11	latency	O
12	genes	O
13	of	O
14	murine	O
15	gammaHV68	O
16	,	O
17	(	O
18	ii	O
19	)	O
20	expression	O
21	of	O
22	genes	O
23	during	O
24	latency	O
25	may	O
26	be	O
27	different	O
28	in	O
29	different	O
30	organs	O
31	,	O
32	consistent	O
33	with	O
34	multiple	O
35	latency	O
36	programs	O
37	and	O
38	/	O
39	or	O
40	multiple	O
41	cellular	O
42	sites	O
43	of	O
44	latency	O
45	,	O
46	and	O
47	(	O
48	iii	O
49	)	O
50	regions	O
51	of	O
52	the	O
53	viral	O
54	genome	O
55	(	O
56	v	B
57	-	I
58	bcl	I
59	-	I
60	2	I
61	gene	I
62	,	O
63	v	B
64	-	I
65	GCR	I
66	gene	I
67	,	O
68	and	O
69	gene	O
70	73	O
71	)	O
72	are	O
73	transcribed	O
74	during	O
75	latency	O
76	with	O
77	both	O
78	gammaHV68	O
79	and	O
80	primate	O
81	gammaherpesviruses	O
82	.	O

0	Band	O
1	-	O
2	shift	O
3	assays	O
4	were	O
5	performed	O
6	using	O
7	the	O
8	LPS	B
9	-	I
10	and	I
11	IL	I
12	-	I
13	1	I
14	-	I
15	responsive	I
16	element	I
17	(	O
18	LILRE	O
19	)	O
20	oligonucleotide	O
21	,	O
22	a	O
23	gamma	B
24	interferon	I
25	activation	I
26	site	I
27	-	I
28	like	I
29	site	I
30	that	O
31	is	O
32	present	O
33	in	O
34	the	O
35	human	B
36	IL	I
37	-	I
38	1beta	I
39	promoter	I
40	.	O

0	Resistance	O
1	to	O
2	the	O
3	simulated	O
4	physiologic	O
5	environment	O
6	was	O
7	tested	O
8	by	O
9	measured	O
10	retention	O
11	of	O
12	mechanical	O
13	properties	O
14	after	O
15	immersion	O
16	times	O
17	in	O
18	pseudo	O
19	-	O
20	extracellular	O
21	fluid	O
22	(	O
23	PECF	O
24	)	O
25	at	O
26	37	O
27	degrees	O
28	C	O
29	for	O
30	as	O
31	long	O
32	as	O
33	three	O
34	years	O
35	.	O

0	MATERIAL	O
1	AND	O
2	METHODS	O
3	:	O
4	The	O
5	authors	O
6	analyzed	O
7	41	O
8	persons	O
9	formerly	O
10	submitted	O
11	to	O
12	surgery	O
13	(	O
14	after	O
15	8	O
16	years	O
17	and	O
18	4	O
19	months	O
20	,	O
21	as	O
22	a	O
23	mean	O
24	),	O
25	31	O
26	to	O
27	highly	O
28	selective	O
29	vagotomy	O
30	,	O
31	and	O
32	10	O
33	to	O
34	truncal	O
35	or	O
36	selective	O
37	vagotomy	O
38	plus	O
39	gastroduodenal	O
40	drainage	O
41	.	O

0	RESULTS	O
1	:	O
2	The	O
3	overall	O
4	FNF	O
5	for	O
6	1992	O
7	was	O
8	12	O
9	.	O
10	3	O
11	%	O
12	and	O
13	was	O
14	19	O
15	.	O
16	1	O
17	%,	O
18	22	O
19	.	O
20	2	O
21	%,	O
22	3	O
23	.	O
24	8	O
25	%	O
26	and	O
27	6	O
28	.	O
29	1	O
30	%	O
31	per	O
32	successive	O
33	quarters	O
34	in	O
35	1992	O
36	.	O

0	For	O
1	this	O
2	purpose	O
3	,	O
4	the	O
5	writhing	O
6	test	O
7	,	O
8	capsaicin	O
9	and	O
10	formalin	O
11	induced	O
12	-	O
13	pain	O
14	in	O
15	mice	O
16	were	O
17	used	O
18	.	O

0	Clear	O
1	and	O
2	evidenced	O
3	-	O
4	based	O
5	information	O
6	should	O
7	be	O
8	provided	O
9	to	O
10	patients	O
11	as	O
12	to	O
13	the	O
14	means	O
15	of	O
16	prevention	O
17	with	O
18	special	O
19	attention	O
20	to	O
21	individual	O
22	risk	O
23	groups	O
24	such	O
25	as	O
26	IV	O
27	drug	O
28	abusers	O
29	.	O

0	The	O
1	mustard	B
2	chloroplast	I
3	gene	I
4	rps16	I
5	is	O
6	split	O
7	by	O
8	an	O
9	887	O
10	bp	O
11	group	O
12	II	O
13	(	O
14	or	O
15	III	O
16	)	O
17	intron	O
18	.	O

0	In	O
1	patients	O
2	with	O
3	limited	O
4	disease	O
5	,	O
6	the	O
7	survival	O
8	in	O
9	the	O
10	alternating	O
11	arm	O
12	was	O
13	significantly	O
14	superior	O
15	to	O
16	the	O
17	survival	O
18	in	O
19	the	O
20	CAV	O
21	arm	O
22	(	O
23	P	O
24	=	O
25	.	O
26	014	O
27	)	O
28	or	O
29	the	O
30	survival	O
31	in	O
32	the	O
33	PE	O
34	arm	O
35	(	O
36	P	O
37	=	O
38	.	O
39	023	O
40	).	O

0	In	O
1	contrast	O
2	,	O
3	the	O
4	contractile	O
5	action	O
6	of	O
7	arachidonic	O
8	acid	O
9	,	O
10	via	O
11	a	O
12	presumed	O
13	cyclooxygenase	B
14	product	O
15	that	O
16	mediated	O
17	the	O
18	contractions	O
19	caused	O
20	by	O
21	both	O
22	TF	B
23	and	O
24	EGF	B
25	,	O
26	was	O
27	not	O
28	blocked	O
29	by	O
30	any	O
31	of	O
32	the	O
33	signal	O
34	pathway	O
35	probe	O
36	inhibitors	O
37	.	O

0	All	O
1	subsequent	O
2	patients	O
3	were	O
4	treated	O
5	at	O
6	the	O
7	maximal	O
8	tolerated	O
9	dose	O
10	of	O
11	EDXR	O
12	(	O
13	35	O
14	mg	O
15	/	O
16	m2	O
17	/	O
18	day	O
19	).	O

0	7	O
1	.	O

0	Further	O
1	studies	O
2	established	O
3	that	O
4	the	O
5	Ep	B
6	-	O
7	induced	O
8	increase	O
9	in	O
10	beta	B
11	-	I
12	globin	I
13	mRNA	I
14	could	O
15	be	O
16	inhibited	O
17	by	O
18	the	O
19	tyrosine	B
20	kinase	I
21	inhibitor	O
22	genistein	B
23	and	O
24	the	O
25	protein	B
26	kinase	I
27	C	I
28	inhibitor	O
29	Compound	B
30	3	I
31	.(	O
32	ABSTRACT	O
33	TRUNCATED	O
34	AT	O
35	250	O
36	WORDS	O
37	)	O

0	Clinical	O
1	evaluation	O
2	of	O
3	the	O
4	Allergan	O
5	Humphrey	O
6	500	O
7	autorefractor	O
8	and	O
9	the	O
10	Nidek	B
11	AR	I
12	-	I
13	1000	I
14	autorefractor	I
15	.	O

0	We	O
1	isolated	O
2	a	O
3	ribosomal	B
4	protein	I
5	L18	I
6	by	O
7	interaction	O
8	with	O
9	PKR	B
10	.	O

0	Competition	O
1	experiments	O
2	demonstrate	O
3	a	O
4	negative	O
5	allosteric	O
6	relationship	O
7	between	O
8	these	O
9	RGD	B
10	recognition	I
11	sites	I
12	.	O

0	During	O
1	IC	O
2	breaths	O
3	and	O
4	following	O
5	EC	O
6	and	O
7	VC	O
8	breaths	O
9	at	O
10	rest	O
11	,	O
12	end	O
13	-	O
14	tidal	O
15	CO2	O
16	pressure	O
17	(	O
18	PET	O
19	,	O
20	CO2	O
21	)	O
22	fell	O
23	by	O
24	7	O
25	.	O
26	5	O
27	,	O
28	8	O
29	.	O
30	5	O
31	and	O
32	9	O
33	.	O
34	5	O
35	mmHg	O
36	,	O
37	respectively	O
38	.	O

0	Hemolytic	O
1	jaundice	O
2	due	O
3	to	O
4	G6PD	B
5	deficiency	O
6	causing	O
7	kernicterus	O
8	in	O
9	a	O
10	female	O
11	newborn	O
12	.	O

0	Here	O
1	,	O
2	we	O
3	report	O
4	theoretical	O
5	models	O
6	for	O
7	the	O
8	Gla	B
9	and	O
10	EGF	B
11	-	I
12	1	I
13	modules	I
14	of	O
15	human	B
16	PS	I
17	constructed	O
18	using	O
19	prothrombin	B
20	and	O
21	factor	B
22	X	I
23	experimental	O
24	structures	O
25	.	O

0	Although	O
1	YopH	B
2	is	O
3	a	O
4	highly	O
5	active	O
6	PTP	B
7	,	O
8	it	O
9	preferentially	O
10	targets	O
11	a	O
12	subset	O
13	of	O
14	tyrosine	O
15	-	O
16	phosphorylated	O
17	proteins	O
18	in	O
19	host	O
20	cells	O
21	,	O
22	including	O
23	p130Cas	B
24	.	O

0	Significant	O
1	treatment	O
2	-	O
3	related	O
4	problems	O
5	appeared	O
6	during	O
7	the	O
8	second	O
9	decade	O
10	in	O
11	5	O
12	patients	O
13	,	O
14	including	O
15	one	O
16	chest	O
17	wall	O
18	sarcoma	O
19	;	O
20	all	O
21	of	O
22	these	O
23	patients	O
24	had	O
25	received	O
26	at	O
27	least	O
28	60	O
29	Gy	O
30	to	O
31	breast	O
32	and	O
33	regional	O
34	nodal	O
35	areas	O
36	.	O

0	Cp	B
1	is	O
2	normally	O
3	the	O
4	main	O
5	promoter	O
6	for	O
7	EBNA	B
8	mRNA	I
9	initiation	O
10	,	O
11	so	O
12	it	O
13	appears	O
14	that	O
15	EBNA3C	B
16	contributes	O
17	to	O
18	a	O
19	negative	O
20	autoregulatory	O
21	control	O
22	loop	O
23	.	O

0	The	O
1	study	O
2	was	O
3	repeated	O
4	after	O
5	administration	O
6	of	O
7	oral	O
8	amiodarone	O
9	,	O
10	50	O
11	mg	O
12	/	O
13	kg	O
14	/	O
15	day	O
16	for	O
17	2	O
18	days	O
19	in	O
20	8	O
21	divided	O
22	doses	O
23	(	O
24	mean	O
25	dose	O
26	6	O
27	.	O
28	9	O
29	+/-	O
30	0	O
31	.	O
32	4	O
33	g	O
34	).	O

0	However	O
1	,	O
2	when	O
3	,	O
4	where	O
5	and	O
6	how	O
7	the	O
8	DSPP	O
9	is	O
10	cleaved	O
11	into	O
12	DSP	O
13	and	O
14	DPP	O
15	is	O
16	not	O
17	clear	O
18	.	O

0	The	O
1	E1	B
2	gene	I
3	is	O
4	located	O
5	within	O
6	the	O
7	first	O
8	intron	O
9	of	O
10	the	O
11	gene	O
12	for	O
13	RCC1	B
14	,	O
15	a	O
16	protein	O
17	that	O
18	regulates	O
19	onset	O
20	of	O
21	mitosis	O
22	.	O

0	To	O
1	study	O
2	the	O
3	origin	O
4	of	O
5	different	O
6	fMLF	B
7	-	I
8	R	I
9	transcripts	I
10	,	O
11	the	O
12	genetic	O
13	linkage	O
14	of	O
15	chemotactic	B
16	receptor	I
17	genes	I
18	,	O
19	and	O
20	the	O
21	regulation	O
22	of	O
23	fMLF	B
24	-	I
25	R	I
26	gene	I
27	expression	O
28	,	O
29	we	O
30	determined	O
31	the	O
32	copy	O
33	number	O
34	,	O
35	chromosomal	O
36	location	O
37	,	O
38	structural	O
39	organization	O
40	,	O
41	and	O
42	5	O
43	'-	O
44	flanking	O
45	sequence	O
46	of	O
47	the	O
48	human	B
49	fMLF	I
50	-	I
51	R	I
52	gene	I
53	.	O

0	Lower	O
1	extremity	O
2	weight	O
3	bearing	O
4	under	O
5	various	O
6	standing	O
7	conditions	O
8	in	O
9	independently	O
10	ambulatory	O
11	patients	O
12	with	O
13	hemiparesis	O
14	.	O

0	As	O
1	a	O
2	consequence	O
3	of	O
4	dark	O
5	rearing	O
6	,	O
7	the	O
8	numerical	O
9	density	O
10	of	O
11	cortical	O
12	neurons	O
13	in	O
14	area	O
15	17	O
16	amounted	O
17	to	O
18	about	O
19	double	O
20	of	O
21	the	O
22	value	O
23	observed	O
24	in	O
25	normally	O
26	reared	O
27	kittens	O
28	and	O
29	was	O
30	also	O
31	significantly	O
32	higher	O
33	in	O
34	area	O
35	18	O
36	.	O

0	Oligonucleotide	O
1	-	O
2	directed	O
3	mutagenesis	O
4	was	O
5	used	O
6	to	O
7	create	O
8	an	O
9	NdeI	B
10	restriction	I
11	site	I
12	at	O
13	the	O
14	natural	O
15	ATG	O
16	of	O
17	the	O
18	yeast	O
19	R	O
20	.	O

0	We	O
1	have	O
2	also	O
3	found	O
4	that	O
5	the	O
6	in	O
7	vitro	O
8	interaction	O
9	between	O
10	the	O
11	SV40	B
12	octamer	I
13	motif	I
14	and	O
15	the	O
16	lymphoid	B
17	cell	I
18	-	I
19	specific	I
20	protein	I
21	oct	I
22	-	I
23	B2	I
24	was	O
25	negatively	O
26	modulated	O
27	by	O
28	a	O
29	component	O
30	present	O
31	in	O
32	the	O
33	nuclear	O
34	extracts	O
35	from	O
36	several	O
37	lymphoid	O
38	cell	O
39	lines	O
40	.	O

0	Weaned	O
1	rats	O
2	were	O
3	fed	O
4	a	O
5	normal	O
6	diet	O
7	or	O
8	a	O
9	low	O
10	-	O
11	protein	O
12	,	O
13	low	O
14	-	O
15	energy	O
16	diet	O
17	,	O
18	and	O
19	injected	O
20	with	O
21	saline	O
22	or	O
23	thyroxine	O
24	(	O
25	5	O
26	micrograms	O
27	/	O
28	100	O
29	g	O
30	BW	O
31	)	O
32	for	O
33	22	O
34	days	O
35	.	O

0	Retrogradely	O
1	labelled	O
2	neurons	O
3	significantly	O
4	prevailed	O
5	in	O
6	the	O
7	ipsilateral	O
8	substantia	O
9	nigra	O
10	pars	O
11	compacta	O
12	.	O

0	At	O
1	the	O
2	end	O
3	of	O
4	the	O
5	experiment	O
6	the	O
7	urinary	O
8	porphyrin	O
9	excretion	O
10	and	O
11	the	O
12	porphyrin	O
13	content	O
14	in	O
15	lijver	O
16	and	O
17	skin	O
18	were	O
19	diminished	O
20	in	O
21	HCB	O
22	-	O
23	CQ	O
24	-	O
25	treated	O
26	animals	O
27	by	O
28	about	O
29	50	O
30	%	O
31	compared	O
32	to	O
33	the	O
34	HCB	O
35	controls	O
36	.	O

0	Urinary	O
1	N	O
2	-	O
3	acetylglucosaminidase	O
4	activity	O
5	per	O
6	mg	O
7	creatinine	O
8	did	O
9	not	O
10	differ	O
11	significantly	O
12	between	O
13	groups	O
14	.	O

0	Anoxia	O
1	was	O
2	introduced	O
3	by	O
4	perfusing	O
5	the	O
6	gill	O
7	with	O
8	water	O
9	deprived	O
10	of	O
11	oxygen	O
12	or	O
13	by	O
14	halting	O
15	the	O
16	water	O
17	flow	O
18	to	O
19	the	O
20	gill	O
21	.	O

0	Signaling	O
1	from	O
2	the	O
3	small	B
4	GTP	I
5	-	I
6	binding	I
7	proteins	I
8	Rac1	I
9	and	O
10	Cdc42	B
11	to	O
12	the	O
13	c	B
14	-	I
15	Jun	I
16	N	I
17	-	I
18	terminal	I
19	kinase	I
20	/	O
21	stress	B
22	-	I
23	activated	I
24	protein	I
25	kinase	I
26	pathway	O
27	.	O

0	In	O
1	addition	O
2	,	O
3	the	O
4	affinities	O
5	of	O
6	CBF2	B
7	for	O
8	binding	O
9	to	O
10	the	O
11	LMP	B
12	-	I
13	1	I
14	,	O
15	LMP	B
16	-	I
17	2	I
18	,	O
19	and	O
20	CD23	B
21	promoters	I
22	were	O
23	also	O
24	measured	O
25	.	O

0	Chronic	O
1	administration	O
2	of	O
3	sodium	O
4	cyanate	O
5	decreases	O
6	O2	O
7	extraction	O
8	ratio	O
9	in	O
10	dogs	O
11	.	O

0	An	O
1	unexpected	O
2	finding	O
3	was	O
4	the	O
5	presence	O
6	at	O
7	position	O
8	-	O
9	403	O
10	to	O
11	-	O
12	385	O
13	of	O
14	a	O
15	putative	O
16	dioxin	O
17	responsive	O
18	element	O
19	,	O
20	a	O
21	sequence	O
22	found	O
23	to	O
24	be	O
25	responsible	O
26	for	O
27	the	O
28	induction	O
29	of	O
30	transcription	O
31	of	O
32	the	O
33	cytochrome	B
34	P450IA1	I
35	gene	I
36	(	O
37	CYPIA1	B
38	)	O
39	and	O
40	other	O
41	genes	O
42	involved	O
43	in	O
44	detoxification	O
45	/	O
46	activation	O
47	of	O
48	polycyclic	O
49	aromatic	O
50	hydrocarbons	O
51	.	O

0	Processivity	O
1	of	O
2	DNA	O
3	synthesis	O
4	by	O
5	the	O
6	mutant	O
7	holoenzyme	O
8	containing	O
9	pcna	B
10	-	O
11	79	O
12	was	O
13	unaffected	O
14	on	O
15	poly	O
16	(	O
17	dA	O
18	)	O
19	x	O
20	oligo	O
21	(	O
22	dT	O
23	)	O
24	but	O
25	was	O
26	dramatically	O
27	reduced	O
28	on	O
29	a	O
30	natural	O
31	template	O
32	with	O
33	secondary	O
34	structure	O
35	.	O

0	Using	O
1	the	O
2	yeast	O
3	one	O
4	-	O
5	hybrid	O
6	screen	O
7	with	O
8	integrated	O
9	NRE	O
10	and	O
11	flanking	O
12	DNA	O
13	as	O
14	bait	O
15	,	O
16	the	O
17	predominant	O
18	clone	O
19	obtained	O
20	was	O
21	bovine	O
22	Nrl	O
23	.	O

0	This	O
1	study	O
2	is	O
3	a	O
4	further	O
5	and	O
6	more	O
7	extensive	O
8	validation	O
9	of	O
10	the	O
11	clinician	O
12	rated	O
13	NIMH	O
14	-	O
15	LCM	O
16	-	O
17	p	O
18	.	O

0	For	O
1	EPV	O
2	3	O
3	,	O
4	10	O
5	,	O
6	or	O
7	40	O
8	,	O
9	the	O
10	bias	O
11	exceeded	O
12	25	O
13	%	O
14	for	O
15	7	O
16	,	O
17	3	O
18	,	O
19	and	O
20	1	O
21	in	O
22	the	O
23	8	O
24	-	O
25	predictor	O
26	model	O
27	respectively	O
28	,	O
29	when	O
30	a	O
31	conventional	O
32	selection	O
33	criterion	O
34	was	O
35	used	O
36	(	O
37	alpha	O
38	=	O
39	0	O
40	.	O
41	05	O
42	).	O

0	All	O
1	89	O
2	participating	O
3	household	O
4	members	O
5	were	O
6	anti	O
7	-	O
8	HIV	O
9	seronegative	O
10	,	O
11	and	O
12	78	O
13	who	O
14	were	O
15	tested	O
16	were	O
17	serum	B
18	p24	B
19	antigen	I
20	negative	O
21	.	O

0	Changes	O
1	in	O
2	xanthine	B
3	oxidase	I
4	activity	O
5	in	O
6	patients	O
7	with	O
8	circulatory	O
9	failure	O

0	Glycogen	O
1	utilization	O
2	was	O
3	increased	O
4	,	O
5	but	O
6	tissue	O
7	levels	O
8	of	O
9	creatine	O
10	phosphate	O
11	,	O
12	ATP	O
13	,	O
14	and	O
15	lactate	O
16	were	O
17	similar	O
18	to	O
19	those	O
20	in	O
21	hearts	O
22	receiving	O
23	normal	O
24	flow	O
25	.	O

0	We	O
1	show	O
2	here	O
3	that	O
4	the	O
5	binding	O
6	of	O
7	C1F	B
8	in	O
9	vitro	O
10	is	O
11	sensitive	O
12	to	O
13	the	O
14	concentration	O
15	of	O
16	calcium	O
17	ions	O
18	.	O

0	Supershift	O
1	EMSAs	O
2	identified	O
3	that	O
4	upstream	B
5	stimulatory	I
6	factor	I
7	-	I
8	1	I
9	and	I
10	-	I
11	2	I
12	(	O
13	USF	B
14	-	I
15	1	I
16	and	I
17	-	I
18	2	I
19	)	O
20	were	O
21	part	O
22	of	O
23	these	O
24	complexes	O
25	.	O

0	Orthop	O
1	.	O

0	Renal	O
1	pathology	O
2	and	O
3	long	O
4	-	O
5	term	O
6	outcome	O
7	in	O
8	childhood	O
9	SLE	O
10	.	O

0	The	O
1	amino	O
2	acid	O
3	changes	O
4	D206A	O
5	and	O
6	D208A	O
7	abolish	O
8	singly	O
9	or	O
10	in	O
11	combination	O
12	the	O
13	exonuclease	O
14	activity	O
15	in	O
16	vivo	O
17	.	O

0	Diabetes	O
1	care	O
2	:	O
3	a	O
4	guideline	O
5	to	O
6	the	O
7	facilities	O
8	needed	O
9	to	O
10	support	O
11	internationally	O
12	endorsed	O
13	standards	O
14	.	O

0	Further	O
1	,	O
2	the	O
3	PIP2	B
4	content	O
5	of	O
6	the	O
7	85	O
8	-	O
9	90	O
10	kDa	O
11	protein	O
12	appeared	O
13	to	O
14	decrease	O
15	with	O
16	CSF	B
17	-	I
18	1	I
19	treatment	O
20	.	O

0	Only	O
1	after	O
2	a	O
3	pretreatment	O
4	aimed	O
5	at	O
6	increasing	O
7	its	O
8	oxide	O
9	surface	O
10	layer	O
11	was	O
12	titanium	O
13	powder	O
14	found	O
15	to	O
16	accelerate	O
17	the	O
18	precipitation	O
19	from	O
20	solutions	O
21	containing	O
22	2	O
23	mmol	O
24	/	O
25	L	O
26	CaCl2	O
27	,	O
28	2	O
29	mmol	O
30	/	O
31	L	O
32	KH2PO4	O
33	,	O
34	50	O
35	mmol	O
36	/	O
37	L	O
38	Hepes	O
39	,	O
40	pH	O
41	7	O
42	.	O
43	2	O
44	,	O
45	and	O
46	to	O
47	induce	O
48	precipitation	O
49	from	O
50	metastable	O
51	solutions	O
52	containing	O
53	1	O
54	.	O
55	2	O
56	mmol	O
57	/	O
58	L	O
59	CaCl2	O
60	,	O
61	1	O
62	.	O
63	2	O
64	mmol	O
65	/	O
66	L	O
67	KH2PO4	O
68	,	O
69	50	O
70	mmol	O
71	/	O
72	L	O
73	Hepes	O
74	,	O
75	pH	O
76	7	O
77	.	O
78	2	O
79	,	O
80	at	O
81	37	O
82	degrees	O
83	C	O
84	.	O

0	These	O
1	data	O
2	indicate	O
3	that	O
4	expansion	O
5	of	O
6	the	O
7	dodecamer	O
8	repeat	O
9	located	O
10	in	O
11	the	O
12	proximal	O
13	promoter	O
14	of	O
15	CSTB	B
16	severely	O
17	disrupts	O
18	the	O
19	function	O
20	of	O
21	the	O
22	promoter	O
23	and	O
24	thereby	O
25	reduces	O
26	transcription	O
27	of	O
28	CSTB	B
29	.	O

0	The	O
1	sequence	O
2	has	O
3	a	O
4	1092	O
5	-	O
6	bp	O
7	open	O
8	reading	O
9	frame	O
10	encoding	O
11	a	O
12	protein	O
13	of	O
14	364	O
15	amino	O
16	acids	O
17	.	O

0	The	O
1	treatments	O
2	were	O
3	60	O
4	mg	O
5	t	O
6	.	O
7	i	O
8	.	O
9	d	O
10	.	O
11	and	O
12	120	O
13	mg	O
14	t	O
15	.	O
16	i	O
17	.	O
18	d	O
19	.	O
20	during	O
21	14	O
22	days	O
23	'	O
24	treatment	O
25	,	O
26	with	O
27	the	O
28	last	O
29	dose	O
30	pulsed	O
31	with	O
32	1	O
33	.	O
34	85	O
35	MBq	O
36	[	O
37	14C	O
38	]	O
39	diltiazem	O
40	.	O

0	The	O
1	diabetic	O
2	state	O
3	was	O
4	characterized	O
5	by	O
6	mild	O
7	insulin	B
8	deficiency	O
9	,	O
10	plasma	O
11	levels	O
12	being	O
13	73	O
14	%	O
15	of	O
16	controls	O
17	,	O
18	and	O
19	mild	O
20	hyperglycemia	O
21	,	O
22	with	O
23	nonfasting	O
24	plasma	O
25	glucose	O
26	levels	O
27	of	O
28	1	O
29	.	O
30	5	O
31	times	O
32	normal	O
33	.	O

0	Alternative	O
1	transcript	O
2	of	O
3	the	O
4	nonselective	B
5	-	I
6	type	I
7	endothelin	I
8	receptor	I
9	from	O
10	rat	O
11	brain	O
12	.	O

0	Altogether	O
1	these	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	in	O
7	KG1a	O
8	cells	O
9	,	O
10	TNFalpha	B
11	can	O
12	stimulate	O
13	in	O
14	parallel	O
15	PC	B
16	-	I
17	PLC	I
18	and	O
19	PLD	B
20	,	O
21	whose	O
22	lipid	O
23	products	O
24	activate	O
25	in	O
26	turn	O
27	mitogen	B
28	-	I
29	activated	I
30	protein	I
31	kinase	I
32	(	O
33	MAP	B
34	kinase	I
35	)	O
36	and	O
37	NF	B
38	-	I
39	kappaB	I
40	signalling	O
41	respectively	O
42	.	O

0	4	O
1	.	O

0	Twenty	O
1	-	O
2	one	O
3	percent	O
4	of	O
5	these	O
6	patients	O
7	had	O
8	neurologic	O
9	disease	O
10	that	O
11	appeared	O
12	to	O
13	be	O
14	responsible	O
15	for	O
16	the	O
17	tinnitus	O
18	.	O

0	We	O
1	have	O
2	introduced	O
3	a	O
4	mutation	O
5	(	O
6	Ser36	B
7	-->	O
8	Asn	O
9	)	O
10	into	O
11	this	O
12	domain	O
13	of	O
14	p190	B
15	that	O
16	decreased	O
17	its	O
18	ability	O
19	to	O
20	bind	O
21	guanine	O
22	nucleotide	O
23	when	O
24	expressed	O
25	as	O
26	a	O
27	hemagglutinin	B
28	(	I
29	HA	I
30	)-	O
31	tagged	O
32	protein	O
33	in	O
34	COS	O
35	cells	O
36	.	O

0	Characterization	O
1	of	O
2	polymorphic	O
3	TNRs	O
4	in	O
5	novel	O
6	and	O
7	even	O
8	known	O
9	genes	O
10	expressed	O
11	in	O
12	human	O
13	spinal	O
14	cord	O
15	is	O
16	likely	O
17	to	O
18	help	O
19	in	O
20	the	O
21	identification	O
22	of	O
23	new	O
24	candidates	O
25	for	O
26	genes	O
27	involved	O
28	in	O
29	neurodegenerative	O
30	disorders	O
31	.	O

0	BACKGROUND	O
1	:	O
2	Gamma	O
3	knife	O
4	radiosurgery	O
5	(	O
6	GKR	O
7	)	O
8	is	O
9	a	O
10	safe	O
11	and	O
12	effective	O
13	alternative	O
14	to	O
15	surgery	O
16	for	O
17	intracranial	O
18	lesions	O
19	.	O

0	Serum	B
1	lactate	I
2	dehydrogenase	I
3	and	O
4	haptoglobin	B
5	levels	O
6	were	O
7	normal	O
8	,	O
9	and	O
10	total	O
11	bilirubin	O
12	was	O
13	only	O
14	slightly	O
15	elevated	O
16	.	O

0	In	O
1	broken	O
2	L	O
3	-	O
4	cell	O
5	membranes	O
6	expressing	O
7	wild	O
8	type	O
9	or	O
10	mutant	O
11	M6P	I
12	/	I
13	IGF	I
14	II	I
15	receptors	I
16	,	O
17	30	B
18	nM	I
19	IGF	I
20	II	I
21	also	O
22	failed	O
23	to	O
24	affect	O
25	the	O
26	pertussis	B
27	toxin	I
28	substrate	I
29	activity	O
30	.	O

0	Using	O
1	this	O
2	method	O
3	,	O
4	we	O
5	were	O
6	able	O
7	to	O
8	select	O
9	strong	O
10	enhancer	O
11	-	O
12	type	O
13	activation	O
14	domains	O
15	from	O
16	the	O
17	immediate	O
18	early	O
19	regions	O
20	of	O
21	two	O
22	herpesviruses	O
23	,	O
24	namely	O
25	pseudorabies	O
26	virus	O
27	and	O
28	bovine	O
29	herpesvirus	O
30	1	O
31	.	O

0	When	O
1	expressed	O
2	per	O
3	kilogram	O
4	body	O
5	weight	O
6	,	O
7	mean	O
8	GIT	O
9	increased	O
10	in	O
11	the	O
12	dF	O
13	group	O
14	from	O
15	0	O
16	.	O
17	14	O
18	%	O
19	to	O
20	0	O
21	.	O
22	16	O
23	%	O
24	above	O
25	RMR	O
26	,	O
27	with	O
28	a	O
29	significant	O
30	decrease	O
31	from	O
32	0	O
33	.	O
34	15	O
35	%	O
36	to	O
37	0	O
38	.	O
39	13	O
40	%	O
41	in	O
42	the	O
43	P	O
44	group	O
45	.	O

0	Delayed	O
1	or	O
2	paradoxically	O
3	emptying	O
4	regions	O
5	of	O
6	the	O
7	left	O
8	ventricle	O
9	were	O
10	detected	O
11	by	O
12	a	O
13	relatively	O
14	new	O
15	nuclear	O
16	technique	O
17	--	O
18	phase	O
19	imaging	O
20	.	O

0	Both	O
1	mutations	O
2	confer	O
3	amino	O
4	acid	O
5	substitutions	O
6	in	O
7	the	O
8	viral	B
9	coat	I
10	protein	I
11	but	O
12	differ	O
13	in	O
14	their	O
15	relative	O
16	abilities	O
17	to	O
18	utilize	O
19	the	O
20	foreign	O
21	scaffolding	O
22	protein	O
23	.	O

0	Expression	O
1	in	O
2	early	O
3	postnatal	O
4	pituitary	O
5	and	O
6	in	O
7	pre	O
8	-	O
9	somatotrophic	O
10	cells	O
11	suggests	O
12	that	O
13	Zn	B
14	-	I
15	16	I
16	could	O
17	play	O
18	a	O
19	role	O
20	in	O
21	pituitary	O
22	development	O
23	prior	O
24	to	O
25	somatotroph	O
26	differentiation	O
27	.	O

0	Transgenic	O
1	mice	O
2	harboring	O
3	the	O
4	rat	B
5	TnI	I
6	-	O
7	CAT	B
8	fusion	O
9	gene	O
10	expressed	O
11	the	O
12	reporter	O
13	specifically	O
14	in	O
15	the	O
16	skeletal	O
17	muscle	O
18	.	O

0	No	O
1	UOxase	B
2	mRNA	I
3	was	O
4	detected	O
5	in	O
6	11	O
7	nonhepatic	O
8	tissues	O
9	of	O
10	rat	O
11	,	O
12	suggesting	O
13	tissue	O
14	specificity	O
15	of	O
16	expression	O
17	of	O
18	this	O
19	UOxase	B
20	gene	I
21	.	O

0	Sequence	O
1	analysis	O
2	and	O
3	identification	O
4	of	O
5	two	O
6	hyp	B
7	regulatory	I
8	mutants	I
9	.	O

0	Although	O
1	E2FBP1	B
2	lacks	O
3	the	O
4	transactivation	O
5	domain	O
6	,	O
7	it	O
8	stimulates	O
9	E2F	B
10	site	I
11	-	O
12	dependent	O
13	transcription	O
14	in	O
15	cooperation	O
16	with	O
17	E2F	B
18	-	I
19	1	I
20	.	O

0	The	O
1	Tax	B
2	/	O
3	IKKgamma	B
4	interaction	O
5	serves	O
6	to	O
7	recruit	O
8	Tax	B
9	to	O
10	the	O
11	IKK	B
12	catalytic	I
13	subunits	I
14	,	O
15	IKKalpha	B
16	and	O
17	IKKbeta	B
18	,	O
19	and	O
20	this	O
21	recruitment	O
22	appears	O
23	to	O
24	be	O
25	an	O
26	essential	O
27	mechanism	O
28	by	O
29	which	O
30	Tax	B
31	stimulates	O
32	the	O
33	activity	O
34	of	O
35	IKK	B
36	.	O

0	On	O
1	the	O
2	basis	O
3	of	O
4	these	O
5	unique	O
6	properties	O
7	,	O
8	the	O
9	newly	O
10	characterized	O
11	hemagglutinin	B
12	has	O
13	been	O
14	termed	O
15	Limulus	B
16	18K	I
17	agglutination	I
18	-	I
19	aggregation	I
20	factor	I
21	(	O
22	18K	B
23	-	I
24	LAF	I
25	).	O

0	Furthermore	O
1	,	O
2	MOM	B
3	-	I
4	4	I
5	and	O
6	TAK1	B
7	bind	O
8	related	O
9	proteins	O
10	that	O
11	promote	O
12	their	O
13	kinase	O
14	activities	O
15	.	O

0	The	O
1	population	O
2	of	O
3	between	O
4	75	O
5	,	O
6	000	O
7	and	O
8	100	O
9	,	O
10	000	O
11	was	O
12	largely	O
13	unstable	O
14	,	O
15	and	O
16	cost	O
17	per	O
18	capita	O
19	was	O
20	$	O
21	0	O
22	.	O
23	95	O
24	to	O
25	$	O
26	1	O
27	.	O
28	21	O
29	.	O

0	All	O
1	numbers	O
2	refer	O
3	to	O
4	nucleotide	O
5	positions	O
6	on	O
7	the	O
8	wild	B
9	-	I
10	type	I
11	HIV	I
12	-	I
13	1	I
14	transcript	I
15	.	O

0	Surprisingly	O
1	,	O
2	there	O
3	is	O
4	no	O
5	sequence	O
6	homology	O
7	between	O
8	this	O
9	region	O
10	of	O
11	Ly	B
12	-	I
13	6E	I
14	and	O
15	the	O
16	established	O
17	consensus	O
18	for	O
19	the	O
20	interferon	B
21	-	O
22	stimulated	O
23	response	O
24	element	O
25	,	O
26	which	O
27	has	O
28	been	O
29	shown	O
30	functionally	O
31	important	O
32	to	O
33	all	O
34	previously	O
35	characterized	O
36	alpha	B
37	/	I
38	beta	I
39	interferon	I
40	-	I
41	inducible	I
42	promoters	I
43	.	O

0	It	O
1	acts	O
2	on	O
3	Cdks	B
4	in	O
5	the	O
6	G1	O
7	and	O
8	S	O
9	phases	O
10	of	O
11	the	O
12	cell	O
13	cycle	O
14	,	O
15	and	O
16	also	O
17	binds	O
18	to	O
19	proliferating	O
20	cell	B
21	nuclear	I
22	antigen	I
23	(	O
24	PCNA	B
25	),	O
26	blocking	O
27	DNA	O
28	replication	O
29	in	O
30	vitro	O
31	.	O

0	Both	O
1	alleles	O
2	are	O
3	functionally	O
4	expressed	O
5	and	O
6	are	O
7	distributed	O
8	within	O
9	CD4	B
10	+/	O
11	CD8	B
12	+	O
13	T	O
14	cell	O
15	subsets	O
16	.	O

0	Role	O
1	of	O
2	c	B
3	-	I
4	myc	I
5	in	O
6	simian	B
7	virus	I
8	40	I
9	large	I
10	tumor	I
11	antigen	I
12	-	O
13	induced	O
14	DNA	O
15	synthesis	O
16	in	O
17	quiescent	O
18	3T3	O
19	-	O
20	L1	O
21	mouse	O
22	fibroblasts	O
23	.	O

0	Vibrio	O
1	cholerae	O
2	O139	O
3	in	O
4	Calcutta	O
5	.	O

0	The	O
1	most	O
2	striking	O
3	difference	O
4	in	O
5	the	O
6	birch	O
7	NAD	O
8	(	O
9	P	O
10	)	O
11	H	O
12	-	O
13	NR	O
14	sequence	O
15	in	O
16	comparison	O
17	to	O
18	NADH	O
19	-	O
20	NR	O
21	sequences	O
22	was	O
23	found	O
24	at	O
25	the	O
26	putative	O
27	pyridine	O
28	nucleotide	O
29	binding	O
30	site	O
31	.	O

0	A	O
1	catalytic	O
2	domain	O
3	of	O
4	eukaryotic	B
5	DNA	I
6	topoisomerase	I
7	I	I
8	.	O

0	In	O
1	this	O
2	study	O
3	,	O
4	we	O
5	investigated	O
6	the	O
7	molecular	O
8	mechanisms	O
9	underlying	O
10	the	O
11	inducible	O
12	expression	O
13	of	O
14	the	O
15	flt	B
16	-	I
17	1	I
18	gene	I
19	during	O
20	the	O
21	activation	O
22	of	O
23	THP	B
24	-	I
25	1	I
26	cells	O
27	.	O

0	In	O
1	viral	O
2	infections	O
3	,	O
4	G	B
5	-	I
6	CSF	I
7	was	O
8	correlated	O
9	with	O
10	mononuclear	O
11	cells	O
12	(	O
13	rs	O
14	=	O
15	0	O
16	.	O
17	41	O
18	,	O
19	P	O
20	<	O
21	0	O
22	.	O
23	05	O
24	),	O
25	white	O
26	blood	O
27	cell	O
28	counts	O
29	(	O
30	rs	O
31	=	O
32	0	O
33	.	O
34	56	O
35	,	O
36	P	O
37	<	O
38	0	O
39	.	O
40	01	O
41	),	O
42	neutrophils	O
43	(	O
44	rs	O
45	=	O
46	0	O
47	.	O
48	41	O
49	,	O
50	P	O
51	<	O
52	0	O
53	.	O
54	05	O
55	)	O
56	and	O
57	CRP	O
58	(	O
59	rs	O
60	=	O
61	0	O
62	.	O
63	47	O
64	,	O
65	P	O
66	<	O
67	0	O
68	.	O
69	05	O
70	).	O

0	Retinoblastoma	O
1	:	O
2	a	O
3	study	O
4	of	O
5	natural	O
6	history	O
7	and	O
8	prognosis	O
9	of	O
10	268	O
11	cases	O
12	.	O

0	The	O
1	influence	O
2	of	O
3	Epstein	O
4	-	O
5	Barr	O
6	virus	O
7	seropositivity	O
8	on	O
9	the	O
10	efficacy	O
11	of	O
12	intravenous	O
13	immune	I
14	globulin	I
15	in	O
16	children	O
17	with	O
18	immune	O
19	thrombocytopenic	O
20	purpura	O
21	.	O

0	Liu	O
1	,	O
2	B	O
3	.	O

0	The	O
1	results	O
2	of	O
3	this	O
4	study	O
5	suggest	O
6	that	O
7	NF	B
8	-	I
9	kappaB	I
10	activity	O
11	may	O
12	be	O
13	regulated	O
14	by	O
15	its	O
16	interaction	O
17	with	O
18	the	O
19	cell	O
20	cycle	O
21	regulatory	O
22	protein	O
23	,	O
24	E2F	B
25	-	I
26	1	I
27	.	O

0	Records	O
1	of	O
2	31	O
3	children	O
4	with	O
5	AIDS	O
6	or	O
7	AIDS	O
8	-	O
9	related	O
10	complex	O
11	admitted	O
12	to	O
13	the	O
14	pediatric	O
15	intensive	O
16	care	O
17	unit	O
18	for	O
19	acute	O
20	respiratory	O
21	failure	O
22	throughout	O
23	a	O
24	46	O
25	-	O
26	month	O
27	period	O
28	were	O
29	reviewed	O
30	.	O

0	This	O
1	region	O
2	constitutes	O
3	the	O
4	DNA	O
5	-	O
6	binding	O
7	domain	O
8	with	O
9	basic	O
10	-	O
11	helix	O
12	-	O
13	loop	O
14	-	O
15	helix	O
16	and	O
17	leucine	O
18	-	O
19	zipper	O
20	motifs	O
21	,	O
22	features	O
23	common	O
24	to	O
25	the	O
26	myc	B
27	-	I
28	related	I
29	transcription	I
30	factor	I
31	family	I
32	.	O

0	After	O
1	14	O
2	d	O
3	of	O
4	overfeeding	O
5	,	O
6	hepatic	O
7	PL	O
8	profiles	O
9	were	O
10	identical	O
11	in	O
12	the	O
13	two	O
14	breeds	O
15	and	O
16	similar	O
17	to	O
18	that	O
19	in	O
20	control	O
21	livers	O
22	;	O
23	choline	O
24	-	O
25	containing	O
26	PL	O
27	accounted	O
28	for	O
29	95	O
30	%	O
31	of	O
32	total	O
33	PL	O
34	.	O

0	In	O
1	this	O
2	study	O
3	,	O
4	we	O
5	used	O
6	footprinting	O
7	and	O
8	gel	O
9	mobility	O
10	retardation	O
11	assays	O
12	to	O
13	reveal	O
14	that	O
15	bacterially	O
16	synthesized	O
17	Zta	B
18	fusion	I
19	proteins	I
20	bound	O
21	directly	O
22	to	O
23	six	O
24	TGTGCAA	O
25	-	O
26	like	O
27	motifs	O
28	within	O
29	DSL	B
30	.	O

0	Cerebral125	O
1	albumin	I
2	was	O
3	increased	O
4	to	O
5	similar	O
6	proportions	O
7	in	O
8	those	O
9	groups	O
10	submitted	O
11	to	O
12	hyperosmolality	O
13	.	O

0	The	O
1	possibility	O
2	of	O
3	selective	O
4	chemotherapy	O
5	of	O
6	progressive	O
7	recurring	O
8	ovarian	O
9	carcinoma	O
10	with	O
11	the	O
12	aid	O
13	of	O
14	cytodiagnosis	O
15	and	O
16	incorporation	O
17	of	O
18	tagged	O
19	idoxuridine	O

0	A	O
1	5	O
2	'	O
3	RNA	O
4	stem	O
5	-	O
6	loop	O
7	participates	O
8	in	O
9	the	O
10	transcription	O
11	attenuation	O
12	mechanism	O
13	that	O
14	controls	O
15	expression	O
16	of	O
17	the	O
18	Bacillus	B
19	subtilis	I
20	trpEDCFBA	I
21	operon	I
22	.	O

0	Recombinant	O
1	plasmid	O
2	pFV100	O
3	was	O
4	subsequently	O
5	isolated	O
6	by	O
7	its	O
8	ability	O
9	to	O
10	complement	O
11	B	O
12	-	O
13	band	O
14	expression	O
15	in	O
16	ge6	B
17	.	O

0	Induction	O
1	was	O
2	reversed	O
3	by	O
4	coexpression	O
5	of	O
6	A	B
7	-	I
8	Fos	I
9	,	O
10	a	O
11	dominant	O
12	negative	O
13	to	O
14	AP	B
15	-	I
16	1	I
17	.	O

0	In	O
1	contrast	O
2	,	O
3	a	O
4	similar	O
5	fragment	O
6	lacking	O
7	the	O
8	38	O
9	-	O
10	base	O
11	-	O
12	pair	O
13	region	O
14	had	O
15	no	O
16	such	O
17	stabilizing	O
18	effect	O
19	.	O

0	Transformations	O
1	in	O
2	the	O
3	morphine	O
4	series	O
5	.	O

0	1993	O
1	.	O

0	I	B
1	hypothesize	O
2	that	O
3	white	B
4	gene	I
5	expression	O
6	from	O
7	P	B
8	[	I
9	en	I
10	]	I
11	is	O
12	repressed	O
13	by	O
14	the	O
15	formation	O
16	of	O
17	a	O
18	protein	O
19	complex	O
20	which	O
21	is	O
22	initiated	O
23	at	O
24	the	O
25	engrailed	O
26	PS	B
27	sites	I
28	and	O
29	also	O
30	requires	O
31	interactions	O
32	with	O
33	flanking	O
34	genomic	O
35	DNA	O
36	.	O

0	(	O
1	i	O
2	)	O
3	Complete	O
4	Grb10	B
5	expression	O
6	from	O
7	cDNA	O
8	with	O
9	an	O
10	ecdysone	O
11	-	O
12	regulated	O
13	transient	O
14	expression	O
15	system	O
16	stimulated	O
17	PDGF	B
18	-	I
19	BB	I
20	-,	I
21	IGF	B
22	-	I
23	I	I
24	,	O
25	and	O
26	insulin	B
27	-	O
28	but	O
29	not	O
30	epidermal	B
31	growth	I
32	factor	I
33	(	O
34	EGF	B
35	)-	O
36	induced	O
37	DNA	O
38	synthesis	O
39	in	O
40	an	O
41	ecdysone	O
42	dose	O
43	-	O
44	responsive	O
45	fashion	O
46	.	O

0	The	O
1	hormonal	O
2	response	O
3	to	O
4	a	O
5	standardized	O
6	bicycle	O
7	exercise	O
8	test	O
9	was	O
10	studied	O
11	in	O
12	11	O
13	male	O
14	cadets	O
15	exposed	O
16	to	O
17	a	O
18	course	O
19	of	O
20	107	O
21	h	O
22	of	O
23	continuous	O
24	activity	O
25	with	O
26	less	O
27	than	O
28	2	O
29	h	O
30	sleep	O
31	.	O

0	Transient	O
1	overexpression	O
2	of	O
3	c	B
4	-	I
5	Jun	I
6	induced	O
7	tenascin	B
8	-	I
9	C	I
10	expression	O
11	in	O
12	primary	O
13	REF	B
14	and	O
15	in	O
16	FR3T3	B
17	,	O
18	an	O
19	established	O
20	fibroblast	O
21	cell	O
22	line	O
23	.	O

0	Blood	B
1	GSH	I
2	-	O
3	Px	B
4	activity	O
5	was	O
6	measured	O
7	with	O
8	a	O
9	spectrophotometer	O
10	,	O
11	using	O
12	a	O
13	modification	O
14	of	O
15	a	O
16	previously	O
17	described	O
18	assay	O
19	.	O

0	Human	O
1	and	O
2	Chinese	B
3	hamster	I
4	S14	I
5	protein	I
6	sequences	I
7	deduced	O
8	from	O
9	the	O
10	cDNAs	O
11	are	O
12	identical	O
13	.	O

0	Simian	O
1	immunodeficiency	O
2	virus	O
3	(	O
4	SIV	O
5	)	O
6	is	O
7	a	O
8	lentivirus	O
9	with	O
10	morphological	O
11	and	O
12	antigenic	O
13	similarities	O
14	to	O
15	human	O
16	immunodeficiency	O
17	virus	O
18	,	O
19	the	O
20	causative	O
21	agent	O
22	of	O
23	acquired	O
24	immunodeficiency	O
25	syndrome	O
26	(	O
27	AIDS	O
28	)	O
29	of	O
30	humans	O
31	.	O

0	The	O
1	results	O
2	demonstrate	O
3	that	O
4	(	O
5	i	O
6	)	O
7	no	O
8	intact	O
9	capsids	O
10	were	O
11	assembled	O
12	when	O
13	the	O
14	full	O
15	-	O
16	length	O
17	or	O
18	a	O
19	truncated	O
20	(	O
21	missing	O
22	the	O
23	C	O
24	-	O
25	terminal	O
26	65	O
27	amino	O
28	acids	O
29	)	O
30	UL80	B
31	.	I
32	5	I
33	protein	I
34	was	O
35	tested	O
36	;	O
37	(	O
38	ii	O
39	)	O
40	when	O
41	the	O
42	C	O
43	-	O
44	terminal	O
45	65	O
46	amino	O
47	acids	O
48	of	O
49	the	O
50	UL80	B
51	.	I
52	5	I
53	protein	I
54	were	O
55	replaced	O
56	with	O
57	the	O
58	C	O
59	-	O
60	terminal	O
61	25	O
62	amino	O
63	acids	O
64	of	O
65	the	O
66	UL26	B
67	.	I
68	5	I
69	protein	I
70	,	O
71	intact	O
72	capsids	O
73	were	O
74	made	O
75	and	O
76	direct	O
77	interaction	O
78	of	O
79	the	O
80	UL80	B
81	.	I
82	5	I
83	protein	I
84	with	O
85	VP5	B
86	was	O
87	detected	O
88	;	O
89	(	O
90	iii	O
91	)	O
92	assembly	O
93	of	O
94	intact	O
95	capsids	O
96	was	O
97	demonstrated	O
98	when	O
99	the	O
100	sequence	O
101	of	O
102	the	O
103	last	O
104	12	O
105	amino	O
106	acids	O
107	of	O
108	the	O
109	UL80	B
110	.	I
111	5	I
112	protein	I
113	was	O
114	changed	O
115	from	O
116	RRIFVA	O
117	ALNKLE	O
118	to	O
119	RRIFVAAMMKLE	O
120	;	O
121	(	O
122	iv	O
123	)	O
124	self	O
125	-	O
126	interaction	O
127	of	O
128	the	O
129	scaffold	O
130	proteins	O
131	is	O
132	mediated	O
133	by	O
134	sequences	O
135	N	O
136	terminal	O
137	to	O
138	the	O
139	maturation	O
140	cleavage	O
141	site	O
142	;	O
143	and	O
144	(	O
145	v	O
146	)	O
147	the	O
148	UL26	B
149	.	I
150	5	I
151	and	O
152	UL80	B
153	.	I
154	5	I
155	proteins	I
156	will	O
157	not	O
158	coassemble	O
159	into	O
160	scaffold	O
161	structures	O
162	.	O

0	Two	O
1	alternatively	O
2	spliced	O
3	5	O
4	'	O
5	UTRs	O
6	,	O
7	designated	O
8	type	O
9	I	O
10	and	O
11	type	O
12	II	O
13	,	O
14	of	O
15	222	O
16	and	O
17	115	O
18	bp	O
19	,	O
20	respectively	O
21	,	O
22	were	O
23	found	O
24	associated	O
25	with	O
26	PFP	B
27	.	O

0	Analysis	O
1	of	O
2	viral	O
3	mutants	O
4	in	O
5	vivo	O
6	demonstrated	O
7	that	O
8	the	O
9	NFIII	B
10	/	O
11	OCT	B
12	-	I
13	1	I
14	binding	O
15	site	O
16	and	O
17	a	O
18	conserved	O
19	ATF	B
20	motif	I
21	were	O
22	important	O
23	for	O
24	efficient	O
25	viral	O
26	growth	O
27	.	O

0	On	O
1	long	O
2	-	O
3	term	O
4	follow	O
5	-	O
6	up	O
7	,	O
8	there	O
9	was	O
10	no	O
11	significant	O
12	difference	O
13	in	O
14	the	O
15	incidence	O
16	of	O
17	hospitalizations	O
18	(	O
19	1	O
20	per	O
21	2	O
22	.	O
23	1	O
24	vs	O
25	.	O

0	TDEYA	O
1	at	O
2	doses	O
3	of	O
4	200	O
5	to	O
6	500	O
7	mg	O
8	/	O
9	kg	O
10	significantly	O
11	suppressed	O
12	xanthine	B
13	oxidase	I
14	(	O
15	XO	B
16	)	O
17	activity	O
18	in	O
19	the	O
20	stomach	O
21	tissue	O
22	following	O
23	its	O
24	oral	O
25	administration	O
26	.	O

0	These	O
1	data	O
2	suggest	O
3	that	O
4	hypocitraturia	O
5	in	O
6	type	O
7	I	O
8	renal	O
9	tubular	O
10	acidosis	O
11	may	O
12	be	O
13	due	O
14	to	O
15	a	O
16	defect	O
17	in	O
18	proximal	O
19	tubule	O
20	function	O
21	.	O

0	Molecular	O
1	cloning	O
2	of	O
3	the	O
4	human	B
5	homolog	I
6	of	I
7	a	I
8	striatum	B
9	-	I
10	enriched	I
11	phosphatase	I
12	(	O
13	STEP	B
14	)	O
15	gene	O
16	and	O
17	chromosomal	O
18	mapping	O
19	of	O
20	the	O
21	human	O
22	and	O
23	murine	O
24	loci	O
25	.	O

0	According	O
1	to	O
2	the	O
3	investigation	O
4	,	O
5	the	O
6	recent	O
7	burst	O
8	of	O
9	pseudoterranovosis	O
10	in	O
11	this	O
12	area	O
13	can	O
14	be	O
15	attributed	O
16	to	O
17	the	O
18	increased	O
19	presence	O
20	of	O
21	sea	O
22	lions	O
23	,	O
24	which	O
25	proliferate	O
26	in	O
27	the	O
28	Arctic	O
29	region	O
30	,	O
31	then	O
32	migrate	O
33	to	O
34	the	O
35	northern	O
36	Japan	O
37	Sea	O
38	and	O
39	eat	O
40	the	O
41	intermediate	O
42	host	O
43	fish	O
44	.	O

0	In	O
1	rats	O
2	anaesthetized	O
3	with	O
4	+-	O
5	chloralose	O
6	the	O
7	changes	O
8	in	O
9	extracellular	O
10	pH	O
11	and	O
12	K	O
13	+	O
14	in	O
15	spinal	O
16	cord	O
17	dorsal	O
18	horn	O
19	were	O
20	studied	O
21	using	O
22	pH	O
23	and	O
24	K	O
25	+	O
26	ion	O
27	-	O
28	selective	O
29	electrodes	O
30	.	O

0	Mutations	O
1	at	O
2	the	O
3	extreme	O
4	C	O
5	-	O
6	terminus	O
7	of	O
8	EIAV	B
9	Tat	I
10	impaired	O
11	both	O
12	RNA	O
13	binding	O
14	and	O
15	activation	O
16	domain	O
17	functions	O
18	,	O
19	suggesting	O
20	effects	O
21	on	O
22	secondary	O
23	or	O
24	tertiary	O
25	structure	O
26	.	O

0	Computer	O
1	-	O
2	aided	O
3	"	O
4	FRAME	O
5	"	O
6	analysis	O
7	revealed	O
8	four	O
9	possible	O
10	open	O
11	reading	O
12	frames	O
13	(	O
14	ORFs	O
15	),	O
16	three	O
17	in	O
18	one	O
19	direction	O
20	and	O
21	one	O
22	in	O
23	the	O
24	opposite	O
25	direction	O
26	.	O

0	All	O
1	anti	B
2	-	I
3	I	I
4	and	O
5	anti	B
6	-	I
7	i	I
8	CA	I
9	were	O
10	shown	O
11	to	O
12	express	O
13	VH4	B
14	heavy	I
15	chains	I
16	,	O
17	and	O
18	14	O
19	of	O
20	17	O
21	CA	O
22	expressed	O
23	a	O
24	previously	O
25	described	O
26	VH4	B
27	second	O
28	hypervariable	O
29	region	O
30	determinant	O
31	,	O
32	termed	O
33	VH4	B
34	-	O
35	HV2a	O
36	.	O

0	Analysis	O
1	of	O
2	the	O
3	DNA	O
4	from	O
5	15	O
6	cases	O
7	of	O
8	sporadic	O
9	and	O
10	familial	O
11	Wilms	O
12	'	O
13	tumor	O
14	did	O
15	not	O
16	reveal	O
17	any	O
18	changes	O
19	,	O
20	indicating	O
21	that	O
22	the	O
23	translocation	O
24	breakpoint	O
25	does	O
26	not	O
27	reside	O
28	in	O
29	this	O
30	gene	O
31	.	O

0	The	O
1	cloned	O
2	alcR	B
3	gene	I
4	provided	O
5	in	O
6	trans	O
7	restored	O
8	these	O
9	siderophore	O
10	system	O
11	activities	O
12	to	O
13	the	O
14	mutants	O
15	.	O

0	Atcys1	B
1	,	O
2	Athyp1	B
3	,	O
4	AKin10	B
5	and	O
6	the	O
7	ORF	O
8	are	O
9	very	O
10	close	O
11	to	O
12	each	O
13	other	O
14	and	O
15	organized	O
16	in	O
17	the	O
18	same	O
19	polarity	O
20	;	O
21	hence	O
22	,	O
23	the	O
24	intergenic	O
25	regions	O
26	probably	O
27	contain	O
28	,	O
29	within	O
30	less	O
31	than	O
32	0	O
33	.	O
34	5	O
35	kb	O
36	,	O
37	all	O
38	the	O
39	regulatory	O
40	elements	O
41	necessary	O
42	to	O
43	govern	O
44	initiation	O
45	and	O
46	termination	O
47	of	O
48	transcription	O
49	.	O

0	The	O
1	identification	O
2	of	O
3	the	O
4	hepatitis	O
5	C	O
6	virus	O
7	as	O
8	the	O
9	major	O
10	cause	O
11	of	O
12	liver	O
13	disease	O
14	both	O
15	in	O
16	dialysis	O
17	patients	O
18	and	O
19	in	O
20	transplant	O
21	patients	O
22	has	O
23	focused	O
24	attention	O
25	on	O
26	the	O
27	epidemiology	O
28	and	O
29	the	O
30	impact	O
31	of	O
32	continuing	O
33	infection	O
34	in	O
35	these	O
36	patient	O
37	groups	O
38	.	O

0	A	O
1	recombinant	O
2	with	O
3	a	O
4	5	O
5	'	O
6	end	O
7	from	O
8	src	B
9	and	O
10	a	O
11	3	O
12	'	O
13	end	O
14	from	O
15	ros	B
16	,	O
17	called	O
18	SRC	B
19	x	O
20	ROS	O
21	,	O
22	transformed	O
23	chicken	O
24	embryo	O
25	fibroblasts	O
26	(	O
27	CEF	O
28	)	O
29	to	O
30	a	O
31	spindle	O
32	shape	O
33	morphology	O
34	,	O
35	mimicking	O
36	that	O
37	of	O
38	UR2	B
39	.	O

0	Interestingly	O
1	,	O
2	the	O
3	RNA	O
4	sequences	O
5	selected	O
6	by	O
7	the	O
8	mutated	O
9	zinc	B
10	knuckle	I
11	9G8	I
12	variant	I
13	are	O
14	efficiently	O
15	recognized	O
16	by	O
17	SRp20	B
18	,	O
19	in	O
20	agreement	O
21	with	O
22	the	O
23	fact	O
24	that	O
25	the	O
26	RBD	B
27	of	I
28	9G8	I
29	and	O
30	SRp20	B
31	are	O
32	similar	O
33	.	O

0	The	O
1	sequence	O
2	similarity	O
3	has	O
4	suggested	O
5	that	O
6	SCG10	B
7	and	O
8	stathmin	B
9	have	O
10	been	O
11	derived	O
12	from	O
13	structurally	O
14	and	O
15	evolutionarily	O
16	related	O
17	genes	O
18	.	O

0	Despite	O
1	i	O
2	.	O
3	v	O
4	.	O
5	steroid	O
6	therapy	O
7	,	O
8	[	O
9	NOexh	O
10	]	O
11	remained	O
12	elevated	O
13	throughout	O
14	recovery	O
15	(	O
16	37	O
17	.	O
18	9	O
19	+/-	O
20	4	O
21	.	O
22	8	O
23	ppb	O
24	,	O
25	p	O
26	<	O
27	0	O
28	.	O
29	001	O
30	)	O
31	until	O
32	discharge	O
33	(	O
34	40	O
35	.	O
36	9	O
37	+/-	O
38	4	O
39	.	O
40	3	O
41	ppb	O
42	,	O
43	p	O
44	<	O
45	0	O
46	.	O
47	001	O
48	).	O

0	DATA	O
1	SOURCES	O
2	:	O
3	Epidemiologic	O
4	studies	O
5	,	O
6	research	O
7	studies	O
8	,	O
9	review	O
10	articles	O
11	,	O
12	and	O
13	government	O
14	reports	O
15	pertaining	O
16	to	O
17	epidemiology	O
18	of	O
19	lung	O
20	cancer	O
21	.	O

0	Standardized	O
1	gastric	O
2	wall	O
3	specimens	O
4	from	O
5	the	O
6	area	O
7	of	O
8	grossly	O
9	healed	O
10	ulcers	O
11	were	O
12	obtained	O
13	,	O
14	processed	O
15	,	O
16	and	O
17	evaluated	O
18	by	O
19	light	O
20	microscopy	O
21	and	O
22	by	O
23	transmission	O
24	electron	O
25	microscopy	O
26	.	O

0	The	O
1	rhaB	B
2	transcription	I
3	start	I
4	site	I
5	was	O
6	mapped	O
7	to	O
8	-	O
9	24	O
10	relative	O
11	to	O
12	the	O
13	start	O
14	of	O
15	translation	O
16	.	O

0	A	O
1	highly	O
2	hydrophobic	O
3	sequence	O
4	located	O
5	near	O
6	the	O
7	carboxyl	O
8	-	O
9	terminal	O
10	extremity	O
11	of	O
12	the	O
13	molecule	O
14	most	O
15	likely	O
16	constitutes	O
17	the	O
18	anchor	O
19	to	O
20	the	O
21	plasma	O
22	membrane	O
23	.	O

0	Results	O
1	of	O
2	two	O
3	-	O
4	hybrid	O
5	assays	O
6	and	O
7	electrophoretic	O
8	mobility	O
9	shift	O
10	assays	O
11	strongly	O
12	suggest	O
13	that	O
14	all	O
15	HD	B
16	-	I
17	Zip	I
18	proteins	I
19	of	O
20	families	O
21	I	O
22	and	O
23	II	O
24	can	O
25	form	O
26	homodimers	O
27	and	O
28	also	O
29	heterodimers	O
30	with	O
31	all	O
32	HD	B
33	-	I
34	Zip	I
35	proteins	I
36	of	O
37	the	O
38	same	O
39	family	O
40	.	O

0	Chagas	O
1	'	O
2	disease	O
3	,	O
4	visceral	O
5	leishmaniasis	O
6	,	O
7	anti	B
8	-	I
9	nuclear	I
10	factor	I
11	,	O
12	schistosomiasis	O
13	,	O
14	rheumatoid	B
15	factor	I
16	and	O
17	normal	O
18	controls	O
19	.	O

0	In	O
1	3Y1	O
2	and	O
3	3Y1	O
4	v	O
5	-	O
6	crk	B
7	-	O
8	transformed	O
9	fibroblasts	O
10	,	O
11	almost	O
12	all	O
13	of	O
14	the	O
15	total	O
16	PTP1B	B
17	and	O
18	about	O
19	40	O
20	%	O
21	of	O
22	total	O
23	p130	B
24	(	O
25	Cas	B
26	)	O
27	co	O
28	-	O
29	sediment	O
30	with	O
31	membranes	O
32	composed	O
33	primarily	O
34	of	O
35	endoplasmic	O
36	reticulum	O
37	.	O

0	Neither	O
1	of	O
2	these	O
3	proteins	O
4	,	O
5	individually	O
6	or	O
7	as	O
8	a	O
9	pair	O
10	,	O
11	can	O
12	bind	O
13	the	O
14	alpha	B
15	-	I
16	globin	I
17	3	I
18	'	I
19	UTR	I
20	unless	O
21	they	O
22	are	O
23	complexed	O
24	with	O
25	the	O
26	remaining	O
27	non	O
28	-	O
29	poly	O
30	(	O
31	C	O
32	)	O
33	binding	O
34	proteins	O
35	of	O
36	the	O
37	alpha	B
38	-	I
39	complex	I
40	.	O

0	We	O
1	and	O
2	others	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	c	B
8	-	I
9	cbl	I
10	proto	I
11	-	I
12	oncogene	I
13	product	I
14	is	O
15	one	O
16	of	O
17	the	O
18	earliest	O
19	targets	O
20	of	O
21	tyrosine	O
22	phosphorylation	O
23	upon	O
24	T	B
25	cell	I
26	receptor	I
27	stimulation	O
28	.	O

0	Mutation	O
1	of	O
2	nucleotides	O
3	adjacent	O
4	to	O
5	the	O
6	AP	B
7	-	I
8	1	I
9	cis	I
10	-	O
11	response	O
12	elements	O
13	had	O
14	no	O
15	effect	O
16	on	O
17	trans	O
18	-	O
19	activation	O
20	.	O

0	Whereas	O
1	both	O
2	MAP	B
3	and	O
4	MSNA	B
5	increase	O
6	during	O
7	SHG	B
8	,	O
9	the	O
10	transition	O
11	from	O
12	SHG	B
13	to	O
14	PHI	B
15	is	O
16	characterized	O
17	by	O
18	a	O
19	transient	O
20	reduction	O
21	in	O
22	MAP	B
23	but	O
24	sustained	O
25	elevation	O
26	in	O
27	MSNA	O
28	,	O
29	facilitating	O
30	separation	O
31	of	O
32	these	O
33	factors	O
34	in	O
35	vivo	O
36	.	O

0	Antithrombin	B
1	III	I
2	in	O
3	hip	O
4	surgery	O

0	Two	O
1	activities	O
2	of	O
3	the	O
4	D	B
5	protein	I
6	of	O
7	the	O
8	miniF	O
9	plasmid	O
10	have	O
11	been	O
12	found	O
13	.	O

0	Pit	B
1	-	I
2	1	I
3	is	O
4	a	O
5	tissue	O
6	-	O
7	specific	O
8	POU	B
9	domain	I
10	factor	I
11	obligatory	O
12	for	O
13	the	O
14	appearance	O
15	of	O
16	three	O
17	cell	O
18	phenotypes	O
19	in	O
20	the	O
21	anterior	O
22	pituitary	O
23	gland	O
24	.	O

0	Value	O
1	of	O
2	Normotest	B
3	and	O
4	antithrombin	B
5	3	I
6	in	O
7	the	O
8	assessment	O
9	of	O
10	liver	O
11	function	O
12	.	O

0	This	O
1	cluster	O
2	consisted	O
3	of	O
4	four	O
5	apparently	O
6	unrelated	O
7	ESTs	B
8	and	O
9	two	O
10	genes	O
11	,	O
12	pregnancy	B
13	-	I
14	associated	I
15	plasma	I
16	protein	I
17	-	I
18	A	I
19	(	O
20	PAPP	B
21	-	I
22	A	I
23	)	O
24	and	O
25	a	O
26	novel	O
27	gene	O
28	(	O
29	tentatively	O
30	named	O
31	EST	B
32	-	I
33	YD1	I
34	).	O

0	The	O
1	results	O
2	suggest	O
3	that	O
4	the	O
5	calcium	O
6	antagonist	O
7	,	O
8	diltiazem	O
9	,	O
10	may	O
11	modify	O
12	the	O
13	effects	O
14	of	O
15	isoflurane	O
16	on	O
17	myocardial	O
18	function	O
19	.	O

0	The	O
1	beta	O
2	subunit	O
3	of	O
4	the	O
5	heterotrimeric	B
6	G	I
7	proteins	I
8	that	O
9	transduce	O
10	signals	O
11	across	O
12	the	O
13	plasma	O
14	membrane	O
15	is	O
16	made	O
17	up	O
18	of	O
19	an	O
20	amino	O
21	-	O
22	terminal	O
23	alpha	O
24	-	O
25	helical	O
26	segment	O
27	followed	O
28	by	O
29	seven	O
30	repeating	O
31	units	O
32	called	O
33	WD	O
34	(	O
35	Trp	O
36	-	O
37	Asp	O
38	)	O
39	repeats	O
40	that	O
41	occur	O
42	in	O
43	about	O
44	140	O
45	different	O
46	proteins	O
47	.	O

0	On	O
1	physical	O
2	examination	O
3	a	O
4	mild	O
5	symmetrical	O
6	polyarthritis	O
7	of	O
8	small	O
9	and	O
10	large	O
11	joints	O
12	was	O
13	seen	O
14	.	O

0	Data	O
1	from	O
2	the	O
3	V	O
4	-	O
5	HeFT	O
6	II	O
7	show	O
8	that	O
9	at	O
10	2	O
11	-	O
12	year	O
13	follow	O
14	-	O
15	up	O
16	,	O
17	a	O
18	progressive	O
19	rise	O
20	of	O
21	plasma	O
22	norepinephrine	O
23	was	O
24	observed	O
25	in	O
26	both	O
27	treatment	O
28	arms	O
29	,	O
30	suggesting	O
31	that	O
32	disease	O
33	progresses	O
34	despite	O
35	treatment	O
36	with	O
37	either	O
38	an	O
39	angiotensin	B
40	-	I
41	converting	I
42	enzyme	I
43	inhibitor	O
44	,	O
45	enalapril	O
46	,	O
47	or	O
48	vasodilator	O
49	therapy	O
50	with	O
51	hydralazine	O
52	/	O
53	isosorbide	O
54	dinitrate	O
55	.	O

0	Lysozyme	B
1	activity	O
2	was	O
3	evidently	O
4	increased	O
5	as	O
6	well	O
7	in	O
8	undiluted	O
9	as	O
10	in	O
11	diluted	O
12	sera	O
13	in	O
14	all	O
15	our	O
16	tested	O
17	patients	O
18	.	O

0	The	O
1	retention	O
2	of	O
3	75SeHCAT	O
4	was	O
5	low	O
6	.	O

0	The	O
1	activity	O
2	of	O
3	6	O
4	-	O
5	fluoroquinolones	O
6	and	O
7	their	O
8	nonfluorinated	O
9	derivatives	O
10	is	O
11	compared	O
12	in	O
13	general	O
14	.	O

0	We	O
1	have	O
2	isolated	O
3	a	O
4	new	O
5	,	O
6	larger	O
7	rat	B
8	B	I
9	-	I
10	myc	I
11	genomic	O
12	clone	O
13	.	O

0	The	O
1	Escherichia	B
2	coli	I
3	tet	I
4	-	I
5	repressor	I
6	(	O
7	TetR	B
8	)	O
9	operator	O
10	system	O
11	was	O
12	used	O
13	to	O
14	develop	O
15	a	O
16	variation	O
17	of	O
18	the	O
19	yeast	O
20	two	O
21	-	O
22	hybrid	O
23	assay	O
24	in	O
25	which	O
26	disruptions	O
27	of	O
28	protein	O
29	-	O
30	protein	O
31	interactions	O
32	can	O
33	be	O
34	identified	O
35	by	O
36	a	O
37	positive	O
38	selection	O
39	.	O

0	We	O
1	also	O
2	observed	O
3	that	O
4	the	O
5	predictive	O
6	ability	O
7	of	O
8	the	O
9	selected	O
10	attitudes	O
11	and	O
12	orientations	O
13	increased	O
14	considerably	O
15	from	O
16	1975	O
17	to	O
18	1982	O
19	.	O

0	Using	O
1	a	O
2	battery	O
3	of	O
4	I	B
5	kappa	I
6	B	I
7	alpha	I
8	mutants	I
9	,	O
10	we	O
11	show	O
12	that	O
13	(	O
14	i	O
15	)	O
16	a	O
17	dimer	O
18	binds	O
19	a	O
20	single	O
21	I	B
22	kappa	I
23	B	I
24	alpha	I
25	molecule	I
26	,	O
27	(	O
28	ii	O
29	)	O
30	the	O
31	acidic	O
32	C	O
33	-	O
34	terminal	O
35	region	O
36	of	O
37	I	B
38	kappa	I
39	B	I
40	alpha	I
41	is	O
42	not	O
43	required	O
44	for	O
45	protein	O
46	-	O
47	protein	O
48	binding	O
49	and	O
50	does	O
51	not	O
52	mask	O
53	the	O
54	nuclear	O
55	localization	O
56	signal	O
57	of	O
58	the	O
59	dimer	O
60	,	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	same	O
66	C	O
67	-	O
68	terminal	O
69	region	O
70	is	O
71	required	O
72	for	O
73	inhibition	O
74	of	O
75	DNA	O
76	binding	O
77	,	O
78	and	O
79	(	O
80	iv	O
81	)	O
82	this	O
83	inhibition	O
84	may	O
85	be	O
86	accomplished	O
87	by	O
88	direct	O
89	interaction	O
90	between	O
91	the	O
92	PEST	O
93	-	O
94	like	O
95	region	O
96	and	O
97	the	O
98	DNA	O
99	-	O
100	binding	O
101	region	O
102	of	O
103	one	O
104	of	O
105	the	O
106	subunits	O
107	of	O
108	the	O
109	dimer	O
110	.	O

0	Significant	O
1	alterations	O
2	in	O
3	the	O
4	vasectomized	O
5	rats	O
6	from	O
7	sham	O
8	rats	O
9	included	O
10	:	O
11	testicular	O
12	and	O
13	epididymal	O
14	hypertrophy	O
15	,	O
16	formation	O
17	of	O
18	pathologic	O
19	vas	O
20	deferens	O
21	granulomas	O
22	,	O
23	decreased	O
24	total	O
25	serum	O
26	protein	O
27	,	O
28	lowered	O
29	alpha	B
30	-	I
31	globulin	I
32	levels	O
33	as	O
34	shown	O
35	by	O
36	serum	O
37	electrophoresis	O
38	,	O
39	and	O
40	increased	O
41	sperm	B
42	agglutinin	I
43	antibody	I
44	titers	O
45	.	O

0	Chem	O
1	.	O

0	When	O
1	the	O
2	E1A	B
3	N	I
4	-	I
5	terminus	I
6	is	O
7	used	O
8	as	O
9	a	O
10	competitor	O
11	in	O
12	squelshing	O
13	experiments	O
14	it	O
15	abolishes	O
16	CBP	B
17	-	O
18	induced	O
19	activation	O
20	of	O
21	E2F1	B
22	/	O
23	DP1	B
24	,	O
25	whereas	O
26	an	O
27	E1A	B
28	mutant	I
29	lacking	O
30	CBP	B
31	binding	O
32	ability	O
33	fails	O
34	to	O
35	do	O
36	so	O
37	.	O

0	Not	O
1	even	O
2	extensive	O
3	pancreatic	O
4	resection	O
5	could	O
6	prevent	O
7	pancreatic	O
8	remnant	O
9	infection	O
10	.	O

0	Finally	O
1	,	O
2	we	O
3	present	O
4	evidence	O
5	that	O
6	fimbrin	B
7	is	O
8	a	O
9	third	O
10	distinct	O
11	plastin	B
12	isoform	I
13	which	O
14	is	O
15	specifically	O
16	expressed	O
17	at	O
18	high	O
19	levels	O
20	in	O
21	the	O
22	small	O
23	intestine	O
24	.	O

0	Accepting	O
1	arbitrarily	O
2	chosen	O
3	limits	O
4	of	O
5	maximized	O
6	errors	O
7	of	O
8	+/-	O
9	10	O
10	%,	O
11	it	O
12	could	O
13	be	O
14	shown	O
15	that	O
16	the	O
17	system	O
18	did	O
19	not	O
20	work	O
21	acceptably	O
22	when	O
23	the	O
24	mean	O
25	carbon	O
26	dioxide	O
27	concentration	O
28	was	O
29	below	O
30	1	O
31	.	O
32	5	O
33	vol	O
34	.%	O
35	within	O
36	the	O
37	fresh	O
38	gas	O
39	flow	O
40	rates	O
41	(	O
42	2	O
43	.	O
44	2	O
45	--	O
46	7	O
47	.	O
48	7	O
49	1	O
50	min	O
51	-	O
52	1	O
53	)	O
54	and	O
55	the	O
56	range	O
57	of	O
58	minute	O
59	ventilation	O
60	(	O
61	4	O
62	--	O
63	10	O
64	1	O
65	min	O
66	-	O
67	1	O
68	)	O
69	employed	O
70	.	O

0	The	O
1	presence	O
2	of	O
3	PDZ	B
4	and	O
5	SAM	B
6	domains	O
7	in	O
8	the	O
9	KS5	B
10	protein	I
11	suggests	O
12	that	O
13	it	O
14	may	O
15	act	O
16	as	O
17	a	O
18	molecular	O
19	adaptor	O
20	,	O
21	promoting	O
22	and	O
23	relaying	O
24	information	O
25	in	O
26	a	O
27	signal	O
28	transduction	O
29	pathway	O
30	.	O

0	Nursing	O
1	education	O
2	--	O
3	the	O
4	computer	O
5	obligation	O
6	.	O

0	We	O
1	have	O
2	recently	O
3	detected	O
4	high	O
5	levels	O
6	of	O
7	CKB	B
8	mRNA	I
9	in	O
10	HeLa	O
11	cells	O
12	and	O
13	,	O
14	in	O
15	this	O
16	study	O
17	,	O
18	have	O
19	tested	O
20	whether	O
21	this	O
22	may	O
23	be	O
24	due	O
25	to	O
26	the	O
27	extremely	O
28	low	O
29	amounts	O
30	of	O
31	p53	B
32	protein	I
33	present	O
34	in	O
35	HeLa	O
36	cells	O
37	.	O

0	Pancreatic	O
1	and	O
2	biliary	O
3	secretion	O
4	and	O
5	gastric	O
6	emptying	O
7	rates	O
8	of	O
9	a	O
10	liquid	O
11	test	O
12	meal	O
13	(	O
14	LTM	O
15	)	O
16	were	O
17	determined	O
18	in	O
19	normal	O
20	persons	O
21	,	O
22	in	O
23	patients	O
24	with	O
25	subtotal	O
26	gastrectomy	O
27	with	O
28	gastroduodenostomy	O
29	(	O
30	STG	O
31	-	O
32	BI	O
33	)	O
34	or	O
35	with	O
36	gastrojejunostomy	O
37	(	O
38	STG	O
39	-	O
40	BII	O
41	),	O
42	and	O
43	in	O
44	patients	O
45	with	O
46	truncal	O
47	vagotomy	O
48	and	O
49	pyloroplasty	O
50	(	O
51	V	O
52	&	O
53	P	O
54	).	O

0	To	O
1	assess	O
2	the	O
3	effects	O
4	of	O
5	alveolar	O
6	hypoxia	O
7	and	O
8	angiotensin	B
9	II	I
10	infusion	O
11	on	O
12	distribution	O
13	of	O
14	blood	O
15	flow	O
16	to	O
17	the	O
18	lung	O
19	we	O
20	performed	O
21	perfusion	O
22	lung	O
23	scans	O
24	on	O
25	anesthetized	O
26	mechanically	O
27	ventilated	O
28	lambs	O
29	.	O

0	Interestingly	O
1	,	O
2	addition	O
3	of	O
4	purified	O
5	CBP	B
6	to	O
7	the	O
8	nuclear	O
9	extracts	O
10	of	O
11	T47D	O
12	cells	O
13	markedly	O
14	stimulated	O
15	progesterone	O
16	-	O
17	and	O
18	PR	O
19	-	O
20	dependent	O
21	transcription	O
22	from	O
23	a	O
24	nucleosome	O
25	-	O
26	free	O
27	,	O
28	progesterone	O
29	response	O
30	element	O
31	(	O
32	PRE	O
33	)-	O
34	linked	O
35	reporter	O
36	DNA	O
37	template	O
38	.	O

0	Eight	O
1	highly	O
2	trained	O
3	male	O
4	kayakers	O
5	were	O
6	studied	O
7	to	O
8	determine	O
9	the	O
10	relationship	O
11	between	O
12	critical	O
13	power	O
14	(	O
15	CP	O
16	)	O
17	and	O
18	the	O
19	onset	O
20	of	O
21	blood	O
22	lactate	O
23	accumulation	O
24	(	O
25	OBLA	O
26	).	O

0	A	O
1	striking	O
2	finding	O
3	in	O
4	all	O
5	of	O
6	the	O
7	studies	O
8	was	O
9	a	O
10	positive	O
11	correlation	O
12	between	O
13	PI	B
14	ACTH	I
15	and	O
16	MSH	B
17	contents	O
18	.	O

0	The	O
1	frequency	O
2	of	O
3	PPNG	O
4	strains	O
5	increased	O
6	from	O
7	1	O
8	.	O
9	7	O
10	%	O
11	in	O
12	1981	O
13	to	O
14	6	O
15	.	O
16	7	O
17	%	O
18	in	O
19	1985	O
20	.	O

0	We	O
1	linked	O
2	a	O
3	4	O
4	.	O
5	1	O
6	-	O
7	kilobase	O
8	pair	O
9	HindIII	B
10	DNA	I
11	fragment	I
12	from	O
13	the	O
14	region	O
15	upstream	O
16	of	O
17	the	O
18	human	B
19	AP	I
20	endonuclease	I
21	gene	I
22	(	O
23	APE	B
24	)	O
25	to	O
26	the	O
27	chloramphenicol	B
28	acetyltransferase	I
29	(	O
30	CAT	B
31	)	O
32	gene	O
33	.	O

0	Egd1p	B
1	is	O
2	homologous	O
3	to	O
4	human	B
5	BTF3b	I
6	,	O
7	recently	O
8	identified	O
9	as	O
10	the	O
11	beta	O
12	subunit	O
13	of	O
14	the	O
15	heterodimeric	B
16	nascent	I
17	-	I
18	polypeptide	I
19	-	I
20	associated	I
21	complex	I
22	(	O
23	NAC	B
24	)	O
25	involved	O
26	in	O
27	ensuring	O
28	signal	O
29	-	O
30	sequence	O
31	-	O
32	specific	O
33	protein	O
34	sorting	O
35	and	O
36	translocation	O
37	[	O
38	Wiedmann	O
39	et	O
40	al	O
41	.,	O
42	Nature	O
43	370	O
44	(	O
45	1994	O
46	)	O
47	434	O
48	-	O
49	440	O
50	].	O

0	This	O
1	Tbx6	B
2	-	I
3	subfamily	I
4	gene	I
5	is	O
6	likely	O
7	to	O
8	participate	O
9	in	O
10	paraxial	O
11	mesoderm	O
12	formation	O
13	and	O
14	somitogenesis	O
15	in	O
16	human	O
17	embryo	O
18	.	O

0	For	O
1	signal	O
2	durations	O
3	less	O
4	than	O
5	10	O
6	ms	O
7	,	O
8	however	O
9	,	O
10	the	O
11	SoNo	O
12	and	O
13	S	O
14	pi	O
15	No	O
16	threshold	O
17	functions	O
18	converged	O
19	and	O
20	the	O
21	masking	O
22	-	O
23	level	O
24	difference	O
25	decreased	O
26	.	O

0	The	O
1	effects	O
2	of	O
3	cardioselective	O
4	beta	O
5	-	O
6	1	O
7	adrenergic	O
8	agonist	O
9	,	O
10	1	O
11	-(	O
12	4	O
13	-	O
14	hydroxyphenoxy	O
15	)-	O
16	isopropylamino	O
17	-	O
18	2	O
19	-	O
20	propanol	O
21	),	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	prenalterol	O
27	,	O
28	were	O
29	examined	O
30	on	O
31	direct	O
32	and	O
33	continuous	O
34	measurements	O
35	of	O
36	left	O
37	ventricular	O
38	(	O
39	LV	O
40	)	O
41	pressure	O
42	,	O
43	diameter	O
44	,	O
45	dP	O
46	/	O
47	dt	O
48	,	O
49	velocity	O
50	of	O
51	shortening	O
52	,	O
53	arterial	O
54	pressure	O
55	,	O
56	iliac	O
57	blood	O
58	flow	O
59	and	O
60	heart	O
61	rate	O
62	in	O
63	10	O
64	conscious	O
65	dogs	O
66	.	O

0	The	O
1	correlation	O
2	between	O
3	PaCO2	O
4	and	O
5	PtcO2	O
6	in	O
7	RDS	O
8	was	O
9	insufficient	O
10	to	O
11	make	O
12	clinical	O
13	judgement	O
14	.	O

0	In	O
1	the	O
2	study	O
3	on	O
4	PCI	B
5	mRNA	I
6	expression	O
7	in	O
8	the	O
9	reproductive	O
10	organs	O
11	,	O
12	we	O
13	first	O
14	cloned	O
15	rat	B
16	PCI	I
17	cDNA	I
18	and	O
19	then	O
20	evaluated	O
21	the	O
22	effect	O
23	of	O
24	androgen	O
25	on	O
26	the	O
27	PCI	B
28	mRNA	I
29	expression	O
30	.	O

0	The	O
1	growing	O
2	drug	O
3	problem	O
4	is	O
5	also	O
6	reflected	O
7	in	O
8	the	O
9	increasing	O
10	number	O
11	of	O
12	cases	O
13	of	O
14	hepatitis	O
15	B	O
16	and	O
17	of	O
18	drug	O
19	-	O
20	related	O
21	deaths	O
22	.	O

0	Five	O
1	concensus	B
2	poly	I
3	A	I
4	addition	I
5	sites	I
6	are	O
7	located	O
8	in	O
9	the	O
10	350	O
11	base	O
12	pairs	O
13	immediately	O
14	following	O
15	the	O
16	protein	B
17	IX	I
18	coding	I
19	region	I
20	.	O

0	As	O
1	extensively	O
2	examined	O
3	with	O
4	the	O
5	myogenin	B
6	promoter	I
7	,	O
8	presence	O
9	of	O
10	one	O
11	or	O
12	multiple	O
13	copies	O
14	of	O
15	Me	B
16	in	O
17	the	O
18	vectors	O
19	elevated	O
20	the	O
21	expression	O
22	activity	O
23	in	O
24	myotubes	O
25	by	O
26	4	O
27	.	O
28	5	O
29	-	O
30	to	O
31	19	O
32	-	O
33	fold	O
34	over	O
35	those	O
36	without	O
37	Me	B
38	,	O
39	but	O
40	not	O
41	significantly	O
42	in	O
43	myoblasts	O
44	.	O

0	A	O
1	variety	O
2	of	O
3	professional	O
4	and	O
5	self	O
6	-	O
7	applied	O
8	fluoride	O
9	products	O
10	are	O
11	available	O
12	and	O
13	new	O
14	fluoride	O
15	delivery	O
16	systems	O
17	have	O
18	recently	O
19	entered	O
20	the	O
21	market	O
22	.	O

0	Quantum	O
1	-	O
2	statistical	O
3	theory	O
4	of	O
5	high	O
6	-	O
7	field	O
8	transport	O
9	phenomena	O
10	.	O

0	Several	O
1	genes	O
2	or	O
3	transcriptional	O
4	units	O
5	were	O
6	identified	O
7	,	O
8	including	O
9	the	O
10	3	O
11	'	O
12	end	O
13	of	O
14	ribosomal	B
15	s6	I
16	kinase	I
17	(	O
18	Rsk3	B
19	);	O
20	two	O
21	apparently	O
22	intronless	O
23	and	O
24	ORF	O
25	-	O
26	less	O
27	genes	O
28	;	O
29	and	O
30	Gpr31	B
31	,	O
32	an	O
33	intronless	O
34	,	O
35	putative	O
36	G	B
37	-	I
38	protein	I
39	coupled	I
40	receptor	I
41	.	O

0	The	O
1	major	O
2	promoter	O
3	responds	O
4	strongly	O
5	to	O
6	virus	O
7	-	O
8	encoded	O
9	trans	O
10	activators	O
11	EIA	O
12	and	O
13	EIV	O
14	and	O
15	contains	O
16	four	O
17	elements	O
18	:	O
19	a	O
20	TAGA	O
21	motif	O
22	analogous	O
23	to	O
24	the	O
25	TATA	O
26	box	O
27	,	O
28	two	O
29	EIIF	B
30	sites	I
31	present	O
32	in	O
33	an	O
34	inverted	O
35	orientation	O
36	,	O
37	and	O
38	an	O
39	ATF	B
40	/	O
41	CREB	B
42	site	O
43	.	O

0	Green	O
1	fluorescent	O
2	protein	O
3	-	O
4	tagged	O
5	UNC	B
6	-	I
7	49B	I
8	and	O
9	UNC	B
10	-	I
11	49C	I
12	subunits	I
13	are	O
14	coexpressed	O
15	in	O
16	muscle	O
17	cells	O
18	and	O
19	are	O
20	colocalized	O
21	to	O
22	synaptic	O
23	regions	O
24	.	O

0	The	O
1	development	O
2	and	O
3	histostructural	O
4	organization	O
5	of	O
6	intrahepatic	O
7	biliary	O
8	ducts	O
9	were	O
10	studied	O
11	on	O
12	a	O
13	human	O
14	embryofetal	O
15	material	O
16	6	O
17	to	O
18	32	O
19	weeks	O
20	old	O
21	.	O

0	Using	O
1	this	O
2	method	O
3	,	O
4	VLPs	O
5	were	O
6	obtained	O
7	in	O
8	quantities	O
9	sufficient	O
10	for	O
11	further	O
12	characterization	O
13	.	O

0	We	O
1	have	O
2	obtained	O
3	the	O
4	human	B
5	EP4	I
6	receptor	I
7	gene	I
8	sequence	I
9	and	O
10	determined	O
11	its	O
12	structure	O
13	relative	O
14	to	O
15	EP4R	B
16	cDNA	I
17	synthesized	O
18	from	O
19	peripheral	O
20	blood	O
21	lymphocytes	O
22	.	O

0	They	O
1	lack	O
2	a	O
3	predicted	O
4	single	O
5	stranded	O
6	(	O
7	ss	O
8	)	O
9	DNA	O
10	binding	O
11	motif	O
12	that	O
13	is	O
14	unique	O
15	the	O
16	large	B
17	terminase	I
18	proteins	I
19	in	O
20	T4	B
21	gp17	I
22	,	O
23	and	O
24	that	O
25	has	O
26	been	O
27	implicated	O
28	in	O
29	recognizing	O
30	ssDNA	O
31	regions	O
32	in	O
33	replicating	O
34	and	O
35	recombining	O
36	T4DNA	O
37	destined	O
38	to	O
39	be	O
40	packaged	O
41	.	O

0	We	O
1	report	O
2	here	O
3	the	O
4	isolation	O
5	of	O
6	a	O
7	full	O
8	-	O
9	length	O
10	cDNA	O
11	clone	O
12	coding	O
13	for	O
14	a	O
15	hitherto	O
16	undiscovered	O
17	isoform	O
18	of	O
19	the	O
20	bovine	O
21	C	O
22	-	O
23	subunit	O
24	.	O

0	Functional	O
1	effects	O
2	following	O
3	subacute	O
4	administration	O
5	.	O

0	HBB	O
1	concentration	O
2	in	O
3	the	O
4	fetuses	O
5	indicated	O
6	little	O
7	,	O
8	if	O
9	any	O
10	accumulation	O
11	.	O

0	RNA	O
1	in	O
2	situ	O
3	hybridization	O
4	on	O
5	brain	O
6	sections	O
7	of	O
8	normal	O
9	human	O
10	embryos	O
11	revealed	O
12	a	O
13	strong	O
14	labeling	O
15	in	O
16	restricted	O
17	areas	O
18	of	O
19	the	O
20	cerebral	O
21	cortex	O
22	.	O

0	Examination	O
1	of	O
2	DNA	O
3	:	O
4	protein	O
5	binding	O
6	complexes	O
7	by	O
8	gel	O
9	-	O
10	shift	O
11	analysis	O
12	indicated	O
13	that	O
14	nuclear	O
15	factors	O
16	from	O
17	both	O
18	proliferative	O
19	and	O
20	growth	O
21	-	O
22	arrested	O
23	cells	O
24	bound	O
25	to	O
26	the	O
27	DNA	O
28	fragment	O
29	spanning	O
30	-	O
31	949	O
32	-	O
33	-	O
34	722	O
35	bp	O
36	.	O

0	Circulating	O
1	platelets	O
2	may	O
3	be	O
4	activated	O
5	by	O
6	exposed	O
7	triple	B
8	-	I
9	helical	I
10	collagen	I
11	in	O
12	atherosclerotic	O
13	lesions	O
14	in	O
15	Mg	O
16	-	O
17	deficient	O
18	ruminants	O
19	.	O

0	The	O
1	amino	O
2	-	O
3	terminal	O
4	DNA	O
5	-	O
6	binding	O
7	domain	O
8	of	O
9	Pip	B
10	exhibits	O
11	a	O
12	high	O
13	degree	O
14	of	O
15	homology	O
16	to	O
17	the	O
18	DNA	O
19	-	O
20	binding	O
21	domains	O
22	of	O
23	members	O
24	of	O
25	the	O
26	interferon	B
27	regulatory	I
28	factor	I
29	(	O
30	IRF	B
31	)	O
32	family	O
33	,	O
34	which	O
35	includes	O
36	IRF	B
37	-	I
38	1	I
39	,	O
40	IRF	B
41	-	I
42	2	I
43	,	O
44	ICSBP	B
45	,	O
46	and	O
47	ISGF3	B
48	gamma	I
49	.	O

0	CONCLUSIONS	O
1	:	O
2	A	O
3	comparison	O
4	of	O
5	the	O
6	LysU	B
7	crystal	O
8	structure	O
9	with	O
10	the	O
11	structures	O
12	of	O
13	seryl	B
14	-	I
15	and	I
16	aspartyl	I
17	-	I
18	tRNA	I
19	synthetases	I
20	enables	O
21	a	O
22	conserved	O
23	core	O
24	to	O
25	be	O
26	identified	O
27	.	O

0	This	O
1	protein	O
2	-	O
3	protein	O
4	interaction	O
5	does	O
6	not	O
7	require	O
8	the	O
9	simultaneous	O
10	binding	O
11	of	O
12	Oct	B
13	proteins	I
14	to	O
15	DNA	O
16	,	O
17	and	O
18	high	O
19	resolution	O
20	footprinting	O
21	of	O
22	the	O
23	Oct	B
24	-	O
25	DNA	O
26	interaction	O
27	reveals	O
28	that	O
29	binding	O
30	of	O
31	BOB	B
32	.	I
33	1	I
34	/	O
35	OBF	B
36	.	I
37	1	I
38	to	O
39	Oct1	B
40	or	O
41	Oct2	B
42	does	O
43	not	O
44	alter	O
45	the	O
46	interaction	O
47	with	O
48	DNA	O
49	.	O

0	The	O
1	general	O
2	recombination	O
3	at	O
4	a	O
5	polarizing	O
6	voltage	O
7	of	O
8	300	O
9	V	O
10	is	O
11	less	O
12	than	O
13	2	O
14	%	O
15	for	O
16	dose	O
17	-	O
18	rates	O
19	up	O
20	to	O
21	about	O
22	100	O
23	mGy	O
24	min	O
25	-	O
26	1	O
27	.	O

0	Letter	O
1	:	O
2	Lactose	O
3	tolerance	O
4	tests	O
5	as	O
6	a	O
7	predictor	O
8	of	O
9	milk	O
10	tolerance	O
11	.	O

0	Reproductive	O
1	period	O
2	affects	O
3	water	O
4	intake	O
5	in	O
6	heat	O
7	-	O
8	stressed	O
9	dehydrated	O
10	goats	O
11	.	O

0	The	O
1	alterations	O
2	in	O
3	differentiation	O
4	of	O
5	osteoprogenitor	O
6	cells	O
7	,	O
8	together	O
9	with	O
10	the	O
11	failure	O
12	of	O
13	mineralization	O
14	,	O
15	resulted	O
16	in	O
17	significantly	O
18	lower	O
19	rates	O
20	of	O
21	bone	O
22	formation	O
23	(	O
24	as	O
25	measured	O
26	by	O
27	fluorochrome	O
28	labeling	O
29	)	O
30	in	O
31	the	O
32	magnesium	O
33	-	O
34	deficient	O
35	rats	O
36	.	O

0	The	O
1	incompatibility	O
2	group	O
3	W	O
4	plasmid	O
5	pSa	O
6	suppresses	O
7	Agrobacterium	O
8	tumefaciens	O
9	oncogenicity	O
10	(	O
11	J	O
12	.	O

0	However	O
1	,	O
2	both	O
3	TPN	O
4	groups	O
5	showed	O
6	a	O
7	marked	O
8	increase	O
9	in	O
10	activities	O
11	of	O
12	liver	O
13	lysosomal	O
14	enzymes	O
15	.	O

0	The	O
1	results	O
2	of	O
3	this	O
4	study	O
5	demonstrate	O
6	that	O
7	strongyloidiasis	O
8	was	O
9	the	O
10	cause	O
11	of	O
12	sudden	O
13	death	O
14	.	O

0	A	O
1	complementary	O
2	study	O
3	,	O
4	showing	O
5	a	O
6	good	O
7	agreement	O
8	between	O
9	surface	O
10	and	O
11	oesophageal	O
12	EMGd	O
13	seems	O
14	to	O
15	confirm	O
16	that	O
17	surface	O
18	EMGd	O
19	is	O
20	a	O
21	useful	O
22	and	O
23	promising	O
24	tool	O
25	for	O
26	clinical	O
27	investigation	O
28	.	O

0	Constructs	O
1	designed	O
2	and	O
3	expressed	O
4	were	O
5	E2L1	B
6	(	O
7	1	O
8	-	O
9	98	O
10	),	O
11	E2L1	B
12	.	O
13	H1	O
14	(	O
15	1	O
16	-	O
17	128	O
18	),	O
19	E2L2	B
20	(	O
21	120	O
22	-	O
23	233	O
24	),	O
25	E2H1	B
26	.	O
27	L2	O
28	(	O
29	98	O
30	-	O
31	233	O
32	),	O
33	and	O
34	E2L1	B
35	.	O
36	H1	O
37	.	O
38	L2	O
39	(	O
40	1	O
41	-	O
42	233	O
43	),	O
44	where	O
45	numbers	O
46	in	O
47	parentheses	O
48	give	O
49	the	O
50	amino	O
51	acid	O
52	sequence	O
53	for	O
54	the	O
55	portions	O
56	of	O
57	the	O
58	E2	O
59	component	O
60	incorporated	O
61	into	O
62	a	O
63	construct	O
64	.	O

0	Human	O
1	adenovirus	O
2	type	O
3	41	O
4	contains	O
5	two	O
6	fibers	O
7	.	O

0	Quantitative	O
1	evaluation	O
2	of	O
3	magneto	O
4	-	O
5	optical	O
6	parameters	O
7	is	O
8	necessary	O
9	in	O
10	order	O
11	to	O
12	apply	O
13	scanning	O
14	near	O
15	-	O
16	field	O
17	optical	O
18	microscope	O
19	(	O
20	SNOM	O
21	)	O
22	technology	O
23	to	O
24	the	O
25	study	O
26	of	O
27	magnetism	O
28	on	O
29	the	O
30	mesoscopic	O
31	scale	O
32	.	O

0	In	O
1	addition	O
2	to	O
3	the	O
4	significant	O
5	reduction	O
6	in	O
7	blood	O
8	pressure	O
9	,	O
10	the	O
11	angiotensin	B
12	converting	I
13	enzyme	I
14	(	O
15	ACE	B
16	)	O
17	inhibitor	O
18	ramipril	O
19	caused	O
20	a	O
21	significant	O
22	regression	O
23	of	O
24	pathologic	O
25	left	O
26	ventricular	O
27	hypertrophy	O
28	demonstrated	O
29	by	O
30	magnetic	O
31	resonance	O
32	imaging	O
33	and	O
34	echocardiography	O
35	.	O

0	Molecular	O
1	dissection	O
2	of	O
3	the	O
4	multimeric	O
5	CD3	B
6	-	O
7	TCR	B
8	complex	O
9	revealed	O
10	that	O
11	at	O
12	least	O
13	two	O
14	associated	O
15	polypeptides	O
16	,	O
17	CD3	B
18	zeta	I
19	and	O
20	CD3	B
21	epsilon	I
22	,	O
23	autonomously	O
24	couple	O
25	antigenic	O
26	recognition	O
27	event	O
28	to	O
29	early	O
30	and	O
31	late	O
32	events	O
33	of	O
34	the	O
35	intracytoplasmic	O
36	activation	O
37	cascade	O
38	.	O

0	This	O
1	shows	O
2	that	O
3	the	O
4	characteristically	O
5	diffuse	O
6	banding	O
7	pattern	O
8	of	O
9	plant	O
10	nuclear	O
11	proteins	O
12	interacting	O
13	with	O
14	the	O
15	G	O
16	-	O
17	box	O
18	is	O
19	also	O
20	observed	O
21	in	O
22	a	O
23	binding	O
24	assay	O
25	using	O
26	only	O
27	one	O
28	recombinant	B
29	GBF	I
30	.	O

0	Serum	O
1	ascorbic	O
2	acid	O
3	had	O
4	an	O
5	inverse	O
6	and	O
7	the	O
8	strongest	O
9	association	O
10	with	O
11	systolic	O
12	blood	O
13	pressure	O
14	among	O
15	the	O
16	risk	O
17	factors	O
18	including	O
19	blood	O
20	pressure	O
21	,	O
22	total	O
23	cholesterol	O
24	,	O
25	triglyceride	O
26	,	O
27	gamma	O
28	-	O
29	GTP	O
30	and	O
31	obesity	O
32	.	O

0	Evaluation	O
1	of	O
2	the	O
3	Du	O
4	Pont	O
5	aca	O
6	ammonia	O
7	procedure	O
8	.	O

0	Convulsive	O
1	status	O
2	epilepticus	O
3	after	O
4	infusion	O
5	of	O
6	cisplatin	O

0	It	O
1	may	O
2	also	O
3	be	O
4	suggested	O
5	that	O
6	particular	O
7	care	O
8	should	O
9	be	O
10	taken	O
11	when	O
12	such	O
13	a	O
14	trans	O
15	-	O
16	dominant	O
17	Rev	B
18	mutant	I
19	is	O
20	considered	O
21	to	O
22	be	O
23	used	O
24	as	O
25	a	O
26	genetic	O
27	therapy	O
28	against	O
29	HIV	O
30	-	O
31	I	O
32	infection	O
33	,	O
34	in	O
35	individuals	O
36	infected	O
37	with	O
38	both	O
39	HIV	O
40	-	O
41	I	O
42	and	O
43	HTLV	O
44	-	O
45	1	O
46	.	O

0	Among	O
1	six	O
2	different	O
3	library	O
4	isolates	O
5	containing	O
6	6	O
7	.	O
8	5	O
9	-	O
10	to	O
11	7	O
12	-	O
13	kb	O
14	IAP	O
15	units	O
16	,	O
17	some	O
18	restriction	O
19	sites	O
20	were	O
21	highly	O
22	conserved	O
23	whereas	O
24	others	O
25	varied	O
26	in	O
27	both	O
28	occurrence	O
29	and	O
30	position	O
31	.	O

0	An	O
1	overexpression	O
2	of	O
3	the	O
4	betaAPP	B
5	gene	I
6	in	O
7	certain	O
8	areas	O
9	of	O
10	the	O
11	AD	O
12	brain	O
13	has	O
14	been	O
15	suggested	O
16	to	O
17	be	O
18	an	O
19	important	O
20	factor	O
21	in	O
22	the	O
23	neuropathology	O
24	of	O
25	AD	O
26	.	O

0	Eight	O
1	patients	O
2	with	O
3	ARC	O
4	and	O
5	renal	O
6	failure	O
7	were	O
8	recently	O
9	evaluated	O
10	.	O

0	Overexpression	O
1	of	O
2	Sed5p	B
3	allowed	O
4	growth	O
5	in	O
6	the	O
7	absence	O
8	of	O
9	Vti1p	B
10	.	O

0	Children	O
1	'	O
2	s	O
3	temperament	O
4	and	O
5	maternal	O
6	socialization	O
7	at	O
8	Time	O
9	1	O
10	(	O
11	n	O
12	=	O
13	103	O
14	,	O
15	aged	O
16	2	O
17	-	O
18	3	O
19	years	O
20	)	O
21	were	O
22	considered	O
23	predictors	O
24	of	O
25	future	O
26	conscience	O
27	,	O
28	assessed	O
29	using	O
30	new	O
31	observational	O
32	and	O
33	narrative	O
34	measures	O
35	.	O

0	We	O
1	argue	O
2	that	O
3	the	O
4	primary	O
5	role	O
6	of	O
7	hh	B
8	in	O
9	controlling	O
10	polarity	O
11	is	O
12	to	O
13	cause	O
14	anterior	O
15	compartment	O
16	cells	O
17	to	O
18	reverse	O
19	their	O
20	interpretation	O
21	of	O
22	an	O
23	underlying	O
24	symmetric	O
25	polarization	O
26	.	O

0	For	O
1	85Sr	O
2	,	O
3	larger	O
4	-	O
5	than	O
6	-	O
7	expected	O
8	distribution	O
9	coefficients	O
10	were	O
11	obtained	O
12	in	O
13	the	O
14	desorption	O
15	experiments	O
16	,	O
17	an	O
18	indication	O
19	of	O
20	the	O
21	irreversible	O
22	formation	O
23	of	O
24	metal	O
25	-	O
26	oxyhydroxides	O
27	during	O
28	a	O
29	slow	O
30	reaction	O
31	.	O

0	On	O
1	d	O
2	112	O
3	,	O
4	progesterone	O
5	was	O
6	higher	O
7	(	O
8	P	O
9	less	O
10	than	O
11	.	O
12	05	O
13	)	O
14	in	O
15	hysterectomized	O
16	heifers	O
17	than	O
18	in	O
19	other	O
20	treatment	O
21	groups	O
22	.	O

0	We	O
1	also	O
2	found	O
3	that	O
4	the	O
5	same	O
6	males	O
7	,	O
8	breeding	O
9	in	O
10	different	O
11	years	O
12	on	O
13	the	O
14	same	O
15	territories	O
16	,	O
17	had	O
18	significantly	O
19	larger	O
20	harems	O
21	in	O
22	the	O
23	years	O
24	they	O
25	had	O
26	familiar	O
27	neighbors	O
28	.	O

0	The	O
1	C	O
2	/	O
3	D	O
4	ratio	O
5	was	O
6	equal	O
7	to	O
8	or	O
9	over	O
10	0	O
11	.	O
12	6	O
13	in	O
14	9	O
15	cases	O
16	(	O
17	16	O
18	eyes	O
19	),	O
20	and	O
21	the	O
22	values	O
23	were	O
24	inconsistent	O
25	between	O
26	both	O
27	eyes	O
28	in	O
29	55	O
30	%	O
31	of	O
32	the	O
33	patients	O
34	.	O

0	Lower	O
1	limits	O
2	(	O
3	to	O
4	10	O
5	micrograms	O
6	/	O
7	kg	O
8	)	O
9	were	O
10	detectable	O
11	,	O
12	but	O
13	with	O
14	lower	O
15	reliability	O
16	(	O
17	60	O
18	%).	O

0	To	O
1	identify	O
2	some	O
3	of	O
4	the	O
5	genes	O
6	expressed	O
7	in	O
8	LPS	O
9	-	O
10	activated	O
11	coelomocytes	O
12	,	O
13	we	O
14	sequenced	O
15	randomly	O
16	chosen	O
17	clones	O
18	from	O
19	a	O
20	directionally	O
21	constructed	O
22	cDNA	O
23	library	O
24	to	O
25	produce	O
26	a	O
27	set	O
28	of	O
29	expressed	O
30	sequence	O
31	tags	O
32	(	O
33	ESTs	O
34	).	O

0	The	O
1	study	O
2	suggests	O
3	the	O
4	presence	O
5	of	O
6	an	O
7	anatomical	O
8	sphincter	O
9	at	O
10	the	O
11	RSJ	O
12	which	O
13	seems	O
14	to	O
15	regulate	O
16	the	O
17	passage	O
18	of	O
19	stools	O
20	from	O
21	the	O
22	sigmoid	O
23	colon	O
24	to	O
25	the	O
26	rectum	O
27	.	O

0	Using	O
1	Spurr	O
2	'	O
3	s	O
4	resin	O
5	as	O
6	a	O
7	mounting	O
8	medium	O
9	,	O
10	we	O
11	could	O
12	observe	O
13	thick	O
14	specimens	O
15	with	O
16	oil	O
17	immersion	O
18	objective	O
19	lens	O
20	without	O
21	the	O
22	use	O
23	of	O
24	coverslips	O
25	,	O
26	then	O
27	avoid	O
28	air	O
29	bubbles	O
30	near	O
31	the	O
32	specimen	O
33	.	O

0	The	O
1	patients	O
2	in	O
3	one	O
4	group	O
5	had	O
6	intrauterine	O
7	catheters	O
8	inserted	O
9	and	O
10	oxytocin	O
11	was	O
12	titrated	O
13	to	O
14	achieve	O
15	the	O
16	75th	O
17	percentile	O
18	of	O
19	uterine	O
20	activity	O
21	observed	O
22	in	O
23	spontaneous	O
24	normal	O
25	labour	O
26	according	O
27	to	O
28	parity	O
29	.	O

0	No	O
1	difference	O
2	in	O
3	percentage	O
4	of	O
5	males	O
6	in	O
7	semen	O
8	production	O
9	was	O
10	noted	O
11	between	O
12	strains	O
13	,	O
14	CP	O
15	levels	O
16	,	O
17	or	O
18	feeding	O
19	regimens	O
20	.	O

0	MotA	B
1	also	O
2	binds	O
3	a	O
4	DNA	O
5	sequence	O
6	(	O
7	a	O
8	MotA	B
9	box	O
10	),	O
11	centered	O
12	at	O
13	position	O
14	-	O
15	30	O
16	.	O

0	A	O
1	hypothesis	O
2	.	O

0	These	O
1	results	O
2	indicate	O
3	that	O
4	TGF	B
5	-	I
6	betaf	I
7	potentiates	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	SRE	I
13	activated	O
14	by	O
15	PKC	B
16	through	O
17	the	O
18	SRF	B
19	binding	I
20	site	I
21	.	O

0	In	O
1	the	O
2	Arithmetic	O
3	subtest	O
4	one	O
5	of	O
6	the	O
7	items	O
8	would	O
9	not	O
10	meet	O
11	the	O
12	difficulty	O
13	grading	O
14	shown	O
15	while	O
16	the	O
17	last	O
18	two	O
19	items	O
20	offer	O
21	very	O
22	little	O
23	possibility	O
24	of	O
25	success	O
26	for	O
27	all	O
28	subjects	O
29	.(	O
30	ABSTRACT	O
31	TRUNCATED	O
32	AT	O
33	250	O
34	WORDS	O
35	)	O

0	The	O
1	effect	O
2	of	O
3	pure	O
4	natural	O
5	porcine	B
6	secretin	I
7	on	O
8	endocrine	O
9	and	O
10	exocrine	O
11	pancreatic	O
12	secretion	O
13	was	O
14	studied	O
15	in	O
16	the	O
17	totally	O
18	isolated	O
19	perfused	O
20	porcine	O
21	pancreas	O
22	.	O

0	The	O
1	character	O
2	of	O
3	specific	O
4	immune	O
5	response	O
6	in	O
7	101	O
8	immunized	O
9	children	O
10	and	O
11	in	O
12	12	O
13	adults	O
14	belonging	O
15	to	O
16	a	O
17	high	O
18	risk	O
19	group	O
20	with	O
21	respect	O
22	to	O
23	VHB	O
24	.	O

0	AF154055	O
1	.	O

0	Treatment	O
1	and	O
2	care	O
3	of	O
4	adult	O
5	diabetes	O
6	mellitus	O
7	without	O
8	coma	O

0	The	O
1	gcd2	B
2	-	I
3	503	I
4	mutation	I
5	also	O
6	results	O
7	in	O
8	polysome	O
9	runoff	O
10	,	O
11	accumulation	O
12	of	O
13	inactive	O
14	80S	B
15	ribosomal	I
16	couples	I
17	,	O
18	and	O
19	accumulation	O
20	of	O
21	at	O
22	least	O
23	one	O
24	of	O
25	the	O
26	subunits	O
27	of	O
28	the	O
29	general	B
30	translation	I
31	initiation	I
32	factor	I
33	2	I
34	(	O
35	eIF	B
36	-	I
37	2	I
38	alpha	I
39	)	O
40	in	O
41	43S	O
42	-	O
43	48S	O
44	particles	O
45	following	O
46	a	O
47	shift	O
48	to	O
49	the	O
50	restrictive	O
51	temperature	O
52	.	O

0	To	O
1	define	O
2	the	O
3	mechanism	O
4	responsible	O
5	for	O
6	the	O
7	loss	O
8	of	O
9	transcription	O
10	elongation	O
11	blockage	O
12	and	O
13	resulting	O
14	c	B
15	-	I
16	myc	I
17	deregulation	O
18	in	O
19	Burkitt	O
20	'	O
21	s	O
22	lymphoma	O
23	,	O
24	we	O
25	analyzed	O
26	transcription	O
27	patterns	O
28	after	O
29	transfer	O
30	of	O
31	normal	O
32	and	O
33	Burkitt	O
34	'	O
35	s	O
36	lymphoma	O
37	c	B
38	-	I
39	myc	I
40	alleles	I
41	into	O
42	murine	O
43	cells	O
44	and	O
45	Xenopus	O
46	oocyte	O
47	germinal	O
48	vesicles	O
49	.	O

0	The	O
1	heterogeneous	O
2	nuclear	B
3	ribonucleoprotein	I
4	C	I
5	protein	I
6	tetramer	I
7	binds	O
8	U1	B
9	,	O
10	U2	B
11	,	O
12	and	O
13	U6	B
14	snRNAs	I
15	through	O
16	its	O
17	high	O
18	affinity	O
19	RNA	O
20	binding	O
21	domain	O
22	(	O
23	the	O
24	bZIP	B
25	-	I
26	like	I
27	motif	I
28	).	O

0	Induced	O
1	expression	O
2	of	O
3	c	B
4	-	I
5	myc	I
6	is	O
7	likely	O
8	to	O
9	contribute	O
10	to	O
11	the	O
12	proliferation	O
13	of	O
14	Stat1	B
15	-	O
16	null	O
17	cells	O
18	in	O
19	response	O
20	to	O
21	IFNs	B
22	.	O

0	Nucleotide	O
1	sequence	O
2	analysis	O
3	of	O
4	R	O
5	has	O
6	revealed	O
7	similarities	O
8	to	O
9	the	O
10	R1	O
11	plasmid	O
12	found	O
13	in	O
14	some	O
15	South	O
16	American	O
17	maize	O
18	races	O
19	with	O
20	RU	O
21	cytoplasm	O
22	,	O
23	to	O
24	the	O
25	M1	O
26	plasmid	O
27	found	O
28	in	O
29	one	O
30	source	O
31	of	O
32	Zea	O
33	luxurians	O
34	teosinte	O
35	,	O
36	to	O
37	the	O
38	atp9	B
39	mitochondrial	I
40	gene	I
41	and	O
42	its	O
43	3	O
44	'	O
45	flanking	O
46	sequence	O
47	,	O
48	and	O
49	also	O
50	to	O
51	a	O
52	region	O
53	3	O
54	'	O
55	to	O
56	the	O
57	orf221	B
58	gene	I
59	.	O

0	In	O
1	F42A	B
2	-	O
3	stimulated	O
4	internalization	O
5	assays	O
6	on	O
7	forskolin	B
8	-	O
9	induced	O
10	YT	O
11	-	O
12	1	O
13	cells	O
14	,	O
15	the	O
16	IL	B
17	-	I
18	2R	I
19	alpha	I
20	chain	I
21	is	O
22	consistently	O
23	endocytosed	O
24	together	O
25	with	O
26	the	O
27	IL	B
28	-	I
29	2R	I
30	beta	I
31	subunit	I
32	indicating	O
33	that	O
34	IL	B
35	-	I
36	2R	I
37	alpha	I
38	is	O
39	stably	O
40	associated	O
41	with	O
42	the	O
43	F42A	B
44	-	O
45	IL	B
46	-	I
47	2R	I
48	beta	I
49	complex	O
50	even	O
51	though	O
52	the	O
53	alpha	O
54	-	O
55	subunit	O
56	contributes	O
57	little	O
58	if	O
59	any	O
60	affinity	O
61	to	O
62	the	O
63	F42A	B
64	binding	O
65	reaction	O
66	.	O

0	Only	O
1	two	O
2	of	O
3	the	O
4	isoforms	O
5	possess	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	zinc	O
11	finger	O
12	domain	O
13	that	O
14	is	O
15	necessary	O
16	and	O
17	sufficient	O
18	for	O
19	TdT	B
20	promoter	I
21	binding	O
22	.	O

0	Together	O
1	,	O
2	these	O
3	results	O
4	suggest	O
5	that	O
6	EGF	B
7	/	O
8	Ras	B
9	/	O
10	Raf	B
11	induces	O
12	transcription	O
13	via	O
14	combined	O
15	activation	O
16	of	O
17	ATF3	B
18	/	O
19	c	B
20	-	I
21	Jun	I
22	and	O
23	a	O
24	52	O
25	-	O
26	kDa	O
27	nuclear	O
28	factor	O
29	,	O
30	whereas	O
31	JunD	B
32	acts	O
33	as	O
34	a	O
35	repressor	O
36	of	O
37	this	O
38	response	O
39	.	O

0	The	O
1	14	B
2	.	I
3	1	I
4	(	O
5	IGLL1	B
6	)	O
7	gene	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	lineage	O
13	-	O
14	and	O
15	stage	O
16	-	O
17	restricted	O
18	manner	O
19	.	O

0	Eleven	O
1	healthy	O
2	,	O
3	normotensive	O
4	males	O
5	undergoing	O
6	routine	O
7	restorative	O
8	dental	O
9	care	O
10	were	O
11	evaluated	O
12	during	O
13	treatment	O
14	for	O
15	possible	O
16	hemodynamic	O
17	alterations	O
18	in	O
19	response	O
20	to	O
21	potential	O
22	sympathetic	O
23	nervous	O
24	system	O
25	stimulation	O
26	.	O

0	Stress	B
1	-	I
2	activated	I
3	protein	I
4	kinase	I
5	1	I
6	(	O
7	SAPK1	B
8	),	O
9	also	O
10	called	O
11	c	B
12	-	I
13	Jun	I
14	N	I
15	-	I
16	terminal	I
17	kinase	I
18	(	O
19	JNK	B
20	),	O
21	becomes	O
22	activated	O
23	in	O
24	vivo	O
25	in	O
26	response	O
27	to	O
28	pro	O
29	-	O
30	inflammatory	O
31	cytokines	O
32	or	O
33	cellular	O
34	stresses	O
35	.	O

0	A	O
1	reversed	O
2	-	O
3	phase	O
4	high	O
5	-	O
6	performance	O
7	liquid	O
8	chromatographic	O
9	(	O
10	HPLC	O
11	)	O
12	method	O
13	for	O
14	the	O
15	determination	O
16	of	O
17	cocaine	O
18	metabolites	O
19	produced	O
20	in	O
21	vitro	O
22	by	O
23	serum	O
24	and	O
25	liver	O
26	esterases	O
27	is	O
28	described	O
29	.	O

0	Site	O
1	-	O
2	directed	O
3	mutagenesis	O
4	revealed	O
5	that	O
6	two	O
7	clusters	O
8	of	O
9	basic	O
10	amino	O
11	acids	O
12	within	O
13	a	O
14	conserved	O
15	basic	O
16	region	O
17	and	O
18	two	O
19	amphipathic	O
20	helices	O
21	within	O
22	the	O
23	adjacent	O
24	HLH	B
25	domain	I
26	are	O
27	essential	O
28	for	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	binding	O
34	and	O
35	hetero	O
36	-	O
37	oligomerization	O
38	,	O
39	respectively	O
40	.	O

0	Wild	O
1	-	O
2	type	O
3	and	O
4	mutant	O
5	MyoD	I
6	were	O
7	introduced	O
8	into	O
9	cells	O
10	using	O
11	an	O
12	E1	O
13	,	O
14	E3	B
15	-	O
16	deleted	O
17	adenoviral	O
18	vector	O
19	.	O

0	These	O
1	data	O
2	may	O
3	also	O
4	aid	O
5	in	O
6	the	O
7	localization	O
8	of	O
9	other	O
10	disease	O
11	loci	O
12	mapped	O
13	to	O
14	this	O
15	region	O
16	,	O
17	including	O
18	the	O
19	gene	O
20	for	O
21	tricho	O
22	-	O
23	dento	O
24	-	O
25	osseous	O
26	syndrome	O
27	and	O
28	a	O
29	murine	O
30	locus	O
31	for	O
32	susceptibility	O
33	to	O
34	ozone	O
35	-	O
36	induced	O
37	acute	O
38	lung	O
39	injury	O
40	.	O

0	Roentgenographically	O
1	,	O
2	the	O
3	lesion	O
4	was	O
5	usually	O
6	a	O
7	well	O
8	-	O
9	defined	O
10	and	O
11	benign	O
12	appearing	O
13	one	O
14	,	O
15	either	O
16	purely	O
17	lytic	O
18	(	O
19	3	O
20	cases	O
21	)	O
22	or	O
23	with	O
24	central	O
25	radiodensity	O
26	(	O
27	2	O
28	cases	O
29	).	O

0	Both	O
1	carbachol	O
2	(	O
3	100	O
4	microM	O
5	)	O
6	and	O
7	EGF	O
8	(	O
9	10	O
10	nM	O
11	)	O
12	induced	O
13	Ras	B
14	activation	O
15	.	O

0	Recently	O
1	,	O
2	a	O
3	mutation	O
4	in	O
5	the	O
6	amino	O
7	-	O
8	terminus	O
9	of	O
10	IB1	B
11	was	O
12	associated	O
13	with	O
14	diabetes	O
15	.	O

0	The	O
1	positive	O
2	-	O
3	acting	O
4	global	B
5	sulfur	I
6	regulatory	I
7	protein	I
8	,	O
9	CYS3	B
10	,	O
11	of	O
12	Neurospora	O
13	crassa	O
14	turns	O
15	on	O
16	the	O
17	expression	O
18	of	O
19	a	O
20	family	O
21	of	O
22	unlinked	O
23	structural	O
24	genes	O
25	that	O
26	encode	O
27	enzymes	O
28	of	O
29	sulfur	O
30	catabolism	O
31	.	O

0	Cloning	O
1	and	O
2	expression	O
3	of	O
4	two	O
5	genes	O
6	encoding	O
7	auxin	B
8	-	I
9	binding	I
10	proteins	I
11	from	O
12	tobacco	O
13	.	O

0	In	O
1	addition	O
2	,	O
3	a	O
4	catalytically	O
5	inactive	O
6	version	O
7	of	O
8	the	O
9	Src	B
10	family	I
11	member	I
12	,	O
13	Lck	B
14	(	O
15	lymphoid	B
16	cell	I
17	kinase	I
18	),	O
19	was	O
20	expressed	O
21	,	O
22	purified	O
23	,	O
24	and	O
25	evaluated	O
26	as	O
27	a	O
28	Csk	B
29	substrate	O
30	.	O

0	The	O
1	occurrence	O
2	,	O
3	maintenance	O
4	and	O
5	possible	O
6	involvement	O
7	of	O
8	these	O
9	repeated	O
10	sequences	O
11	,	O
12	capable	O
13	of	O
14	forming	O
15	stable	O
16	secondary	O
17	structures	O
18	,	O
19	are	O
20	discussed	O
21	in	O
22	relation	O
23	to	O
24	their	O
25	location	O
26	in	O
27	the	O
28	region	O
29	of	O
30	control	O
31	signals	O
32	.	O

0	Thus	O
1	,	O
2	in	O
3	the	O
4	presence	O
5	of	O
6	active	O
7	S	B
8	-	I
9	CDKs	I
10	and	O
11	Dbf4	B
12	/	O
13	Cdc7	B
14	,	O
15	Mcms	B
16	may	O
17	open	O
18	origins	O
19	and	O
20	thereby	O
21	facilitate	O
22	the	O
23	loading	O
24	of	O
25	RPA	O
26	.	O

0	A	O
1	causal	O
2	analysis	O
3	of	O
4	secondary	O
5	variables	O
6	showed	O
7	that	O
8	the	O
9	formation	O
10	of	O
11	FB	O
12	memories	O
13	was	O
14	primarily	O
15	associated	O
16	with	O
17	the	O
18	level	O
19	of	O
20	importance	O
21	attached	O
22	to	O
23	the	O
24	event	O
25	and	O
26	level	O
27	of	O
28	affective	O
29	response	O
30	to	O
31	the	O
32	news	O
33	.	O

0	The	O
1	minus	O
2	-	O
3	end	O
4	-	O
5	directed	O
6	microtubule	O
7	motors	O
8	,	O
9	the	O
10	dyneins	B
11	,	O
12	may	O
13	also	O
14	constitute	O
15	a	O
16	superfamily	O
17	of	O
18	force	O
19	-	O
20	generating	O
21	proteins	O
22	with	O
23	distinct	O
24	attachment	O
25	domains	O
26	.	O

0	Oscilloscope	O
1	triggering	O
2	circuit	O
3	for	O
4	recording	O
5	long	O
6	transients	O
7	at	O
8	fast	O
9	sweep	O
10	speeds	O
11	.	O

0	In	O
1	nine	O
2	patients	O
3	with	O
4	renal	O
5	failure	O
6	routine	O
7	haemodialysis	O
8	was	O
9	accompanied	O
10	by	O
11	a	O
12	30	O
13	per	O
14	cent	O
15	reduction	O
16	in	O
17	plasma	B
18	ANP	I
19	concentration	O
20	.	O

0	The	O
1	5	O
2	'-	O
3	nontranslated	O
4	sequences	O
5	and	O
6	parts	O
7	of	O
8	the	O
9	coding	O
10	sequences	O
11	of	O
12	various	O
13	yeast	O
14	genes	O
15	have	O
16	been	O
17	cloned	O
18	into	O
19	representative	O
20	lacZ	B
21	fusion	O
22	vectors	O
23	.	O

0	We	O
1	speculate	O
2	that	O
3	the	O
4	human	O
5	papillomavirus	O
6	late	O
7	mRNAs	O
8	,	O
9	produced	O
10	from	O
11	several	O
12	hundred	O
13	copies	O
14	of	O
15	the	O
16	virus	O
17	genome	O
18	present	O
19	in	O
20	infected	O
21	cells	O
22	,	O
23	compete	O
24	with	O
25	the	O
26	c	B
27	-	I
28	fos	I
29	mRNAs	I
30	for	O
31	destabilizing	O
32	cellular	O
33	factors	O
34	and	O
35	that	O
36	this	O
37	may	O
38	lead	O
39	to	O
40	elevated	O
41	Fos	B
42	protein	I
43	levels	O
44	in	O
45	human	O
46	papillomavirus	O
47	infected	O
48	cells	O
49	.	O

0	The	O
1	size	O
2	discrepancy	O
3	is	O
4	not	O
5	due	O
6	to	O
7	glycosylation	O
8	or	O
9	phosphorylation	O
10	of	O
11	Ag35	B
12	but	O
13	may	O
14	result	O
15	from	O
16	a	O
17	proline	O
18	-	O
19	rich	O
20	sequence	O
21	which	O
22	occurs	O
23	in	O
24	this	O
25	polypeptide	O
26	.	O

0	Uptake	O
1	of	O
2	ofloxacin	O
3	by	O
4	Escherichia	O
5	coli	O

0	The	O
1	POEMS	O
2	syndrome	O
3	(	O
4	Polyneuropathy	O
5	,	O
6	Organomegaly	O
7	,	O
8	Endocrinopathy	O
9	,	O
10	Monoclonal	O
11	component	O
12	,	O
13	Skin	O
14	).	O

0	Demographic	O
1	and	O
2	clinical	O
3	data	O
4	were	O
5	compared	O
6	with	O
7	a	O
8	control	O
9	group	O
10	of	O
11	339	O
12	healthy	O
13	age	O
14	-	O
15	matched	O
16	women	O
17	and	O
18	with	O
19	a	O
20	sample	O
21	of	O
22	224	O
23	women	O
24	with	O
25	wrist	O
26	fracture	O
27	.	O

0	When	O
1	normalized	O
2	for	O
3	imaging	O
4	time	O
5	,	O
6	all	O
7	parameters	O
8	are	O
9	significantly	O
10	higher	O
11	with	O
12	RASE	O
13	,	O
14	with	O
15	a	O
16	C	O
17	/	O
18	A	O
19	per	O
20	unit	O
21	time	O
22	that	O
23	was	O
24	338	O
25	%	O
26	higher	O
27	.	O

0	Of	O
1	254	O
2	children	O
3	with	O
4	neuroblastoma	O
5	treated	O
6	at	O
7	St	O
8	.	O

0	Similarly	O
1	,	O
2	co	O
3	-	O
4	expression	O
5	of	O
6	a	O
7	dominant	O
8	-	O
9	negative	O
10	mutant	O
11	of	O
12	p38alpha	B
13	,	O
14	but	O
15	not	O
16	of	O
17	ERK1	B
18	,	O
19	ERK2	B
20	,	O
21	JNK1	B
22	,	O
23	or	O
24	JNK2	B
25	,	O
26	reduces	O
27	basal	O
28	and	O
29	cadmium	O
30	-	O
31	induced	O
32	pE1	B
33	-	I
34	luc	I
35	activity	O
36	.	O

0	OBJECTIVE	O
1	:	O
2	To	O
3	perform	O
4	a	O
5	cost	O
6	-	O
7	effectiveness	O
8	analysis	O
9	(	O
10	CEA	O
11	)	O
12	between	O
13	a	O
14	standard	O
15	antiemetic	O
16	regimen	O
17	-	O
18	chlorpromazine	O
19	+	O
20	dexamethasone	O
21	(	O
22	CPM	O
23	-	O
24	DEX	O
25	)-	O
26	and	O
27	a	O
28	5	B
29	-	I
30	HT3	I
31	receptor	I
32	antagonist	O
33	-	O
34	tropisetron	O
35	(	O
36	TROP	O
37	)--	O
38	in	O
39	the	O
40	control	O
41	of	O
42	acute	O
43	emesis	O
44	induced	O
45	by	O
46	highly	O
47	emetogenic	O
48	chemotherapy	O
49	in	O
50	children	O
51	,	O
52	considering	O
53	two	O
54	analytic	O
55	perspectives	O
56	:	O
57	hospital	O
58	and	O
59	patients	O
60	.	O

0	The	O
1	sera	O
2	and	O
3	nasal	O
4	secretions	O
5	of	O
6	142	O
7	patients	O
8	,	O
9	who	O
10	were	O
11	positive	O
12	in	O
13	HD	O
14	or	O
15	mites	O
16	skin	O
17	test	O
18	,	O
19	were	O
20	subjected	O
21	to	O
22	a	O
23	radioallergosorbent	O
24	test	O
25	(	O
26	RAST	O
27	)	O
28	for	O
29	estimating	O
30	the	O
31	specific	O
32	IgE	B
33	antibody	I
34	activity	O
35	to	O
36	mites	O
37	.	O

0	A	O
1	variety	O
2	of	O
3	nuclear	O
4	ribonucleoproteins	O
5	are	O
6	believed	O
7	to	O
8	associate	O
9	directly	O
10	with	O
11	nascent	O
12	RNA	B
13	polymerase	I
14	II	I
15	transcripts	I
16	and	O
17	remain	O
18	associated	O
19	during	O
20	subsequent	O
21	nuclear	O
22	RNA	O
23	processing	O
24	reactions	O
25	,	O
26	including	O
27	pre	O
28	-	O
29	mRNA	O
30	polyadenylation	O
31	and	O
32	splicing	O
33	as	O
34	well	O
35	as	O
36	nucleocytoplasmic	O
37	mRNA	O
38	transport	O
39	.	O

0	Angiography	O
1	of	O
2	aneurysmal	O
3	bone	O
4	cyst	O
5	.	O

0	The	O
1	interferon	B
2	-	I
3	inducible	I
4	protein	I
5	kinase	I
6	PKR	I
7	modulates	O
8	the	O
9	transcriptional	O
10	activation	O
11	of	O
12	immunoglobulin	B
13	kappa	I
14	gene	I
15	.	O

0	IE2	B
1	-	O
2	IE2	B
3	interactions	O
4	were	O
5	mapped	O
6	to	O
7	a	O
8	domain	O
9	containing	O
10	a	O
11	putative	O
12	helix	O
13	-	O
14	turn	O
15	-	O
16	helix	O
17	motif	O
18	located	O
19	near	O
20	the	O
21	C	O
22	terminus	O
23	of	O
24	IE2	B
25	,	O
26	between	O
27	amino	O
28	acids	O
29	456	O
30	and	O
31	539	O
32	.	O

0	Comparison	O
1	of	O
2	the	O
3	proportion	O
4	of	O
5	nonsynonymous	O
6	(	O
7	pN	B
8	)	O
9	and	O
10	synonymous	O
11	(	O
12	pS	O
13	)	O
14	substitutions	O
15	occurring	O
16	per	O
17	site	O
18	within	O
19	tamarin	B
20	variable	I
21	region	I
22	genes	I
23	demonstrated	O
24	a	O
25	reduction	O
26	in	O
27	pN	B
28	in	O
29	the	O
30	framework	O
31	regions	O
32	compared	O
33	with	O
34	pN	B
35	in	O
36	the	O
37	presumed	O
38	MHC	B
39	contact	O
40	regions	O
41	(	O
42	CDR1	B
43	and	O
44	CDR2	B
45	).	O

0	Therefore	O
1	,	O
2	we	O
3	have	O
4	developed	O
5	a	O
6	system	O
7	to	O
8	study	O
9	nuclear	O
10	targeting	O
11	in	O
12	plants	O
13	and	O
14	have	O
15	established	O
16	that	O
17	the	O
18	nuclear	O
19	transport	O
20	machinery	O
21	is	O
22	similar	O
23	in	O
24	monocots	O
25	and	O
26	dicots	O
27	.	O

0	Finally	O
1	,	O
2	some	O
3	point	O
4	mutations	O
5	in	O
6	the	O
7	Gag	B
8	-	I
9	Pol	I
10	PR	I
11	domain	I
12	inhibited	O
13	activation	O
14	of	O
15	RT	B
16	in	O
17	trans	O
18	by	O
19	a	O
20	wild	B
21	-	I
22	type	I
23	PR	I
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	correct	O
29	conformation	O
30	of	O
31	the	O
32	PR	B
33	domain	I
34	in	O
35	Gag	B
36	-	I
37	Pol	I
38	is	O
39	prerequisite	O
40	for	O
41	activation	O
42	of	O
43	RT	B
44	.	O

0	Losses	O
1	during	O
2	the	O
3	complete	O
4	procedure	O
5	are	O
6	corrected	O
7	for	O
8	using	O
9	radioactive	O
10	estrogen	O
11	conjugates	O
12	during	O
13	the	O
14	first	O
15	steps	O
16	and	O
17	later	O
18	by	O
19	adding	O
20	deuterated	O
21	internal	O
22	standards	O
23	of	O
24	all	O
25	compounds	O
26	measured	O
27	(	O
28	matairesinol	O
29	,	O
30	enterodiol	O
31	,	O
32	enterolactone	O
33	,	O
34	daidzein	O
35	,	O
36	O	O
37	-	O
38	desmethylangolensin	O
39	,	O
40	equol	O
41	,	O
42	and	O
43	genistein	O
44	).	O

0	An	O
1	implant	O
2	may	O
3	release	O
4	a	O
5	drug	O
6	either	O
7	by	O
8	diffusion	O
9	concurrent	O
10	with	O
11	dissolution	O
12	of	O
13	the	O
14	polymeric	O
15	implant	O
16	material	O
17	without	O
18	depolymerization	O
19	(	O
20	Type	O
21	A	O
22	)	O
23	or	O
24	by	O
25	bioerosion	O
26	involving	O
27	depolymerization	O
28	(	O
29	Type	O
30	B	O
31	).	O

0	The	O
1	intensity	O
2	of	O
3	the	O
4	SSTEs	O
5	is	O
6	an	O
7	order	O
8	of	O
9	magnitude	O
10	larger	O
11	than	O
12	that	O
13	of	O
14	the	O
15	MSEs	O
16	and	O
17	determines	O
18	the	O
19	signal	O
20	contrast	O
21	if	O
22	both	O
23	effects	O
24	are	O
25	selected	O
26	simultaneously	O
27	.	O

0	Ten	O
1	out	O
2	of	O
3	10	O
4	patients	O
5	with	O
6	progressive	O
7	disease	O
8	had	O
9	mast	O
10	cells	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	0	O
17	.	O
18	5	O
19	%,	O
20	hyaluronan	O
21	greater	O
22	than	O
23	or	O
24	equal	O
25	to	O
26	50	O
27	micrograms	O
28	.	O
29	l	B
30	-	I
31	1	I
32	and	O
33	fibronectin	B
34	greater	O
35	than	O
36	or	O
37	equal	O
38	to	O
39	350	O
40	micrograms	O
41	.	O
42	l	B
43	-	I
44	1	I
45	compared	O
46	to	O
47	eight	O
48	out	O
49	of	O
50	41	O
51	patients	O
52	with	O
53	stable	O
54	or	O
55	regressive	O
56	disease	O
57	.(	O
58	ABSTRACT	O
59	TRUNCATED	O
60	AT	O
61	250	O
62	WORDS	O
63	)	O

0	Kaposi	O
1	'	O
2	s	O
3	sarcoma	B
4	-	I
5	associated	I
6	herpesvirus	I
7	viral	I
8	interferon	I
9	regulatory	I
10	factor	I
11	confers	O
12	resistance	O
13	to	O
14	the	O
15	antiproliferative	O
16	effect	O
17	of	O
18	interferon	B
19	-	I
20	alpha	I
21	.	O

0	Cotransfections	O
1	with	O
2	ATF	B
3	-	I
4	2	I
5	and	O
6	HNF	B
7	-	I
8	4	I
9	expression	O
10	plasmids	O
11	resulted	O
12	in	O
13	additive	O
14	transactivation	O
15	of	O
16	the	O
17	apoCIII	B
18	promoter	I
19	.	O

0	A	O
1	more	O
2	complete	O
3	analysis	O
4	of	O
5	dose	O
6	response	O
7	,	O
8	time	O
9	and	O
10	mode	O
11	of	O
12	Ga	O
13	administration	O
14	(	O
15	preinjury	O
16	or	O
17	postinjury	O
18	),	O
19	and	O
20	availability	O
21	of	O
22	Ga	O
23	across	O
24	the	O
25	blood	O
26	-	O
27	brain	O
28	barrier	O
29	is	O
30	needed	O
31	to	O
32	further	O
33	evaluate	O
34	the	O
35	efficacy	O
36	of	O
37	this	O
38	compound	O
39	.	O

0	Mutational	O
1	analysis	O
2	supports	O
3	a	O
4	role	O
5	for	O
6	multiple	O
7	structural	O
8	features	O
9	in	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	secretion	O
15	signal	O
16	of	O
17	Escherichia	B
18	coli	I
19	haemolysin	I
20	.	O

0	Cortical	O
1	dysplasias	O
2	,	O
3	genetics	O
4	,	O
5	and	O
6	epileptogenesis	O
7	.	O

0	To	O
1	test	O
2	whether	O
3	or	O
4	not	O
5	SOCS	B
6	-	I
7	3	I
8	also	O
9	binds	O
10	to	O
11	the	O
12	IGFIR	B
13	,	O
14	we	O
15	cloned	O
16	human	B
17	SOCS	I
18	-	I
19	3	I
20	by	O
21	reverse	O
22	transcription	O
23	-	O
24	polymerase	O
25	chain	O
26	reaction	O
27	from	O
28	human	O
29	skeletal	O
30	muscle	O
31	mRNA	O
32	.	O

0	Individuals	O
1	attending	O
2	the	O
3	GUM	O
4	Department	O
5	in	O
6	the	O
7	Royal	O
8	Infirmary	O
9	of	O
10	Edinburgh	O
11	between	O
12	1990	O
13	and	O
14	1994	O
15	with	O
16	the	O
17	diagnosis	O
18	of	O
19	HIV	O
20	infection	O
21	,	O
22	genital	O
23	warts	O
24	,	O
25	genital	O
26	herpes	O
27	,	O
28	non	O
29	-	O
30	specific	O
31	genital	O
32	infection	O
33	(	O
34	NSGI	O
35	),	O
36	gonorrhoea	O
37	and	O
38	syphilis	O
39	were	O
40	included	O
41	in	O
42	the	O
43	study	O
44	.	O

0	In	O
1	addition	O
2	,	O
3	on	O
4	the	O
5	Cohler	O
6	'	O
7	s	O
8	maternal	O
9	scale	O
10	,	O
11	Korean	O
12	mothers	O
13	were	O
14	found	O
15	to	O
16	view	O
17	their	O
18	infants	O
19	as	O
20	more	O
21	passive	O
22	and	O
23	dependent	O
24	than	O
25	American	O
26	mothers	O
27	did	O
28	(	O
29	P	O
30	less	O
31	than	O
32	0	O
33	.	O
34	00	O
35	).	O

0	This	O
1	emancipation	O
2	of	O
3	the	O
4	ability	O
5	to	O
6	copulate	O
7	from	O
8	hormonal	O
9	influence	O
10	makes	O
11	female	O
12	sexual	O
13	motivation	O
14	the	O
15	primary	O
16	regulator	O
17	of	O
18	mating	O
19	in	O
20	primates	O
21	.	O

0	These	O
1	data	O
2	indicate	O
3	that	O
4	activation	O
5	of	O
6	these	O
7	enzymes	O
8	is	O
9	not	O
10	sufficient	O
11	for	O
12	the	O
13	acute	O
14	stimulation	O
15	of	O
16	glucose	O
17	transport	O
18	.	O

0	Although	O
1	the	O
2	N13	O
3	-	O
4	N20	O
5	interpeak	O
6	interval	O
7	remained	O
8	stable	O
9	because	O
10	of	O
11	the	O
12	parallel	O
13	shift	O
14	of	O
15	the	O
16	2	O
17	peaks	O
18	,	O
19	the	O
20	central	O
21	conduction	O
22	time	O
23	measured	O
24	from	O
25	onset	O
26	latencies	O
27	of	O
28	N11	O
29	and	O
30	N20	O
31	significantly	O
32	increased	O
33	.	O

0	With	O
1	respect	O
2	to	O
3	the	O
4	distribution	O
5	of	O
6	active	O
7	MREs	B
8	over	O
9	the	O
10	promoter	O
11	region	O
12	,	O
13	the	O
14	hMT	B
15	-	I
16	IIA	I
17	gene	I
18	is	O
19	largely	O
20	different	O
21	from	O
22	the	O
23	mouse	B
24	metallothionein	I
25	-	I
26	I	I
27	gene	I
28	,	O
29	suggesting	O
30	that	O
31	MRE	B
32	arrangement	O
33	is	O
34	not	O
35	an	O
36	important	O
37	factor	O
38	for	O
39	metal	O
40	regulation	O
41	.	O

0	Detection	O
1	of	O
2	anti	B
3	-	I
4	lymphocyte	I
5	antibodies	I
6	using	O
7	the	O
8	immunoperoxidase	B
9	antiglobulin	I
10	technic	O
11	.	O

0	A	O
1	cDNA	O
2	clone	O
3	was	O
4	identified	O
5	encoding	O
6	a	O
7	second	O
8	GHS	B
9	-	I
10	R	I
11	-	I
12	related	I
13	gene	I
14	(	O
15	GPR39	B
16	).	O

0	To	O
1	determine	O
2	which	O
3	region	O
4	of	O
5	SulA	B
6	is	O
7	essential	O
8	for	O
9	the	O
10	inhibition	O
11	of	O
12	cell	O
13	division	O
14	,	O
15	we	O
16	constructed	O
17	a	O
18	series	O
19	of	O
20	N	O
21	-	O
22	terminal	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	deletions	O
28	of	O
29	SulA	B
30	and	O
31	a	O
32	series	O
33	of	O
34	alanine	O
35	substitution	O
36	mutants	O
37	.	O

0	Three	O
1	separate	O
2	activation	O
3	subdomains	O
4	,	O
5	and	O
6	one	O
7	negative	O
8	-	O
9	acting	O
10	region	O
11	,	O
12	which	O
13	function	O
14	in	O
15	yeast	O
16	were	O
17	located	O
18	in	O
19	the	O
20	carboxyl	O
21	-	O
22	terminal	O
23	region	O
24	of	O
25	NIT4	B
26	.	O

0	This	O
1	study	O
2	indicates	O
3	that	O
4	this	O
5	dose	O
6	-	O
7	intense	O
8	regimen	O
9	can	O
10	be	O
11	safely	O
12	administered	O
13	,	O
14	even	O
15	with	O
16	the	O
17	use	O
18	of	O
19	purged	O
20	marrow	O
21	,	O
22	with	O
23	an	O
24	acceptable	O
25	toxicity	O
26	profile	O
27	.	O

0	Cloning	O
1	of	O
2	a	O
3	human	B
4	phosphoinositide	I
5	3	I
6	-	I
7	kinase	I
8	with	O
9	a	O
10	C2	O
11	domain	O
12	that	O
13	displays	O
14	reduced	O
15	sensitivity	O
16	to	O
17	the	O
18	inhibitor	O
19	wortmannin	O
20	.	O

0	Its	O
1	transcription	O
2	has	O
3	been	O
4	shown	O
5	to	O
6	be	O
7	induced	O
8	40	O
9	-	O
10	50	O
11	-	O
12	fold	O
13	in	O
14	response	O
15	to	O
16	oxygen	O
17	or	O
18	heme	O
19	deficiency	O
20	,	O
21	in	O
22	part	O
23	through	O
24	relief	O
25	of	O
26	repression	O
27	exerted	O
28	by	O
29	Rox1p	B
30	and	O
31	in	O
32	part	O
33	by	O
34	activation	O
35	mediated	O
36	by	O
37	an	O
38	upstream	O
39	activation	O
40	sequence	O
41	(	O
42	UAS	O
43	).	O

0	Among	O
1	mammalian	O
2	HSFs	I
3	,	O
4	HSF1	B
5	has	O
6	been	O
7	shown	O
8	to	O
9	be	O
10	important	O
11	for	O
12	regulation	O
13	of	O
14	the	O
15	heat	O
16	-	O
17	induced	O
18	stress	O
19	gene	O
20	expression	O
21	,	O
22	whereas	O
23	the	O
24	function	O
25	of	O
26	HSF2	B
27	in	O
28	stress	O
29	response	O
30	is	O
31	unclear	O
32	.	O

0	The	O
1	retention	O
2	index	O
3	of	O
4	201Tl	O
5	SPECT	O
6	is	O
7	a	O
8	useful	O
9	indicator	O
10	of	O
11	metastatic	O
12	potential	O
13	,	O
14	thereby	O
15	facilitating	O
16	the	O
17	prediction	O
18	of	O
19	prognosis	O
20	,	O
21	and	O
22	provides	O
23	insight	O
24	into	O
25	the	O
26	relationship	O
27	between	O
28	201Tl	O
29	uptake	O
30	and	O
31	malignancy	O
32	.	O

0	A	O
1	late	O
2	diagnosis	O
3	of	O
4	retinoblastoma	O
5	is	O
6	an	O
7	unquestionable	O
8	fact	O
9	that	O
10	allows	O
11	its	O
12	growth	O
13	and	O
14	leads	O
15	to	O
16	a	O
17	deterioration	O
18	in	O
19	the	O
20	outlook	O
21	.	O

0	In	O
1	a	O
2	prospective	O
3	randomized	O
4	study	O
5	,	O
6	287	O
7	patients	O
8	with	O
9	advanced	O
10	non	O
11	-	O
12	small	O
13	cell	O
14	lung	O
15	cancer	O
16	(	O
17	NSCLC	O
18	)	O
19	stage	O
20	IIIb	O
21	or	O
22	IV	O
23	with	O
24	ECOG	O
25	performance	O
26	status	O
27	(	O
28	PS	O
29	)	O
30	0	O
31	-	O
32	1	O
33	or	O
34	2	O
35	were	O
36	randomly	O
37	assigned	O
38	to	O
39	receive	O
40	either	O
41	best	O
42	supportive	O
43	care	O
44	(	O
45	BSC	O
46	)	O
47	or	O
48	supportive	O
49	care	O
50	plus	O
51	combination	O
52	chemotherapy	O
53	(	O
54	IEP	O
55	regimen	O
56	:	O
57	ifosfamide	O
58	3	O
59	gm	O
60	/	O
61	m2	O
62	IV	O
63	with	O
64	mesna	O
65	uroprotection	O
66	,	O
67	epirubicin	O
68	60	O
69	mg	O
70	/	O
71	m2	O
72	IV	O
73	on	O
74	day	O
75	1	O
76	and	O
77	cisplatin	O
78	60	O
79	mg	O
80	/	O
81	m2	O
82	IV	O
83	on	O
84	day	O
85	2	O
86	;	O
87	or	O
88	MVP	O
89	regimen	O
90	:	O
91	mitomycin	O
92	-	O
93	C	O
94	8	O
95	mg	O
96	/	O
97	m2	O
98	,	O
99	cisplatin	O
100	100	O
101	mg	O
102	/	O
103	m2	O
104	IV	O
105	on	O
106	day	O
107	1	O
108	,	O
109	vinblastine	O
110	4	O
111	mg	O
112	/	O
113	m2	O
114	IV	O
115	on	O
116	days	O
117	1	O
118	and	O
119	15	O
120	).	O

0	Only	O
1	the	O
2	3	O
3	.	O
4	0	O
5	-	O
6	kb	O
7	transcript	O
8	was	O
9	detected	O
10	in	O
11	adult	O
12	tissues	O
13	,	O
14	where	O
15	its	O
16	expression	O
17	was	O
18	restricted	O
19	almost	O
20	exclusively	O
21	to	O
22	the	O
23	central	O
24	nervous	O
25	system	O
26	.	O

